FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Glasser, JR Mallampalli, RK AF Glasser, Jennifer R. Mallampalli, Rama K. TI Surfactant and its role in the pathobiology of pulmonary infection SO MICROBES AND INFECTION LA English DT Review DE Surfactant; Collectin; Phospholipid; Infection ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; INNATE HOST-DEFENSE; PROTEIN-A; APOPTOTIC MIMICRY; II PNEUMOCYTES; VIRUS ENTRY; SP-C; COLLECTINS; DISEASE AB Pulmonary surfactant is a complex surface-active substance comprised of key phospholipids and proteins that has many essential functions. Surfactant's unique composition is integrally related to its surface-active properties, its critical role in host defense, and emerging immunomodulatory activities ascribed to surfactant lipids. Together these effector functions provide for lung stability and protection from a barrage of potentially virulent infectious pathogens. (C) 2011 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. C1 [Glasser, Jennifer R.; Mallampalli, Rama K.] Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15213 USA. RP Mallampalli, RK (reprint author), PACCM, Dept Med, NW628 Montefiore,3459 5th Ave, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174] FX We thank Ms. Tiffany Coon for critical review of the manuscript and helpful suggestions. This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health R01 grants HL096376, HL097376 and HL098174 (to R.K.M.). The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government. NR 67 TC 20 Z9 24 U1 1 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1286-4579 J9 MICROBES INFECT JI Microbes Infect. PD JAN PY 2012 VL 14 IS 1 BP 17 EP 25 DI 10.1016/j.micinf.2011.08.019 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 888UO UT WOS:000300030300003 PM 21945366 ER PT J AU Tanner, JM Chang, TI AF Tanner, Jeffrey M. Chang, Tina I. TI Syndrome Z: A comparison of prevalence between females and males SO SLEEP MEDICINE LA English DT Letter C1 [Tanner, Jeffrey M.; Chang, Tina I.] VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Dent Serv, Los Angeles, CA 90073 USA. [Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Chang, TI (reprint author), VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Dent Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM tinachangdmdmd@gmail.com NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 J9 SLEEP MED JI Sleep Med. PD JAN PY 2012 VL 13 IS 1 BP 119 EP 120 DI 10.1016/j.sleep.2011.06.005 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 890GA UT WOS:000300131900025 PM 21982339 ER PT J AU Anderson, AL Li, SH Biswas, K McSherry, F Holmes, T Iturriaga, E Kahn, R Chiang, N Beresford, T Campbell, J Haning, W Mawhinney, J McCann, M Rawson, R Stock, C Weis, D Yu, E Elkashef, AM AF Anderson, Ann L. Li, Shou-Hua Biswas, Kousick McSherry, Frances Holmes, Tyson Iturriaga, Erin Kahn, Roberta Chiang, Nora Beresford, Thomas Campbell, Jan Haning, William Mawhinney, Joseph McCann, Michael Rawson, Richard Stock, Christopher Weis, Dennis Yu, Elmer Elkashef, Ahmed M. TI Modafinil for the treatment of methamphetamine dependence SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Methamphetamine; Substance-related disorders; Drug therapy; Modafinil; Medication adherence; Attention Deficit Hyperactivity Disorders ID PLACEBO-CONTROLLED TRIAL; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; INDUCED WAKEFULNESS; COCAINE DEPENDENCE AB Aim: Modafinil was tested for efficacy in decreasing use in methamphetamine-dependent participants, compared to placebo. Methods: This was a randomized, double-blind, placebo-controlled study, with 12 weeks of treatment and a 4-week follow-up. Eight outpatient substance abuse treatment clinics participated in the study. There were 210 treatment-seekers randomized, who all had a DSM-IV diagnosis of methamphetamine dependence; 68 participants to placebo, 72 to modafinil 200 mg, and 70 to modafinil 400 mg, taken once daily on awakening. Participants came to the clinic three times per week for assessments, urine drug screens, and group psychotherapy. The primary outcome measure was a methamphetamine non-use week, which required all the week's qualitative urine drug screens to be negative for methamphetamine. Results: Regression analysis showed no significant difference between either modafinil group (200 or 400 mg) or placebo in change in weekly percentage having a methamphetamine non-use week over the 12-week treatment period (p=0.53). Similarly, a number of secondary outcomes did not show significant effects of modafinil. However, an ad-hoc analysis of medication compliance, by urinalysis for modafinil and its metabolite, did find a significant difference in maximum duration of abstinence (23 days vs. 10 days, p=0.003), between those having the top quartile of compliance (> 85% of urines were positive for modafinil, N=36), and the lower three quartiles of modafinil 200 and 400 mg groups (N=106). Conclusions: Although these data suggest that modafinil, plus group behavioral therapy, was not effective for decreasing methamphetamine use, the study is probably inconclusive because of inadequate compliance with taking medication. Published by Elsevier Ireland Ltd. C1 [Anderson, Ann L.] Natl Inst Drug Abuse, DPMC, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Bethesda, MD 20892 USA. [Biswas, Kousick; McSherry, Frances] VA Maryland Healthcare Ctr, Coop Studies Program, Perry Point, MD USA. [Holmes, Tyson] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Beresford, Thomas] VA Med Ctr, Psychiat Serv, Denver, CO USA. [Campbell, Jan] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA. [Haning, William] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA. [Mawhinney, Joseph] S Bay Treatment Ctr, San Diego, CA USA. [McCann, Michael] Matrix Inst Addict, Los Angeles, CA USA. [Rawson, Richard] UCLA Integrated Subst Abuse Program, Los Angeles, CA USA. [Stock, Christopher] VA Salt Lake City Healthcare Syst, Salt Lake City, UT USA. [Weis, Dennis] Iowa Lutheran Hosp, Des Moines, IA USA. [Yu, Elmer] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Anderson, AL (reprint author), Natl Inst Drug Abuse, DPMC, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, 6001 Execut Blvd,Rm 4149, Bethesda, MD 20892 USA. EM aa135m@nih.gov FU NIDA [Y1-DA-4006-01] FX Funding for this study was provided by NIDA Contract # Y1-DA-4006-01. The National Institute on Drug Abuse-NIH had a major role in study design, in the analysis and interpretation of data, and in the writing and submission of this manuscript for publication. NR 28 TC 44 Z9 45 U1 1 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 1 PY 2012 VL 120 IS 1-3 BP 135 EP 141 DI 10.1016/j.drugalcdep.2011.07.007 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 881PY UT WOS:000299499800019 PM 21840138 ER PT J AU Baca, CB Vickrey, BG Vassar, SD Berg, AT AF Baca, Christine B. Vickrey, Barbara G. Vassar, Stefanie D. Berg, Anne T. TI Seizure recency and quality of life in adolescents with childhood-onset epilepsy SO EPILEPSY & BEHAVIOR LA English DT Article DE Epilepsy; Children and adolescents; Health-related quality of life; Seizure recency; Seizure remission; Parent-proxy reports ID TEMPORAL-LOBE EPILEPSY; LONG-TERM PROGNOSIS; CHILDREN; HEALTH; SURGERY; IMPACT; OUTCOMES; SYMPTOMS; ANXIETY; ADULTS AB Health-related quality of life (HRQOL) is associated with seizure recency among adults with epilepsy. In a prospective, community-based study of long-term outcomes of childhood-onset epilepsy, we evaluated whether worse HRQOL is associated with more recent seizures among children and adolescents with epilepsy. We used the Child Health Questionnaire (CHQ), a generic measure with child and parent-proxy versions, to measure HRQOL Among 277 children with epilepsy (CWE) assessed 9 years after diagnosis, parent-proxy reported but not child self-reported HRQOL was significantly worse for those having seizures in the prior year than for those who were seizure free >= 1 year across the majority of scales. There were no differences between CWE in remission for 1-5 years and those seizure free >= 5 years for child and parent-proxy reported HRQOL with the exception of the parent Emotional Impact scale, suggesting that HRQOL differences related to seizure recency level off after the initial year of remission. Published by Elsevier Inc. C1 [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. [Berg, Anne T.] NW Childrens Mem Hosp, Epilepsy Ctr, Chicago, IL USA. RP Baca, CB (reprint author), UCLA Neurol, RNRC, C-247, Los Angeles, CA 90095 USA. EM cbower@mednet.ucla.edu FU National Institutes of Health (PI) [NINDS R37-NS31146] FX This work was supported by Grant NINDS R37-NS31146 from the National Institutes of Health (PI-Berg). NR 40 TC 10 Z9 10 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD JAN PY 2012 VL 23 IS 1 BP 47 EP 51 DI 10.1016/j.yebeh.2011.10.010 PG 5 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 883XO UT WOS:000299668400009 PM 22134098 ER PT J AU Strutt, AM Simpson, R Jankovic, J York, MK AF Strutt, A. M. Simpson, R. Jankovic, J. York, M. K. TI Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE cognition; depression; emotion; motor symptoms; Parkinson's disease; subthalamic nucleus deep brain stimulation; treatment ID DEEP-BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS STIMULATION; QUALITY-OF-LIFE; TRIAL; MOOD; METAANALYSIS; MULTICENTER; OUTCOMES; ANXIETY; SCALES AB Background and purpose: Subthalamic nucleus deep brain stimulation (STN-DBS) has been shown to have beneficial effects on the motor features of Parkinsons disease (PD), but its impact on non-motor symptoms, most notably mood, has not been fully explored. Methods: In the first study to independently compare the emotional-cognitive and somatic/ physiological symptoms of depression, we examined mood differences in 17 bilateral STN-DBS and 22 matched non-surgical PD patients at baseline and 6 months. Results: The STN-DBS group reported higher levels of depression at baseline with significant endorsement of physical symptomatology. Postoperatively, no significant between-group differences in physical symptoms of depression were found. In contrast, a significant group by time interaction for cognitive-emotional symptoms of depression was found, with the STN-DBS group reporting an increase in psychological symptoms of distress. The STN-DBS group also reported an increase in anxiety following surgery. The suicide rate of 5% found in our study is consistent with other postoperative studies in PD. The impact of changes in levodopa and psychotropic medication are also explored. Conclusions: Preliminary results suggest that the motor improvement often observed in patients with PD following bilateral STN-DBS may be partially offset by an increase in affective-cognitive symptoms of depression. C1 [Strutt, A. M.; Jankovic, J.; York, M. K.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Strutt, A. M.; Jankovic, J.; York, M. K.] Baylor Coll Med, Parkinsons Dis Movement Disorder Clin, Houston, TX 77030 USA. [Simpson, R.] Methodist Neurol Inst, Dept Neurosurg, Houston, TX USA. [York, M. K.] PADRECC, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Strutt, AM (reprint author), 6550 Fannin,Smith 1801, Houston, TX 77030 USA. EM adrianam@bcm.edu FU NIH/NINDS [K23] FX Work funded by a NIH/NINDS K23 grant (PI: York) and supported with resources from the Michael E. DeBakey Veteran's Affairs Hospital, Houston, TX, USA. The authors thank Kara M. Rherer for her assistance with data management, the participants of this study and the National Parkinson's Foundation. NR 35 TC 20 Z9 20 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 J9 EUR J NEUROL JI Eur. J. Neurol. PD JAN PY 2012 VL 19 IS 1 BP 121 EP 127 DI 10.1111/j.1468-1331.2011.03447.x PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 878JW UT WOS:000299254100021 PM 21668586 ER PT J AU Armstrong, EJ Yeo, KK Javed, U Mahmud, E Patel, M Shunk, KA MacGregor, JS Low, RI Rogers, JH AF Armstrong, Ehrin J. Yeo, Khung Keong Javed, Usman Mahmud, Ehtisham Patel, Mitul Shunk, Kendrick A. MacGregor, John S. Low, Reginald I. Rogers, Jason H. TI Angiographic Stent Thrombosis at Coronary Bifurcations Short- and Long-Term Prognosis SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE bifurcation; stent thrombosis; thrombus ID DRUG-ELUTING STENTS; ELEVATION MYOCARDIAL-INFARCTION; IMPLANTATION; REGISTRY; LESIONS; RISK; PREDICTORS; SIROLIMUS; TRIALS AB Objectives This study sought to describe the presentation, management, and outcomes of patients presenting with angiographic definite stent thrombosis (ST) at coronary bifurcations. Background The development of drug-eluting stents has made it increasingly feasible to treat bifurcation lesions percutaneously. However, ST at coronary bifurcations may be associated with greater mortality than ST elsewhere. Methods We analyzed a multicenter California registry comprising all cases of angiographic definite ST at 5 academic hospitals from 2005 to 2010. Stenting was defined as occurring at a bifurcation if the main vessel stent crossed a side branch >= 2.0 mm in diameter (provisional single-stent approach), or if there was a prior 2-stent bifurcation approach. Results Among 173 cases of angiographic definite ST, we identified 20 cases of ST at coronary bifurcations. Nine of 20 bifurcation ST (45%) occurred with a stent present in both the parent and branch vessel. Eight cases had thrombus present in both the parent and side branch vessels. In-hospital mortality was much higher for subjects with bifurcation ST than ST at a nonbifurcation site (20% vs. 2%, p < 0.0001). During a median follow-up of 2.3 years, ST at a coronary bifurcation was associated with increased long-term mortality (hazard ratio [HR]: 3.3, 95% confidence interval [Cl]: 1.4 to 7.7, p = 0.007) and a significantly higher risk for major adverse cardiovascular events (HR: 2.2, 95% Cl: 1.04 to 4.8, p = 0.04) relative to ST at a nonbifurcation site. Conclusions ST at coronary bifurcations is associated with a higher in-hospital and long-term mortality than ST at nonbifurcation lesions. (Stent Thrombus in Acute Coronary Syndromes; NCT00931502) (J Am Coll Cardiol Intv 2012;5:57-63) (C) 2012 by the American College of Cardiology Foundation C1 [Armstrong, Ehrin J.; Yeo, Khung Keong; Javed, Usman; Low, Reginald I.; Rogers, Jason H.] Univ Calif Davis, Davis Med Ctr, Div Cardiovasc Med, Sacramento, CA 95817 USA. [Mahmud, Ehtisham; Patel, Mitul] Univ Calif San Diego, Med Ctr, Div Cardiol, San Diego, CA 92103 USA. [Shunk, Kendrick A.; MacGregor, John S.] Univ Calif San Francisco, Div Cardiol, Med Ctr, San Francisco, CA USA. [Shunk, Kendrick A.] San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA USA. [MacGregor, John S.] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA. RP Rogers, JH (reprint author), Univ Calif Davis, Davis Med Ctr, Div Cardiovasc Med, 4860 Y St,Suite 2820, Sacramento, CA 95817 USA. EM jason.rogers@ucdmc.ucdavis.edu FU Boston Scientific; Abbott Vascular; Accumetrics; sanofi-aventis FX Dr. Mahmud serves on the Speaker's Bureau for Medtronic and Eli Lilly; is a consultant for Eli Lilly; and receives research support from Boston Scientific, Abbott Vascular, Accumetrics, and sanofi-aventis. Dr. Low is on the advisory board of and is a consultant for Abbott Vascular and Boston Scientific. Dr. Rogers is a consultant for Volcano, Medtronic, and Boston Scientific. All other authors have reported that they have relationships relevant to the contents of this paper to disclose. NR 21 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD JAN PY 2012 VL 5 IS 1 BP 57 EP 63 DI 10.1016/j.jcin.2011.09.015 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 883XU UT WOS:000299669000008 PM 22230151 ER PT J AU Wong, KK Muller, MLTM Kuwabara, H Studenski, SA Bohnen, NI AF Wong, Ka Kit Mueller, Martijn L. T. M. Kuwabara, Hiroto Studenski, Stephanie A. Bohnen, Nicolaas I. TI Gender differences in nigrostriatal dopaminergic innervation are present at young-to-middle but not at older age in normal adults SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Aging; Gender; Basal ganglia; Dopamine; Menopause; Parkinson's disease; Positron emission tomography ID SEX-DIFFERENCES; TRANSPORTER AVAILABILITY; SPECT AB Gender differences in brain dopaminergic activity have been variably reported in the literature. We performed an evaluation for gender effects on striatal dopamine transporter (DAT) binding in a group of normal subjects. Community-dwelling adults (n = 85, 50F/35M, mean age 62.7 +/- 16.2 SD, range 20-85) underwent DAT[C-11]-beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (beta-CFT) positron emission tomography (PET) imaging. Gender effects for DAT binding were compared using ANCOVA for two subgroups; young-to-middle aged adults and older adults, using an age threshold of 60 years. There were 54 subjects (24M/30F; mean age 72.9 +/- 7.3) 60 years and older and 31 (11M/20F; mean age 45.0 +/- 11.4) subjects younger than 60. Age-adjusted striatal DAT gender effects were present in the young-to-middle (F = 10.4, P = 0.003) but not in the elderly age group (F = 0.5, ns). Gender differences in nigrostriatal dopaminergic innervation are present, with higher levels of DAT binding in young-to-middle age women compared to men, but not present in the elderly. Published by Elsevier Ltd. C1 [Wong, Ka Kit; Bohnen, Nicolaas I.] VA Ann Arbor Healthcare Syst, GRECC, Ann Arbor, MI USA. [Mueller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Radiol, Ann Arbor, MI 48105 USA. [Mueller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Neurol, Ann Arbor, MI 48105 USA. [Kuwabara, Hiroto] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA. [Studenski, Stephanie A.] VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. [Studenski, Stephanie A.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [Wong, Ka Kit] Univ Michigan, Dept Nucl Med Radiol, Ann Arbor, MI 48105 USA. RP Bohnen, NI (reprint author), VA Ann Arbor Healthcare Syst, GRECC, Ann Arbor, MI USA. EM nbohnen@umich.edu RI Muller, Martijn/A-7205-2010 OI Muller, Martijn/0000-0002-1133-7202 FU Department of Veterans Affairs FX This study was funded by the Department of Veterans Affairs. NR 7 TC 13 Z9 13 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD JAN PY 2012 VL 19 IS 1 BP 183 EP 184 DI 10.1016/j.jocn.2011.05.013 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 882YP UT WOS:000299600100042 PM 22030267 ER PT J AU Aspinall, SL Good, CB Cunningham, FE AF Aspinall, Sherrie L. Good, Chester B. Cunningham, Francesca E. TI Glycemic Control Was Unchanged in Veterans Health Administration Patients Converted from Glyburide to Glipizide SO JOURNAL OF MANAGED CARE PHARMACY LA English DT Letter C1 [Aspinall, Sherrie L.; Good, Chester B.; Cunningham, Francesca E.] VA Ctr Medicat Safety, Hines, IL USA. [Good, Chester B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Aspinall, SL (reprint author), VA Ctr Medicat Safety, Hines, IL USA. EM sherrie.aspinall@va.gov NR 3 TC 0 Z9 0 U1 2 U2 2 PU ACAD MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 1083-4087 J9 J MANAGE CARE PHARM JI J. Manag. Care Pharm. PD JAN-FEB PY 2012 VL 18 IS 1 BP 73 EP 73 PG 1 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA 885BI UT WOS:000299753100007 PM 22235958 ER PT J AU Tanner, JM Chang, TI Harada, ND Santiago, SM Weinreb, JE Friedlander, AH AF Tanner, Jeffrey M. Chang, Tina I. Harada, Nancy D. Santiago, Silverio M. Weinreb, Jane E. Friedlander, Arthur H. TI Prevalence of Comorbid Obstructive Sleep Apnea and Metabolic Syndrome: Syndrome Z and Maxillofacial Surgery Implications SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; ABDOMINAL OBESITY; APNOEA/HYPOPNOEA SYNDROME; MORBID-OBESITY; BLOOD-PRESSURE; FATTY-ACIDS; RISK-FACTOR; FOLLOW-UP AB Purpose: To determine the prevalence of the recently identified syndrome Z (SZ), which is the co-occurrence of obstructive sleep apnea (OSA; hypoxia, systemic and pulmonary hypertension, nocturnal arrhythmias) and metabolic syndrome (MetS; increased abdominal girth, hypertriglyceridemia, decreased high-density lipoprotein, hypertension, increased fasting glucose), which places the surgical patient at heightened risk of perioperative complications (myocardial infarction, stroke, pneumonia, wound infection). Materials and Methods: Electronic medical records of 296 male veterans were assessed for the presence of SZ using the American Academy of Sleep Medicine definition of OSA and a modified Adult Treatment Panel III definition of MetS, where obesity was defined by a body mass index of at least 30 kg/m2 rather than by waist circumference. Results: SZ was diagnosed in 59% of patients. These individuals commonly exhibited severe OSA and least commonly mild OSA. The more severe the OSA, the more likely (60%) that patients manifested moderate (4 risk markers) or severe (5 risk markers) MetS. Furthermore, with increasing apnea-hypopnea index values, the more severe were the MetS elements. Conclusions: The results of this study demonstrate the high prevalence rate of MetS in patients with OSA seeking treatment. Given the risk of perioperative complications, it is suggested that all patients scheduled for maxillofacial surgical procedures to treat OSA be evaluated for SZ. This is a US government work. There are no restrictions on its use. Published by Elsevier Inc on behalf of the American Association of Oral and Maxillofacial Surgeons. J Oral Maxillofac Surg 70:179-187, 2012 C1 [Tanner, Jeffrey M.] VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Sect, Dent Serv, Los Angeles, CA USA. [Chang, Tina I.] VA Greater Los Angeles Healthcare Syst, Staff Oral & Maxillofacial Surg, Los Angeles, CA USA. [Chang, Tina I.; Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Harada, Nancy D.; Santiago, Silverio M.; Weinreb, Jane E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Weinreb, Jane E.] Cedar Sinai Med Ctr, Los Angeles, CA USA. [Weinreb, Jane E.] VA Greater Los Angeles Healthcare Syst, Diabet Program, Los Angeles, CA USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA. RP Friedlander, AH (reprint author), VA Med Ctr, 11301 Wilshire Blvd B218,Rm 210A, Los Angeles, CA 90073 USA. EM arthur.friedlander@med.va.gov NR 84 TC 1 Z9 2 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JAN PY 2012 VL 70 IS 1 BP 179 EP 187 DI 10.1016/j.joms.2011.01.012 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 877WX UT WOS:000299214500046 PM 21601341 ER PT J AU Loboprabhu, S Molinari, V AF Loboprabhu, Sheila Molinari, Victor TI Severe Loneliness in Community-Dwelling Aging Adults with Mental Illness SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Article DE loneliness; attachment; aging; community; depression ID SOCIAL-ISOLATION; OLDER-PEOPLE; LATER LIFE; SUICIDE; PERSPECTIVES AB Successful aging involves adapting to changing needs. The 2009 U.S. Census noted that 43% of adult Americans are single and that the oldest-old population is the most rapidly growing aging segment. Geriatric, lonely, hopeless individuals are at high risk for depression and suicide. Lonely individuals fail to adapt to their circumstances; and physical and mental illness place them at risk for neglect, morbidity, and mortality. The authors discuss the role of attachment in the individual's subjective experience of loneliness and suggest how attachment theory can be used to guide interventions to improve the individual's self-esteem, coping, and problem-solving abilities. This article also discusses the use of multimodal therapy, including psychodynamic, interpersonal, and cognitive-behavior therapy and coping skills training, to improve the individual's ability to adapt to the surrounding environment and to reintegrate into the community. (Journal of Psychiatric Practice 2012;18:20-28) C1 [Loboprabhu, Sheila] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. [Loboprabhu, Sheila] S Cent MIRECC, Houston, TX USA. [Loboprabhu, Sheila] Baylor Coll Med, Houston, TX 77030 USA. [Molinari, Victor] Univ S Florida, Tampa, FL USA. RP Loboprabhu, S (reprint author), Michael E DeBakey Dept Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM SheilaM.Loboprabhu@va.gov NR 45 TC 1 Z9 1 U1 3 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1527-4160 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD JAN PY 2012 VL 18 IS 1 BP 20 EP 28 DI 10.1097/01.pra.0000410984.15852.59 PG 9 WC Psychiatry SC Psychiatry GA 883XP UT WOS:000299668500004 PM 22261980 ER PT J AU Cirnigliaro, CM Lesser, M Moyer, J Kirshblum, SC Bauman, WA Spungen, AM AF Cirnigliaro, Christopher M. Lesser, Marvin Moyer, Jeremy Kirshblum, Steven C. Bauman, William A. Spungen, Ann M. TI Reproducibility and effect of posture on impulse oscillation parameters in persons with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injuries; Paraplegia; Tetraplegia; Forced oscillation technique; Airway dynamics; Respiratory resistance; Airway obstruction; Spirometry; Plethysmography ID RESPIRATORY IMPEDANCE; FORCED OSCILLATION; LUNG; RESISTANCE; MECHANICS; PLETHYSMOGRAPHY; OSCILLOMETRY; QUADRIPLEGIA; SPIROMETRY; OBESITY AB Background: The impulse oscillation system (IOS) offers significant value in the assessment of airway dynamics in persons with spinal cord injury (SCI) because of minimal patient effort but measurement reproducibility in SCI is unknown. Objective: To evaluate between-day reproducibility and the effect of posture on airway resistance [respiratory resistances at 5 Hz (R5) and 20 Hz (R20)] in subjects with tetraplegia, paraplegia and able-bodied controls. Methods: Ten subjects with tetraplegia, 10 subjects with paraplegia and 11 able-bodied individuals were evaluated using IOS. Three 30 second trials were obtained in each while in the seated and supine position on Day 1, and repeated on Day 2. Results: The within-day coefficient of variation (CV%) for R5 and R20 were comparable in the 3 study groups in the seated and supine positions. Compared to controls, the between-day CV% for the combined data was higher in subjects with tetraplegia and paraplegia for R5 seated, and was higher in subjects with tetraplegia for R5 supine. Conclusions: IOS has applicability to the study of within-day respiratory resistance in SCI. However, performing longer-term studies in subjects with tetraplegia and paraplegia may be problematic because of the greater variability for R5 when compared to able-bodied individuals. C1 [Cirnigliaro, Christopher M.; Kirshblum, Steven C.] VA Ctr Excellence Med Consequences SCI, Kessler Inst Rehabil, W Orange, NJ 07052 USA. [Cirnigliaro, Christopher M.; Lesser, Marvin; Moyer, Jeremy; Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY USA. [Lesser, Marvin; Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Med & Spinal Cord Injury Serv, Bronx, NY USA. [Lesser, Marvin; Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Lesser, Marvin; Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Kirshblum, Steven C.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP Cirnigliaro, CM (reprint author), VA Ctr Excellence Med Consequences SCI, Kessler Inst Rehabil, Room L052m,1199 Pleasant Valley Way, W Orange, NJ 07052 USA. EM christopher.cirnigliaro@va.gov FU James J. Peters Medical Center, Bronx, NY; Department of Veterans Affairs Rehabilitation Research and Development Service; Kessler Institute for Rehabilitation; United Spinal Association [208] FX The authors thank The James J. Peters Medical Center, Bronx, NY, The Department of Veterans Affairs Rehabilitation Research and Development Service, and Kessler Institute for Rehabilitation for their support. This work was funded by a clinical SCI Grant (#208) from United Spinal Association. NR 25 TC 0 Z9 0 U1 0 U2 1 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD JAN PY 2012 VL 35 IS 1 BP 28 EP 34 DI 10.1179/2045772311Y.0000000047 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 879PX UT WOS:000299345200005 PM 22330188 ER PT J AU Konrad-Martin, D Dille, MF McMillan, G Griest, S McDermott, D Fausti, SA Austin, DF AF Konrad-Martin, Dawn Dille, Marilyn F. McMillan, Garnett Griest, Susan McDermott, Daniel Fausti, Stephen A. Austin, Donald F. TI Age-Related Changes in the Auditory Brainstem Response SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE Aging; auditory brainstem response; auditory nerve; hearing loss; veterans ID DIABETES-RELATED CHANGES; WAVE-V LATENCY; EVOKED-POTENTIALS; HEARING-LOSS; NERVE ACTIVITY; SEX; CARBOPLATIN; MODEL; ABR; THRESHOLDS AB Purpose: This cross-sectional study had two goals: (1) Identify and quantify the effects of aging on the auditory brainstem response (ABR); (2) Describe how click rate and hearing impairment modify effects of aging. Research Design and Analysis: ABR measures were obtained from 131 predominately male Veteran participants aged 26 to 71 yr. Metrics analyzed include amplitude and latency for waves I, Ill, and V, and the I V interpeak latency interval (IPI) at three repetition rates (11, 51, and 71 clicks/sec) using both polarities. In order to avoid confounding from missing data due to hearing impairment, participants had hearing thresholds <40 dB HL at 2 kHz and 70 dB HL at 4 kHz in at least one ear. Additionally, the median 2, 3, and 4 kHz pure tone threshold average (PTA(2,3,4)) for the sample, similar to 17 dB HL, was used to delineate subgroups of better and worse hearing ears, and only the better hearing sample was modeled statistically. We modeled ABR responses using age, repetition rate, and PTA(2,3,4) as covariates. Random effects were used to model correlation between the two ears of a subject and across repetition rates. Inferences regarding effects of aging on ABR measures at each rate were derived from the fitted model. Results were compared to data from subjects with poorer hearing. Results: Aging substantially diminished amplitudes of all of the principal ABR peaks, largely independent of any threshold differences within the group. For waves I and III, age-related amplitude decrements were greatest at a low (11/sec) click rate. At the 11/sec rate, the model-based mean wave III amplitude was significantly smaller in older compared with younger subjects even after adjusting for wave I amplitude. Aging also increased ABR peak latencies, with significant shifts limited to early waves. The I-V IPI did not change with age. For both younger and older subjects, increasing click presentation rate significantly decreased amplitudes of early peaks and prolonged latencies of later peaks, resulting in increased IPIs. Advanced age did not enhance effects of rate. Instead, the rate effect on wave I and III amplitudes was attenuated for the older subjects due to reduced peak amplitudes at lower click rates. Compared with model predictions from the sample of better hearing subjects, mean ABR amplitudes were diminished in the group with poorer hearing, and wave V latencies were prolonged. Conclusions: In a sample of veterans, aging substantially reduced amplitudes of all principal ABR peaks, with significant latency shifts limited to waves 1 and III. Aging did not influence the I V IPI even at high click rates, suggesting that the observed absolute latency changes associated with aging can be attributed to changes in auditory nerve input. In contrast, ABR amplitude changes with age are not adequately explained by changes in wave I. Results suggest that aging reduces the numbers and/or synchrony of contributing auditory nerve units. Results also support the concept that aging reduces the numbers, though perhaps not the synchrony, of central ABR generators. C1 [Konrad-Martin, Dawn; Dille, Marilyn F.; McMillan, Garnett; Griest, Susan; McDermott, Daniel; Fausti, Stephen A.; Austin, Donald F.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Konrad-Martin, Dawn; Griest, Susan] Oregon Hlth & Sci Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Austin, Donald F.] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. RP Konrad-Martin, D (reprint author), NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM dawn.martin@va.gov FU National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders (NIDCD) [R03 DC008203]; Office of Rehabilitation Research and Development Service (RR&D), Department of Veterans Affairs [C4447K, C3446R] FX This work was supported by grants from the National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders (NIDCD) (Grant R03 DC008203 awarded to the first author), and the Office of Rehabilitation Research and Development Service (RR&D), Department of Veterans Affairs (grant C4447K awarded to the first author and C3446R awarded to the last author for the parent study on diabetes mellitus). NR 42 TC 30 Z9 35 U1 0 U2 21 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD JAN PY 2012 VL 23 IS 1 BP 18 EP 35 DI 10.3766/jaaa.23.1.3 PG 18 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 883QV UT WOS:000299649700003 PM 22284838 ER PT J AU Jones, EG El-Zawahry, AM AF Jones, Elizabeth Geiger El-Zawahry, Ahmed M. TI Curative Treatment Without Surgical ReconstructionaAftr Perineal Debridement of Fournier's Gangrene SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Article ID HYPERBARIC-OXYGEN; MANAGEMENT; THERAPY AB BACKGROUND: Fournier's gangrene (necrotizing fasciitis) is an acute life-threatening disease of the perineal area that requires urgent medical intervention. Once the affected area is surgically debrided and the patient is stabilized, surgical management typically involves 1 or more additional procedures that may include split-thickness skin grafts, flaps, or an elective diverting urostomy and/or colostomy. The professional literature discussing nonsurgical approaches to healing for Fournier's gangrene after surgical debridement is sparse. CASE: We present 3 cases of male patients with Fournier's gangrene from our facility who healed uneventfully with negative pressure wound therapy placed after extensive debridement without further surgical intervention. An added benefit was a satisfactory aesthetic effect. CONCLUSION: Expert wound management including negative pressure wound therapy after surgical debridement of Fournier's gangrene eliminated the need for further operative procedures and prolonged hospitalizations in these cases. We believe that surgical teams should consider using negative pressure wound therapy as part of the initial curative plan of care after debridement, and that plans for restorative plastic surgery should be restricted to patients who do not exhibit adequate improvement with conservative wound management. C1 [El-Zawahry, Ahmed M.] Med Univ S Carolina, Charleston, SC USA. [El-Zawahry, Ahmed M.] Ralph H Johnson VA Med Ctr, Dept Urol, Charleston, SC 29401 USA. EM Gwammyliz@heavi.tv NR 15 TC 2 Z9 2 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1071-5754 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD JAN-FEB PY 2012 VL 39 IS 1 BP 98 EP 102 DI 10.1097/WON.0b013e31823fe212 PG 5 WC Nursing SC Nursing GA 881OY UT WOS:000299497200012 PM 22237647 ER PT J AU Joyce, VR Barnett, PG Chow, A Bayoumi, AM Griffin, SC Sun, HY Holodniy, M Brown, ST Kyriakides, TC Cameron, DW Youle, M Sculpher, M Anis, AH Owens, DK AF Joyce, Vilija R. Barnett, Paul G. Chow, Adam Bayoumi, Ahmed M. Griffin, Susan C. Sun, Huiying Holodniy, Mark Brown, Sheldon T. Kyriakides, Tassos C. Cameron, D. William Youle, Mike Sculpher, Mark Anis, Aslam H. Owens, Douglas K. TI Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV: A Randomized, Controlled Trial SO MEDICAL DECISION MAKING LA English DT Article DE AIDS; HIV; highly active antiretroviral therapy; quality of life; treatment interruption; treatment intensification; randomized trial ID HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 CELL COUNTS; STRUCTURED TREATMENT INTERRUPTIONS; INFECTED PATIENTS; HIV-1-INFECTED PATIENTS; DRUG-RESISTANCE; VIROLOGICAL FAILURE; CUBIC MILLIMETER; UTILITY SCORES; CLINICAL-TRIAL AB Background. The effect of antiretroviral therapy (ART) interruption or intensification on health-related quality of life (HRQoL) in advanced HIV patients is unknown. Objective. To assess the impact of temporary treatment interruption and intensification of ART on HRQoL. Design. A 2 x 2 factorial open label randomized controlled trial. Setting. Hospitals in the United States, Canada, and the United Kingdom. Patients. Multidrug resistant (MDR) HIV patients. Intervention. Patients were randomized to receive a 12-wk interruption or not, and ART intensification or standard ART. Measurements. The Health Utilities Index (HUI3), EQ-5D, standard gamble (SG), time tradeoff (TTO), visual analog scale (VAS), and the Medical Outcomes Study HIV Health Survey (MOS-HIV). Results. There were no significant differences in HRQoL among the four groups during follow-up; however, there was a temporary significant decline in HRQoL on some measures within the interruption group during interruption (HUI3 -0.05, P = 0.03; VAS -5.9, P = 0.002; physical health summary -2.9, P = 0.001; mental health summary -1.9, P = 0.02). Scores declined slightly overall during follow-up. Multivariate analysis showed significantly lower HRQoL associated with some clinical events. Limitations. The results may not apply to HIV patients who have not experienced multiple treatment failures or who have not developed MDR HIV. Conclusions. Temporary ART interruption and ART intensification provided neither superior nor inferior HRQoL compared with no interruption and standard ART. Among surviving patients, HRQoL scores declined only slightly over years of follow-up in this advanced HIV cohort; however, approximately one-third of patients died during the trial follow up. Lower HRQoL was associated with adverse clinical events. C1 [Joyce, Vilija R.; Barnett, Paul G.; Chow, Adam] VA Palo Alto Hlth Care Syst, VA Cooperat Studies Program Coordinating Ctr, VA HSR&D Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA. [Bayoumi, Ahmed M.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Ctr Res Inner City Hlth, Toronto, ON M5B 1W8, Canada. [Bayoumi, Ahmed M.] St Michaels Hosp, Div Gen Internal Med, Toronto, ON M5B 1W8, Canada. [Bayoumi, Ahmed M.] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada. [Bayoumi, Ahmed M.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada. [Griffin, Susan C.; Sculpher, Mark] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England. [Sun, Huiying] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada. [Sun, Huiying; Anis, Aslam H.] Canadian HIV Trials Network, Vancouver, BC, Canada. [Holodniy, Mark; Owens, Douglas K.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA. [Kyriakides, Tassos C.] VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA. [Cameron, D. William] Univ Ottawa, Ottawa Hosp Res Inst, Div Infect Dis, Ottawa, ON, Canada. [Youle, Mike] Royal Free Hosp, London NW3 2QG, England. [Anis, Aslam H.] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada. [Owens, Douglas K.] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. RP Joyce, VR (reprint author), VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA. EM vilija.joyce@va.gov RI Joyce, Vilija/A-2578-2013 OI Joyce, Vilija/0000-0002-2484-4625; Cameron, Bill/0000-0002-0090-3539 FU Ontario HIV Treatment Network, Ontario Ministry of Health; Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; UK Medical Research Council; Canadian Institutes for Health Research; United Kingdom Medical Research Council FX Dr. Cameron is supported by a Career Scientist Award of the Ontario HIV Treatment Network, Ontario Ministry of Health. We thank the investigators and staff at the participating sites. We also thank Dr. Diane Fairclough for her expertise in missing data analysis techniques and longitudinal modeling.; Received 14 July 2010 from the VA Palo Alto Health Care System, VA Cooperative Studies Program Coordinating Center, VA HSR&D Health Economics Resource Center, Menlo Park, California (VRJ, PGB, AC); Centre for Research on Inner City Health, The Keenan Research Centre in the Li Ka Shing Knowledge Institute and Division of General Internal Medicine, St. Michael's Hospital, Toronto, Ontario, Canada and Departments of Medicine and Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada (AMB); Centre for Health Economics, University of York, York, United Kingdom (SCG, MS); Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, British Columbia, Canada (HS); Canadian HIV Trials Network, Vancouver, British Columbia, Canada (HS, AHA); VA Palo Alto Health Care System, Palo Alto, California (MH, DKO); James J. Peters VA Medical Center, Bronx, New York (STB); VA Cooperative Studies Program Coordinating Center, West Haven, Connecticut (TCK); Division of Infectious Diseases, University of Ottawa at the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (DWC); Royal Free Hospital, London, United Kingdom (MY); Department of Health Care and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada (AHA); and Center for Primary Care and Outcomes Research, Stanford University, Stanford, California (DKO). Earlier versions of this work were presented at the Canadian Association for HIV Research Conference, Vancouver, Canada, April 2009 and at the Society for Medical Decision Making Annual Meeting, Los Angeles, California, October 2009. This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Cooperative Studies Program; the UK Medical Research Council; and the Canadian Institutes for Health Research. Options in Management with Antiretrovirals is the initial trial of the newly established trinational program involving the above 3 agencies. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. Primary funding source: Department of Veterans Affairs Cooperative Studies Program, the United Kingdom Medical Research Council, and the Canadian Institutes for Health Research. Trial registration: http://clinicaltrials.gov, No. NCT00050089. Revision accepted for publication 8 December 2010. NR 50 TC 4 Z9 4 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD JAN-FEB PY 2012 VL 32 IS 1 BP 70 EP 82 DI 10.1177/0272989X10397615 PG 13 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 884JN UT WOS:000299701100011 PM 21383086 ER PT J AU Singh, JA Kundukulam, JA Bhandari, M AF Singh, Jasvinder A. Kundukulam, Joseph A. Bhandari, Mohit TI A systematic review of validated methods for identifying orthopedic implant removal and revision using administrative data SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Review DE systematic review; orthopedic implant; implant removal; revision; total hip arthroplasty; arthroplasty ID TOTAL KNEE ARTHROPLASTY; TOTAL HIP-ARTHROPLASTY; STATES MEDICARE POPULATION; TOTAL JOINT ARTHROPLASTY; TOTAL SHOULDER ARTHROPLASTY; TERM COMPLICATION RATES; QUALITY-OF-LIFE; UNITED-STATES; PATIENT OUTCOMES; HOSPITAL VOLUME AB Purpose To identify studies that have validated administrative and claims database algorithms for identifying patients with orthopedic device revision or removal. Methods As a part of the Food and Drug Administration's Mini-Sentinel pilot program, we performed a systematic review to identify algorithms for orthopedic implant removal/ revision in administrative and claims databases in the USA or Canada. Results Five studies examined the validity of database algorithms against a gold standard of documentation in medical records (n = 3) or codes/ documentation in another database (n = 2). The positive predictive values (PPV) of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and/or the Current Procedural Terminology codes for revision total hip arthroplasty (THA) in the US Medicare population compared with medical record review were 92% and 91%, respectively. In another study of the US Medicare population, multiple ICD-9 codes for revision total knee arthroplasty were compared with newly available single ICD-9-CM codes for revision knee arthroplasty; sensitivity was 87% and specificity was 99% (PPV not provided). The fourth study validated the ICD-9-CM codes for revision total knee arthroplasty against Ontario health insurance physician fee service claims as the gold standard and found a PPV of 32%. In the last study in Medicare population, the accuracy of the attribution of revision THA to the same side as the earlier index primary THA was examined; PPV for same laterality of revision THA was 71% (using ICD-9-CM codes). Conclusions Validation data, with regard to the ICD-9-CM or the Current Procedural Terminology code algorithms for revision THA in the Medicare population, exist. More validation studies are needed to confirm these findings and examine other large databases. Copyright c (C) 2012 John Wiley & Sons, Ltd. C1 [Singh, Jasvinder A.; Kundukulam, Joseph A.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. [Bhandari, Mohit] McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada. RP Singh, JA (reprint author), Univ Alabama, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU Allergan; Takeda; Savient; Wyeth; Amgen; URL pharmaceuticals; Novartis; Stryker; Smith; Nephew; Zimmer; Pfizer; DePuy; FDA through the Department of Health and Human Services (HHS) [HHSF223200910006I] FX There are no financial conflicts related to this work. J.A.S. has received speaker honoraria from Abbott; research and travel grants from Allergan, Takeda, Savient, Wyeth, and Amgen; and consultant fees from Savient, URL pharmaceuticals, and Novartis. M.B. has received research funding from Stryker, Smith, and Nephew, Zimmer, Pfizer, Amgen, and DePuy. J.A.K. has no financial relationships.; This work was supported by the FDA through the Department of Health and Human Services (HHS) contract number HHSF223200910006I. The study sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. The views expressed in this document do not necessarily reflect the official policies of the Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the US government. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 61 TC 8 Z9 8 U1 1 U2 7 PU WILEY PERIODICALS, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD JAN PY 2012 VL 21 SU 1 BP 265 EP 273 DI 10.1002/pds.2309 PG 9 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 878JU UT WOS:000299253900031 PM 22262616 ER PT J AU Hoerster, KD Butler, DA Mayer, JA Finlayson, T Gallo, LC AF Hoerster, Katherine D. Butler, Dalila A. Mayer, Joni A. Finlayson, Tracy Gallo, Linda C. TI Use of conventional care and complementary/alternative medicine among US adults with arthritis SO PREVENTIVE MEDICINE LA English DT Article DE Arthritis; Epidemiology; Disparities; Access to care ID ALTERNATIVE MEDICINE; ACTIVITY LIMITATIONS; IMPACT AB Objective: Managing arthritis and co-morbid conditions is of public health importance. It is therefore critical to have a comprehensive understanding of healthcare utilization among US adults with arthritis. Thus, the present study identified characteristics associated with using both complementary and alternative medicine (CAM) and conventional healthcare. Method: Using 2007 National Health Interview Survey data, multinomial logistic regression was performed to compare four categories of past year healthcare use (both CAM and conventional care vs. conventional care only, CAM only, and no healthcare use) on their potential correlates. Results: The sample (n = 3850) was 62.8% female and 80.4% non-Hispanic White. Nearly half were at least 65 years old, and had used both CAM and conventional services in the previous year. The following characteristics were associated with having used neither CAM nor conventional care in the previous year (vs. having used both CAM and conventional care): being from an ethnic and racial minority group (ORs = 2.44. 3.26, and 3.91) and being uninsured (OR = 4.06), identifying individuals potentially at risk for unmet need. Conclusion: To ensure access to comprehensive care, potentially underserved populations should be targeted with outreach (e.g., providing low-cost, accessible care, and education about benefits of various treatments for arthritis and co-morbid conditions). Published by Elsevier Inc. C1 [Hoerster, Katherine D.; Butler, Dalila A.; Mayer, Joni A.; Finlayson, Tracy] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92123 USA. [Hoerster, Katherine D.; Gallo, Linda C.] Univ Calif San Diego, San Diego State Univ, San Diego Joint Doctoral Program Clin Psychol, San Diego, CA 92120 USA. San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA. RP Hoerster, KD (reprint author), VA Puget Sound Healthcare Syst, Seattle Div, 1660 S Columbian Way S-116, Seattle, WA 98108 USA. EM Katherine.Hoerster@va.gov OI Gallo, Linda C./0000-0002-3678-5888 NR 14 TC 6 Z9 6 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD JAN 1 PY 2012 VL 54 IS 1 BP 13 EP 17 DI 10.1016/j.ypmed.2011.08.023 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 881BM UT WOS:000299455500005 PM 21889528 ER PT J AU Khanna, D Maranian, P Rothrock, N Cella, D Gershon, R Khanna, PP Spiegel, B Furst, DE Clements, PJ Bechtel, A Hays, RD AF Khanna, Dinesh Maranian, Paul Rothrock, Nan Cella, David Gershon, Richard Khanna, Puja P. Spiegel, Brennan Furst, Daniel E. Clements, Phil J. Bechtel, Amber Hays, Ron D. TI Feasibility and Construct Validity of PROMIS and "Legacy" Instruments in an Academic Scleroderma Clinic SO VALUE IN HEALTH LA English DT Article DE construct validity; health-related quality of life; systemic sclerosis; PROMIS ID INFORMATION-SYSTEM PROMIS; QUALITY-OF-LIFE; QUESTIONNAIRE-DISABILITY INDEX; MEDICAL OUTCOMES; SCLEROSIS; HEALTH; POPULATION; PREVALENCE; DEPRESSION; ARTHRITIS AB Objective: The National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) roadmap initiative is a cooperative group program of research designed to develop, evaluate, and standardize item banks to measure patient-reported outcomes relevant across medical conditions. The objective of the current study was to assess feasibility and evaluation of the construct validity of PROMIS item banks versus legacy measures in an observational study in systemic sclerosis (SSc). We hypothesized that the PROMIS item banks can be administered in a clinical setting if there is adequate staff support without disrupting the flow of clinic. Methods: Patients with SSc in a single academic center completed computerized adaptive test (CAT) administered PROMIS item banks during the clinic visit and legacy measures (using paper and pencil). The construct validity of PROMIS items was evaluated by examining correlations with corresponding legacy measures using multitrait-multimethod analysis. Results: Participants consisted of 143 SSc patients with an average age of 51.5 years; 71% were female and 68% were white. The average number of items completed for each CAT-administered item bank ranged from 5 to 8 (69 CAT items per patient), and the average time to complete each CAT-administered item bank ranged from 48 seconds to 1.9 minutes per patient (average time similar to 11.9 minutes/ per patient for 11 banks). All correlations between PROMIS domains and respective legacy measures were large and in the hypothesized direction (ranged from 0.61 to 0.82). Conclusion: Our study supports the construct validity of the CAT-administered PROMIS item banks and shows that they can be administered successfully in a clinic with support staff. Future studies should assess the feasibility of PROMIS item banks in a busy clinical practice. C1 [Khanna, Dinesh] Univ Michigan, Scleroderma Program, Div Rheumatol, Dept Internal Med, Ann Arbor, MI 48106 USA. [Maranian, Paul; Furst, Daniel E.; Clements, Phil J.; Bechtel, Amber] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA. [Rothrock, Nan; Cella, David; Gershon, Richard] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA. [Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Hays, Ron D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Hays, Ron D.] RAND, Los Angeles, CA USA. RP Khanna, D (reprint author), Univ Michigan, Scleroderma Program, Div Rheumatol, Dept Internal Med, 24 Frank Lloyd Wright Dr,Lobby M,Suite 2500,SPC 5, Ann Arbor, MI 48106 USA. EM khannad@med.umich.edu RI Hays, Ronald/D-5629-2013 FU National Institutes of Health (NIH/ NIAMS) [U01 AR057936A]; National Institutes of Health through NIH [AR052177]; NIAMS [K23 AR053858-05]; Scleroderma Foundation; National Institutes of Health [T32 AR 053463]; UCLA Resource Center for Minority Aging Research/Center for Health Improvement in Minority Elderly (RCMAR/CHIME); NIH/NIA [P30AG021684]; UCLA/ Drew, EXPORT, NCMHD [2P20MD000182] FX D. Khanna, Maranian, Rothrock, Cella, Gershon, Furst, PP Khanna, Spiegel, Bechtel and Hays were supported by a National Institutes of Health Award (NIH/ NIAMS U01 AR057936A), and the National Institutes of Health through the NIH Roadmap for Medical Research Grant (AR052177). D. Khanna is also supported by NIAMS K23 AR053858-05 and the Scleroderma Foundation (New Investigator Award). Dr. PP Khanna was also supported by National Institutes of Health Award (T32 AR 053463). Hays was also supported by the UCLA Resource Center for Minority Aging Research/Center for Health Improvement in Minority Elderly (RCMAR/CHIME), NIH/NIA Grant Award Number P30AG021684, and the UCLA/ Drew Project EXPORT, NCMHD, 2P20MD000182. NR 37 TC 20 Z9 20 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD JAN-FEB PY 2012 VL 15 IS 1 BP 128 EP 134 DI 10.1016/j.jval.2011.08.006 PG 7 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 879GU UT WOS:000299318500015 PM 22264980 ER PT J AU Xu, S Shetterly, S Powers, D Raebel, MA Tsai, TT Ho, PM Magid, D AF Xu, Stanley Shetterly, Susan Powers, David Raebel, Marsha A. Tsai, Thomas T. Ho, P. Michael Magid, David TI Extension of Kaplan-Meier Methods in Observational Studies with Time-Varying Treatment SO VALUE IN HEALTH LA English DT Article DE Kaplan Meier estimates; Observational study; Stabilized weights; Stents; Time-varying treatment ID MARGINAL STRUCTURAL MODELS; PROPENSITY SCORE; INVERSE PROBABILITY; ANTIRETROVIRAL THERAPY; SURVIVAL; EPIDEMIOLOGY; ZIDOVUDINE; MORTALITY; WEIGHTS; SAMPLES AB Objectives: Inverse probability of treatment weighted Kaplan-Meier estimates have been developed to compare two treatments in the presence of confounders in observational studies. Recently, stabilized weights were developed to reduce the influence of extreme inverse probability of treatment-weighted weights in estimating treatment effects. The objective of this research was to use adjusted Kaplan-Meier estimates and modified log-rank and Wilcoxon tests to examine the effect of a treatment that varies over time in an observational study. Methods: We proposed stabilized weight adjusted Kaplan-Meier estimates and modified log-rank and Wilcoxon tests when the treatment was time-varying over the follow-up period. We applied these new methods in examining the effect of an anti-platelet agent, clopidogrel, on subsequent events, including bleeding, myocardial infarction, and death after a drug-eluting stent was implanted into a coronary artery. In this population, clopidogrel use may change over time based on a patient's behavior (e. g., nonadherence) and physicians' recommendations (e. g., end of duration of therapy). Consequently, clopidogrel use was treated as a time-varying variable. Results: We demonstrate that 1) the sample sizes at three chosen time points are almost identical in the original and weighted datasets; and 2) the covariates between patients on and off clopidogrel were well balanced after stabilized weights were applied to the original samples. Conclusions: The stabilized weight-adjusted Kaplan-Meier estimates and modified log-rank and Wilcoxon tests are useful in presenting and comparing survival functions for time-varying treatments in observational studies while adjusting for known confounders. C1 [Xu, Stanley; Shetterly, Susan; Powers, David; Raebel, Marsha A.; Tsai, Thomas T.; Ho, P. Michael; Magid, David] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80111 USA. [Xu, Stanley; Raebel, Marsha A.; Tsai, Thomas T.; Ho, P. Michael; Magid, David] Univ Colorado, Denver, CO 80202 USA. [Tsai, Thomas T.; Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA. RP Xu, S (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, 10065 E Harvard Ave, Denver, CO 80111 USA. EM stan.xu@kp.org FU Strategic Initiatives Funds of Kaiser Permanente Colorado; NIH/NCRR Colorado CTSI [TL1 RR025780]; Agency for Healthcare Research and Quality [290-05-0033]; US Department of Health and Human Services FX This project was supported by Strategic Initiatives Funds of Kaiser Permanente Colorado, supported by NIH/NCRR Colorado CTSI grant No. TL1 RR025780, and funded under Contract No. 290-05-0033 from the Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of the Developing Evidence to Inform Decisions about Effectiveness 16 program. NR 28 TC 8 Z9 9 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD JAN-FEB PY 2012 VL 15 IS 1 BP 167 EP 174 DI 10.1016/j.jval.2011.07.010 PG 8 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 879GU UT WOS:000299318500020 PM 22264985 ER PT J AU Haisley, E Volpp, KG Pellathy, T Loewenstein, G AF Haisley, Emily Volpp, Kevin G. Pellathy, Thomas Loewenstein, George TI The Impact of Alternative Incentive Schemes on Completion of Health Risk Assessments SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Behavioral Economics; Corporate Wellness Programs; Health Incentives; Health Risk Assessments; Preventive Health Care; Prevention Research ID RANDOMIZED-TRIAL; PROMOTION; LIFE AB Purpose. The biggest challenge for corporate wellness initiatives is low rates of employee participation. We test whether a behavioral economic approach to incentive design (i.e., a lottery) is more effective than a direct economic payment of equivalent monetary value (i.e., a grocery gift certificate) in encouraging employees to complete health risk assessments (HRAs). Design. Employees were assigned to one of three arms. Assignment to a treatment arm versus the nontreatment arm was determined by management. Assignment to an arm among those eligible for treatment was randomized by office. Setting. A large health care management and information technology consulting company. Patients. A total of 1299 employees across 14 offices participated. Intervention. All employees were eligible to receive $25 for completing the HRA. Those in the lottery condition were assigned to teams of four to eight people and, conditional on HRA completion, were entered into a lottery with a prize of $100 (expected value, $25) and a bonus value of an additional $25 if 80% of team members participated. Those in the grocery gift certificate condition who completed an HRA received a $25 grocery gift certificate. Those in the comparison condition received no additional incentive. Measures. HRA completion rates. Analysis. Logistic regression analysis. Results. HRA completion rates were significantly higher among participations in the lottery incentive condition (64%) than in both the grocery gift certificate condition (44%) and the comparison condition (40%). Effects were larger for lower-income employees, as indicated by a significant interaction between income and the lottery incentive. Conclusion. Lottery incentives that incorporate regret aversion and social pressure can provide higher impact for the same amount of money as simple economic incentives. (Am J Health Promot 2012;26131:184-188.) C1 [Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. [Haisley, Emily] Barclays Wealth, Behav Finance Grp, London, England. [Volpp, Kevin G.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr,Wharton Sch, Dept Med,Sch Med,Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Pellathy, Thomas] McKinsey & Co Inc, Pittsburgh, PA USA. RP Loewenstein, G (reprint author), Carnegie Mellon Univ, Dept Social & Decis Sci, 5000 Forbes Ave, Pittsburgh, PA 15213 USA. EM g120@andrew.cmu.edu NR 12 TC 24 Z9 24 U1 1 U2 19 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD JAN-FEB PY 2012 VL 26 IS 3 BP 184 EP 188 DI 10.4278/ajhp.100729-ARB-257 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 880ZE UT WOS:000299448300010 PM 22208418 ER PT J AU DiMartini, A Cruz, RJ Dew, MA Fitzgerald, MG Chiappetta, L Myaskovsky, L DeVera, ME AF DiMartini, A. Cruz, R. J., Jr. Dew, M. A. Fitzgerald, M. G. Chiappetta, L. Myaskovsky, L. DeVera, M. E. TI Motives and Decision Making of Potential Living Liver Donors: Comparisons Between Gender, Relationships and Ambivalence SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Donor screening; living liver donors; psychological characteristics of donors ID BONE-MARROW DONORS; DONATION; OUTCOMES; TRANSPLANTATION AB The motives and decision making of potential living liver donors are critical areas for transplant clinicians evaluating these candidates to understand, yet these topics remain relatively unstudied. Thus, we surveyed 77 prospective living liver donors at the point of donation evaluation using structured instruments to gather more information on their approach to and concerns about donation. We collected information on donation decision making, motives for donation and anticipated social and physical concerns about postdonation outcomes. We examined three additional characteristics of donors: gender, the relationship of the donor to the intended recipient and the presence of ambivalence about donation. Women had more concerns about their family/social responsibilities. Those donating to nonimmediate family were more likely to have been asked to donate but less likely to feel they had to donate. However, ambivalent donors were the most distinct having difficulties and concerns across most areas from their motivations for donating, to deciding to be tested and to donate, to concerns about the postdonation outcomes. We discuss the clinical relevance of these findings to donor evaluation and preparation. C1 [DiMartini, A.; Dew, M. A.; Fitzgerald, M. G.; Chiappetta, L.; Myaskovsky, L.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA. [DiMartini, A.; Cruz, R. J., Jr.; DeVera, M. E.] Univ Pittsburgh, Med Ctr, Dept Transplantat Surg, Pittsburgh, PA USA. [DiMartini, A.; Cruz, R. J., Jr.; Fitzgerald, M. G.; DeVera, M. E.] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA. [Dew, M. A.] Univ Pittsburgh, Dept Psychol, Med Ctr, Pittsburgh, PA 15260 USA. [Dew, M. A.] Univ Pittsburgh, Dept Epidemiol, Med Ctr, Pittsburgh, PA 15261 USA. [Myaskovsky, L.] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA. [Myaskovsky, L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP DiMartini, A (reprint author), Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA. EM dimartiniaf@upmc.edu FU Starzl Transplant Institute; International Transplant Nurses Society FX This research is funded by grants from the Starzl Transplant Institute Junior Investigator Award (Cruz) and an International Transplant Nurses Society research program grant. NR 22 TC 14 Z9 14 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JAN PY 2012 VL 12 IS 1 BP 136 EP 151 DI 10.1111/j.1600-6143.2011.03805.x PG 16 WC Surgery; Transplantation SC Surgery; Transplantation GA 875XU UT WOS:000299069300018 PM 22081865 ER PT J AU Arling, G Reeves, M Ross, J Williams, LS Keyhani, S Chumbler, N Phipps, MS Roumie, C Myers, LJ Salanitro, AH Ordin, DL Myers, J Bravata, DM AF Arling, Greg Reeves, Mathew Ross, Joseph Williams, Linda S. Keyhani, Salomeh Chumbler, Neale Phipps, Michael S. Roumie, Christianne Myers, Laura J. Salanitro, Amanda H. Ordin, Diana L. Myers, Jennifer Bravata, Dawn M. TI Estimating and Reporting on the Quality of Inpatient Stroke Care by Veterans Health Administration Medical Centers SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE acute stroke; performance measurement; quality indicators; stroke management; statistics ID ACUTE ISCHEMIC-STROKE; PLASMINOGEN-ACTIVATOR; PERFORMANCE-MEASURES; OF-CARE; OUTCOMES; MORTALITY; MODELS; IMPACT; INTERVENTION; IMPROVEMENT AB Background-Reporting of quality indicators (QIs) in Veterans Health Administration Medical Centers is complicated by estimation error caused by small numbers of eligible patients per facility. We applied multilevel modeling and empirical Bayes (EB) estimation in addressing this issue in performance reporting of stroke care quality in the Medical Centers. Methods and Results-We studied a retrospective cohort of 3812 veterans admitted to 106 Medical Centers with ischemic stroke during fiscal year 2007. The median number of study patients per facility was 34 (range, 12-105). Inpatient stroke care quality was measured with 13 evidence-based QIs. Eligible patients could either pass or fail each indicator. Multilevel modeling of a patient's pass/fail on individual QIs was used to produce facility-level EB-estimated QI pass rates and confidence intervals. The EB estimation reduced interfacility variation in QI rates. Small facilities and those with exceptionally high or low rates were most affected. We recommended 8 of the 13 QIs for performance reporting: dysphagia screening, National Institutes of Health Stroke Scale documentation, early ambulation, fall risk assessment, pressure ulcer risk assessment, Functional Independence Measure documentation, lipid management, and deep vein thrombosis prophylaxis. These QIs displayed sufficient variation across facilities, had room for improvement, and identified sites with performance that was significantly above or below the population average. The remaining 5 QIs were not recommended because of too few eligible patients or high pass rates with little variation. Conclusions-Considerations of statistical uncertainty should inform the choice of QIs and their application to performance reporting. (Circ Cardiovasc Qual Outcomes. 2012;5:44-51.) C1 [Arling, Greg; Williams, Linda S.; Chumbler, Neale; Bravata, Dawn M.] Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA. [Arling, Greg; Reeves, Mathew; Williams, Linda S.; Chumbler, Neale; Myers, Laura J.; Ordin, Diana L.; Myers, Jennifer; Bravata, Dawn M.] Stroke Qual Enhancement Res Initiat QUERI, VHA Hlth Serv Res & Dev HSR& D, Indianapolis, IN USA. [Ordin, Diana L.] VHA, Off Informat & Analyt, Washington, DC USA. [Arling, Greg; Myers, Laura J.; Bravata, Dawn M.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA. [Reeves, Mathew] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA. [Ross, Joseph] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA. [Ross, Joseph] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Williams, Linda S.; Chumbler, Neale; Myers, Laura J.; Myers, Jennifer; Bravata, Dawn M.] Richard L Roudebush VHA Med Ctr, VHA HSR&D Ctr Excellence Implementing Evidence Ba, Indianapolis, IN USA. [Williams, Linda S.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA. [Keyhani, Salomeh] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Keyhani, Salomeh] San Francisco VA Med Ctr, HSR&D Res Enhancement Award Program, San Francisco, CA USA. [Chumbler, Neale] Indiana Univ Purdue Univ, Indiana Univ, Sch Liberal Arts, Dept Sociol, Indianapolis, IN 46202 USA. [Phipps, Michael S.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA. [Phipps, Michael S.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. [Roumie, Christianne] Vet Affairs Tennessee Valley Healthcare Syst, HSR&D Targeted Res Enhancement Program Ctr, GRECC, Nashville, TN USA. [Roumie, Christianne] Vet Affairs Tennessee Valley Healthcare Syst, Clin Res Training Ctr Excellence, Nashville, TN USA. [Roumie, Christianne; Salanitro, Amanda H.] Vanderbilt Univ, Med Ctr, Inst Med & Publ Hlth, Nashville, TN USA. [Salanitro, Amanda H.] Vanderbilt Univ, Med Ctr, Sect Hosp Med, Nashville, TN USA. RP Arling, G (reprint author), Regenstrief Inst Hlth Care, 410 W 10th St,Suite 2000, Indianapolis, IN 46202 USA. EM GArling@IUPUI.edu OI Phipps, Michael/0000-0001-8398-5404 FU Department of Veterans Affairs, Veterans Health Administration (VHA), Office of Quality and Performance and Health Services Research, and Development Service Quality Enhancement Research Initiative [RRP 09-184]; National Institute on Aging; American Federation of Aging Research [K08 AG032886]; VA HSRD FX The Department of Veterans Affairs, Veterans Health Administration (VHA), Office of Quality and Performance and Health Services Research, and Development Service Quality Enhancement Research Initiative (RRP 09-184) supported this project. Dr Ross is supported by the National Institute on Aging and by the American Federation of Aging Research through the Paul B. Beason Career Development Award Program (K08 AG032886). Dr Keyhani is supported by a VA HSR&D Career Development Award. NR 42 TC 18 Z9 19 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JAN PY 2012 VL 5 IS 1 BP 44 EP U102 DI 10.1161/CIRCOUTCOMES.111.961474 PG 23 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 880ML UT WOS:000299411100009 PM 22147888 ER PT J AU Brennan, JM Peterson, ED Messenger, JC Rumsfeld, JS Weintraub, WS Anstrom, KJ Eisenstein, EL Milford-Beland, S Grau-Sepulveda, MV Booth, ME Dokholyan, RS Douglas, PS AF Brennan, J. Matthew Peterson, Eric D. Messenger, John C. Rumsfeld, John S. Weintraub, William S. Anstrom, Kevin J. Eisenstein, Eric L. Milford-Beland, Sarah Grau-Sepulveda, Maria V. Booth, Michael E. Dokholyan, Rachel S. Douglas, Pamela S. CA Duke Clinical Res Inst DEcIDE Team TI Linking the National Cardiovascular Data Registry CathPCI Registry With Medicare Claims Data Validation of a Longitudinal Cohort of Elderly Patients Undergoing Cardiac Catheterization SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE catheterization; data linkage; outcomes AB Background-The National Cardiovascular Data Registry CathPCI Registry was recently linked with longitudinal Centers for Medicare & Medicaid (CMS) claims data. The degree to which this linked cohort is representative of the overall CathPCI Registry and CMS PCI populations is unknown. Methods and Results-CathPCI Registry records were linked to CMS inpatient claims using indirect identifiers. We examined the degree to which hospitals and patients in the linked cohort are representative of the elderly (>= 65 years) CathPCI Registry and CMS populations. From 2004 to 2006, 1492 hospitals filed CMS PCI claims and 663 contributed CathPCI Registry data. Of these hospitals, 643 (97%) were linked across data sources. Compared with all CMS PCI hospitals, the linked data set contained fewer governmental, northeastern, southern, and low-volume (<200 beds) sites. Among CMS beneficiaries, 993 351 PCI procedures were performed, including 398 508 (40.1%) at centers in the linked database. Of these, 341 916 (86%) were linked to CathPCI Registry records. Linked and unlinked CMS patients had similar demographic and clinical features. In the CathPCI Registry database, 477 456 elderly patients underwent PCI, with 359 077 (75%) linked to CMS claims. Linked and unlinked National Cardiovascular Data Registry patients were similar, except for less commercial or health maintenance organization insurance in the linked cohort. Conclusions-By using deterministic matching strategies, a large and representative cohort with detailed clinical data from the CathPCI Registry and longitudinal follow-up from CMS claims has been created. (Circ Cardiovasc Qual Outcomes. 2012;5:134-140.) C1 [Brennan, J. Matthew; Peterson, Eric D.; Eisenstein, Eric L.; Milford-Beland, Sarah; Grau-Sepulveda, Maria V.; Booth, Michael E.; Dokholyan, Rachel S.; Douglas, Pamela S.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC 27705 USA. [Messenger, John C.; Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. RP Brennan, JM (reprint author), Duke Univ, Duke Clin Res Inst, Med Ctr, 2400 Pratt St, Durham, NC 27705 USA. EM brenn009@mc.duke.edu FU Agency for Healthcare Research and Quality, US Department of Health and Human Services, Rockville, MD [24-EHC-1, HHSAA290-2005, 0032-TO4-WA2]; National Cardiovascular Data Registry, American College of Cardiology, Washington, DC; BMS/Sanofi; Merck; Lilly; JJ; Society of Thoracic Surgeons; ACC; Alexion; AstraZeneca; Bristol Myers Squibb; Innocoll Pharmaceuticals; Medtronic; Pfizer; Proctor Gamble; Eli Lilly FX This project was sponsored by the Agency for Healthcare Research and Quality, US Department of Health and Human Services, Rockville, MD, as part of the Cardiovascular Consortium and funded under Project ID: 24-EHC-1 and Work Assignment No. HHSAA290-2005 to 0032-TO4-WA2 as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. Additional support was obtained from the National Cardiovascular Data Registry, American College of Cardiology, Washington, DC.; Dr Peterson reports receiving research funding from BMS/Sanofi, Merck, Lilly, J&J, Society of Thoracic Surgeons, and ACC (significant). Dr Messenger reports serving as the site principal investigator for the Resolute Study and the EDUCATE study: Medtronic, Inc (modest). Dr Rumsfeld is the Chief Science Officer for National Cardiovascular Data Registry. Dr Anstrom reports receiving research and salary support from Alexion, AstraZeneca, Bristol Myers Squibb, Lilly, Innocoll Pharmaceuticals, Medtronic, Pfizer, and Proctor & Gamble (modest); being on the data safety monitoring boards of Pfizer and Vertex (modest); and providing consulting services to Pacific Therapeutics, Bristol Myers Squibb, and AstraZeneca (modest). Dr Eisenstein reports receiving research funding from Medtronic and Eli Lilly (significant). NR 6 TC 26 Z9 26 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JAN PY 2012 VL 5 IS 1 BP 134 EP 140 DI 10.1161/CIRCOUTCOMES.111.963280 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 880ML UT WOS:000299411100020 PM 22253370 ER PT J AU DeFronzo, RA Davidson, JA Del Prato, S AF DeFronzo, R. A. Davidson, J. A. Del Prato, S. TI The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia SO DIABETES OBESITY & METABOLISM LA English DT Review DE clinical trials; diabetes; glucose homeostasis; glycosuria; hyperglycaemia; kidneys; renal glucose transport; SGLT2; SGLT2 inhibitors; sodium-glucose cotransporters ID TYPE-2 DIABETES-MELLITUS; SELECTIVE SGLT2 INHIBITOR; JAPANESE HEALTHY-VOLUNTEERS; RENAL PROXIMAL TUBULES; BETA-CELL DYSFUNCTION; FREE FATTY-ACIDS; INSULIN-RESISTANCE; BLOOD-GLUCOSE; DOUBLE-BLIND; BODY-WEIGHT AB The maintenance of normal glucose homeostasis requires a complex, highly integrated interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system. Recent studies have showed that the kidneys also play a central role in glucose homeostasis by reabsorbing all the filtered glucose, an adaptive mechanism that ensures sufficient energy is available during fasting periods. This mechanism becomes maladaptive in diabetes, however, as hyperglycaemia augments the expression and activity of the sodiumglucose cotransporter (SGLT) 2 in the proximal tubule of the kidney. As a result, glucose reabsorption may be increased by as much as 20% in individuals with poorly controlled diabetes. SGLT2 is a low-affinity, high-capacity glucose transport protein that reabsorbs 90% of filtered glucose, while the high-affinity, low-capacity SGLT1 transporter reabsorbs the remaining 10%. SGLT2 represents a novel target for the treatment of diabetes. In animal studies, SGLT2 inhibition reduces plasma glucose levels, resulting in improved beta-cell function and enhanced insulin sensitivity in liver and muscle. Human studies have confirmed the efficacy of SLGT2 inhibitors in improving glucose control and reducing the A1c. Because the mechanism of SGLT2 inhibition is independent of circulating insulin levels or insulin sensitivity, these agents can be combined with all other antidiabetic classes, including exogenous insulin. Although the long-term efficacy and safety of SGLT2 inhibitors remain under study, the class represents a novel therapeutic approach with potential for the treatment of both type 2 and 1 diabetes. C1 [DeFronzo, R. A.] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Med, San Antonio, TX 78229 USA. [DeFronzo, R. A.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. [Davidson, J. A.] Univ Texas SW Med Sch, Diabet Div, Dallas, TX USA. [Del Prato, S.] Univ Pisa, Diabet Div, Pisa, Italy. RP DeFronzo, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM albarado@uthscsa.edu; davidsonmd@sbcglobal.net RI Del Prato, Stefano/K-3405-2016 OI Del Prato, Stefano/0000-0002-5388-0270 FU AstraZeneca; Bayer Healthcare; Bristol-Myers Squibb; GlaxoSmithKline; Johnson Johnson; Merck Sharp Dohme; Novartis; Novo Nordisk; Pfizer Inc; Sanofi-Aventis FX The authors have drafted this article on behalf of the Worldwide Initiative for Diabetes Education (WorldWIDE). WorldWIDE had no input into writing the initial version of the manuscript or into any revisions of the manuscript. WorldWIDE is a charitable foundation that provides training, education and information to healthcare providers. The mission of WorldWIDE is to challenge and shape the future management of diabetes in order to provide optimal treatment for all patients and to enhance professional education for physicians and other diabetes professionals. Publication of the article would help to achieve this goal. WorldWIDE receives financial support from AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck Sharp &Dohme, Novartis, Novo Nordisk, Pfizer Inc and Sanofi-Aventis. The authors acknowledge the editorial assistance of IntraMed Educational Group in the styling of this manuscript. NR 76 TC 152 Z9 164 U1 6 U2 35 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-8902 EI 1463-1326 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD JAN PY 2012 VL 14 IS 1 BP 5 EP 14 DI 10.1111/j.1463-1326.2011.01511.x PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 862AW UT WOS:000298063200002 PM 21955459 ER PT J AU Henry, RR Aroda, VR Mudaliar, S Garvey, WT Chou, HS Jones, MR AF Henry, R. R. Aroda, V. R. Mudaliar, S. Garvey, W. T. Chou, H. S. Jones, M. R. TI Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus SO DIABETES OBESITY & METABOLISM LA English DT Article DE bile acid sequestrant; colesevelam; glucose; insulin sensitivity; type 2 diabetes mellitus ID GLYCEMIC CONTROL; SECRETION; THERAPY; HYDROCHLORIDE AB Aim: Colesevelam lowers glucose and low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. This study examined the mechanisms by which colesevelam might affect glucose control. Methods: In this 12-week, randomized, double-blind, placebo-controlled study, subjects with type 2 diabetes and haemoglobin A(1c)(HbA(1c)) >= 7.5% on either stable diet and exercise or sulphonylurea therapy were randomized to colesevelam 3.75 g/day (n = 16) or placebo (n = 14). Hepatic/peripheral insulin sensitivity was evaluated at baseline and at week 12 by infusion of (3)H-labelled glucose followed by a 2-step hyperinsulinemic-euglycemic clamp. Two 75-g oral glucose tolerance tests (OGTTs) were conducted at baseline, one with and one without co-administration of colesevelam. A final OGTT was conducted at week 12. HbA(1c) and fasting plasma glucose (FPG) levels were evaluated pre- and post-treatment. Results: Treatment with colesevelam, compared to placebo, had no significant effects on basal endogenous glucose output, response to insulin or on maximal steady-state glucose disposal rate. At baseline, co-administration of colesevelam with oral glucose reduced total area under the glucose curve (AUCg) but not incremental AUCg. At week 12, neither total AUCg nor incremental AUCg were changed from pre-treatment values in either group. Post-load insulin levels increased with colesevelam at 30 and 120 min, but these changes in total area under the insulin curve (AUCi) and incremental AUCi did not differ between groups. Both HbA(1c) and FPG improved with colesevelam, but treatment differences were not significant. Conclusions: Colesevelam does not affect hepatic or peripheral insulin sensitivity and does not directly affect glucose absorption. C1 [Henry, R. R.; Mudaliar, S.] VA San Diego Healthcare Syst, Sect Diabet Endocrinol & Metab, San Diego, CA 92161 USA. [Henry, R. R.; Mudaliar, S.] Univ Calif San Diego, San Diego, CA 92161 USA. [Aroda, V. R.] MedStar Hlth Res Inst, Hyattsville, MD USA. [Garvey, W. T.] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. T.] Birmingham VA Med Ctr, Birmingham, AL USA. [Chou, H. S.] Daiichi Sankyo Prod Dev, Edison, NJ USA. [Jones, M. R.] Daiichi Sankyo Inc, Parsippany, NJ USA. RP Henry, RR (reprint author), VA San Diego Healthcare Syst, Sect Diabet Endocrinol & Metab, 3350 La Jolla Village Dr,111G, San Diego, CA 92161 USA. EM rrhenry@vapop.ucsd.edu FU Daiichi Sankyo Inc.; VA San Diego Healthcare System; Department of Veteran Affairs; Veterans Medical Research Foundation; Diabetes Education and Research Center [DK 063491]; General Clinical Research Center [MO1 RR-00827]; University of Alabama Birmingham from the Center for Clinical and Translational Science [UL1 RR02577]; Diabetes Research and Training Center [P60 DK079626] FX This study was sponsored by Daiichi Sankyo Inc. Editorial assistance was provided by Karen Stauffer, PhD, of inScience Communications, a Wolters Kluwer business. This assistance was performed in compliance with Good Publication Practices outlined by the International Committee of Medical Journal Editors and was funded by Daiichi Sankyo Inc. Support is acknowledged in San Diego from the VA San Diego Healthcare System, Department of Veteran Affairs, Veterans Medical Research Foundation, the Diabetes Education and Research Center DK 063491, and the General Clinical Research Center MO1 RR-00827. Support is acknowledged from the University of Alabama Birmingham from the Center for Clinical and Translational Science (UL1 RR02577) and the Diabetes Research and Training Center (P60 DK079626). NR 13 TC 12 Z9 12 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1462-8902 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD JAN PY 2012 VL 14 IS 1 BP 40 EP 46 DI 10.1111/j.1463-1326.2011.01486.x PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 862AW UT WOS:000298063200006 PM 21831167 ER PT J AU Nicolau, DP Carmeli, Y Crank, CW Goff, DA Graber, CJ Lima, ALL Goldstein, EJC AF Nicolau, David P. Carmeli, Yehuda Crank, Christopher W. Goff, Debra A. Graber, Christopher J. Lima, Ana Lucia L. Goldstein, Ellie J. C. TI Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Review DE Carbapenem; Ecology; Ertapenem; Pseudomonas; Stewardship; Susceptibility ID 25 HOSPITALS; AERUGINOSA; IMIPENEM; THERAPY; IMPACT AB The group 2 carbapenems (imipenem, meropenem and, more recently, doripenem) have been a mainstay of treatment for patients with serious hospital infections caused by Pseudomonas aeruginosa, Enterobacteriaceae and other difficult-to-treat Gram-negative pathogens as well as mixed aerobic/anaerobic infections. When ertapenem, a group 1 carbapenem, was introduced, questions were raised about the potential for ertapenem to select for imipenem-and meropenem-resistant Pseudomonas. Results from ten clinical studies evaluating the effect of ertapenem use on the susceptibility of Pseudomonas to carbapenems have uniformly shown that ertapenem use does not result in decreased Pseudomonas susceptibility to these antipseudomonal carbapenems. Here we review these studies evaluating the evidence of how ertapenem use affects P. aeruginosa as well as provide considerations for ertapenem use in the context of institutional stewardship initiatives. (C) 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. C1 [Nicolau, David P.] Hartford Hosp, Ctr Anti Infect Res & Dev, Hartford, CT 06102 USA. [Carmeli, Yehuda] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Epidemiol, IL-69978 Tel Aviv, Israel. [Crank, Christopher W.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Goff, Debra A.] Ohio State Univ, Med Ctr, Dept Pharm, Coll Pharm, Columbus, OH 43210 USA. [Graber, Christopher J.; Goldstein, Ellie J. C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. [Lima, Ana Lucia L.] Univ Sao Paulo, Sch Med, Hosp Clin, Inst Orthopaed & Traumatol, Sao Paulo, Brazil. [Goldstein, Ellie J. C.] St Johns Hlth Ctr, Dept Infect Dis, Santa Monica, CA USA. RP Nicolau, DP (reprint author), Hartford Hosp, Ctr Anti Infect Res & Dev, 80 Seymour St, Hartford, CT 06102 USA. EM dnicola@harthosp.org OI Lima, Ana/0000-0002-1055-0554; Lima, Ana Lucia Munhoz/0000-0002-2396-9880 FU Achaogen Inc.; Basilea Pharmaceutica; BioLine Therapeutics; Cempra Pharmaceuticals Inc.; Intercell AG; Johnson and Johnson Pharmaceuticals; Merck; Cubist; Ortho Pharmaceuticals; Schering-Plough Pharmaceuticals; Optimer Pharmaceuticals; Theravance Inc.; Pfizer Inc.; Astellas Inc.; Cerexa Inc.; Impex Pharmaceuticals; Novexel; Novartis; Clinical Microbiology Institute; Genzyme; NanoPacific Holdings Inc.; Romark Laboratories LC; ViroXis Corp.; Warner Chilcott; Avid-Biotics Corp.; GLSynthesis Inc.; Immunome Inc.; Toltec Pharma LLC.; Ortho-McNeil-Janssen; Sanofi-Aventis; Bayer-Schering Pharma; AstraZeneca; Cerexa; Forest; Johnson Johnson; Pfizer FX Competing interests: YC has served on speaker bureaus, scientific advisory boards and/or received research grants from Achaogen Inc., Basilea Pharmaceutica, BioLine Therapeutics, Cempra Pharmaceuticals Inc., Intercell AG, Johnson and Johnson Pharmaceuticals and Merck. DAG has served on speaker bureaus and/or received research grants from Cubist, Merck and Ortho Pharmaceuticals. EJCG has served on advisory boards for Merck, Optimer Pharmaceuticals, Bayer Pharmaceuticals, Theravance Inc., BioK+, ViroPharma and Kindred Healthcare Corp., on speaker bureaus for Bayer Inc., Merck, Sanofi Pasteur and Forest Labs, and has received research grants from Merck, Schering-Plough Pharmaceuticals, Optimer Pharmaceuticals, Theravance Inc., Cubist, Pfizer Inc., Astellas Inc., Cerexa Inc., Impex Pharmaceuticals, Novexel, Novartis, Clinical Microbiology Institute, Genzyme, NanoPacific Holdings Inc., Romark Laboratories LC, ViroXis Corp., Warner Chilcott, Avid-Biotics Corp., GLSynthesis Inc., Immunome Inc. and Toltec Pharma LLC. CJG has received a research grant from Merck and an unrestricted educational grant from Ortho-McNeil-Janssen, and has served on an advisory board for Pfizer. ALLL has served on speaker bureaus and/or received research grants from Merck, Sanofi-Aventis and Bayer-Schering Pharma. DPN has served on speaker bureaus and/or received research grants from AstraZeneca, Cerexa, Cubist, Forest, Johnson & Johnson, Merck and Pfizer. CWC declares no competing interests. NR 19 TC 22 Z9 25 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PD JAN PY 2012 VL 39 IS 1 BP 11 EP 15 DI 10.1016/j.ijantimicag.2011.08.018 PG 5 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 863DO UT WOS:000298143200002 PM 22047702 ER PT J AU Farr, SA Price, TO Dominguez, LJ Motisi, A Saiano, F Niehoff, ML Morley, JE Banks, WA Ercal, N Barbagallo, M AF Farr, Susan A. Price, Tulin O. Dominguez, Ligia J. Motisi, Antonio Saiano, Filippo Niehoff, Michael L. Morley, John E. Banks, William A. Ercal, Nuran Barbagallo, Mario TI Extra Virgin Olive Oil Improves Learning and Memory in SAMP8 Mice SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Extra virgin olive oil; learning; memory; object recognition; oxidative stress; SAMP8; T-maze ID SENESCENCE-ACCELERATED MICE; ALPHA-LIPOIC ACID; ALZHEIMERS-DISEASE; MEDITERRANEAN DIET; AMYLOID-BETA; GLUTATHIONE DISULFIDE; SENSORY PROPERTIES; OXIDATIVE STRESS; FATTY-ACIDS; MOUSE MODEL AB Polyphenols are potent antioxidants found in extra virgin olive oil (EVOO); antioxidants have been shown to reverse age-and disease-related learning and memory deficits. We examined the effects of EVOO on learning and memory in SAMP8 mice, an age-related learning/memory impairment model associated with increased amyloid-beta protein and brain oxidative damage. We administered EVOO, coconut oil, or butter to 11 month old SAMP8 mice for 6 weeks. Mice were tested in T-maze foot shock avoidance and one-trial novel object recognition with a 24 h delay. Mice which received EVOO had improved acquisition in the T-maze and spent more time with the novel object in one-trial novel object recognition versus mice which received coconut oil or butter. Mice that received EVOO had improve T-maze retention compared to the mice that received butter. EVOO increased brain glutathione levels suggesting reduced oxidative stress as a possible mechanism. These effects plus increased glutathione reductase activity, superoxide dismutase activity, and decreased tissue levels of 4-hydroxynoneal and 3-nitrotyrosine were enhanced with enriched EVOO (3x and 5x polyphenols concentration). Our findings suggest that EVOO has beneficial effects on learning and memory deficits found in aging and diseases, such as those related to the overproduction of amyloid-beta protein, by reversing oxidative damage in the brain, effects that are augmented with increasing concentrations of polyphenols in EVOO. C1 [Farr, Susan A.] St Louis Univ, Sch Med, VA Med Ctr, Dept Internal Med,Div Geriatr Med, St Louis, MO 63106 USA. [Farr, Susan A.; Morley, John E.] VA Med Ctr, GRECC, St Louis, MO USA. [Price, Tulin O.] St Louis Univ, Sch Med, Div Endocrinol, Dept Internal Med, St Louis, MO 63106 USA. [Dominguez, Ligia J.; Motisi, Antonio; Barbagallo, Mario] Univ Palermo, Div Geriatr Med, Palermo, Italy. [Saiano, Filippo] Univ Palermo, Fac Agron, Dept DEMETRA, Palermo, Italy. Univ Palermo, Dept Agroenvironm Syst, Palermo, Italy. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Banks, William A.] Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Dept Internal Med, Seattle, WA USA. [Ercal, Nuran] Missouri Univ Sci & Technol, Dept Chem, Rolla, MO USA. RP Farr, SA (reprint author), St Louis Univ, Sch Med, VA Med Ctr, Dept Internal Med,Div Geriatr Med, 915 N Grand Blvd,151-JC, St Louis, MO 63106 USA. EM farrsa@slu.edu OI BARBAGALLO, MARIO/0000-0002-1349-6530; dominguez, ligia j/0000-0003-1466-8610 FU VA Medical Center, St. Louis, MO FX This work was supported by VA Medical Center, St. Louis, MO. NR 54 TC 52 Z9 53 U1 2 U2 14 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 28 IS 1 BP 81 EP 92 DI 10.3233/JAD-2011-110662 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 879EG UT WOS:000299311900007 PM 21955812 ER PT J AU Baker, LD Bayer-Carter, JL Skinner, J Montine, TJ Cholerton, BA Callaghan, M Leverenz, JB Walter, BK Tsai, E Postupna, N Lampe, J Craft, S AF Baker, Laura D. Bayer-Carter, Jennifer L. Skinner, Jeannine Montine, Thomas J. Cholerton, Brenna A. Callaghan, Maureen Leverenz, James B. Walter, Brooke K. Tsai, Elaine Postupna, Nadia Lampe, Johanna Craft, Suzanne TI High-Intensity Physical Activity Modulates Diet Effects on Cerebrospinal Amyloid-beta Levels in Normal Aging and Mild Cognitive Impairment SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aging; Alzheimer's disease; amyloid; biomarker; brain; diet; exercise; interleukin; mild cognitive impairment; tau ID TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; OLDER-ADULTS; CALORIC RESTRICTION; VOLUNTARY EXERCISE; MEDITERRANEAN DIET; RISK; BRAIN; MICE; AGE AB We previously showed that amyloid-beta 1-42 (A beta(42)) levels in cerebrospinal fluid (CSF) were markedly altered in response to a 4-week dietary intervention in normal aging and mild cognitive impairment (MCI). Here, we re-examined the data to assess whether diet-induced effects on CSF A beta(42) were modulated by high intensity physical activity (hi-PA). Normal older adults (n = 18, mean age = 68.6 +/- 7.4 y) and adults with amnestic MCI (n = 23, mean age = 68.0 +/- 6.5 y) received a low saturated fat/low glycemic index (LOW) diet or a high saturated fat/high glycemic index (HIGH) diet, and CSF levels of A beta(42), tau, and IL-8 were measured at baseline and week 4. Pre-study activity levels were assessed using a 7-d questionnaire, and weekly duration of hi-PA was quantified. At baseline, increased hi-PA in normals predicted lower CSF levels of tau (r = -0.54, p = 0.020) and IL-8 (r = -0.70, p = 0.025). Diet-induced effects on CSF A beta(42) during the intervention study were modulated by hi-PA, and the nature of this effect differed for normals and MCI (ANOVA, p = 0.039). That is, for normal adults, increased hi-PA attenuated the effects of the HIGH diet on CSF A beta(42) whereas in MCI, increased hi-PA potentiated the effects of the LOW diet. Our results suggest that normal adults who engage in hi-PA are less vulnerable to the pathological effects of an unhealthy diet, while in MCI, the benefit of a healthy diet on A beta modulation is greatest when paired with hi-PA. Exercise may thus interact with diet to alter pathological processes that ultimately modify risk of Alzheimer's disease. C1 [Baker, Laura D.; Bayer-Carter, Jennifer L.; Skinner, Jeannine; Cholerton, Brenna A.; Callaghan, Maureen; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness & Parkinson Dis Res Ctr, Seattle, WA USA. [Baker, Laura D.; Skinner, Jeannine; Cholerton, Brenna A.; Walter, Brooke K.; Tsai, Elaine; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Montine, Thomas J.; Postupna, Nadia] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Leverenz, James B.; Walter, Brooke K.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Lampe, Johanna] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness & Parkinson Educ Ctr, Seattle, WA USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness & Parkinson Clin Ctr, Seattle, WA USA. RP Baker, LD (reprint author), S-182-GRECC,VAPSHCS 1660 S Columbian Way, Seattle, WA 98108 USA. EM ldbaker@uw.edu FU NIA [R37 AG-10880, P50 AG05136, 5T32 AG000258]; Nancy and Buster Alvord Endowment; Office of Research and Development Medical Research Service; Geriatric Research, Education and Clinical Center of the Department of Veterans Affairs FX This research was supported by NIA R37 AG-10880 (Craft), NIA P50 AG05136 Project 1 (Montine), NIA 5T32 AG000258 (Postupna), the Nancy and Buster Alvord Endowment, and the Office of Research and Development Medical Research Service and the Geriatric Research, Education and Clinical Center of the Department of Veterans Affairs. Dr. Baker had full access to all data and takes responsibility for its integrity and the accuracy of the data analysis which was conducted without input from the funding agencies. NR 60 TC 13 Z9 13 U1 3 U2 24 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 28 IS 1 BP 137 EP 146 DI 10.3233/JAD-2011-111076 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 879EG UT WOS:000299311900012 PM 21971406 ER PT J AU Nielson, CM Zmuda, JM Carlos, AS Wagoner, WJ Larson, EA Orwoll, ES Klein, RF AF Nielson, Carrie M. Zmuda, Joseph M. Carlos, Amy S. Wagoner, Wendy J. Larson, Emily A. Orwoll, Eric S. Klein, Robert F. TI Rare coding variants in ALPL are associated with low serum alkaline phosphatase and low bone mineral density SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE OSTEOPOROSIS; HEREDITY; GENETICS; ALKALINE PHOSPHATASE ID QUANTITATIVE TRAIT LOCI; GENOME-WIDE ASSOCIATION; INFANTILE HYPOPHOSPHATASIA; OSTEOPOROTIC FRACTURES; LINKAGE ANALYSIS; INBRED STRAINS; PLASMA-LEVELS; MICE; C57BL/6J; GENES AB Alkaline phosphatase (ALP) plays an essential role in the regulation of tissue mineralization, and its activity is highly heritable. Guided by genetic associations discovered in a murine model, we hypothesized a role for rare coding variants in determining serum ALP level and bone mineral density (BMD) in humans. We sequenced the coding regions of the ALP gene (ALPL) in men with low and normal serum ALP activity levels. Single-nucleotide ALPL variants, including 19 rare nonsynonymous variants (minor allele frequency <1%), were much more frequent among the low ALP group (33.8%) than the normal group (1.4%, p=1 x 10(-11)). Within the low ALP group, men with a rare, nonsynonymous variant had 11.2% lower mean serum ALP (p=3.9x 10(-4)), 6.7% lower BMD (p=0.03), and 11.1% higher serum phosphate (p=0.002) than those without. In contrast, common nonsynonymous variants had no association with serum ALP, phosphate, or BMD. Multiple rare ALPL coding variants are present in the general population, and nonsynonymous coding variants may be responsible for heritable differences in mineralization and thus BMD. (C) 2012 American Society for Bone and Mineral Research C1 [Nielson, Carrie M.; Carlos, Amy S.; Wagoner, Wendy J.; Larson, Emily A.; Orwoll, Eric S.; Klein, Robert F.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Dept Med, Portland, OR 97239 USA. [Zmuda, Joseph M.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Zmuda, Joseph M.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. [Klein, Robert F.] Portland VA Med Ctr, Portland, OR USA. RP Klein, RF (reprint author), Oregon Hlth & Sci Univ, Bone & Mineral Unit CR113, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM Kleinro@ohsu.edu OI Orwoll, Eric/0000-0002-8520-7355 FU National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [AR44659, R01-AR051124]; National Institute on Aging (NIA) [R01-AG033618]; National Center for Research Resources (NCRR); NIH Roadmap for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140]; Office of Research on Women's Health; National Institute of Child Health and Human Development, Building Interdisciplinary Research Careers in Women's Health (BIRCWH) [HD043488-08]; VA Medical Research Service FX The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding; the following institutes provide support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Center for Research Resources (NCRR), and NIH Roadmap for Medical Research under the following grant numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. Dr. Nielson is also supported by the Office of Research on Women's Health and the National Institute of Child Health and Human Development, Building Interdisciplinary Research Careers in Women's Health (BIRCWH) grant number HD043488-08. Dr. Klein's research effort is supported by the National Institute of Arthritis, Musculoskeletal and Skin Diseases (AR44659) and the VA Medical Research Service. Dr. Zmuda's research effort is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR051124) and by the National Institute on Aging (R01-AG033618). NR 61 TC 10 Z9 10 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JAN PY 2012 VL 27 IS 1 BP 93 EP 103 DI 10.1002/jbmr.527 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 867UA UT WOS:000298479000009 PM 21956185 ER PT J AU Barber, JP Barrett, MS Gallop, R Rynn, MA Rickels, K AF Barber, Jacques P. Barrett, Marna S. Gallop, Robert Rynn, Moira A. Rickels, Karl TI Short-Term Dynamic Psychotherapy Versus Pharmacotherapy for Major Depressive Disorder: A Randomized, Placebo-Controlled Trial SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID COLLABORATIVE RESEARCH-PROGRAM; MENTAL-HEALTH TREATMENT; STAR-ASTERISK-D; CLINICAL-TRIALS; COGNITIVE THERAPY; PSYCHODYNAMIC PSYCHOTHERAPY; NATIONAL-INSTITUTE; RATING-SCALE; CARE; CITALOPRAM AB Objective: To determine whether supportive-expressive psychotherapy (SET), a form of dynamic psychotherapy, and pharmacotherapy + clinical management (MED) for major depressive disorder (MDD) are more effective than pill-placebo + clinical management (PBO). Method:This National Institute of Mental Health (NIMH)-sponsored randomized controlled trial was conducted (from November 2001 through June 2007) at the University of Pennsylvania Medical School. The sample included 156 patients diagnosed with MDD (DSM-IV) and having a 17-item Hamilton Rating Scale for Depression (HRSD17) score >= 14 for at least 2 consecutive weeks. This was an underserved sample in which 41% were male, 52% were self-designated minorities, and 76% had an annual income under $30,000. Treatment lasted 16 weeks. Medication patients not responsive by week 8 (maximum dose 200 mg/d of sertraline) were switched to venlafaxine (maximum dose 375 mg/d). Nonresponsive placebo patients at week 8 were switched to a different placebo. Results: Patients' depression improved over the 16 weeks (P<.0001), with no between-group differences (P=.95), even among severely (HRSD17 score >= 20) depressed patients (P=.45). Response rates did not differ between groups (P=.73). Gender and minority status moderated outcome (P=.014), with psychotherapy more efficacious for minority men than MED (P=.027, Cohen d=1.02) and PBO (P=.019, d=1.09). PBO was more efficacious for white men than MED (P=.03, d=0.62) and SET (P=.003, d=1.07). For white women, MED (P=.005, d=0.77) and SET (P=.033, d=0.71) were more efficacious than placebo. No differences among treatments were found for minority women. Conclusions:This trial of urban MDD patients failed to confirm that either active treatment was better than placebo. Minority status and gender had significant and differential effects on outcome that warrant replication in future studies. C1 [Barber, Jacques P.; Barrett, Marna S.; Gallop, Robert] Univ Penn, Sch Med, Dept Psychiat, Ctr Psychotherapy Res, Philadelphia, PA 19104 USA. [Barber, Jacques P.] Philadelphia VA Med Ctr, CESATE, Philadelphia, PA USA. [Barber, Jacques P.] Philadelphia VA Med Ctr, MIRECC, Philadelphia, PA USA. [Barrett, Marna S.; Rynn, Moira A.; Rickels, Karl] Univ Penn, Sch Med, Dept Psychiat, Mood & Anxiety Disorders Sect, Philadelphia, PA 19104 USA. [Rynn, Moira A.] Columbia Univ, Div Child & Adolescent Psychiat, New York, NY USA. [Rynn, Moira A.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Barber, JP (reprint author), Adelphi Univ, Hy Weinberg Ctr, Derner Inst Adv Psychol Studies, Rm 301,1 South Ave,POB 701, Garden City, NY 11530 USA. EM jbarber@adelphi.edu FU National Institute of Mental Health (NIMH) [R01 MH 061410]; National Institute on Drug Abuse (NIDA); Guilford Press; Basic Books; Cambridge University Press; Boehringer Ingelheim Pharmaceuticals; Wyeth Pharmaceuticals; Neuropharm; Astra Zeneca; Pfizer Pharmaceuticals; Eli Lilly and Company; Forest Laboratories; Bristol-Myers Squibb; Organon; Cephalon; Johnson & Johnson Pharmaceutical Research Development; AstraZeneca; Bristol-Meyers Squibb; Epix Pharmaceuticals; Genaissance Pharmaceuticals (PGxHealth); GlaxoSmithkline; Merck Co; Pamlab; Pfizer; Somerset Pharmaceuticals; Wyeth Laboratory; Pfizer Corp. FX Dr Barber has received funding from the National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA); authors' fees from Guilford Press, Basic Books, and Cambridge University Press; and honoraria from Lundbeck. Dr Rynn has received research support from NIMH, Boehringer Ingelheim Pharmaceuticals, Wyeth Pharmaceuticals, Neuropharm, Astra Zeneca, Pfizer Pharmaceuticals, Eli Lilly and Company, Forest Laboratories, Bristol-Myers Squibb, Organon, Cephalon, and Johnson & Johnson Pharmaceutical Research & Development; has served as a consultant for Wyeth Pharmaceuticals, Pfizer Pharmaceuticals, Astra Zeneca, Pharmastar, Eli Lilly and Company, and Pepper Hamilton; has been on speakers' bureaus for Pfizer Pharmaceuticals and Wyeth Pharmaceuticals; has received royalties from APPI Press; and has received honoraria from Post Graduate Institute for Medicine, American Psychiatric Association, American Education Services, Oxford University Press, Case Western Reserve University, and Pennsylvania Medical Society. Please note that during this time period there are Grand Rounds for which she does not have the documentation of the funding source. Dr Rickels (from 2002 to 2009) has received honoraria and served as a consultant or on advisory boards to Cephalon, DOV Pharmaceuticals, Eli Lilly & Co, Hoffman-La Roche, Jazz Pharmaceuticals, Johnson & Johnson, Novartis Pharmaceuticals, Pfizer Inc, Epix (PreDix) Pharmaceuticals, PGxHealth, and Sanofi-Synthelabo Research; and has received research grants (issued to the University of Pennsylvania) from AstraZeneca, Bristol-Meyers Squibb, Cephalon, Epix Pharmaceuticals, Genaissance Pharmaceuticals (PGxHealth), GlaxoSmithkline, Merck & Co, NIMH, Pamlab, Pfizer, Somerset Pharmaceuticals, and Wyeth Laboratory. Drs Barrett and Gallops have no potential conflict of interest to disclose.; Written with support from NIMH grant R01 MH 061410 (Jacques P. Barber, PI). The sertraline and placebo pills were provided by a grant from Pfizer Corp. Neither sponsor had any role in the study besides funding the study (NIMH) or supplying the sertraline and placebo pills (Pfizer). NR 47 TC 57 Z9 57 U1 1 U2 19 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2012 VL 73 IS 1 BP 66 EP 73 DI 10.4088/JCP.11m06831 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 880LK UT WOS:000299408400010 PM 22152401 ER PT J AU Mohamed, S Rosenheck, R Lyketsos, CG Kaczynski, R Sultzer, DL Schneider, LS AF Mohamed, Somaia Rosenheck, Robert Lyketsos, Constantine G. Kaczynski, Richard Sultzer, David L. Schneider, Lon S. TI Effect of Second-Generation Antipsychotics on Caregiver Burden in Alzheimer's Disease SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID RATING-SCALE BPRS; FAMILY CAREGIVERS; BEHAVIORAL DISTURBANCES; DEMENTIA VICTIMS; OLDER-ADULTS; CATIE-AD; HEALTH; PREDICTORS; TRIAL; DEPRESSION AB Background: Alzheimer's disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers' experience of burden. These symptoms may be improved with atypical antipsychotic treatment. Objective: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) trial were used to evaluate the effect of atypical antipsychotics versus placebo on the experiences of caregivers of outpatients with AD. Method: We compared the effect of atypical antipsychotic drugs (olanzapine, risperidone, or quetiapine considered together as a group) versus placebo on the experiences of caregivers of AD outpatients (diagnosed according to DSM-IV-TR). We also evaluated whether improvement in patients' psychiatric and behavioral symptoms mediated the relationship between drug treatment and caregiver burden. The CATIE-AD trial, conducted from April 2001 through November 2004, included outpatients (mean age = 77.9 years [SD = 7.5 years]) in usual care settings and assessed treatment effectiveness over a 9-month period at 42 US sites. In a set of secondary analyses, data from CATIE-AD participants who had at least 1 postbaseline outcome assessment and data from their caregivers were examined in an intention-to-treat (ITT) analysis (N = 361). A phase 1-only analysis was conducted including only observations while patients were receiving the initially randomized drug (N = 153). The Burden Interview, the Beck Depression Inventory, and the Neuropsychiatric Inventory (NPI) Caregiver Distress Scale were used to evaluate caregiver burden. Results: In both ITT and phase 1-only analyses, caregivers of patients treated with second-generation antipsychotics scored significantly lower than caregivers of patients receiving placebo on both the Burden Interview (P = .0090) and the NPI Caregiver Distress Scale (P = .0209). These differences appeared to have been mediated by lower levels of agitation, hostility, and psychotic distortions. Conclusion: In AD patients with symptoms of psychosis, agitation, or aggressive behavior, medications can have a small but significant impact on caregiver burden. J Clin Psychiatry 2012;73(1):121-128 (C) Copyright 2011 Physicians Postgraduate Press, Inc. C1 [Mohamed, Somaia; Rosenheck, Robert; Kaczynski, Richard] Vet Affairs New England Mental Illness Res Educ &, West Haven, CT USA. [Mohamed, Somaia; Rosenheck, Robert; Kaczynski, Richard] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Lyketsos, Constantine G.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA. [Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Sultzer, David L.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. RP Mohamed, S (reprint author), Vet Affairs Connecticut Hlth Care Syst, 950 Campbell Ave,182, West Haven, CT 06516 USA. EM Somaia.Mohamed@yale.edu FU Eli Lilly; Janssen; AstraZeneca; Pfizer; National Institute of Mental Health (NIMH) [N01 MH9001]; National Institute on Aging; Associated Jewish Federation of Baltimore; Harry and Jeanette Weinberg Foundation; Forest; GlaxoSmithKline; Eisai; Ortho-McNeil; Bristol-Myers Squibb; Novartis; National Football League (NFL); Elan; Supernus; Adlyfe; Takeda; Lundbeck; Merz; Genentech; NFL Players Association; Forest Research Institute; Johnson Johnson; National Institutes of Health (NIH) [P50 AG05142, P01 AG05146]; Pfizer, Madison, New Jersey; Department of Veterans Affairs FX Dr Rosenheck has received research support from Eli Lilly, Janssen, AstraZeneca, and Wyeth (currently Pfizer); has been a consultant to GlaxoSmithKline, Bristol-Myers Squibb, Organon, and Janssen; and has provided expert testimony in matters pertaining to Eli Lilly, Eli Lilly Canada, Novapharm, Janssen-Ortho, and Janssen. Dr Lyketsos has received grant support (for research or CME) from the National Institute of Mental Health (NIMH), the National Institute on Aging, The Associated Jewish Federation of Baltimore, The Harry and Jeanette Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Eli Lilly, Ortho-McNeil, Bristol-Myers Squibb, Novartis, National Football League (NFL), and Elan; has received consulting fees from AstraZeneca, GlaxoSmithKline, Eisai, Elan, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth (currently Pfizer), Lundbeck, Merz, Eli Lilly, Genentech, Pfizer, NFL Players Association, and the NFL; and has received speaking honoraria or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. Dr Sultzer has received research support from Eli Lilly and Forest Research Institute. Dr Schneider has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Novartis, Johnson & Johnson, and Pfizer and has received research grant support from Novartis, Eli Lilly, and Pfizer. Drs Mohamed and Kaczynski have no potential conflicts of interest with regard to the subject of this article.; Conduct of the study was supported by grant N01 MH9001 from NIMH, the National Institutes of Health (NIH) (to Dr Schneider). Dr Schneider's efforts in writing the manuscript were partially supported by grant P50 AG05142 from NIH to the University of Southern California Alzheimer Disease Research Center, Los Angeles, California. Dr Mohamed's efforts in writing the manuscript were partially supported by a contract with Wyeth Pharmaceuticals (currently Pfizer), Madison, New Jersey. Dr Lyketsos' efforts in writing the manuscript were supported by grant P01 AG05146 from NIH to the Johns Hopkins University Alzheimer's Disease Research Center, Baltimore, Maryland. Dr Sultzer's efforts in writing the manuscript were partially supported by the Department of Veterans Affairs (Merit Review Program). NR 47 TC 7 Z9 7 U1 3 U2 8 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2012 VL 73 IS 1 BP 121 EP 128 DI 10.4088/JCP.10m06574 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 880LK UT WOS:000299408400018 PM 21939611 ER PT J AU Carlson, KF Meis, LA Jensen, AC Simon, AB Gravely, AA Taylor, BC Bangerter, A Schaaf, KW Griffin, JM AF Carlson, Kathleen F. Meis, Laura A. Jensen, Agnes C. Simon, Alisha Baines Gravely, Amy A. Taylor, Brent C. Bangerter, Ann Schaaf, Katy Wilder Griffin, Joan M. TI Caregiver Reports of Subsequent Injuries Among Veterans With Traumatic Brain Injury After Discharge From Inpatient Polytrauma Rehabilitation Programs SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE caregivers; health services; rehabilitation; traumatic brain injury; trauma; injury ID SPINAL-CORD-INJURY; RISK; MORTALITY; POPULATION; BEHAVIOR; DEATH; CARE; INDIVIDUALS; POSTINJURY; CHILDREN AB Objective: We examined prevalence of, and potential risk factors for, nonfatal injuries among Veterans with traumatic brain injury (TBI) postdischarge from Veterans Affairs inpatient polytrauma rehabilitation programs. Methods: We surveyed caregivers of patients who had military service anytime from 2001 to 2009, sustained polytrauma including TBI, received Veterans Affairs inpatient care from 2001 to 2009, were discharged at least 3 months before the study, and were alive when the study was fielded about caregiver and patient health, including patients' medically treated "accidents/new injuries" since discharge. We examined prevalence and source(s) of subsequent injuries and estimated patients' injury risk in reference to hypothesized risk factors. Odds ratios and 95% confidence intervals were calculated using multivariate logistic regression. Results: Caregivers reported that nearly one-third (32%) of patients incurred medically treated injuries after discharge; most were associated with falls (49%) and motor vehicles (37%). Odds of subsequent injury were associated with select demographics, initial injury characteristics, and postdischarge health and functioning. Characteristics of caregivers, including physical and mental health, were also associated with patients' odds of subsequent injury. Conclusions: A significant number of caregivers reported subsequent nonfatal injuries among patients treated for TBI/polytrauma in inpatient rehabilitation settings. Enhanced injury prevention efforts may be beneficial for this population. C1 [Carlson, Kathleen F.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA. [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Meis, Laura A.; Jensen, Agnes C.; Simon, Alisha Baines; Gravely, Amy A.; Taylor, Brent C.; Bangerter, Ann; Griffin, Joan M.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Taylor, Brent C.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Meis, Laura A.; Taylor, Brent C.; Griffin, Joan M.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Schaaf, Katy Wilder] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Neuropsychol & Rehabil Psychol Serv, Richmond, VA USA. [Schaaf, Katy Wilder] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. RP Carlson, KF (reprint author), Portland VA Med Ctr R&D 66, Portland Ctr Study Chron Comorbid Mental & Phys D, 3715 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kathleen.carlson@va.gov RI Taylor, Brent/A-8069-2009 OI Taylor, Brent/0000-0002-2140-8377 FU Veterans Health Administration Health Services Research and Development Service [SDR 07-044, CDA 08-025] FX This work was supported by grants from the Veterans Health Administration Health Services Research and Development Service (SDR 07-044; CDA 08-025). The opinions expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 50 TC 10 Z9 10 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD JAN-FEB PY 2012 VL 27 IS 1 BP 14 EP 25 DI 10.1097/HTR.0b013e318236bd86 PG 12 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 879JV UT WOS:000299326400002 PM 22218200 ER PT J AU Afzali, A Berry, K Ioannou, GN AF Afzali, Anita Berry, Kristin Ioannou, George N. TI Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States SO LIVER TRANSPLANTATION LA English DT Article ID FATTY LIVER-DISEASE; CRYPTOGENIC CIRRHOSIS; NATURAL-HISTORY; TRANSPLANTATION; POPULATION; PREVALENCE AB Because of the ongoing epidemics of obesity and diabetes, nonalcoholic steatohepatitis (NASH) may become a leading indication for liver transplantation. There are concerns about the posttransplant survival of patients with NASH because of associated cardiovascular and metabolic risk factors. We aimed to determine recent trends in the proportion of patients undergoing transplantation for NASH-related cirrhosis in the United States and to estimate their posttransplant survival. We used data provided by the United Network for Organ Sharing for first-time adult cadaveric liver transplants performed in the United States between January 1, 1997 and October 31, 2010 (n = 53,738). The proportion of liver transplants performed for NASH-related cirrhosis increased dramatically from 1.2% in 1997-2003 to 7.4% in 2010 when NASH was the fourth most common indication for transplantation. The posttransplant survival of patients with NASH (n = 1810) at 1 (87.6%), 3 (82.2%), and 5 years (76.7%) was superior to the survival of patients with hepatocellular carcinoma, hepatitis C virus, alcoholic liver disease, acute hepatic necrosis, hemochromatosis, or cryptogenic liver disease and was inferior to the survival of only 4 groups of patients (those with primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, or hepatitis B virus). In conclusion, NASH-related cirrhosis is increasing rapidly as an indication for liver transplantation in the United States and is associated with excellent posttransplant survival. Liver Transpl 18:2937, 2012. (C) 2011 AASLD. C1 [Afzali, Anita; Ioannou, George N.] Univ Washington, Div Gastroenterol, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Berry, Kristin] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Afzali, Anita; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA. RP Afzali, A (reprint author), Univ Washington, Div Gastroenterol, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, 1959 NE Pacific St,Suite AA103,Box 356424, Seattle, WA 98195 USA. EM anitaa@medicine.washington.edu FU Health Resources and Services Administration [234-2005-370011C] FX This work was supported in part by the Health Resources and Services Administration (contract 234-2005-370011C). The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. NR 21 TC 50 Z9 51 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD JAN PY 2012 VL 18 IS 1 BP 29 EP 37 DI 10.1002/lt.22435 PG 9 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 867VO UT WOS:000298483100005 PM 21932374 ER PT J AU Ueno, K Hirata, H Majid, S Yamamura, S Shahryari, V Tabatabai, ZL Hinoda, Y Dahiya, R AF Ueno, Koji Hirata, Hiroshi Majid, Shahana Yamamura, Soichiro Shahryari, Varahram Tabatabai, Z. Laura Hinoda, Yuji Dahiya, Rajvir TI Tumor Suppressor MicroRNA-493 Decreases Cell Motility and Migration Ability in Human Bladder Cancer Cells by Downregulating RhoC and FZD4 SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID IN-VITRO; HEPATOCELLULAR-CARCINOMA; GENOMIC ANALYSIS; METASTASIS; INVASION; PATHWAY; PROGRESSION; INHIBITION; BIOMARKERS; ACTIVATION AB The purpose of this study was to identify new tumor suppressor microRNAs (miRNA; miR) in bladder cancer, conduct functional analysis of their suppressive role, and identify their specific target genes. To explore tumor suppressor miRs in bladder cancer, miR microarray was conducted using SV-HUC-1, T24, J82, and TCCSUP cells. Expression of miR-493 in bladder cancer (T24, J82, and TCCSUP) cells was downregulated compared with normal SV-HUC-1 cells. Also, the expression of miR-493 was significantly lower in bladder cancer tissues than in their corresponding noncancerous tissues. Transfection of miR-493 into T24 or J82 cells decreased their cell growth andmigration abilities. On the basis of this result, to identify potential miR-493 target genes, we used target scan algorithms to identify target oncogenes related to invasion and migration. miR-493 decreased 30-untranslated region luciferase activity and protein expression of FZD4 and RhoC. miR-493 also decreased binding of RhoC and Rock-1. miR-493 is a new tumor suppressor miRNA in bladder cancer and inhibits cell motility through downregulation of RhoC and FZD4. Mol Cancer Ther; 11(1); 244-53. (C) 2011 AACR. C1 [Ueno, Koji; Hirata, Hiroshi; Majid, Shahana; Yamamura, Soichiro; Shahryari, Varahram; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA. [Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Ube, Yamaguchi 755, Japan. RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu FU NIH [R01CA130860, R01CA138642, R01CA111470, T32DK007790]; VA FX This study was supported by grants R01CA130860, R01CA138642, R01CA111470, T32DK007790 from the NIH, VA Research Enhancement Award Program (REAP), and Merit Review grants. NR 30 TC 40 Z9 43 U1 2 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD JAN PY 2012 VL 11 IS 1 BP 244 EP 253 DI 10.1158/1535-7163.MCT-11-0592 PG 10 WC Oncology SC Oncology GA 879CV UT WOS:000299308200024 PM 22057916 ER PT J AU Li, YX Berenji, GR Shaba, WF Tafti, B Yevdayev, E Dadparvar, S AF Li, Yuxin Berenji, Gholam R. Shaba, Wisam F. Tafti, Bashir Yevdayev, Ella Dadparvar, Simin TI Association of vascular fluoride uptake with vascular calcification and coronary artery disease SO NUCLEAR MEDICINE COMMUNICATIONS LA English DT Article DE atherosclerosis; bone scan; sodium [(18)F] fluoride; positron emission tomography; vascular calcification ID BEAM COMPUTED-TOMOGRAPHY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR EVENTS; PET; CALCIUM; FEASIBILITY; RISK; FLUORODEOXYGLUCOSE; F-18-FLUORIDE; INFLAMMATION AB Objective The feasibility of a fluoride positron emission tomography/computed tomography (PET/CT) scan for imaging atherosclerosis has not been well documented. The purpose of this study was to assess fluoride uptake of vascular calcification in various major arteries, including coronary arteries. Methods We retrospectively reviewed the imaging data and cardiovascular history of 61 patients who received whole-body sodium [(18)F] fluoride PET/CT studies at our institution from 2009 to 2010. Fluoride uptake and calcification in major arteries, including coronary arteries, were analyzed by both visual assessment and standardized uptake value measurement. Results Fluoride uptake in vascular walls was demonstrated in 361 sites of 54 (96%) patients, whereas calcification was observed in 317 sites of 49 (88%) patients. Significant correlation between fluoride uptake and calcification was observed in most of the arterial walls, except in those of the abdominal aorta. Fluoride uptake in coronary arteries was demonstrated in 28 (46%) patients and coronary calcifications were observed in 34 (56%) patients. There was significant correlation between history of cardiovascular events and presence of fluoride uptake in coronary arteries. The coronary fluoride uptake value in patients with cardiovascular events was significantly higher than in patients without cardiovascular events. Conclusion sodium [(18)F] fluoride PET/CT might be useful in the evaluation of the atherosclerotic process in major arteries, including coronary arteries. An increased fluoride uptake in coronary arteries may be associated with an increased cardiovascular risk. Nucl Med Commun 33:14-20 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Berenji, Gholam R.] VA Greater Los Angeles Healthcare Syst, Nucl Med Serv 115, Los Angeles, CA 90073 USA. [Dadparvar, Simin] Univ PA Hlth Syst, Philadelphia, PA USA. RP Berenji, GR (reprint author), VA Greater Los Angeles Healthcare Syst, Nucl Med Serv 115, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Gholam.Berenji@va.gov NR 33 TC 29 Z9 29 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0143-3636 J9 NUCL MED COMMUN JI Nucl. Med. Commun. PD JAN PY 2012 VL 33 IS 1 BP 14 EP 20 DI 10.1097/MNM.0b013e32834c187e PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 872ZL UT WOS:000298850000003 PM 21946616 ER PT J AU Robertson, SM Stanley, MA Cully, JA Naik, AD AF Robertson, Suzanne M. Stanley, Melinda A. Cully, Jeffrey A. Naik, Aanand D. TI Positive Emotional Health and Diabetes Care: Concepts, Measurement, and Clinical Implications SO PSYCHOSOMATICS LA English DT Review ID QUALITY-OF-LIFE; TREATMENT SATISFACTION; GLYCEMIC CONTROL; PSYCHOLOGICAL ADJUSTMENT; CONTROLLED TRIAL; SELF-MANAGEMENT; NEGATIVE AFFECT; MOOD; RESILIENCE; PEOPLE AB Background: Numerous studies describe the effect of emotional problems, including diabetes-related distress and depression, on diabetes outcomes. Little attention has been devoted to positive emotional health and its potential role in facilitating patients' self-management and improved outcomes. Objective: This review describes the conceptualization and measurement of three empirically-tested aspects of positive emotional health (well-being, positive affect, resilience) in the diabetes literature and their relationship to diabetes outcomes. Method: A literature review was conducted using PubMed and the Cochrane Library databases from 1970 to January 2011 to identify studies focused on well-being, positive affect, and resilience in diabetes patients. Results: Twenty-two studies were identified based on our inclusion criteria. Well-being studies were least. likely to include conceptualizations and relied on two primary measurement instruments compared to more heterogeneous presentations found in positive affect and resilience studies. All three aspects of positive emotional health were linked to health-related outcomes and self-management. Conclusion: Positive emotional health may facilitate chronic care self-management and improved health outcomes. We present a model to guide future research and intervention development efforts designed to enhance positive emotional health. (Psychosomatics 2012; 53:1-12) C1 [Robertson, Suzanne M.; Stanley, Melinda A.; Cully, Jeffrey A.; Naik, Aanand D.] Houston Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Stanley, Melinda A.; Cully, Jeffrey A.; Naik, Aanand D.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Stanley, Melinda A.; Cully, Jeffrey A.; Naik, Aanand D.] VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA. RP Robertson, SM (reprint author), Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,MEDVAMC 152, Houston, TX 77030 USA. EM smr1@bcm.tmc.edu FU Houston VA Health Services Research and Development Center of Excellence [HFP90-020]; VA Office of Academic Affiliations; National Institute of Aging [5K23AG027144]; Doris Duke Charitable Foundation FX This review is supported with resources and the use of facilities at the Houston VA Health Services Research and Development Center of Excellence (HFP90-020) at the Michael E. DeBakey VA Medical Center, Houston, TX Suzanne M. Robertson is a VA HSR post-doctoral fellow supported by VA Office of Academic Affiliations. Aanand D. Naik receives support from a National Institute of Aging Career Development Award (5K23AG027144) and a Doris Duke Charitable Foundation Clinical Scientist Development Award. The views expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs or Baylor College of Medicine. NR 47 TC 9 Z9 9 U1 1 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD JAN-FEB PY 2012 VL 53 IS 1 BP 1 EP 12 PG 12 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 882TB UT WOS:000299585700001 PM 22221716 ER PT J AU Saperstein, AM Thysen, J Medalia, A AF Saperstein, Alice M. Thysen, Julie Medalia, Alice TI The Measure of Insight into Cognition: Reliability and validity of clinician-rated and self-report scales of neurocognitive insight for schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Neurocognition; Insight ID PSYCHOSIS; ILLNESS; CONSEQUENCES; PERFORMANCE; DEPRESSION; AWARENESS; SYMPTOMS; DEFICITS AB Poor insight into the neurocognitive deficits in schizophrenia-spectrum disorders may have significant clinical implications for treatment. The purpose of this study was to replicate and extend the psychometric findings initially reported on the Measure of Insight into Cognition Clinician-Rated (MIC-CR) and Self-Report (MIC-SR) which assess awareness, attribution, and frequency of neurocognitive deficits. Assessments conducted one week apart allowed for internal consistency, test-retest reliability, concurrent validity, and administration order effects to be determined. In this study sample (N = 80), 73 demonstrated significant neurocognitive impairment, yet on the MIC-CR, the average awareness and attribution scores indicated only partial awareness and attribution of neurocognitive deficits. The average MIC-SR score indicated rare frequency of cognitive difficulty in everyday life. Cronbach's alphas for the MIC-CR (0.83) and MIC-SR (0.93) were consistent with the initial validation study; test-retest reliability for both MIC assessments was significant (p < 0.001). In new analyses, concurrent validity was demonstrated by significant correlations between the MIC-CR and MIC-SR in the first validation sample: r=-0.75 (p < 0.001) and the current replication sample: r=-0.70 (p < 0.001). Effect sizes were large when frequencies of neurocognitive complaints (MIC-SR) were compared between subjects with good versus poor awareness on the MIC-CR. Reliability and concurrent validity results were similar and significant regardless of order of MIC-CR and MIC-SR administration. The MIC-CR and MIC-SR are thus reliable and valid complementary instruments to assess neurocognitive insight in people with schizophrenia spectrum disorders. (C) 2011 Elsevier B.V. All rights reserved. C1 [Saperstein, Alice M.; Medalia, Alice] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. [Thysen, Julie] James J Peters VA Med Ctr, Mt Sinai Sch Med, Bronx, NY 10468 USA. RP Saperstein, AM (reprint author), Columbia Univ Coll Phys & Surg, Dept Psychiat, 1051 Riverside Dr, New York, NY 10032 USA. EM saperst@nyspi.columbia.edu; am2938@columbia.edu FU Eli Lilly [F1D-US-X310] FX This research was supported by an Eli Lilly Investigator Initiated Trial, Grant # F1D-US-X310, PI: Alice Medalia, PhD. This institution had no further role in the study design, in the collection, analysis or interpretation of data, in writing the report, or in the decision to submit the paper for publication. NR 24 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 2012 VL 134 IS 1 BP 54 EP 58 DI 10.1016/j.schres.2011.10.002 PG 5 WC Psychiatry SC Psychiatry GA 881NH UT WOS:000299492900009 PM 22036020 ER PT J AU Smith, GE Camp, C Cooley, S Gonzalez, HM Hartman-Stein, P LaRue, A Pachana, NA Zeiss, A AF Smith, Glenn E. Camp, Cameron Cooley, Susan Gonzalez, Hector M. Hartman-Stein, Paula LaRue, Asenath Pachana, Nancy A. Zeiss, Antonette CA Amer Psychological Assoc TI Guidelines for the Evaluation of Dementia and Age-Related Cognitive Change SO AMERICAN PSYCHOLOGIST LA English DT Article ID DIAGNOSTIC-CRITERIA; ALZHEIMERS-DISEASE; INFORMANT INTERVIEW; IMPAIRMENT; PREVALENCE; MANAGEMENT; AGITATION; CONSENSUS C1 [Smith, Glenn E.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA. [Camp, Cameron] Hearthstone Alzheimer Care, Res & Prod Dev, Woburn, MA USA. [Cooley, Susan] US Dept Vet Affairs, Off Geriatr & Extended Care, Geriatr Res & Dev & Dementia Initiat, Washington, DC USA. [Gonzalez, Hector M.] Wayne State Univ, Inst Gerontol, Detroit, MI 48202 USA. [Gonzalez, Hector M.] Wayne State Univ, Dept Family Med & Publ Hlth Sci, Detroit, MI 48202 USA. [Hartman-Stein, Paula] Ctr Hlth Aging, Kent, OH USA. [Hartman-Stein, Paula] Kent State Univ, E Liverpool, OH USA. [LaRue, Asenath] Univ Wisconsin, Wisconsin Alzheimers Inst, Madison, WI 53706 USA. [Pachana, Nancy A.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia. [Pachana, Nancy A.] Univ Queensland, Ageing Mind Initiat, Brisbane, Qld 4072, Australia. [Zeiss, Antonette] US Dept Vet Affairs, Off Patient Care Serv, Off Mental Hlth Serv, Washington, DC USA. RP Smith, GE (reprint author), Amer Psychol Assoc, Publ Interest Directorate, Off Aging, 750 1st St,NE, Washington, DC 20002 USA. NR 41 TC 14 Z9 14 U1 2 U2 7 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X J9 AM PSYCHOL JI Am. Psychol. PD JAN PY 2012 VL 67 IS 1 BP 1 EP 9 DI 10.1037/a0024643 PG 9 WC Psychology, Multidisciplinary SC Psychology GA 878BP UT WOS:000299226800001 ER PT J AU Hook, V Funkelstein, L Wegrzyn, J Bark, S Kindy, M Hook, G AF Hook, Vivian Funkelstein, Lydiane Wegrzyn, Jill Bark, Steven Kindy, Mark Hook, Gregory TI Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease SO BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS LA English DT Review DE Cathepsin L; Cathepsin B; Secretory vesicle; Peptide neurotransmitters; beta-amyloid; Alzheimer's disease ID PRECURSOR PROTEIN; TRANSGENIC MICE; IN-VIVO; CHROMOGRANIN-A; WILD-TYPE; SELECTIVE INHIBITOR; CHROMAFFIN GRANULES; NEUROPEPTIDE-Y; FULL-LENGTH; MOUSE-BRAIN AB Recent new findings indicate significant biological roles of cysteine cathepsin proteases in secretory vesicles for production of biologically active peptides. Notably, cathepsin L in secretory vesicles functions as a key protease for proteolytic processing of proneuropeptides (and prohormones) into active neuropeptides that are released to mediate cell-cell communication in the nervous system for neurotransmission. Moreover, cathepsin B in secretory vesicles has been recently identified as a beta-secretase for production of neurotoxic beta-amyloid (A beta) peptides that accumulate in Alzheimer's disease (AD), participating as a notable factor in the severe memory loss in AD. These secretory vesicle functions of cathepsins L and B for production of biologically active peptides contrast with the well-known role of cathepsin proteases in lysosomes for the degradation of proteins to result in their inactivation. The unique secretory vesicle proteome indicates proteins of distinct functional categories that provide the intravesicular environment for support of cysteine cathepsin functions. Features of the secretory vesicle protein systems insure optimized intravesicular conditions that support the proteolytic activity of cathepsins. These new findings of recently discovered biological roles of cathepsins L and B indicate their significance in human health and disease. This article is part of a Special Issue entitled: Proteolysis 50 years after the discovery of lysosome. (C) 2011 Elsevier B.V. All rights reserved. C1 [Hook, Vivian; Funkelstein, Lydiane; Wegrzyn, Jill; Bark, Steven] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Neurosci, La Jolla, CA 92093 USA. [Hook, Vivian; Funkelstein, Lydiane; Wegrzyn, Jill; Bark, Steven] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmacol, La Jolla, CA 92093 USA. [Hook, Vivian; Funkelstein, Lydiane; Wegrzyn, Jill; Bark, Steven] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Med, La Jolla, CA 92093 USA. [Kindy, Mark] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Hook, Gregory] Amer Life Sci Pharmaceut Inc, San Diego, CA 92109 USA. RP Hook, V (reprint author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Neurosci, 9500 Gilman Dr,MC 0744, La Jolla, CA 92093 USA. EM vhook@ucsd.edu OI Wegrzyn, Jill/0000-0001-5923-0888 FU National Institutes of Health [R01DA04271, R01NS24553, R01MH077305, P01HL58120, K01DA023065]; Alzheimer's Association; NIA/NIH [AG027446, 1R44AG032784]; [P30NS047101] FX The cathepsin L and proteomics research was supported by grants from the National Institutes of Health to V. Hook consisting of R01DA04271, R01NS24553, R01MH077305, P01HL58120 from the NIH, a grant from the Alzheimer's Association, and a grant to J. Gleeson, P30NS047101, for the microscopy core. S. Bark was supported by a NIH Mentored Scientist Award (K01DA023065). The authors also appreciate scientific advice by Dr. Shin-Rong Hwang, and technical assistance by Mr. Thomas Toneff, at the Skaggs School of Pharmacy and Pharmaceutical Sciences, Univ. of Calif., San Diego, La Jolla, CA. The authors appreciate collaboration of these studies with Dr. Thomas Reinheckel and Dr. Christoph Peters at the Albert-Ludwigs University, Freiburg, Germany.; The cathepsin B and Alzheimer's research was supported by the NIA/NIH R21 Grant AG027446 and 1R44AG032784 (to American Life Science Pharmaceuticals (ALSP)), and by an award from the Alzheimer's Association to V. Hook. V.H. holds equity in ALSP and serves on the Scientific Advisory Board of ALSP. The terms of this agreement have been reviewed by the University of California, San Diego, in accordance with its conflict of interest policies. G.H. holds equity in and is employed by ALSP. NR 121 TC 22 Z9 23 U1 1 U2 24 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-9639 J9 BBA-PROTEINS PROTEOM JI BBA-Proteins Proteomics PD JAN PY 2012 VL 1824 IS 1 SI SI BP 89 EP 104 DI 10.1016/j.bbapap.2011.08.015 PG 16 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 871CS UT WOS:000298715900010 PM 21925292 ER PT J AU Li, Y Schiepers, C Lake, R Dadparvar, S Berenji, GR AF Li, Yuxin Schiepers, Christiaan Lake, Ralph Dadparvar, Simin Berenji, Gholam R. TI Clinical utility of F-18-fluoride PET/CT in benign and malignant bone diseases SO BONE LA English DT Review DE F-18-sodium fluoride; Positron emission tomography, computed tomography, PET-CT; Bone scan ID POSITRON-EMISSION-TOMOGRAPHY; F-18 FLUORIDE-ION; BRAIN TRANSFER CONSTANTS; CELL LUNG-CANCER; TIME UPTAKE DATA; WHOLE-BODY PET; BREAST-CANCER; PROSTATE-CANCER; METABOLIC-ACTIVITY; SODIUM-FLUORIDE AB F-18 labeled sodium fluoride is a positron-emitting, bone seeking agent with more favorable skeletal kinetics than conventional phosphate and diphosphonate compounds. With the expanding clinical usage of PET/CT', there is renewed interest in using F-18-fluoride PET/CT for imaging bone diseases. Growing evidence indicates that F-18 fluoride PET/CT offers increased sensitivity, specificity, and diagnostic accuracy in evaluating metastatic bone disease compared to Tc-99m based bone scintigraphy. National Oncologic PET Registry (NOPR) has expanded coverage for F-18 sodium fluoride PET scans since February 2011 for the evaluation of osseous metastatic disease. In this article, we reviewed the pharmacological characteristics of sodium fluoride, as well as the clinical utility of PET/CT' using F-18-fluoride in both benign and malignant bone disorders. Published by Elsevier Inc. C1 [Berenji, Gholam R.] VA Greater Los Angeles Healthcare Syst, Nucl Med Serv 115, Los Angeles, CA 90073 USA. [Schiepers, Christiaan] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Dadparvar, Simin] Univ PA Hlth Syst, Philadelphia, PA USA. RP Berenji, GR (reprint author), VA Greater Los Angeles Healthcare Syst, Nucl Med Serv 115, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Gholam.Berenji@va.gov NR 75 TC 34 Z9 34 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD JAN PY 2012 VL 50 IS 1 BP 128 EP 139 DI 10.1016/j.bone.2011.09.053 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 875VV UT WOS:000299064200017 PM 22001678 ER PT J AU Hendrickson, RG McKeown, NJ AF Hendrickson, Robert G. McKeown, Nathanael J. TI Is maternal opioid use hazardous to breast-fed infants? SO CLINICAL TOXICOLOGY LA English DT Editorial Material DE Opioids; Breast milk; Human milk; Breastfeeding; Analgesics ID PATIENT-CONTROLLED ANALGESIA; HUMAN-MILK; HUMAN LIVER; CODEINE USE; METHADONE-MAINTENANCE; NEONATAL-PERIOD; PREGNANT-WOMEN; DRUG-THERAPY; IN-VITRO; MORPHINE AB Over the last few decades, the rate of breastfeeding has increased steadily in the developed countries of the world. During this time, opioid use in the general population has steadily increased as well. Despite this, clinicians remain unclear whether opioid use is safe during breastfeeding. While the vast majority of medications used during breastfeeding occur without incident, case reports and studies have reported possible opioid toxicity in breast-fed infants. Multiple enzymes are involved in the metabolism of opioids. CYP2D6 catabolizes O-demethylation of codeine, tramadol, oxycodone, and hydrocodone to more potent metabolites. CYP3A4 inactivates methadone, meperidine, and buprenorphine. Glucoronide conjugation by the UGT enzyme family inactivates morphine and hydromorphone. Genetic polymorphisms and interfering medications affect the maternal metabolism, which in turn determines the exposure and risk to the breast-fed neonate. We review the production of breast milk, the transfer of xenobiotics from blood to milk, the characteristics that alter xenobiotic breast-milk concentrations, and we review the evidence of specific common opioids and infant toxicity. The short-term maternal use of prescription opioids is usually safe and infrequently presents a hazard to the newborn. C1 [Hendrickson, Robert G.; McKeown, Nathanael J.] Oregon Hlth & Sci Univ, Portland, OR 97219 USA. [Hendrickson, Robert G.; McKeown, Nathanael J.] Oregon Poison Ctr, Portland, OR USA. [McKeown, Nathanael J.] Portland VA Med Ctr, Portland, OR USA. RP Hendrickson, RG (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code CB550, Portland, OR 97219 USA. EM hendriro@ohsu.edu NR 110 TC 17 Z9 18 U1 3 U2 14 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1556-3650 J9 CLIN TOXICOL JI Clin. Toxicol. PD JAN PY 2012 VL 50 IS 1 BP 1 EP 14 DI 10.3109/15563650.2011.635147 PG 14 WC Toxicology SC Toxicology GA 876RZ UT WOS:000299126700001 PM 22148986 ER PT J AU Fiedler, SE Sisson, JH Wyatt, TA Pavlik, JA Gambling, TM Carson, JL Carr, DW AF Fiedler, Sarah E. Sisson, Joseph H. Wyatt, Todd A. Pavlik, Jacqueline A. Gambling, Todd M. Carson, Johnny L. Carr, Daniel W. TI Loss of ASP but not ROPN1 reduces mammalian ciliary motility SO CYTOSKELETON LA English DT Article DE ROPN1L; ropporin; A-kinase anchoring protein; OmniBank (R) ID KINASE ANCHORING PROTEIN; RADIAL SPOKE PROTEIN-3; AIRWAY EPITHELIAL-CELLS; BEAT FREQUENCY; DEPENDENT PHOSPHORYLATION; FLAGELLAR MOTILITY; REGULATORY SUBUNIT; BINDING-PROTEIN; FIBROUS SHEATH; CAMP AB Protein kinase A (PKA) signaling is targeted by interactions with A-kinase anchoring proteins (AKAPs) via a dimerization/docking domain on the regulatory (R) subunit of PKA. Four other mammalian proteins [AKAP-associated sperm protein (ASP), ropporin (ROPN1), sperm protein 17 (SP17) and calcium binding tyrosine-(Y)-phosphorylation regulated protein (CABYR)] share this highly conserved RII dimerization/docking (R2D2) domain. ASP and ROPN1 are 41% identical in sequence, interact with a variety of AKAPs in a manner similar to PKA, and are expressed in ciliated and flagellated human cells. To test the hypothesis that these proteins regulate motility, we developed mutant mouse lines lacking ASP or ROPN1. Both mutant lines produced normal numbers of cilia with intact ciliary ultrastructure. Lack of ROPN1 had no effect on ciliary motility. However, the beat frequency of cilia from mice lacking ASP is significantly slower than wild type, indicating that ASP signaling may regulate ciliary motility. This is the first demonstration of in vivo function for ASP. Similar localization of ASP in mice and humans indicates that these findings may translate to human physiology, and that these mice will be an excellent model for future studies related to the pathogenesis of human disease. (C) 2011 Wiley Periodicals, Inc. C1 [Fiedler, Sarah E.; Carr, Daniel W.] VA Med Ctr, Portland, OR USA. [Fiedler, Sarah E.; Carr, Daniel W.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Sisson, Joseph H.; Wyatt, Todd A.; Pavlik, Jacqueline A.] Univ Nebraska Med Ctr, Dept Internal Med, Pulm Crit Care Sleep & Allergy Div, Durham Res Ctr 2 1046, Omaha, NE USA. [Gambling, Todd M.; Carson, Johnny L.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA. [Carson, Johnny L.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA. RP Carr, DW (reprint author), Portland VA Med Ctr, Mail Code R&D8,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM carrd@ohsu.edu FU NIH [HD 36408, 5 R37AA008769-18]; VA Merit Award; Flight Attendant Medical Research Institute; US Environmental Protection Agency [CR833463-01]; Center for Environmental Medicine, Asthma, and Lung Biology at the University of North Carolina at Chapel Hill FX Funding for this project is provided by NIH Grant HD 36408 (DWC), VA Merit Award (DWC), NIH Grant 5 R37AA008769-18 (JHS), a Clinical Innovator Award (JLC) from the Flight Attendant Medical Research Institute, and the US Environmental Protection Agency (JLC). Although the research described in this article has been funded wholly or in part by the US Environmental Protection Agency through cooperative agreement CR833463-01 with the Center for Environmental Medicine, Asthma, and Lung Biology at the University of North Carolina at Chapel Hill, it has not been subjected to the agency's required peer and policy review, and therefore does not necessarily reflect the views of the agency and no official endorsement should be inferred. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. NR 39 TC 8 Z9 8 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1949-3584 J9 CYTOSKELETON JI Cytoskeleton PD JAN PY 2012 VL 69 IS 1 BP 22 EP 32 DI 10.1002/cm.20539 PG 11 WC Cell Biology SC Cell Biology GA 877DG UT WOS:000299156500002 PM 22021175 ER PT J AU Lampiris, HW AF Lampiris, Harry W. TI Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY LA English DT Article DE cobicistat; elvitegravir; HIV-1 integrase; integrase drug interactions; integrase inhibitor; integrase pharmacokinetics; integrase resistance ID ANTIRETROVIRAL THERAPY; EXPERIENCED PATIENTS; STRAND TRANSFER; IN-VITRO; RESISTANCE; RALTEGRAVIR; PHARMACOKINETICS; INFECTION; FAILURE; EVOLUTION AB The development of HIV-1 integrase strand transfer inhibitors (INSTIs) has been a major therapeutic breakthrough in the management of HIV-1 infection. The first HIV-1 integrase inhibitor, raltegravir, was licensed in 2007 and was subsequently approved for use in treatment-naive patients. Since then, newer members of the INSTI class have been developed, including elvitegravir (EVG), which is in advanced clinical development and is being developed for use in both treatment-naive and treatment-experienced patients. EVG utilizes pharmacokinetic boosting to achieve adequate serum levels with once-daily dosing. Boosting agents with which it is being studied include ritonavir and cobicistat. In addition, EVG is being studied as a once-daily INSTI in a coformulated fixed-dose combination pill with the agents tenofovir disoproxil fumarate, emtricitabine and cobicistat (QUAD pill), which has the additional potential benefit of convenient once-daily dosing. The in vitro activity, pharmacokinetic and pharmacodynamic properties, results of Phase I-III clinical trials, resistance profile and drug-drug interactions of EVG will be reviewed in this article. C1 [Lampiris, Harry W.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lampiris, Harry W.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Lampiris, HW (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. EM harry.lampiris@va.gov NR 40 TC 11 Z9 12 U1 1 U2 2 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-7210 J9 EXPERT REV ANTI-INFE JI Expert Rev. Anti-Infect. Ther. PD JAN PY 2012 VL 10 IS 1 BP 13 EP 20 DI 10.1586/ERI.11.157 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 875ES UT WOS:000299013800007 PM 22149610 ER PT J AU Chattergoon, NN Giraud, GD Louey, S Stork, P Fowden, AL Thornburg, KL AF Chattergoon, Natasha N. Giraud, George D. Louey, Samantha Stork, Philip Fowden, Abigail L. Thornburg, Kent L. TI Thyroid hormone drives fetal cardiomyocyte maturation SO FASEB JOURNAL LA English DT Article DE proliferation; sheep fetus; p21 ID SIGNAL-REGULATED KINASE; CELL-CYCLE ACTIVITY; INTRAUTERINE GROWTH RESTRICTION; ATRIAL-NATRIURETIC-FACTOR; ACTIVATED PROTEIN-KINASE; CARDIAC-MUSCLE-CELLS; MEK-ERK PATHWAY; SARCOPLASMIC-RETICULUM; POSTNATAL-DEVELOPMENT; SHEEP CARDIOMYOCYTES AB Tri-iodo-L-thyronine (T-3) suppresses the proliferation of near-term serum-stimulated fetal ovine cardiomyocytes in vitro. Thus, we hypothesized that T-3 is a major stimulant of cardiomyocyte maturation in vivo. We studied 3 groups of sheep fetuses on gestational days 125-130 (term similar to 145 d): a T-3-infusion group, to mimic fetal term levels (plasma T-3 levels increased from similar to 0.1 to similar to 1.0 ng/ml; t(1/2) similar to 24 h); a thyroidectomized group, to produce low thyroid hormone levels; and a vehicle-infusion group, to serve as intact controls. At 130 d of gestation, sections of left ventricular freewall were harvested, and the remaining myocardium was enzymatically dissociated. Proteins involved in cell cycle regulation (p21, cyclin D1), proliferation (ERK), and hypertrophy (mTOR) were measured in left ventricular tissue. Evidence that elevated T-3 augmented the maturation rate of cardiomyocytes included 14% increased width, 31% increase in binucleation, 39% reduction in proliferation, 150% reduction in cyclin D1 protein, and 500% increase in p21 protein. Increased expression of phospho-mTOR, ANP, and SERCA2a also suggests that T-3 promotes maturation and hypertrophy of fetal cardiomyocytes. Thyroidectomized fetuses had reduced cell cycle activity and binucleation. These findings support the hypothesis that T-3 is a prime driver of prenatal cardiomyocyte maturation.-Chattergoon, N. N., Giraud, G. D., Louey, S., Stork, P., Fowden, A. L., Thornburg, K. L. Thyroid hormone drives fetal cardiomyocyte maturation FASEB J. 26, 397-408 (2012). www.fasebj.org C1 [Chattergoon, Natasha N.; Giraud, George D.; Louey, Samantha; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97239 USA. [Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Giraud, George D.; Louey, Samantha; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Stork, Philip] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA. [Giraud, George D.] Portland VA Med Ctr, Portland, OR USA. [Fowden, Abigail L.] Univ Cambridge, Physiol Lab, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England. RP Thornburg, KL (reprint author), Oregon Hlth & Sci Univ, Heart Res Ctr, 3303 SW Bond Ave,CH15H, Portland, OR 97239 USA. EM thornbur@ohsu.edu FU U.S. National Institute of Child Health and Human Development [P01 HD 34430]; National Heart, Lung, and Blood Institute (NHLBI) [R21 HL093617, T32HL094294]; National Institutes of Health [R01 HL102763] FX The authors thank Mr. Robert Webber and Ms. Loni Socha for excellent technical assistance. The authors appreciate support from the M. Lowell Edwards Endowment. This study was supported by funds from U.S. National Institute of Child Health and Human Development grant P01 HD 34430, National Heart, Lung, and Blood Institute (NHLBI) grant R21 HL093617, and National Institutes of Health grant R01 HL102763. N.N.C. was supported by NHLBI training grant T32HL094294. NR 91 TC 38 Z9 39 U1 2 U2 11 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD JAN PY 2012 VL 26 IS 1 BP 397 EP 408 DI 10.1096/fj.10-179895 PG 12 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 877SF UT WOS:000299202200039 PM 21974928 ER PT J AU Johnson, KA Hartwell, K LeMatty, T Borckardt, J Morgan, PS Govindarajan, K Brady, K George, MS AF Johnson, Kevin A. Hartwell, Karen LeMatty, Todd Borckardt, Jeffrey Morgan, Paul S. Govindarajan, Koushik Brady, Kathleen George, Mark S. TI Intermittent "Real-time" fMRI Feedback Is Superior to Continuous Presentation for a Motor Imagery Task: A Pilot Study SO JOURNAL OF NEUROIMAGING LA English DT Article DE fMRI; neurofeedback; real-time fMRI; motor imagery ID RESONANCE-IMAGING FMRI; CORTICAL ACTIVITY; BRAIN ACTIVATION; SELF-REGULATION; FUNCTIONAL MRI; NEUROFEEDBACK AB BACKGROUND Real-time functional MRI feedback (RTfMRIf) is a developing technique, with unanswered methodological questions. Given a delay of seconds between neural activity and the measurable hemodynamic response, one issue is the optimal method for presentation of neurofeedback to subjects. The primary objective of this preliminary study was to compare the methods of continuous and intermittent presentation of neural feedback on targeted brain activity. METHODS Thirteen participants performed a motor imagery task and were instructed to increase activation in an individually defined region of left premotor cortex using RTfMRIf. The fMRI signal change was compared between real and false feedback for scans with either continuous or intermittent feedback presentation. RESULTS More individuals were able to increase their fMRI signal with intermittent feedback, while some individuals had decreased signal with continuous feedback. The evaluation of feedback itself activated an extensive amount of brain regions, and false feedback resulted in brain activation outside of the individually defined region of interest. CONCLUSIONS As implemented in this study, intermittent presentation of feedback is more effective than continuous presentation in promoting self-modulation of brain activity. Furthermore, it appears that the process of evaluating feedback involves many brain regions that can be isolated using intermittent presentation. C1 [Johnson, Kevin A.] Stanford Univ, Dept Anesthesiol, Syst Neurosci & Pain Lab, Palo Alto, CA 94304 USA. [Hartwell, Karen; LeMatty, Todd; Brady, Kathleen] Med Univ S Carolina, Dept Psychiat, CNS Div, Charleston, SC 29425 USA. [Johnson, Kevin A.; Borckardt, Jeffrey; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [Johnson, Kevin A.; Morgan, Paul S.; Govindarajan, Koushik; George, Mark S.] Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [Morgan, Paul S.] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. [Hartwell, Karen; Brady, Kathleen; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Johnson, KA (reprint author), Stanford Univ, Dept Anesthesiol, Syst Neurosci & Pain Lab, 780 Welch Rd 208, Palo Alto, CA 94304 USA. EM johnsk@stanford.edu OI Morgan, Paul/0000-0002-5870-1446 FU NIH/NIDA (Brady, George) [1R21DA026085-01] FX The authors have no conflicts of interest to disclose. This study is supported in part by NIH/NIDA 1R21DA026085-01 (Brady, George). NR 17 TC 37 Z9 39 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1051-2284 J9 J NEUROIMAGING JI J. Neuroimaging PD JAN PY 2012 VL 22 IS 1 BP 58 EP 66 DI 10.1111/j.1552-6569.2010.00529.x PG 9 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 877DZ UT WOS:000299158500011 PM 20977537 ER PT J AU Marcum, ZA Amuan, ME Hanlon, JT Aspinall, SL Handler, SM Ruby, CM Pugh, MJV AF Marcum, Zachary A. Amuan, Megan E. Hanlon, Joseph T. Aspinall, Sherrie L. Handler, Steven M. Ruby, Christine M. Pugh, Mary Jo V. TI Prevalence of Unplanned Hospitalizations Caused by Adverse Drug Reactions in Older Veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE adverse drug reactions; veterans; aged; pharmacoepidemiology ID MEDICATION-USE; ELDERLY-PATIENTS; AMBULATORY-CARE; ADULTS; EVENTS; ADMISSION; GUIDELINES; POLYPHARMACY; PATIENT; RATES AB OBJECTIVES: To describe the prevalence of unplanned hospitalizations caused by adverse drug reactions (ADRs) in older veterans and to examine the association between this outcome and polypharmacy after controlling for comorbidities and other patient characteristics. DESIGN: Retrospective cohort. SETTING: Veterans Affairs Medical Centers. PARTICIPANTS: Six hundred seventy-eight randomly selected unplanned hospitalizations of older (aged >= 65) veterans between October 1, 2003, and September 30, 2006. MEASUREMENTS: Naranjo ADR algorithm, ADR preventability, and polypharmacy (0-4, 5-8, and >= 9 scheduled medications). RESULTS: Seventy ADRs involving 113 drugs were found in 68 (10%) hospitalizations of older veterans, of which 25 (36.8%) were preventable. Extrapolating to the population of more than 2.4 million older veterans receiving care during the study period, 8,000 hospitalizations may have been unnecessary. The most common ADRs that occurred were bradycardia (n = 6; beta-blockers, digoxin), hypoglycemia (n = 6; sulfonylureas, insulin), falls (n = 6; antidepressants, angiotensin-converting enzyme inhibitors), and mental status changes (n = 6; anticonvulsants, benzodiazepines). Overall, 44.8% of veterans took nine or more outpatient medications and 35.4% took five to eight. Using multivariable logistic regression and controlling for demographic, health-status, and access-to-care variables, polypharmacy (>= 9 and 5-8) was associated with greater risk of ADR-related hospitalization (adjusted odds ratio (AOR) = 3.90, 95% confidence interval (CI) = 1.43-10.61 and AOR = 2.85, 95% CI = 1.03-7.85, respectively). CONCLUSION: ADRs, determined using a validated causality algorithm, are a common cause of unplanned hospitalization in older veterans, are frequently preventable, and are associated with polypharmacy. J Am Geriatr Soc 60:34-41, 2012. C1 [Marcum, Zachary A.; Hanlon, Joseph T.; Handler, Steven M.; Ruby, Christine M.] Univ Pittsburgh, Sch Med, Dept Geriatr, Pittsburgh, PA 15213 USA. [Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.; Aspinall, Sherrie L.; Ruby, Christine M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Amuan, Megan E.] Bedford Vet Affairs Med Ctr, Bedford, MA USA. [Hanlon, Joseph T.; Handler, Steven M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Hanlon, Joseph T.; Aspinall, Sherrie L.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Aspinall, Sherrie L.] Vet Affairs Ctr Medicat Safety, Hines, IL USA. [Pugh, Mary Jo V.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr & Gerontol, Dept Med, San Antonio, TX 78229 USA. RP Marcum, ZA (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA. EM zam12@pitt.edu OI Handler, Steven/0000-0002-3940-3224; Pugh, Mary Jo/0000-0003-4196-7763 FU National Institute on Aging (NIA) [R01AG027017, P30AG024827, T32AG021885, K07AG033174, R01AG034056]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01NR010135]; Agency for Healthcare Research and Quality [R01HS017695, R01HS018721, R18HS018151, K12HS019461]; VA Health Services Research and Development Service (HSR D) [IIR-06-062, DHI 09-237, IIR 02274, IIR 08-274, SDR-07-042, IIR-05-121, IAF-06-080, IIR-09335]; NIA [K07AG033174, U01 AG012553]; Pennsylvania Department of Aging; Epilepsy Foundation; SHP [08-140] FX Dr. Hanlon has received research funding from National Institute on Aging (NIA) Grants R01AG027017, P30AG024827, T32AG021885, K07AG033174, and R01AG034056; National Institute of Mental Health Grant R34 MH082682, National Institute of Nursing Research Grant R01NR010135, Agency for Healthcare Research and Quality Grant R01HS017695, and VA Health Services Research and Development Service (HSR& D) IIR-06-062. Dr. Handler has received research funding from Agency for Healthcare Research and Quality Grants R01HS018721 and R18HS018151; NIA Grant K07AG033174, a Pennsylvania Department of Aging grant, and from VA HSR& D IIR-06-062. Dr. Pugh has received research funding from VA HSR& D DHI 09-237 (PI); VA HSR& D IIR-06-062 (PI), Epilepsy Foundation (PI), VA HSR& D PPO 09-295 PI, VA HSR& D IIR 02274 PI. Pugh as co-I: VA HSR& D IIR 08-274, VA HSR& D SDR-07-042, IIR-05-121, IAF-06-080, IIR-09335, SHP 08-140, TRX 01-091 Department of Defense CDMRP 09090014, NIH R01-NR010828, Pugh Speaker Honoraria: 2009 Kelsey Seybold Research Foundation. The investigators received support from NIA Grant U01 AG012553 and Agency for Healthcare Research and Quality Grant K12HS019461. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 50 TC 47 Z9 48 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2012 VL 60 IS 1 BP 34 EP 41 DI 10.1111/j.1532-5415.2011.03772.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 875PN UT WOS:000299044100005 PM 22150441 ER PT J AU Shega, JW Dale, W Andrew, M Paice, J Rockwood, K Weiner, DK AF Shega, Joseph W. Dale, William Andrew, Melissa Paice, Judith Rockwood, Kenneth Weiner, Debra K. TI Persistent Pain and Frailty: A Case for Homeostenosis SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pain; frailty; older adults; homeostenosis ID LOW-BACK-PAIN; OLDER-ADULTS; MORTALITY; PEOPLE; PREVALENCE; MANAGEMENT; DEMENTIA; IMPACT; CARE; 3MS AB OBJECTIVES: To compare the association between self-reported moderate to severe pain and frailty. DESIGN: Cross-sectional analysis of the Canadian Study of Health and Aging Wave 2. SETTING: Community. PARTICIPANTS: Representative sample of persons aged 65 and older in Canada. MEASUREMENTS: Pain (exposure) was categorized as no or very mild pain versus moderate or greater pain. Frailty (outcome) was operationalized as the accumulation of 33 possible self-reported health attitudes, illnesses, and functional abilities, subsequently divided into tertiles (not frail, prefrail, and frail). Multivariable logistic regression assessed for the association between pain and frailty. RESULTS: Of participants who reported moderate or greater pain (35.5%, 1,765/4,968), 16.2% were not frail, 34.1% were prefrail, and 49.8% were frail. For persons with moderate or greater pain, the odds of being prefrail rather than not frail were higher by a factor of 2.52 (95% confidence interval (CI) = 2.13-2.99; P < .001). For persons with moderate or greater pain, the odds of being frail rather than not frail were higher by a factor of 5.52 (95% CI = 4.49-6.64 P < .001). CONCLUSION: Moderate or higher pain was independently associated with frailty. Although causality cannot be ascertained in a cross-sectional analysis, interventions to improve pain management may help prevent or ameliorate frailty. J Am Geriatr Soc 60:113-117, 2012. C1 [Shega, Joseph W.; Dale, William] Univ Chicago, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA. [Shega, Joseph W.] Univ Chicago, Sect Hematol & Oncol, Chicago, IL 60637 USA. [Andrew, Melissa; Rockwood, Kenneth] Dalhousie Univ, Div Geriatr Med, Halifax, NS, Canada. [Paice, Judith] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA. [Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. RP Shega, JW (reprint author), Univ Chicago, Sect Geriatr & Palliat Med, MC 6098,5841 S Maryland Ave, Chicago, IL 60637 USA. EM jshega@gmail.com FU National Health Research Development Program; Seniors' Independence Research program [6606-3954-MC(S)]; National Institute on Aging [K23AG029815]; Canadian Institutes of Health Research [MOP-62823]; Dalhousie Medical Research Foundation; QEII Research Foundation FX All the data reported here were gathered using public funding from the National Health Research Development Program, which administrated a grant from the Seniors' Independence Research program (6606-3954-MC(S)). Funding for these analyses came from a career development award K23AG029815 from the National Institute on Aging and from the Canadian Institutes of Health Research through operating grant MOP-62823. Additional support came from the Dalhousie Medical Research Foundation (career support to KR as Kathryn Allen Weldon Professor of Alzheimer Research) and the Fountain Innovation Fund of the QEII Research Foundation. NR 29 TC 22 Z9 22 U1 2 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2012 VL 60 IS 1 BP 113 EP 117 DI 10.1111/j.1532-5415.2011.03769.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 875PN UT WOS:000299044100015 PM 22150394 ER PT J AU O'Hare, AM AF O'Hare, Ann M. TI Age and Access to Kidney Transplantation SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material ID OLDER-ADULTS; PROGNOSTIC INDEX; MORTALITY; VALIDATION C1 [O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA. [O'Hare, Ann M.] Grp Hlth Res Inst Seattle, Seattle, WA USA. RP O'Hare, AM (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. NR 15 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2012 VL 60 IS 1 BP 151 EP 153 DI 10.1111/j.1532-5415.2011.03790.x PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 875PN UT WOS:000299044100022 PM 22239294 ER PT J AU Zhan, W Kang, GA Glass, GA Zhang, Y Shirley, C Millin, R Possin, KL Nezamzadeh, M Weiner, MW Marks, WJ Schuff, N AF Zhan, Wang Kang, Gail A. Glass, Graham A. Zhang, Yu Shirley, Cheryl Millin, Rachel Possin, Katherine L. Nezamzadeh, Marzieh Weiner, Michael W. Marks, William J., Jr. Schuff, Norbert TI Regional Alterations of Brain Microstructure in Parkinson's Disease Using Diffusion Tensor Imaging SO MOVEMENT DISORDERS LA English DT Article DE diffusion tensor imaging; magnetic resonance imaging; Parkinson's disease; subtypes ID SUBSTANTIA-NIGRA; BASAL GANGLIA; RAT MODEL; TRACT; SENSORIMOTOR; DISORDERS; DEMENTIA; MRI AB This study tested the hypothesis that diffusion tensor imaging can detect alteration in microscopic integrity of white matter and basal ganglia regions known to be involved in Parkinson's disease (PD) pathology. It was also hypothesized that there is an association between diffusion abnormality and PD severity and subtype. Diffusion tensor imaging at 4 Tesla was obtained in 12 PD and 20 control subjects, and measures of fractional anisotropy and mean diffusivity were evaluated using both region-of-interest and voxel-based methods. Movement deficits and subtypes in PD subjects were assessed using the Motor Subscale (Part III) of the Unified Parkinson's Disease Rating Scale. Reduced fractional anisotropy (P < .05, corrected) was found in PD subjects in regions related to the precentral gyrus, substantia nigra, putamen, posterior striatum, frontal lobe, and the supplementary motor areas. Reduced fractional anisotropy in the substantia nigra correlated (P < .05, corrected) with the increased rating scale motor scores. Significant spatial correlations between fractional anisotropy alterations in the putamen and other PD-affected regions were also found in the context of PD subtypes index analysis. Our data suggest that microstructural alterations detected with diffusion tensor might serve as a potential biomarker for PD. (C) 2011 Movement Disorder Society C1 [Zhan, Wang; Zhang, Yu; Shirley, Cheryl; Millin, Rachel; Nezamzadeh, Marzieh; Weiner, Michael W.; Schuff, Norbert] Univ Calif San Francisco, Dept Radiol & Med Imaging, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Kang, Gail A.; Glass, Graham A.; Marks, William J., Jr.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. [Kang, Gail A.; Glass, Graham A.; Possin, Katherine L.; Marks, William J., Jr.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. RP Zhan, W (reprint author), Univ Calif San Francisco, Dept Radiol, VA Med Ctr 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM Wang.Zhan@gmail.com FU Michael J. Fox Foundation [MJJF-BM2007]; NIH/NIRR "Research Resource for MRI of Neurodegenerative Disorders" [1 P41RR023953]; Larry L. Hillblom Foundation [2008-A-020-FEL] FX This work was supported in part by the Michael J. Fox Foundation for Parkinson's Research, "Multimodal MRI Markers for Parkinson's Disease" (MJJF-BM2007); NIH/NIRR "Research Resource for MRI of Neurodegenerative Disorders" (1 P41RR023953); and the Larry L. Hillblom Foundation, "Early markers and brain bases of spatial impairment in alpha-synuclein disorders" (2008-A-020-FEL). NR 47 TC 59 Z9 61 U1 1 U2 13 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN PY 2012 VL 27 IS 1 BP 90 EP 97 DI 10.1002/mds.23917 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 877DA UT WOS:000299155900015 PM 21850668 ER PT J AU Flaherty, P Natsoulis, G Muralidharan, O Winters, M Buenrostro, J Bell, J Brown, S Holodniy, M Zhang, N Ji, HP AF Flaherty, Patrick Natsoulis, Georges Muralidharan, Omkar Winters, Mark Buenrostro, Jason Bell, John Brown, Sheldon Holodniy, Mark Zhang, Nancy Ji, Hanlee P. TI Ultrasensitive detection of rare mutations using next-generation targeted resequencing SO NUCLEIC ACIDS RESEARCH LA English DT Article ID DNA; VARIANTS; PERFORMANCE; CANCER AB With next-generation DNA sequencing technologies, one can interrogate a specific genomic region of interest at very high depth of coverage and identify less prevalent, rare mutations in heterogeneous clinical samples. However, the mutation detection levels are limited by the error rate of the sequencing technology as well as by the availability of variant-calling algorithms with high statistical power and low false positive rates. We demonstrate that we can robustly detect mutations at 0.1% fractional representation. This represents accurate detection of one mutant per every 1000 wild-type alleles. To achieve this sensitive level of mutation detection, we integrate a high accuracy indexing strategy and reference replication for estimating sequencing error variance. We employ a statistical model to estimate the error rate at each position of the reference and to quantify the fraction of variant base in the sample. Our method is highly specific (99%) and sensitive (100%) when applied to a known 0.1% sample fraction admixture of two synthetic DNA samples to validate our method. As a clinical application of this method, we analyzed nine clinical samples of H1N1 influenza A and detected an oseltamivir (antiviral therapy) resistance mutation in the H1N1 neuraminidase gene at a sample fraction of 0.18%. C1 [Flaherty, Patrick; Natsoulis, Georges; Buenrostro, Jason; Bell, John; Ji, Hanlee P.] Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA. [Flaherty, Patrick] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA. [Muralidharan, Omkar; Zhang, Nancy] Stanford Univ, Dept Stat, Stanford, CA 94305 USA. [Winters, Mark; Holodniy, Mark] Stanford Univ, Div Infect Dis, Dept Med, Stanford, CA 94305 USA. [Brown, Sheldon] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Holodniy, Mark] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Ji, Hanlee P.] Stanford Univ, Div Oncol, Dept Med, Sch Med, Stanford, CA 94305 USA. RP Ji, HP (reprint author), Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA. EM genomics_ji@stanford.edu FU National Science Foundation, Division of Mathematical Sciences (NSF DMS) DMS [1043204]; Department of Veterans Affairs; National Institutes of Health (NIH) [5K08CA96879-6, DK56339, 2P01HG000205, R21CA140089]; Doris Duke Clinical Foundation; Reddere Foundation; Liu Bie Ju Cha and Family Fellowship in Cancer; Wang Family Foundation; Howard Hughes Medical Foundation FX National Science Foundation, Division of Mathematical Sciences (NSF DMS) DMS (Grant #1043204 to N.Z. and H.P.J.); Department of Veterans Affairs (in part, to M. H.); National Institutes of Health (NIH) (grants 5K08CA96879-6 to H.P.J., DK56339 to H.P.J, 2P01HG000205 to J.B., J.M.B., H.P.J. and P. F. and R21CA140089 to G.N. and H.P.J.); Doris Duke Clinical Foundation (to H.P.J.); Reddere Foundation (to H.P.J.); Liu Bie Ju Cha and Family Fellowship in Cancer (to H.P.J.); Wang Family Foundation (to H.P.J.); Howard Hughes Medical Foundation (to H.P.J.). Funding for open access charge: NIH (grant 2P01HG000205) and NSF DMS (grant 1043204). NR 21 TC 54 Z9 54 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD JAN PY 2012 VL 40 IS 1 AR e2 DI 10.1093/nar/gkr861 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 871JG UT WOS:000298733500002 PM 22013163 ER PT J AU Livhits, M Mercado, C Yermilov, I Parikh, JA Dutson, E Mehran, A Ko, CY Gibbons, MM AF Livhits, Masha Mercado, Cheryl Yermilov, Irina Parikh, Janak A. Dutson, Erik Mehran, Amir Ko, Clifford Y. Gibbons, Melinda Maggard TI Preoperative Predictors of Weight Loss Following Bariatric Surgery: Systematic Review SO OBESITY SURGERY LA English DT Review DE Bariatric surgery; Predictors; Weight loss; Preoperative; Outcomes ID Y GASTRIC BYPASS; VERTICAL BANDED GASTROPLASTY; QUALITY-OF-LIFE; MORBIDLY OBESE-PATIENTS; BODY-MASS INDEX; 12-MONTH POSTOPERATIVE OUTCOMES; DUODENAL SWITCH OPERATION; CHILDHOOD SEXUAL-ABUSE; BINGE-EATING DISORDER; RISKS VS. BENEFITS AB Obesity affects 32% of adults in the USA. Surgery generates substantial weight loss, but 20-30% fails to achieve successful weight loss. Our objective was to identify preoperative psychosocial factors associated with weight loss following bariatric surgery. We performed a literature search of PubMedA (R) and the Cochrane Database of Reviews of Effectiveness between 1988 and April 2010. Articles were screened for bariatric surgery and weight loss if they included a preoperative predictor of weight loss: body mass index (BMI), preoperative weight loss, eating disorders, or psychiatric disorder/substance abuse. One thousand seven titles were reviewed, 534 articles screened, and 115 included in the review. Factors that may be positively associated with weight loss after surgery include mandatory preoperative weight loss (7 of 14 studies with positive association). Factors that may be negatively associated with weight loss include preoperative BMI (37 out of 62 studies with negative association), super-obesity (24 out of 33 studies), and personality disorders (7 out of 14 studies). Meta-analysis revealed a decrease of 10.1% excess weight loss (EWL) for super-obese patients (95% confidence interval (CI) [3.7-16.5%]), though there was significant heterogeneity in the meta-analysis, and an increase of 5.9% EWL for patients with binge eating at 12 months after surgery (95% CI [1.9-9.8%]). Further studies are necessary to investigate whether preoperative factors can predict a clinically meaningful difference in weight loss after bariatric surgery. The identification of predictive factors may improve patient selection and help develop interventions targeting specific needs of patients. C1 [Livhits, Masha; Yermilov, Irina; Parikh, Janak A.; Ko, Clifford Y.; Gibbons, Melinda Maggard] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA. [Livhits, Masha; Mercado, Cheryl; Yermilov, Irina; Parikh, Janak A.; Dutson, Erik; Mehran, Amir; Ko, Clifford Y.; Gibbons, Melinda Maggard] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Gibbons, Melinda Maggard] Olive View UCLA, Dept Surg, Los Angeles, CA 91342 USA. RP Livhits, M (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Surg, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mlivhits@mednet.ucla.edu FU VA Department of Surgery; Robert Wood Johnson Physician Faculty FX We would like to acknowledge the generous contribution of Paul G. Shekelle to the design of our project and critical review of the analysis. The VA Department of Surgery provided support for Dr. Livhits and Dr. Gibbons. Dr. Gibbons's time was supported in part by a grant from the Robert Wood Johnson Physician Faculty Scholars program. NR 145 TC 154 Z9 155 U1 5 U2 42 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0960-8923 EI 1708-0428 J9 OBES SURG JI Obes. Surg. PD JAN PY 2012 VL 22 IS 1 BP 70 EP 89 DI 10.1007/s11695-011-0472-4 PG 20 WC Surgery SC Surgery GA 876PU UT WOS:000299120700013 PM 21833817 ER PT J AU Bourguignon, LYW Earle, C Wong, G Spevak, CC Krueger, K AF Bourguignon, L. Y. W. Earle, C. Wong, G. Spevak, C. C. Krueger, K. TI Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells SO ONCOGENE LA English DT Article DE nanog; Stat-3; miR-21; hyaluronan; CD44; head & neck cancer ID NF-KAPPA-B; CANCER STATISTICS; GENE-EXPRESSION; TUMOR-CELLS; RHO-KINASE; HYALURONAN; BREAST; PROGRESSION; ACTIVATION; TRANSCRIPTION AB MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog-Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. Oncogene (2012) 31, 149-160; doi:10.1038/onc.2011.222; published online 20 June 2011 C1 [Bourguignon, L. Y. W.] Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA. EM lilly.bourguignon@ucsf.edu FU Veterans Affairs (VA) Merit Review grant; United States Public Health grants [R01 CA66163, R01 CA78633, P01 AR39448] FX We gratefully acknowledge the assistance of Drs Gerard J Bourguignon and Walter M Holleran in the preparation and review of this manuscript. We are grateful for Ms Christina Camacho for her assistance in preparing graphs and illustrations. We would also like to thank for Dr Shaomeng Wang from the University of Michigan for providing us an IAP inhibitor, SM164. This work was supported by Veterans Affairs (VA) Merit Review grant and United States Public Health grants (R01 CA66163, R01 CA78633 and P01 AR39448). LYWB is a VA Senior Research Career Scientist. NR 30 TC 90 Z9 94 U1 2 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD JAN PY 2012 VL 31 IS 2 BP 149 EP 160 DI 10.1038/onc.2011.222 PG 12 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 879CN UT WOS:000299307400002 PM 21685938 ER PT J AU Meghani, SH Polomano, RC Tait, RC Vallerand, AH Anderson, KO Gallagher, RM AF Meghani, Salimah H. Polomano, Rosemary C. Tait, Raymond C. Vallerand, April H. Anderson, Karen O. Gallagher, Rollin M. TI Advancing a National Agenda to Eliminate Disparities in Pain Care: Directions for Health Policy, Education, Practice, and Research SO PAIN MEDICINE LA English DT Article DE Pain; Disparities-Ethnic; Disparities-Racial; Pain Management; Pain Treatment; Policy; Advocacy; Legislation; Ethnic Disparities; Opioids; Analgesics; United States ID LIMITED ENGLISH PROFICIENCY; PATIENT-PHYSICIAN RELATIONSHIP; RANDOMIZED CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; UNITED-STATES; CULTURAL COMPETENCE; ETHNIC DISPARITIES; WHITE AMERICANS; CANCER-PATIENTS; MUSCULOSKELETAL PAIN AB Background. Pain is strongly associated with significant personal and societal costs. A crucial element of any initiative on pain must focus on eliminating pain care disparities that are pervasive throughout the United States health care settings. Objectives. This report focuses on macro-level factors related to pain care disparities in the United States that may be amenable to policy interventions. Methods. We identify concrete opportunities for achieving equity in pain care, especially those occasioned by recent legislative changes in the United States health care system. An aggressive policy, advocacy, and research agenda is synthesized in five domains: 1) structural/system; 2) policy and advocacy; 3) workforce; 4) provider; and 5) research. Results. Inequities in pain care remain an important and neglected health policy concern. Many direct and indirect provisions within the Affordable Care Act (ACA) and other national initiatives that leverage on ACA offer opportunities to achieve equity in pain care. These include changes in insurance, in public, provider, and legislative education, in primary care and pain specialist training, improving workforce diversity, achieving uniformity in race/ethnicity data collection, emphasizing patient-centered outcomes research, and encouraging focus on pain care disparities within the comparative effectiveness research paradigm. Conclusions. Recent national legislative initiatives within ACA are expected to generate multilevel efforts that will impact the flow of funding to address the pervasive issue of disparities. It is an opportune time for the pain community to take a lead in implementing a concerted agenda on pain care disparities in order to leverage these national initiatives. C1 [Meghani, Salimah H.] Univ Penn, Ctr Bioeth, NewCourtland Ctr Transit & Hlth, Dept Biobehav Hlth Sci,Sch Nursing, Philadelphia, PA 19104 USA. [Tait, Raymond C.] St Louis Univ, St Louis, MO 63103 USA. [Vallerand, April H.] Wayne State Univ, Detroit, MI USA. [Anderson, Karen O.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Gallagher, Rollin M.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Meghani, SH (reprint author), Univ Penn, Ctr Bioeth, NewCourtland Ctr Transit & Hlth, Dept Biobehav Hlth Sci,Sch Nursing, Claire M Fagin Hall,418 Curie Blvd,Room 337, Philadelphia, PA 19104 USA. EM meghanis@nursing.upenn.edu RI Vallerand, April/I-8150-2012 FU Pricara, Unit of Ortho-McNeil, Inc. FX This work was supported by an unrestricted educational grant to the Philadelphia Research and Education Foundation, Philadelphia VA Medical Center, from Pricara, Unit of Ortho-McNeil, Inc., administered by Ortho-McNeil Janssen Scientific Affairs. NR 152 TC 34 Z9 34 U1 4 U2 22 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD JAN PY 2012 VL 13 IS 1 BP 5 EP 28 DI 10.1111/j.1526-4637.2011.01289.x PG 24 WC Medicine, General & Internal SC General & Internal Medicine GA 874KB UT WOS:000298954200002 PM 22142450 ER PT J AU Wu, Y Collier, L Pan, J Qin, W Bauman, WA Cardozo, CP AF Wu, Y. Collier, L. Pan, J. Qin, W. Bauman, W. A. Cardozo, C. P. TI Testosterone reduced methylprednisolone-induced muscle atrophy in spinal cord-injured rats SO SPINAL CORD LA English DT Article DE Spinal cord injury; methylprednisolone; muscle atrophy; atrogenes; testosterone ID HIGH-DOSE METHYLPREDNISOLONE; GROWTH-FACTOR-I; SKELETAL-MUSCLE; SERUM TESTOSTERONE; CONTROLLED-TRIAL; GENE-EXPRESSION; UP-REGULATION; MYOSTATIN; DIAPHRAGM; PROTEIN AB Study design: Male rats with complete transections of the spinal cord were administered vehicle or methylprednisolone (MP) for 24 h, with or without infusion, for 7 days, of testosterone at either a replacement or low pharmacological doses. Muscles were collected at 7 days after SCI. Objective: The objective of this study is to determine, in a rat model of complete spinal cord transection, whether testosterone reduces muscle atrophy or upregulates muscle atrophy-linked genes, induced by 24 h of MP administration at doses comparable to those prescribed in man during the period immediately following acute spinal cord injury (SCI) in an attempt to preserve neurological function. Results: MP significantly reduced the mass of triceps, soleus and plantaris, and significantly increased expression of genes that promote atrophy. Testosterone significantly reduced muscle atrophy induced by MP, but did not prevent it; there was no difference between low-or high-dose testosterone in reducing MP-induced muscle loss. High-dose testosterone reduced expression of muscle atrophy genes more than did low dose. Testosterone-induced declines in mRNA levels for these atrophy-associated genes did not correlate well with protection against MP-induced muscle atrophy. Conclusions: MP induces marked and lasting changes in the biology of muscle that persisted for at least 7 days, or 6 days after MP has been eliminated from the body. Testosterone partially protected against muscle atrophy and gene expression changes caused by 1 day of MP. Spinal Cord (2012) 50, 57-62; doi:10.1038/sc.2011.91; published online 20 September 2011 C1 [Wu, Y.; Collier, L.; Pan, J.; Qin, W.; Bauman, W. A.; Cardozo, C. P.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Bronx, NY 10468 USA. [Qin, W.; Bauman, W. A.; Cardozo, C. P.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, W. A.; Cardozo, C. P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Cardozo, CP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Room 7A-13,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Chris.Cardozo@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B4162C, B3347 K] FX This research was supported by the Veterans Health Administration, Rehabilitation Research and Development Service (B4162C and B3347 K). NR 33 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD JAN PY 2012 VL 50 IS 1 BP 57 EP 62 DI 10.1038/sc.2011.91 PG 6 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 879FB UT WOS:000299314000011 PM 21931329 ER PT J AU Williams, RE Bauman, WA Spungen, AM Vinnakota, RR Farid, RZ Galea, M Korsten, MA AF Williams, R. E., III Bauman, W. A. Spungen, A. M. Vinnakota, R. R. Farid, R. Z. Galea, M. Korsten, M. A. TI SmartPill technology provides safe and effective assessment of gastrointestinal function in persons with spinal cord injury SO SPINAL CORD LA English DT Article DE spinal cord injury; gastric emptying time; colonic transit time; whole gut transit time; gastroesophageal reflux disease ID CAPSULE AB Study design: Spinal cord injury (SCI) results in gastrointestinal (GI) complications, including gastroesophageal reflux disease and constipation, but much of the data is based on older technology. Objective: GI transit times were determined in subjects with SCI using a new device called a SmartPill. Our principal goal was to assess whether this new technology can be applied in persons with SCI. Methods: SCI and age-and gender-matched able-bodied (AB) control subjects not taking proton pump inhibitors were studied. Following an 8-h overnight fast, subjects consumed 120 g EggBeaters (60 kcal), two slices of white bread (120 kcal) and 30g strawberry jam (74 kcal). A pH calibrated SmartPill capsule was swallowed with 8 ounces of water, after which subjects fasted for an additional 6 h prior to consuming an Ensure Plus nutrition shake (350kcal). Subjects remained fasted for an additional 2 h, after which time they resumed their regular diets. Results: Twenty subjects with SCI and 10 AB control subjects were studied. Data are expressed as mean +/- s.d. Comparing the group with SCI to the AB control group, gastric emptying time (GET), colonic transit time (CTT) and whole gut transit time (WGTT) were prolonged (GET: 10.6 +/- 7.2 vs 3.5 +/- 1.0h, P < 0.01; CTT: 52.3 +/- 42.9 vs 14.2 +/- 7.6 h, P = 0.01; WGTT: 3.3 +/- 2.5 vs 1.0 +/- 0.7 days, P < 0.01). No complications or side effects were reported. Conclusion: Our results indicate that the SmartPill technology is a safe, non-invasive assessment technique that provides valid diagnostic information in persons with SCI. Spinal Cord (2012) 50, 81-84; doi:10.1038/sc.2011.92; published online 30 August 2011 C1 [Korsten, M. A.] James J Peters Vet Affairs Med Ctr, Gastroenterol Serv, VA RR&D Ctr Excellence Med Consequences Spinal Co, Bronx, NY 10468 USA. [Bauman, W. A.; Spungen, A. M.; Korsten, M. A.] James J Peters Vet Affairs Med Ctr, Med Serv, Bronx, NY 10468 USA. [Bauman, W. A.; Spungen, A. M.; Korsten, M. A.] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA. [Bauman, W. A.; Spungen, A. M.; Korsten, M. A.] Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA. [Galea, M.] James J Peters Vet Affairs Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA. RP Korsten, MA (reprint author), James J Peters Vet Affairs Med Ctr, Gastroenterol Serv, VA RR&D Ctr Excellence Med Consequences Spinal Co, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM mark.korsten@va.gov FU Department of Veteran Affairs Rehabilitation Research and Development Service Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162-C]; James J Peters VA Medical Center FX The Department of Veteran Affairs Rehabilitation Research and Development Service Center of Excellence for the Medical Consequences of Spinal Cord Injury (#B4162-C) and the James J Peters VA Medical Center have provided the support that made this work possible. NR 11 TC 8 Z9 8 U1 3 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD JAN PY 2012 VL 50 IS 1 BP 81 EP 84 DI 10.1038/sc.2011.92 PG 4 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 879FB UT WOS:000299314000016 PM 21876549 ER PT J AU Tomedi, LE Bogen, DL Hanusa, BH Wisner, KL Bodnar, LM AF Tomedi, Laura Elizabeth Bogen, Debra L. Hanusa, Barbara H. Wisner, Katherine L. Bodnar, Lisa M. TI A Pilot Study of the Nutritional Status of Opiate-Using Pregnant Women on Methadone Maintenance Therapy SO SUBSTANCE USE & MISUSE LA English DT Article DE methadone; pregnancy; nutrition; obesity; dietary intake; nutritional biomarkers ID POSTNATAL DEPRESSION SCALE; NEURAL-TUBE DEFECTS; ILLICIT DRUG-USE; HISTORY QUESTIONNAIRE; SUBSTANCE USE; BIRTH-WEIGHT; LIFE-STYLE; VITAMIN; PREVALENCE; VALIDATION AB Pregnant women in methadone maintenance therapy may have poor nutrition during pregnancy. In 2006-2008, methadone-treated pregnant women (n = 22) were recruited at an urban academic medical center and compared with nondrug-using pregnant women (n = 119) at 20-35 weeks' gestation. We measured adiposity using prepregnancy body mass index (BMI), dietary intake using a food frequency questionnaire, and micronutrient and essential fatty acid status using biomarkers. Methadone-treated women had lower BMI, consumed more calories, had lower serum carotenoid concentrations, and higher plasma homocysteine concentrations than controls. The study's limitations and implications for future research are discussed. C1 [Tomedi, Laura Elizabeth; Wisner, Katherine L.; Bodnar, Lisa M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Bogen, Debra L.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Div Gen Acad Pediat, Pittsburgh, PA USA. [Hanusa, Barbara H.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Wisner, Katherine L.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Wisner, Katherine L.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Sch Med, Pittsburgh, PA USA. RP Tomedi, LE (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. EM let20@pitt.edu FU Children's Hospital of Pittsburgh Research Advisory Committee; Gerber Foundation; National Institutes of Health (NIH) [MO1RR00056]; Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Award [K12 HD043441]; NIH/NIMH (National Institute of Mental Health) [R01 MH060335, K01 MH074092]; National Institute of Child Health and Human Development (NICHD) [HD 055 162-03 NIH NRSA T32] FX This study was funded by the Children's Hospital of Pittsburgh Research Advisory Committee and the Gerber Foundation. Study visits were conducted in the Magee-Womens Hospital Clinical and Translational Research Center, which is funded by National Institutes of Health (NIH; grant MO1RR00056). The authors' contributions to this work were supported by K12 HD043441 [Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Award], NIH/NIMH (National Institute of Mental Health) grants R01 MH060335 and K01 MH074092, and the Reproductive, Perinatal and Pediatric Epidemiology grant HD 055 162-03 NIH NRSA T32 [National Institute of Child Health and Human Development (NICHD)]. NR 52 TC 2 Z9 2 U1 3 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1082-6084 EI 1532-2491 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2012 VL 47 IS 3 BP 286 EP 295 DI 10.3109/10826084.2011.635324 PG 10 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA 873BT UT WOS:000298856500008 PM 22217127 ER PT J AU Mufson, EJ Binder, L Counts, SE DeKosky, ST deToledo-Morrell, L Ginsberg, SD Ikonomovic, MD Perez, SE Scheff, SW AF Mufson, Elliott J. Binder, Lester Counts, Scott E. DeKosky, Steven T. deToledo-Morrell, Leyla Ginsberg, Stephen D. Ikonomovic, Milos D. Perez, Sylvia E. Scheff, Stephen W. TI Mild cognitive impairment: pathology and mechanisms SO ACTA NEUROPATHOLOGICA LA English DT Review DE Alzheimer's disease; Amyloid; Cholinergic; Dementia; MCI; Neurofibrillary tangles; Neuropathology; Molecular; Neurotrophins; Synapses ID EARLY ALZHEIMERS-DISEASE; CHOLINERGIC BASAL FOREBRAIN; AMYLOID PRECURSOR PROTEIN; NICOTINIC ACETYLCHOLINE-RECEPTOR; ENTORHINAL CORTEX NEURONS; CENTRAL-NERVOUS-SYSTEM; PRIMARY VISUAL-CORTEX; E TYPE-4 ALLELE; SUBSTANTIA INNOMINATA; NUCLEUS BASALIS AB Mild cognitive impairment (MCI) is rapidly becoming one of the most common clinical manifestations affecting the elderly. The pathologic and molecular substrate of people diagnosed with MCI is not well established. Since MCI is a human specific disorder and neither the clinical nor the neuropathological course appears to follow a direct linear path, it is imperative to characterize neuropathology changes in the brains of people who came to autopsy with a well-characterized clinical diagnosis of MCI. Herein, we discuss findings derived from clinical pathologic studies of autopsy cases who died with a clinical diagnosis of MCI. The heterogeneity of clinical MCI imparts significant challenges to any review of this subject. The pathologic substrate of MCI is equally complex and must take into account not only conventional plaque and tangle pathology but also a wide range of cellular, biochemical and molecular deficits, many of which relate to cognitive decline as well as compensatory responses to the progressive disease process. The multifaceted nature of the neuronal disconnection syndrome associated with MCI suggests that there is no single event which precipitates this prodromal stage of AD. In fact, it can be argued that neuronal degeneration initiated at different levels of the central nervous system drives cognitive decline as a final common pathway at this stage of the dementing disease process. C1 [Mufson, Elliott J.; Counts, Scott E.; deToledo-Morrell, Leyla; Perez, Sylvia E.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Binder, Lester] Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA. [DeKosky, Steven T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Ginsberg, Stephen D.] NYU, Langone Med Ctr, Ctr Dementia Res, Nathan Kline Inst,Dept Psychiat, Orangeburg, NY 10962 USA. [Ginsberg, Stephen D.] NYU, Langone Med Ctr, Ctr Dementia Res, Nathan Kline Inst,Dept Physiol, Orangeburg, NY 10962 USA. [Ginsberg, Stephen D.] NYU, Langone Med Ctr, Ctr Dementia Res, Nathan Kline Inst,Dept Neurosci, Orangeburg, NY 10962 USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Educ & Clin Ctr, Pittsburgh, PA 15260 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Educ & Clin Ctr, Pittsburgh, PA USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Geriatr Res, Educ & Clin Ctr, Pittsburgh, PA USA. [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. RP Mufson, EJ (reprint author), Rush Univ, Med Ctr, Dept Neurol Sci, 1735 W Harrison St,Suite 300, Chicago, IL 60612 USA. EM emufson@rush.edu OI Ginsberg, Stephen /0000-0002-1797-4288 FU NIA [PO1 AG14999, PO1 AG09466, AG10688, AG025204] FX This study was supported by NIA grants PO1 AG14999, PO1 AG09466, AG10688 and AG025204. We thank all our collaborators and the participants in each Alzheimer's Disease Center, institute and organization without whom the information reviewed would not have been possible. NR 188 TC 62 Z9 62 U1 5 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD JAN PY 2012 VL 123 IS 1 BP 13 EP 30 DI 10.1007/s00401-011-0884-1 PG 18 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 870BF UT WOS:000298643400002 PM 22101321 ER PT J AU White, WB Grady, D Giudice, LC Berry, SM Zborowski, J Snabes, MC AF White, William B. Grady, Deborah Giudice, Linda C. Berry, Scott M. Zborowski, Joanne Snabes, Michael C. TI A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disordera SO AMERICAN HEART JOURNAL LA English DT Article ID SURGICALLY MENOPAUSAL WOMEN; METABOLIC SYNDROME; BREAST-CANCER; UNITED-STATES; HEALTH; DYSFUNCTION; PREVALENCE; EVENTS; MEN; ESTROGEN AB Evaluation of the safety of hormonal preparations for the treatment of female sexual dysfunction is important to assess the benefit-to-risk profile of these drugs and has been strongly encouraged by the Food and Drug Administration. LibiGel (Biosante Pharmaceuticals, Inc., Lincolnshire, IL), a low-dose testosterone gel, is under development for the treatment of hypoactive sexual desire disorder (HSDD) in oophorectomized women. To evaluate the long-term effects of LibiGel on risk for cardiovascular (CV) events, breast cancer, and general safety, a randomized, placebo-controlled clinical study using a novel adaptive design to optimize sample size and power is being conducted. The primary end point of the BioSante LibiGel Safety Study (BLISS) is a composite of CV events including death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, hospitalized unstable angina, and venous thromboembolic events. Breast cancer is a coprimary end point. Postmenopausal women (both surgically and naturally) with HSDD and increased risk for CV events will be followed up for up to 5 years postrandomization with an interim data analysis for regulatory approval after the last woman enrolled has been on therapy for at least 12 months. Determination of the number of subjects to enroll is based on an adaptive design that uses interim data to estimate the predictive probability of study success. In agreement with the Food and Drug Administration, LibiGel will be declared safe if the upper limit of the 97.2% CI of the hazard ratio is <= 2.0 or the upper bound of the 97.2% CI for the absolute difference between CV event rates per 100 person-years is <= 1% and the observed hazard ratio is <= 2.0. The BLISS study will define the CV safety profile of low-dose testosterone therapy in the formulation of LibiGel for postmenopausal women with HSDD, and the trial design may provide a paradigm for studies that aim to document long-term safety when the proposed outcome under study is an uncommon adverse event. (Am Heart J 2012;163:27-32.) C1 [White, William B.] Univ Connecticut, Sch Med, Calhoun Cardiol Ctr, Div Hypertens & Clin Pharmacol, Farmington, CT 06030 USA. [Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Grady, Deborah] Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA. [Giudice, Linda C.] Univ Calif San Francisco, Dept Obstet & Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Berry, Scott M.] Berry Consultants, Austin, TX USA. [Zborowski, Joanne; Snabes, Michael C.] Biosante Pharmaceut Inc, Lincolnshire, IL USA. RP White, WB (reprint author), Univ Connecticut, Sch Med, Calhoun Cardiol Ctr, Div Hypertens & Clin Pharmacol, 263 Farmington Ave, Farmington, CT 06030 USA. EM wwhite@nso1.uchc.edu FU BioSante Pharmaceuticals, Inc, Lincolnshire, IL FX The sponsor of this study is BioSante Pharmaceuticals, Inc, Lincolnshire, IL. NR 26 TC 24 Z9 26 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD JAN PY 2012 VL 163 IS 1 BP 27 EP 32 DI 10.1016/j.ahj.2011.09.021 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 863HI UT WOS:000298153000007 PM 22172433 ER PT J AU Goodfriend, T AF Goodfriend, Theodore TI Molecular Trafficking of Angiotensin Receptors SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Editorial Material C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Goodfriend, T (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM tgoodfri@facstaff.wisc.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD JAN PY 2012 VL 25 IS 1 BP 23 EP 23 DI 10.1038/ajh.2011.222 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 864UE UT WOS:000298264800008 PM 22170076 ER PT J AU Peralta, CA Jacobs, DR Katz, R Ix, JH Madero, M Duprez, DA Sarnak, MJ Criqui, MH Kramer, HJ Palmas, W Herrington, D Shlipak, MG AF Peralta, Carmen A. Jacobs, David R., Jr. Katz, Ronit Ix, Joachim H. Madero, Magdalena Duprez, Daniel A. Sarnak, Mark J. Criqui, Michael H. Kramer, Holly J. Palmas, Walter Herrington, David Shlipak, Michael G. TI Association of Pulse Pressure, Arterial Elasticity, and Endothelial Function With Kidney Function Decline Among Adults With Estimated GFR > 60 mL/min/1.73 m(2): The Multi-Ethnic Study of Atherosclerosis (MESA) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Kidney function; arterial elasticity; chronic kidney disease; atherosclerosis ID GLOMERULAR-FILTRATION-RATE; BLOOD-PRESSURE; HYPERTENSIVE PATIENTS; CARDIOVASCULAR-DISEASE; RENAL-FUNCTION; WAVE VELOCITY; STIFFNESS; RISK; DYSFUNCTION; POPULATION AB Background: The association of subclinical vascular disease and early declines in kidney function has not been well studied. Study Design: Prospective cohort study. Setting & Participants: Multi-Ethnic Study of Atherosclerosis (MESA) participants with estimated glomerular filtration rate (eGFR) >= 60 mL/min/1.73 m(2) with follow-up of 5 years. Predictors: Pulse pressure, small (SAE) and large arterial elasticity (LAE), and flow-mediated dilation. Outcomes: Kidney function decline. Measurements: SAE and LAE were measured by pulse contour analysis of the radial artery. Kidney function was assessed by eGFR based on serum creatinine (eGFR(SCr)) and cystatin C (eGFR(SCysC)). Results: For 4,853 adults, higher pulse pressure and lower SAE and LAE had independent and linear associations with faster rates of kidney function decline. Compared with persons with pulse pressure of 40-50 mm Hg, eGFR(SCysC) declines were 0.29 (P = 0.006), 0.56 (P < 0.001), and 0.91 (P < 0.001) mL/min/1.73 m(2)/y faster in persons with pulse pressure of 50-60, 60-70, and >70 mm Hg, respectively. Compared with the highest quartile of SAE (most elastic), eGFR(SCysC) declines were 0.26 (P = 0.009), 0.35 (P = 0.001), and 0.70 (P < 0.001) mL/min/1.73 m(2)/y faster for the second, third, and fourth quartiles, respectively. For LAE, compared with the highest quartile, eGFR(SCysC) declines were 0.28 (P = 0.004), 0.58 (P < 0.001), and 0.83 (P < 0.001) mL/min/1.73 m(2)/y faster for each decreasing quartile of LAE. Findings were similar for eGFR(SCr). In contrast, for 2,997 adults with flow-mediated dilation and kidney function measures, flow-mediated dilation was not associated significantly with kidney function decline. For every 1-standard deviation greater flow-mediated dilation, eGFR(SCysC) and eGFR(SCr) changed by 0.05 (P = 0.3) and 0.06 mL/min/1.73 m(2)/y (P = 0.04), respectively. Limitations: We had no direct measure of GFR, in common with nearly all large population-based studies. Conclusions: Higher pulse pressure and lower arterial elasticity, but not flow-mediated dilation, were associated linearly and independently with faster kidney function decline in persons with eGFR >= 60 mL/min/1.73 m(2). Future studies should investigate whether treatments to decrease the stiffness of large and small arteries may slow the rate of kidney function loss. Am J Kidney Dis. 59(1):41-49. (C) 2011 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Madero, Magdalena] Inst Nacl Cardiol Ignacio Chavez, Div Nephrol, Mexico City, DF, Mexico. [Duprez, Daniel A.] Univ Minnesota, Div Cardiovasc, Sch Med, Minneapolis, MN 55455 USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Criqui, Michael H.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Kramer, Holly J.] Loyola Univ, Med Ctr, Div Nephrol, Maywood, IL 60153 USA. [Palmas, Walter] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [Herrington, David] Wake Forest Univ, Sch Med, Internal Med Sect Cardiol, Winston Salem, NC 27109 USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu OI Kramer, Holly/0000-0002-6374-837X FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169]; National Institute of Diabetes and Digestive and Kidney Disease [1K23DK082793-01] FX This research was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute and by the National Institute of Diabetes and Digestive and Kidney Disease (grant 1K23DK082793-01, Dr Peralta). These funding sources had no involvement in the design or execution of this study. NR 44 TC 41 Z9 42 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JAN PY 2012 VL 59 IS 1 BP 41 EP 49 DI 10.1053/j.ajkd.2011.08.015 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 863HO UT WOS:000298153600011 PM 22000727 ER PT J AU Johansen, KL Painter, P AF Johansen, Kirsten L. Painter, Patricia TI Exercise in Individuals With CKD SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Review DE Exercise; physical activity; chronic kidney disease ID CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; AMERICAN-HEART-ASSOCIATION; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; CARDIOVASCULAR OUTCOMES; PREDIALYSIS PATIENTS; SPORTS-MEDICINE; RISK-FACTOR; CAPACITY AB There are few studies evaluating exercise in the nondialysis chronic kidney disease (CKD) population. This review covers the rationale for exercise in patients with CKD not requiring dialysis and the effects of exercise training on physical functioning, progression of kidney disease, and cardiovascular risk factors. In addition, we address the issue of the risk of exercise and make recommendations for implementation of exercise in this population. Evidence from uncontrolled studies and small randomized controlled trials shows that exercise training results in improved physical performance and functioning in patients with CKD. In addition, although there are no studies examining cardiovascular outcomes, several studies suggest that cardiovascular risk factors such as hypertension, inflammation, and oxidative stress may be improved with exercise training in this population. Although the current literature does not allow for definitive conclusions about whether exercise training slows the progression of kidney disease, no study has reported worsening of kidney function as a result of exercise training. In the absence of guidelines specific to the CKD population, recent guidelines developed for older individuals and patients with chronic disease should be applied to the CKD population. In sum, exercise appears to be safe in this patient population if begun at moderate intensity and increased gradually. The evidence suggests that the risk of remaining inactive is higher. Patients should be advised to increase their physical activity when possible and be referred to physical therapy or cardiac rehabilitation programs when appropriate. Am J Kidney Dis. 59(1):126-134. (C) 2011 by the National Kidney Foundation, Inc. C1 [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Painter, Patricia] Univ Minnesota, Sch Nursing, Div Hypertens & Renal Dis, Minneapolis, MN 55455 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St,111J, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU NIDDK NIH HHS [K24 DK085153, K24 DK085153-01A1, K24 DK085153-02, K24 DK085153-03] NR 52 TC 65 Z9 69 U1 1 U2 24 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JAN PY 2012 VL 59 IS 1 BP 126 EP 134 DI 10.1053/j.ajkd.2011.10.008 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 863HO UT WOS:000298153600022 PM 22113127 ER PT J AU New, DD Block, K Bhandhari, B Gorin, Y Abboud, HE AF New, David D. Block, Karen Bhandhari, Basant Gorin, Yves Abboud, Hanna E. TI IGF-I increases the expression of fibronectin by Nox4-dependent Akt phosphorylation in renal tubular epithelial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE extracellular matrix; growth factor signaling; kidney; reactive oxygen species; redox signaling; NADPH oxidase 4; insulin-like growth factor ID GROWTH-FACTOR-I; MESSENGER-RNA TRANSLATION; SMOOTH-MUSCLE-CELLS; NAD(P)H OXIDASE; DIABETIC-NEPHROPATHY; NADPH OXIDASES; HIGH GLUCOSE; PROTEIN-SYNTHESIS; MESANGIAL CELLS; ANGIOTENSIN-II AB New DD, Block K, Bhandhari B, Gorin Y, Abboud HE. IGF-I increases the expression of fibronectin by Nox4-dependent Akt phosphorylation in renal tubular epithelial cells. Am J Physiol Cell Physiol 302: C122-C130, 2012. First published September 21, 2011; doi:10.1152/ajpcell.00141.2011.-Extracellular matrix accumulation contributes to the progression of chronic kidney disease. Many growth factors including insulin-like growth factor-I (IGF-I) enhance matrix protein accumulation. Proximal tubular epithelial cells (PTCs) synthesize matrix proteins. NADPH oxidases are major sources of reactive oxygen species (ROS), important signaling molecules that mediate biological responses in a variety of cells and tissue. We investigated the mechanism by which IGF-I regulates fibronectin accumulation in PTCs and the role of a potential redox-dependent signaling pathway. IGF-I induces an increase in NADPH-dependent superoxide generation, enhances the release of hydrogen peroxide, and increases the expression of NADPH oxidase 4 (Nox4) in PTCs. IGF-I also stimulates phosphorylation of Akt, and inhibition of Akt or its upstream activator phosphatidylinositol 3-kinase attenuates IGF-I-induced fibronectin accumulation. Expression of dominant negative Akt also inhibits IGF-I-induced expression of fibronectin, indicating a role for this kinase in fibronectin accumulation. Expression of dominant negative adenovirus Nox4 inhibits IGF-I-induced NADPH oxidase activity, Akt phosphorylation, and fibronectin protein expression. Moreover, transfection of small interfering RNA targeting Nox4 decreases Nox4 protein expression and blocks IGF-I-induced Akt phosphorylation and the increase in fibronectin, placing Nox4 and ROS upstream of Akt signaling pathway. To confirm the role of Nox4, PTCs were infected with adenovirus construct expressing wild-type Nox4. Ad-Nox4, but not control Ad-green fluorescent protein, upregulated Nox4 expression and increased NADPH oxidase activity as well as fibronectin expression. Taken together, these results provide the first evidence for a role of Nox4 in IGF-I-induced Akt phosphorylation and fibronectin expression in tubular epithelial cells. C1 [Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Block, Karen] Audie L Murphy Mem Hosp, S Texas Vet Healthcare Syst, San Antonio, TX USA. RP Abboud, HE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM abboud@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU Veterans Administration; National Institutes of Health [DK-R01-078971, CA131272, DK-079996]; Juvenile Diabetes Research Foundation; Career Development Award FX Support for these studies was provided by the following sources: Veterans Administration Merit Review grant and National Institutes of Health Grant DK-R01-078971 (H. E. Abboud) and Career Development Award and National Institutes of Health Grant CA131272 (K. Block), Juvenile Diabetes Research Foundation regular research grant, and National Institutes of Health Grant DK-079996 (Y. Gorin). NR 51 TC 28 Z9 28 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD JAN PY 2012 VL 302 IS 1 BP C122 EP C130 DI 10.1152/ajpcell.00141.2011 PG 9 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 866IN UT WOS:000298374100015 PM 21940672 ER PT J AU Morton, GJ Thatcher, BS Reidelberger, RD Ogimoto, K Wolden-Hanson, T Baskin, DG Schwartz, MW Blevins, JE AF Morton, Gregory J. Thatcher, Brendan S. Reidelberger, Roger D. Ogimoto, Kayoko Wolden-Hanson, Tami Baskin, Denis G. Schwartz, Michael W. Blevins, James E. TI Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE leptin; food intake ID BRAIN-STEM NUCLEI; CENTRALLY ADMINISTERED OXYTOCIN; DEFICIENT MICE; PARAVENTRICULAR NUCLEUS; ENERGY-EXPENDITURE; LEPTIN RESISTANCE; SPINAL-CORD; SIM1 GENE; HYPERPHAGIC OBESITY; SOLITARY TRACT AB Morton GJ, Thatcher BS, Reidelberger RD, Ogimoto K, Wolden-Hanson T, Baskin DG, Schwartz MW, Blevins JE. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab 302: E134-E144, 2012. First published October 18, 2011; doi:10.1152/ajpendo.00296.2011.-Growing evidence suggests that oxytocin plays an important role in the regulation of energy balance and that central oxytocin administration induces weight loss in diet-induced obese (DIO) animals. To gain a better understanding of how oxytocin mediates these effects, we examined feeding and neuronal responses to oxytocin in animals rendered obese following exposure to either a high-fat (HFD) or low-fat diet (LFD). Our findings demonstrate that peripheral administration of oxytocin dose-dependently reduces food intake and body weight to a similar extent in rats maintained on either diet. Moreover, the effect of oxytocin to induce weight loss remained intact in leptin receptor-deficient Koletsky (fak/fak) rats relative to their lean littermates. To determine whether systemically administered oxytocin activates hindbrain areas that regulate meal size, we measured neuronal c-Fos induction in the nucleus of the solitary tract (NTS) and area postrema (AP). We observed a robust neuronal response to oxytocin in these hindbrain areas that was unexpectedly increased in rats rendered obese on a HFD relative to lean, LFD-fed controls. Finally, we report that repeated daily peripheral administration of oxytocin in DIO animals elicited a sustained reduction of food intake and body weight while preventing the reduction of energy expenditure characteristic of weight-reduced animals. These findings extend recent evidence suggesting that oxytocin circumvents leptin resistance and induces weight-loss in DIO animals through a mechanism involving activation of neurons in the NTS and AP, key hindbrain areas for processing satiety-related inputs. C1 [Morton, Gregory J.; Ogimoto, Kayoko; Schwartz, Michael W.] Univ Washington, Dept Med, Diabet & Obes Ctr Excellence, Seattle, WA USA. [Morton, Gregory J.; Baskin, Denis G.; Schwartz, Michael W.; Blevins, James E.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Thatcher, Brendan S.; Wolden-Hanson, Tami; Baskin, Denis G.; Blevins, James E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Vet Affairs Med Ctr, Off Res & Dev, Med Res Serv, Seattle, WA USA. [Reidelberger, Roger D.] Nebraska Western Iowa Hlth Care Syst, Dept Vet Affairs, Omaha, NE USA. [Reidelberger, Roger D.] Creighton Univ, Dept Biomed Sci, Omaha, NE 68178 USA. RP Morton, GJ (reprint author), Univ Washington S Lake Union, Dept Med, 815 Mercer St,N334,Box 358055, Seattle, WA 98109 USA. EM gjmorton@u.washington.edu RI Schwartz, Michael/H-9950-2012 FU Office of Research and Development, Medical Research Service, Department of Veterans Affairs; Veterans Affairs Puget Sound Health Care System; Department of Veterans Affairs; Department of Veterans Affairs Nebraska Western Iowa Health Care System; NIH [DK-068304, DK-083042, DK-052989, DK-089056]; American Heart Association; Cellular and Molecular Imaging Core of the National Institutes of Health (NIH) Diabetes Endocrinology Research Center (DERC) [P30 DK-17047]; NIH Nutrition Obesity Research Unit Animal Studies Physiology Core at the University of Washington (NORC) [P30 DK-035816]; NIH Mouse Metabolic Phenotyping Center Diabetes and Energy Balance Core (MMPC) [U24 DK-076126] FX This work was supported by resources from the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, including the Department of Veterans Affairs Career Development Program, Merit Review Research Program, and the Career Scientist Program. D. G. Baskin is the recipient of a Department of Veterans Affairs Senior Research Career Scientist Award at the Veterans Affairs Puget Sound Health Care System. R. D. Reidelberger is the recipient of a Department of Veterans Affairs Research Career Scientist Award at the Department of Veterans Affairs Nebraska Western Iowa Health Care System. M. W. Schwartz is supported by NIH grants (DK-068304, DK-083042, DK-052989). G. J. Morton is supported by an NIH grant (DK-089056) and a Scientist Development Grant from the American Heart Association. This research was also supported by the Cellular and Molecular Imaging Core of the National Institutes of Health (NIH) Diabetes Endocrinology Research Center (DERC, P30 DK-17047), the NIH Nutrition Obesity Research Unit Animal Studies Physiology Core at the University of Washington (NORC, P30 DK-035816), and the NIH Mouse Metabolic Phenotyping Center Diabetes and Energy Balance Core (MMPC, U24 DK-076126). NR 64 TC 63 Z9 64 U1 1 U2 16 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD JAN PY 2012 VL 302 IS 1 BP E134 EP E144 DI 10.1152/ajpendo.00296.2011 PG 11 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 866JU UT WOS:000298377600015 PM 22008455 ER PT J AU Zhao, KQ Xiong, GX Wilber, M Cohen, NA Kreindler, JL AF Zhao, Ke-Qing Xiong, Guoxiang Wilber, Morgan Cohen, Noam A. Kreindler, James L. TI A role for two-pore K+ channels in modulating Na+ absorption and Cl- secretion in normal human bronchial epithelial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE chloride secretion; cystic fibrosis; ion transport ID CHLORIDE SECRETION; ANION SECRETION; POTASSIUM CHANNELS; AIRWAY EPITHELIA; ION-TRANSPORT; LUNG-DISEASE; LINE CALU-3; CONDUCTANCE; MEMBRANE; LIQUID AB Zhao KQ, Xiong G, Wilber M, Cohen NA, Kreindler JL. A role for two-pore K+ channels in modulating Na+ absorption and Cl- secretion in normal human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 302: L4-L12, 2012. First published September 30, 2011; doi: 10.1152/ajplung.00102.2011.-Mucociliary clearance is the primary innate physical defense mechanism against inhaled pathogens and toxins. Vectorial ion transport, primarily sodium absorption and anion secretion, by airway epithelial cells supports mucociliary clearance. This is evidenced by diseases of abnormal ion transport such as cystic fibrosis and pseudohypoaldosteronism that are characterized by changes in mucociliary clearance. Sodium absorption and chloride secretion in human bronchial epithelial cells depend on potassium channel activity, which creates a favorable electrochemical gradient for both by hyperpolarizing the apical plasma membrane. Although the role of basolateral membrane potassium channels is firmly established and extensively studied, a role for apical membrane potassium channels has also been described. Here, we demonstrate that bupivacaine and quinidine, blockers of four-transmembrane domain, two-pore potassium (K2P) channels, inhibit both amiloride-sensitive sodium absorption and forskolin-stimulated anion secretion in polarized, normal human bronchial epithelial cells at lower concentrations when applied to the mucosal surface than when applied to the serosal surface. Transcripts from four genes, KCNK1 (TWIK-1), KCNK2 (TREK-1), KCNK5 (TASK-2), and KCNK6 (TWIK-2), encoding K2P channels were identified by RT-PCR. Protein expression at the apical membrane was confirmed by immunofluorescence. Our data provide further evidence that potassium channels, in particular K2P channels, are expressed and functional in the apical membrane of airway epithelial cells where they may be targets for therapeutic manipulation. C1 [Zhao, Ke-Qing] Fudan Univ, Sch Shanghai Med, Dept Otorhinolaryngol Head & Neck Surg, Eye & Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China. [Zhao, Ke-Qing; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Xiong, Guoxiang] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. [Kreindler, James L.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. RP Kreindler, JL (reprint author), Abramson Res Ctr, 3615 Civ Ctr Blvd,Rm 1016-D, Philadelphia, PA 19104 USA. EM kreindler@email.chop.edu OI Cohen, Noam/0000-0002-9462-3932 FU National Heart, Lung, and Blood Institute [K08-HL-081080]; Children's Hospital of Philadelphia FX This work was funded by National Heart, Lung, and Blood Institute Grant K08-HL-081080 (to J. L. Kreindler) and by institutional funds from the Children's Hospital of Philadelphia. NR 33 TC 19 Z9 21 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD JAN PY 2012 VL 302 IS 1 BP L4 EP L12 DI 10.1152/ajplung.00102.2011 PG 9 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 866VC UT WOS:000298413000002 PM 21964404 ER PT J AU Cannuscio, C Bugos, E Hersh, S Asch, DA Weiss, EE AF Cannuscio, Carolyn Bugos, Eva Hersh, Shari Asch, David A. Weiss, Eve E. TI Using ART to AMPLIFY Youth Voices on Housing Insecurity SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material C1 [Cannuscio, Carolyn; Asch, David A.] Univ Penn, Ctr Hlth Equi Res & Promot, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Cannuscio, Carolyn; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Cannuscio, Carolyn] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Cannuscio, Carolyn; Bugos, Eva; Weiss, Eve E.] Univ Penn, Mixed Methods Res Lab, Philadelphia, PA 19104 USA. [Cannuscio, Carolyn; Bugos, Eva; Weiss, Eve E.] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA. [Hersh, Shari] Mural Arts Program, Philadelphia, PA USA. RP Cannuscio, C (reprint author), Univ Penn, Ctr Hlth Equi Res & Promot, Philadelphia VA Med Ctr, 3620 Hamilton Walk,Anat & Chem Bldg,Room 145, Philadelphia, PA 19104 USA. EM carolyncannu@gmail.com OI Asch, David/0000-0002-7970-286X NR 4 TC 2 Z9 2 U1 2 U2 14 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2012 VL 102 IS 1 BP 10 EP 12 DI 10.2105/AJPH.2011.300494 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 867IZ UT WOS:000298449400005 PM 22095365 ER PT J AU Dick, AA Mercer, LD Smith, JM McDonald, RA Young, B Healey, PJ AF Dick, Andre A. Mercer, Laina D. Smith, Jodi M. McDonald, Ruth A. Young, Bessie Healey, Patrick J. TI Living Donor Kidney Transplantation in Adolescents: Does Size Matter? SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American-Society-of-Transplant-Surgeons (ASTS) 12th Annual State of the Art Winter Symposium/North-American-Transplant-Coordinators-Organization (NATCO) Symposium for Advanced Transplant Professionals CY JAN 12-15, 2012 CL Miami, FL SP Amer Soc Transplant Surg (ASTS), N Amer Transplant Coordinators Org (NATCO) C1 [Dick, Andre A.; Healey, Patrick J.] Seattle Childrens Hosp, Div Pediat Transplantat, Seattle, WA USA. [Mercer, Laina D.] Seattle Childrens Hosp, Seattle Childrens Res Inst, Seattle, WA USA. [Smith, Jodi M.; McDonald, Ruth A.] Seattle Childrens Hosp, Div Nephrol, Dept Pediat, Seattle, WA USA. [Young, Bessie] VA Puget Sound Hlth Care Syst, Div Nephrol, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JAN PY 2012 VL 12 SU 2 SI SI BP 70 EP 70 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 867UW UT WOS:000298481300050 ER PT J AU Azadani, AN Chitsaz, S Matthews, PB Jaussaud, N Leung, J Tsinman, T Ge, L Tseng, EE AF Azadani, Ali N. Chitsaz, Sam Matthews, Peter B. Jaussaud, Nicolas Leung, James Tsinman, Tonia Ge, Liang Tseng, Elaine E. TI Comparison of Mechanical Properties of Human Ascending Aorta and Aortic Sinuses SO ANNALS OF THORACIC SURGERY LA English DT Article ID FINITE-ELEMENT; VALVE INCOMPETENCE; ROOT; ANEURYSM; ARTERIES; MODEL; AGE AB Background. Computational finite element models of the aortic root have previously used material properties of the ascending aorta to describe both aortic sinuses and ascending aorta. We have previously demonstrated significant material property differences between ascending aorta and sinuses in pigs. However, it is unknown whether these regional material property differences exist in humans. The main objective of this study was to investigate biomechanics of fresh human ascending aorta and aortic sinuses and compare nonlinear material properties of these regions. Methods. Fresh human aortic root specimens obtained from the California Transplant Donor Network (Oakland, CA) were subjected to displacement-controlled equibiaxial stretch testing within 24 hours of harvest. Stress-strain data recorded were used to derive strain energy functions for each region. Tissue behavior was quantified by tissue stiffness and a direct comparison was made between different regions of aortic root at physiologic stress levels. Results. All regions demonstrated a nonlinear response to strain during stretch testing in both circumferential and longitudinal directions. No significant difference in tissue stiffness was found between anterior and posterior regions of the ascending aorta or among the three sinuses in both directions. However, our results demonstrated that human ascending aorta is significantly more compliant than aortic sinuses in both circumferential and longitudinal directions within the physiologic stress range. Conclusions. Significant material and structural differences were observed between human ascending aorta and aortic sinuses. Regionally specific material properties should be employed in computational models used to assess treatments of structural aortic root disease. (Ann Thorac Surg 2012;93:87-94) (C) 2012 by The Society of Thoracic Surgeons C1 [Tseng, Elaine E.] Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, 500 Parnassus Ave,Ste 405W,Box 0118, San Francisco, CA 94143 USA. EM elaine.tseng@ucsfmedctr.org RI Chitsaz, Sam/C-4586-2008 FU American Heart Association FX We thank Dr Philip Ursell for his histologic characterization and the California Transplant Donor Network for the hearts. This work was supported by an American Heart Association Grant-in-Aid, which was administered by the Northern California Institute for Research and Education with resources of the Veterans Affairs Medical Center, San Francisco, California. NR 18 TC 20 Z9 20 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JAN PY 2012 VL 93 IS 1 BP 87 EP 94 DI 10.1016/j.athoracsur.2011.08.002 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 864QR UT WOS:000298255400019 PM 22075218 ER PT J AU Roussos, P Katsel, P Davis, KL Bitsios, P Giakoumaki, SG Jogia, J Rozsnyai, K Collier, D Frangou, S Siever, LJ Haroutunian, V AF Roussos, Panos Katsel, Pavel Davis, Kenneth L. Bitsios, Panos Giakoumaki, Stella G. Jogia, Jigar Rozsnyai, Kinga Collier, David Frangou, Sophia Siever, Larry J. Haroutunian, Vahram TI Molecular and Genetic Evidence for Abnormalities in the Nodes of Ranvier in Schizophrenia SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID MULTIPLE BRAIN-REGIONS; ANTERIOR CINGULATE CORTEX; GENOME-WIDE ASSOCIATION; MILD ALZHEIMER-DISEASE; BIPOLAR DISORDER; EXPRESSION; MYELIN; HIPPOCAMPUS; DYSFUNCTION; PHENOTYPE AB Context: Genetic, neuroimaging, and molecular neurobiological evidence support the hypothesis that the disconnectivity syndrome in schizophrenia (SZ) could arise from failures of saltatory conduction and abnormalities at the nodes of Ranvier (NOR) interface where myelin and axons interact. Objective: To identify abnormalities in the expression of oligodendroglial genes and proteins that participate in the formation, maintenance, and integrity of the NOR in SZ. Design: The messenger RNA (mRNA) expression levels of multiple NOR genes were quantified in 2 independent postmortem brain cohorts of individuals with SZ, and generalizability to protein expression was confirmed. The effect of the ANK3 genotype on the mRNA expression level was tested in postmortem human brain. Case-control analysis tested the association of the ANK3 genotype with SZ. The ANK3 genotype's influence on cognitive task performance and functional magnetic resonance imaging activation was tested in 2 independent cohorts of healthy individuals. Setting: Research hospital. Patients: Postmortem samples from patients with SZ and healthy controls were used for the brain expression study (n=46) and the case-control analysis (n=272). Healthy white men and women participated in the cognitive (n=513) and neuroimaging (n=52) studies. Main Outcome Measures: The mRNA and protein levels in postmortem brain samples, genetic association with schizophrenia, cognitive performance, and blood oxygenation level-dependent functional magnetic resonance imaging. Results: The mRNA expression of multiple NOR genes was decreased in schizophrenia. The ANK3 rs9804190 C allele was associated with lower ANK3 mRNA expression levels, higher risk for SZ in the case-control cohort, and poorer working memory and executive function performance and increased prefrontal activation during a working memory task in healthy individuals. Conclusions: These results point to abnormalities in the expression of genes and protein associated with the integrity of the NOR and suggest them as substrates for the disconnectivity syndrome in SZ. The association of ANK3 with lower brain mRNA expression levels implicates a molecular mechanism for its genetic, clinical, and cognitive associations with SZ. C1 [Roussos, Panos; Katsel, Pavel; Davis, Kenneth L.; Siever, Larry J.; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Roussos, Panos; Siever, Larry J.; Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Roussos, Panos; Bitsios, Panos; Giakoumaki, Stella G.] Univ Crete, Dept Psychiat & Behav Sci, Fac Med, Iraklion, Crete, Greece. [Jogia, Jigar; Frangou, Sophia] Kings Coll London, Sect Neurobiol Psychosis, Inst Psychiat, London, England. [Rozsnyai, Kinga; Collier, David] Kings Coll London, Social Genet & Dev Psychiat Res Ctr, Inst Psychiat, London, England. RP Haroutunian, V (reprint author), Mt Sinai Sch Med, Dept Psychiat, Room 4F-33,130 Kingsbridge Rd, Bronx, NY 10468 USA. EM vahram.haroutunian@mssm.edu RI Frangou, Sophia/A-2672-2013; Collier, David/D-1649-2011; Roussos, Panos/J-7090-2013 OI Collier, David/0000-0003-4087-1559; Roussos, Panos/0000-0002-4640-6239; Jogia, Jigar/0000-0003-1799-1245 FU National Institutes of Health [MH066392, MH064673]; Veterans Affairs Mental Illness Research Education and Clinical Center; Veterans Affairs FX This work was supported by grants MH066392 and MH064673 from the National Institutes of Health (Dr Haroutunian), a Veterans Affairs Mental Illness Research Education and Clinical Center award (Dr Siever), and a Veterans Affairs merit award (Dr Haroutunian). NR 39 TC 45 Z9 48 U1 0 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD JAN PY 2012 VL 69 IS 1 BP 7 EP 15 DI 10.1001/archgenpsychiatry.2011.110 PG 9 WC Psychiatry SC Psychiatry GA 870NH UT WOS:000298675700002 PM 21893642 ER PT J AU Olfson, M Marcus, SC Bridge, JA AF Olfson, Mark Marcus, Steven C. Bridge, Jeffrey A. TI Emergency Treatment of Deliberate Self-harm SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID BORDERLINE PERSONALITY-DISORDER; ATTEMPTED-SUICIDE; FOLLOW-UP; COMPLETED SUICIDE; DEPARTMENT VISITS; HEALTH-CARE; COHORT; ADULTS; RISK; DEPRESSION AB Context: Although concern exists over the quality of emergency mental health services, little is known about the mental health care of adults who are admitted to emergency departments for deliberately harming themselves and then discharged to the community. Objective: To describe the predictors of emergency department discharge, the emergency mental health assessments, and the follow-up outpatient mental health care of adult Medicaid beneficiaries treated for deliberate self-harm. Design: A retrospective longitudinal cohort analysis. Setting: National Medicaid claims data supplemented with county-level sociodemographic variables and Medicaid state policy survey data. Participants: Adults aged 21 to 64 years who were treated in emergency departments for 7355 episodes of deliberate self-harm, focusing on those who were discharged to the community (4595 episodes). Main Outcome Measures: Rates and adjusted risk ratios (ARRs) of discharge to the community, mental health assessments in the emergency department, and outpatient mental health visits during the 30 days following the emergency department visit. Results: Most patients (62.5%) were discharged to the community. Emergency department discharge was directly related to younger patient age (21-31 years vs 45-64 years) (ARR, 1.18 [99% confidence interval {CI}, 1.10-1.25]) and self-harm by cutting (ARR, 1.18 [99% CI, 1.12-1.24]) and inversely related to poisoning (ARR, 0.84 [99% CI, 0.80-0.89]) and recent psychiatric hospitalization (ARR, 0.74 [99% CI, 0.67-0.81]). Approximately one-half of discharged patients (47.5%) received a mental health assessment in the emergency department, and a similar percentage of discharged patients (52.4%) received a follow-up outpatient mental health visit within 30 days. Follow-up mental health care was directly related to recent outpatient mental health care (ARR, 2.30 [99% CI, 2.11-2.50]) and treatment in a state with Medicaid coverage of mental health clinic services (ARR, 1.13 [99% CI, 1.05-1.22]) and inversely related to African American (ARR, 0.86 [99% CI, 0.75-0.96]) and Hispanic (ARR, 0.86 [99% CI, 0.75-0.99]) race/ethnicity. Conclusion: Most adult Medicaid beneficiaries who present for emergency care for deliberate self-harm are discharged to the community, and many do not receive emergency mental health assessments or follow-up outpatient mental health care. C1 [Olfson, Mark] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, Coll Phys & Surg, New York, NY 10032 USA. [Marcus, Steven C.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Bridge, Jeffrey A.] Ohio State Univ, Res Inst, Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, Columbus, OH USA. [Bridge, Jeffrey A.] Ohio State Univ, Dept Pediat, Columbus, OH USA. RP Olfson, M (reprint author), Columbia Univ, New York State Psychiat Inst, Dept Psychiat, Coll Phys & Surg, 1051 Riverside Dr, New York, NY 10032 USA. EM mo49@columbia.edu FU Eli Lilly; Bristol-Myers Squibb; AstraZeneca; Dainippon Sumitomo; Forest Research Institute; Ortho-McNeil-Janssen; Pfizer Inc; Roche Pharmaceuticals; sanofi-aventis; Schering-Plough; Sepracor; United BioSource; Lundbeck; American Foundation for Suicide Prevention FX Dr Olfson has received a research grant to Columbia University from Eli Lilly and Bristol-Myers Squibb. Dr Bridge has received honoraria for participation in a suicidality consensus conference supported by independent educational or other unrestricted grant support from AstraZeneca, Dainippon Sumitomo, Eli Lilly, Forest Research Institute, Ortho-McNeil-Janssen, Pfizer Inc, Roche Pharmaceuticals, sanofi-aventis, Schering-Plough, Sepracor, and United BioSource; and he has presented on suicide prevention in children and adolescents at a conference supported in part by Eli Lilly and Lundbeck.; This research was funded by a grant to Columbia University from the American Foundation for Suicide Prevention. NR 60 TC 24 Z9 24 U1 5 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD JAN PY 2012 VL 69 IS 1 BP 80 EP 88 DI 10.1001/archgenpsychiatry.2011.108 PG 9 WC Psychiatry SC Psychiatry GA 870NH UT WOS:000298675700010 PM 21893643 ER PT J AU Craft, S Baker, LD Montine, TJ Minoshima, S Watson, GS Claxton, A Arbuckle, M Callaghan, M Tsai, E Plymate, SR Green, PS Leverenz, J Cross, D Gerton, B AF Craft, Suzanne Baker, Laura D. Montine, Thomas J. Minoshima, Satoshi Watson, G. Stennis Claxton, Amy Arbuckle, Matthew Callaghan, Maureen Tsai, Elaine Plymate, Stephen R. Green, Pattie S. Leverenz, James Cross, Donna Gerton, Brooke TI Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial SO ARCHIVES OF NEUROLOGY LA English DT Article ID AMYLOID-BETA; RATING-SCALE; OLDER-ADULTS; HUMAN BRAIN; IN-VIVO; MECHANISMS; PLASTICITY; INCREASES; OLIGOMERS; SEVERITY AB Objective: To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive impairment or Alzheimer disease (AD). Design: Randomized, double-blind, placebo-controlled trial. Setting: Clinical research unit of a Veterans Affairs medical center. Participants: The intent-to-treat sample consisted of 104 adults with amnestic mild cognitive impairment (n=64) or mild to moderate AD (n=40). Intervention: Participants received placebo (n=30), 20 IU of insulin (n=36), or 40 IU of insulin (n=38) for 4 months, administered with a nasal drug delivery device (Kurve Technology, Bothell, Washington). Main Outcome Measures: Primary measures consisted of delayed story recall score and the Dementia Severity Rating Scale score, and secondary measures included the Alzheimer Disease's Assessment Scale-cognitive subscale (ADAS-cog) score and the Alzheimer's Disease Cooperative Study-activities of daily living (ADCS-ADL) scale. A subset of participants underwent lumbar puncture (n=23) and positron emission tomography with fludeoxyglucose F 18 (n=40) before and after treatment. Results: Outcome measures were analyzed using repeated-measures analysis of covariance. Treatment with 20 IU of insulin improved delayedmemory(P <.05), and both doses of insulin (20 and 40 IU) preserved caregiver-rated functional ability (P <.01). Both insulin doses also preserved general cognition as assessed by the ADAS-cog score for younger participants and functional abilities as assessed by the ADCS-ADL scale for adults with AD (P <.05). Cerebrospinal fluid biomarkers did not change for insulin-treated participants as a group, but, in exploratory analyses, changes in memory and function were associated with changes in the A beta 42 level and in the tau protein-to-A beta 42 ratio in cerebrospinal fluid. Placebo-assigned participants showed decreased fludeoxyglucose F 18 uptake in the parietotemporal, frontal, precuneus, and cuneus regions and insulin-minimized progression. No treatment-related severe adverse events occurred. Conclusions: These results support longer trials of intranasal insulin therapy for patients with amnestic mild cognitive impairment and patients with AD. C1 [Craft, Suzanne; Baker, Laura D.; Watson, G. Stennis; Claxton, Amy; Arbuckle, Matthew; Callaghan, Maureen; Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Leverenz, James; Gerton, Brooke] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Craft, Suzanne; Baker, Laura D.; Watson, G. Stennis; Claxton, Amy; Leverenz, James] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Minoshima, Satoshi; Cross, Donna] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Tsai, Elaine; Plymate, Stephen R.; Green, Pattie S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Leverenz, James; Gerton, Brooke] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. RP Craft, S (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM scraft@uw.edu FU National Institute of Aging [AG027415, P50 AG05136, T32 AG000258]; Nancy and Buster Alvord Endowment; Department of Veterans Affairs FX This research was supported by National Institute of Aging grants AG027415 (to Dr Craft), P50 AG05136 (to Dr Montine), and T32 AG000258 (to Dr Claxton), the Nancy and Buster Alvord Endowment, and the Department of Veterans Affairs. This material is the result of work supported in part by resources from the Veterans Affairs Puget Sound Health Care System, Seattle, Washington. NR 31 TC 394 Z9 401 U1 17 U2 83 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JAN PY 2012 VL 69 IS 1 BP 29 EP 38 DI 10.1001/archneurol.2011.233 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 874GX UT WOS:000298944500004 PM 21911655 ER PT J AU Grossman, JM Ranganath, VK Chen, WL Furst, DE McMahon, M Volkmann, E Gordon, R Deal, C Caplan, L Curtis, JR Patkar, NM Saag, KG AF Grossman, Jennifer M. Ranganath, Veena K. Chen, Weiling Furst, Daniel E. McMahon, Maureen Volkmann, Elizabeth Gordon, Rebecca Deal, Chad Caplan, Liron Curtis, Jeffrey R. Patkar, Nivedita M. Saag, Kenneth G. TI Fracture risk in glucocorticoid-induced osteoporosis: comment on the article by Grossman et al SO ARTHRITIS CARE & RESEARCH LA English DT Letter C1 [Grossman, Jennifer M.; Ranganath, Veena K.; Chen, Weiling; Furst, Daniel E.; McMahon, Maureen; Volkmann, Elizabeth; Gordon, Rebecca] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Gordon, Rebecca] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Deal, Chad] Cleveland Clin, Cleveland, OH 44106 USA. [Caplan, Liron] Univ Colorado, Denver, CO 80202 USA. [Curtis, Jeffrey R.; Patkar, Nivedita M.; Saag, Kenneth G.] Univ Alabama, Birmingham, AL USA. RP Grossman, JM (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90024 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JAN PY 2012 VL 64 IS 1 BP 157 EP 158 DI 10.1002/acr.20650 PG 2 WC Rheumatology SC Rheumatology GA 868QB UT WOS:000298536700025 ER PT J AU Smolderen, KG Spertus, JA Reid, KJ Buchanan, DM Vaccarino, V Lichtman, JH Bekelman, DB Chan, PS AF Smolderen, Kim G. Spertus, John A. Reid, Kimberly J. Buchanan, Donna M. Vaccarino, Viola Lichtman, Judith H. Bekelman, David B. Chan, Paul S. TI Association of Somatic and Cognitive Depressive Symptoms and Biomarkers in Acute Myocardial Infarction: Insights from the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status Registry SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Coagulation; depressive symptoms; inflammation; mechanisms; myocardial infarction; neurohormones ID C-REACTIVE PROTEIN; ACUTE CORONARY SYNDROMES; BRAIN NATRIURETIC PEPTIDE; HEART-RATE-VARIABILITY; N-TERMINAL PROATRIAL; CARDIOVASCULAR-DISEASE; INFLAMMATORY BIOMARKERS; SICKNESS BEHAVIOR; NATIONAL-HEART; PROGNOSIS AB Background: Somatic depressive symptoms and certain biomarkers are each associated with worse acute myocardial infarction (AMI) prognosis, but the relationship between depressive symptom domains and inflammatory, neurohormonal, and coagulation markers is unknown. Methods: We examined the relationship between depressive symptoms and 1-month biomarker levels (high-sensitivity C-reactive protein [hs-CRP], N-terminal pro-brain natriuretic peptide [NT-proBNP], white blood cell [WBC], platelet counts) in 1265 AMI patients. Depressive symptoms (9-item Patient Health Questionnaire) were assessed during index hospitalization and categorized as somatic or cognitive. Using median regression models, the upper quartile of somatic and cognitive depression scores and each biomarker were compared with the lower three quartiles, adjusting for site, demographics, and clinical characteristics. Results: Although hs-CRP values were higher in patients with somatic symptoms, this association was attenuated after adjustment (B(per SD increase) = .02, 95% confidence interval: .00; .05, p = .07). WBC count was independently associated with somatic depressive symptoms (B(per SD increase) = .28, 95% confidence interval: .12; .44, p = .001). Cognitive depressive symptoms were not associated with hs-CRP or WBC count. Neither dimension was associated with NT-proBNP or platelet levels. For each biomarker, the depression dimensions explained <1% of their variation. Conclusions: Neither somatic nor cognitive depressive symptoms were meaningfully associated with hs-CRP, NT-proBNP, WBC, or platelet counts 1 month after AMI, suggesting that the association between depression and long-term outcomes may be unrelated to these biomarkers. Future research should explore other biomarkers to better illuminate pathways by which depression adversely impacts AMI prognosis. C1 [Smolderen, Kim G.; Spertus, John A.; Reid, Kimberly J.; Buchanan, Donna M.; Chan, Paul S.] St Lukes Mid Amer Heart & Vasc Inst, Kansas City, MO 64111 USA. [Smolderen, Kim G.] Tilburg Univ, Dept Med Psychol, Ctr Res Psychol Somat Dis, NL-5000 LE Tilburg, Netherlands. [Spertus, John A.; Chan, Paul S.] Univ Missouri, Dept Med, Kansas City, MO 64110 USA. [Spertus, John A.; Chan, Paul S.] Univ Missouri, Dept Biomed & Hlth Informat, Kansas City, MO 64110 USA. [Vaccarino, Viola] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Lichtman, Judith H.] Yale Univ, Sch Publ Hlth, Div Chron Dis Epidemiol, New Haven, CT USA. [Bekelman, David B.] Denver Vet Affairs Med Ctr, Res Sect, Denver, CO USA. [Bekelman, David B.] Denver Vet Affairs Med Ctr, Geriatr Sect, Denver, CO USA. [Vaccarino, Viola] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA. RP Smolderen, KG (reprint author), St Lukes Mid Amer Heart & Vasc Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA. EM k.g.e.smolderen@gmail.com RI Smolderen, Kim/B-8078-2015 FU National Heart, Lung, and Blood Institute Specialized Center of Clinically Oriented Research in Cardiac Dysfunction and Disease [P50 HL077113]; CV Therapeutics, Palo Alto, California; American Heart Association [AHA: 0875149N]; Netherlands Organization for Scientific Research [916.11.179] FX Grant support was received from the National Heart, Lung, and Blood Institute Specialized Center of Clinically Oriented Research in Cardiac Dysfunction and Disease (Grant number P50 HL077113) and CV Therapeutics, Palo Alto, California. Dr. Smolderen was supported by the Outcomes Research postdoctoral fellowship awarded by the American Heart Association Pharmaceutical Roundtable and David and Stevie Spina (Grant number AHA: 0875149N) and by The Netherlands Organization for Scientific Research (Veni Grant number: 916.11.179). NR 50 TC 8 Z9 9 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JAN 1 PY 2012 VL 71 IS 1 BP 22 EP 29 DI 10.1016/j.biopsych.2011.07.029 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 863BI UT WOS:000298137400007 PM 21903199 ER PT J AU Singh, H Giardina, TD Petersen, LA Smith, MW Paul, LW Dismukes, K Bhagwath, G Thomas, EJ AF Singh, Hardeep Giardina, Traber Davis Petersen, Laura A. Smith, Michael W. Paul, Lindsey Wilson Dismukes, Key Bhagwath, Gayathri Thomas, Eric J. TI Exploring situational awareness in diagnostic errors in primary care SO BMJ QUALITY & SAFETY LA English DT Article ID PATIENT SAFETY; MALPRACTICE CLAIMS; DECISION-MAKING; MISSED OPPORTUNITIES; CANCER DIAGNOSIS; DYNAMIC-SYSTEMS; ADVERSE EVENTS; MEDICINE; STRATEGIES; COGNITION AB Objective: Diagnostic errors in primary care are harmful but poorly studied. To facilitate the understanding of diagnostic errors in real-world primary care settings that use electronic health records (EHRs), this study explored the use of the situational awareness (SA) framework from aviation human factors research. Methods: A mixed-methods study was conducted involving reviews of EHR data followed by semi-structured interviews of selected providers from two institutions in the USA. The study population included 380 consecutive patients with colorectal and lung cancers diagnosed between February 2008 and January 2009. Using a pre-tested data collection instrument, trained physicians identified diagnostic errors, defined as lack of timely action on one or more established indications for diagnostic work-up for lung and colorectal cancers. Twenty-six providers involved in cases with and without errors were interviewed. Interviews probed for providers' lack of SA and how this may have influenced the diagnostic process. Results: Of 254 cases meeting inclusion criteria, errors were found in 30 of 92 (32.6%) lung cancer cases and 56 of 167 (33.5%) colorectal cancer cases. Analysis of interviews related to error cases revealed evidence of lack of one of four levels of SA applicable to primary care practice: information perception, information comprehension, forecasting future events, and choosing appropriate action based on the first three levels. In cases without error, application of the SA framework provided insight into processes involved in attention management. Conclusions: A framework of SA can help analyse and understand diagnostic errors in primary care settings that use EHRs. C1 [Singh, Hardeep; Giardina, Traber Davis; Petersen, Laura A.; Smith, Michael W.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep; Giardina, Traber Davis; Petersen, Laura A.; Smith, Michael W.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Paul, Lindsey Wilson] Univ Texas Austin, Sch Social Work, Austin, TX 78712 USA. [Dismukes, Key] NASA, Ames Res Ctr, Moffett Field, CA 94035 USA. [Bhagwath, Gayathri] Univ Texas Galveston, Med Branch, Dept Internal Med, Div Hematol Oncol, Galveston, TX 77550 USA. [Thomas, Eric J.] Univ Texas Houston, Sch Med, Dept Med, Div Gen Med, Houston, TX 77030 USA. [Thomas, Eric J.] Univ Texas Houston, Sch Med, Mem Hermann Ctr Healthcare Qual, Houston, TX USA. RP Singh, H (reprint author), Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu OI Davis Giardina, Traber/0000-0002-9184-6524 FU NIH [K23CA125585]; Houston VA HSR&D Center of Excellence [HFP90-020] FX This study was supported by an NIH K23 career development award (K23CA125585) to Dr Singh, and in part by the Houston VA HSR&D Center of Excellence (HFP90-020). These sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 77 TC 19 Z9 20 U1 4 U2 14 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD JAN PY 2012 VL 21 IS 1 BP 30 EP 38 DI 10.1136/bmjqs-2011-000310 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 862ZZ UT WOS:000298133900005 PM 21890757 ER PT J AU Rahbar, H Tavakkol, Z Bhargava, P AF Rahbar, H. Tavakkol, Z. Bhargava, P. TI Characteristic CT appearance of lung cysts prompting the diagnosis of a rare genodermatosis SO BRITISH JOURNAL OF RADIOLOGY LA English DT Editorial Material ID HOGG-DUBE-SYNDROME; HEREDITARY C1 [Rahbar, H.; Bhargava, P.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Rahbar, H.; Bhargava, P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Tavakkol, Z.] Univ Washington, Div Dermatol, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Bhargava, P (reprint author), VA Puget Sound Hlth Care Ctr, Mail Box 358280,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@u.washington.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 6 TC 0 Z9 0 U1 0 U2 0 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0007-1285 J9 BRIT J RADIOL JI Br. J. Radiol. PD JAN PY 2012 VL 85 IS 1009 BP 93 EP 95 DI 10.1259/bjr/13687494 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 866RH UT WOS:000298398900018 PM 22190751 ER PT J AU Dunn, JH Ellis, LZ Fujita, M AF Dunn, Jeffrey H. Ellis, Lixia Z. Fujita, Mayumi TI Inflammasomes as molecular mediators of inflammation and cancer: Potential role in melanoma SO CANCER LETTERS LA English DT Review DE Inflammasome; Inflammation; Cancer; Melanoma; IL-1 beta; ASC ID INTERLEUKIN-1 INDUCES INTERLEUKIN-1; CASPASE RECRUITMENT DOMAIN; INNATE IMMUNE-RESPONSE; FAMILIAL MEDITERRANEAN FEVER; TUMOR-HOST INTERACTIONS; TOLL-LIKE RECEPTORS; SPECK-LIKE PROTEIN; NF-KAPPA-B; NALP3 INFLAMMASOME; IN-VITRO AB The inflammasome is a multi-protein complex that mediates immune responses to microbial, host, and environmental signals. When active, inflammasomes regulate caspase-1 activation and IL-1 beta secretion. There is a strong link between inflammation and cancer, and IL-1 beta is one of the major molecules involved in both of these disease processes. Here we review the role of inflammasomes in regulating IL-1 beta secretion, and the impact of this pathway on cancer pathogenesis, with a focus on melanoma. This represents an exciting new area of research, and could potentially result in new targets for melanoma therapeutics in the future. Published by Elsevier Ireland Ltd. C1 [Dunn, Jeffrey H.; Ellis, Lixia Z.; Fujita, Mayumi] Univ Colorado Denver, Dept Dermatol, Sch Med, Aurora, CO 80045 USA. [Fujita, Mayumi] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Fujita, M (reprint author), Univ Colorado Denver, Dept Dermatol, Sch Med, Mail Stop 8127,12801 E 17th Ave,RC-1 S,Rm 4124, Aurora, CO 80045 USA. EM mayumi.fujita@ucdenver.edu FU Dermatology Foundation; Wendy Will Case Cancer Fund grant; Cancer League of Colorado; Tadamitsu Cancer Research Fund FX The authors thank Charles A Dinarello, MD, Miyako Okamoto, MD, PhD and Weimin Liu, MD (University of Colorado Denver) for helpful discussions. This work was supported, in whole or in part, by Dermatology Foundation (to M.F.), Wendy Will Case Cancer Fund grant (to M.F.), Cancer League of Colorado (to M.F.) and Tadamitsu Cancer Research Fund (to M.F.). The funders had no role in study design, data collection, analysis and interpretation, manuscript preparation and decision to submit the manuscript. NR 163 TC 29 Z9 29 U1 1 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3835 J9 CANCER LETT JI Cancer Lett. PD JAN 1 PY 2012 VL 314 IS 1 BP 24 EP 33 DI 10.1016/j.canlet.2011.10.001 PG 10 WC Oncology SC Oncology GA 868OF UT WOS:000298531900003 PM 22050907 ER PT J AU Hirata, H Hinoda, Y Ueno, K Shahryari, V Tabatabai, ZL Dahiya, R AF Hirata, Hiroshi Hinoda, Yuji Ueno, Koji Shahryari, Varahram Tabatabai, Z. Laura Dahiya, Rajvir TI MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer SO CARCINOGENESIS LA English DT Article ID LYMPH-NODE METASTASIS; FACTOR-C EXPRESSION; SIGNAL-TRANSDUCTION; KINASE CASCADE; CELL-LINES; TUMORS; LYMPHANGIOGENESIS; ACTIVATION; BIOMARKERS; CARCINOMA AB The Wnt/beta-catenin (CTNNB1) and Ras-Raf-MEK-ERK signaling pathway play an important role in bladder cancer (BC) progression. Tumor-suppressive microRNAs (miRNAs) targeting these cancer pathways may provide a new therapeutic approach for BC. We initially identified miRNA-1826 potentially targeting CTNNB1, VEGFC and MEK1 using several target scan algorithms. Also 3' untranslated region luciferase activity and protein expression of these target genes were significantly downregulated in miR-1826-transfected BC cells (J82 and T24). The expression of miR-1826 was lower in BC tissues and inverse correlation of miR-1826 with several clinical parameters (pT, grade) was observed. Also the expression of miR-1826 was much lower in three BC cell lines (J82, T24 and TCCSUP) compared with a normal bladder cell line (SV-HUC-1). We then performed analyses to look at miR-1826 function and found that miR-1826 inhibited BC cell viability, invasion and migration. We also found increased apoptosis and G(1) cell cycle arrest in miR-1826-transfected BC cells. To examine whether the effect of miR-1826 was through CTNNB1 (beta-catenin) or MEK1 knockdown, we knocked down CTNNB1/MEK1 messenger RNA using a small interfering RNA (siRNA) technique. We observed that CTNNB1 or MEK1 siRNA knockdown resulted in effects similar to those with miR-1826 in BC cells. In conclusion, our data suggest that the miR-1826 plays an important role as tumor suppressor via CTNNB1/MEK1/VEGFC downregulation in BC. C1 [Hirata, Hiroshi; Ueno, Koji; Shahryari, Varahram; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. [Hinoda, Yuji; Tabatabai, Z. Laura] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Hinoda, Yuji; Tabatabai, Z. Laura] Yamaguchi Univ, Grad Sch Med, Dept Oncol AnLab Med, Yamaguchi 7558505, Japan. [Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA 94121 USA. RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu FU National Institutes of Health [RO1CA130860, RO1CA111470, RO1CA138642, T32-DK07790]; VA Research Enhancement Award Program; Merit Review grants; Yamada Science Foundation FX RO1CA130860, RO1CA111470, RO1CA138642, T32-DK07790 from the National Institutes of Health, VA Research Enhancement Award Program, Merit Review grants and Yamada Science Foundation. NR 36 TC 40 Z9 43 U1 2 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD JAN PY 2012 VL 33 IS 1 BP 41 EP 48 DI 10.1093/carcin/bgr239 PG 8 WC Oncology SC Oncology GA 870HF UT WOS:000298659200006 PM 22049531 ER PT J AU Zemans, RL Stream, AR Musani, AI Dhaliwal, G AF Zemans, Rachel L. Stream, Amanda R. Musani, Ali I. Dhaliwal, Gurpreet TI A 46-Year-Old Man With Seizures, Brain Lesions, and Pulmonary Infiltrates SO CHEST LA English DT Editorial Material ID ALVEOLAR PROTEINOSIS; THERAPY C1 [Zemans, Rachel L.; Musani, Ali I.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Zemans, Rachel L.; Stream, Amanda R.; Musani, Ali I.] Univ Colorado Denver, Dept Med, Aurora, CO USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Zemans, RL (reprint author), Natl Jewish Hlth, Dept Med, 1400 Jackson St,A555, Denver, CO 80206 USA. EM ZemansR@NJHealth.org FU NHLBI NIH HHS [HL103772, K08 HL103772] NR 10 TC 0 Z9 0 U1 1 U2 2 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2012 VL 141 IS 1 BP 265 EP 269 DI 10.1378/chest.11-1397 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 874FW UT WOS:000298941800041 PM 22215837 ER PT J AU Butt, AA Kanwal, F AF Butt, Adeel A. Kanwal, Fasiha TI Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID GENOTYPE 1 INFECTION; PROTEASE INHIBITOR; ANTIVIRAL THERAPY; PLUS RIBAVIRIN; INTERFERON; RESISTANCE AB Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a major advance in the management of HCV infection. These DAAs, boceprevir and telaprevir, when given with pegylated interferon alfa (Peg-IFN) and ribavirin (RBV), result in a much higher sustained virologic response rate compared with Peg-IFN and RBV. The DAA-containing regimens are approved for HCV genotype 1 infection in HCV treatment-naive and HCV treatment-experienced patients. In this review, we present an overview of pharmacology, efficacy, adverse events, and emergence of resistance-associated variants with the use of these agents. As with all drugs, especially newly approved drugs, clinicians must consult the package insert for detailed prescribing information, list of all reported adverse events, contraindications, and drug interactions. C1 [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Div Infect Dis, Dept Med, Pittsburgh, PA 15213 USA. [Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.] Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kanwal, Fasiha] St Louis Univ, Sch Med, St Louis Vet Affairs Med Ctr, St Louis, MO 63103 USA. [Kanwal, Fasiha] St Louis Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, St Louis, MO 63103 USA. RP Butt, AA (reprint author), Univ Pittsburgh, Sch Med, Dept Med & Infect Dis, 3601 5th Ave,Ste 3A, Pittsburgh, PA 15213 USA. EM aabutt@pitt.edu FU Merck Sharp Dohme Corp. FX A. A. B. has received investigator-initiated grant support (to University of Pittsburgh) from Merck Sharp & Dohme Corp. NR 21 TC 45 Z9 48 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2012 VL 54 IS 1 BP 96 EP 104 DI 10.1093/cid/cir774 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 866LX UT WOS:000298383500020 PM 22156853 ER PT J AU Daniel, BS Hertl, M Werth, VP Eming, R Murrell, DF AF Daniel, Benjamin S. Hertl, Michael Werth, Victoria P. Eming, Ruediger Murrell, Dedee F. TI Severity score indexes for blistering diseases SO CLINICS IN DERMATOLOGY LA English DT Article ID PEMPHIGUS-VULGARIS; ORAL PEMPHIGUS; IMMUNOADSORPTION; AUTOANTIBODIES; PROGRESSION; ANTIBODIES; RITUXIMAB AB Scoring systems are used to assess the severity of a disease and the response to treatment. The main severity scoring indexes are the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and the Pemphigus Disease Area Index (PDAI). They have been validated and are already used in the evaluation of pemphigus and in clinical trials. They quantify disease severity by performing a global assessment of all lesions. In recent years, other severity scoring systems have been developed for pemphigus and other autoimmune blistering diseases. (C) 2012 Elsevier Inc. All rights reserved. C1 [Daniel, Benjamin S.; Murrell, Dedee F.] St George Hosp, Dept Dermatol, Sydney, NSW, Australia. [Daniel, Benjamin S.; Murrell, Dedee F.] Univ New S Wales, Dept Dermatol, Sydney, NSW, Australia. [Hertl, Michael; Eming, Ruediger] Univ Marburg, Dept Dermatol, Marburg, Germany. [Werth, Victoria P.] Philadelphia VA Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Murrell, DF (reprint author), St George Hosp, Dept Dermatol, Sydney, NSW, Australia. EM d.murrell@unsw.edu.au FU National Institutes of Health [NIH K24-AR 02207] FX This work was supported in part by the National Institutes of Health (grant number NIH K24-AR 02207) to VPW. NR 28 TC 26 Z9 28 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0738-081X J9 CLIN DERMATOL JI Clin. Dermatol. PD JAN-FEB PY 2012 VL 30 IS 1 BP 108 EP 113 DI 10.1016/j.clindermatol.2011.03.017 PG 6 WC Dermatology SC Dermatology GA 864BS UT WOS:000298212600014 PM 22137234 ER PT J AU Ripoll, LH AF Ripoll, Luis H. TI Clinical psychopharmacology of borderline personality disorder: an update on the available evidence in light of the Diagnostic and Statistical Manual of Mental Disorders-5 SO CURRENT OPINION IN PSYCHIATRY LA English DT Review DE Borderline personality disorder; Diagnostic and Statistical Manual of Mental Disorders-5; psychopharmacology ID 18-MONTH FOLLOW-UP; POSITRON-EMISSION-TOMOGRAPHY; DIALECTICAL BEHAVIOR-THERAPY; SELF-INJURIOUS-BEHAVIOR; DOUBLE-BLIND; TOPIRAMATE TREATMENT; 10-YEAR COURSE; PART II; PHARMACOLOGICAL-TREATMENT; AFFECTIVE INSTABILITY AB Purpose of review Clinical considerations for evidence-based treatment of borderline personality disorder (BPD) are outlined in the context of the best available evidence, discussed with reference to BPD traits currently identified in the upcoming Diagnostic and Statistical Manual of Mental Disorders - 5 (DSM-5) revision. The DSM-5 will highlight refractory affective, interpersonal, and identity symptoms in BPD as potential treatment targets. In addition to providing a framework for clinical decision-making, future research strategies will also focus on neurotransmitter systems of greater relevance to understanding overall personality functioning. Recent findings Although only a few randomized controlled trials of psychopharmacological treatments for BPD have been published recently, several meta-analyses and systematic reviews converge on the consensus effectiveness of lamotrigine, topiramate, valproate, aripiprazole, olanzapine, and omega-3 fatty acid supplementation. Stronger evidence exists for treating disinhibition and antagonism than negative affectivity, particularly interpersonal facets of such traits. In addition, basic research suggests a future role for modifying glutamatergic, opioid, and oxytocinergic neurotransmitter systems to treat BPD. Summary Clinicians should utilize omega-3, anticonvulsants, and atypical antipsychotic agents in treating specific DSM-5 BPD traits, notably disinhibition, antagonism, and some aspects of negative affectivity. Future research will focus on normalizing opioid and oxytocin dysregulation, as an adjunct to evidence-based psychotherapy, in an effort to improve interpersonal functioning. C1 [Ripoll, Luis H.] MIRECC, James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Ripoll, Luis H.] Mt Sinai Sch Med, Mood & Personal Res Program, New York, NY USA. RP Ripoll, LH (reprint author), MIRECC, James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM luis.ripoll@mssm.edu FU US Department of Veteran Affairs via a MIRECC FX The author has nothing to disclose, in terms of private funding relevant to this research. At present, he is funded entirely through US Department of Veteran Affairs via a MIRECC Fellowship. NR 91 TC 7 Z9 7 U1 1 U2 25 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7367 J9 CURR OPIN PSYCHIATR JI Curr. Opin. Psychiatr. PD JAN PY 2012 VL 25 IS 1 BP 52 EP 58 DI 10.1097/YCO.0b013e32834c3f19 PG 7 WC Psychiatry SC Psychiatry GA 863CS UT WOS:000298141000009 PM 22037092 ER PT J AU Sikanderkhel, S Luthra, M Chavalitdhamrong, D AF Sikanderkhel, Saad Luthra, Munish Chavalitdhamrong, Disaya TI SNAKESKIN-LIKE PATTERN MIMICKING PORTAL HYPERTENSIVE GASTROPATHY IN PATIENT WITH EOSINOPHILIC GASTRITIS SO DIGESTIVE ENDOSCOPY LA English DT Editorial Material C1 [Sikanderkhel, Saad; Luthra, Munish; Chavalitdhamrong, Disaya] Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Sikanderkhel, S (reprint author), Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 4 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0915-5635 J9 DIGEST ENDOSC JI Dig. Endosc. PD JAN PY 2012 VL 24 IS 1 BP 53 EP 53 DI 10.1111/j.1443-1661.2011.01155.x PG 1 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 869KT UT WOS:000298597500013 PM 22211417 ER PT J AU Sonnenberg, A AF Sonnenberg, A. TI Test sequence in the management of gastrointestinal bleeding SO ENDOSCOPY LA English DT Article ID EPIDEMIOLOGY; DIAGNOSIS AB Background and study aim: A large variety of test procedures is available to diagnose and treat patients with suspected gastrointestinal bleeding. The aim of the study was to investigate which test sequence should be utilized in managing gastrointestinal bleeding. Methods: For each endoscopic, radiologic, or laboratory test procedure, professional fees and facility costs were estimated based on payments allowed by the US Centers for Medicare and Medicaid Services during the fiscal year 2010. A threshold analysis was used to compare the costs associated with different test sequences of varying clinical scenarios. Results: A threshold represents the lowest expected probability of success, for which a test would still be indicated. In a work-up including all possible management options, the threshold associated with laboratory tests and gastric lavage was 1%, esophagogastroduodenoscopy (EGD) 8%, colonoscopy 9%, nuclear scan 9%, enteroscopy 11%, computed tomography (CT) angiography 14%, capsule endoscopy 23%, and angiography with transcatheter embolization 25%. Varying sets of thresholds were calculated for different clinical scenarios. The thresholds of EGD and colonoscopy remained low in most scenarios. In sensitivity analysis, rising risk of complications or costs of a procedure also lead to rising threshold values for it, potentially rendering the particular procedure untenable. Conclusions: A low threshold indicated a preferred management option that should be used early rather than late in a sequence of multiple possible test procedures to work up instances of gastrointestinal bleeding. C1 [Sonnenberg, A.] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 8 TC 5 Z9 5 U1 2 U2 2 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X J9 ENDOSCOPY JI Endoscopy PD JAN PY 2012 VL 44 IS 1 BP 43 EP 47 DI 10.1055/s-0031-1291536 PG 5 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 866TF UT WOS:000298405400008 PM 22198774 ER PT J AU Graber, CJ Hutchings, C Dong, F Lee, W Chung, JK Tran, T AF Graber, C. J. Hutchings, C. Dong, F. Lee, W. Chung, J. K. Tran, T. TI Changes in antibiotic usage and susceptibility in nosocomial Enterobacteriaceae and Pseudomonas isolates following the introduction of ertapenem to hospital formulary SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Antibiotic resistance; antibiotics; hospital-acquired (nosocomial) infections; hospital microbiology; Pseudomonas ID TIME-SERIES ANALYSIS; RESISTANT; AERUGINOSA; IMIPENEM; THERAPY; RATES AB There is concern that widespread usage of ertapenem may promote cross-resistance to other carbapenems. To analyse the impact that adding ertapenem to our hospital formulary had on usage of other broad-spectrum agents and on susceptibilities of nosocomial Enterobacteriaceae and Pseudomonas isolates, we performed interrupted time-series analyses to determine the change in linear trend in antibiotic usage and change in mean proportion and linear trend of susceptibility pre-(March 2004-June 2005) and post-(July 2005-December 2008) ertapenem introduction. Usage of piperacillin-tazobactam (P = 0.0013) and ampicillin-sulbactam (P = 0.035) declined post-ertapenem introduction. For Enterobacteriaceae, the mean proportion susceptible to ciprofloxacin (P = 0.016) and piperacillin-tazobactam (P = 0.038) increased, while the linear trend in susceptibility significantly increased for cefepime (P = 0.012) but declined for ceftriaxone (P = 0.0032). For Pseudomonas, the mean proportion susceptible to cefepime (P = 0.011) and piperacillin-tazobactam (P = 0.028) increased, as did the linear trend in susceptibility to ciprofloxacin (P = 0.028). Notably, no significant changes in carbapenem susceptibility were observed. C1 [Graber, C. J.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Infect Dis Sect, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Graber, C. J.; Tran, T.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. [Hutchings, C.; Dong, F.; Tran, T.] VA Greater Los Angeles Healthcare Syst, Serv Pharm, Los Angeles, CA USA. [Lee, W.] Univ So Calif, Keck Sch Med, Dept Biostat, Los Angeles, CA 90033 USA. [Chung, J. K.] Univ So Calif, Sch Pharm, Los Angeles, CA USA. RP Graber, CJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA Infect Dis Sect, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA. EM cgraber@ucla.edu FU Merck Pharmaceuticals; Ortho-McNeil-Janssen FX This project was supported by a grant from Merck Pharmaceuticals.; C.J.G. has received an unrestricted educational grant from Ortho-McNeil-Janssen and has served on an advisory board for Pfizer. NR 13 TC 3 Z9 3 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JAN PY 2012 VL 140 IS 1 BP 115 EP 125 DI 10.1017/S0950268811000082 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 868TC UT WOS:000298547400015 PM 21303590 ER PT J AU Styskal, J Van Remmen, H Richardson, A Salmon, AB AF Styskal, JennaLynn Van Remmen, Holly Richardson, Arlan Salmon, Adam B. TI Oxidative stress and diabetes: What can we learn about insulin resistance from antioxidant mutant mouse models? SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Review DE Oxidative stress; Diabetes; Obesity; Adipose; Insulin resistance ID EXTRACELLULAR-SUPEROXIDE-DISMUTASE; CELLULAR GLUTATHIONE-PEROXIDASE; METHIONINE SULFOXIDE REDUCTASE; MEMBRANE LIPID-PEROXIDATION; OXIDANT TISSUE-INJURY; RAT SKELETAL-MUSCLE; GENE-TARGETED MICE; ALPHA-LIPOIC ACID; RED-BLOOD-CELLS; NF-KAPPA-B AB The development of metabolic dysfunctions like diabetes and insulin resistance in mammals is regulated by a myriad of factors. Oxidative stress seems to play a central role in this process as recent evidence shows a general increase in oxidative damage and a decrease in oxidative defense associated with several metabolic diseases. These changes in oxidative stress can be directly correlated with increased fat accumulation, obesity, and consumption of high-calorie/high-fat diets. Modulation of oxidant protection through either genetic mutation or treatment with antioxidants can significantly alter oxidative stress resistance and accumulation of oxidative damage in laboratory rodents. Antioxidant mutant mice have previously been utilized to examine the role of oxidative stress in other disease models, but have been relatively unexplored as models to study the regulation of glucose metabolism. In this review, we will discuss the evidence for oxidative stress as a primary mechanism linking obesity and metabolic disorders and whether alteration of antioxidant status in laboratory rodents can significantly alter the development of insulin resistance or diabetes. (C) 2011 Elsevier Inc. All rights reserved. C1 [Styskal, JennaLynn; Van Remmen, Holly; Richardson, Arlan; Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Styskal, JennaLynn; Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Van Remmen, Holly; Richardson, Arlan; Salmon, Adam B.] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA. RP Salmon, AB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr,MSC 7755, San Antonio, TX 78245 USA. EM salmona@uthscsa.edu FU NIH [T32 AG021890-05, R01AG015908, R01AG023843, P01AG19316, P01AG020591, R37AG026557]; Department of Veterans Affairs; San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging FX This work was supported by NIH Training Grant T32 AG021890-05, NIH Grants R01AG015908, R01AG023843, P01AG19316, P01AG020591, and R37AG026557, the Department of Veterans Affairs (Merit Grants and a Research Enhancement Award Program), and the Mitocondrial Function and Oxidative Damage Core Facility of the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging. NR 184 TC 90 Z9 91 U1 1 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JAN 1 PY 2012 VL 52 IS 1 BP 46 EP 58 DI 10.1016/j.freeradbiomed.2011.10.441 PG 13 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 874RJ UT WOS:000298975500005 PM 22056908 ER PT J AU Parshall, MB Carle, AC Ice, U Taylor, R Powers, J AF Parshall, Mark B. Carle, Adam C. Ice, Unchalee Taylor, Robert Powers, Joyce TI Validation of a three-factor measurement model of dyspnea in hospitalized adults with heart failure SO HEART & LUNG LA English DT Article DE Chronic obstructive pulmonary disease; Confirmatory factor analysis; Dyspnea; Respiratory sensation ID OBSTRUCTIVE PULMONARY-DISEASE; CO2-INDUCED AIR HUNGER; RESPIRATORY SENSATIONS; CARDIORESPIRATORY DISEASES; VENTILATED QUADRIPLEGICS; RESPONSE CHARACTERISTICS; QUALITATIVE ASPECTS; CLINICAL-TRIALS; FIT INDEXES; BREATHLESSNESS AB OBJECTIVE: The purpose of this study was to validate a 3-factor measurement model of dyspnea sensory quality (WORK-EFFORT, TIGHTNESS, SMOTHERING-AIR HUNGER) originally derived in patients with exacerbated chronic obstructive pulmonary disease. METHODS: In this validation study, adult patients with heart failure were enrolled after hospital admission (median hospital day 1) and asked to rate the intensity of dyspnea sensory quality descriptors on the day of enrollment (study day 1; N = 119) and in a recall version for the day of admission (study day 0; n = 97). RESULTS: Confirmatory factor analysis demonstrated good model fit for both days. Cronbach's alpha for each factor was greater than .87 for both study days. CONCLUSION: This is the first study to validate a previously specified measurement model of dyspnea sensory quality in an independent sample. Results indicate that measurement of dyspnea sensory quality in exacerbated cardiopulmonary disease does not necessarily require disease-specific questionnaires. Cite this article: Parshall, M. B., Carle, A. C., Ice, U., Taylor, R., & Powers, J. (2012, JANUARY/FEBRUARY). Validation of a three-factor measurement model of dyspnea in hospitalized adults with heart failure. Heart & Lung, 41(1), 44-56. doi:10.1016/j.hrtlng.2011.05.003. C1 [Parshall, Mark B.; Ice, Unchalee] Univ New Mexico, Coll Nursing, Hlth Sci Ctr, Albuquerque, NM 87131 USA. [Carle, Adam C.] Univ Cincinnati, Coll Med, James M Anderson Ctr Hlth Syst Excellence, Cincinnati, OH USA. [Taylor, Robert] Univ New Mexico, Sch Med, Dept Internal Med, Div Cardiol,Hlth Sci Ctr, Albuquerque, NM 87131 USA. [Powers, Joyce] US Dept Vet Affairs, Raymond G Murphy VA Med Ctr, Albuquerque, NM USA. RP Parshall, MB (reprint author), Univ New Mexico, Coll Nursing, Hlth Sci Ctr, MSC 09 5350,1 Univ New Mexico, Albuquerque, NM 87131 USA. EM mparshall@salud.unm.edu FU National Institute of Nursing Research [1 R15 NR008883] FX Funded by a grant from the National Institute of Nursing Research (1 R15 NR008883). The opinions expressed in this article are solely those, of the authors. NR 78 TC 6 Z9 6 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-9563 J9 HEART LUNG JI Heart Lung PD JAN-FEB PY 2012 VL 41 IS 1 BP 44 EP 56 DI 10.1016/j.hrtlng.2011.05.003 PG 13 WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System SC Cardiovascular System & Cardiology; Nursing; Respiratory System GA 875KE UT WOS:000299028000008 PM 21794918 ER PT J AU Anderson, J Wagner, J Bessesen, M Williams, LC AF Anderson, Judith Wagner, Julia Bessesen, Mary Williams, Linda C. TI Usability testing in the hospital SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES LA English DT Article DE Patient safety; Usability; Hospital; Healthcare; Human factors engineering ID CONSULTATION; IMPROVE AB It is not unusual for hospitals to purchase equipment, devices, and materials based on preferences expressed by staff, based on economics and the best offer, or based on the promise of improvement by a new version. However, routinely subjecting potential purchases to basic usability testing provides valuable information upon which to base the decisions. Responsible manufacturers are interested in knowing of needed improvements to their products. Usability testing will also guide training for implementation. Usability testing is included in an introductory human factors engineering (HFE) session as part of a patient safety training course for physicians. Clinicians equipped with this skill are able to build evidence to support purchase decisions, make demands for improved design, and encourage a more thorough HFE evaluation by experts. (c) 2011 Wiley Periodicals, Inc. C1 [Anderson, Judith] VA Natl Ctr Patient Safety, Denver, CO USA. [Wagner, Julia; Bessesen, Mary] Denver VAMC, Denver, CO USA. [Williams, Linda C.] VA Natl Ctr Patient Safety, Ann Arbor, MI USA. RP Williams, LC (reprint author), 24 Frank Lloyd Wright Dr,M2100, Ann Arbor, MI 48106 USA. EM linbywilliams@gmail.com OI Bessesen, Mary/0000-0001-9305-1293 NR 16 TC 1 Z9 1 U1 1 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1090-8471 J9 HUM FACTOR ERGON MAN JI Hum. Factors Ergonom. Manuf. Serv. Ind. PD JAN-FEB PY 2012 VL 22 IS 1 SI SI BP 52 EP 63 DI 10.1002/hfm.20277 PG 12 WC Engineering, Manufacturing; Ergonomics SC Engineering GA 869JG UT WOS:000298593600006 ER PT J AU Lesselroth, BJ Dorr, DA Adams, K Church, V Adams, S Mazur, D Russ, Y Felder, R Douglas, DM AF Lesselroth, Blake J. Dorr, David A. Adams, Kathleen Church, Victoria Adams, Shawn Mazur, Dennis Russ, Yelizaveta Felder, Robert Douglas, David M. TI Medication review software to improve the accuracy of outpatient medication histories: protocol for a randomized controlled trial SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES LA English DT Review DE Medication reconciliation; Medication errors; Technology assessment; Biomedical; Adverse drug events; Medical records systems; Computerized; Consumer health information ID ADVERSE DRUG EVENTS; HOSPITAL DISCHARGE; CLINICAL IMPORTANCE; RECONCILIATION; DISCREPANCIES; ERRORS; CARE; IMPLEMENTATION; ADMISSION; DESIGN AB Medication-prescribing errors generated at interfaces-in-care are the most common cause of preventable health care errors and contribute substantially to adverse patient outcomes. For this reason, standardized medication reconciliation (MR) processes need to be inserted at these interfaces. However, MR is an inherently complex task, and little data exist to inform system-based operationalization. The Portland Informatics Center addressed this challenge by creating an electronic patient-directed multimedia survey to automate the medication history collection. This article describes a research protocol designed to compare the software's medication discrepancy detection rate with traditional history collection strategies. For this randomized, controlled, single-blind trial, participants are randomly allocated into one of two groups: the control group reviews a paper list printed from the electronic record, whereas the intervention group uses a computer-assisted reconciliation survey that includes display of visual data (i.e., medication pictures). (c) 2011 Wiley Periodicals, Inc. C1 [Lesselroth, Blake J.; Adams, Kathleen; Church, Victoria; Adams, Shawn; Mazur, Dennis; Russ, Yelizaveta; Felder, Robert; Douglas, David M.] Portland Oregon Vet Affairs Med Ctr, Portland, OR USA. [Lesselroth, Blake J.; Dorr, David A.; Mazur, Dennis] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Lesselroth, BJ (reprint author), Portland VA Med Ctr, P3 MED,3710 SW US Vet Hosp Dr, Portland, OR 97239 USA. EM blake.lesselroth@va.gov FU VA National Center for Patient Safety FX The authors thank the VA National Center for Patient Safety for support of this project. The authors also thank Ms. Kelly Finley for assistance preparing this manuscript for publication. NR 56 TC 4 Z9 4 U1 1 U2 12 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1090-8471 J9 HUM FACTOR ERGON MAN JI Hum. Factors Ergonom. Manuf. Serv. Ind. PD JAN-FEB PY 2012 VL 22 IS 1 SI SI BP 72 EP 86 DI 10.1002/hfm.20287 PG 15 WC Engineering, Manufacturing; Ergonomics SC Engineering GA 869JG UT WOS:000298593600008 ER PT J AU Izadi, N Goetz, MB Graber, CJ AF Izadi, Neema Goetz, Matthew Bidwell Graber, Christopher J. TI Inverse Correlation of Initial CD8 Lymphocyte Count and CD4 Lymphocyte Response to Combination Antiretroviral Therapy in Treatment-Naive HIV-Infected Patients SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter ID T-CELL-ACTIVATION; HIV-1-INFECTED PATIENTS; COLLABORATIVE ANALYSIS; IMMUNE ACTIVATION; PREDICT; COHORT; SUPPRESSION; RECOVERY; MARKER; DEATH C1 [Izadi, Neema; Goetz, Matthew Bidwell; Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Goetz, Matthew Bidwell; Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect, Los Angeles, CA USA. RP Izadi, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. OI Goetz, Matthew/0000-0003-4542-992X NR 19 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2012 VL 59 IS 1 BP E1 EP E3 DI 10.1097/QAI.0b013e31823d3277 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 865DW UT WOS:000298292000001 PM 22156822 ER PT J AU Watson, KE Dovi, WF Conhaim, RL AF Watson, Kal E. Dovi, William F. Conhaim, Robert L. TI Evidence for active control of perfusion within lung microvessels SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE pulmonary circulation; microcirculation; vasoconstriction; circulatory control; vasoreactivity ID ESTIMATED FUNCTIONAL DIAMETER; ALVEOLAR SEPTAL MICROVESSELS; ISOLATED RAT LUNGS; PULMONARY-HYPERTENSION; VASCULAR-RESISTANCE; THROMBOXANE; CONTRACTILE; CIRCULATION; HYPOXIA; MUSCLE AB Watson KE, Dovi WF, Conhaim RL. Evidence for active control of perfusion within lung microvessels. J Appl Physiol 112: 48-53, 2012. First published October 13, 2011; doi:10.1152/japplphysiol.00820.2011.-Vasoconstrictors cause contraction of pulmonary microvascular endothelial cells in culture. We wondered if this meant that contraction of these cells in situ caused active control of microvascular perfusion. If true, it would mean that pulmonary microvessels were not simply passive tubes and that control of pulmonary microvascular perfusion was not mainly due to the contraction and dilation of arterioles. To test this idea, we vasoconstricted isolated perfused rat lungs with angiotensin II, bradykinin, serotonin, or U46619 (a thromboxane analog) at concentrations that produced equal flows. We also perfused matched-flow controls. We then infused a bolus of 3 mu m diameter particles into each lung and measured the rate of appearance of the particles in the venous effluent. We also measured microscopic trapping patterns of particles retained within each lung. Thirty seconds after particle infusion, venous particle concentrations were significantly lower (P <= 0.05) for lungs perfused with angiotensin II or bradykinin than for those perfused with U46619, but not significantly different from serotonin perfused lungs or matched flow controls. Microscopic clustering of particles retained within the lungs was significantly greater (P <= 0.05) for lungs perfused with angiotensin II, bradykinin, or serotonin, than for lungs perfused with U46619 or for matched flow controls. Our results suggest that these agents did not produce vasoconstriction by a common mechanism and support the idea that pulmonary microvessels possess a level of active control and are not simply passive exchange vessels. C1 [Dovi, William F.; Conhaim, Robert L.] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp, Madison, WI USA. [Watson, Kal E.; Conhaim, Robert L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. RP Conhaim, RL (reprint author), H5-301 BX3236,600 Highland Ave, Madison, WI 53792 USA. EM conhaim@surgery.wisc.edu FU Veterans Health Administration, Office of Research and Development, Department of Veterans Affairs, Biomedical Laboratory Research and Development Service FX This work was supported by the Veterans Health Administration, Office of Research and Development, Department of Veterans Affairs, Biomedical Laboratory Research and Development Service. NR 23 TC 3 Z9 3 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JAN PY 2012 VL 112 IS 1 BP 48 EP 53 DI 10.1152/japplphysiol.00820.2011 PG 6 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 866SR UT WOS:000298403700007 PM 21998262 ER PT J AU Trivedi, RB Piette, J Fihn, SD Edelman, D AF Trivedi, Ranak B. Piette, John Fihn, Stephan D. Edelman, David TI Examining the Interrelatedness of Patient and Spousal Stress in Heart Failure Conceptual Model and Pilot Data SO JOURNAL OF CARDIOVASCULAR NURSING LA English DT Article DE caregivers; heart failure; patient compliance; social support; spouse ID SELF-CARE; PSYCHOSOCIAL INTERVENTIONS; PROGNOSTIC IMPORTANCE; HOSPITAL READMISSION; MARITAL QUALITY; CHRONIC ILLNESS; SOCIAL SUPPORT; RISK-FACTOR; DEPRESSION; FAMILY AB Background and Research Objective: Recent research has highlighted the positive influence that spouses can have on patient outcomes. It is not clear whether patients and spouses influence each other's well-being reciprocally or whether spousal well-being affects the success of patients' disease management. Our goals were 2-fold: (a) to propose a conceptual framework to examine the reciprocity between patient and spouses' well-being, especially as it relates to disease management, and (b) to begin to assess the validity of this model using pilot data. Subjects and Methods: Twenty-three veterans with heart failure (HF) and their spouses were recruited into a pilot cross-sectional observational study. Participants completed psychosocial surveys to assess depressive symptoms, caregiver burden, relationship satisfaction, and disease management. Descriptive analyses and bivariate correlations between these measures were calculated. Results: Using standard cutoffs, analyses suggested clinically significant depressive symptoms in patients (Center for Epidemiological Studies-Depression score >16; mean, 21.8 [SD, 13]) and a high level of caregiver burden among spouses (Zarit Burden Interview score >15; mean, 22.4 [SD, 15.4]). Both patients and spouses reported high relationship satisfaction levels (Dyadic Adjustment Scale score >100; mean, 112.6 [SD, 26.5] and 115.9 [SD, 14.4], respectively). On average, patients reported poor disease management (Self-care of Heart Failure Index subscale <70 across all subscales: confidence = 53.3 [SD, 28.2]; maintenance = 59.7 [SD, 17.3]; management = 54.0 [SD, 19.4]). Patient depressive symptoms were positively correlated with spouse depressive symptoms (r = 0.53) and caregiver burden (r = 0.64; all P's < .05). Spouses' depressive symptoms were additionally correlated with lower levels of perceived social support among patients (r = -0.47), poor patient relationship satisfaction (r = -0.51), and worse patient confidence in HF management (r = -0.48). Greater caregiver burden was associated with more patient disease complaints (r = 0.49), poorer patients' relationship satisfaction (r = -0.72), and poorer patients' perceived social support (r = -0.73). Conclusions: These results provide preliminary support to the proposed conceptual model. Further research is necessary to determine which spousal factors appear to be most relevant to disease management. Disease management interventions may benefit from engaging spouses in a way that enhances their role without adding to their burden. C1 [Trivedi, Ranak B.] VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA USA. [Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Piette, John] Ann Arbor HSR&D Ctr Excellence, Ann Arbor, MI USA. [Fihn, Stephan D.] Vet Affairs Puget Sound, NW HSR&D Ctr Excellence, Seattle, WA USA. [Edelman, David] Duke Univ, Med Ctr, Durham, NC USA. RP Trivedi, RB (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM ranak.trivedi@va.gov OI Edelman, David/0000-0001-7112-6151 FU VA Puget Sound Health Care System; Durham VA Medical Center FX This work was supported in part by the resources provided by the VA Puget Sound Health Care System and the NR 46 TC 10 Z9 10 U1 5 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0889-4655 J9 J CARDIOVASC NURS JI J. Cardiovasc. Nurs. PD JAN-FEB PY 2012 VL 27 IS 1 BP 24 EP 32 DI 10.1097/JCN.0b013e3182129ce7 PG 9 WC Cardiac & Cardiovascular Systems; Nursing SC Cardiovascular System & Cardiology; Nursing GA 866JO UT WOS:000298376900004 PM 21743348 ER PT J AU Davila, JA Duan, ZG McGlynn, KA El-Serag, HB AF Davila, Jessica A. Duan, Zhigang McGlynn, Katherine A. El-Serag, Hashem B. TI Utilization and Outcomes of Palliative Therapy for Hepatocellular Carcinoma A Population-based Study in the United States SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE hepatocellular carcinoma; palliative treatment; chemotherapy ID RANDOMIZED CONTROLLED TRIAL; CHEMOEMBOLIZATION; DOXORUBICIN AB Goals: To evaluate the utilization and determinants of receiving palliative treatment for hepatocellular carcinoma (HCC), and its effect on survival. Background: Palliative treatment for HCC, including transarterial chemoembolization (TACE) and systemic chemotherapy, is available for patients who do not receive potentially curative therapy. The utilization and outcomes of these therapies in clinical practice are unknown. Study: We conducted a population-based cohort study using the Surveillance, Epidemiology, and End-Results Registry data linked to Medicare claims of HCC patients aged above 65 years diagnosed during 2000 to 2005 who did not receive liver transplant, resection, or ablation. The proportions of patients who received TACE or systemic chemotherapy were calculated by tumor stage, liver disease status, and non-HCC comorbidity. Determinants of receiving palliative therapy were examined in logistic regression models and propensity scores were calculated. Cox proportional hazards models were used to evaluate mortality risk. Results: We identified 3163 HCC patients (median age, 75 y; 67% men) who did not receive potentially curative treatment. Approximately 12.5% of patients received TACE and 11.0% received chemotherapy. In patients with early or intermediate stage HCC, no liver decompensation, and little or no comorbidity, only 22.8% received TACE and 13.8% received chemotherapy. Median survival was significantly higher among patients who received TACE (14.0 mo) compared with who received chemotherapy (5.0 mo) or no therapy (2.0 mo). A significant reduction in overall mortality was observed for TACE (54%) and chemotherapy (33%). Conclusions: Utilization of palliative treatment for HCC is low, which could not be explained by clinical features. However, misclassification could have occurred due to the data source. Receipt of TACE or systemic chemotherapy was associated with a reduction in mortality. C1 [Davila, Jessica A.; Duan, Zhigang] Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA. [El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Davila, JA (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,152, Houston, TX 77030 USA. EM jdavila@bcm.tmc.edu FU Onyx Pharmaceuticals; Houston VA HSR&D Center of Excellence [HFP90-020] FX Supported in part by Onyx Pharmaceuticals and the Houston VA HSR&D Center of Excellence (HFP90-020). NR 19 TC 29 Z9 30 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD JAN PY 2012 VL 46 IS 1 BP 71 EP 77 DI 10.1097/MCG.0b013e318224d669 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 863FA UT WOS:000298147000016 PM 22157221 ER PT J AU Cushman, WC Davis, BR Pressel, SL Cutler, JA Einhorn, PT Ford, CE Oparil, S Probstfield, JL Whelton, PK Wright, JT Alderman, MH Basile, JN Black, HR Grimm, RH Hamilton, BP Haywood, LJ Ong, ST Piller, LB Simpson, LM Stanford, C Weiss, RJ AF Cushman, William C. Davis, Barry R. Pressel, Sara L. Cutler, Jeffrey A. Einhorn, Paula T. Ford, Charles E. Oparil, Suzanne Probstfield, Jeffrey L. Whelton, Paul K. Wright, Jackson T., Jr. Alderman, Michael H. Basile, Jan N. Black, Henry R. Grimm, Richard H., Jr. Hamilton, Bruce P. Haywood, L. Julian Ong, Stephen T. Piller, Linda B. Simpson, Lara M. Stanford, Carol Weiss, Robert J. CA ALLHAT Collaborative Res Grp TI Mortality and Morbidity During and After the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID CONVERTING-ENZYME-INHIBITOR; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS; FOLLOW-UP; ALLHAT; OUTCOMES; THERAPY; RISK; PARTICIPANTS; HYPERTENSION AB A randomized, double-blind, active-controlled, multicenter trial assigned 32,804 participants aged 55 years and older with hypertension and =1 other coronary heart disease risk factors to receive chlorthalidone (n=15,002), amlodipine (n=8898), or lisinopril (n=8904) for 4 to 8 years, when double-blinded therapy was discontinued. Passive surveillance continued for a total follow-up of 8 to 13 years using national administrative databases to ascertain deaths and hospitalizations. During the post-trial period, fatal outcomes and nonfatal outcomes were available for 98% and 65% of participants, respectively, due to lack of access to administrative databases for the remainder. This paper assesses whether mortality and morbidity differences persisted or new differences developed during the extended follow-up. Primary outcome was cardiovascular mortality and secondary outcomes were mortality, stroke, coronary heart disease, heart failure, cardiovascular disease, and end-stage renal disease. For the post-trial period, data are not available on medications or blood pressure levels. No significant differences (P<.05) appeared in cardiovascular mortality for amlodipine (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.931.06) or lisinopril (HR, 0.97; CI, 0.901.03), each compared with chlorthalidone. The only significant differences in secondary outcomes were for heart failure, which was higher with amlodipine (HR, 1.12; CI, 1.021.22), and stroke mortality, which was higher with lisinopril (HR, 1.20; CI, 1.011.41), each compared with chlorthalidone. Similar to the previously reported in-trial result, there was a significant treatment-by-race interaction for cardiovascular disease for lisinopril vs chlorthalidone. Black participants had higher risk than non-black participants taking lisinopril compared with chlorthalidone. After accounting for multiple comparisons, none of these results were significant. These findings suggest that neither calcium channel blockers nor angiotensin-converting enzyme inhibitors are superior to diuretics for the long-term prevention of major cardiovascular complications of hypertension. J Clin Hypertens (Greenwich). 2012; 14: 20-31. (C) 2011 Wiley Periodicals, Inc. C1 [Pressel, Sara L.] Univ Texas Hlth Sci Ctr Houston, Univ Texas Houston, ALLHAT Clin Trials Ctr, Sch Publ Hlth, Houston, TX 77030 USA. [Cushman, William C.] Memphis Vet Affairs Med Ctr, Memphis, TN USA. [Cutler, Jeffrey A.; Einhorn, Paula T.] Natl Heart Lung & Blood Inst, Bethesda, MD USA. [Oparil, Suzanne] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Probstfield, Jeffrey L.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Whelton, Paul K.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Wright, Jackson T., Jr.] Case Western Reserve Univ, Med Ctr, Cleveland, OH 44106 USA. [Alderman, Michael H.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Basile, Jan N.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Black, Henry R.] NYU, Langone Med Ctr, New York, NY USA. [Grimm, Richard H., Jr.] Berman Ctr Outcomes & Clin Res, Minneapolis, MN USA. [Hamilton, Bruce P.] Baltimore Vet Adm, Med Ctr, Baltimore, MD USA. [Haywood, L. Julian] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Ong, Stephen T.] Healthcare Greater Washington, Oxon Hill, MD USA. [Stanford, Carol] Univ Missouri, Kansas City Sch Med, Kansas City, MO 64110 USA. [Weiss, Robert J.] Androscoggin Cardiol Associates, Auburn, AL USA. RP Pressel, SL (reprint author), Univ Texas Hlth Sci Ctr Houston, Univ Texas Houston, ALLHAT Clin Trials Ctr, Sch Publ Hlth, RAS W908,,1200 Herman Pressler Dr, Houston, TX 77030 USA. EM sara.l.pressel@uth.tmc.edu FU National Heart, Lung, and Blood Institute (NHLBI) [NO1-HC-35130]; Pfizer; AstraZeneca; Bristol-Myers Squibb; Pfizer Inc.; Merck; GlaxoSmithKline; Forest; Novartis; Takeda FX This study was supported by contract NO1-HC-35130 with the National Heart, Lung, and Blood Institute (NHLBI). ALLHAT investigators received contributions of study medications supplied by Pfizer (amlodipine besylate and doxazosin mesylate), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin), and financial support provided by Pfizer Inc. The authors report no conflicts of interest with regard to this paper. Michael H. Alderman has consulted for AstraZeneca, Merck, and Sankyo; has received honoraria from Bristol-Myers Squibb and Merck; has had grants/contracts with Sankyo; and has held a financial interest in Merck. Jan N. Basile has consulted for Abbott Laboratories, Boehringer Ingelheim, Daiichi Sankyo, Forest Laboratories, Forest Pharmaceuticals, Merck, Novartis, Reddy Pharmaceuticals, Sankyo, and SmithKline Beecham/Glaxo Wellcome; and has received honoraria from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Forest Laboratories, Merck, Novartis, and Pfizer; Henry R. Black has consulted for Abbott Laboratories, AstraZeneca, Aventis, Bayer Corporation, Biovail, Boehringer Ingelheim, Bristol-Meyers Squibb, CVRx, Daiichi Sankyo, Forest Pharmaceuticals, Gilead, GlaxoSmithKline, Horizons Pharmaceuticals, Inter-cure, Merck, Novartis, Pfizer, Sankyo, Sanofi Aventis, Sanofi-Synthelabo, Servier, and Takeda; has received honoraria from Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CV Therapeutics, Forest Laboratories, Merck, Novartis, Pfizer, Sanofi-Synthelabo, and Servier; and has had grants/contracts with Pfizer. William C. Cushman has consulted for Abbott Laboratories, Bristol-Myers Squibb, Calpis, Daiichi Sankyo, Forest Pharmaceuticals, Gilead Colorado, Johnson and Johnson, King, Myogen, Novartis, Pfizer, Pharmacopeia, Reddy Pharmaceuticals, Roche, Sankyo, Sanofi Aventis, Sanofi-Synthelabo, Sciele, Takeda, and Theravance; has received honoraria from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Forest Pharmaceuticals, King, and Novartis and has had grants/contracts with Abbott Laboratories, Biovail, King, and Novartis. Barry R. Davis has consulted for BioMarin, Forest Pharmaceuticals, GlaxoSmithKline, Merck, Proctor and Gamble, and Takeda; and has held a financial interest in Amgen. Charles E. Ford has consulted for BioMarin. Richard H. Grimm, Jr has consulted for Calpis, Merck, Merck/SP, Novartis, Pfizer, and Takeda; has received honoraria from AstraZeneca, Merck, Novartis, and Takeda; and has had grants/contracts with Merck, Novartis, and Pfizer. Bruce P. Hamilton has had grants/contracts with GlaxoSmithKline. L. Julian Haywood has held a financial interest in Pfizer. Stephen T. Ong has received honoraria from Novartis; and has had grants/contracts with Abbott Laboratories, Arena, Daiichi Sankyo, Ferring, Forest Pharmaceutical, Gilead Colorado, GlaxoSmithKline, Mylan Bertek, Novartis, Pharmacopeia, Roche, Sankyo, and Sanofi Aventis. Suzanne Oparil has consulted for Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Encysive Pharm, Forest Pharmaceuticals, GlaxoSmithKline, Merck, NicOx, Novartis, Pfizer, Salt Institute, Sankyo, Sanofi Aventis, Schering Plough, and SmithKline Beecham/Glaxo Wellcome; has received honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, and Encysive Pharm; has had grants/contracts with Daiichi Sankyo, Eisai Medical Research, Encysive Pharm, Gilead, Novartis, Pfizer, Sankyo, and Takeda; and has held a financial interest in Encysive Pharm. Jeffrey L.; Prob-stfield has consulted for Boehringer Ingelheim, King, and King Pharmceuticals/Monarch; has received honoraria from Boehringer Ingelheim; and has had grants/contracts with Boehringer Ingelheim, King, King Pharmaceuticals/Monarch, KOS, and Sanofi Aventis. Carol Stanford has held a financial interest in Pfizer. Robert J. Weiss has had grants/contracts with Forest, Novartis, and Takeda. Jackson T. Wright, Jr has consulted for Abbott Laboratories, AstraZeneca, Bayer Corporation, Biovail, CV Therapeutics, CVRx, Daiichi Sankyo, Forest Pharmaceuticals, GlaxoSmithKline, Merck, NitroMed, Novartis, Pfizer, Reliant Pharm, Sankyo, Sanofi Aventis, Sanofi-Synthelabo, and SmithKline Beecham/Glaxo Wellcome; and has had grants/contracts with GlaxoSmithKline and Novartis. Jeffrey A. Cutler, Paula T. Einhorn, Linda B. Piller, Sara L. Pressel, Lara M. Simpson, and Paul K. Whelton have no financial conflicts of interest to report. The NHLBI sponsored the study and was involved in all aspects other than direct operations of the study centers. This included collection, analysis, and interpretation of the data plus the decision to submit the manuscript for publication. Pfizer Inc, AstraZeneca, and Bristol-Myers Squibb had no role in the design and conduct of the study, the collection, analysis, and interpretation of the data or the preparation or approval of the manuscript. Editorial assistance was provided by Ellen Breckenridge, an employee of the ALLHAT Collaborative Research Group. The position was paid for by grant funds provided by the NHLBI for the ALLHAT project. NR 27 TC 21 Z9 24 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JAN PY 2012 VL 14 IS 1 BP 20 EP 31 DI 10.1111/j.1751-7176.2011.00568.x PG 12 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 871IV UT WOS:000298732400006 PM 22235820 ER PT J AU Kearney, DJ McDermott, K Malte, C Martinez, M Simpson, TL AF Kearney, David J. McDermott, Kelly Malte, Carol Martinez, Michelle Simpson, Tracy L. TI Association of participation in a mindfulness program with measures of PTSD, depression and quality of life in a veteran sample SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE mindfulness; posttraumatic stress disorder; acceptance; depression; meditation ID POSTTRAUMATIC-STRESS-DISORDER; PROSTATE-CANCER OUTPATIENTS; NATIONAL COMORBIDITY SURVEY; BEHAVIORAL ACTIVATION; REDUCTION PROGRAM; COGNITIVE THERAPY; SEXUAL TRAUMA; SCALE BADS; SYMPTOMS; MEDITATION AB Objectives: To assess outcomes of veterans who participated in mindfulness-based stress reduction (MBSR). Design: Posttraumatic stress disorder (PTSD) symptoms, depression, functional status, behavioral activation, experiential avoidance, and mindfulness were assessed at baseline, and 2 and 6 months after enrollment. Results: At 6 months, there were significant improvements in PTSD symptoms (standardized effect size, d = -0.64, p< 0.001); depression (d = -0.70, p<0.001); behavioral activation (d = 0.62, p<0.001); mental component summary score of the Short Form-8 (d = 0.72, p<0.001); acceptance (d = 0.67, p<0.001); and mindfulness (d = 0.78, p<0.001), and 47.7% of veterans had clinically significant improvements in PTSD symptoms. Conclusions: MBSR shows promise as an intervention for PTSD and warrants further study in randomized controlled trials. (c) 2011 Wiley Periodicals, Inc. J Clin Psychol 68:116, 2012. C1 [Kearney, David J.; McDermott, Kelly; Malte, Carol; Martinez, Michelle; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Kearney, DJ (reprint author), Seattle VAMC 111GI,1660 S Columbian Way, Seattle, WA 98108 USA. EM david.kearney@va.gov RI Schueter, nicos/A-3625-2014 NR 59 TC 72 Z9 72 U1 3 U2 55 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD JAN PY 2012 VL 68 IS 1 BP 101 EP 116 DI 10.1002/jclp.20853 PG 16 WC Psychology, Clinical SC Psychology GA 865HE UT WOS:000298301000009 PM 22125187 ER PT J AU Li, Y Rimbara, E Thirumurthi, S Trespalacios, A Reddy, R Sabounchi, S Attumi, TA Graham, DY AF Li, Yuan Rimbara, Emiko Thirumurthi, Selvi Trespalacios, Alba Reddy, Rita Sabounchi, Saman Attumi, Taraq Assed Graham, David Yates TI Detection of clarithromycin resistance in Helicobacter pylori following noncryogenic storage of rapid urease tests for 30 days SO JOURNAL OF DIGESTIVE DISEASES LA English DT Article DE clarithromycin resistance; Helicobacter pylori; noncryogenic storage; polymerase chain reaction; rapid urease test; susceptibility test ID POLYMERASE-CHAIN-REACTION; 23S RIBOSOMAL-RNA; ANTIBIOTIC-RESISTANCE; BIOPSY SPECIMENS; GASTRIC TISSUE; INFECTION; SUSCEPTIBILITY; POLYMORPHISM; PREVALENCE; MUTATIONS AB OBJECTIVE: Traditional Helicobacter pylori (H. pylori) eradication therapy has been undermined by increasing antimicrobial, especially clarithromycin, resistance. Susceptibility testing in some areas is difficult to achieve or unavailable. We aimed to determine whether gastric biopsy specimens stored at room temperature for rapid urease test (RUT) were suitable for clarithromycin susceptibility testing of H. pylori. METHODS: After 30 days of storage at room temperature, DNA was extracted from gastric biopsies present in RUTs (Hpfast). H. pylori status and clarithromycin susceptibility were evaluated using H. pylori- specific polymerase chain reaction (PCR) for ureA, vacA, and allele- specific primer- PCR of the 23S rRNA genes. The PCR results were compared with histology, RUT, and culture results. H. pylori positive was defined as RUT and either culture or histology positive; H. pylori negative as RUT, culture and histology negative. RESULTS: Samples from 31 patients were evaluated; 11 were H. pylori positive including 9 by culture; seven of which had allele- specific primer- PCR results from the RUT specimen for the detection of mutations of the 23S rRNA gene. When both tests were available, culture and PCR results were concordant in 7 cases. In 15 of the 20 histology, RUT and culture negative patients, three PCR were negative. In one patient, all of the three tests were positive; and in three only the 23S rRNA was positive and in one only ureA was positive. CONCLUSION: Gastric biopsy specimens stored in the gel of RUT for 30 days can be used for molecular testing to confirm the diagnosis of H. pylori infection and test for clarithromycin susceptibility. C1 [Li, Yuan; Rimbara, Emiko; Thirumurthi, Selvi; Trespalacios, Alba; Reddy, Rita; Sabounchi, Saman; Attumi, Taraq Assed; Graham, David Yates] Baylor Coll Med, Ben Taub Gen Hosp, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Graham, DY (reprint author), Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs, Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.edu RI Rimbara, Emiko/F-4113-2017 OI Rimbara, Emiko/0000-0001-8847-1840 FU Office of Research and Development Medical Research Service, Department of Veterans Affairs, Public Health Service [DK56338]; Texas Medical Center Digestive Diseases Center [DK067366, CA116845] FX Dr GRAHAM is supported in part by the Office of Research and Development Medical Research Service, Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center, DK067366 and CA116845. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the Veterans Affairs or National Institutes of Health. Dr GRAHAM is an unpaid consultant for Novartis in relation to vaccine development for the treatment or prevention of H. pylori infection. Dr GRAHAM is also a paid consultant for Otsuka Pharmaceuticals regarding diagnostic testing and has received royalties on the Baylor College of Medicine patent covering materials related to the 13C-urea breath test. The other authors have nothing to declare. NR 21 TC 8 Z9 9 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1751-2972 J9 J DIGEST DIS JI J. Dig. Dis. PD JAN PY 2012 VL 13 IS 1 BP 54 EP 59 DI 10.1111/j.1751-2980.2011.00549.x PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 867UK UT WOS:000298480100009 PM 22188917 ER PT J AU Burks, DJ Robbins, R AF Burks, Derek J. Robbins, Rockey TI Psychologists' Authenticity: Implications for Work in Professional and Therapeutic Settings SO JOURNAL OF HUMANISTIC PSYCHOLOGY LA English DT Article DE authenticity; genuineness; humanistic psychotherapy; therapeutic relationship ID QUALITATIVE RESEARCH; CONCEPTUALIZATION AB Psychologists engage in a multitude of social roles of varying degrees of emotionality, subjectivity, and objectivity because of the nature of their profession as well as their unique backgrounds that have drawn them to that profession. This study sought to understand how psychologists recognize and experience the concept of authenticity in the context of their professional lives. A purposeful sample of 17 clinical psychologists from metropolitan areas in the Southwest and the Pacific Northwest were interviewed. Using a phenomenological, qualitative research design, 262 significant statements were extracted and grouped together, resulting in 11 emergent themes specifically relating to a therapeutic, health care context. Rigor and thoroughness were achieved via multiple validation procedures. Psychologists defined authenticity as the matching of one's inner thoughts, beliefs, and feelings with one's outer presentation and behaviors. They believed that authenticity involves sensory and emotional qualities rather than purely cognitive or verbal qualities. Concepts of self-disclosure and mindful awareness were discussed as related to authenticity. It is of note that both humanistic and nonhumanistically inclined psychologists equally valued authenticity in the professional and therapeutic setting. Participants also discussed how authenticity and inauthenticity are experienced and modified in the therapeutic relationship, as well as the negative effects of inauthenticity in professional contexts. C1 [Robbins, Rockey] Univ Oklahoma, Coll Educ, Norman, OK 73019 USA. RP Burks, DJ (reprint author), Portland VA Med Ctr, P3MIRECC,POB 1034, Portland, OR 97207 USA. EM derek.burks@va.gov NR 41 TC 2 Z9 4 U1 1 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-1678 J9 J HUMANIST PSYCHOL JI J. Humanist. Psychol. PD JAN PY 2012 VL 52 IS 1 BP 75 EP 104 DI 10.1177/0022167810381472 PG 30 WC Psychology, Multidisciplinary SC Psychology GA 868YR UT WOS:000298563000005 ER PT J AU Grobman, LE Wu, DY Dong, DZ Wu, PC AF Grobman, L. E. Wu, D. Y. Dong, D. Z. Wu, P. C. TI THE ROLE OF COXSACKIE-ADENOVIRUS RECEPTOR AS A SENESCENCE BIOMARKER DURING RECTAL CANCER TREATMENT SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Grobman, L. E.; Wu, D. Y.; Wu, P. C.] Univ Washington, Seattle, WA 98195 USA. [Wu, D. Y.; Dong, D. Z.; Wu, P. C.] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 148 EP 148 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634401081 ER PT J AU MIller, M Knaub, L Reusch, JE AF MIller, M. Knaub, L. Reusch, J. E. TI ATTENUATION OF ACUTE EXERCISE-INDUCED MITOCHONDRIAL BIOGENESIS AND OXIDANT DEFENSE IN A MODEL OF INSULIN RESISTANT DIABETES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [MIller, M.; Knaub, L.; Reusch, J. E.] Univ Colorado, Sch Med, Aurora, CO USA. [Reusch, J. E.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 176 EP 176 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634401178 ER PT J AU Hartvigson, PE Erikson, MA Banks, WA AF Hartvigson, P. E. Erikson, M. A. Banks, W. A. TI SYSTEMIC INFLAMMATION INHIBITS LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1 MEDIATED CLEARANCE OF AMYLOID-beta FROM BLOOD: IMPLICATIONS FOR ALZHEIMER'S DISEASE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Hartvigson, P. E.; Erikson, M. A.; Banks, W. A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Hartvigson, P. E.; Banks, W. A.] Univ Washington, Sch Med, Seattle, WA USA. [Erikson, M. A.] St Louis Univ, St Louis, MO 63103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 240 EP 240 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634401409 ER PT J AU Obioha, O Bassett, J Saigal, C Bennett, C AF Obioha, O. Bassett, J. Saigal, C. Bennett, C. TI DISSEMINATION OF TOBACCO CONTROL GUIDELINES TO A SPECIALTY CARE SETTING: A UROLOGIC PERSPECTIVE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Obioha, O.; Bassett, J.; Saigal, C.; Bennett, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Bassett, J.; Saigal, C.; Bennett, C.] W Los Angeles VA Hosp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 244 EP 245 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634401424 ER PT J AU Bains, S Egede, LE AF Bains, S. Egede, L. E. TI ASSOCIATIONS BETWEEN HEALTH LITERACY AND PREVENTATIVE CARE BEHAVIOR: ANALYSIS OF A NATIONAL SAMPLE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Bains, S.; Egede, L. E.] Med Univ S Carolina, Charleston, SC 29425 USA. [Egede, L. E.] Ralph H Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 353 EP 353 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634402152 ER PT J AU Vasquez, K Wagner, BT AF Vasquez, K. Wagner, B. T. TI NEPHROGENIC SYSTEMIC FIBROSIS: THE CONTRIBUTION OF BONE MARROW-DERIVED FIBROCYTES TO SKIN LESIONS AND ASSOCIATION WITH L-CATHEPSIN SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Vasquez, K.; Wagner, B. T.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Vasquez, K.; Wagner, B. T.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 425 EP 425 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634402416 ER PT J AU Billue, K Safford, M Salanitro, A Houston, T Curry, W Kim, Y Allison, J Estrada, C AF Billue, K. Safford, M. Salanitro, A. Houston, T. Curry, W. Kim, Y. Allison, J. Estrada, C. TI DIABETES MEDICATION INTENSIFICATION IN RURAL PRIMARY CARE PRACTICES: A CLUSTER-RANDOMIZED EFFECTIVENESS TRIAL SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Billue, K.; Safford, M.; Salanitro, A.; Curry, W.; Kim, Y.; Estrada, C.] Univ Alabama, Birmingham, AL USA. [Estrada, C.] Birmingham VAMC, Birmingham, AL USA. [Houston, T.; Allison, J.] Univ Massachusetts, Sch Med, Worcester, MA USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 460 EP 461 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634402541 ER PT J AU Bains, S Egede, LE AF Bains, S. Egede, L. E. TI DEMOGRAPHIC, GEOGRAPHIC AND LANGUAGE PREDICTORS OF HEALTH LITERACY: ANALYSIS OF THE 2003 NATIONAL ASSESSMENT OF ADULT LITERACY SURVEY SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Bains, S.; Egede, L. E.] Med Univ S Carolina, Charleston, SC 29425 USA. [Egede, L. E.] Ralph H Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 463 EP 463 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634402551 ER PT J AU Newsom, J Taylor, B AF Newsom, J. Taylor, B. TI CAN MEDICAL TEAM MEMBERS PREDICT 30-DAY READMISSION RISK ON ADMISSION? SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Newsom, J.; Taylor, B.] Univ Alabama, Birmingham, AL USA. [Newsom, J.; Taylor, B.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 463 EP 464 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634402552 ER PT J AU Newsom, J Kraemer, R Estrada, C Morris, J Willett, L AF Newsom, J. Kraemer, R. Estrada, C. Morris, J. Willett, L. TI EXTERNAL VALIDATION OF A CLINICAL VIGNETTE SCORING TOOL SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Newsom, J.; Kraemer, R.; Estrada, C.; Morris, J.; Willett, L.] Univ Alabama, Birmingham, AL USA. [Newsom, J.; Estrada, C.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 464 EP 464 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634402553 ER PT J AU Kertesz, S Steward, J Johnson, N Pollio, D Holt, C Austin, E Gordon, A Stringfellow, E Granstaff, U AF Kertesz, S. Steward, J. Johnson, N. Pollio, D. Holt, C. Austin, E. Gordon, A. Stringfellow, E. Granstaff, U. TI COMPARISON OF CUSTOMIZED VERSUS MAINSTREAM PRIMARY CARE FOR HOMELESS INDIVIDUALS: THE PRIMARY CARE QUALITY-HOMELESS SURVEY SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting CY JAN 25-28, 2012 CL Carmel, CA C1 [Kertesz, S.; Johnson, N.; Austin, E.; Granstaff, U.] Birmingham VAMC, Birmingham, AL USA. [Kertesz, S.; Steward, J.] Univ Alabama, Birmingham, AL USA. [Pollio, D.] Univ Alabama, Tuscaloosa, AL USA. [Holt, C.] Univ Maryland, Baltimore, MD 21201 USA. [Gordon, A.] Pittsburgh VAMC, Pittsburgh, PA USA. [Stringfellow, E.] Boston HCH, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2012 VL 60 IS 1 BP 465 EP 465 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 869XV UT WOS:000298634402556 ER PT J AU Potter, RM Harikumar, KG Wu, SV Miller, LJ AF Potter, Ross M. Harikumar, Kaleeckal G. Wu, S. Vincent Miller, Laurence J. TI Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol SO JOURNAL OF LIPID RESEARCH LA English DT Article DE receptor binding; biological activity; chimeric receptors; G protein-coupled receptors; perfringolysin ID PROTEIN-COUPLED RECEPTOR; PERFRINGOLYSIN-O; BETA(2)-ADRENERGIC RECEPTOR; CANNABINOID RECEPTORS; INTRACELLULAR LOOP; HUMAN GALLBLADDERS; PLASMA-MEMBRANE; LIGAND-BINDING; CCK RECEPTOR; II-RECEPTOR AB Recent studies indicate that membrane cholesterol can associate with G protein-coupled receptors (GPCRs) and affect their function. Previously, we reported that manipulation of membrane cholesterol affects ligand binding and signal transduction of the type 1 cholecystokinin receptor (CCK1R), a Class A GPCR. We now demonstrate that the closely related type 2 cholecystokinin receptor (CCK2R) does not share this cholesterol sensitivity. The sequences of both receptors reveal almost identical cholesterol interaction motifs in analogous locations in transmembrane segments two, three, four, and five. The disparity in cholesterol sensitivity between these receptors, despite their close structural relationship, provides a unique opportunity to define the possible structural basis of cholesterol sensitivity of CCK1R. To evaluate the relative contributions of different regions of CCK1R to cholesterol sensitivity, we performed ligand binding studies and biological activity assays of wildtype and CCK2R/CCK1R chimeric receptor-bearing Chinese hamster ovary cells after manipulation of membrane cholesterol. We also extended these studies to site-directed mutations within the cholesterol interaction motifs. The results contribute to a better understanding of the structural requirements for cholesterol sensitivity in CCK1R and provides insight into the function of other cholesterol-sensitive Class A GPCRs.-Potter, R.M., K.G. Harikumar, S.V. Wu, and L.J. Miller. Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol. J. Lipid Res. 2012. 53: 137-148. C1 [Potter, Ross M.; Harikumar, Kaleeckal G.; Miller, Laurence J.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA. [Wu, S. Vincent] Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. RP Miller, LJ (reprint author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA. EM miller@mayo.edu FU National Institutes of Health [DK-32878]; Mayo Clinic FX This work was supported by Grant DK-32878 from the National Institutes of Health and by the Mayo Clinic-Kinney Career Development Award. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or other granting agencies. NR 62 TC 17 Z9 17 U1 0 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD JAN PY 2012 VL 53 IS 1 BP 137 EP 148 DI 10.1194/jlr.M020065 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 866TI UT WOS:000298405900014 PM 22021636 ER PT J AU Eatesam, M Noworolski, SM Tien, PC Nystrom, M Dodge, JL Merriman, RB Qayyum, A AF Eatesam, Mamak Noworolski, Susan M. Tien, Phyllis C. Nystrom, Michelle Dodge, Jennifer L. Merriman, Raphael B. Qayyum, Aliya TI Liver diffusivity in healthy volunteers and patients with chronic liver disease: Comparison of breathhold and free-breathing techniques SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE diffusion-weighted imaging (DWI); breathhold (BH); free-breathing (FB); nonalcoholic fatty liver disease (NAFLD); hepatitis C (HCV) ID WOMENS INTERAGENCY HIV; WEIGHTED MRI; FIBROSIS; COEFFICIENT; EXPERIENCE; DIAGNOSIS; CIRRHOSIS; REPRODUCIBILITY; PARAMETERS; HEPATITIS AB Purpose: To compare liver ADC obtained with breathhold and free-breathing diffusion weighted imaging (DWI) in healthy volunteers and patients with liver disease. Materials and Methods: Twenty-eight subjects, 12 healthy volunteers and 16 patients (9 NAFLD, 7 chronic active HCV), underwent breathhold (BH) and free-breathing (FB) DWI MRI at 1.5 Tesla. Pearson's correlation coefficient was used to determine correlation while paired t-tests assessed differences between BH and FB ADC. Estimated bias was calculated using the Bland-Altman method. Results: Liver ADC (x10(-3) mm(2)/s) was lower on BH for all groups (mean difference 0.36 +/- 0.20; P < 0.01). ADC was higher in healthy volunteers (BH 1.80 +/- 0.18; FB 2.24 +/- 0.20) compared with NAFLD patients (BH 1.43 +/- 0.27; FB 1.78 +/- 0.28) (P < 0.001) and HCV patients (BH 1.63 +/- 0.191; FB 1.88 +/- 0.12). Overall correlation between BH and FB ADC was (r = 0.75), greatest in NAFLD (r = 0.90) compared with the correlation in HCV (r = 0.24) and healthy subjects (r = 0.34). Bland-Altman plots did not show agreement in mean absolute difference and estimated bias between subjects. Conclusion: Correlation between BH and FB liver ADC is moderate indicating that BH and FB should not be used interchangeably. Additionally, the lower ADC values in BH versus FB should be accounted for when comparing different liver DWI studies. C1 [Eatesam, Mamak; Noworolski, Susan M.; Nystrom, Michelle; Qayyum, Aliya] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Noworolski, Susan M.] Univ Calif San Francisco & Berkeley, Grad Grp Bioengn, Berkeley, CA USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. [Dodge, Jennifer L.] Univ Calif San Francisco, Dept Internal Med, Fresno Med Educ Program, San Francisco, CA 94143 USA. [Merriman, Raphael B.] Calif Pacific Med Ctr, Dept Med, San Francisco, CA USA. RP Qayyum, A (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0628,M-372,505 Parnassus Ave, San Francisco, CA 94143 USA. EM aliya.qayyum@radiology.ucsf.edu FU NIH [K23 AI-66943, UO1 AI-34989, MO1-RR-00083, R01 DK061738-SI, R01 DK074718-01]; National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131]; UCSF FX Contract grant sponsor: NIH; Contract grant number: K23 AI-66943, UO1 AI-34989, MO1-RR-00083, R01 DK061738-SI, R01 DK074718-01; Contract grant sponsor: National Institute of Allergy and Infectious Diseases; Contract grant number: UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590; Contract grant sponsor: National Institute of Child Health and Human Development; Contract grant number: UO1-HD-32632; Contract grant sponsor: National Cancer Institute; Contract grant sponsor: National Institute on Drug Abuse; Contract grant sponsor: National Institute on Deafness and Other Communication Disorders; Contract grant sponsor: National Center for Research Resources (UCSF-CTSI); Contract grant number: UL1 RR024131; Contract grant sponsor: UCSF Hellman Family Award. NR 30 TC 3 Z9 4 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD JAN PY 2012 VL 35 IS 1 BP 103 EP 109 DI 10.1002/jmri.22748 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 862LT UT WOS:000298093200011 PM 22034200 ER PT J AU Baer, JS Carpenter, KM Beadnell, B Stoner, SA Ingalsbe, MH Hartzler, B Rosengren, DB Drager, Z AF Baer, John S. Carpenter, Kelly M. Beadnell, Blair Stoner, Susan A. Ingalsbe, Michelle Hansten Hartzler, Bryan Rosengren, David B. Drager, Zach TI Computer Assessment of Simulated Patient Interviews (CASPI): Psychometric Properties of a Web-Based System for the Assessment of Motivational Interviewing Skills SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID VIDEO ASSESSMENT; CLINICIAN; COMPETENCE; VALIDITY; RELIABILITY; VALIDATION; ADDICTION; BEHAVIOR; SCALE; VASE AB Objective: Benefits of empirically supported interventions hinge on clinician skill, particularly for motivational interviewing (MI). Existing MI skill assessments are limited with respect to validity (e.g., self-report) and practicality (e.g., coding session tapes). To address these limitations, we developed and evaluated two versions of a web-based assessment of MI skills, the Computer Assessment of Simulated Patient Interviews (CASPI). Method: Ninety-six counselors from the community and 24 members of the Motivational Interviewing Network of Trainers (MINT) completed the CASPI (N = 120), in which they verbally responded via microphones to video clips comprising three 9-item vignettes. Three coders used an emergent coding scheme, which was compared with alternative MI skills measures. Results: CASPI demonstrated excellent internal consistency when averaging across two or three vignettes (alpha's = .86.89). Intraclass correlations were above 40 for most items. Confirmatory factor analyses supported a correlated three-factor model: MI-consistent, resistance-engendering, and global change talk orientation rating. Means and factor loadings were invariant across forms (i.e., the two alternative versions of CASPI), and factor loadings were invariant across subgroup (i.e., community counselor or MINT member). Test retest reliability was good for MI-consistent and resistance-engendering scores (r = .74 and .80, respectively) but low for change talk orientation (r = .29) unless coder was taken into account (r = .69). CASPI showed excellent construct and criterion-related validity. Conclusions: CASPI represents a promising method of assessing MI skills. Future studies are needed to establish its performance in real-world contexts. (J. Stud. Alcohol Drugs, 73, 154-164, 2012) C1 [Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Baer, John S.; Ingalsbe, Michelle Hansten; Hartzler, Bryan; Rosengren, David B.] Univ Washington, Inst Alcohol & Drug Abuse, Seattle, WA 98195 USA. [Carpenter, Kelly M.; Stoner, Susan A.; Drager, Zach] Talaria Inc, Seattle, WA USA. [Beadnell, Blair] Univ Washington, Sch Social Work, Seattle, WA 98195 USA. [Beadnell, Blair; Rosengren, David B.] Prevent Res Inst, Lexington, KY USA. RP Baer, JS (reprint author), VA Puget Sound HCS, S-116-ATC,1660 S Columbian Way, Seattle, WA 98108 USA. EM jsbaer@uw.edu FU National Institute on Drug Abuse [R42 DA020284] FX This research was supported by a Small Business Technology Transfer grant from the National Institute on Drug Abuse (R42 DA020284). NR 24 TC 4 Z9 4 U1 0 U2 2 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD JAN PY 2012 VL 73 IS 1 BP 154 EP 164 PG 11 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 873QP UT WOS:000298898400020 PM 22152673 ER PT J AU Klein, AA Slaymaker, VJ Dugosh, KL Mckay, JR AF Klein, Audrey A. Slaymaker, Valerie J. Dugosh, Karen L. Mckay, James R. TI Computerized continuing care support for alcohol and drug dependence: A preliminary analysis of usage and outcomes SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Alcohol dependence; Drug dependence; Continuing care; Computer based; Residential treatment ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; ASSISTED INTERVENTION; PROBLEM DRINKERS; CLINICAL-TRIAL; DIABETES CARE; FOLLOW-UP; RELIABILITY; PROGRAM; INSTRUMENT AB The central aim of this administrative data analysis was to examine usage of a Web-based disease management program designed to provide continuing recovery support to patients discharged from residential drug and alcohol treatment. Tailored clinical content was delivered in a multimedia format over the course of 18 months posttreatment. The program also included access to a recovery coach across the 18 months. Consistent with other disease management programs, program usage decreased over time. A small subsample of patients accessed a large number of program modules in the year following treatment; these patients had significantly higher abstinence rates and consumed less alcohol than patients accessing few or no modules. Regression analyses revealed a significant relationship between the number of modules accessed and substance use outcomes in the year following treatment when controlling for motivation, self-efficacy, and pretreatment substance use. Limiting the analyses to only the more compliant patients did not reduce the magnitude of these effects. These preliminary results suggest that computerized support programs may be beneficial to patients recently treated for drug and alcohol issues. Methods to increase program engagement need additional study. (C) 2012 Elsevier Inc. All rights reserved. C1 [Klein, Audrey A.; Slaymaker, Valerie J.] Hazelden Fdn, Butler Ctr Res, Ctr City, MN 55012 USA. [Dugosh, Karen L.] Treatment Res Inst, Philadelphia, PA USA. [Mckay, James R.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Mckay, James R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Klein, AA (reprint author), Hazelden Fdn, Butler Ctr Res, POB 11,BC-4, Ctr City, MN 55012 USA. EM aklein@hazelden.org NR 27 TC 14 Z9 15 U1 0 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JAN PY 2012 VL 42 IS 1 BP 25 EP 34 DI 10.1016/j.jsat.2011.07.002 PG 10 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 860OF UT WOS:000297956900004 PM 21862275 ER PT J AU Brewster, LP Palmatier, J Manley, CJ Hall, DE Brems, JJ AF Brewster, Luke P. Palmatier, Jason Manley, C. J. Hall, Daniel E. Brems, J. J. TI Limitations on Surrogate Decision-Making for Emergent Liver Transplantation SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE surrogate consent; ethics; fulminant hepatic failure; liver transplantation ID RISK-RELATED STANDARDS; INFORMED-CONSENT; OF-LIFE; COMPETENCE; ACCURACY; PERSPECTIVE; DEBATE; ETHICS; CARE AB Background. Surrogate consent is an accepted form of promoting patient autonomy when patients cannot consent, but it can lead to surrogate duress and may be unreliable. Since consent for liver transplantation in patients with fulminant hepatic failure (FHF) is typically performed by surrogates and these patients typically regain decisional capacity, we chose this population to query patients' opinion on the surrogate consent process. Materials and Methods. We developed a questionnaire that queried transplanted patients' experience and opinion on surrogate consent, suitability of surrogates, and return of decisional capacity. This survey was then sent to consecutive survivors of liver transplantation for FHF at our institution. Results. Eleven of 14 patients eligible to participate completed the questionnaire. The mean follow-up for all survivors was 41 mo, with a range of survival since transplant of 5 mo to 10 y. Although 10/11 respondents agreed with their surrogates to consent to liver transplantation, all 11 patients thought that surrogates should not be able to decline liver transplantation for this condition. In distinction, 3/11 patients believed patients could decline liver transplantation. Conclusions. This is the first study to demonstrate that liver transplant patients do not think surrogate decision-makers should be permitted to contravene physician recommendations regarding transplant. In clinical settings when patients cannot speak for themselves, it may be appropriate for surrogates and clinicians to act together according to the patients' best interest rather than attempt to determine what the patient would want. This approach might reduce surrogate distress, better represent patient preferences, and improve the decision-making process for affected patients. (C) 2012 Elsevier Inc. All rights reserved. C1 [Brewster, Luke P.] Emory Univ Hosp, Dept Surg, Atlanta, GA 30322 USA. [Palmatier, Jason; Manley, C. J.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. [Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Med Ctr, Pittsburgh, PA USA. [Brems, J. J.] Sherman Hosp, Dept Surg, Elgin, IL USA. RP Brewster, LP (reprint author), Emory Univ Hosp, Dept Surg, 676 N Parkwood Rd, Decatur, GA 30030 USA. EM lukebrewst@aol.com RI Hall, Daniel/H-4843-2013 OI Hall, Daniel/0000-0001-6382-0522 NR 31 TC 1 Z9 1 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD JAN PY 2012 VL 172 IS 1 BP 48 EP 52 DI 10.1016/j.jss.2011.04.042 PG 5 WC Surgery SC Surgery GA 864DK UT WOS:000298217000007 PM 21696773 ER PT J AU Mukherjee, R Snipes, JM Saunders, SM Zavadzkas, JA Spinale, FG AF Mukherjee, Rupak Snipes, Jonathan M. Saunders, Stuart M. Zavadzkas, Juozas A. Spinale, Francis G. TI Discordant Activation of Gene Promoters for Matrix Metalloproteinases and Tissue Inhibitors of the Metalloproteinases Following Myocardial Infarction SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE matrix metalloproteinase; tissue inhibitor of metalloproteinase; myocardial infarction; remodeling ID LEFT-VENTRICULAR ENLARGEMENT; EXTRACELLULAR-MATRIX; HEART-FAILURE; TRANSCRIPTIONAL REGULATION; TARGETED DELETION; TRANSGENIC MICE; CARDIAC RUPTURE; EXPRESSION; RAT; INDUCTION AB Background. Left ventricular (LV) remodeling following myocardial infarction (MI) is associated with increased levels of specific matrix metalloproteinases (MMPs) and relative reduction of endogenous tissue inhibitors of the MMPs (TIMPs). However, transcriptional mechanisms for the disparate post-MI MMP/TIMP expression remain unknown. Using murine constructs designed to report gene promoter activation, this study tested the hypothesis that distinctly different temporal profiles of MMP-2, MMP-9, and TIMP-1 transcription occurs post-MI. Methods/Results. Transcriptional activity (beta-galactosidase (beta-gal) reporter constructs) of MMP-2 (n = 49), MMP-9 (n = 62), or TIMP-1 (n = 40) was assayed at 1 h (acute), and 1-28 d after MI (coronary ligation) in transgenic reporter mice. At 7 d post-MI, the area of promoter activation normalized to LV area was increased from acute values for MMP-2 (63.4 +/- 5.8 versus 1.1% +/- 1.0%, P < 0.05) and MMP-9 (53.1 +/- 6.1 versus 1.3% +/- 0.9%, P < 0.05). While TIMP-1 promoter activation at 7 d post-MI increased from acute values (3.6 +/- 1.3 versus 0.3% +/- 0.5%, P < 0.05), this increase was smaller than that for MMP-2 or MMP-9 (both P < 0.05). MMP-2 promoter activation peaked in the MI region at 7 d post-MI and MMP-9 promoter activation was highest in the border region at 7 and 14 d post-MI. TIMP-1 promoter activation peaked within the MI region at 7 d post-MI and within the remote region at 14 d post-MI. Conclusions. These findings provided direct in vivo evidence that discordant changes in temporal and spatial patterns of MMP/TIMP transcription occurs with MI. Restoration of TIMP-1 promoter activation may represent a molecular therapeutic target to attenuate/prevent adverse post-MI LV remodeling. (C) 2012 Elsevier Inc. All rights reserved. C1 [Mukherjee, Rupak; Snipes, Jonathan M.; Saunders, Stuart M.; Zavadzkas, Juozas A.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Spinale, Francis G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Mukherjee, R (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Strom Thurmond Res Bldg,770 MUSC Complex,Suite 62, Charleston, SC 29425 USA. EM mukherr@musc.edu FU National Institutes of Health [HL-66029, HL-45024, HL-97012, PO1-HL48788] FX This study was supported by National Institutes of Health grants HL-66029 (RM), HL-45024, HL-97012, and PO1-HL48788 (FGS). NR 36 TC 2 Z9 4 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD JAN PY 2012 VL 172 IS 1 BP 59 EP 67 DI 10.1016/j.jss.2010.06.015 PG 9 WC Surgery SC Surgery GA 864DK UT WOS:000298217000009 PM 20863528 ER PT J AU Yarbrough, WM Mukherjee, R Stroud, RE Rivers, WT Oelsen, JM Dixon, JA Eckhouse, SR Ikonomidis, JS Zile, MR Spinale, FG AF Yarbrough, William M. Mukherjee, Rupak Stroud, Robert E. Rivers, William T. Oelsen, J. Marshall Dixon, Jennifer A. Eckhouse, Shaina R. Ikonomidis, John S. Zile, Michael R. Spinale, Francis G. TI Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 91st Annual Meeting of the American-Association-for-Thoracic-Surgery CY MAY 07-11, 2011 CL Philadelphia, PA SP Amer Assoc Thorac Surg ID AORTIC-VALVE-REPLACEMENT; HEART-FAILURE; TISSUE INHIBITOR; GENE-EXPRESSION; DIASTOLIC DYSFUNCTION; CARDIAC FIBROBLASTS; DEPENDENT CHANGES; FIBROSIS; HYPERTROPHY; DISEASE AB Objective: Patients with severe left ventricular pressure overload secondary to aortic stenosis can present with signs and symptoms of heart failure despite normal left ventricular ejection fraction. This process occurs, at least in part, as a result of left ventricular pressure overload-induced extracellular matrix remodeling that promulgates increased left ventricular stiffness and impaired diastolic function. However, the determinants that drive extracellular matrix remodeling in this form of left ventricular pressure overload remain to be fully defined. Methods: Left ventricular pressure overload was induced in mature pigs (n = 15) by progressive ascending aortic cuff inflation (once per week for 4 weeks), whereby left ventricular mass, left ventricular ejection fraction, and regional myocardial stiffness (rK(m)) were compared with referent controls (n = 12). Determinants of extracellular matrix remodeling were assessed by measuring levels of mRNA expression for fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinase 1 and 4. Results: With left ventricular pressure overload, left ventricular mass and rK(m) increased by 2- and 3-fold, respectively, compared with control, with no change in left ventricular ejection fraction. Left ventricular myocardial collagen increased approximately 2-fold, which was accompanied by reduced solubility (ie, increased cross-linking) with left ventricular pressure overload, but mRNA expression for fibrillar collagen and matrix metalloproteinases remained relatively unchanged. In contrast, a robust increase in mRNA expression for tissue inhibitors of matrix metalloproteinase-1 and 4 occurred with left ventricular pressure overload. Conclusions: In a progressive model of left ventricular pressure overload, which recapitulates the phenotype of aortic stenosis, increased extracellular matrix accumulation and subsequently increased myocardial stiffness were not due to increased fibrillar collagen expression but rather to determinants of post-translational control that included increased collagen stability (thereby resistant to matrix metalloproteinase degradation) and increased endogenous matrix metalloproteinase inhibition. Targeting these extracellular matrix post-translational events with left ventricular pressure overload may hold both diagnostic and therapeutic relevance. (J Thorac Cardiovasc Surg 2012;143:215-23) C1 [Spinale, Francis G.] Univ S Carolina, Sch Med, CBA, Cardiovasc Translat Res Ctr, Columbia, SC 29208 USA. [Yarbrough, William M.] Sisters Char Providence Hosp, Columbia, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Mukherjee, Rupak; Stroud, Robert E.; Rivers, William T.; Oelsen, J. Marshall; Dixon, Jennifer A.; Eckhouse, Shaina R.; Ikonomidis, John S.; Spinale, Francis G.] Div Cardiothorac Surg & Adult Cardiol, Charleston, SC USA. [Zile, Michael R.; Spinale, Francis G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Univ S Carolina, Sch Med, CBA, Cardiovasc Translat Res Ctr, 6439 Garners Ferry Rd, Columbia, SC 29208 USA. EM cvctrc@uscmed.sc.edu FU NHLBI NIH HHS [R01 HL057952-12, HL 57952, HL059165, HL057952, R01 HL095608-03, HL095608, R01 HL057952, R01 HL095608, T32 HL007260, R01 HL059165, R01 HL111090, R01 HL059165-08] NR 32 TC 20 Z9 21 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JAN PY 2012 VL 143 IS 1 BP 215 EP 223 DI 10.1016/j.jtcvs.2011.09.032 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 863GW UT WOS:000298151800031 PM 22056365 ER PT J AU He, JC Chuang, PY Ma'ayan, A Iyengar, R AF He, John Cijiang Chuang, Peter Y. Ma'ayan, Avi Iyengar, Ravi TI Systems biology of kidney diseases SO KIDNEY INTERNATIONAL LA English DT Review DE cell signaling; gene transcription; kidney disease; microarray analysis; protein interaction ID HUMAN DIABETIC-NEPHROPATHY; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GENOME-WIDE ASSOCIATION; BLOOD-PRESSURE REGULATION; VEGF-A EXPRESSION; GENE-EXPRESSION; PROTEOMIC ANALYSIS; AFRICAN-AMERICANS; HUMAN URINE; 3-DIMENSIONAL RECONSTRUCTION AB Kidney diseases manifest in progressive loss of renal function, which ultimately leads to complete kidney failure. The mechanisms underlying the origins and progression of kidney diseases are not fully understood. Multiple factors involved in the pathogenesis of kidney diseases have made the traditional candidate gene approach of limited value toward full understanding of the molecular mechanisms of these diseases. A systems biology approach that integrates computational modeling with large-scale data gathering of the molecular changes could be useful in identifying the multiple interacting genes and their products that drive kidney diseases. Advances in biotechnology now make it possible to gather large data sets to characterize the role of the genome, epigenome, transcriptome, proteome, and metabolome in kidney diseases. When combined with computational analyses, these experimental approaches will provide a comprehensive understanding of the underlying biological processes. Multiscale analysis that connects the molecular interactions and cell biology of different kidney cells to renal physiology and pathology can be utilized to identify modules of biological and clinical importance that are perturbed in disease processes. This integration of experimental approaches and computational modeling is expected to generate new knowledge that can help to identify marker sets to guide the diagnosis, monitor disease progression, and identify new therapeutic targets. Kidney International (2012) 81, 22-39; doi:10.1038/ki.2011.314; published online 31 August 2011 C1 [He, John Cijiang] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA. [He, John Cijiang; Ma'ayan, Avi; Iyengar, Ravi] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [He, John Cijiang] James J Peters VAMC, Dept Med, New York, NY USA. [Ma'ayan, Avi; Iyengar, Ravi] Mt Sinai Sch Med, Syst Biol Ctr New York, New York, NY 10029 USA. RP He, JC (reprint author), Mt Sinai Sch Med, Dept Med, Div Nephrol, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM cijiang.he@mssm.edu FU NIH [1R01DK078897, 1R01DK088541, 1RC4DK090860, RC2LM010994-01, 5R01DK087650, 5K08DK082760]; Systems Biology Center [5P50GM071558] FX JCH is supported by NIH 1R01DK078897 and VA Merit Award; JCH and AM are supported by NIH 1R01DK088541 and 1RC4DK090860; AM is supported by NIH RC2LM010994-01. RI and AM are supported by the Systems Biology Center grant 5P50GM071558; RI and JCH are supported by NIH 5R01DK087650. PYC is supported by NIH 5K08DK082760. NR 127 TC 39 Z9 39 U1 1 U2 22 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2012 VL 81 IS 1 BP 22 EP 39 DI 10.1038/ki.2011.314 PG 18 WC Urology & Nephrology SC Urology & Nephrology GA 869XP UT WOS:000298633600006 PM 21881558 ER PT J AU Barchue, SM AF Barchue, Sylvia M. TI Should Children Visit Patients in an Intensive Care Unit (ICU)? SO MCN-THE AMERICAN JOURNAL OF MATERNAL-CHILD NURSING LA English DT Editorial Material C1 James J Peters VA Med Ctr, Patient Care Ctr, Med Surg Units, ICU,ED & Pulm Care, Bronx, NY USA. RP Barchue, SM (reprint author), James J Peters VA Med Ctr, Patient Care Ctr, Med Surg Units, ICU,ED & Pulm Care, Bronx, NY USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0361-929X J9 MCN-AM J MATERN-CHIL JI MCN-Am. J. Matern.-Child Nurs. PD JAN-FEB PY 2012 VL 37 IS 1 BP 8 EP 8 PG 1 WC Nursing SC Nursing GA 864OR UT WOS:000298250000002 ER PT J AU Morgan, A AF Morgan, Aneita TI Coordinated by Kathleen Leask Capitulo, DNSc, RN, FAAN SO MCN-THE AMERICAN JOURNAL OF MATERNAL-CHILD NURSING LA English DT Editorial Material C1 James J Peters VA Med Ctr, Clin Care Team, Intens Care Unit, Bronx, NY USA. RP Morgan, A (reprint author), James J Peters VA Med Ctr, Clin Care Team, Intens Care Unit, Bronx, NY USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0361-929X J9 MCN-AM J MATERN-CHIL JI MCN-Am. J. Matern.-Child Nurs. PD JAN-FEB PY 2012 VL 37 IS 1 BP 9 EP 9 PG 1 WC Nursing SC Nursing GA 864OR UT WOS:000298250000003 ER PT J AU Epstein, AJ Ketcham, JD Rathore, SS Groeneveld, PW AF Epstein, Andrew J. Ketcham, Jonathan D. Rathore, Saif S. Groeneveld, Peter W. TI Variations in the Use of an Innovative Technology by Payer The Case of Drug-Eluting Stents SO MEDICAL CARE LA English DT Article DE variations in care; technology; access ID ACUTE CORONARY SYNDROMES; HEALTH-CARE COSTS; INSURANCE TYPE; OUTCOMES; CLOPIDOGREL; PREDICTORS; REGISTRY; THERAPY; ARTERY AB Background: Despite receiving identical reimbursement for treating heart disease patients with bare metal stents (BMS) or drug-eluting coronary stents (DES), cardiologists' use of the new technology (DES) may have varied by patient payer type as DES diffused. Payer-related factors that differ between hospitals and/or differential treatment inside hospitals might explain any overall differences by payer type. Objectives: To assess the association between payer and DES use and to examine between-hospital and within-hospital variation in DES use over time. Methods: We conducted a retrospective analysis of 4.1 million hospitalizations involving DES or BMS from 2003 to 2008 Nationwide Inpatient Sample. We estimated hybrid-fixed effects logit models and calculated the adjusted within-quarter, cross-payer differences in DES use. Results: Coronary stent patients with Medicaid or without insurance were significantly less likely to receive DES than were patients with private insurance throughout the study period. The differences fluctuated over time as the popularity of DES relative to BMS increased and decreased. The within-hospital gaps paralleled the overall differences, and were largest in Q3 2003 (Medicaid: 11.9, uninsured: 10.9% points) and Q4 2008 (Medicaid: 12.8, uninsured: 20.7% points), and smallest in Q4 2004 (Medicaid: 1.4, uninsured: 1.1% points). The between-hospital adjusted differences in DES use by payer were small and rarely significant. Conclusions: We found substantial differences in DES use by payer within hospitals, suggesting physicians selected the new technology for patients in a manner associated with patients' payer type. C1 [Epstein, Andrew J.; Groeneveld, Peter W.] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Epstein, Andrew J.; Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Ketcham, Jonathan D.] Arizona State Univ, WP Carey Sch Business, Dept Mkt, Tempe, AZ USA. [Rathore, Saif S.] Yale Univ, Sch Med, MD PhD Program, New Haven, CT USA. RP Epstein, AJ (reprint author), Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, 423 Guardian Dr,11th Floor, Philadelphia, PA 19104 USA. EM eandrew@mail.med.upenn.edu FU National Heart, Lung, and Blood Institute [1R01HL086919]; Agency for Healthcare Research and Quality [1R01HS018403] FX This research was supported by the National Heart, Lung, and Blood Institute (1R01HL086919) and by the Agency for Healthcare Research and Quality (1R01HS018403). The content of this study does not reflect the views of the VA or the United States government. NR 38 TC 8 Z9 8 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2012 VL 50 IS 1 BP 1 EP 9 DI 10.1097/MLR.0b013e31822d5de9 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 863IY UT WOS:000298157200001 PM 22167062 ER PT J AU Epstein, AJ Polsky, D Yang, FF Yang, L Groeneveld, PW AF Epstein, Andrew J. Polsky, Daniel Yang, Feifei Yang, Lin Groeneveld, Peter W. TI Geographic Variation in Implantable Cardioverter-Defibrillator Use and Heart Failure Survival SO MEDICAL CARE LA English DT Article DE cardiovascular disease; congestive heart failure; health care technology; mortality; utilization ID CARDIAC RESYNCHRONIZATION THERAPY; PROPHYLACTIC IMPLANTATION; PRIMARY PREVENTION; PROPENSITY SCORE; COMORBIDITY; DYSFUNCTION; COMMUNITY AB Background: Implantable cardioverter-defibrillators and cardiac resynchronization therapy-defibrillators (ICD/CRT-Ds) are evidence-based preventative treatments for many patients with heart failure (HF), yet large numbers of eligible patients remain untreated. It is uncertain if localities with more frequent ICD/CRT-D use have had better rates of HF survival. Objectives: To determine if US Hospital Referral Regions (HRRs) with larger increases in the rate of ICD/CRT-D utilization during 2002 to 2007 also had commensurate increases in HF survival. Research Design: Retrospective cohort. Participants: Medicare beneficiaries age 66 to 80 nonelectively hospitalized for HF from 2002 to 2007. Measures: Each HRR's annual ICD/CRT-D rate was estimated from the cohort's Medicare procedure claims. Survival duration was determined from Medicare mortality records. HRR-year-level panel regression models were estimated to assess whether an HRR's ICD/CRT-D rate predicted HF survival, adjusting for baseline differences in survival across HRRs and secular trends. Results: A total of 883,002 HF patients were propensity-score matched within HRR across 2002 to 2007. Across HRRs, growth in ICD/CRT-D use among such patients varied from 1 to 12 percentage points. Regression models indicated that a 1 percentage point increase in an HRR's ICD/CRT-D utilization among hospitalized HF patients was associated with an increase in 1-year survival of 0.12% [95% confidence interval (CI), 0.03%-0.21%, P = 0.009] and with a 0.26% increase in HF survival at 2 years (95% CI, 0.14%-0.37%, P < 0.001). Conclusions: Localities with greater increases in ICD/CRT-D utilization from 2002 to 2007 also had greater improvements in HF survival. Areas with persistently low ICD/CRT-D use may be good targets for programs designed to increase the evidence-based use of defibrillators. C1 [Epstein, Andrew J.; Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA. [Epstein, Andrew J.; Polsky, Daniel; Yang, Feifei; Yang, Lin; Groeneveld, Peter W.] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Epstein, Andrew J.; Polsky, Daniel; Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Groeneveld, PW (reprint author), 1229 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM petergro@mail.med.upenn.edu FU National Heart, Lung, and Blood Institute [1R01HL086919]; Agency for Healthcare Research and Quality [1R01HS018403]; Department of Veterans Affairs' Health Services Research and Development Service, Washington, DC; Pennsylvania Department of Health FX Supported by the National Heart, Lung, and Blood Institute (1R01HL086919) and by the Agency for Healthcare Research and Quality (1R01HS018403). Dr Groeneveld was additionally supported by a Career Development Transition Award from the Department of Veterans Affairs' Health Services Research and Development Service, Washington, DC. This project was also funded, in part, under a grant from the Pennsylvania Department of Health, which specifically disclaims responsibility for any analyses, interpretations, or conclusions. NR 27 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2012 VL 50 IS 1 BP 10 EP 17 DI 10.1097/MLR.0b013e3182293510 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 863IY UT WOS:000298157200002 PM 22167063 ER PT J AU Keyhani, S Arling, G Williams, LS Ross, JS Ordin, DL Myers, J Tyndall, G Vogel, B Bravata, DM AF Keyhani, Salomeh Arling, Greg Williams, Linda S. Ross, Joseph S. Ordin, Diana L. Myers, Jennifer Tyndall, Gary Vogel, Bruce Bravata, Dawn M. TI The Use and Misuse of Thrombolytic Therapy Within the Veterans Health Administration SO MEDICAL CARE LA English DT Article DE stroke; thrombolytic therapy; health services research ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; QUALITY-OF-CARE; ASSOCIATION; IMPROVEMENT; GUIDELINES; CENTERS; SYSTEM; ATTACK AB Background: Within the Veterans Health Administration (VHA), approximately 6000 veterans are hospitalized with acute ischemic stroke annually. We examined the use and misuse of thrombolytic therapy with tissue plasminogen activator (tPA) in a national sample of veterans who were admitted to a VHA Medical Center (VAMC) with acute ischemic stroke. Methods: Medical record reviews were conducted on 5000 acute stroke patients who were admitted to a VAMC in 2007. Patients were defined as eligible to receive tPA if they arrived at the hospital within 3 hours of stroke symptom onset and had no contra-indications to tPA. We compared eligible patients who received tPA to those who did not and examined the distribution of eligible patients across the 129 VAMCs included in this study. Results: Among the 3931 ischemic stroke patients, 174 (4.4%) were eligible for tPA. Among the 135 patients who arrived within 2 hours of symptom onset which allowed adequate time for testing and evaluation, 19 (14.1%) received tPA. An additional 11 patients received tPA but did not meet eligibility criteria. Eligible patients receiving tPA were similar to eligible patients not receiving tPA in terms of clinical conditions and time to brain imaging. Among the 30 patients that received tPA, 5 (16.6%) received the wrong dose. Among the 85 VAMCs that received Z1 eligible patient, on average 2.3 patients were eligible for tPA annually. Conclusions: Relatively few eligible veterans receive thrombolysis across the VHA system. Strategies to improve thrombolysis delivery will have to account for the low annual volume of eligible stroke patients cared for at individual VAMCs. C1 [Keyhani, Salomeh] Univ Calif San Francisco, Dept Vet Affairs VHA, Hlth Serv Res & Dev Serv HSR&D, REAP, San Francisco, CA 94143 USA. [Keyhani, Salomeh] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Keyhani, Salomeh; Williams, Linda S.; Ordin, Diana L.; Myers, Jennifer; Vogel, Bruce; Bravata, Dawn M.] VHA HSR&D Stroke Qual Enhancement Res Initiat QUE, Indianapolis, IN USA. [Arling, Greg] Indiana Univ Sch Med, Indiana Univ Ctr Aging Res, Indianapolis, IN USA. [Arling, Greg; Williams, Linda S.; Bravata, Dawn M.] Regenstrief Inst Hlth Care, Indianapolis, IN USA. [Williams, Linda S.; Myers, Jennifer; Bravata, Dawn M.] Richard L Roudebush VA Med Ctr, VHA HSR&D Ctr Excellence Implementing Evidence Ba, Indianapolis, IN USA. [Williams, Linda S.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA. [Ross, Joseph S.] Yale Univ, Sch Med, Washington, DC USA. [Ordin, Diana L.] VHA Off Qual & Performance OQP, Washington, DC USA. [Tyndall, Gary] Syracuse VA Med Ctr, Emergency Dept, Syracuse, NY USA. [Vogel, Bruce] N Florida S Georgia Vet Hlth Syst, VHA Rehabil Outcomes Res Ctr RORC, Gainesville, FL USA. [Bravata, Dawn M.] Indiana Univ Sch Med, Dept Internal Med, Indianapolis, IN USA. RP Keyhani, S (reprint author), San Francisco VA Med Ctr, 4150 Clement,111A1, San Francisco, CA 94121 USA. EM salomeh.keyhani@va.gov OI Tyndall, Gary/0000-0001-9984-4809 FU Department of Veterans Affairs; Veterans Health Administration (VHA); Office of Quality and Performance and Health Services Research and Development Service Quality Enhancement Research Initiative [RRP 09-184]; VA HSRD FX The project reported here was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), Office of Quality and Performance and Health Services Research and Development Service Quality Enhancement Research Initiative (RRP 09-184). Dr. Keyhani is also supported by a VA HSR&D Career Development Award. NR 25 TC 9 Z9 9 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2012 VL 50 IS 1 BP 66 EP 73 DI 10.1097/MLR.0b013e3182294092 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 863IY UT WOS:000298157200009 PM 22182924 ER PT J AU Afrin, LB AF Afrin, Lawrence B. TI Mast Cell Activation Syndrome Masquerading as Agranulocytosis SO MILITARY MEDICINE LA English DT Article ID SYSTEMIC MASTOCYTOSIS; DISEASE; KIT AB Acquired agranulocytosis is a Tare, life-threatening disorder. The few known causes/associations usually are readily identifiable (e.g., drug reaction. Felty syndrome, megaloblastosis, large granular lymphocytic leukemia, etc.). We report a novel association with mast cell disease. A 61-year-old morbidly obese man developed rheumatoid arthritis unresponsive to several medications. Agranulocytosis developed shortly alter sulfasalazine was started but did not improve when the drug was soon stopped. Other symptoms across many systems developed including hives and presyncope. Marrow aspiration and biopsy showed only neutropenia. Serum tryptase was mildly elevated; urinary prostaglandin D, was markedly elevated. Other causes were not found. Mast cell activation syndrome (MCAS) was diagnosed. Oral antihistamines, montelukast, and cromolyn were unhelpful; aspirin was initially felt contraindicated. Imatinib immediately increased neutrophils from 0% to 25% but did not help symptoms; subsequent addition of aspirin increased neutrophils further and abated symptoms. Different presentations of different MCAS patients reflect elaboration of different mediators likely consequent to different Kit mutations. Mast cells (MCs) help regulate adipocytes, and adipocytes can inhibit granulopoiesis; thus, a Kit-mutated MC clone may have directly and/or indirectly driven agranulocytosis. MCAS should be considered in otherwise idiopathic agranulocytosis presenting with comorbidities best explained by MC mediator release. C1 [Afrin, Lawrence B.] Ralph H Johnson Vet Affairs Med Ctr, Hematol Oncol Sect, Med Serv, Charleston, SC 29401 USA. [Afrin, Lawrence B.] Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA. RP Afrin, LB (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Hematol Oncol Sect, Med Serv, 103 Bee St, Charleston, SC 29401 USA. NR 16 TC 6 Z9 6 U1 0 U2 1 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD JAN PY 2012 VL 177 IS 1 BP 113 EP 117 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 874RP UT WOS:000298976100025 PM 22338992 ER PT J AU Jensen, DM AF Jensen, Dennis M. TI ULCER Prediction and prevention of peptic ulcer rebleeding SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY LA English DT Editorial Material ID UPPER-GASTROINTESTINAL HEMORRHAGE C1 VA Greater Los Angeles Healthcare Syst, CURE DDRC, Los Angeles, CA 90073 USA. RP Jensen, DM (reprint author), VA Greater Los Angeles Healthcare Syst, CURE DDRC, Room 318,Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM djensen@mednet.ucla.edu NR 9 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5045 J9 NAT REV GASTRO HEPAT JI Nat. Rev. Gastroenterol. Hepatol. PD JAN PY 2012 VL 9 IS 1 BP 7 EP 8 DI 10.1038/nrgastro.2011.243 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 866FY UT WOS:000298367100001 PM 22143269 ER PT J AU Barkhof, F Simon, JH Fazekas, F Rovaris, M Kappos, L de Stefano, N Polman, CH Petkau, J Radue, EW Sormani, MP Li, DK O'Connor, P Montalban, X Miller, DH Filippi, M AF Barkhof, Frederik Simon, Jack H. Fazekas, Franz Rovaris, Marco Kappos, Ludwig de Stefano, Nicola Polman, Chris H. Petkau, John Radue, Ernst W. Sormani, Maria P. Li, David K. O'Connor, Paul Montalban, Xavier Miller, David H. Filippi, Massimo TI MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials SO NATURE REVIEWS NEUROLOGY LA English DT Review ID PLACEBO-CONTROLLED TRIAL; GADOLINIUM-ENHANCED MRI; SURROGATE END-POINTS; CONTROLLED PHASE IIB; DOUBLE-BLIND; CLINICAL-TRIALS; SPINAL-CORD; ORAL FINGOLIMOD; INTRAMUSCULAR INTERFERON; CONTROLLED MULTICENTER AB Over the past 15 years, MRI lesion activity has become the accepted surrogate primary outcome measure in proof-of-concept placebo-controlled clinical trials of new immunomodulating therapies in relapse-onset multiple sclerosis (MS). In parallel, the number of patients that are available for the placebo arm of trials has declined, and more-aggressive drugs are being developed. A critical review is warranted to ensure efficient MRI-and patient-resource utilization. Recently, an international panel reviewed the methodology for efficient use of MRI-monitored trials in relapse-onset MS. In this article, we provide up-to-date recommendations for scan acquisition, image analysis, outcome-measure definition and standards of reporting. Factors to consider for optimizing trial design, such as outcome measure selection and the unique requirements of phase II and phase III trials, including active-comparator studies, are outlined. Finally, we address safety considerations in the use of MRI in MS trials, and the safety-related responsibilities of the various parties involved in conducting such trials. C1 [Barkhof, Frederik; Polman, Chris H.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands. [Simon, Jack H.] Portland VA Med Ctr, Portland, OR USA. [Fazekas, Franz] Med Univ Graz, Graz, Austria. [Rovaris, Marco] Sci Inst Fdn Don Gnocchi, Milan, Italy. [Kappos, Ludwig; Radue, Ernst W.] Univ Basel Hosp, Basel, Switzerland. [de Stefano, Nicola] Univ Siena, I-53100 Siena, Italy. [Petkau, John; Li, David K.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Sormani, Maria P.] Univ Genoa, I-16126 Genoa, Italy. [O'Connor, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Montalban, Xavier] Hosp Valle De Hebron, Barcelona, Spain. [Miller, David H.] UCL, London WC1E 6BT, England. [Filippi, Massimo] Inst Sci, Milan, Italy. [Filippi, Massimo] Univ Hosp San Raffaele, Milan, Italy. RP Barkhof, F (reprint author), Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands. EM f.barkhof@vumc.nl FU MAGNIMS; US National Multiple Sclerosis Society; Multiple Sclerosis Society of Canada; Bayer-Schering Pharma FX This work is based on a workshop of the Magnetic Resonance Imaging Network in Multiple Sclerosis (MAGNIMS) working group, co-sponsored by MAGNIMS, the US National Multiple Sclerosis Society and the Multiple Sclerosis Society of Canada, and supported by an unrestricted educational grant by Bayer-Schering Pharma. We thank A. Thompson and J. Palace for their helpful input. NR 80 TC 22 Z9 22 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4758 EI 1759-4766 J9 NAT REV NEUROL JI Nat. Rev. Neurol. PD JAN PY 2012 VL 8 IS 1 BP 13 EP 21 DI 10.1038/nrneurol.2011.190 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 866VT UT WOS:000298415000006 PM 22143362 ER PT J AU Aasly, JO Shi, M Sossi, V Stewart, T Johansen, KK Wszolek, ZK Uitti, RJ Hasegawa, K Yokoyama, T Zabetian, CP Kim, HM Leverenz, JB Ginghina, C Armaly, J Edwards, KL Snapinn, KW Stoessl, AJ Zhang, J AF Aasly, J. O. Shi, M. Sossi, V. Stewart, T. Johansen, K. K. Wszolek, Z. K. Uitti, R. J. Hasegawa, K. Yokoyama, T. Zabetian, C. P. Kim, H. M. Leverenz, J. B. Ginghina, C. Armaly, J. Edwards, K. L. Snapinn, K. W. Stoessl, A. J. Zhang, J. TI Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers SO NEUROLOGY LA English DT Article ID PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; COGNITIVE DECLINE; ALZHEIMERS; PET AB Objective: The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid beta (A beta) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A beta and tau as markers of early or presymptomatic PD. Methods: CSF A beta 42, total tau, and phosphorylated tau were measured with Luminex assays in 26 LRRK2 mutation carriers, who were either asymptomatic (n = 18) or had a phenotype resembling sporadic PD (n = 8). All patients also underwent PET scans with (18)F-6-fluoro-L-dopa (FD), (11)C-(+/-)-alpha-dihydrotetrabenazine (DTBZ), and (11)C-d-threo-methylphenidate (MP) to measure dopaminergic function in the striatum. The levels of CSF markers were then compared to each PET measurement. Results: Reduced CSF A beta 42 and tau levels correlated with lower striatal dopaminergic function as determined by all 3 PET tracers, with a significant association between A beta 42 and FD uptake. When cases were restricted to carriers of the G2019S mutation, the most common LRRK2 variant in our cohort, significant correlations were also observed for tau. Conclusions: The disposition of A beta and tau is likely important in both LRRK2-related and sporadic PD, even during early phases of the disease. A better understanding of their production, aggregation, and degradation, including changes in their CSF levels, may provide insights into the pathogenesis of PD and the potential utility of these proteins as biomarkers. Neurology (R) 2012;78:55-61 C1 [Shi, M.; Stewart, T.; Ginghina, C.; Armaly, J.; Zhang, J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Aasly, J. O.; Johansen, K. K.] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway. [Aasly, J. O.; Johansen, K. K.] St Olavs Univ Hosp, Dept Neurol, Trondheim, Norway. [Zabetian, C. P.; Kim, H. M.; Leverenz, J. B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Leverenz, J. B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Sossi, V.] Univ British Columbia, Dept Phys & Astron, Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada. [Wszolek, Z. K.; Uitti, R. J.] Mayo Clin Florida, Dept Neurol, Jacksonville, FL USA. [Hasegawa, K.; Yokoyama, T.] Sagamihara Natl Hosp, Natl Hosp Org, Dept Neurol, Sagamihara, Kanagawa, Japan. [Zabetian, C. P.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Zabetian, C. P.; Kim, H. M.; Leverenz, J. B.] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, J. B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Edwards, K. L.; Snapinn, K. W.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Stoessl, A. J.] Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V5Z 1M9, Canada. [Stoessl, A. J.] Vancouver Coastal Hlth, Vancouver, BC, Canada. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU NIH [AG025327, AG033398, P30ES007033-6364, ES004696-5897, ES012703, ES016873, NS057567, NS060252, P50NS062684, NS065070, P50NS072187]; Department of Veterans Affairs [1I01BX000531]; Canadian Institutes of Health Research; Michael Smith Foundation for Health Research; Pacific Alzheimer Research Foundation; Canada Research Chairs program; Mayo Clinic Florida Research Committee; Research Committee of CNS Degenerative Diseases; Ministry of Health, Labour and Welfare of Japan; Lundbeck Inc.; Allergan, Inc.; NIH/NINDS; Pacific Alzheimer Research Foundation (Canada); CIHR; NIH; NIH (NINDS/NIA); US Department of Veterans Affairs; Parkinson's Disease Foundation; American Parkinson Disease Association; NIH/NIND; Michael J. Fox Foundation; Washington Chapter American Parkinson's Disease Association/Northwest Collaborative Care; Centers for Disease Control FX Supported by NIH (AG025327, AG033398, P30ES007033-6364, ES004696-5897, ES012703, ES016873, NS057567, NS060252 to J.Z., P50NS062684 to C.P.Z., J.B.L., and J.Z., NS065070 to C.P.Z., NS057567 and P50NS072187 to Z.K.W. and R.J.U.), Department of Veterans Affairs (to J.B.L. and H. M. K., and 1I01BX000531 to C.P.Z.), Canadian Institutes of Health Research (to A.J.S.), Michael Smith Foundation for Health Research (to A.J.S.), Pacific Alzheimer Research Foundation (to A.J.S.), Canada Research Chairs program (to A.J.S.), TRIUMF (to A.J.S.), Mayo Clinic Florida Research Committee CR program (to Z.K.W. and R.J.U.), the gift from Carl Edward Bolch, Jr. and Susan Bass Bolch (to Z.K.W. and R.J.U.), and Grants-in-Aid from the Research Committee of CNS Degenerative Diseases, the Ministry of Health, Labour and Welfare of Japan (to K.H. and T.Y.).; Dr. Aasly serves on the editorial boards of Parkinsonism and Related Disorders, Parkinson's Disease, and the Journal of the Norwegian Medical Association; and his institution receives annual royalties from Lundbeck Inc. from the licensing of the technology related to PARK8/LRRK2. Dr. Shi reports no disclosures. Dr. Sossi has received research support from Pacific Alzheimer Research Foundation. Dr. Stewart and Dr. Johansen report no disclosures. Dr. Wszolek serves as Co-Editor-in-Chief of Parkinsonism and Related Disorders, Regional Editor of the European Journal of Neurology, and on the editorial boards of Neurologia i Neurochirurgia Polska, Advances in Rehabilitation, the Medical Journal of the Rzeszow University, and Clinical and Experimental Medical Letters; holds and has contractual rights for receipt of future royalty payments from patents re: A novel polynucleotide involved in heritable Parkinson's disease; receives royalties from publishing Parkinsonism and Related Disorders (Elsevier, 2007, 2008, 2009) and the European Journal of Neurology (Wiley-Blackwell, 2007, 2008, 2009); and receives research support from Allergan, Inc., the NIH/NINDS, Mayo Clinic Florida Research Committee CR program, the Pacific Alzheimer Research Foundation (Canada), the CIHR, the Mayo Clinic Florida Research Committee CR program, and a gift from Carl Edward Bolch, Jr., and Susan Bass Bolch. Dr. Uitti serves as an Associate Editor of Neurology (R); has received research support from Advanced Neuromodulations Systems and from the NIH; and his institution receives annual royalties from Lundbeck Inc. from the licensing of the technology related to PARK8/LRRK2. Dr. Hasegawa and Dr. Yokoyama report no disclosures. Dr. Zabetian has received research support from NIH (NINDS/NIA), the US Department of Veterans Affairs, the Parkinson's Disease Foundation, and the American Parkinson Disease Association. Dr. Kim reports no disclosures. Dr. Leverenz has served as a consultant for Bayer Schering Pharma, Novartis, and Teva Pharmaceutical Industries Ltd.; has received speaker honoraria from Novartis; and receives research support from the NIH/NIND, the Michael J. Fox Foundation, the Washington Chapter American Parkinson's Disease Association/Northwest Collaborative Care, and the US Department of Veterans Affairs. Dr. Ginghina and J. Armaly report no disclosures. Dr. Edwards has received research support from the NIH and the Centers for Disease Control. K. W. Snapinn has received research support from the NIH, the US Department of Veterans Affairs, and the Centers for Disease Control. Dr. Stoessl serves on a scientific advisory board for Biovail Corporation/Medgenesis; has received funding for travel and speaker honoraria from Novartis, Teva Pharmaceutical Industries Ltd., Allergan, Inc., and Abbott; serves on the editorial boards of Annals of Neurology, Lancet Neurology, and Parkinsonism & Related Disorders; and receives research support from CIHR, the Michael Smith Foundation for Health Research, the Michael J. Fox Foundation, and the Pacific Alzheimer Research Foundation. Dr. Zhang serves on the editorial boards of Neurological Disease, Neurochemical Research, the Journal of Alzheimer's Disease, and Proteomics; and has received research support from the NIH. NR 20 TC 22 Z9 22 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 2012 VL 78 IS 1 BP 55 EP 61 DI 10.1212/WNL.0b013e31823ed101 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 869YG UT WOS:000298635700011 PM 22170881 ER PT J AU Yoon, N Kwon, JW Seo, SW Ahn, G Choi, YL AF Yoon, Nara Kwon, Jong Won Seo, Sung Wook Ahn, Geunghwan Choi, Yoon-La TI Sclerosing epithelioid fibrosarcoma: Cytogenetic analysis of FUS rearrangement SO PATHOLOGY INTERNATIONAL LA English DT Article DE beta-catenin; FUS; sclerosing epithelioid fibrosarcoma ID GRADE FIBROMYXOID SARCOMA; DESMOID TUMORS; BETA-CATENIN; GENE AB Sclerosing epithelioid fibrosarcoma (SEF) is a rare but distinct variant of fibrosarcoma. A 43-year-old man presented with a lesion in his back that had been present for three years but had recently increased in size. Magnetic resonance imaging (MRI) revealed a 6-cm sized ovoid mass showing low intensities on T1 and T2 weighted images. Histologically, the tumor was of moderate cellularity, and the cells were relatively uniform in size and shape. The cells were epithelioid, round, oval and polygonal with clear and slightly eosinophilic cytoplasm, forming nests, cords, or sheet-like patterns with a dense collagenous and hyalinized matrix. The tumor was positive for vimentin, but negative for smooth muscle actin, desmin, HMB45, and CD34. Although the tumor showed nuclear overexpression of beta-catenin protein, the CTNNB1 exon3 mutation was not detected. Fluorescent in situ hybridization for FUS using dual color break-apart probes showed rearrangement of the FUS. In accordance with previous studies, our case showed positive findings of FUS rearrangement, reinforcing the notion of a close relationship between low grade fibromyxoid sarcoma and SEF. C1 [Choi, Yoon-La] Sungkyunkwan Univ, Dept Pathol, Samsung Med Ctr, Sch Med,Coll Med, Seoul 135710, South Korea. [Kwon, Jong Won] Sungkyunkwan Univ, Dept Radiol, Samsung Med Ctr, Coll Med, Seoul 135710, South Korea. [Seo, Sung Wook] Sungkyunkwan Univ, Dept Orthoped Surg, Samsung Med Ctr, Coll Med, Seoul 135710, South Korea. [Ahn, Geunghwan] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Pathol, San Francisco, CA 94143 USA. RP Choi, YL (reprint author), Sungkyunkwan Univ, Dept Pathol, Samsung Med Ctr, Sch Med,Coll Med, 50 Ilwondong, Seoul 135710, South Korea. EM ylachoi@skku.edu NR 15 TC 6 Z9 6 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1320-5463 J9 PATHOL INT JI Pathol. Int. PD JAN PY 2012 VL 62 IS 1 BP 65 EP 68 DI 10.1111/j.1440-1827.2011.02752.x PG 4 WC Pathology SC Pathology GA 867US UT WOS:000298480900010 PM 22192807 ER PT J AU Jahshan, C Cadenhead, KS Rissling, AJ Kirihara, K Braff, DL Light, GA AF Jahshan, C. Cadenhead, K. S. Rissling, A. J. Kirihara, K. Braff, D. L. Light, G. A. TI Automatic sensory information processing abnormalities across the illness course of schizophrenia SO PSYCHOLOGICAL MEDICINE LA English DT Article DE MMN; prodromal; P300; RON; schizophrenia ID MISMATCH NEGATIVITY GENERATION; EVENT-RELATED POTENTIALS; NEUROCOGNITIVE DEFICITS; 1ST-EPISODE SCHIZOPHRENIA; 1ST EPISODE; PRODROMAL SCHIZOPHRENIA; INVOLUNTARY ATTENTION; AUDITORY DISTRACTION; SELECTIVE-ATTENTION; SPECTRUM DISORDERS AB Background. Deficits in automatic sensory discrimination, as indexed by a reduction in the mismatch negativity (MMN) and P3a event-related potential amplitudes, are well documented in chronic schizophrenia. However, MMN and P3a have not been sufficiently studied early in the course of psychotic illness. The present study aimed to investigate MMN, P3a and reorienting negativity (RON) across the course of schizophrenia. Method. MMN, P3a, and RON were assessed in 118 subjects across four groups: (1) individuals at risk for psychosis (n=26); (2) recent-onset patients (n=31); (3) chronic patients (n=33); and (4) normal controls (n=28) using a duration-deviant auditory oddball paradigm. Results. Frontocentral deficits in MMN and P3a were present in all patient groups. The at-risk group's MMN and P3a amplitudes were intermediate to those of the control and recent-onset groups. The recent-onset and chronic patients, but not the at-risk subjects, showed significant RON amplitude reductions, relative to the control group. Associations between MMN, P3a, RON and psychosocial functioning were present in the chronic patients. In the at-risk subjects, P3a and RON deficits were significantly associated with higher levels of negative symptoms. Conclusions. Abnormalities in the automatic processes of sensory discrimination, orienting and reorienting of attention are evident in the early phases of schizophrenia and raise the possibility of progressive worsening across stages of the illness. The finding that MMN and P3a, but not RON, were reduced before psychosis onset supports the continued examination of these components as potential early biomarkers of schizophrenia. C1 [Cadenhead, K. S.; Rissling, A. J.; Kirihara, K.; Braff, D. L.; Light, G. A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Jahshan, C.] Vet Affairs Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA. RP Light, GA (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM glight@ucsd.edu FU Department of Veteran Affairs (VISN 22 Mental Illness Research, Education, and Clinical Center); National Institute of Mental Health [MH079777, MH042228, MH065571] FX This work was supported by grants from the Department of Veteran Affairs (VISN 22 Mental Illness Research, Education, and Clinical Center) and National Institute of Mental Health (MH079777; MH042228, and MH065571). The authors wish to thank Jason Nunag, Steven Reding, Kathleen Shafer, Marlena Pela, Joyce Sprock, and Richard Sharp for their assistance. NR 86 TC 52 Z9 52 U1 1 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD JAN PY 2012 VL 42 IS 1 BP 85 EP 97 DI 10.1017/S0033291711001061 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 874MG UT WOS:000298961600008 PM 21740622 ER PT J AU Butler, PD Chen, Y Ford, JM Geyer, MA Silverstein, SM Green, MF AF Butler, Pamela D. Chen, Yue Ford, Judith M. Geyer, Mark A. Silverstein, Steven M. Green, Michael F. TI Perceptual Measurement in Schizophrenia: Promising Electrophysiology and Neuroimaging Paradigms From CNTRICS SO SCHIZOPHRENIA BULLETIN LA English DT Article DE perception; CNTRICS; sensory processes; gain control; integration ID PREPULSE INHIBITION; COROLLARY DISCHARGE; MISMATCH NEGATIVITY; AUDITORY HALLUCINATIONS; EVOKED-POTENTIALS; MOTION PERCEPTION; ACOUSTIC STARTLE; GATING DEFICITS; VISUAL-CORTEX; HUMANS AB The sixth meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) focused on selecting promising imaging paradigms for each of the cognitive constructs selected in the first CNTRICS meeting. In the domain of perception, the 2 constructs of interest were "gain control" and "visual integration." CNTRICS received 6 task nominations for imaging paradigms for gain control and 3 task nominations for integration. The breakout group for perception evaluated the degree to which each of these tasks met prespecified criteria. For gain control, the breakout group believed that one task (mismatch negativity) was already mature and was being incorporated into multisite clinical trials. The breakout group recommended that I visual task (steady-state visual evoked potentials to magnocellular- vs parvocellular-biased stimuli) and 2 auditory measures (an event-related potential (ERP) measure of corollary discharge and a functional magnetic resonance imaging (fMRI) version of prepulse inhibition of startle) be adapted for use in clinical trials in schizophrenia research. For visual integration, the breakout group recommended that fMRI and ERP versions of a contour integration test and an fMRI version of a coherent motion test be adapted for use in clinical trials. This manuscript describes the ways in which each of these tasks met the criteria used in the breakout group to evaluate and recommend tasks for further development. C1 [Butler, Pamela D.] Schizophrenia Res Ctr, Nathan Kline Inst Psychiat Res, Orangeburg, NY USA. [Butler, Pamela D.] NYU, Sch Med, Dept Psychiat, New York, NY USA. [Chen, Yue] Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, Belmont, MA USA. [Ford, Judith M.] Univ Calif San Francisco, VA Med Ctr, Dept Psychiat, San Francisco, CA 94143 USA. [Geyer, Mark A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Silverstein, Steven M.] Univ Behav HealthCare, Univ Med & Dent New Jersey, Div Schizophrenia Res, Piscataway, NJ USA. [Silverstein, Steven M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA. [Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Butler, PD (reprint author), 140 Old Orangeburg Rd, Orangeburg, NY 10962 USA. EM butler@nki.rfmh.org FU National Institutes of Health [MH84848, MH61824, MH58262, MH067967, MH052885, MH084828, MH043292]; Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center; VA Merit FX National Institutes of Health (MH84848 to P.D.B., MH61824 to Y.C., MH58262 and MH067967 to J.M.F., MH052885 to M.A.G., MH084828 to S.M.S., MH043292 to M.F.G.); Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center to M.F.G. and M.A.G.; VA Merit to J.M.F. NR 50 TC 37 Z9 38 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JAN PY 2012 VL 38 IS 1 BP 81 EP 91 DI 10.1093/schbul/sbr106 PG 11 WC Psychiatry SC Psychiatry GA 875DZ UT WOS:000299011900012 PM 21890745 ER PT J AU Huang, JN Schmeidler, J Beeri, MS Rosendorff, C Bhatia, S West, RK Bespalova, IN Mavris, R Silverman, JM AF Huang, Jennifer Schmeidler, James Beeri, Michal S. Rosendorff, Clive Bhatia, Simmi West, Rebecca K. Bespalova, Irina N. Mavris, Rizalina Silverman, Jeremy M. TI Haemoglobin A(1c) and cognitive function in very old, cognitively intact men SO AGE AND AGEING LA English DT Article ID DIABETES-MELLITUS; ALZHEIMER-DISEASE; ANTAGONISTIC PLEIOTROPY; ELDERLY SUBJECTS; RISK-FACTORS; DECLINE; DEMENTIA; MEMORY; AGE; IMPAIRMENT C1 [Schmeidler, James; Beeri, Michal S.; West, Rebecca K.; Bespalova, Irina N.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Beeri, Michal S.; Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Silverman, JM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM jeremy.silverman@mssm.edu FU National Institute of Aging [P01-AG02219, K01 AG023515, P50-AG05138]; United States Department of Veterans Affairs; Berkman Charitable Trust FX This work was supported by National Institute of Aging (grant numbers: P01-AG02219, K01 AG023515, P50-AG05138); United States Department of Veterans Affairs; Berkman Charitable Trust NR 30 TC 5 Z9 5 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0002-0729 J9 AGE AGEING JI Age Ageing PD JAN PY 2012 VL 41 IS 1 BP 125 EP 128 DI 10.1093/ageing/afr124 PG 4 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 859EL UT WOS:000297858700025 PM 21930529 ER PT J AU Schally, AV Halmos, G AF Schally, Andrew V. Halmos, Gabor BE Kratz, F Senter, P Steinhagen, H TI Targeting to Peptide Receptors SO DRUG DELIVERY IN ONCOLOGY: FROM BASIC RESEARCH TO CANCER THERAPY, VOLS 1-3 LA English DT Article; Book Chapter ID HORMONE-RELEASING-HORMONE; CYTOTOXIC SOMATOSTATIN ANALOG; HUMAN BREAST CANCERS; MULTIDRUG-RESISTANCE PROTEINS; EPIDERMAL-GROWTH-FACTOR; BOMBESIN-LIKE PEPTIDES; RENAL-CELL CARCINOMAS; HUMAN PROSTATE-CANCER; HUMAN OVARIAN CANCERS; HUMAN ENDOMETRIAL CANCERS C1 [Schally, Andrew V.] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA. [Schally, Andrew V.] Univ Miami, Miller Sch Med, Div Hematol Oncol, Dept Med, Coral Gables, FL 33124 USA. [Schally, Andrew V.] Vet Affairs Med Ctr, Polypeptide Canc Inst, Miami, FL 33125 USA. [Schally, Andrew V.] US Dept Vet Affairs, Ford City, PA USA. [Halmos, Gabor] Univ Debrecen, Med & Hlth Sci Ctr, Dept Biopharm, Debrecen, Hungary. RP Schally, AV (reprint author), Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA. NR 140 TC 5 Z9 5 U1 0 U2 1 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA PAPPELALLEE 3, W-69469 WEINHEIM, GERMANY BN 978-3-527-32823-9 PY 2012 BP 1219 EP 1261 PG 43 WC Biochemistry & Molecular Biology; Oncology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Oncology; Pharmacology & Pharmacy GA BA8DL UT WOS:000338009100041 ER PT J AU Linville, D Brown, T O'Neil, M AF Linville, Deanna Brown, Tiffany O'Neil, Maya TI Medical Providers' Self Perceived Knowledge and Skills for Working With Eating Disorders: A National Survey SO EATING DISORDERS LA English DT Article AB Research indicates that individuals suffering from an eating disorder (ED) consult their general practitioners more frequently than those without an eating disorder (Mond, Myers, Crosby, Hay, & Mitchell, 2010). However, little is known about medical providers' existing knowledge of and training in ED detection, intervention, and treatment. This study aimed to examine national medical providers' self-perceived knowledge, skills, and needs around eating disorder screening and intervention strategies. Utilizing survey design, a randomized sample of national medical providers responded to a 23-question survey. Sixty-eight percent of respondents indicated that they did not think to screen for an eating disorder because it was not the presenting concern and nearly 59% of providers did not feel like they had the skills necessary to intervene with eating disorders. Training implications and future research directions are discussed. C1 [Linville, Deanna] Univ Oregon, Coll Educ, Dept Counseling Psychol & Human Serv, Eugene, OR 97403 USA. [Brown, Tiffany] Pacific Lutheran Univ, Dept Marriage & Family Therapy, Div Social Sci, Tacoma, WA 98447 USA. [O'Neil, Maya] Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, OR USA. [O'Neil, Maya] Portland VA Med Ctr, Dept Psychiat, Portland, OR USA. [O'Neil, Maya] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Linville, D (reprint author), 5251 Univ Oregon, Coll Educ, Dept Counseling Psychol & Human Serv, Eugene, OR 97403 USA. EM Linville@uoregon.edu NR 26 TC 6 Z9 7 U1 0 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1064-0266 EI 1532-530X J9 EAT DISORD JI Eat. Disord PY 2012 VL 20 IS 1 BP 1 EP 13 DI 10.1080/10640266.2012.635557 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA V32PE UT WOS:000208962300001 PM 22188056 ER PT B AU Ripoll, LH Triebwasser, J Siever, LJ AF Ripoll, Luis H. Triebwasser, Joseph Siever, Larry J. BE Stein, DJ Lerer, B Stahl, SM TI Evidence-based pharmacotherapy of personality disorders SO ESSENTIAL EVIDENCE-BASED PSYCHOPHARMACOLOGY, 2ND EDITION LA English DT Article; Book Chapter ID SOCIAL ANXIETY DISORDER; PLACEBO-CONTROLLED-TRIAL; SELF-INJURIOUS-BEHAVIOR; POSITRON-EMISSION-TOMOGRAPHY; 18-MONTH FOLLOW-UP; POSTTRAUMATIC-STRESS-DISORDER; IMPULSIVE AGGRESSIVE-BEHAVIOR; RANDOMIZED CONTROLLED-TRIAL; VENLAFAXINE EXTENDED-RELEASE; FEMALE BORDERLINE-PATIENTS C1 [Ripoll, Luis H.; Triebwasser, Joseph; Siever, Larry J.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Ripoll, LH (reprint author), James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. NR 185 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-40010-8; 978-1-107-00795-6 PY 2012 BP 278 EP 315 D2 10.1017/CBO9780511910395 PG 38 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA BJM92 UT WOS:000329193200015 ER PT J AU Chao, LL Weiner, MW Neylan, TC AF Chao, Linda L. Weiner, Michael W. Neylan, Thomas C. TI Regional cerebral volumes in veterans with current versus remitted posttraumatic stress disorder: a study at 4 Tesla SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Meeting Abstract DE veterans; PTSD; brain volume C1 [Chao, Linda L.; Weiner, Michael W.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Chao, Linda L.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Chao, Linda L.; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Chao, Linda L.; Neylan, Thomas C.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2012 VL 3 SU 1 DI 10.3402/ejpt.v3i0.19425 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31FC UT WOS:000208868500186 ER PT J AU Hazlett, EA Fernandez, N Sasso, S New, AS Goodman, M AF Hazlett, Erin A. Fernandez, Nicholas Sasso, Scott New, Antonia S. Goodman, Marianne TI A non-verbal, quantitative measure of emotion dysregulation in veterans: is affective startle a potential biomarker for suicide? SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Meeting Abstract DE emotion; emotion dysregulation; fear/defensive brain circuitry; affective startle eyeblink modulation; suicide ideation; suicidal behavior C1 [Hazlett, Erin A.; Fernandez, Nicholas; Sasso, Scott; New, Antonia S.; Goodman, Marianne] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN, New York, NY USA. [Hazlett, Erin A.; New, Antonia S.; Goodman, Marianne] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2012 VL 3 SU 1 DI 10.3402/ejpt.v3i0.19368 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31FC UT WOS:000208868500183 ER PT J AU Luxenberg, A O'Donovan, A Inslicht, SS Metzler, TJ Hlavin, J Weiner, MW Neylan, TC AF Luxenberg, Adam O'Donovan, Aoife Inslicht, Sabra S. Metzler, Thomas J. Hlavin, Jennifer Weiner, Michael W. Neylan, Thomas C. TI Exaggerated autonomic responding to acoustic stimuli in Gulf War Veterans with current versus remitted post-traumatic stress disorder SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Meeting Abstract DE veterans; Gulf War; PTSD; autonomic response C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Northern Calif Inst Res & Educ, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2012 VL 3 SU 1 DI 10.3402/ejpt.v3i0.19369 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31FC UT WOS:000208868500184 ER PT J AU O'Donovan, A Cohen, BE Bertenthal, D Margaretten, M Seal, K Neylan, TC AF O'Donovan, Aoife Cohen, Beth E. Bertenthal, Dan Margaretten, Mary Seal, Karen Neylan, Thomas C. TI Association of posttraumatic stress disorder with increased prevalence of autoimmune disorders in Iraq and Afghanistan veterans SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Meeting Abstract DE autoimmune disorders; inflammation; post-traumatic stress disorder; psychiatric disorders; traumatic stress; veterans C1 [O'Donovan, Aoife; Margaretten, Mary; Seal, Karen] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cohen, Beth E.; Bertenthal, Dan] San Francisco VA Med Ctr, San Francisco, CA USA. [Neylan, Thomas C.] Northern Calif Inst Res & Educ, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2012 VL 3 SU 1 DI 10.3402/ejpt.v3i0.19511 PG 1 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31FC UT WOS:000208868500053 ER PT J AU Peskind, ER Cross, DJ Yarnykh, V Pagulayan, K Hoff, D Hart, K Martin, N Richards, T Raskind, MA Minoshima, S Petrie, EC AF Peskind, Elaine R. Cross, Donna J. Yarnykh, Vasily Pagulayan, Kathleen Hoff, David Hart, Kim Martin, Nathalie Richards, Todd Raskind, Murray A. Minoshima, Satoshi Petrie, Eric C. TI Neuroimaging biomarkers in veterans with blast-mild traumatic brain injury with or without comorbid PTSD SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Meeting Abstract DE mild traumatic brain injury; neuroimaging; biomarkers; PTSD; magnetic resonance imaging; FDG-PET C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RI Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014 OI Yarnykh, Vasily/0000-0002-1583-8979; NR 0 TC 0 Z9 0 U1 0 U2 4 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2012 VL 3 SU 1 DI 10.3402/ejpt.v3i0.19376 PG 1 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31FC UT WOS:000208868500185 ER PT J AU Sher, L Holmes, K Flory, JD Bierer, LM Yehuda, R AF Sher, Leo Holmes, Kristin Flory, Janine D. Bierer, Linda M. Yehuda, Rachel TI Clinical features of military veterans with or without a history of suicide attempt SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Meeting Abstract DE suicide; veterans; substance dependence; psychosis; bipolar disorder C1 James J Peters Vet Adm Med Ctr, New York, NY USA. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2012 VL 3 SU 1 DI 10.3402/ejpt.v3i0.19476 PG 1 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31FC UT WOS:000208868500188 ER PT J AU Talbot, L Richards, A Inslicht, SS O'Donovan, A Neylan, TC AF Talbot, Lisa Richards, Anne Inslicht, Sabra S. O'Donovan, Aoife Neylan, Thomas C. TI Sleep and lipids in posttraumatic stress disorder SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Meeting Abstract DE sleep; PTSD; lipids; cardiovascular risk; metabolism C1 [Talbot, Lisa; Richards, Anne; Inslicht, Sabra S.; O'Donovan, Aoife; Neylan, Thomas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Talbot, Lisa; Richards, Anne; Inslicht, Sabra S.; O'Donovan, Aoife; Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2012 VL 3 SU 1 DI 10.3402/ejpt.v3i0.19496 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31FC UT WOS:000208868500012 ER PT J AU Edwards, CK Green, JS Volk, HD Schiff, M Kotzin, BL Mitsuya, H Kawaguchi, T Sakata, KM Cheronis, J Trollinger, D Bankaitis-Davis, D Dinarello, CA Norris, DA Bevilacqua, MP Fujita, M Burmester, GR AF Edwards, Carl K., III Green, Julie S. Volk, Hans-Dieter Schiff, Michael Kotzin, Brian L. Mitsuya, Hiroaki Kawaguchi, Tatsuya Sakata, Ken-Mei Cheronis, John Trollinger, David Bankaitis-Davis, Danute Dinarello, Charles A. Norris, David A. Bevilacqua, Michael P. Fujita, Mayumi Burmester, Gerd-Rudiger TI Combined anti-tumor necrosis factor-alpha therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone SO FRONTIERS IN IMMUNOLOGY LA English DT Article DE gene expression; rheumatoid arthritis; anti-TNF-alpha; whole blood; biomarker AB Periodic assessment of gene expression for diagnosis and monitoring in rheumatoid arthritis (RA) may provide a readily available and useful method to detect subclinical disease progression and follow responses to therapy with disease modifying anti-rheumatic agents (DMARDs) or anti-INF-a therapy. We used quantitative real-time PCR to compare peripheral blood gene expression profiles in active ("unstable") RA patients on DMARDs, stable RA patients on DMARDs, and stable RA patients treated with a combination of a disease-modifying anti-rheumatoid drug (DMARD) and an anti-TNF-e agent (infliximab or etanercept) to healthy human controls. The expression of 48 inflammatory genes were compared between healthy controls (N = 122), unstable DMARD patients (N = 18), stable DMARD patients (N = 26), and stable patients on combination therapy (N = 20). Expression of 13 genes was very low or undetectable in all study groups. Compared to healthy controls, patients with unstable RA on DMARDs exhibited increased expression of 25 genes, stable DMARD patients exhibited increased expression of 14 genes and decreased expression of five genes, and combined therapy patients exhibited increased expression of six genes and decreased expression of 10 genes. These findings demonstrate that active RA is associated with increased expression of circulating inflammatory markers whereas increases in inflammatory gene expression are diminished in patients with stable disease on either DMARD or anti-INF-a therapy. Furthermore, combination DMARD and anti-INF-a therapy is associated with greater reductions in circulating inflammatory gene expression compared to DMARD therapy alone. These results suggest that assessment of peripheral blood gene expression may prove useful to monitor disease progression and response to therapy. C1 [Edwards, Carl K., III; Green, Julie S.; Norris, David A.; Bevilacqua, Michael P.; Fujita, Mayumi] Univ Colorado Denver, Dept Dermatol, Aurora, CO 80045 USA. [Edwards, Carl K., III; Schiff, Michael; Kotzin, Brian L.] Univ Colorado Denver, Dept Rheumatol, Aurora, CO 80045 USA. [Volk, Hans-Dieter; Burmester, Gerd-Rudiger] Campus Charite Mitte Inst Med Immunol, Berlin, Germany. [Mitsuya, Hiroaki; Kawaguchi, Tatsuya; Sakata, Ken-Mei] Kumamoto Univ, Sch Med, Kumamoto 860, Japan. [Cheronis, John; Trollinger, David; Bankaitis-Davis, Danute; Bevilacqua, Michael P.] Source Precis Med, Boulder, CO USA. [Dinarello, Charles A.] Univ Colorado Denver, Dept Infect Dis, Aurora, CO 80045 USA. [Norris, David A.; Fujita, Mayumi] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Fujita, M (reprint author), Univ Colorado Denver, Anschutz Med Campus,12801 East17thAvenue RC-1, Aurora, CO 80045 USA. EM carl.edwards@ucdenver.edu; mayumi.fujita@ucdenver.edu NR 53 TC 4 Z9 4 U1 1 U2 1 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PY 2012 VL 3 AR 366 DI 10.3389/fimmu.2012.00366 PG 10 WC Immunology SC Immunology GA V40TQ UT WOS:000209501300361 PM 23264777 ER PT J AU Harriff, MJ Purdy, GE Lewinsohn, DM AF Harriff, Melanie J. Purdy, Georgiana E. Lewinsohn, David M. TI Escape from the phagosome: the explanation for MHC-I processing of mycobacterial antigens? SO FRONTIERS IN IMMUNOLOGY LA English DT Review DE Mycobacterium tuberculosis; phagosome; MHC-I antigen processing; CD8(+) T cells AB Mycobacterium tuberculosis (Mtb) is thought to live in an altered phagosomal environment. In this setting, the mechanisms by which mycobacterial antigens access the major histocompatibility class I (MHC-I) processing machinery remain incompletely understood. There is evidence that Mtb antigens can be processed in both endocytic and cytosolic environments, with different mechanisms being proposed for how Mtb antigens can access the cytosol. Recently, electron microscopy was used to demonstrate that Mtb has the potential to escape the phagosome and reside in the cytosol. This was postulated as the primary mechanism by which Mtb antigens enter the MHC-I processing and presentation pathway. In this commentary, we will review data on the escape of Mtb from the cytosol and whether this escape is required for antigen presentation to CD8(+) T cells. C1 [Harriff, Melanie J.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR USA. [Harriff, Melanie J.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97239 USA. [Purdy, Georgiana E.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. RP Lewinsohn, DM (reprint author), Oregon Hlth & Sci Univ, Pulm & Crit Care Med, 3181 SW Sam Jackson Pk Rd,Mail Code VA R&D11, Portland, OR 97239 USA. EM lewinsod@ohsu.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 NR 94 TC 16 Z9 16 U1 0 U2 1 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PY 2012 VL 3 AR 40 DI 10.3389/fimmu.2012.00040 PG 11 WC Immunology SC Immunology GA V40TQ UT WOS:000209501300039 PM 22566923 ER PT J AU Stengel, A Tache, Y AF Stengel, Andreas Tache, Yvette TI Ghrelin a pleiotropic hormone secreted from endocrine X/A-like cells of the stomach SO FRONTIERS IN NEUROSCIENCE LA English DT Review DE acyl and desacyl; GOAT; ghrelin; nesfatin-1; NUCB2; endocrine cells; stress AB The gastric X/A-like endocrine cell receives growing attention due to its peptide products with ghrelin being the best characterized. This peptide hormone was identified a decade ago as a stimulator of food intake and to date remains the only known peripherally produced and centrally acting orexigenic hormone. In addition, subsequent studies identified numerous other functions of this peptide including the stimulation of gastrointestinal motility, the maintenance of energy homeostasis and an impact on reproduction. Moreover, ghrelin is also involved in the response to stress and assumed to play a role in coping functions and exert a modulatory action on immune pathways. Our knowledge on the regulation of ghrelin has markedly advanced during the past years by the identification of the ghrelin acylating enzyme, ghrelin-O-acyltransferase, and by the description of changes in expression, activation, and release under different metabolic as well as physically and psychically challenging conditions. However, our insight on regulatory processes of ghrelin at the cellular and subcellular levels is still very limited and warrants further investigation. C1 [Stengel, Andreas] Charite, Dept Med, Div Psychosomat Med & Psychotherapy, D-13353 Berlin, Germany. [Tache, Yvette] Univ Calif Los Angeles, Dept Med, Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Tache, Yvette] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90024 USA. [Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIH [R01 DK-33061]; NUT [DK-41301]; VA Research Career Scientist; Charite University funding FX This work was supported by NIH R01 DK-33061, NUT (enter Grant DK-41301 (Animal Core), VA Research Career Scientist (Yvette Tache), and Charite University funding (Andreas Stengel). We thank Ms. Eugenia Hu for careful reading of the manuscript. NR 231 TC 22 Z9 25 U1 1 U2 7 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-453X J9 FRONT NEUROSCI-SWITZ JI Front. Neurosci. PY 2012 VL 6 AR UNSP 24 DI 10.3389/fnins.2012.00024 PG 16 WC Neurosciences SC Neurosciences & Neurology GA V35RF UT WOS:000209165300040 PM 22355282 ER PT J AU Viveros, MP Mendrek, A Paus, T Lopez-Rodriguez, AB Marco, EM Yehuda, R Cohen, H Lehrner, A Wagner, EJ AF Viveros, Maria-Paz Mendrek, Adriana Paus, Tomas Belen Lopez-Rodriguez, Ana Maria Marco, Eva Yehuda, Rachel Cohen, Hagit Lehrner, Amy Wagner, Edward J. TI A comparative, developmental, and clinical perspective of neurobehavioral sexual dimorphisms SO FRONTIERS IN NEUROSCIENCE LA English DT Review DE sexual differentiation; adolescence; schizophrenia; depression; bipolar disorders; posttraumatic disorders; addiction; animal models AB Women and men differ in a wide variety of behavioral traits and in their vulnerability to developing certain mental disorders. This review endeavors to explore how recent preclinical and clinical research findings have enhanced our understanding of the factors that underlie these disparities. We start with a brief overview of some of the important genetic, molecular, and hormonal determinants that contribute to the process of sexual differentiation. We then discuss the importance of animal models in studying the mechanisms responsible for sex differences in neuropsychiatric disorders (e.g., drug dependence) with a special emphasis on experimental models based on the neurodevelopmental and "three hits" hypotheses. Next, we describe the most common brain phenotypes observed in vivo with magnetic resonance imaging. We discuss the challenges in interpreting these phenotypes vis-a-vis the underlying neurobiology and revisit the known sex differences in brain structure from birth, through adolescence, and into adulthood. This is followed by a presentation of pertinent clinical and epidemiological data that point to important sex differences in the prevalence, course, and expression of psychopathologies such as schizophrenia, and mood disorders including major depression and posttraumatic stress disorder. Recent evidence implies that mood disorders and psychosis share some common genetic predispositions and neurobiological bases. Therefore, modern research is emphasizing dimensional representation of mental disorders and conceptualization of schizophrenia and major depression as a continuum of cognitive deficits and neurobiological abnormalities. Herein, we examine available evidence on cerebral sexual dimorphism to verify if sex differences vary quantitatively and/or qualitatively along the psychoses-depression continuum. Finally, sex differences in the prevalence of posttraumatic disorder and drug abuse have been described, and we consider the genomic and molecular data supporting these differences. C1 [Viveros, Maria-Paz; Belen Lopez-Rodriguez, Ana; Maria Marco, Eva] Univ Complutense, Fac Biol, Physiol Dept Anim Physiol 2, Hlth Res Inst,Hosp Clin San Carlos, E-28040 Madrid, Spain. [Mendrek, Adriana] Bishops Univ, Dept Psychol, Sherbrooke, PQ, Canada. [Paus, Tomas] Univ Toronto, Rotman Res Inst, Toronto, ON, Canada. [Paus, Tomas] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada. [Yehuda, Rachel] Mt Sinai Sch Med, New York, NY USA. [Yehuda, Rachel; Cohen, Hagit] Ben Gurion Univ Negev, Fac Hlth Sci, Minist Hlth, Anxiety & Stress Res Unit,Mental Hlth Ctr, IL-84105 Beer Sheva, Israel. [Lehrner, Amy] James J Peters Vet Affairs Med Ctr, Traumat Stress Studies Div, Bronx, NY USA. [Wagner, Edward J.] Western Univ Hlth Sci, Coll Osteopath Med Pacific, Dept Basic Med Sci, Pomona, CA USA. RP Viveros, MP (reprint author), Univ Complutense, Fac Biol, Dept Fisiol Fisiol Anim 2, C Jose Antonio Novais 2, E-28040 Madrid, Spain. EM pazviver@bio.ucm.es RI Lopez-Rodriguez, Ana Belen/A-8384-2015; Marco, Eva/K-8224-2015; Viveros, Maria-Paz/S-6855-2016 OI Marco, Eva/0000-0002-2457-475X; FU Instituto de Salud Carlos III, Redes tematicas de Investigacion Cooperativa en salud (ISCIII y FEDER): Red de trastornos adictivos [RD06/0001/1013]; GRUPOS UCM-BSCH [951579]; Ministerio de Ciencia e Innovacion [BFU2009-10109]; Plan Nacional sobre Drogas [SAS/1250/2009] FX This work was supported by Instituto de Salud Carlos III, Redes tematicas de Investigacion Cooperativa en salud (ISCIII y FEDER): Red de trastornos adictivos RD06/0001/1013; GRUPOS UCM-BSCH - 951579; Ministerio de Ciencia e Innovacion BFU2009-10109, and Plan Nacional sobre Drogas at SAS/1250/2009 official notification. NR 257 TC 13 Z9 14 U1 3 U2 9 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-453X J9 FRONT NEUROSCI-SWITZ JI Front. Neurosci. PY 2012 VL 6 AR UNSP 84 DI 10.3389/fnins.2012.00084 PG 21 WC Neurosciences SC Neurosciences & Neurology GA V35RF UT WOS:000209165300093 PM 22701400 ER PT J AU Durazzo, TC Hutchison, KE Fryer, SL Mon, A Meyerhoff, DJ AF Durazzo, Timothy C. Hutchison, Kent E. Fryer, Susanna L. Mon, Anderson Meyerhoff, Dieter J. TI Associations of cigarette smoking and polymorphisms in brain-derived neurotrophic factor and catechol-O-methyltransferase with neurocognition in alcohol dependent individuals during early abstinence SO FRONTIERS IN PHARMACOLOGY LA English DT Article DE cigarette smoking; brain-derived neurotrophic factor; catechol-O-methyltransferase; neurocognition; alcohol dependence AB Chronic cigarette smoking and polymorphisms in brain-derived neurotrophic factor (BDNF) and catechol-O-methyltransferase (COMT) are associated with neurocognition in normal controls and those with various neuropsychiatric conditions. The influence of BDNF and COMT on neurocognition in alcohol dependence is unclear. The primary goal of this report was to investigate the associations of single nucleotide polymorphisms (SNPs) in BDNF Val66Met (rs6265) and COMT Val158Met (rs4680) with neurocognition in a treatment-seeking alcohol dependent cohort and determine if neurocognitive differences between non-smokers and smokers previously observed in this cohort persist when controlled for these functional SNPs. Genotyping was conducted on 70 primarily male treatment-seeking alcohol dependent participants (ALC) who completed a comprehensive neuropsychological battery after 33 +/- 9 days of monitored abstinence. After controlling for COMT and BDNF genotypes, smoking ALC performed significantly worse than non-smoking ALC on the domains of auditory-verbal and visuospatial learning and memory, cognitive efficiency, general intelligence, processing speed, and global neurocognition. In smoking ALC, greater number of years of smoking over lifetime was related to poorer performance on multiple domains after controlling for genotypes and alcohol consumption. In addition, COMT Met homozygotes were superior to Val homozygotes on measures of executive skills and showed trends for higher general intelligence and visuospatial skills, while COMT Val/Met heterozygotes showed significantly better general intelligence than Val homozygotes. COMT Val homozygotes performed better than heterozygotes on auditory-verbal memory. BDNF genotype was not related to any neurocognitive domain. The findings are consistent with studies in normal controls and neuropsychiatric cohorts that reported COMT Met carriers demonstrated better performance on measures of executive skills and general intelligence. Results also indicated that the poorer performance of smoking compared to non-smoking ALC across multiple neurocognitive domains was not mediated by COMT or BDNF genotype. Overall, the findings lend support to the expanding clinical movement to make smoking cessation programs available to smokers at the inception of treatment for alcohol/substance use disorders. C1 [Durazzo, Timothy C.; Fryer, Susanna L.; Mon, Anderson; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Durazzo, Timothy C.; Fryer, Susanna L.; Mon, Anderson; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Hutchison, Kent E.] Univ Colorado, Boulder, CO 80309 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu FU National Institute on Alcohol Abuse and Alcoholism [AA10788, AA012238]; National Institute on Drug Abuse [DA24136] FX This material is the result of work supported by the National Institute on Alcohol Abuse and Alcoholism (AA10788 to Dieter J. Meyerhoff; AA012238 to Kent E. Hutchison) and the National Institute on Drug Abuse (DA24136 to Timothy C. Durazzo) with resources and the use of facilities at the San Francisco Veterans Administration Medical Center, San Francisco, CA, USA. We thank Mary Rebecca Young, Kathleen Altieri, Ricky Chen, and Drs. Peter Banys and Ellen Herbst of the Veterans Administration Substance Abuse Day Hospital (which routinely offers smoking cessation with substance abuse treatment), and Dr. David Pating, Karen Moise, and their colleagues at the Kaiser Permanente Chemical Dependency Recovery Program in San Francisco for their valuable assistance in recruiting participants. We thank Dr. Wendy Ooteman for assistance in collecting blood samples for DNA extraction. We also wish to extend our gratitude to the study participants, who made this research possible. NR 86 TC 3 Z9 3 U1 1 U2 2 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1663-9812 J9 FRONT PHARMACOL JI Front. Pharmacol. PY 2012 VL 3 AR UNSP 178 DI 10.3389/fphar.2012.00178 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA V35XE UT WOS:000209177700172 PM 23087644 ER PT J AU Yuan, JZ Liu, YN Tan, T Guha, S Gukovsky, I Gukovskaya, A Pandol, SJ AF Yuan, Jingzhen Liu, Yannan Tan, Tanya Guha, Sushovan Gukovsky, Ilya Gukovskaya, Anna Pandol, Stephen J. TI Protein kinase D regulates cell death pathways in experimental pancreatitis SO FRONTIERS IN PHYSIOLOGY LA English DT Article DE pancreatic acinar cells; CCK; CID755673; CRT0066101; apoptosis; necrosis AB Inflammation and acinar cell necrosis are two major pathological responses of acute pancreatitis, a serious disorder with no current therapies directed to its molecular pathogenesis. Serine/threonine protein kinase D family, which includes PKD/PKD1, PKD2, and PKD3, has been increasingly implicated in the regulation of multiple physiological and pathophysiological effects. We recently reported that PKD/PKD1, the predominant PKD isoform expressed in rat pancreatic acinar cells, mediates early events of pancreatitis including NE-kappa B activation and inappropriate intracellular digestive enzyme activation. In current studies, we investigated the role and mechanisms of PKD/PKD1 in the regulation of necrosis in pancreatic acinar cells by using two novel small molecule PKD inhibitors CID755673 and CR10066101 and molecular approaches in in vitro and in vivo experimental models of acute pancreatitis. Our results demonstrated that both CID755673 and CR10066101 are PKD-specific inhibitors and that PKD/PKD1 inhibition by either the chemical inhibitors or specific PKD/PKD1 siRNAs attenuated necrosis while promoting apoptosis induced by pathological doses of cholecystokinin-octapeptide (CCK) in pancreatic acinar cells. Conversely, up-regulation of PKD expression in pancreatic acinar cells increased necrosis and decreased apoptosis. We further showed that PKD/PKD1 regulated several key cell death signals including inhibitors of apoptotic proteins, caspases, receptor-interacting protein kinase 1 to promote necrosis. PKD/PKD1 inhibition by CID755673 significantly ameliorated necrosis and severity of pancreatitis in an in vivo experimental model of acute pancreatitis. Thus, our studies indicate that PKD/PKD1 is a key mediator of necrosis in acute pancreatitis and that PKD/PKD1 may represent a potential therapeutic target in acute pancreatitis. C1 [Yuan, Jingzhen; Liu, Yannan; Tan, Tanya; Gukovsky, Ilya; Gukovskaya, Anna; Pandol, Stephen J.] Univ Calif Los Angeles, South California Res Ctr Alcohol Liver & Pancreat, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Liu, Yannan] Beijing Hosp, Beijing, Peoples R China. [Guha, Sushovan] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA. RP Yuan, JZ (reprint author), Univ Calif Los Angeles, South California Res Ctr Alcohol Liver & Pancreat, Vet Affairs Greater Los Angeles Healthcare Syst, West Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd,Bldg 258,Room 340, Los Angeles, CA 90073 USA. EM jzyuan@ucla.edu FU Department of Veterans Affairs Merits Grant; Southern California Research Center for Alcoholic Liver and Pancreatic Diseases (NIH) [P50-A11999]; UCLA Center of Excellence in Pancreatic Diseases (NIH) [1P01AT0003960-01]; Lee Summer Student Research Award from Southern California Research Center for Liver and Pancreatic Diseases FX The authors would like to thank Dr. Aurelia Lugea for discussion and help in animal experiment design and TUNEL staining, Dr. Olga Mareninova for discussion of acinar cell staining. The authors also thank Dr. Edwin Thrower (Yale University School of Medicine) and Dr. Christopher R. Ireson and his group at the Cancer Research Technology Discovery Laboratories, London, UK for providing us with CR10066101. This study was supported by the Department of Veterans Affairs Merits Grant and the Southern California Research Center for Alcoholic Liver and Pancreatic Diseases (NIH Grant P50-A11999); UCLA Center of Excellence in Pancreatic Diseases (NIH Grant 1P01AT0003960-01); and Lee Summer Student Research Award from Southern California Research Center for Liver and Pancreatic Diseases (to Tanya Tan). NR 51 TC 17 Z9 18 U1 1 U2 4 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-042X J9 FRONT PHYSIOL JI Front. Physiol. PY 2012 VL 3 AR UNSP 60 DI 10.3389/fphys.2012.00060 PG 17 WC Physiology SC Physiology GA V35UH UT WOS:000209173000059 PM 22470346 ER PT J AU Zhang, Z Sun, K Saloner, DA Wallace, AW Ge, L Baker, AJ Guccione, JM Ratcliffe, MB AF Zhang, Zhihong Sun, Kay Saloner, David A. Wallace, Arthur W. Ge, Liang Baker, Anthony J. Guccione, Julius M. Ratcliffe, Mark B. TI The benefit of enhanced contractility in the infarct borderzone: a virtual experiment SO FRONTIERS IN PHYSIOLOGY LA English DT Article DE myocardial Infarction; borderzone; finite element AB Objectives: Contractile function in the normally perfused infarct borderzone (BZ) is depressed. However, the impact of reduced BZ contractility on left ventricular (LV) pump function is unknown. As a consequence, there have been no therapies specifically designed to improve BZ contractility. We tested the hypothesis that an improvement in borderzone contractility will improve LV pump function. Methods: From a previously reported study, magnetic resonance imaging (MRI) images with non-invasive tags were used to calculate 3D myocardial strain in five sheep 16 weeks after anteroapical myocardial infarction. Animal-specific finite element (FE) models were created using MRI data and LV pressure obtained at early diastolic filling. Analysis of borderzone function using those FE models has been previously reported. Chamber stiffness, pump function (Starling's law) and stress in the fiber, cross fiber, and circumferential directions were calculated. Animal-specific FE models were performed for three cases: (a) impaired BZ contractility (INJURED); (b) BZ-contractility fully restored (100% BZ IMPROVEMENT); or (c) BZ-contractility partially restored (50% BZ IMPROVEMENT). Results: 100% BZ IMPROVEMENT and 50% BZ IMPROVEMENT both caused an upward shift in the Starling relationship, resulting in a large (36 and 26%) increase in stroke volume at LVPED = 20 mmHg (8.0 ml, p < 0.001). Moreover, there were a leftward shift in the end-systolic pressure volume relationship, resulting in a 7 and 5% increase in LVPES at 110 mmHg (7.7 ml, p < 0.005). It showed that even 50% BZ IMPROVEMENT was sufficient to drive much of the calculated increase in function. Conclusion: Improved borderzone contractility has a beneficial effect on LV pump function. Partial improvement of borderzone contractility was sufficient to drive much of the calculated increase in function. Therapies specifically designed to improve borderzone contractility should be developed. C1 [Zhang, Zhihong; Sun, Kay; Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Zhang, Zhihong; Sun, Kay; Saloner, David A.; Wallace, Arthur W.; Ge, Liang; Baker, Anthony J.; Guccione, Julius M.; Ratcliffe, Mark B.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Saloner, David A.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. [Wallace, Arthur W.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. [Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. [Baker, Anthony J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@va.gov FU NIH [R01-HL-77921, R01-HL-63348] FX This study was supported by NIH grant R01-HL-77921 (Dr. Guccione), and R01-HL-63348 (Dr. Ratcliffe). This support is gratefully acknowledged. NR 19 TC 3 Z9 3 U1 0 U2 0 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-042X J9 FRONT PHYSIOL JI Front. Physiol. PY 2012 VL 3 AR UNSP 86 DI 10.3389/fphys.2012.00086 PG 6 WC Physiology SC Physiology GA V35UH UT WOS:000209173000084 PM 22509168 ER PT J AU Clark, DG AF Clark, David Glenn TI Storage costs and heuristics interact to produce patterns of aphasic sentence comprehension performance SO FRONTIERS IN PSYCHOLOGY LA English DT Article DE aphasia; syntax; semantics; sentence comprehension AB Background: Despite general agreement that aphasic individuals exhibit difficulty understanding complex sentences, the nature of sentence complexity itself is unresolved. In addition, aphasic individuals appear to make use of heuristic strategies for understanding sentences. This research is a comparison of predictions derived from two approaches to the quantification of sentence complexity, one based on the hierarchical structure of sentences, and the other based on dependency locality theory (DLT). Complexity metrics derived from these theories are evaluated under various assumptions of heuristic use. Method: A set of complexity metrics was derived from each general theory of sentence complexity and paired with assumptions of heuristic use. Probability spaces were generated that summarized the possible patterns of performance across 16 different sentence structures. The maximum likelihood of comprehension scores of 42 aphasic individuals was then computed for each probability space and the expected scores from the best-fitting points in the space were recorded for comparison to the actual scores. Predictions were then compared using measures of fit quality derived from linear mixed effects models. Results: All three of the metrics that provide the most consistently accurate predictions of patient scores rely on storage costs based on the DLT. Patients appear to employ an Agent Theme heuristic, but vary in their tendency to accept heuristically generated interpretations. Furthermore, the ability to apply the heuristic may be degraded in proportion to aphasia severity. Conclusion: DLT-derived storage costs provide the best prediction of sentence comprehension patterns in aphasia. Because these costs are estimated by counting incomplete syntactic dependencies at each point in a sentence, this finding suggests that aphasia is associated with reduced availability of cognitive resources for maintaining these dependencies. C1 [Clark, David Glenn] Birmingham VA Med Ctr, Birmingham, AL USA. [Clark, David Glenn] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. RP Clark, DG (reprint author), Univ Alabama Birmingham, Dept Neurol, 1720 7th Ave South SC 620C, Birmingham, AL 35294 USA. EM dgclark@uab.edu NR 64 TC 0 Z9 0 U1 3 U2 5 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-1078 J9 FRONT PSYCHOL JI Front. Psychol. PY 2012 VL 3 AR 135 DI 10.3389/fpsyg.2012.00135 PG 19 WC Psychology, Multidisciplinary SC Psychology GA V31DI UT WOS:000208863900147 PM 22590462 ER PT S AU Mahanian, M Fiala, M Mizwicki, MT La Cava, A AF Mahanian, Michelle Fiala, Milan Mizwicki, Mathew T. La Cava, Antonio BE Aggarwal, BB Krishnan, S Guha, S TI Immune Modulation of Inflammation in Neurodegenerative Diseases Alzheimer's Disease and Amyotrophic Lateral Sclerosis SO INFLAMMATION, LIFESTYLE AND CHRONIC DISEASES: THE SILENT LINK SE Oxidative Stress and Disease LA English DT Article; Book Chapter ID CEREBRAL AMYLOID ANGIOPATHY; INNATE IMMUNITY; BETA-PROTEIN; MOUSE MODEL; MACROPHAGES; ACTIVATION; MICROGLIA; CELLS; MICE; ALS C1 [Mahanian, Michelle; Fiala, Milan; La Cava, Antonio] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Fiala, Milan] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Mizwicki, Mathew T.] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA. RP Mahanian, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. NR 50 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA SN 2155-0255 BN 978-1-4398-3990-4; 978-1-4398-3989-8 J9 OXIDAT STRESS DIS PY 2012 BP 41 EP 55 PG 15 WC Primary Health Care; Immunology SC General & Internal Medicine; Immunology GA BC8CS UT WOS:000355550900003 ER PT B AU Pekow, CA AF Pekow, Cynthia A. BE Suckow, MA Stevens, KA Wilson, RP TI Basic Experimental Methods in the Rabbit SO LABORATORY RABBIT, GUINEA PIG, HAMSTER, AND OTHER RODENTS SE American College of Laboratory Animal Medicine Series LA English DT Article; Book Chapter ID ARTIFICIAL-INSEMINATION; ACCESS; CATHETERIZATION; COLLECTION; DEVICE; BLOOD; SUBSTANCES; INTUBATION; ANIMALS; MODEL C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Pekow, CA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 63 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-380921-6; 978-0-12-380920-9 J9 AM COLL LAB PY 2012 BP 243 EP 258 DI 10.1016/B978-0-12-380920-9.00010-9 PG 16 WC Veterinary Sciences SC Veterinary Sciences GA BA2YY UT WOS:000333993900011 ER PT J AU Kim, S Beyer, BA Lewis, C Nadel, JA AF Kim, S. Beyer, B. A. Lewis, C. Nadel, J. A. TI Normal CFTR inhibits a pro-inflammatory IL-1R-TACE-EGFR pathway in airway epithelial cells. SO MOLECULAR BIOLOGY OF THE CELL LA English DT Meeting Abstract C1 [Kim, S.; Beyer, B. A.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Lewis, C.; Nadel, J. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 EI 1939-4586 J9 MOL BIOL CELL JI Mol. Biol. Cell PY 2012 VL 23 MA 685 PG 1 WC Cell Biology SC Cell Biology GA V38MX UT WOS:000209348602318 ER PT J AU Minchew, CL Didenko, VV AF Minchew, C. L. Didenko, V. V. TI Color-shifting FRET sensor for detection of phagocytic phase of apoptosis. SO MOLECULAR BIOLOGY OF THE CELL LA English DT Meeting Abstract C1 [Minchew, C. L.; Didenko, V. V.] Baylor Coll Med, Neurosurg & Mol & Cellular Biol, Houston, TX 77030 USA. [Minchew, C. L.; Didenko, V. V.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 EI 1939-4586 J9 MOL BIOL CELL JI Mol. Biol. Cell PY 2012 VL 23 MA 1708 PG 1 WC Cell Biology SC Cell Biology GA V38MX UT WOS:000209348605076 ER PT B AU Sepulveda, JL AF Sepulveda, Jorge L. BE Dasgupta, A Langman, LJ TI Genetic Aspect of Opiate Metabolism and Addiction SO PHARMACOGENOMICS OF ALCOHOL AND DRUGS OF ABUSE LA English DT Article; Book Chapter ID OPIOID RECEPTOR GENE; METHADONE-MAINTENANCE TREATMENT; HUMAN LIVER-MICROSOMES; SINGLE-NUCLEOTIDE POLYMORPHISM; P-GLYCOPROTEIN; ALCOHOL DEPENDENCE; GLUCURONOSYLTRANSFERASE 2B7; HEROIN-ADDICTION; N-DEMETHYLATION; CANCER-PATIENTS C1 [Sepulveda, Jorge L.] Philadelphia VA Med Ctr, Pathol & Lab Med Serv, Philadelphia, PA 19104 USA. [Sepulveda, Jorge L.] Univ Penn, Philadelphia, PA 19104 USA. RP Sepulveda, JL (reprint author), Philadelphia VA Med Ctr, Pathol & Lab Med Serv, Philadelphia, PA 19104 USA. NR 139 TC 0 Z9 0 U1 1 U2 3 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-5612-3; 978-1-4398-5611-6 PY 2012 BP 165 EP 194 D2 10.1201/b11879 PG 30 WC Substance Abuse; Pharmacology & Pharmacy SC Substance Abuse; Pharmacology & Pharmacy GA BC9LX UT WOS:000356613400009 ER PT B AU Sepulveda, JL AF Sepulveda, Jorge L. BE Dasgupta, A Langman, LJ TI Methodologies in Pharmacogenetics Testing SO PHARMACOGENOMICS OF ALCOHOL AND DRUGS OF ABUSE LA English DT Article; Book Chapter ID DNA; DIAGNOSTICS; ASSAY; NANOPORE; INVADER C1 [Sepulveda, Jorge L.] Philadelphia VA Med Ctr, Pathol & Lab Med Serv, Philadelphia, PA 19104 USA. [Sepulveda, Jorge L.] Univ Penn, Philadelphia, PA 19104 USA. RP Sepulveda, JL (reprint author), Philadelphia VA Med Ctr, Pathol & Lab Med Serv, Philadelphia, PA 19104 USA. NR 27 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-5612-3; 978-1-4398-5611-6 PY 2012 BP 211 EP 228 D2 10.1201/b11879 PG 18 WC Substance Abuse; Pharmacology & Pharmacy SC Substance Abuse; Pharmacology & Pharmacy GA BC9LX UT WOS:000356613400011 ER PT B AU Farid, M Spiegel, B AF Farid, Mary Spiegel, Brennan BE Plevris, JN Howden, CW TI The Clinical Approach to Dyspepsia SO PROBLEM-BASED APPROACH TO GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PATIENTS; PEPTIC-ULCER DISEASE; HELICOBACTER-PYLORI; MANAGEMENT C1 [Farid, Mary] Univ Calif Los Angeles, Affiliated Training Program Digest Dis, Los Angeles, CA 90095 USA. [Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Spiegel, Brennan] UCLA VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. RP Farid, M (reprint author), Univ Calif Los Angeles, Affiliated Training Program Digest Dis, Los Angeles, CA 90095 USA. RI Plevris, John/O-3517-2014 NR 10 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-4051-8227-0; 978-1-4443-4635-0 PY 2012 BP 39 EP 43 D2 10.1002/9781444346381 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BA6GX UT WOS:000337140200004 ER PT J AU Maguen, S Cohen, B Ren, L Bosch, J Kimerling, R Seal, K AF Maguen, Shira Cohen, Beth Ren, Li Bosch, Jeane Kimerling, Rachel Seal, Karen TI Gender Differences in Military Sexual Trauma and Mental Health Diagnoses among Iraq and Afghanistan Veterans with Posttraumatic Stress Disorder SO WOMENS HEALTH ISSUES LA English DT Article AB Objective: We examined correlates of posttraumatic stress disorder (PTSD), including military sexual trauma (MST), in Iraq and Afghanistan veterans. We also compared mental health comorbidities by gender among veterans with PTSD, with and without MST. Methods: Retrospective data analyses were conducted using Department of Veterans Affairs (VA) administrative data from 213,803 Iraq and Afghanistan veterans and the subset diagnosed with PTSD from April 1, 2002, to October 1, 2008. We used descriptive statistics and multivariate logistic regression compared by gender to investigate independent correlates and mental health comorbidities associated with PTSD, with and without MST. Results: Among women with PTSD, 31% screened positive for MST; 1% of men with PTSD screened positive for MST. Among those with PTSD, veterans with MST had more comorbid mental health diagnoses than those without MST. Women with PTSD and MST were more likely to receive comorbid depression, anxiety, and eating disorder diagnoses, and men were more likely to receive comorbid substance use disorder diagnoses. Conclusions: MST is associated with an increased prevalence of mental health disorders comorbid with PTSD. Better understanding comorbidity patterns will allow for targeted evaluation and treatment of returning veterans with MST. Published by Elsevier Inc. C1 [Maguen, Shira; Cohen, Beth; Ren, Li; Bosch, Jeane; Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Maguen, Shira; Cohen, Beth; Seal, Karen] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kimerling, Rachel] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St,116-P, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov RI Schueter, nicos/A-3625-2014 OI Kimerling, Rachel/0000-0003-0996-4212 FU NHLBI NIH HHS [K23 HL 094765-01] NR 26 TC 54 Z9 54 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JAN-FEB PY 2012 VL 22 IS 1 BP E61 EP E66 DI 10.1016/j.whi.2011.07.010 PG 6 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA V33SP UT WOS:000209038800008 PM 21907590 ER PT J AU Subramanian, SL Hull, RL Zraika, S Aston-Mourney, K Udayasankar, J Kahn, SE AF Subramanian, S. L. Hull, R. L. Zraika, S. Aston-Mourney, K. Udayasankar, J. Kahn, S. E. TI cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets SO DIABETOLOGIA LA English DT Article DE Beta cell apoptosis; hIAPP; Islet amyloid; JNK activation ID ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; HUMAN AMYLIN; DIABETES-MELLITUS; ER STRESS; TYPE-2; EXPRESSION; INSULIN; GLUCOSE; PROTEIN AB Aggregation of human islet amyloid polypeptide (hIAPP) as islet amyloid is associated with increased beta cell apoptosis and reduced beta cell mass in type 2 diabetes. Islet amyloid formation induces oxidative stress, which contributes to beta cell apoptosis. The cJUN N-terminal kinase (JNK) pathway is a critical mediator of beta cell apoptosis in response to stress stimuli including oxidative stress and exogenous application of hIAPP. We determined whether amyloid formation by endogenous hIAPP mediates beta cell apoptosis through JNK activation and downstream signalling pathways. hIAPP transgenic and non-transgenic mouse islets were cultured for up to 144 h in 16.7 mmol/l glucose to induce islet amyloid in the presence or absence of the amyloid inhibitor Congo Red or a cell-permeable JNK inhibitor. Amyloid, beta cell apoptosis, JNK signalling and activation of downstream targets in the intrinsic and extrinsic apoptotic pathways were measured. JNK activation occurred with islet amyloid formation in hIAPP transgenic islets after 48 and 144 h in culture. Neither high glucose nor the hIAPP transgene alone was sufficient to activate JNK independent of islet amyloid. Inhibition of islet amyloid formation with Congo Red reduced beta cell apoptosis and partially decreased JNK activation. JNK inhibitor treatment reduced beta cell apoptosis without affecting islet amyloid. Islet amyloid increased mRNA levels of markers of the extrinsic (Fas, Fadd) and intrinsic (Bim [also known as Bcl2l11]) apoptotic pathways, caspase 3 and the anti-apoptotic molecule Bclxl (also known as Bcl2l1) in a JNK-dependent manner. Islet amyloid formation induces JNK activation, which upregulates predominantly pro-apoptotic signals in both extrinsic and intrinsic pathways, resulting in beta cell apoptosis. C1 [Subramanian, S. L.; Hull, R. L.; Zraika, S.; Aston-Mourney, K.; Udayasankar, J.; Kahn, S. E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Subramanian, S. L.; Hull, R. L.; Zraika, S.; Aston-Mourney, K.; Udayasankar, J.; Kahn, S. E.] Univ Washington, Seattle, WA 98108 USA. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu OI Aston-Mourney, Kathryn/0000-0003-1412-6715; Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087 FU Department of Veterans Affairs; National Institutes of Health [DK-075998, DK-074404, DK-080945, DK-007247, DK-017047]; American Diabetes Association; University of Washington; Juvenile Diabetes Research Foundation FX We thank B. Barrow, C. Braddock, M. Cone, C. Forsyth, M. Peters, M. Watts and J. Willard for their excellent technical support. This work was supported by the Department of Veterans Affairs and National Institutes of Health grants DK-075998 (S. E. Kahn), DK-074404 (R. L. Hull), DK-080945 (S. Zraika), DK-007247 and DK-017047. S. Subramanian and K. Aston-Mourney were supported by an American Diabetes Association Mentor-Based Fellowship. K. Aston-Mourney was also supported by a University of Washington McAbee Fellowship. J. Udayasankar was supported by a Juvenile Diabetes Research Foundation Postdoctoral Fellowship. NR 47 TC 30 Z9 31 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD JAN PY 2012 VL 55 IS 1 BP 166 EP 174 DI 10.1007/s00125-011-2338-7 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 857SI UT WOS:000297739000023 PM 22038516 ER PT J AU Wenger, A Englund, M Wirth, W Hudelmaier, M Kwoh, K Eckstein, F AF Wenger, Andrea Englund, Martin Wirth, Wolfgang Hudelmaier, Martin Kwoh, Kent Eckstein, Felix CA OAI Investigators TI Relationship of 3D meniscal morphology and position with knee pain in subjects with knee osteoarthritis: a pilot study SO EUROPEAN RADIOLOGY LA English DT Article DE Meniscus; Extrusion; Pain; Knee osteoarthritis; Magnetic resonance imaging ID BONE-MARROW LESIONS; CARTILAGE LOSS; MULTICENTER OSTEOARTHRITIS; ARTICULAR-CARTILAGE; ELDERLY PERSONS; INITIATIVE OAI; RISK-FACTORS; JOINT; ASSOCIATION; TEARS AB To explore whether quantitative, three-dimensional measurements of meniscal position and size are associated with knee pain using a within-person, between-knee study design. We studied 53 subjects (19 men, 34 women) from the Osteoarthritis Initiative, with identical radiographic OA grades in both knees, but frequent pain in one and no pain in the other knee. The tibial plateau and menisci were analyzed using coronally reconstructed double echo steady-state sequence with water excitation (DESSwe) MRI. The medial meniscus covered a smaller proportion of the tibial plateau (-5%) and displayed greater extrusion of the body (+15%) in painful than in painless knees (paired t-test; p < 0.05). The external margin of the lateral meniscus showed greater extrusion of the body in painful knees (+22%; p = 0.03), but no significant difference in the position of its internal margin or tibial coverage. Medial or lateral extrusion a parts per thousand yen3 mm was more frequent in painful (n = 23) than in painless knees (n = 12; McNemar's test; p = 0.02). No significant association was observed between meniscal size and knee pain. These data suggest a relationship between extrusion of the meniscal body, as measured with quantitative MRI, and knee pain in subjects with knee OA. Further studies need to confirm these findings and their clinical relevance. Meniscal segmentation provides quantitative measures of meniscal size/position Between-knee, within-person approaches can explore potential sources of knee pain Meniscal extrusion may be a potential source of knee pain. C1 [Wenger, Andrea; Wirth, Wolfgang; Hudelmaier, Martin; Eckstein, Felix] Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, A-5020 Salzburg, Austria. [Englund, Martin] Lund Univ, Dept Orthoped, Lund, Sweden. [Englund, Martin] Boston Univ, Sch Med, Clin Epidemiol Res & Training Unit, Boston, MA 02118 USA. [Wirth, Wolfgang; Hudelmaier, Martin; Eckstein, Felix] Chondrometrics GmbH, Ainring, Germany. [Kwoh, Kent] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA. [Kwoh, Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Wenger, A (reprint author), Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria. EM andrea.wenger@pmu.ac.at RI Wirth, Wolfgang/C-8724-2011; Englund, Martin/J-7245-2012 OI Wirth, Wolfgang/0000-0002-2297-8283; Englund, Martin/0000-0003-3320-2437 FU OAI [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; National Institutes of Health; Pfizer, Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories; GlaxoSmithKline; Paracelsus Medical University; Swedish Research Council; Faculty of Medicine, Lund University; Royal Physiographic Society in Lund; [AR054731] FX The study and image acquisition was supported by the OAI (contract nos. N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health and conducted by the OAI Study Investigators. Private funding partners include Pfizer, Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories; and GlaxoSmithKline. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript has received the approval of the OAI Publications Committee based on a review of its scientific content and data interpretation.; The image analysis was supported by funds from Paracelsus Medical University (PMU Forschungsfond). Dr. Englund is supported by the Swedish Research Council, the Faculty of Medicine, Lund University, and the Royal Physiographic Society in Lund and Dr. Kwoh by grant AR054731. Felix Eckstein is CEO and co- owner of Chondrometrics GmbH; he also provides consulting services to MerckSerono, Novartis and Sanofi Aventis. Wolfgang Wirth is co-owner of Chondrometrics GmbH. NR 53 TC 28 Z9 28 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0938-7994 J9 EUR RADIOL JI Eur. Radiol. PD JAN PY 2012 VL 22 IS 1 BP 211 EP 220 DI 10.1007/s00330-011-2234-z PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 857UX UT WOS:000297749100022 PM 21842432 ER PT J AU Holmes, B Artinian, N Anderson, L Martin, J Masri, J Cloninger, C Bernath, A Bashir, T Benavides-Serrato, A Gera, J AF Holmes, Brent Artinian, Nicholas Anderson, Lauren Martin, Jheralyn Masri, Janine Cloninger, Cheri Bernath, Andrew Bashir, Tariq Benavides-Serrato, Angelica Gera, Joseph TI Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress SO CELLULAR SIGNALLING LA English DT Article DE Protor-2; Tristetraprolin; mTORC2; mRNA stability; Stress ID AU-RICH ELEMENTS; PROTEIN-KINASE; MTOR; BINDING; CANCER; RICTOR; TURNOVER; GRANULES; ALPHA; DEADENYLATION AB The A/U-rich RNA-binding protein tristetraprolin (TIP) is an mRNA destabilizing factor which plays a role in the regulated turnover of many transcripts encoding proteins involved in immune function and cell growth control. TTP also plays a role in stress-induced destabilization of mRNAs. Here we report the interaction of TTP with a component of the mTORC2 kinase, Protor-2 (PRR5-L, protein Q6MZQ0/FLJ14213/CAE45978). Protor-2 is structurally similar to human PRR5 and has been demonstrated to bind mTORC2 via Rictor and/or Sin1 and may signal downstream events promoting apoptosis. Protor-2 dissociates from mTORC2 upon hyperactivation of the kinase and is not required for mTORC2 integrity or activity. We identified Protor-2 in a yeast two-hybrid screen as a TTP interactor using the C-terminal mRNA decay domain of TTP as bait. The interaction of Protor-2 with TTP was also confirmed in vivo in co-immunoprecipitation experiments and Protor-2 was also detected in immunoprecipitates of Rictor. Protor-2 was shown to stimulate UP-mediated mRNA turnover of several TIP-associated mRNAs (TNF-alpha, GM-CSF, IL-3 and COX-2) in Jurkat cells when overexpressed while the half-lives of transcripts which do not decay via a TTP-mediated mechanism were unaffected. Knockdown of Protor-2 via RNAi inhibited TIP-mediated mRNA turnover of these TTP-associated mRNAs and inhibited association of TTP with cytoplasmic stress granules (SG) or mRNA processing bodies (P-bodies) following induction of the integrated stress response. These results suggest that Protor-2 associates with TTP to accelerate TTP-mediated mRNA turnover and functionally links the control of TIP-regulated mRNA stability to mTORC2 activity. (C) 2011 Elsevier Inc. All rights reserved. C1 [Holmes, Brent; Artinian, Nicholas; Anderson, Lauren; Martin, Jheralyn; Masri, Janine; Cloninger, Cheri; Bernath, Andrew; Bashir, Tariq; Benavides-Serrato, Angelica; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA. [Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA. [Gera, Joseph] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90048 USA. [Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90048 USA. RP Gera, J (reprint author), VA UCLA Med Ctr, Dept Res & Dev, 16111 Plummer St 151,Bldg 1,Rm C111A, North Hills, CA 91343 USA. EM jgera@mednet.ucla.edu FU NIH [RO1CA109312]; US Department of Veterans Affairs FX We thank Drs. Michael Hall and William Rigby for providing cell lines and antibodies, Dr. Robert Nishimura for critical reading of the manuscript and Ardella Sherwood for excellent administrative assistance. This work was supported, in part, by grants from the NIH (RO1CA109312) and the US Department of Veterans Affairs. NR 45 TC 7 Z9 7 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 J9 CELL SIGNAL JI Cell. Signal. PD JAN PY 2012 VL 24 IS 1 BP 309 EP 315 DI 10.1016/j.cellsig.2011.09.015 PG 7 WC Cell Biology SC Cell Biology GA 852YH UT WOS:000297392900034 PM 21964062 ER PT B AU Ghassemi, KA Jensen, DM AF Ghassemi, Kevin A. Jensen, Dennis M. BE Esrailian, E TI NONVARICEAL UPPER GASTROINTESTINAL BLEEDING SO GUT INSTINCTS: A CLINICIAN'S HANDBOOK OF DIGESTIVE AND LIVER DISEASES LA English DT Article; Book Chapter ID MANAGEMENT C1 [Ghassemi, Kevin A.; Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Jensen, Dennis M.] UCLA Med Centet, W Los Angeles VA Med Ctr, CURE Digest Dis Res Ctr, Los Angeles, CA USA. RP Ghassemi, KA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-977-4 PY 2012 BP 59 EP 63 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BWY89 UT WOS:000295343100009 ER PT B AU Kovacs, TOG AF Kovacs, Thomas O. G. BE Esrailian, E TI ACID-PEPTIC DISORDERS SO GUT INSTINCTS: A CLINICIAN'S HANDBOOK OF DIGESTIVE AND LIVER DISEASES LA English DT Article; Book Chapter C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA. RP Kovacs, TOG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-977-4 PY 2012 BP 65 EP 69 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BWY89 UT WOS:000295343100010 ER PT B AU Bhat, YM Singh, IM AF Bhat, Yasser M. Singh, Inder M. BE Esrailian, E TI BILIARY DISEASES SO GUT INSTINCTS: A CLINICIAN'S HANDBOOK OF DIGESTIVE AND LIVER DISEASES LA English DT Article; Book Chapter C1 [Bhat, Yasser M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Bhat, Yasser M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Singh, Inder M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-977-4 PY 2012 BP 85 EP 93 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BWY89 UT WOS:000295343100013 ER PT J AU Wilhelm, CJ Murphy-Crews, A Menasco, DJ Huckans, MS Loftis, JM AF Wilhelm, Clare J. Murphy-Crews, Aaron Menasco, Daniel J. Huckans, Marilyn S. Loftis, Jennifer M. TI Corticotropin releasing factor-1 receptor antagonism alters the biochemical, but not behavioral effects of repeated interleukin-1 beta administration SO NEUROPHARMACOLOGY LA English DT Article DE Sickness behavior; Interleukin-1beta; Corticotropin releasing factor; Forced swim test; p38 MAPK; Weight regulation; Cytokines ID MAJOR DEPRESSIVE DISORDER; ACTIVATED PROTEIN-KINASE; CHEMOTHERAPY-RELATED SYMPTOMS; INTERFERON-ALPHA; FORCED SWIM; SICKNESS BEHAVIOR; CANCER; HORMONE; LIPOPOLYSACCHARIDE; RATS AB Activation of the immune system via administration of cytokines is used for the treatment of chronic viral infections such as hepatitis C and for cancers resistant to radiotherapy. Cytokine-based treatments induce a range of "sickness" behaviors (e.g. depression, anxiety, pain, anorexia, and fatigue). Activation of the hypothalamic pituitary-adrenal axis via the induction of corticotropin releasing factor (CRF) may underlie these unwanted side effects. This study used repeated systemic injections of the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) to model the sickness behaviors and biochemical effects of immune system activation. We assessed the ability of CRF type I receptor (CRF1) antagonism to reduce biochemical and behavioral signs of sickness induced by IL-1 beta treatment. Forty Wistar rats were assigned to one of four groups: 1) saline + vehicle; 2) saline + DMP904 (CRF1 antagonist); 3) IL-1 beta + vehicle; 4) IL-1 beta + DMP904. Rats received intraperitoneal injections of either DMP904 or vehicle and of IL-1 beta or saline for six days. Sickness behavior was evaluated using body weight assessments and forced swim testing (FST). Blood and brain samples were collected to measure cytokine, p38 mitogen-activated protein kinase (MAPK), and phospho-p38 MAPK levels using multiplex techniques. There were significant reductions in body weights and FST immobility times associated with IL-1 beta administration. Rats administered IL-1 beta had significantly higher serum levels of IL-1 beta, but not interferon-gamma. Within the hippocampus, IL-1 beta reduced levels of p38 MAPK, but had no impact on levels of phospho-p38 MAPK except in the presence of DMP904. When administered alone, DMP904 had no significant effect on p38 MAPK or phospho-p38 MAPK in the hippocampus, but when given with IL-1 beta led to increased phosphorylation of p38 MAPIC IL-1 beta and DMP904 reduced levels of p38 MAPK within the hypothalamus, while co-administration of IL-1 beta and DMP904 abolished the effects of either drug alone. IL-1 beta decreased immobility time in the FST, and led to reductions in body weight, changes in serum cytokine levels and p38 MAPK regulation within the hippocampus and hypothalamus. DMP904 blocked some of the neurochemical effects of IL-1 beta, but did not impact the behavioral measures, or serum cytokines. Thus, additional studies will be needed to determine whether CRF1 antagonism is an effective treatment for cytokine-induced sickness. This article is part of a Special Issue entitled 'Anxiety and Depression'. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Wilhelm, Clare J.; Menasco, Daniel J.; Huckans, Marilyn S.; Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Wilhelm, Clare J.; Huckans, Marilyn S.; Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Murphy-Crews, Aaron; Loftis, Jennifer M.] Reed Coll, Portland, OR 97202 USA. [Huckans, Marilyn S.] Portland VA Med Ctr, Div Mental Hlth, Portland, OR 97239 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Res & Dev Serv R&D 16, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM wilhelmc@ohsu.edu; aaron.murphycrews@gmail.com; dmenasco@mac.com; Marilyn.huckans@va.gov; loftisj@ohsu.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and Clinical Sciences Research and Development; Department of Veterans Affairs, Veterans Health Administration; Reed College (Portland, Oregon, USA); National Institute of Mental Health [1-F32-MH071137-01] FX This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and Clinical Sciences Research and Development. JML and MSH are supported by career development awards from the Department of Veterans Affairs, Veterans Health Administration. This work was also supported by Reed College (Portland, Oregon, USA) and the National Institute of Mental Health (# 1-F32-MH071137-01). The authors would also like to thank Bristol-Myers Squibb for generously providing the DMP904. NR 76 TC 5 Z9 6 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 EI 1873-7064 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD JAN PY 2012 VL 62 IS 1 SI SI BP 313 EP 321 DI 10.1016/j.neuropharm.2011.07.040 PG 9 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 845MM UT WOS:000296826800035 PM 21839099 ER PT J AU Anaya, DA Cormier, JN Xing, Y Koller, P Gaido, L Hadfield, D Chemaly, RF Feig, BW AF Anaya, Daniel A. Cormier, Janice N. Xing, Yan Koller, Paul Gaido, Lindsay Hadfield, Donna Chemaly, Roy F. Feig, Barry W. TI Development and Validation of a Novel Stratification Tool for Identifying Cancer Patients at Increased Risk of Surgical Site Infection SO ANNALS OF SURGERY LA English DT Article ID LYMPH-NODE BIOPSY; WOUND-INFECTION; SURVEILLANCE NETWORK; POSTOPERATIVE COMPLICATIONS; POSTDISCHARGE SURVEILLANCE; ANTIBIOTIC-PROPHYLAXIS; MALIGNANT-MELANOMA; ABDOMINAL-SURGERY; CARDIAC-SURGERY; SYSTEM AB Objective: To identify cancer-specific predictors of postoperative surgical site infection (SSI), and to develop a risk-stratification prognostic tool and compare its performance with traditional measures. Background: The incidence and risk factors for SSI in cancer patients are unknown; current risk-stratification tools are not cancer-specific. Methods: A prospective cohort study of patients undergoing elective operations (n = 503) at a tertiary cancer center was conducted. SSI was assessed using postdischarge active surveillance. Multivariate logistic regression analyses were performed to identify predictors of SSI, and beta-coefficients were used to create a scoring system. The sum of these was used to create a Risk of Surgical Site Infection in Cancer (RSSIC) score. The RSSIC was validated using bootstrapping techniques, and its discrimination was compared with the National Nosocomial Infection Surveillance (NNIS) risk index. Results: The 30-day SSI incidence was 24%. Significant predictors of SSI included preoperative chemotherapy (OR = 1.94 [95% CI, 1.16-3.25]), clean-contaminated wounds (OR = 2.1 [95% CI, 1.24-3.55]), operative time = 2 hours (OR = 1.75 [95% CI, 1.01-3.04]) and = 4 hours (OR = 2.24 [95% CI, 1.22-4.1]), and surgical site: groin (OR = 4.65 [95% CI, 1.69-12.83]), and head/neck (OR = 0.12 [95% CI, 0.02-0.89]). The RSSIC score stratified patients into 4 risk strata for SSI. The performance of this score exceeded that of the NNIS score (AUC = 0.70 vs. 0.63, respectively; P = 0.01). Conclusion: SSIs are common following cancer surgery. Preoperative chemotherapy, in addition to other common risk factors, was identified as a significant predictor for SSI in cancer patients. The RSSIC improves risk-stratification of cancer patients and identifies those that may benefit from more aggressive or novel preventive strategies. C1 [Anaya, Daniel A.] Michael E DeBakey Dept Surg Surg Oncol, Houston, TX USA. [Anaya, Daniel A.] Baylor Coll Med, Houston Hlth Serv, Houston, TX 77030 USA. [Anaya, Daniel A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Res Ctr Excellence, Houston, TX 77030 USA. [Cormier, Janice N.; Xing, Yan; Koller, Paul; Feig, Barry W.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA. [Gaido, Lindsay; Hadfield, Donna] Univ Texas MD Anderson Canc Ctr, Dept Nursing, Houston, TX 77030 USA. [Chemaly, Roy F.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA. RP Anaya, DA (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM danaya@bcm.edu FU Houston VA HSR&D Center of Excellence [HFP90-020] FX This work was supported in part by the Houston VA HSR&D Center of Excellence (HFP90-020). The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. NR 43 TC 6 Z9 10 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD JAN PY 2012 VL 255 IS 1 BP 134 EP 139 DI 10.1097/SLA.0b013e31823dc107 PG 6 WC Surgery SC Surgery GA 869ZM UT WOS:000298638900021 PM 22143206 ER PT J AU Bains, SS Egede, LE AF Bains, Sujeev S. Egede, Leonard E. TI Association of Health Literacy with Complementary and Alternative Medicine Use: A Cross-Sectional Study in Adult Primary Care Patients SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID QUALITY-OF-LIFE; BREAST-CANCER; SELF-CARE; CAM USE; ADHERENCE; MEDICATION; THERAPIES; KNOWLEDGE; OUTCOMES; HYPERTENSION AB Background: In the United States, it is estimated that 40% of adults utilize complementary and alternative medicine (CAM) therapies. Recently, national surveys report that over 90 million adults have inadequate health literacy. To date, no study has assessed health literacy and its effect on CAM use. The primary objective of this study was to assess the relationship between health literacy and CAM use independent of educational attainment. Second objective was to evaluate the differential effect of health literacy on CAM use by race. Methods: 351 patients were recruited from an outpatient primary care clinic. Validated surveys assessed CAM use (I-CAM-Q), health literacy (REALM-R), and demographic information. We compared demographics by health literacy (adequate vs. inadequate) and overall and individual CAM categories by health literacy using chi square statistics. We found a race by health literacy interaction and ran sequential logistic regression models stratified by race to test the association between health literacy and overall CAM use (Model 1), Model 1 + education (Model 2), and Model 2 + other demographic characteristics (Model 3). We reported the adjusted effect of health literacy on CAM use for both whites and African Americans separately. Results: 75% of the participants had adequate literacy and 80% used CAM. CAM use differed by CAM category. Among whites, adequate health literacy was significantly associated with increased CAM use in both unadjusted (Model 1, OR 7.68; p = 0.001) and models adjusted for education (Model 2, OR 7.70; p = 0.002) and other sociodemographics (Model 3, OR 9.42; p = 0.01). Among African Americans, adequate health literacy was not associated with CAM use in any of the models. Conclusions: We found a race by literacy interaction suggesting that the relationship between health literacy and CAM use differed significantly by race. Adequate health literacy among whites is associated with increased CAM use, but not associated with CAM use in African Americans. C1 [Bains, Sujeev S.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29401 USA. [Bains, Sujeev S.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK NIH HHS [K24 DK093699, T35 DK007431] NR 41 TC 11 Z9 11 U1 2 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6882 J9 BMC COMPLEM ALTERN M JI BMC Complement. Altern. Med. PD DEC 30 PY 2011 VL 11 AR 138 DI 10.1186/1472-6882-11-138 PG 7 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 890LF UT WOS:000300145400001 PM 22208873 ER PT J AU Newman, JC Feldman, R AF Newman, John C. Feldman, Robin TI Copyright and Open Access at the Bedside SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Newman, John C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. [Newman, John C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Feldman, Robin] Univ Calif Hastings Coll Law, Law & Biosci Project, San Francisco, CA USA. RP Newman, JC (reprint author), San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. RI Newman, John/L-8112-2013 NR 4 TC 23 Z9 23 U1 0 U2 12 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 29 PY 2011 VL 365 IS 26 BP 2447 EP 2449 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 868SD UT WOS:000298544600002 PM 22204721 ER PT J AU Wong, ES Wang, BCM Garrison, LP Alfonso-Cristancho, R Flum, DR Arterburn, DE Sullivan, SD AF Wong, Edwin S. Wang, Bruce C. M. Garrison, Louis P. Alfonso-Cristancho, Rafael Flum, David R. Arterburn, David E. Sullivan, Sean D. TI Examining the BMI-mortality relationship using fractional polynomials SO BMC MEDICAL RESEARCH METHODOLOGY LA English DT Article ID BODY-MASS INDEX; ALL-CAUSE MORTALITY; FOLLOW-UP; EXCESS MORTALITY; LIFE EXPECTANCY; UNITED-STATES; OLDER-ADULTS; OBESITY; WEIGHT; WOMEN AB Background: Many previous studies estimating the relationship between body mass index (BMI) and mortality impose assumptions regarding the functional form for BMI and result in conflicting findings. This study investigated a flexible data driven modelling approach to determine the nonlinear and asymmetric functional form for BMI used to examine the relationship between mortality and obesity. This approach was then compared against other commonly used regression models. Methods: This study used data from the National Health Interview Survey, between 1997 and 2000. Respondents were linked to the National Death Index with mortality follow-up through 2005. We estimated 5-year all-cause mortality for adults over age 18 using the logistic regression model adjusting for BMI, age and smoking status. All analyses were stratified by sex. The multivariable fractional polynomials (MFP) procedure was employed to determine the best fitting functional form for BMI and evaluated against the model that includes linear and quadratic terms for BMI and the model that groups BMI into standard weight status categories using a deviance difference test. Estimated BMI-mortality curves across models were then compared graphically. Results: The best fitting adjustment model contained the powers -1 and -2 for BMI. The relationship between 5-year mortality and BMI when estimated using the MFP approach exhibited a J-shaped pattern for women and a U-shaped pattern for men. A deviance difference test showed a statistically significant improvement in model fit compared to other BMI functions. We found important differences between the MFP model and other commonly used models with regard to the shape and nadir of the BMI-mortality curve and mortality estimates. Conclusions: The MFP approach provides a robust alternative to categorization or conventional linear-quadratic models for BMI, which limit the number of curve shapes. The approach is potentially useful in estimating the relationship between the full spectrum of BMI values and other health outcomes, or costs. C1 [Wong, Edwin S.; Wang, Bruce C. M.; Garrison, Louis P.; Alfonso-Cristancho, Rafael; Sullivan, Sean D.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA. [Wong, Edwin S.] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA. [Flum, David R.] Univ Washington, Surg Outcomes Res Ctr, Seattle, WA 98195 USA. [Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA. RP Wong, ES (reprint author), Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA. EM eswong@uw.edu FU HQ Air Force Surgeon General [FA7014-08-2-0002]; U.S. Air Force; Department of Veterans Affairs [TPP 61-024] FX This paper was written for the Bariatric Obesity Outcome Modeling Collaborative. Members are listed at the end of the manuscript. This work was supported by the HQ Air Force Surgeon General under Award No. FA7014-08-2-0002. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Air Force. Dr. Wong was supported by the Department of Veterans Affairs, Health Services Research and Development Post-Doctoral Fellowship TPP 61-024. NR 41 TC 15 Z9 15 U1 1 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2288 J9 BMC MED RES METHODOL JI BMC Med. Res. Methodol. PD DEC 28 PY 2011 VL 11 AR 175 DI 10.1186/1471-2288-11-175 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 890SQ UT WOS:000300165600001 PM 22204699 ER PT J AU Mathes, DW Hwang, B Graves, SS Edwards, J Chang, J Storer, BE Butts-Miwongtum, T Sale, GE Nash, RA Storb, R AF Mathes, David W. Hwang, Billanna Graves, Scott S. Edwards, James Chang, Jeff Storer, Barry E. Butts-Miwongtum, Tiffany Sale, George E. Nash, Richard A. Storb, Rainer TI Tolerance to Vascularized Composite Allografts in Canine Mixed Hematopoietic Chimeras SO TRANSPLANTATION LA English DT Article DE Dog; Nonmyeloablative conditioning regimen; Mixed hematopoietic chimerism; Skin grafting; Hematopoietic cell transplantation; CTA transplantation; FoxP3; Tolerance; Vascularized Composite Allograft ID TISSUE ALLOTRANSPLANT SURVIVAL; MESENCHYMAL STEM-CELLS; TOTAL-BODY IRRADIATION; REGULATORY T-CELLS; LARGE-ANIMAL-MODEL; PHARMACOLOGICAL IMMUNOSUPPRESSION; TRANSPLANTATION TOLERANCE; MARROW TRANSPLANTATION; ADOPTIVE IMMUNOTHERAPY; MOLECULAR ANALYSIS AB Background. Mixed donor-host chimerism, established through hematopoietic cell transplantation (HCT), is a reproducible strategy for the induction of tolerance toward solid organs. Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed donor-host chimerism leads to tolerance of antigenic vascularized composite allografts. Methods. Stable mixed chimerism was established in dogs given a sublethal dose (1-2 Gy) total body irradiation before and a short course of immunosuppression after dog leukocyte antigen-identical marrow transplantation. Vascularized composite allografts from marrow donors were performed after a median of 36 months (range, 4-54 months) after HCT. Results. All marrow recipients maintained mixed donor-host hematopoietic chimerism and accepted vascularized composite allografts for periods ranging between 52 and 90 weeks; in turn, marrow donors rejected vascularized composite allografts from their respective marrow recipients within 18 to 29 days. Biopsies of muscle and skin of vascularized composite allografts from mixed chimeras showed few infiltrating cells compared with extensive infiltrates in biopsies of vascularized composite allografts from marrow donors. Elevated levels of CD3+ FoxP3+ T-regulatory cells were found in skin and muscle of vascularized composite allografts of mixed chimeras compared with normal tissues. In mixed chimeras, increased numbers of T-regulatory cells were found in draining compared with nondraining lymph nodes of vascularized composite allografts. Conclusions. These data suggest that nonmyeloablative HCT may form the basis for future clinical applications of solid organ transplantation and that T-regulatory cells may function toward maintenance of the vascularized composite allograft. C1 [Mathes, David W.; Hwang, Billanna; Graves, Scott S.; Chang, Jeff; Storer, Barry E.; Butts-Miwongtum, Tiffany; Sale, George E.; Nash, Richard A.; Storb, Rainer] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Mathes, David W.; Edwards, James; Chang, Jeff] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Graves, Scott S.; Nash, Richard A.; Storb, Rainer] Univ Washington, Dept Med, Seattle, WA USA. [Storer, Barry E.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Sale, George E.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Mathes, David W.] VA Puget Sound Hlth Care Syst, Plast Surg Serv, Seattle, WA USA. RP Mathes, DW (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, POB 19024,D1-100,1100 Fairview Ave N, Seattle, WA 98109 USA. EM dmathes@fhcrc.org FU National Institutes of Health, Bethesda, MD [P01CA078902, P30CA015704]; National Endowment for Plastic Surgery; Plastic Surgery Educational Foundation FX This work was supported by the National Institutes of Health, Bethesda, MD, grants P01CA078902 and P30CA015704.; David Mathes received support from the National Endowment for Plastic Surgery Grant from the Plastic Surgery Educational Foundation. Other authors declare no conflicts of interest. NR 50 TC 27 Z9 27 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD DEC 27 PY 2011 VL 92 IS 12 BP 1301 EP 1308 DI 10.1097/TP.0b013e318237d6d4 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 863FW UT WOS:000298149200007 PM 22082819 ER PT J AU Khodyakov, D Hempel, S Rubenstein, L Shekelle, P Foy, R Salem-Schatz, S O'Neill, S Danz, M Dalal, S AF Khodyakov, Dmitry Hempel, Susanne Rubenstein, Lisa Shekelle, Paul Foy, Robbie Salem-Schatz, Susanne O'Neill, Sean Danz, Margie Dalal, Siddhartha TI Conducting Online Expert panels: a feasibility and experimental replicability study SO BMC MEDICAL RESEARCH METHODOLOGY LA English DT Article ID DELPHI TECHNIQUE; GUIDELINE DEVELOPMENT; CONSENSUS METHODS AB Background: This paper has two goals. First, we explore the feasibility of conducting online expert panels to facilitate consensus finding among a large number of geographically distributed stakeholders. Second, we test the replicability of panel findings across four panels of different size. Method: We engaged 119 panelists in an iterative process to identify definitional features of Continuous Quality Improvement (CQI). We conducted four parallel online panels of different size through three one-week phases by using the RAND's ExpertLens process. In Phase I, participants rated potentially definitional CQI features. In Phase II, they discussed rating results online, using asynchronous, anonymous discussion boards. In Phase III, panelists re-rated Phase I features and reported on their experiences as participants. Results: 66% of invited experts participated in all three phases. 62% of Phase I participants contributed to Phase II discussions and 87% of them completed Phase III. Panel disagreement, measured by the mean absolute deviation from the median (MAD-M), decreased after group feedback and discussion in 36 out of 43 judgments about CQI features. Agreement between the four panels after Phase III was fair (four-way kappa = 0.36); they agreed on the status of five out of eleven CQI features. Results of the post-completion survey suggest that participants were generally satisfied with the online process. Compared to participants in smaller panels, those in larger panels were more likely to agree that they had debated each others' view points. Conclusion: It is feasible to conduct online expert panels intended to facilitate consensus finding among geographically distributed participants. The online approach may be practical for engaging large and diverse groups of stakeholders around a range of health services research topics and can help conduct multiple parallel panels to test for the reproducibility of panel conclusions. C1 [Khodyakov, Dmitry; Hempel, Susanne; Rubenstein, Lisa; Shekelle, Paul; O'Neill, Sean; Danz, Margie; Dalal, Siddhartha] RAND Corp, Santa Monica, CA 90401 USA. [Rubenstein, Lisa; Danz, Margie] Vet Affairs Greater Los Angeles Sepulveda, North Hills, CA 91343 USA. [Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9JT, W Yorkshire, England. [Salem-Schatz, Susanne] HealthCare Qual Initiat, Newton, MA 02459 USA. [O'Neill, Sean] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. RP Khodyakov, D (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90401 USA. EM Dmitry_Khodyakov@rand.org OI O'Neill, Sean/0000-0001-7759-8942 FU Robert Wood Johnson Foundation [65113, 67890]; RAND Corporation; Veterans Health Administration FX This study was supported by the Robert Wood Johnson Foundation (Grant ID 65113: Advancing the science of continuous quality improvement: A framework for identifying, classifying and evaluating continuous quality improvement studies and Grant ID 67890: Providing a framework for the identification, classification, and evaluation of quality improvement initiatives) and the RAND Corporation, with additional funding provided by the Veterans Health Administration. NR 30 TC 15 Z9 15 U1 4 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2288 J9 BMC MED RES METHODOL JI BMC Med. Res. Methodol. PD DEC 23 PY 2011 VL 11 AR 174 DI 10.1186/1471-2288-11-174 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 921FJ UT WOS:000302463200001 PM 22196011 ER PT J AU Needham, PG Mikoluk, K Dhakarwal, P Khadem, S Snyder, AC Subramanya, AR Brodsky, JL AF Needham, Patrick G. Mikoluk, Kasia Dhakarwal, Pradeep Khadem, Shaheen Snyder, Avin C. Subramanya, Arohan R. Brodsky, Jeffrey L. TI The Thiazide-sensitive NaCl Cotransporter Is Targeted for Chaperone-dependent Endoplasmic Reticulum-associated Degradation SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TRANSMEMBRANE CONDUCTANCE REGULATOR; INTEGRAL MEMBRANE-PROTEINS; EPITHELIAL SODIUM-CHANNELS; ER-ASSOCIATED DEGRADATION; NA+-CL-COTRANSPORTER; UBIQUITIN-LIGASE; CYSTIC-FIBROSIS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; INTRACELLULAR TRAFFICKING AB The thiazide-sensitive NaCl cotransporter (NCC, SLC12A3) mediates salt reabsorption in the distal nephron of the kidney and is the target of thiazide diuretics, which are commonly prescribed to treat hypertension. Mutations in NCC also give rise to Gitelman syndrome, a hereditary salt-wasting disorder thought in most cases to arise from impaired NCC biogenesis through enhanced endoplasmic reticulum-associated degradation (ERAD). Because the machinery that mediates NCC quality control is completely undefined, we employed yeast as a model heterologous expression system to identify factors involved in NCC degradation. We confirmed that NCC was a bona fide ERAD substrate in yeast, as the majority of NCC polypeptide was integrated into ER membranes, and its turnover rate was sensitive to proteasome inhibition. NCC degradation was primarily dependent on the ER membrane-associated E3 ubiquitin ligase Hrd1. Whereas several ER luminal chaperones were dispensable for NCC ERAD, NCC ubiquitination and degradation required the activity of Ssa1, a cytoplasmic Hsp70 chaperone. Compatible findings were observed when NCC was expressed in mammalian kidney cells, as the cotransporter was polyubiquitinated and degraded by the proteasome, and mammalian cytoplasmic Hsp70 (Hsp72) coexpression stimulated the degradation of newly synthesized NCC. Hsp70 also preferentially associated with the ER-localized NCC glycosylated species, indicating that cytoplasmic Hsp70 plays a critical role in selecting immature forms of NCC for ERAD. Together, these results provide the first survey of components involved in the ERAD of a mammalian SLC12 cation chloride cotransporter and provide a framework for future studies on NCC ER quality control. C1 [Needham, Patrick G.; Mikoluk, Kasia; Brodsky, Jeffrey L.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15261 USA. [Dhakarwal, Pradeep; Khadem, Shaheen; Snyder, Avin C.; Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA. [Khadem, Shaheen; Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. RP Needham, PG (reprint author), 3550 Terrace St,S832 Scaife Hall, Pittsburgh, PA 15261 USA. EM ars129@pitt.edu FU National Institutes of Health [DK79307, GM75061, DK84566]; United States Department of Veterans Affairs; American Heart Association [10BGIA3890010] FX This work was supported, in whole or in part, by National Institutes of Health Grants DK79307 (to the Pittsburgh Center for Kidney Research-Model Organisms Core), GM75061 (to J. L. B.), and DK84566 (to A. R. S.). This work was also supported by a Mid-Level Career Development Award from the United States Department of Veterans Affairs (to A. R. S.) and James A. Shaver Fund of the American Heart Association Grant 10BGIA3890010 (to A. R. S.). NR 64 TC 23 Z9 23 U1 1 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 23 PY 2011 VL 286 IS 51 BP 43611 EP 43621 DI 10.1074/jbc.M111.288928 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 866SH UT WOS:000298402300004 PM 22027832 ER PT J AU Sun, Q Prasad, R Rosenthal, E Katiyar, SK AF Sun, Qian Prasad, Ram Rosenthal, Eben Katiyar, Santosh K. TI Grape seed proanthocyanidins inhibit the invasive potential of head and neck cutaneous squamous cell carcinoma cells by targeting EGFR expression and epithelial-to-mesenchymal transition SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; A431 CELLS; E-CADHERIN; CANCER; FLUOROURACIL; PROGRESSION; ACTIVATION; BERBERINE; DOCETAXEL AB Background: Head and neck squamous cell carcinoma (HNSCC) is responsible for over 20,000 deaths every year in United States. Most of the deaths are due, in large part, to its propensity to metastasize. We have examined the effect of bioactive component grape seed proanthocyanidins (GSPs) on human cutaneous HNSCC cell invasion and the molecular mechanisms underlying these effects using SCC13 cell line as an in vitro model. Methods: The therapeutic effects of GSPs on cancer cell invasion were studied using Boyden chamber and wound healing assays. The effects of GSPs on the levels of various proteins related with cancer cell invasion were determined using western blot analysis. Results: Using in vitro cell invasion assays, we observed that treatment of SCC13 cells with GSPs resulted in a concentration-dependent inhibition of cell invasion of these cells, which was associated with a reduction in the levels of epidermal growth factor receptor (EGFR). Treatment of cells with gefitinib and erlotinib, inhibitors of EGFR, or transient transfection of SCC13 cells with EGFR small interfering RNA, also inhibited invasion of these cells. The inhibition of cell invasion by GSPs was associated with the inhibition of the phosphorylation of ERK1/2, a member of mitogen-activated protein kinase family. Treatment of cells with UO126, an inhibitor of MEK, also inhibited the invasion potential of SCC13 cells. Additionally, inhibition of human cutaneous HNSCC cell invasion by GSPs was associated with reversal of epithelial-to-mesenchymal transition (EMT) process, which resulted in an increase in the levels of epithelial biomarker (E-cadherin) while loss of mesenchymal biomarkers (vimentin, fibronectin and N-cadherin) in cells. Similar effect on EMT biomarkers was also observed when cells were treated with erlotinib. Conclusion: The results obtained from this study indicate that grape seed proanthocyanidins have the ability to inhibit the invasion of human cutaneous HNSCC cells by targeting the EGFR expression and reversing the process of epithelial-to-mesenchymal transition. These data suggest that GSPs can be developed as a complementary and alternative medicine for the prevention of invasion/metastasis of HNSCC cells. C1 [Sun, Qian; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Rosenthal, Eben] Univ Alabama, Dept Surg Otolaryngol, Birmingham, AL USA. [Rosenthal, Eben; Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Nutr Obes Res Ctr, Birmingham, AL USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration; National Cancer Institute/NCCAM/NIH [CA140197, CA140832]; UAB Skin Diseases Research Center [AR050948-01] FX work was supported by the funds from Veterans Administration Merit Review Award (S.K.K.) and National Cancer Institute/NCCAM/NIH (CA140197, CA140832). NHEK were obtained from the UAB Skin Diseases Research Center (AR050948-01). The content of this article does not necessarily reflect the views or policies of the funding sources. NR 25 TC 18 Z9 19 U1 2 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6882 J9 BMC COMPLEM ALTERN M JI BMC Complement. Altern. Med. PD DEC 21 PY 2011 VL 11 AR 134 DI 10.1186/1472-6882-11-134 PG 12 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 876AS UT WOS:000299079800001 PM 22188922 ER PT J AU Chen, JC Brunzell, DH Jackson, K van der Vaart, A Ma, JZ Payne, TJ Sherva, R Farrer, LA Gejman, P Levinson, DF Holmans, P Aggen, SH Damaj, I Kuo, PH Webb, BT Anton, R Kranzler, HR Gelernter, J Li, MD Kendler, KS Chen, XN AF Chen, Jingchun Brunzell, Darlene H. Jackson, Kia van der Vaart, Andrew Ma, Jennie Z. Payne, Thomas J. Sherva, Richard Farrer, Lindsay A. Gejman, Pablo Levinson, Douglas F. Holmans, Peter Aggen, Steven H. Damaj, Imad Kuo, Po-Hsiu Webb, Bradley T. Anton, Raymond Kranzler, Henry R. Gelernter, Joel Li, Ming D. Kendler, Kenneth S. Chen, Xiangning TI ACSL6 Is Associated with the Number of Cigarettes Smoked and Its Expression Is Altered by Chronic Nicotine Exposure SO PLOS ONE LA English DT Article ID CANNABINOID RECEPTOR GENE; FAGERSTROM TOLERANCE QUESTIONNAIRE; GENOME-WIDE ASSOCIATION; NEUROTROPHIC FACTOR; ALCOHOL DEPENDENCE; AFRICAN-AMERICAN; ENDOCANNABINOID SYSTEM; CNR1 POLYMORPHISM; WORKING-MEMORY; HEAVY SMOKING AB Individuals with schizophrenia tend to be heavy smokers and are at high risk for tobacco dependence. However, the nature of the comorbidity is not entirely clear. We previously reported evidence for association of schizophrenia with SNPs and SNP haplotypes in a region of chromosome 5q containing the SPEC2, PDZ-GEF2 and ACSL6 genes. In this current study, analysis of the control subjects of the Molecular Genetics of Schizophrenia (MGS) sample showed similar pattern of association with number of cigarettes smoked per day (numCIG) for the same region. To further test if this locus is associated with tobacco smoking as measured by numCIG and FTND, we conducted replication and meta-analysis in 12 independent samples (n>16,000) for two markers in ACSL6 reported in our previous schizophrenia study. In the meta-analysis of the replication samples, we found that rs667437 and rs477084 were significantly associated with numCIG (p = 0.00038 and 0.00136 respectively) but not with FTND scores. We then used in vitro and in vivo techniques to test if nicotine exposure influences the expression of ACSL6 in brain. Primary cortical culture studies showed that chronic (5-day) exposure to nicotine stimulated ACSL6 mRNA expression. Fourteen days of nicotine administration via osmotic mini pump also increased ACSL6 protein levels in the prefrontal cortex and hippocampus of mice. These increases were suppressed by injection of the nicotinic receptor antagonist mecamylamine, suggesting that elevated expression of ACSL6 requires nicotinic receptor activation. These findings suggest that variations in the ACSL6 gene may contribute to the quantity of cigarettes smoked. The independent associations of this locus with schizophrenia and with numCIG in non-schizophrenic subjects suggest that this locus may be a common liability to both conditions. C1 [Chen, Jingchun; Jackson, Kia; Aggen, Steven H.; Webb, Bradley T.; Kendler, Kenneth S.; Chen, Xiangning] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23284 USA. [Chen, Jingchun; Jackson, Kia; Aggen, Steven H.; Webb, Bradley T.; Kendler, Kenneth S.; Chen, Xiangning] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA. [Brunzell, Darlene H.; Damaj, Imad] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA USA. [Brunzell, Darlene H.; Kendler, Kenneth S.] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, Richmond, VA USA. [Brunzell, Darlene H.] Virginia Commonwealth Univ, Interdisciplinary Neurosci Program, Richmond, VA USA. [van der Vaart, Andrew; Li, Ming D.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA. [Ma, Jennie Z.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA. [Payne, Thomas J.] Univ Mississippi, Med Ctr, Dept Otolaryngol & Communicat Sci, Jackson, MS 39216 USA. [Sherva, Richard; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA. [Gejman, Pablo] NorthShore Univ HealthSyst Res Inst, Ctr Psychiat Genet, Evanston, IL USA. [Levinson, Douglas F.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Holmans, Peter] Cardiff Univ, Sch Med, Med Resource Council,& Neurol,Biostat & Bioinform, Ctr Neuropsychiat Genet & Genom,Dept Psychol Med, Cardiff, S Glam, Wales. [Kuo, Po-Hsiu] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan. [Anton, Raymond] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Treatment Res Ctr, Sch Med 3900, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06510 USA. [Gelernter, Joel] Vet Affairs Connecticut Healthcare Ctr, West Haven, CT USA. [Kendler, Kenneth S.; Chen, Xiangning] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA USA. RP Chen, JC (reprint author), Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23284 USA. EM xchen@vcu.edu RI Webb, Bradley/B-1459-2009; Holmans, Peter/F-4518-2015 OI Webb, Bradley/0000-0002-0576-5366; Holmans, Peter/0000-0003-0870-9412; Farrer, Lindsay/0000-0001-5533-4225; Kuo, Po-Hsiu/0000-0003-0365-3587 FU National Institutes of Health [DA019498, DA011287]; Virginia Tobacco Settlement Foundation [5100004ST]; Virginia Foundation for Healthy Youth [8520667] FX This study was supported by grants DA019498 to XC and DA011287 to KSK from the National Institutes of Health, by funds from the Virginia Tobacco Settlement Foundation through the Virginia Youth Tobacco Project to Virginia Commonwealth University (subcontracted to KSK, #5100004ST) and by a grant from Virginia Foundation for Healthy Youth 8520667 to DHB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 86 TC 5 Z9 5 U1 4 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 20 PY 2011 VL 6 IS 12 AR e28790 DI 10.1371/journal.pone.0028790 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 870JU UT WOS:000298666200011 ER PT J AU Zulman, DM Nazi, KM Turvey, CL Wagner, TH Woods, SS An, LC AF Zulman, Donna M. Nazi, Kim M. Turvey, Carolyn L. Wagner, Todd H. Woods, Susan S. An, Larry C. TI Patient Interest in Sharing Personal Health Record Information A Web-Based Survey SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID SHARED MEDICAL-RECORD; SATISFACTION; EXCHANGE AB Background: Electronic personal health record (PHR) systems are proliferating but largely have not realized their potential for enhancing communication among patients and their network of care providers. Objective: To explore preferences about sharing electronic health information among users of the U.S. Department of Veterans Affairs (VA) PHR system, My HealtheVet. Design: Web-based survey of a convenience sample. Setting: My HealtheVet Web site from 7 July through 4 October 2010. Participants: 18 471 users of My HealtheVet. Measurements: Interest in shared PHR access and preferences about who would receive access, the information that would be shared, and the activities that users would delegate. Results: Survey respondents were predominantly men (92%) and aged 50 to 64 years (51%) or 65 years or older (39%); approximately 39% reported poor or fair health status. Almost 4 of 5 respondents (79%) were interested in sharing access to their PHR with someone outside of their health system (62% with a spouse or partner, 23% with a child, 15% with another family member, and 25% with a non-VA health care provider). Among those who selected a family member other than a spouse or partner, 47% lived apart from the specified person. Preferences about degree of access varied on the basis of the type of information being shared, the type of activity being performed, and the respondent's relationship with the selected person. Limitations: The survey completion rate was 40.8%. Results might not be generalizable to all My HealtheVet users. Conclusion: In a large survey of PHR users in the VA system, most respondents were interested in sharing access to their electronic health information with caregivers and non-VA providers. Existing and evolving PHR systems should explore secure mechanisms for shared PHR access to improve information exchange among patients and the multiple persons involved in their health care. C1 [Zulman, Donna M.] Stanford Univ, Ctr Hlth Care Evaluat, VA Palo Alto Hlth Care Syst, Menlo Pk, CA 94025 USA. Vet Rural Hlth Resource Ctr Cent Reg, Iowa City, IA USA. Vet Affairs Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA. US Dept Vet Affairs, Washington, DC USA. Vet Affairs Hlth Serv Res & Dev Serv, Portland, OR USA. Univ Michigan, Ctr Hlth Commun Res, Ann Arbor, MI 48109 USA. RP Zulman, DM (reprint author), Stanford Univ, Ctr Hlth Care Evaluat, VA Palo Alto Hlth Care Syst, 795 Willow Rd,152-MPD, Menlo Pk, CA 94025 USA. EM dzulman@stanford.edu FU Veterans Health Administration; Robert Wood Johnson Foundation FX Grant Support: By the Veterans Health Administration and The Robert Wood Johnson Foundation Clinical Scholars Program. NR 31 TC 51 Z9 51 U1 6 U2 18 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 20 PY 2011 VL 155 IS 12 BP 805 EP U46 DI 10.7326/0003-4819-155-12-201112200-00002 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 864ZU UT WOS:000298280500014 PM 22184687 ER PT J AU Frazier-Wood, AC Glasser, S Garvey, WT Kabagambe, EK Borecki, IB Tiwari, HK Tsai, MY Hopkins, PN Ordovas, JM Arnett, DK AF Frazier-Wood, Alexis C. Glasser, Stephen Garvey, W. Timothy Kabagambe, Edmond K. Borecki, Ingrid B. Tiwari, Hemant K. Tsai, Michael Y. Hopkins, Paul N. Ordovas, Jose M. Arnett, Donna K. TI A clustering analysis of lipoprotein diameters in the metabolic syndrome SO LIPIDS IN HEALTH AND DISEASE LA English DT Article DE lipoprotein particle diameter; insulin resistance; nuclear resonance spectroscopy; Metabolic Syndrome; latent class analysis; GOLDN; waist circumference; hypertension; hypertriglyceridemia; fasting glucose ID NUCLEAR-MAGNETIC-RESONANCE; INSULIN-RESISTANCE ATHEROSCLEROSIS; LDL SIZE; PARTICLE-SIZE; MEN; HYPERINSULINEMIA; DISEASE AB Background: The presence of smaller low-density lipoproteins (LDL) has been associated with atherosclerosis risk, and the insulin resistance (IR) underlying the metabolic syndrome (MetS). In addition, some research has supported the association of very low-, low-and high-density lipoprotein (VLDL HDL) particle diameters with components of the metabolic syndrome (MetS), although this has been the focus of less research. We aimed to explore the relationship of VLDL, LDL and HDL diameters to MetS and its features, and by clustering individuals by their diameters of VLDL, LDL and HDL particles, to capture information across all three fractions of lipoprotein into a unified phenotype. Methods: We used nuclear magnetic resonance spectroscopy measurements on fasting plasma samples from a general population sample of 1,036 adults (mean +/- SD, 48.8 +/- 16.2 y of age). Using latent class analysis, the sample was grouped by the diameter of their fasting lipoproteins, and mixed effects models tested whether the distribution of MetS components varied across the groups. Results: Eight discrete groups were identified. Two groups (N = 251) were enriched with individuals meeting criteria for the MetS, and were characterized by the smallest LDL/HDL diameters. One of those two groups, one was additionally distinguished by large VLDL, and had significantly higher blood pressure, fasting glucose, triglycerides, and waist circumference (WC; P < .001). However, large VLDL, in the absence of small LDL and HDL particles, did not associate with MetS features. These associations held after additionally controlling for VLDL, LDL and HDL particle concentrations. Conclusions: While small LDL diameters remain associated with IR and the MetS, the occurrence of these in conjunction with a shift to overall larger VLDL diameter may identify those with the highest fasting glucose, TG and WC within the MetS. If replicated, the association of this phenotype with more severe IR-features indicated that it may contribute to identifying of those most at risk for incident type II diabetes and cardiometabolic disease. C1 [Frazier-Wood, Alexis C.; Kabagambe, Edmond K.; Arnett, Donna K.] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Frazier-Wood, Alexis C.; Tiwari, Hemant K.] Univ Alabama, Dept Biostat, Sect Stat Genet, Sch Publ Hlth, Birmingham, AL 35294 USA. [Glasser, Stephen] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. [Kabagambe, Edmond K.; Arnett, Donna K.] Univ Alabama, Sch Publ Hlth, Nutr Obes Res Ctr, Birmingham, AL 35294 USA. [Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet, Div Stat Genom, St Louis, MO 63110 USA. [Tsai, Michael Y.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Hopkins, Paul N.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA. [Ordovas, Jose M.] Tufts Univ, JM USDA HNRCA, Boston, MA 02111 USA. [Ordovas, Jose M.] CNIC, Dept Epidemiol & Populat Genet, Madrid, Spain. [Ordovas, Jose M.] IMDEA Food, Madrid, Spain. RP Frazier-Wood, AC (reprint author), Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. EM LekkiWood@Gmail.com RI Frazier-Wood, Alexis (Lekki)/B-8053-2010 OI Frazier-Wood, Alexis (Lekki)/0000-0001-7616-2119 FU NHLBI [U01HL072524] FX This study was funded by NHLBI grant number U01HL072524. Financial disclosures: None to declare. Disclosure: All authors declare that they have no conflicts of interests. NR 19 TC 3 Z9 4 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-511X J9 LIPIDS HEALTH DIS JI Lipids Health Dis. PD DEC 19 PY 2011 VL 10 AR 237 DI 10.1186/1476-511X-10-237 PG 8 WC Biochemistry & Molecular Biology; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Nutrition & Dietetics GA 878SQ UT WOS:000299277300001 PM 22182248 ER PT J AU Hooker, CI Bruce, L Lincoln, SH Fisher, M Vinogradov, S AF Hooker, Christine I. Bruce, Lori Lincoln, Sarah Hope Fisher, Melissa Vinogradov, Sophia TI Theory of Mind Skills Are Related to Gray Matter Volume in the Ventromedial Prefrontal Cortex in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Empathy; mentalizing; MRI; schizophrenia; social functioning; theory of mind ID VOXEL-BASED MORPHOMETRY; FRONTAL-LOBE PATHOLOGY; SOCIAL COGNITION; 1ST-EPISODE SCHIZOPHRENIA; PROGRESSIVE DECREASE; EMPATHIC ABILITIES; NEURAL BASIS; BRAIN; METAANALYSIS; RECOGNITION AB Background: Among individuals with schizophrenia, deficits in theory of mind (ToM) skills predict poor social functioning. Therefore, identifying the neural basis of ToM may assist the development of treatments that improve social outcomes. Despite growing evidence that the ventromedial prefrontal cortex (VMPFC) facilitates ToM skills among healthy individuals, methodological challenges, such as the influence of general cognitive deficits, have made it difficult to identify the relationship between ToM processing and VMPFC function in schizophrenia. Methods: We used voxel-based morphometry and a multi-method behavioral assessment of ToM processing, including performance-based (Recognition of Faux Pas Test), self-report (Interpersonal Reactivity Index, Perspective-Taking), and interview-rated (Quality of Life Scale-Empathy score) ToM assessments, to investigate whether ToM skills were related to VMPFC gray matter volume (GMV). Standardized neuropsychological measures were used to assess global cognition. Twenty-one schizophrenia and 17 healthy control subjects participated. Results: Between-group behavioral analyses showed that, as compared with healthy participants, schizophrenia participants had worse ToM performance and lower self-reported ToM processing in daily life. The between-group analysis of GMV showed that schizophrenia participants had less VMPFC GMV than healthy participants. Moreover, among schizophrenia participants, all three measures of ToM processing were associated with VMPFC GMV, such that worse ToM skills were related to less VMPFC GMV. This association remained strong for self-reported and interview-rated ToM skills, even when controlling for the influence of global cognition. Conclusions: The findings suggest that among individuals with schizophrenia, reduced VMPFC GMV is associated with deficits using ToM skills to enhance social relationships. C1 [Hooker, Christine I.; Bruce, Lori; Lincoln, Sarah Hope] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Fisher, Melissa; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Fisher, Melissa; Vinogradov, Sophia] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA. RP Hooker, CI (reprint author), Harvard Univ, Dept Psychol, 820 William James Hall,33 Kirkland St, Cambridge, MA 02138 USA. EM chooker@wjh.harvard.edu FU National Alliance for Research on Schizophrenia and Depression Young Investigator Award; National Institute of Mental Health [MH71746, MH68725-02]; Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Grant FX This work was supported by a National Alliance for Research on Schizophrenia and Depression Young Investigator Award (CIH) and National Institute of Mental Health Grants MH71746 (CIH) and MH68725-02 (SV).; Sophia Vinogradov is a paid consultant on an National Institute of Mental Health Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Grant to Brain Plasticity Inc. Christine Hooker, Melissa Fisher, Lori Bruce, and Sarah Hope Lincoln report no biomedical financial interests or potential conflicts of interest. NR 87 TC 42 Z9 44 U1 4 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD DEC 15 PY 2011 VL 70 IS 12 BP 1169 EP 1178 DI 10.1016/j.biopsych.2011.07.027 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 860WW UT WOS:000297980000012 PM 21917239 ER PT J AU Lipsky, BA Hoey, CT Byren, I AF Lipsky, Benjamin A. Hoey, Christopher T. Byren, Ivor TI Chronic Bacterial Prostatitis: Enterococcal Disease? Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID URINARY-TRACT-INFECTIONS; MOXIFLOXACIN; DAPTOMYCIN; RESISTANCE C1 [Lipsky, Benjamin A.] Univ Washington, Gen Med Serv, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Hoey, Christopher T.] VA Puget Sound Hlth Care Syst, Serv Pharm, Seattle, WA USA. [Byren, Ivor] Univ Oxford, Dept Med, Oxford Radcliffe Hosp, Oxford OX1 2JD, England. RP Lipsky, BA (reprint author), Univ Washington, Gen Med Serv, Dept Med, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S GMS 123, Seattle, WA 98108 USA. EM balipsky@uw.edu OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 13 TC 1 Z9 1 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 15 PY 2011 VL 53 IS 12 BP 1307 EP U170 DI 10.1093/cid/cir715 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 851OF UT WOS:000297279700031 ER PT J AU Jani, A Epperson, E Martin, J Pacic, A Ljubanovic, D Martin, SL Edelstein, CL AF Jani, Alkesh Epperson, Elaine Martin, Jessica Pacic, Arijana Ljubanovic, Danica Martin, Sandra L. Edelstein, Charles L. TI Renal Protection From Prolonged Cold Ischemia and Warm Reperfusion in Hibernating Squirrels SO TRANSPLANTATION LA English DT Article DE Cold ischemia; Warm reperfusion; Hibernation ID ARCTIC GROUND-SQUIRRELS; ISCHEMIA/REPERFUSION INJURY; ACCIDENTAL HYPOTHERMIA; SUSPENDED ANIMATION; HYDROGEN-SULFIDE; LOW-TEMPERATURE; APOPTOSIS; KIDNEY; PRESERVATION; SURVIVAL AB Background. We have previously shown that cold ischemia (CI) results in massive increases in caspase-3 activity, tubular apoptosis, and brush border injury (BBI) in mouse kidneys. During hibernation, the 13-lined ground squirrel (GS) cycles through repeated CI during torpor, followed by warm ischemia/reperfusion (WI) during interbout arousal (IBA). We sought to determine whether CI and WI during hibernation caused caspase-3 activation, tubular apoptosis, acute tubular necrosis, or BBI, and reduced renal function. We also determined whether protection was dependent on the stage of hibernation. Methods. Radiotelemeters were implanted in 1-year-old GS, and core body temperature was remotely monitored. GS kidneys at various stages of hibernation were subjected to ex vivo CI. Results. Tubular apoptosis was not detected and caspase-3-like activity was not different between hibernating and summer kidneys. Despite prolonged CI followed by WI and reperfusion, acute tubular necrosis and apoptosis did not occur in hibernating kidneys. BBI was absent in torpid kidneys but significantly increased in IBA kidneys and associated with an increase in caspase-3-like activity, suggesting that IBA kidneys are more susceptible to injury than summer or torpid kidneys. Renal function and urine concentrating ability diminished during torpor but returned during IBA. Conclusions. Despite BBI, IBA kidneys clear serum creatinine and concentrate urine. Kidneys from both summer and hibernating animals tolerated ex vivo CI, confirming that protection from apoptotic and necrotic cell death is independent of the stage of hibernation. An understanding of how renal protection occurs during hibernation may help in understanding the pathophysiology of delayed graft function. C1 [Jani, Alkesh; Martin, Jessica; Edelstein, Charles L.] Univ Colorado, Div Renal Dis & Hypertens, Aurora, CO 80262 USA. [Jani, Alkesh; Martin, Jessica; Edelstein, Charles L.] Univ Colorado, Denver Vet Affairs Med Ctr, Aurora, CO 80262 USA. [Epperson, Elaine; Martin, Sandra L.] Univ Colorado, Dept Cell & Dev Biol, Aurora, CO 80262 USA. [Pacic, Arijana; Ljubanovic, Danica] Univ Zagreb, Sch Med, Dept Pathol, Zagreb Univ Hosp Dubrava, Zagreb 41001, Croatia. RP Jani, A (reprint author), Univ Colorado, Div Renal Dis & Hypertens, Anschutz Med Campus,Box C281,12700 East,19th Ave, Aurora, CO 80262 USA. EM alkesh.jani@ucdenver.edu FU NIH [K08DK69512, R01-HL-089049, RO1-DK-056851, RO1-DK-074835] FX This study was supported by NIH grants K08DK69512 (A.J.), R01-HL-089049 (S. L. M.), and RO1-DK-056851 and RO1-DK-074835 (C. L. E.). NR 44 TC 16 Z9 18 U1 2 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD DEC 15 PY 2011 VL 92 IS 11 BP 1215 EP 1221 DI 10.1097/TP.0b013e3182366401 PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 853DP UT WOS:000297406700010 PM 22082817 ER PT J AU Hershman, DL Wilde, ET Wright, JD Buono, DL Kalinsky, K Malin, J Tsai, WY Neugut, AL AF Hershman, D. L. Wilde, E. T. Wright, J. D. Buono, D. L. Kalinsky, K. Malin, J. Tsai, W. Y. Neugut, A. L. TI Uptake and Economic Impact of First-Cycle Colony Stimulating Factor Use during the Adjuvant Treatment of Breast Cancer. SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Hershman, D. L.; Wilde, E. T.; Wright, J. D.; Buono, D. L.; Kalinsky, K.; Malin, J.; Tsai, W. Y.; Neugut, A. L.] Columbia Univ, New York, NY USA. Mailman Sch Publ Hlth, New York, NY USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD DEC 15 PY 2011 VL 71 SU 24 MA PID06-04 DI 10.1158/0008-5472.SABCS11-P006-04 PG 1 WC Oncology SC Oncology GA V43RZ UT WOS:000209699800108 ER PT J AU Luoh, SW Ramsey, B Park, B Keenan, E AF Luoh, S-W Ramsey, B. Park, B. Keenan, E. TI Borderline Estrogen and Progesterone Receptor Expression and Efficacy of Anti-Estrogen Therapy Analyzed by Subpopulation Treatment Effect Pattern Plot Analysis SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Luoh, S-W; Ramsey, B.; Park, B.; Keenan, E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD DEC 15 PY 2011 VL 71 SU 24 MA P5-13-19 DI 10.1158/0008-5472.SABCS11-P5-13-19 PG 1 WC Oncology SC Oncology GA V43RZ UT WOS:000209699802089 ER PT J AU Bachmann, LH Hobbs, MM Sena, AC Sobel, JD Schwebke, JR Krieger, JN McClelland, RS Workowski, KA AF Bachmann, Laura H. Hobbs, Marcia M. Sena, Arlene C. Sobel, Jack D. Schwebke, Jane R. Krieger, John N. McClelland, R. Scott Workowski, Kimberly A. TI Trichomonas vaginalis Genital Infections: Progress and Challenges SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED INFECTIONS; RANDOMIZED CLINICAL-TRIAL; SINGLE-DOSE TREATMENT; HIV-NEGATIVE WOMEN; RISK-FACTORS; METRONIDAZOLE; TINIDAZOLE; PREVALENCE; URETHRITIS AB Trichomonas vaginalis (TV) infection is the most prevalent curable sexually transmitted infection in the United States and worldwide. Most TV infections are asymptomatic, and the accurate diagnosis of this infection has been limited by lack of sufficiently sensitive and specific diagnostic tests, particularly for men. To provide updates for the 2010 Centers for Disease Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines, a PubMed search was conducted of all TV literature published from 9 January 2004 through 24 September 2008. Approximately 175 pertinent abstracts and articles were reviewed and discussed with national experts. This article describes advances in TV diagnostics which have led to an improved understanding of the epidemiology of this pathogen, as well as potential biologic and epidemiological interactions between TV and human immunodeficiency virus (HIV). New data on treatment outcomes, metronidazole-resistant TV, management of nitroimidazole-allergic patients, frequency of recurrent TV infection following treatment, and screening considerations for TV in certain populations are also presented. C1 [Bachmann, Laura H.] Wake Forest Univ Hlth Sci, Infect Dis Sect, Winston Salem, NC 27157 USA. [Bachmann, Laura H.] WG Bill Hefner Med Ctr, Infect Dis Sect, Salisbury, CT USA. [Sena, Arlene C.] Univ N Carolina, Dept Med, Div Infect Dis, Chapel Hill, NC USA. [Hobbs, Marcia M.] Univ N Carolina, Dept Microbiol, Chapel Hill, NC USA. [Hobbs, Marcia M.] Univ N Carolina, Dept Immunol, Chapel Hill, NC USA. [Sobel, Jack D.] Wayne State Univ, Dept Med, Div Infect Dis, Detroit, MI 48202 USA. [Schwebke, Jane R.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Krieger, John N.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Krieger, John N.] VA Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA USA. [McClelland, R. Scott] Univ Washington, Dept Med, Seattle, WA USA. [McClelland, R. Scott] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [McClelland, R. Scott] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Workowski, Kimberly A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Workowski, Kimberly A.] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. RP Bachmann, LH (reprint author), Wake Forest Univ Hlth Sci, Infect Dis Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM lbachman@wfubmc.edu FU Centers for Disease Control and Prevention FX This article was published as part of a supplement entitled "Sexually Transmitted Disease Treatment Guidelines" sponsored by the Centers for Disease Control and Prevention. NR 73 TC 36 Z9 39 U1 1 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 15 PY 2011 VL 53 SU 3 BP S160 EP S172 DI 10.1093/cid/cir705 PG 13 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 847MY UT WOS:000296978200012 PM 22080269 ER PT J AU Giardina, TD Singh, H AF Giardina, Traber Davis Singh, Hardeep TI Should Patients Get Direct Access to Their Laboratory Test Results? An Answer With Many Questions SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID FOLLOW-UP; RECORDS; MAIL C1 Houston Vet Affairs Hlth Serv Res & Dev, Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu OI Davis Giardina, Traber/0000-0002-9184-6524 NR 10 TC 8 Z9 8 U1 2 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 14 PY 2011 VL 306 IS 22 BP 2502 EP 2503 DI 10.1001/jama.2011.1797 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 860YB UT WOS:000297983300025 ER PT J AU Walter, LC AF Walter, Louise C. TI What Is the Right Cancer Screening Rate for Older Adults? SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID AGE 80 YEARS; WOMEN; MAMMOGRAPHY; BURDENS C1 [Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. [Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Walter, LC (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,181G, San Francisco, CA 94121 USA. EM louise.walter@ucsf.edu FU NCI NIH HHS [R01 CA134425, CA134425] NR 10 TC 7 Z9 7 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD DEC 12 PY 2011 VL 171 IS 22 BP 2037 EP 2039 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 860VD UT WOS:000297975100012 PM 22158574 ER PT J AU Finlay-Schultz, J Canastar, A Short, M El Gazzar, M Coughlan, C Leonard, S AF Finlay-Schultz, Jessica Canastar, Andrew Short, Margaret El Gazzar, Mohamed Coughlan, Christina Leonard, Sherry TI Transcriptional Repression of the alpha 7 Nicotinic Acetylcholine Receptor Subunit Gene (CHRNA7) by Activating Protein-2 alpha (AP-2 alpha) SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RNA-POLYMERASE-II; FACTOR AP-2; DNA-BINDING; FUNCTIONAL-CHARACTERIZATION; LINKAGE ANALYSIS; CARCINOMA-CELLS; FRONTAL-CORTEX; RETINOIC ACID; FACTOR EGR-1; SCHIZOPHRENIA AB The CHRNA7 gene, which encodes the alpha 7 nicotinic acetylcholine receptor (alpha 7*nAChR), has been implicated as a candidate gene in schizophrenia. Expression of the alpha 7*nAChR mRNA and protein are reduced in multiple regions of post-mortem brain from patients diagnosed with schizophrenia. Transcriptional regulation may therefore be an important mechanism for the regulation of this gene. A 230-bp proximal promoter fragment, necessary for transcription in cultured neuroblastoma cells, was used to study a putative AP-2 alpha binding site. Mutation of the site indicates that AP-2 alpha plays a negative role in regulating CHRNA7 transcription. This was confirmed through knockdown and overexpression of AP-2 alpha. Electrophoretic mobility shift assays (EMSAs) identified positive DNA-protein interaction at this same site, and supershift assays indicate that the complex includes AP-2 alpha. The interaction was confirmed in cells using chromatin immunoprecipitation (ChIP). DNA methylation was discovered as an anomalous mechanism for CHRNA7 regulation in one cell line. These studies suggest a role for AP-2 alpha regulation of CHRNA7 mRNA expression in multiple tissues during development. C1 [Finlay-Schultz, Jessica; Canastar, Andrew; El Gazzar, Mohamed; Leonard, Sherry] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA. [Finlay-Schultz, Jessica] Univ Colorado Denver, Dept Biochem & Mol Genet, Aurora, CO 80045 USA. [Leonard, Sherry] Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA. [Coughlan, Christina] Univ Denver, Dept Biol Sci, Denver, CO 80208 USA. [Short, Margaret; Leonard, Sherry] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Leonard, S (reprint author), Univ Colorado Denver, Dept Psychiat, Mail Stop 8344,POB 6511,Anschutz Med Campus, Aurora, CO 80045 USA. EM Sherry.Leonard@ucdenver.edu FU National Institutes of Health [DA009457, MH081177]; Veterans Affairs Medical Research Service Merit Review FX This work was supported, in whole or in part, by National Institutes of Health Grants DA009457 and MH081177 and a Veterans Affairs Medical Research Service Merit Review (to S. L.). NR 75 TC 6 Z9 6 U1 0 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 9 PY 2011 VL 286 IS 49 BP 42123 EP 42132 DI 10.1074/jbc.M111.276014 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 863QI UT WOS:000298180900023 PM 21979958 ER PT J AU Jayaraman, T Tejero, J Chen, BB Blood, AB Frizzell, S Shapiro, C Tiso, M Hood, BL Wang, XD Zhao, XJ Conrads, TP Mallampalli, RK Gladwin, MT AF Jayaraman, Thottala Tejero, Jesus Chen, Bill B. Blood, Arlin B. Frizzell, Sheila Shapiro, Calli Tiso, Mauro Hood, Brian L. Wang, Xunde Zhao, Xuejun Conrads, Thomas P. Mallampalli, Rama K. Gladwin, Mark T. TI 14-3-3 Binding and Phosphorylation of Neuroglobin during Hypoxia Modulate Six-to-Five Heme Pocket Coordination and Rate of Nitrite Reduction to Nitric Oxide SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INDUCIBLE FACTOR-1-ALPHA; OXIDATIVE STRESS; GLOBIN FAMILY; PROTEIN; BRAIN; CYTOGLOBIN; ACTIVATION; CELLS; MECHANISMS AB Neuroglobin protects neurons from hypoxia in vitro and in vivo; however, the underlying mechanisms for this effect remain poorly understood. Most of the neuroglobin is present in a hexacoordinate state with proximal and distal histidines in the heme pocket directly bound to the heme iron. At equilibrium, the concentration of the five-coordinate neuroglobin remains very low (0.1-5%). Recent studies have shown that post-translational redox regulation of neuroglobin surface thiol disulfide formation increases the open probability of the heme pocket and allows nitrite binding and reaction to form NO. We hypothesized that the equilibrium between the six-and five-coordinate states and secondary reactions with nitrite to form NO could be regulated by other hypoxia-dependent post-translational modification(s). Protein sequence models identified candidate sites for both 14-3-3 binding and phosphorylation. In both in vitro experiments and human SH-SY5Y neuronal cells exposed to hypoxia and glucose deprivation, we observed that 1) neuroglobin phosphorylation and protein-protein interactions with 14-3-3 increase during hypoxic and metabolic stress; 2) neuroglobin binding to 14-3-3 stabilizes and increases the half-life of phosphorylation; and 3) phosphorylation increases the open probability of the heme pocket, which increases ligand binding (CO and nitrite) and accelerates the rate of anaerobic nitrite reduction to form NO. These data reveal a series of hypoxia-dependent post-translational modifications to neuroglobin that regulate the six-to-five heme pocket equilibrium and heme access to ligands. Hypoxia-regulated reactions of nitrite and neuroglobin may contribute to the cellular adaptation to hypoxia. C1 [Hood, Brian L.; Conrads, Thomas P.; Gladwin, Mark T.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15261 USA. [Jayaraman, Thottala; Tejero, Jesus; Frizzell, Sheila; Shapiro, Calli; Tiso, Mauro; Zhao, Xuejun; Gladwin, Mark T.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA 15213 USA. [Jayaraman, Thottala; Chen, Bill B.; Mallampalli, Rama K.; Gladwin, Mark T.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Wang, Xunde] NHLBI, NIH, Bethesda, MD 20892 USA. [Blood, Arlin B.] Loma Linda Univ, Sch Med, Dept Pediat, Div Neonatol, Loma Linda, CA 92354 USA. RP Gladwin, MT (reprint author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15261 USA. EM gladwinmt@upmc.edu RI Tejero, Jesus/G-3953-2017 OI Tejero, Jesus/0000-0003-3245-9978 FU National Institutes of Health [R01 HL098032, R01 HL096973, P01 HL103455, R01 HL096376, R01 HL097376, R01 HL098174]; Institute for Transfusion Medicine; Hemophilia Center of Western Pennsylvania FX This work was supported, in whole or in part, by National Institutes of Health Grants R01 HL098032, R01 HL096973, and P01 HL103455 (to M. T. G.) and R01 HL096376, R01 HL097376, and R01 HL098174 (to R. K. M.). This work was also supported by the Institute for Transfusion Medicine and the Hemophilia Center of Western Pennsylvania (to M. T. G.). M. Tiso and M. T. Gladwin are listed as co-inventors on a patent application entitled "Neuroglobin as a Six-to-Five Coordinate-regulated Nitrite Reductase." NR 48 TC 29 Z9 31 U1 3 U2 12 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 9 PY 2011 VL 286 IS 49 BP 42679 EP 42689 DI 10.1074/jbc.M111.271973 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 863QI UT WOS:000298180900075 PM 21965683 ER PT J AU Smith, AK Williams, BA Lo, B AF Smith, Alexander K. Williams, Brie A. Lo, Bernard TI Discussing Overall Prognosis with the Very Elderly SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Smith, Alexander K.; Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Lo, Bernard] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Smith, Alexander K.; Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. FU NCRR NIH HHS [KL2 RR024130] NR 5 TC 31 Z9 31 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 8 PY 2011 VL 365 IS 23 BP 2149 EP 2151 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 857PQ UT WOS:000297731400014 PM 22150033 ER PT J AU Sterling, TR Villarino, ME Borisov, AS Shang, N Gordin, F Bliven-Sizemore, E Hackman, J Hamilton, CD Menzies, D Kerrigan, A Weis, SE Weiner, M Wing, D Conde, MB Bozeman, L Horsburgh, CR Chaisson, RE AF Sterling, Timothy R. Villarino, M. Elsa Borisov, Andrey S. Shang, Nong Gordin, Fred Bliven-Sizemore, Erin Hackman, Judith Hamilton, Carol Dukes Menzies, Dick Kerrigan, Amy Weis, Stephen E. Weiner, Marc Wing, Diane Conde, Marcus B. Bozeman, Lorna Horsburgh, C. Robert, Jr. Chaisson, Richard E. CA TB Trials Consortium PREVENT TB TI Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID PREVENTIVE THERAPY; UNITED-STATES; RANDOMIZED-TRIAL; CLINICAL-TRIAL; HIV-INFECTION; RIFAMPIN; PYRAZINAMIDE; PHARMACOKINETICS; IMMUNOCOMPETENT; RIFABUTIN AB BACKGROUND Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion. METHODS We conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis. Subjects were enrolled from the United States, Canada, Brazil, and Spain and followed for 33 months. The primary end point was confirmed tuberculosis, and the noninferiority margin was 0.75%. RESULTS In the modified intention-to-treat analysis, tuberculosis developed in 7 of 3986 subjects in the combination-therapy group (cumulative rate, 0.19%) and in 15 of 3745 subjects in the isoniazid-only group (cumulative rate, 0.43%), for a difference of 0.24 percentage points. Rates of treatment completion were 82.1% in the combination-therapy group and 69.0% in the isoniazid-only group (P<0.001). Rates of permanent drug discontinuation owing to an adverse event were 4.9% in the combination-therapy group and 3.7% in the isoniazid-only group (P = 0.009). Rates of investigator-assessed drug-related hepatotoxicity were 0.4% and 2.7%, respectively (P<0.001). CONCLUSIONS The use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniazid alone in preventing tuberculosis and had a higher treatment-completion rate. Long-term safety monitoring will be important. (Funded by the Centers for Disease Control and Prevention; PREVENT TB ClinicalTrials.gov number, NCT00023452.) C1 [Villarino, M. Elsa; Borisov, Andrey S.; Shang, Nong; Bliven-Sizemore, Erin; Bozeman, Lorna] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gordin, Fred] George Washington Univ, Washington, DC USA. [Gordin, Fred] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Hackman, Judith; Chaisson, Richard E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Hamilton, Carol Dukes] Family Hlth Int, Durham, NC USA. [Hamilton, Carol Dukes] Duke Univ, Durham, NC USA. [Menzies, Dick] McGill Univ, Montreal Chest Inst, Montreal, PQ, Canada. [Weis, Stephen E.] Univ N Texas Hlth Sci Ctr Ft Worth, Ft Worth, TX USA. [Weiner, Marc] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Weiner, Marc] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Wing, Diane] S Texas Consortium, Harlingen, TX USA. [Conde, Marcus B.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil. [Horsburgh, C. Robert, Jr.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Sterling, Timothy R.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Sterling, TR (reprint author), A2209 Med Ctr N, 1161 21st Ave S, Nashville, TN 37232 USA. EM timothy.sterling@vanderbilt.edu RI Conde, Marcus/A-2501-2013 FU CDC; Bristol-Myers Squibb; Pfizer; Sanofi-Aventis; Otsuka America Pharmaceutical FX Supported by the CDC.; Dr. Sterling reports receiving research grant funding from Bristol-Myers Squibb and Pfizer for HIV observational studies; Dr. Hamilton, being employed by Family Health International; Dr. Weiner, receiving research grant funding from Sanofi-Aventis; and Dr. Horsburgh, receiving payments from Otsuka America Pharmaceutical for scientific reviews of study protocols. No other potential conflict of interest relevant to this article was reported. NR 39 TC 241 Z9 252 U1 4 U2 27 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 8 PY 2011 VL 365 IS 23 BP 2155 EP 2166 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 857PQ UT WOS:000297731400001 PM 22150035 ER PT J AU Warne, JP Alemi, F Reed, AS Varonin, JM Chan, H Piper, ML Mullin, ME Myers, MG Corvera, CU Xu, AW AF Warne, James P. Alemi, Farzad Reed, Alison S. Varonin, Jillian M. Chan, Helen Piper, Merisa L. Mullin, Mark E. Myers, Martin G., Jr. Corvera, Carlos U. Xu, Allison W. TI Impairment of Central Leptin-Mediated PI3K Signaling Manifested as Hepatic Steatosis Independent of Hyperphagia and Obesity (Retracted article. See vol. 21, pg. 648, 2015) SO CELL METABOLISM LA English DT Article; Retracted Publication ID INSULIN-RESISTANCE; ADIPOSE-TISSUE; LIPID-METABOLISM; NERVOUS-SYSTEM; FOOD-INTAKE; MICE; LIVER; RECEPTOR; NEURONS; HYPOTHALAMUS AB Hepatic steatosis is generally thought to develop via peripheral mechanisms associated with obesity. We show that chronic central infusion of leptin suppresses hepatic lipogenic gene expression and reduces triglyceride content via stimulation of hepatic sympathetic activity. This leptin function is independent of feeding and body weight but requires phosphatidylinositol 3-kinase (PI3K) signaling. Attenuation of leptin-induced PI3K signaling, brought about by transgenic expression of phosphatase and tensin homolog (PTEN) in leptin receptor neurons, leads to decreased hepatic sympathetic tone and increased triglyceride levels without affecting adiposity or hepatic insulin signaling. Central leptin's effects on hepatic norepinephrine levels and triglyceride content are blunted in these mutant mice. Simultaneous downregulation of PI3K and signal transducer and activator of transcription-3 (Stat3) in leptin receptor neurons does not exacerbate obesity but causes more severe hepatic steatosis. Together, our results indicate that central cellular leptin resistance in PI3K signaling manifests as hepatic steatosis without causing obesity. C1 [Warne, James P.; Reed, Alison S.; Varonin, Jillian M.; Chan, Helen; Piper, Merisa L.; Mullin, Mark E.; Xu, Allison W.] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA. [Alemi, Farzad; Corvera, Carlos U.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, San Francisco, CA 94143 USA. [Myers, Martin G., Jr.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA. [Myers, Martin G., Jr.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA. RP Xu, AW (reprint author), Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA. EM axu@diabetes.ucsf.edu FU NIH [R01DK080427, T32DK07161, DERC P30 DK063720] FX We thank Drs. Michael Schwartz, Robert Farese, Jr., Jacquelyn Maher, and Jamila Newton for their evaluation of the manuscript. This work was supported by research grant from the NIH (R01DK080427 to A.W.X.) and, in part, by a NIH Pediatric Endocrine Training grant (T32DK07161) to A.S.R. This work was also supported, in part, by core facilities funded by NIH DERC P30 DK063720. NR 44 TC 27 Z9 28 U1 3 U2 11 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 EI 1932-7420 J9 CELL METAB JI Cell Metab. PD DEC 7 PY 2011 VL 14 IS 6 BP 791 EP 803 DI 10.1016/j.cmet.2011.11.001 PG 13 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 862VO UT WOS:000298122400012 PM 22152304 ER PT J AU Grijalva, CG Chen, L Delzell, E Baddley, JW Beukelman, T Winthrop, KL Griffin, MR Herrinton, LJ Liu, LY Ouellet-Hellstrom, R Patkar, NM Solomon, DH Lewis, JD Xie, FL Saag, KG Curtis, JR AF Grijalva, Carlos G. Chen, Lang Delzell, Elizabeth Baddley, John W. Beukelman, Timothy Winthrop, Kevin L. Griffin, Marie R. Herrinton, Lisa J. Liu, Liyan Ouellet-Hellstrom, Rita Patkar, Nivedita M. Solomon, Daniel H. Lewis, James D. Xie, Fenglong Saag, Kenneth G. Curtis, Jeffrey R. TI Initiation of Tumor Necrosis Factor-alpha Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID MODIFYING ANTIRHEUMATIC DRUGS; RHEUMATOID-ARTHRITIS PATIENTS; SERIOUS BACTERIAL-INFECTIONS; PLACEBO-CONTROLLED TRIALS; HAZARDS REGRESSION-MODEL; OPPORTUNISTIC INFECTIONS; BIOLOGICS-REGISTER; BRITISH-SOCIETY; FACTOR THERAPY; METAANALYSIS AB Context Although tumor necrosis factor (TNF)-alpha antagonists are increasingly used in place of nonbiologic comparator medications, their safety profile remains incomplete. Objectives To determine whether initiation of TNF-alpha antagonists compared with nonbiologic comparators is associated with an increased risk of serious infections requiring hospitalization. Design, Setting, and Patients Within a US multi-institutional collaboration, we assembled retrospective cohorts (1998-2007) of patients with rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropathies) combining data from Kaiser Permanente Northern California, New Jersey and Pennsylvania Pharmaceutical Assistance programs, Tennessee Medicaid, and national Medicaid/Medicare. TNF-alpha antagonists and nonbiologic regimens were compared in disease-specific propensity score (PS)-matched cohorts using Cox regression models with nonbiologics as the reference. Baseline glucocorticoid use was evaluated as a separate covariate. Main Outcome Measure Infections requiring hospitalization (serious infections) during the first 12 months after initiation of TNF-alpha antagonists or nonbiologic regimens. Results Study cohorts included 10 484 RA, 2323 IBD, and 3215 psoriasis and spondyloarthropathies matched pairs using TNF-alpha antagonists and comparator medications. Overall, we identified 1172 serious infections, most of which (53%) were pneumonia and skin and soft tissue infections. Among patients with RA, serious infection hospitalization rates were 8.16 (TNF-alpha antagonists) and 7.78 (comparator regimens) per 100 person-years (adjusted hazard ratio [aHR], 1.05 [95% CI, 0.91-1.21]). Among patients with IBD, rates were 10.91 (TNF-alpha antagonists) and 9.60 (comparator) per 100 person-years (aHR, 1.10 [95% CI, 0.83-1.46]). Among patients with psoriasis and spondyloarthropathies, rates were 5.41 (TNF-alpha antagonists) and 5.37 (comparator) per 100 person-years (aHR, 1.05 [95% CI, 0.76-1.45]). Among patients with RA, infliximab was associated with a significant increase in serious infections compared with etanercept (aHR, 1.26 [95% CI, 1.07-1.47]) and adalimumab (aHR, 1.23 [95% CI, 1.02-1.48]). Baseline glucocorticoid use was associated with a dose-dependent increase in infections. Conclusion Among patients with autoimmune diseases, compared with treatment with nonbiologic regimens, initiation of TNF-alpha antagonists was not associated with an increased risk of hospitalizations for serious infections. JAMA. 2011;306(21):2331-2339 Published online November 6, 2011. doi:10.1001/jama.2011.1692 C1 [Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Div Pharmacoepidemiol, Dept Prevent Med, Nashville, TN 37212 USA. [Chen, Lang; Delzell, Elizabeth; Baddley, John W.; Beukelman, Timothy; Patkar, Nivedita M.; Xie, Fenglong; Saag, Kenneth G.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL USA. [Baddley, John W.] Birmingham VA Med Ctr, Birmingham, AL USA. [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Herrinton, Lisa J.; Liu, Liyan] Kaiser Permanente No Calif, Oakland, CA USA. [Ouellet-Hellstrom, Rita] US FDA, Silver Spring, MD USA. [Solomon, Daniel H.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Solomon, Daniel H.] Harvard Univ, Boston, MA 02115 USA. [Lewis, James D.] Univ Penn, Dept Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Lewis, James D.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Grijalva, CG (reprint author), Vanderbilt Univ, Sch Med, Div Pharmacoepidemiol, Dept Prevent Med, 1500 21st Ave S,Ste 2600, Nashville, TN 37212 USA. EM carlos.grijalva@vanderbilt.edu FU Amgen; Genentech; Centocor; Procter Gamble; Abbott; Eli Lilly; Bristol-Myers Squibb; Takeda; Shire; Pfizer; Roche/Genentech; UCB biopharma; CORRONA; Crescendo; Food and Drug Administration (FDA); US Department of Health and Human Services (DHHS); Agency for Healthcare Research and Quality (AHRQ) [U18 HS17919, R01HS018517]; National Institutes of Health (NIH) [AR053351]; NIH via the University of Alabama at Birmingham Center for Clinical and Translational Science [5KL2 RR025776-03]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [5P60AR56116] FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Delzell reported receiving research support from Amgen. Dr Baddley reported consulting for Abbott and Merck. Dr Herrinton reported receiving research support from Genentech, Centocor, and Procter & Gamble. Dr Solomon reported receiving research support from Amgen, Abbott, Eli Lilly, and Bristol-Myers Squibb. Dr Lewis reported consulting for Genentech, Abbott, CORRONA (Consortium of Rheumatology Researchers of North America Inc), Millennium Pharmaceuticals, Elan, AstraZeneca, Procter & Gamble, GlaxoSmithKline, Alios Therapeutics, Roche, and Amgen; he also reported receiving research support from Centocor, Takeda, and Shire, and consultant honoraria from Amgen and Pfizer. Dr Winthrop reported receiving consultant fees from Genentech and Abbott, research support from Pfizer, and speakers honoraria from Amgen and Pfizer. Dr Saag reported receiving research support from Amgen, Genentech, and Pfizer. Dr Curtis reported receiving consultant fees and research grants from Roche/Genentech, UCB biopharma, Centocor, CORRONA, Amgen, Pfizer, Bristol-Myers Squibb, Crescendo, and Abbott. Other authors reported no conflicts.; This work was supported by the Food and Drug Administration (FDA), US Department of Health and Human Services (DHHS), and the Agency for Healthcare Research and Quality (AHRQ) grant U18 HS17919. Dr Curtis receives support from the National Institutes of Health (NIH; AR053351) and AHRQ (R01HS018517). Dr Beukelman was supported by NIH grant 5KL2 RR025776-03 via the University of Alabama at Birmingham Center for Clinical and Translational Science. Drs Grijalva and Griffin receive support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, grant 5P60AR56116. NR 51 TC 141 Z9 146 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 7 PY 2011 VL 306 IS 21 BP 2331 EP 2339 DI 10.1001/jama.2011.1692 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 856YH UT WOS:000297680300018 PM 22056398 ER PT J AU Zile, MR Gottdiener, JS Hetzel, SJ McMurray, JJ Komajda, M McKelvie, R Baicu, CF Massie, BM Carson, PE AF Zile, Michael R. Gottdiener, John S. Hetzel, Scott J. McMurray, John J. Komajda, Michel McKelvie, Robert Baicu, Catalin F. Massie, Barry M. Carson, Peter E. CA I-PRESERVE Investigators TI Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction SO CIRCULATION LA English DT Article DE heart failure; echocardiography; ventricular ejection fraction ID VENTRICULAR DIASTOLIC DYSFUNCTION; SOCIETY-OF-CARDIOLOGY; HYPERTENSIVE PATIENTS; SYSTOLIC FUNCTION; RANDOMIZED-TRIAL; COMMUNITY; ECHOCARDIOGRAPHY; POPULATION; IRBESARTAN; OUTCOMES AB Background-The purpose of this study was to examine the prevalence of abnormalities in cardiac structure and function present in patients with heart failure and a preserved ejection fraction (HFPEF) and to determine whether these alterations in structure and function were associated with cardiovascular morbidity and mortality. Methods and Results-The Irbesartan in HFPEF trial (I-PRESERVE) enrolled 4128 patients; echocardiographic determination of left ventricular (LV) volume, mass, left atrial (LA) size, systolic function, and diastolic function were made at baseline in 745 patients. The primary end point was death or protocol-specific cardiovascular hospitalization. A secondary end point was the composite of heart failure death or heart failure hospitalization. Associations between baseline structure and function and patient outcomes were examined using univariate and multivariable Cox proportional hazard analyses. In this substudy, LV hypertrophy or concentric remodeling was present in 59%, LA enlargement was present in 66%, and diastolic dysfunction was present in 69% of the patients. Multivariable analyses controlling for 7 clinical variables (including log N-terminal pro-B-type natriuretic peptide) indicated that increased LV mass, mass/volume ratio, and LA size were independently associated with an increased risk of both primary and heart failure events (all P < 0.05). Conclusions-Left ventricular hypertrophy or concentric remodeling, LA enlargement, and diastolic dysfunction were present in the majority of patients with HFPEF. Left ventricular mass and LA size were independently associated with an increased risk of morbidity and mortality. The presence of structural remodeling and diastolic dysfunction may be useful additions to diagnostic criteria and provide important prognostic insights in patients with HFPEF. Clinical Trial Registration-http://www.clinicaltrials.gov. Unique identifier: NCT00095238. (Circulation. 2011; 124: 2491-2501.) C1 [Zile, Michael R.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Zile, Michael R.; Baicu, Catalin F.] Vet Affairs Med Ctr, RHJ Dept, Charleston, SC 29403 USA. [Gottdiener, John S.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. [Hetzel, Scott J.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [McMurray, John J.] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Komajda, Michel] Univ Paris 06, Paris, France. [Komajda, Michel] Hop La Pitie Salpetriere, Paris, France. [McKelvie, Robert] McMaster Univ, Hamilton, ON, Canada. [Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Carson, Peter E.] Washington DC VAMC, Washington, DC USA. RP Zile, MR (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Ashley River Towers,25 Courtenay Dr,Room 7067, Charleston, SC 29425 USA. EM zilem@musc.edu OI mcmurray, john/0000-0002-6317-3975 FU Bristol-Myers Squibb; Sanofi-aventis; Servier FX Drs Zile, Gottdiener, and Carson report receiving consulting fees from Bristol-Myers Squibb and Sanofi-aventis. Dr McMurray reports receiving support from Bristol-Myers Squibb (to Glasgow University) for his work on this trial. Dr Komajda reports receiving consulting fees from Bristol-Myers Squibb and Servier and lecture fees from Sanofi-aventis. Dr McKelvie reports receiving consulting fees and lecture fees from Bristol-Myers Squibb and Sanofi-aventis. S.J. Hetzel reports being employed by the Statistical Data Analysis Center at the University of Wisconsin Madison, which conducted the statistical analysis for this trial that was supported by Bristol-Myers Squibb and Sanofi-Aventis. Dr Massie reports receiving grant support and consulting fees from Bristol-Myers Squibb and Sanofi-aventis. NR 38 TC 154 Z9 162 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD DEC 6 PY 2011 VL 124 IS 23 BP 2491 EP 2501 DI 10.1161/CIRCULATIONAHA.110.011031 PG 11 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 863QW UT WOS:000298183300013 PM 22064591 ER PT J AU Cope, EK Goldstein-Daruech, N Kofonow, JM Christensen, L McDermott, B Monroy, F Palmer, JN Chiu, AG Shirtliff, ME Cohen, NA Leid, JG AF Cope, Emily K. Goldstein-Daruech, Natalia Kofonow, Jennifer M. Christensen, Lanette McDermott, Bridget Monroy, Fernando Palmer, James N. Chiu, Alexander G. Shirtliff, Mark E. Cohen, Noam A. Leid, Jeff G. TI Regulation of Virulence Gene Expression Resulting from Streptococcus pneumoniae and Nontypeable Haemophilus influenzae Interactions in Chronic Disease SO PLOS ONE LA English DT Article ID UPPER RESPIRATORY-TRACT; ORAL MICROBIAL COMMUNITIES; CHRONIC RHINOSINUSITIS; OTITIS-MEDIA; IN-VIVO; BIOFILM FORMATION; PSEUDOMONAS-AERUGINOSA; CHINCHILLA MODEL; HUMAN HOST; BACTERIAL AB Chronic rhinosinusitis (CRS) is a common inflammatory disease of the sinonasal cavity mediated, in part, by polymicrobial communities of bacteria. Recent molecular studies have confirmed the importance of Streptococcus pneumoniae and nontypeable Haemophilus influenzae (NTHi) in CRS. Here, we hypothesize that interaction between S. pneumoniae and NTHi mixed-species communities cause a change in bacterial virulence gene expression. We examined CRS as a model human disease to validate these polymicrobial interactions. Clinical strains of S. pneumoniae and NTHi were grown in mono-and co-culture in a standard biofilm assay. Reverse transcriptase real-time PCR (RTqPCR) was used to measure gene expression of key virulence factors. To validate these results, we investigated the presence of the bacterial RNA transcripts in excised human tissue from patients with CRS. Consequences of physical or chemical interactions between microbes were also investigated. Transcription of NTHi type IV pili was only expressed in co-culture in vitro, and expression could be detected ex vivo in diseased tissue. S. pneumoniae pyruvate oxidase was up-regulated in co-culture, while pneumolysin and pneumococcal adherence factor A were down-regulated. These results were confirmed in excised human CRS tissue. Gene expression was differentially regulated by physical contact and secreted factors. Overall, these data suggest that interactions between H. influenzae and S. pneumoniae involve physical and chemical mechanisms that influence virulence gene expression of mixed-species biofilm communities present in chronically diseased human tissue. These results extend previous studies of population-level virulence and provide novel insight into the importance of S. pneumoniae and NTHi in CRS. C1 [Cope, Emily K.; Christensen, Lanette; McDermott, Bridget; Monroy, Fernando; Leid, Jeff G.] No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA. [Goldstein-Daruech, Natalia; Kofonow, Jennifer M.; Palmer, James N.; Chiu, Alexander G.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA 19104 USA. [Shirtliff, Mark E.] Univ Maryland, Sch Dent, Dept Microbial Pathogenesis, Baltimore, MD 21201 USA. RP Cope, EK (reprint author), No Arizona Univ, Dept Biol Sci, Box 5640, Flagstaff, AZ 86011 USA. EM Emily.Cope@nau.edu RI Chiu, Alexander/J-1230-2014; Monroy, Francisco/N-2763-2013 OI Chiu, Alexander/0000-0002-7592-6575; Monroy, Francisco/0000-0001-6455-3083; Cohen, Noam/0000-0002-9462-3932 FU Science Foundation Arizona [GRF 0204-08]; Flight Attendants Medical Research Institute [103019] FX This work was supported by Science Foundation Arizona GRF 0204-08 (http://www.sfaz.org) and the Flight Attendants Medical Research Institute, Clinical Innovator Award #103019. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 62 TC 17 Z9 17 U1 0 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 5 PY 2011 VL 6 IS 12 AR e28523 DI 10.1371/journal.pone.0028523 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 863NX UT WOS:000298172800045 PM 22162775 ER PT J AU Chu, VC Bhattacharya, S Nomoto, A Lin, JH Zaidi, SK Oberley, TD Weinman, SA Azhar, S Huang, TT AF Chu, Victor C. Bhattacharya, Sayanti Nomoto, Ann Lin, Jiahui Zaidi, Syed Kashif Oberley, Terry D. Weinman, Steven A. Azhar, Salman Huang, Ting-Ting TI Persistent Expression of Hepatitis C Virus Non-Structural Proteins Leads to Increased Autophagy and Mitochondrial Injury in Human Hepatoma Cells SO PLOS ONE LA English DT Article ID CORE PROTEIN; OXIDATIVE STRESS; MICROVILLAR LOCALIZATION; SUPEROXIDE-DISMUTASE; SCAVENGER RECEPTOR; ROS PRODUCTION; NS5A PROTEIN; ER STRESS; CLASS-B; REPLICATION AB HCV infection is a major cause of chronic liver disease and liver cancer in the United States. To address the pathogenesis caused by HCV infection, recent studies have focused on the direct cytopathic effects of individual HCV proteins, with the objective of identifying their specific roles in the overall pathogenesis. However, this approach precludes examination of the possible interactions between different HCV proteins and organelles. To obtain a better understanding of the various cytopathic effects of and cellular responses to HCV proteins, we used human hepatoma cells constitutively replicating HCV RNA encoding either the full-length polyprotein or the non-structural proteins, or cells constitutively expressing the structural protein core, to model the state of persistent HCV infection and examined the combination of various HCV proteins in cellular pathogenesis. Increased reactive oxygen species (ROS) generation in the mitochondria, mitochondrial injury and degeneration, and increased lipid accumulation were common among all HCV protein-expressing cells regardless of whether they expressed the structural or non-structural proteins. Expression of the non-structural proteins also led to increased oxidative stress in the cytosol, membrane blebbing in the endoplasmic reticulum, and accumulation of autophagocytic vacuoles. Alterations of cellular redox state, on the other hand, significantly changed the level of autophagy, suggesting a direct link between oxidative stress and HCV-mediated activation of autophagy. With the widespread cytopathic effects, cells with the full-length HCV polyprotein showed a modest antioxidant response and exhibited a significant increase in population doubling time and a concomitant decrease in cyclin D1. In contrast, cells expressing the non-structural proteins were able to launch a vigorous antioxidant response with up-regulation of antioxidant enzymes. The population doubling time and cyclin D1 level were also comparable to that of control cells. Finally, the cytopathic effects of core protein appeared to focus on the mitochondria without remarkable disturbances in the cytosol. C1 Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Nomoto, Ann; Zaidi, Syed Kashif; Azhar, Salman; Huang, Ting-Ting] VA Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA USA. [Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA. [Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Weinman, Steven A.] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA. RP Chu, VC (reprint author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. EM tthuang@stanford.edu RI Zaidi, Syed Kashif /A-6160-2013 OI Zaidi, Syed Kashif /0000-0003-2391-414X FU National Institutes of Health [AA012863, HL33881, CA122499]; Stanford Digestive Disease Center FX This work is supported by funding from National Institutes of Health grant AA012863 to SW, HL33881 to SA, and CA122499 to T-TH, and from Stanford Digestive Disease Center to T-TH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 58 TC 20 Z9 21 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 2 PY 2011 VL 6 IS 12 AR e28551 DI 10.1371/journal.pone.0028551 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 863NO UT WOS:000298171400106 PM 22164304 ER PT J AU Wang, Z Chen, J Boyd, JE Zhang, HY Jia, XZ Qiu, JY Xiao, ZP AF Wang, Zhen Chen, Jue Boyd, Jennifer E. Zhang, Haiyin Jia, Xiuzhen Qiu, Jianyin Xiao, Zeping TI Psychometric Properties of the Chinese Version of the Perceived Stress Scale in Policewomen SO PLOS ONE LA English DT Article ID PSYCHOLOGICAL STRESS; DEPRESSION; VALIDATION; ANXIETY; DISEASE; WOMEN AB Background: The 10-item Perceived Stress Scale (PSS-10) is one of most widely used instruments to measure a global level of perceived stress in a range of clinical and research settings. This study was conducted to examine the psychometric properties of the Simplified Chinese version of the PSS-10 in policewomen. Methodology: A total of 240 policewomen were recruited in this study. The Simplified Chinese versions of the PSS-10, the Beck Depression Inventory Revised (BDI-II), and the Beck Anxiety Inventory (BAI) were administered to all participants, and 36 of the participants were re-tested two weeks after the initial testing. Principal Findings: The overall Cronbach's alpha was 0.86, and the test-retest reliability coefficient was 0.68. Exploratory Factor Analysis (EFA) yielded 2 factors with eigenvalues of 4.76 and 1.48, accounting for 62.41% of variance. Factor 1 consisted of 6 items representing "negative feelings''; whereas Factor 2 consisted of 4 items representing "positive feelings''. The item loadings ranged from 0.72 to 0.83. The Confirmatory factor analysis (CFA) indicated a very good fit of this two-factor model to this sample. The PSS-10 significantly correlated with both BDI-II and BAI, indicating an acceptable concurrent validity. Conclusions: The Simplified Chinese version of the PSS-10 demonstrated adequate psychometric properties for evaluating stress levels. The results support its use among the Chinese population. C1 [Wang, Zhen; Chen, Jue; Zhang, Haiyin; Jia, Xiuzhen; Qiu, Jianyin; Xiao, Zeping] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China. [Boyd, Jennifer E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Boyd, Jennifer E.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Wang, Z (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China. EM xiaozeping@gmail.com FU National Natural Science Fundation [30800370]; Shanghai Pujiang Program [09PJ1408900] FX This study was supported by grants from the National Natural Science Fundation (30800370) and the Shanghai Pujiang Program (09PJ1408900). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 29 Z9 34 U1 3 U2 21 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 2 PY 2011 VL 6 IS 12 AR e28610 DI 10.1371/journal.pone.0028610 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 863NO UT WOS:000298171400113 PM 22164311 ER PT J AU Mason, ZD Pearlman, J Cooper, RA Laferrier, JZ AF Mason, Zachary D. Pearlman, Jon Cooper, Rory A. Laferrier, Justin Z. TI Comparison of prosthetic feet prescribed to active individuals using ISO standards SO PROSTHETICS AND ORTHOTICS INTERNATIONAL LA English DT Article DE Prosthetic feet; testing of prosthetic and orthotic components ID WHEELCHAIR-RELATED ACCIDENTS; UNITED-STATES; AMPUTEES; INJURY; SAFETY; LIFE AB Background: Little research has been done on the robustness of prosthetic feet prescribed to military personnel, and manufacturers are not required to test their products prior to sale. This is problematic because the prosthetic feet used by active individuals are subjected to loading conditions not seen in normal gait. Objectives: To evaluate whether commercially available heavy-duty prosthetic feet intended for use by military personnel meet ISO 10328 standards. Study Design: Bench testing of heavy-duty prosthetic feet using ISO 10328 standards. Methods: Prosthetic feet from three different manufacturers were tested according to ISO 10328 standards, using a testing frame fitted with axial load and displacement transducers. Pass/fail information was recorded as well as the stiffness and creep of each foot before and after cyclic testing. Results: All feet passed the ISO 10328 standards at the highest loading level, and some significant differences were found within a given model of prosthesis when comparing stiffness and creep before and after cyclic testing. Conclusions: This study demonstrated that manufacturers of heavy-duty prosthetic feet adhere to the voluntary ISO 10328 standards. However, these standards may be insufficient because the tests simulate only idealized gait. Further development of the standards may be necessary to reproduce the circumstances that occur during extreme usage to ensure that prosthetic feet do not fail. C1 [Mason, Zachary D.; Pearlman, Jon; Cooper, Rory A.; Laferrier, Justin Z.] Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Mason, Zachary D.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Pearlman, Jon; Cooper, Rory A.; Laferrier, Justin Z.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Pearlman, Jon; Cooper, Rory A.; Laferrier, Justin Z.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. RP Pearlman, J (reprint author), Human Engn Res Labs, 7180 Highland Dr 151R-1H, Pittsburgh, PA 15206 USA. EM jlp46@pitt.edu OI Pearlman, Jon/0000-0003-0830-9136 FU Telemedicine and Advanced Technology Research Center [W81XWH-07-1-0716] FX This study was funded by the Telemedicine and Advanced Technology Research Center under contract number W81XWH-07-1-0716. NR 28 TC 0 Z9 0 U1 1 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0309-3646 J9 PROSTHET ORTHOT INT JI Prosthet. Orthot. Int. PD DEC PY 2011 VL 35 IS 4 BP 418 EP 424 DI 10.1177/0309364611421692 PG 7 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA 962TM UT WOS:000305568000013 PM 22031596 ER PT J AU George, M Fletcher, M AF George, Maureen Fletcher, Monica TI Pulmonary rehabilitation in the management of COPD: more than one way to skin a cat SO PRIMARY CARE RESPIRATORY JOURNAL LA English DT Editorial Material ID RESPIRATORY SOCIETY; PROGRAMS; DISEASE; IMPACT C1 [Fletcher, Monica] Educ Hlth, Warwick CV34 4AB, England. [George, Maureen] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [George, Maureen] Ctr Global Womens Hlth, Philadelphia, PA USA. RP Fletcher, M (reprint author), Educ Hlth, 10 Church St, Warwick CV34 4AB, England. EM m.fletcher@educationforhealth.org NR 16 TC 0 Z9 0 U1 0 U2 3 PU PRIMARY CARE RESPIRATORY SOC-PCRS UK PI WATERBECK PA EDITORIAL OFFICE, SMITHY HOUSE, WATERBECK, LOCKERBIE DG11 3EY, SCOTLAND SN 1471-4418 J9 PRIM CARE RESP J JI Prim. Care Respir. J. PD DEC PY 2011 VL 20 IS 4 BP 355 EP 356 DI 10.4104/pcrj.2011.00100 PG 2 WC Primary Health Care; Respiratory System SC General & Internal Medicine; Respiratory System GA 945MT UT WOS:000304279300005 PM 22089280 ER PT J AU Salerno, A Dixon, LB Myers, RW Smith, AM Lamberti, JS Jewell, TC Essock, SM AF Salerno, Anthony Dixon, Lisa B. Myers, Robert W. Smith, Anne M. Lamberti, J. Steven Jewell, Thomas C. Essock, Susan M. TI A Public-Academic Partnership to Support a State Mental Health Authority's Strategic Planning and Policy Decisions SO PSYCHIATRIC SERVICES LA English DT Article AB Mental health authorities across the country face numerous challenges in developing effective and practical strategies to adopt and sustain research-supported and stakeholder-endorsed mental health practices. This column describes how an academic center assists a mental health authority in making policy decisions by the use of advisory panels of multiple stakeholders, including members of the research community, advocacy organizations, service providers, and consumers. An advisory panel that focused on services involving family members for adults with serious mental health problems serves as a case example. (Psychiatric Services 62:1413-1415, 2011) C1 [Salerno, Anthony; Essock, Susan M.] Columbia Univ, Dept Psychiat, Coll Phys & Surg, New York, NY USA. [Salerno, Anthony] NYU, Silver Sch Social Work, McSilver Inst Poverty Policy & Res, New York, NY USA. [Dixon, Lisa B.] Univ Maryland, Sch Med, Div Hlth Serv Res, Baltimore, MD 21201 USA. [Dixon, Lisa B.] US Dept Vet Affairs, Capitol Hlth Care Network Mental Illness Res Educ, Baltimore, MD USA. [Myers, Robert W.] New York State Off Mental Hlth, Div Adult Serv, Albany, NY USA. [Smith, Anne M.; Jewell, Thomas C.] Univ Rochester, Dept Psychiat, Family Inst Educ Practice & Res, Rochester, NY USA. [Jewell, Thomas C.] Columbia Univ, Ctr Practice Innovat, New York, NY USA. [Lamberti, J. Steven] Univ Rochester, Med Ctr, Severe Mental Disorders Program, Dept Psychiat, Rochester, NY 14642 USA. [Essock, Susan M.] Columbia Univ, Div Mental Hlth Serv & Policy Res, New York, NY USA. RP Salerno, A (reprint author), 92 Winchester Dr, Monroe, NY 10950 USA. EM anthony.salerno@nyu.edu FU New York State Office of Mental Health (NYSOMH); Center for Practice Innovations FX The authors acknowledge the financial support provided by the New York State Office of Mental Health (NYSOMH) to the Family Institute for Education, Practice, and Research at the University of Rochester to develop, field test, and improve the CCFC model. Furthermore, the NYSOMH supported the Center for Practice Innovations, which organized the advisory panel. NR 5 TC 4 Z9 4 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC PY 2011 VL 62 IS 12 BP 1413 EP 1415 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 912OI UT WOS:000301809100002 PM 22193785 ER PT J AU Mancini, GBJ Hartigan, PM Bates, ER Sedlis, SP Maron, DJ Spertus, JA Berman, DS Kostuk, WJ Shaw, LJ Weintraub, WS Teo, KK Dada, M Chaitman, BR O'Rourke, RA Boden, WE AF Mancini, G. B. John Hartigan, Pamela M. Bates, Eric R. Sedlis, Steven P. Maron, David J. Spertus, John A. Berman, Daniel S. Kostuk, William J. Shaw, Leslee J. Weintraub, William S. Teo, Koon K. Dada, Marcin Chaitman, Bernard R. O'Rourke, Robert A. Boden, William E. CA Coordinators, CI TI Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy Observations From the COURAGE Trial SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE coronary artery disease; angiography; angioplasty; atherosclerotic plaque; rupture; revascularization ID CORONARY-ARTERY-DISEASE; FRACTIONAL FLOW RESERVE; ATHEROSCLEROTIC PLAQUES; INTERVENTION; TOMOGRAPHY; CULPRIT; LESIONS AB Background-The extent to which recurrent events in patients with stable coronary artery disease is attributable to progression of an index lesion originally >= 50% diameter stenosis (DS) but not revascularized or originally <50% DS is unknown during optimal medical therapy (OMT). Methods and Results-In the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, 205 patients assigned to OMT plus percutaneous coronary intervention (PCI) and 284 patients assigned to OMT only had symptom-driven angiograms suitable for analysis. Percentages of patients in the OMT + PCI and OMT-only cohorts with index lesions originally <50% DS were 30% and 32%, respectively; 20% and 68% had index lesions originally >= 50% DS. In both groups, index lesions originally <50% or >= 50% DS represented <4% and <25% of all such lesions, respectively. The only angiographic predictor of myocardial infarction or acute coronary syndrome was the number of lesions originally >= 50% DS that had not been revascularized (odds ratio, 1.15; confidence limits, 1.01-1.31; P<0.04). Conclusions-Lesions originally <50% DS were index lesions in one third of patients referred for symptom-driven repeat angiography, but represented <4% of all such lesions. Nonrevascularized lesions originally >= 50% DS were more often index lesions in OMT-only patients, but still represented a minority (<25%) of all such lesions. These findings underscore the need for improved therapies to arrest plaque progression and reliable strategies for selecting stenoses warranting PCI. C1 [Mancini, G. B. John] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Hartigan, Pamela M.] Connecticut VA Healthcare Syst, Vet Affairs Cooperat Studies Program, Coordinating Ctr, West Haven, CT USA. [Bates, Eric R.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Sedlis, Steven P.] Univ Sch Med, VA New York Harbor Hlth Care Syst, New York, NY USA. [Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Spertus, John A.] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Berman, Daniel S.] Univ Calif Los Angeles, Cedars Sinai Heart Inst, Los Angeles, CA USA. [Kostuk, William J.] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada. [Shaw, Leslee J.] Emory Univ, Sch Med, Atlanta, GA USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. [Teo, Koon K.] McMaster Univ, Med Ctr, Hamilton, ON, Canada. [Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA. [Chaitman, Bernard R.] St Louis Univ Hosp, St Louis, MO USA. [O'Rourke, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [O'Rourke, Robert A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Boden, William E.] Buffalo Gen Hosp, Buffalo, NY 14203 USA. [Boden, William E.] SUNY Buffalo, Buffalo, NY 14260 USA. RP Mancini, GBJ (reprint author), Vancouver Hosp Res Pavil, Room 489,828 10th Ave, Vancouver, BC V5Z 1M9, Canada. EM mancini@mail.ubc.ca OI Sedlis, Steven/0000-0002-8194-8017 FU Merck; National Heart, Lung, and Blood Institute; American Heart Association; American College of Cardiology Foundation; Lilly; BMS/Sanofi; Cordis; United Healthcare; Gilead; St Jude Medical FX Dr Mancini has received grant funding from Merck (>$10 000) and honoraria from Merck (>$10 000), GlaxoSmithKline (>$10 000), AstraZeneca, and Pfizer. Dr Spertus has received grant funding of >$10 000 from the National Heart, Lung, and Blood Institute; American Heart Association; American College of Cardiology Foundation; Lilly; BMS/Sanofi; Cordis; and EvaHeart and consulting fees <$10 000 from United Healthcare, Gilead, and St Jude Medical. NR 16 TC 21 Z9 23 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7640 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD DEC PY 2011 VL 4 IS 6 BP 545 EP 552 DI 10.1161/CIRCINTERVENTIONS.110.960062 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 896EZ UT WOS:000300549500005 PM 22045968 ER PT J AU Azadani, AN Tseng, EE AF Azadani, Ali N. Tseng, Elaine E. TI Transcatheter Heart Valves for Failing Bioprostheses State-of-the-Art Review of Valve-in-Valve Implantation SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE valve-in-valve implantation; transcatheter heart valve; transcatheter aortic valve implantation ID SEVERE AORTIC REGURGITATION; EDWARDS-SAPIEN VALVE; HIGH-RISK PATIENTS; COREVALVE REVALVING SYSTEM; DEGENERATED BIOPROSTHESIS; ENERGY-LOSS; FOLLOW-UP; REPLACEMENT; STENOSIS; PERFORMANCE C1 [Tseng, Elaine E.] Univ Calif San Francisco, Div Cardiothorac Surg, Dept Surg, Med Ctr, San Francisco, CA 94143 USA. [Azadani, Ali N.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Tseng, EE (reprint author), Univ Calif San Francisco, Div Cardiothorac Surg, Dept Surg, Med Ctr, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA. EM elaine.tseng@ucsfmedctr.org FU American Heart Association; Northern California Institute for Research and Education FX This study was funded by an American Heart Association Grant-in-Aid and Northern California Institute for Research and Education. No relevant industry relationship is reported. NR 81 TC 19 Z9 19 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7640 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD DEC PY 2011 VL 4 IS 6 BP 621 EP U189 DI 10.1161/CIRCINTERVENTIONS.111.964478 PG 51 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 896EZ UT WOS:000300549500014 PM 22186106 ER PT J AU Tannock, LR AF Tannock, Lisa R. TI Ursolic acid effect on atherosclerosis: Apples and apples, or apples and oranges? SO ATHEROSCLEROSIS LA English DT Editorial Material DE Ursolic acid; Atherosclerosis; Mouse models ID RECEPTOR-DEFICIENT MICE; APOLIPOPROTEIN-E C1 [Tannock, Lisa R.] Univ Kentucky, Div Endocrinol & Mol Med, Lexington, KY 40536 USA. [Tannock, Lisa R.] US Dept Vet Affairs, Lexington, KY USA. RP Tannock, LR (reprint author), Univ Kentucky, Div Endocrinol & Mol Med, Wethington Bldg,Room 567,900 S Limestone St, Lexington, KY 40536 USA. EM Lisa.Tannock@uky.edu NR 8 TC 5 Z9 5 U1 0 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD DEC PY 2011 VL 219 IS 2 BP 397 EP 398 DI 10.1016/j.atherosclerosis.2011.09.029 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 872MN UT WOS:000298813900007 PM 21993411 ER PT J AU Kaz, AM Wong, CJ Luo, YX Virgin, JB Washington, MK Willis, JE Leidner, RS Chak, A Grady, WM AF Kaz, Andrew M. Wong, Chao-Jen Luo, Yanxin Virgin, Jeffrey B. Washington, M. Kay Willis, Joseph E. Leidner, Rom S. Chak, Amitabh Grady, William M. TI DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses SO EPIGENETICS LA English DT Article DE Barrett's esophagus; esophageal adenocarcinoma; DNA methylation; methylation microarray ID HIGH-GRADE DYSPLASIA; NEOPLASTIC PROGRESSION; PREDICTS PROGRESSION; CANCER; PHENOTYPE; RISK; HYPERMETHYLATION; OVEREXPRESSION; METAPLASIA; BIOMARKERS AB Barrett's esophagus (BE) is a metaplastic process whereby the normal stratified, squamous esophageal epithelium is replaced by specialized intestinal epithelium. Barrett's is the only accepted precursor lesion for esophageal adenocarcinoma (EAC), a solid tumor that is rapidly increasing in incidence in western countries. BE evolves into EAC through intermediate steps that involve increasing degrees of dysplasia. Current histologic criteria are quite subjective and the clinical behavior of BE is highly variable and difficult to predict using these standards. It is widely believed that molecular alterations present in BE and EAC will provide more precise prognostic and predictive markers for these conditions than the current clinical and histologic features in use. In order to further define molecular alterations that can classify unique groups of BE and EAC, we utilized methylation microarrays to compare the global gene methylation status of a collection of normal squamous, BE, BE+ high-grade dysplasia (HGD) and EAC cases. We found distinct global methylation signatures, as well as differential methylation of specific genes, that discriminated these histological groups. We also noted high and low methylation epigenotypes among the BE and EAC cases. Additional validation of those CpG sites that distinguished BE from BE + HGD and EAC may lead to the discovery of useful biomarkers with potential clinical applications in the diagnosis and prognosis of BE and EAC. C1 [Kaz, Andrew M.; Luo, Yanxin; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Virgin, Jeffrey B.] VA Puget Sound Hlth Care Syst, Dept Pathol, Seattle, WA USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. [Luo, Yanxin] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510275, Guangdong, Peoples R China. [Luo, Yanxin] Sun Yat Sen Univ, Gastrointestinal Inst, Guangzhou 510275, Guangdong, Peoples R China. [Washington, M. Kay] Vanderbilt Univ, Dept Pathol, Nashville, TN USA. [Willis, Joseph E.] Case Western Reserve Univ, Sch Med, Dept Pathol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA. [Chak, Amitabh] Case Western Reserve Univ, Sch Med, Div Gastroenterol, Case Comprehens Canc Ctr, Cleveland, OH USA. [Leidner, Rom S.; Chak, Amitabh] Case Western Reserve Univ, Sch Med, Div Oncol, Case Comprehens Canc Ctr, Cleveland, OH USA. RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. EM akaz@fhcrc.org; wgrady@fhcrc.org FU NIH/NIDDK [05K08-DK080630, K24DK002800]; NIH/NCI [CA135692]; Midcareer Award in Patient Orient Research; Burroughs Wellcome Fund; [U54 CA163060-01]; [U01CA152756-01] FX This research was supported by NIH/NIDDK grant 05K08-DK080630 (A.M.K.), NIH/NCI CA135692 (A.C.), a Midcareer Award in Patient Orient Research, NIH/NIDDK K24DK002800 (A.C.), U54 CA163060-01 (W.M.G, A.K., A.C.), Burroughs Wellcome Fund (W.M.G.) and U01CA152756-01 (W.M.G). NR 51 TC 22 Z9 24 U1 0 U2 2 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1559-2294 J9 EPIGENETICS-US JI Epigenetics PD DEC PY 2011 VL 6 IS 12 BP 1403 EP 1412 DI 10.4161/epi.6.12.18199 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 886CI UT WOS:000299828200001 PM 22139570 ER PT J AU Miller, AM Boro, MS Korman, NE Ben Davoren, J AF Miller, Allison M. Boro, Maureen S. Korman, Nancy E. Ben Davoren, J. TI Provider and pharmacist responses to warfarin drug-drug interaction alerts: a study of healthcare downstream of CPOE alerts SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID PHYSICIAN ORDER ENTRY; CLINICAL DECISION-SUPPORT; PLASMINOGEN-ACTIVATOR; MYOCARDIAL-INFARCTION; PHASE-I; MEDICATION; SYSTEM; RATES; THROMBOLYSIS; PRESCRIBERS AB Objective To categorize the appropriateness of provider and pharmacist responses to warfarin critical drug-drug interaction (cDDI) alerts, assess responses and actions to the cDDI, and determine the occurrence of warfarin adverse drug events (ADE) after alerts. Design An 18-month, retrospective study of acute care admissions at a single Veterans Affairs medical center using computerized provider order entry (CPOE). Measurements Patients included had at least one warfarin cDDI alert. Chart reviews included baseline laboratory values and demographics, provider actions, patient outcomes, and associated factors, including other interacting medications and number of simultaneously processed alerts. Results 137 admissions were included (133 unique patients). Amiodarone, vitamin E in a multivitamin, sulfamethoxazole, and levothyroxine accounted for 75% of warfarin cDDI. Provider responses were clinically appropriate in 19.7% of admissions and pharmacist responses were appropriate in 9.5% of admissions. There were 50 ADE (36.6% of admissions) with warfarin; 80% were rated as having no or mild clinical effect. An increased number of non-critical alerts at the time of the reference cDDI alert was the only variable associated with an inappropriate provider response (p=0.01). Limitations This study was limited by being a retrospective review and the possibility of confounding variables, such as other interacting medications. Conclusion The large number of CPOE alerts may lead to inappropriate responses by providers and pharmacists. The high rate of ADE suggests a need for improved medication management systems for patients on warfarin. This study highlights the possibility of alert fatigue contributing to the high prevalence of inappropriate alert over-ride text responses. C1 [Miller, Allison M.] Univ Calif San Francisco, Dept Pharmaceut Serv, San Francisco, CA 94143 USA. [Boro, Maureen S.; Korman, Nancy E.] San Francisco VA Med Ctr, Serv Pharm, San Francisco, CA USA. [Ben Davoren, J.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Miller, AM (reprint author), Univ Calif San Francisco, Dept Pharmaceut Serv, 505 Parnassus Ave,Rm M39C,Box 0622, San Francisco, CA 94143 USA. EM allison.miller@ucsfmedctr.org NR 31 TC 20 Z9 20 U1 2 U2 12 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD DEC PY 2011 VL 18 SU 1 BP I45 EP I50 DI 10.1136/amiajnl-2011-000262 PG 6 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 886RJ UT WOS:000299871300009 PM 22037888 ER PT J AU Ding, P Geng, Z Yan, W Zhou, XH AF Ding, Peng Geng, Zhi Yan, Wei Zhou, Xiao-Hua TI Identifiability and Estimation of Causal Effects by Principal Stratification With Outcomes Truncated by Death SO JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION LA English DT Article DE Causal inference; Quality of life; Survivor average causal effect ID INFERENCE; MODELS AB In medical studies, there are many situations where the final outcomes are truncated by death, in which patients die before outcomes of interest are measured. In this article we consider identifiability and estimation of causal effects by principal stratification when some outcomes are truncated by death. Previous studies mostly focused on large sample bounds, Bayesian analysis, sensitivity analysis. In this article, we propose a new method for identifying the causal parameter of interest under a nonparametric and semiparametric model. We show that the causal parameter of interest is identifiable under some regularity assumptions and the assumption that there exists a pretreatment covariate whose conditional distributions among two principal strata are not the same, but our approach does not need the assumption of a mixture normal distribution for outcomes as required by Zhang, Rubin, and Mealli (2009). Hence, the proposed method is applicable not only to a continuous outcome but also to a binary outcome. When some of the assumptions are violated, we discuss biases of estimators and propose methods to reduce these biases. We conduct several simulation studies to evaluate the finite-sample performance of the proposed approach. Finally, we apply the proposed approach to a real dataset from a Southwest Oncology Group (SWOG) clinical trial. C1 [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98105 USA. [Ding, Peng; Geng, Zhi; Yan, Wei] Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China. [Ding, Peng; Geng, Zhi; Yan, Wei] Peking Univ, Ctr Stat Sci, Beijing 100871, Peoples R China. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, Biostat Unit, HSR&D Ctr Excellence, Seattle, WA USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98105 USA. EM pengdingpku@gmail.com; zgeng@math.pku.edu.cn; yanwei1982@pku.edu.cn; azhou@u.washington.edu FU NSFC [30728019, 11021463, 10931002]; NIH [R03 TW007197]; Department of Veterans Affairs [05-196] FX Peng Ding is Postgraduate Student (E-mail: pengdingpku@gmail.com), Zhi Geng is Professor (E-mail: zgeng@math.pku.edu.cn), and Wei Yan is Ph.D. Student (E-mail: yanwei1982@pku.edu.cn), School of Mathematical Sciences and Center for Statistical Science, Peking University, Beijing 100871, China. Xiao-Hua Zhou is Professor, Department of Biostatistics, University of Washington, Seattle, WA 98105, and Director of Biostatistics Unit, HSR&D Center of Excellence, VA Puget Sound Health Care System (E-mail: azhou@u.washington.edu). This research was supported by NSFC grants 30728019, 11021463, 10931002, NIH R03 TW007197, and Department of Veterans Affairs HSR&D RCS Award 05-196. It does not necessarily represent the views of VA HSR&D Service. We thank the editor, the associate editor, and two anonymous referees for their detailed comments and suggestions, which helped us greatly improve our article. We also thank the Genitourinary Committee of the South Oncology Group for providing data and scientific support. NR 24 TC 11 Z9 11 U1 0 U2 16 PU AMER STATISTICAL ASSOC PI ALEXANDRIA PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA SN 0162-1459 J9 J AM STAT ASSOC JI J. Am. Stat. Assoc. PD DEC PY 2011 VL 106 IS 496 BP 1578 EP 1591 DI 10.1198/jasa.2011.tm10265 PG 14 WC Statistics & Probability SC Mathematics GA 883VL UT WOS:000299662900028 ER PT J AU Rubenstein, LZ Vivrette, R Harker, JO Stevens, JA Kramer, BJ AF Rubenstein, Laurence Z. Vivrette, Rebecca Harker, Judith O. Stevens, Judy A. Kramer, B. Josea TI Validating an evidence-based, self-rated fall risk questionnaire (FRQ) for older adults SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Falls; Fall prevention; Geriatrics; Risk assessment ID PREVENTION; PEOPLE; EPIDEMIOLOGY; METAANALYSIS AB Background: Falls are a common, serious, and often unrecognized problem facing older adults. The objective of this study was to provide an initial clinical and statistical validation for a public health strategy of fall risk self-assessment by older adults using a Fall Risk Questionnaire (FRQ). Methods: Adults age 65+ (n = 40) were recruited at a Los Angeles Veterans Affairs (VA) medical facility and at a local assisted living facility. Participants completed the FRQ self-assessment and results were compared to a "gold standard" of a clinical evaluation of risks using the American/British Geriatrics Society guidelines to assess independent predictors of falls: history of previous falls, fear of falling, gait/balance, muscle weakness, incontinence, sensation and proprioception, depression, vision, and medications. For the comparison, we used an iterative statistical approach, weighing items based on relative risk. Results: There was strong agreement between the FRQ and clinical evaluation (kappa = .875, p < .0001). Individual item kappa values ranged from .305-832. After dropping one FRQ item (vision risk) because of inadequate agreement with the clinical evaluation (kappa = .139, p = .321), the final FRQ had good concurrent validity. Conclusions: The FRQ goes beyond existing screening tools in that it is based on both evidence and clinical acceptability and has been initially validated with clinical examination data. A larger validation with longitudinal follow-up should determine the actual strength of the FRQ in predicting future falls. (C) 2011 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Rubenstein, Laurence Z.] Univ Oklahoma, Coll Med, Donald W Reynolds Dept Geriatr Med, Oklahoma City, OK 73104 USA. [Rubenstein, Laurence Z.; Vivrette, Rebecca; Harker, Judith O.] Greater Los Angeles VA Med Ctr 11E, GRECC, Sepulveda, CA 91343 USA. [Stevens, Judy A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Rubenstein, Laurence Z.; Kramer, B. Josea] Univ Calif Los Angeles, Sch Med, Sepulveda, CA 91343 USA. [Rubenstein, Laurence Z.; Kramer, B. Josea] Greater Los Angeles VA Med Ctr, GRECC, Sepulveda, CA 91343 USA. RP Rubenstein, LZ (reprint author), Univ Oklahoma, Coll Med, Donald W Reynolds Dept Geriatr Med, 921 NE 13th St,VAMC 11 G, Oklahoma City, OK 73104 USA. EM Laurence-rubenstein@ouhsc.edu NR 26 TC 7 Z9 7 U1 2 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PD DEC PY 2011 VL 42 IS 6 BP 493 EP 499 DI 10.1016/j.jsr.2011.08.006 PG 7 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 876WQ UT WOS:000299138900012 PM 22152267 ER PT J AU McKay, JR AF McKay, James R. TI Negative Mood, Craving, and Alcohol Relapse: Can Treatment Interrupt the Process? SO CURRENT PSYCHIATRY REPORTS LA English DT Editorial Material DE Alcohol dependence; Behavioral treatment; Moderation; Mediation; Negative mood; Craving; Relapse; Coping with craving; Cognitive-behavioral therapy; Mechanisms of action ID SUBSTANCE USE; LAPSES C1 [McKay, James R.] Univ Penn, Philadelphia, PA 19104 USA. [McKay, James R.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP McKay, JR (reprint author), Univ Penn, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM mckay_j@mail.trc.upenn.edu FU NIAAA NIH HHS [P01 AA016821, P01 AA016821-03] NR 8 TC 3 Z9 4 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD DEC PY 2011 VL 13 IS 6 BP 431 EP 433 DI 10.1007/s11920-011-0225-z PG 3 WC Psychiatry SC Psychiatry GA 876FG UT WOS:000299092300001 PM 21822936 ER PT J AU Thase, ME AF Thase, Michael E. TI Combined Antidepressant Strategies Are Not More Effective Than Vigorous Escitalopram Monotherapy: Results of the CO-MED Study SO CURRENT PSYCHIATRY REPORTS LA English DT Editorial Material DE Major depressive disorder; MDD; Depression; Randomized controlled trial; RCT; Antidepressants; Combination therapy; Monotherapy; Escitalopram; Bupropion; Venlafaxine; Mirtazapine; STAR*D; Depression Treatment Network ID MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RP Thase, ME (reprint author), Univ Penn, Perelman Sch Med, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu NR 9 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD DEC PY 2011 VL 13 IS 6 BP 434 EP 436 DI 10.1007/s11920-011-0236-9 PG 3 WC Psychiatry SC Psychiatry GA 876FG UT WOS:000299092300002 PM 21956831 ER PT J AU Thase, ME AF Thase, Michael E. TI The Small Specific Effects of Antidepressants in Clinical Trials: What Do They Mean to Psychiatrists? SO CURRENT PSYCHIATRY REPORTS LA English DT Article DE Antidepressants; Placebo; Meta-analysis; Randomized controlled trials; RCT; Clinical trials; Psychiatrists ID SEROTONIN REUPTAKE INHIBITORS; NATIONAL PATTERNS; MAJOR DEPRESSION; PLACEBO-RESPONSE; REMISSION RATES; METAANALYSIS; EFFICACY; PSYCHOTHERAPY; PHARMACOTHERAPY; MEDICATION AB Although antidepressants continue to be a mainstay for clinicians who treat people suffering from depressive disorders, there have recently been articles published in both the scientific literature and the popular press that have raised questions about the utility of this class of medications. This paper briefly examines recent meta-analyses that have reported small drug versus placebo differences in randomized controlled trials and, from the perspective of a prescribing psychiatrist, discusses the clinical significance of these findings. It is concluded that antidepressants do have relatively modest effects (as compared with placebo) in contemporary randomized controlled trials, and that the contribution of placebo-expectancy factors to individual outcomes is often underestimated. Nevertheless, it is also concluded that the modest benefits of antidepressants in grouped datasets obscure large, specific, and very meaningful therapeutic effects for 10% to 20% of those treated with antidepressants. C1 Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Perelman Sch Med,Univ Pittsburgh, Philadelphia, PA 19104 USA. RP Thase, ME (reprint author), Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Perelman Sch Med,Univ Pittsburgh, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu FU Agency for Healthcare Research and Quality; Eli Lilly and Company; Forest Pharmaceuticals; GlaxoSmithKline; National Institute of Mental Health; Otsuka Pharmaceutical Co.; Sepracor; American Psychiatric Foundation; Guilford Publications; Herald House; W.W. Norton Company FX Dr. Thase has served as a consultant for Alkermes, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Dey Pharma, Forest Laboratories, Gerson Lehrman Group, GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante, Merck & Co. (formerly Schering-Plough and Organon Pharmaceuticals USA), Neuronetics, Novartis, Otsuka Pharmaceutical Co., Ortho-McNeil Pharmaceuticals (Johnson & Johnson), Pamlab, Pfizer (formerly Wyeth-Ayerst International), PGxHealth, Shire US, Supernus Pharmaceuticals, Takeda Pharmaceuticals North America, and Transcept Pharmaceuticals; has received grant support from the Agency for Healthcare Research and Quality, Eli Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline, the National Institute of Mental Health, Otsuka Pharmaceutical Co., and Sepracor; has received honoraria from AstraZeneca, Bristol-Myers Squibb, Dey Pharma, Eli Lilly and Company, Merck & Co., Pfizer (formerly Wyeth-Ayerst International); has received royalties from the American Psychiatric Foundation, Guilford Publications, Herald House, and W.W. Norton & Company; has received payment for development of educational presentations (including service on speakers' bureaus) from Pfizer and Bristol-Myers Squibb; and has held stock/stock options in MedAvante. His wife has been employed by Embryon (formerly Advogent). NR 39 TC 9 Z9 9 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD DEC PY 2011 VL 13 IS 6 BP 476 EP 482 DI 10.1007/s11920-011-0235-x PG 7 WC Psychiatry SC Psychiatry GA 876FG UT WOS:000299092300008 PM 21964929 ER PT J AU Wang, ZW Baker, DG Harrer, J Hamner, M Price, M Amstadter, A AF Wang, Zhewu Baker, Dewleen G. Harrer, Judith Hamner, Mark Price, Matthew Amstadter, Ananda TI The relationship between combat-related posttraumatic stress disorder and the 5-HTTLPR/rs25531 polymorphism SO DEPRESSION AND ANXIETY LA English DT Article DE post traumatic stress disorder; 5-HTTLPR; combat trauma; genetic risk; 5-HTTLPR genotypes; combat veteran ID ADMINISTERED PTSD SCALE; ENVIRONMENTAL-INFLUENCES; EXPOSED ADULTS; RISK-FACTORS; SEROTONIN; GENE; SYMPTOMS; INJURY; SUSCEPTIBILITY; POPULATION AB Background: Empirical evidence suggests that there is a significant genetic influence in the development of posttraumatic stress disorder (PTSD). The serotonin transporter (5-HTT) gene (SLC6A4) has been identified as a prime candidate for the development of the disorder, as 5-HTT is a working target for selective serotonin reuptake inhibitors (SSRIs), first line treatment agents for PTSD. Several studies have reported associations between 5-HTT-linked promoter region (5-HTTLPR) polymorphism variants and increased rates of PTSD in civilian samples. This study investigated the role of the 5-HTTLPR polymorphism, triallelically classified, in a sample of combat veterans with and without PTSD. Methods: Rates of PTSD were examined across three genotypes in a sample of 388 combat veterans. The short/long polymorphism of 5-HTTLPR and the A-G polymorphism within the 5-HTTLPR (rs25531) were genotyped, and statistical analyses were conducted. Results: There were significant intergroup (PTSD versus non-PTSD) differences in the genotype frequencies of 5-HTTLPR/rs25531 (2[1, n = 388] = 16.23, P = 5.62 x 10-5). The 5- HTTLPR S'/S' (low transcriptionally efficient) genotype was also associated with the PTSD severity score in the 228 participants who had combat severity data (r = .15, P = 0.03). Conclusions: The findings are consistent with previous research among civilian populations that have indicated that the low transcriptionally efficient S'/S' genotype of 5-HTTLPR is a risk factor for the development of PTSD after trauma exposure. Our findings are the first to examine this polymorphism and PTSD in a military sample. Additional large-scale investigations are needed to replicate these findings. Depression and Anxiety, 2011. (C) 2011 Wiley Periodicals, Inc. C1 [Wang, Zhewu; Hamner, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Wang, Zhewu; Hamner, Mark; Price, Matthew] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Baker, Dewleen G.] VA San Diego, VA Ctr Exellence Stress & Mental Hlth, San Diego, CA USA. [Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Harrer, Judith] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Amstadter, Ananda] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA. RP Wang, ZW (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM wanzh@musc.edu RI Schueter, nicos/A-3625-2014 FU Ralph H. Johnson VA Medical Center; Department of Veterans Affairs; NARSAD FX The authors disclose the following financial relationships within the past 3 years: Contract grant sponsors: Ralph H. Johnson VA Medical Center; The Department of Veterans Affairs; NARSAD. NR 33 TC 38 Z9 39 U1 2 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD DEC PY 2011 VL 28 IS 12 BP 1067 EP 1073 DI 10.1002/da.20872 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 855GW UT WOS:000297552900005 PM 21818827 ER PT J AU Kimbrell, T Pyne, JM Kunik, ME Magruder, KM Petersen, NJ Yu, HJ Hudson, TJ Schulz, PE Qureshi, SU AF Kimbrell, Tim Pyne, Jeffrey M. Kunik, Mark E. Magruder, Kathy M. Petersen, Nancy J. Yu, Hong-Jen Hudson, Teresa J. Schulz, Paul E. Qureshi, Salah U. TI The impact of Purple Heart commendation and PTSD on mortality rates in older veterans SO DEPRESSION AND ANXIETY LA English DT Article DE posttraumatic stress; combat; resilience; injury; mortality; veteran ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS; COMBAT; PREVALENCE; RESILIENCE; EXPOSURE; HEALTH; CARE; MEN; COMORBIDITY AB Background: To determine whether having received a Purple Heart (PH) or having been diagnosed with posttraumatic stress disorder (PTSD) affected mortality in older veterans. Methods: We compared mortality rates of older veterans with a PH but without PTSD (PH+/PTSD-) to veterans with a PH and PTSD (PH+/PTSD+), veterans without a PH but with PTSD (PH-/PTSD+), and a comparison group without a PH or PTSD (PH-/PTSD-). Administrative data from the Veterans Integrated Service Network 16 were collected between 10/01/97 and 09/30/99 for veterans who were 65 years or older. Proportional hazards regression was used to compare the survival times for the four groups (n = 10,255) from entry into the study until death or study termination (9/30/2008). The Charleson co-morbidity index was used to control for potential co-morbid illness burden differences between the groups. Results: Older veterans with a PH (PH+/PTSD- and PH+/PTSD+) had significantly lower mortality rates than PH-/PTSD- veterans (hazard ratio [HR] = 0.6, 95% confidence interval [CI] 0.5 to 0.6, P<.0001; and HR = 0.5, 95% CI 0.4 to 0.7, P<.0001). The PH-/PTSD+ group had a higher mortality rate than the PH-/PTSD- group (HR = 1.1, 95% CI 1.0 to 1.2, P<.01). Conclusions: Veterans who had PH citations and survived into their seventh decade had half the mortality rate of veterans without PH citations with or without PTSD. Veterans with PTSD but without a PH had a significantly higher mortality rate compared to (PH-/PTSD-). Veterans who suffer combat injury without developing PTSD may provide a useful study population for determining the factors that confer resilience. Depression and Anxiety, 2011. (C) 2011 Wiley Periodicals, Inc. C1 [Kimbrell, Tim; Pyne, Jeffrey M.; Hudson, Teresa J.] Cent Arkansas Vet Healthcare Syst, Ctr Mental Hlth & Outcomes Res, Little Rock, AR USA. [Kimbrell, Tim; Pyne, Jeffrey M.; Hudson, Teresa J.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Little Rock, AR 72205 USA. [Kimbrell, Tim; Pyne, Jeffrey M.; Kunik, Mark E.; Petersen, Nancy J.; Yu, Hong-Jen; Hudson, Teresa J.; Qureshi, Salah U.] VA S Cent Mental Illness Res Educ & Clin Ctr, Little Rock, AR USA. [Kunik, Mark E.; Petersen, Nancy J.; Yu, Hong-Jen; Qureshi, Salah U.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX USA. [Kunik, Mark E.; Qureshi, Salah U.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Magruder, Kathy M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Schulz, Paul E.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Schulz, Paul E.] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX USA. RP Kimbrell, T (reprint author), Eugene Towbin VA Med Ctr, 116A NLR,2N112 Bldg 170,2200 Ft Roots Dr, N Little Rock, AR 72114 USA. EM timothy.kimbrell@va.gov RI Schueter, nicos/A-3625-2014 FU Houston Center for Quality of Care & Utilization Studies; VA South Central Mental Illness Research and Clinical Center; Central Arkansas Veterans Healthcare System Center for Mental Healthcare and Outcomes Research FX The authors disclose the following financial relationships within the past 3 years: Contract grant sponsors: Houston Center for Quality of Care & Utilization Studies; VA South Central Mental Illness Research and Clinical Center; Central Arkansas Veterans Healthcare System Center for Mental Healthcare and Outcomes Research. NR 29 TC 3 Z9 3 U1 3 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD DEC PY 2011 VL 28 IS 12 BP 1086 EP 1090 DI 10.1002/da.20850 PG 5 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 855GW UT WOS:000297552900008 PM 21751302 ER PT J AU Knapp, H Anaya, HD Feld, JE Hoang, T Goetz, MB AF Knapp, H. Anaya, H. D. Feld, J. E. Hoang, T. Goetz, M. B. TI Launching nurse-initiated HIV rapid testing in Veterans Affairs primary care: a comprehensive overview of a self-sustaining implementation SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE HIV; AIDS; diagnostic; testing; primary care; rapid test; point-of-care test; Veterans Affairs AB Our objectives were to use foundational pilot findings to guide the implementation of an HIV rapid testing (RT) intervention at one Veterans Affairs outpatient clinic and to evaluate the success and sustainability of this intervention over the course of one year. Policy modifications were drafted and adopted to enable nurses to order, administer, interpret and document HIV RTs. Staff enrolled in a two-part training sessions designed to teach pre- and post-test counselling techniques and the mechanics of administering, interpreting and coding test results in the patients' medical records. They were subsequently evaluated on their efforts at: (1) increasing HIV RT, (2) sustaining this effort one year post-launch. Enabling nurses to carry out HIV RT resulted in a significant increase in not only HIV RT, but also HIV testing rates overall at this facility, measured over the first year of this implementation. Our findings indicate that targeted strategies, aimed at increasing HIV RT rates, worked to increase testing rates overall, and also, that our initial testing strategies were independently sustainable, which is in contrast to findings in the literature on implementation science. C1 [Knapp, H.; Anaya, H. D.; Feld, J. E.; Hoang, T.; Goetz, M. B.] VA Greater Los Angeles Healthcare Syst, Vet Affairs Greater Los Angeles Hlth Serv Res & D, Vet Affairs Qual Enhancement Res Initiat HIV & He, Los Angeles, CA USA. [Knapp, H.; Anaya, H. D.; Feld, J. E.; Hoang, T.; Goetz, M. B.] VA Greater Los Angeles Healthcare Syst, Vet Affairs Greater Los Angeles Hlth Serv Res & D, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. [Anaya, H. D.; Goetz, M. B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. RP Knapp, H (reprint author), 11301 Wilshire Blvd,111G,Bldg 500,Off 4681, Los Angeles, CA 90073 USA. EM Herschel.Knapp@va.gov NR 6 TC 1 Z9 1 U1 0 U2 2 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD DEC PY 2011 VL 22 IS 12 SI SI BP 734 EP 737 DI 10.1258/ijsa.2009.009252 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 876ZB UT WOS:000299145200009 PM 22174056 ER PT J AU Vitkin, E Turzhitsky, V Qiu, L Guo, LY Itzkan, I Hanlon, EB Perelman, LT AF Vitkin, Edward Turzhitsky, Vladimir Qiu, Le Guo, Lianyu Itzkan, Irving Hanlon, Eugene B. Perelman, Lev T. TI Photon diffusion near the point-of-entry in anisotropically scattering turbid media SO NATURE COMMUNICATIONS LA English DT Article ID MONTE-CARLO-SIMULATION; CONFOCAL LIGHT-ABSORPTION; REFLECTANCE SPECTROSCOPY; STEADY-STATE; RADIATIVE TRANSPORT; OPTICAL-PROPERTIES; DENSITY WAVES; APPROXIMATION; TISSUE; MICROSCOPY AB From astronomy to cell biology, the manner in which light propagates in turbid media has been of central importance for many decades. However, light propagation near the point-of-entry in turbid media has never been analytically described, until now. Here we report a straightforward and accurate method that overcomes this longstanding, unsolved problem in radiative transport. Our theory properly treats anisotropic photon scattering events and takes the specific form of the phase function into account. As a result, our method correctly predicts the spatially dependent diffuse reflectance of light near the point-of-entry for any arbitrary phase function. We demonstrate that the theory is in excellent agreement with both experimental results and Monte Carlo simulations for several commonly used phase functions. C1 [Vitkin, Edward; Turzhitsky, Vladimir; Qiu, Le; Guo, Lianyu; Itzkan, Irving; Hanlon, Eugene B.; Perelman, Lev T.] Harvard Univ, Dept Obstet Gynecol & Reprod Biol, Ctr Adv Biomed Imaging & Photon, Boston, MA 02215 USA. [Vitkin, Edward; Turzhitsky, Vladimir; Qiu, Le; Guo, Lianyu; Itzkan, Irving; Hanlon, Eugene B.; Perelman, Lev T.] Harvard Univ, Dept Med, Boston, MA 02215 USA. [Vitkin, Edward; Turzhitsky, Vladimir; Qiu, Le; Guo, Lianyu; Itzkan, Irving; Hanlon, Eugene B.; Perelman, Lev T.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Hanlon, Eugene B.] Med Res Serv, US Dept Vet Affairs, Bedford, MA 01730 USA. [Hanlon, Eugene B.] US Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA. RP Perelman, LT (reprint author), Harvard Univ, Dept Obstet Gynecol & Reprod Biol, Ctr Adv Biomed Imaging & Photon, Boston, MA 02215 USA. EM ltperel@caregroup.harvard.edu FU US National Science Foundation [CBET-0922876, CBET-0943180, CBET-1144025]; US National Institutes of Health [R01 EB003472, R01 EB006462, R33 RR017361]; Department of Veterans Affairs, Office of Research and Development FX This work was supported by the US National Science Foundation grants CBET-0922876, CBET-0943180 and CBET-1144025, US National Institutes of Health grants R01 EB003472, R01 EB006462 and R33 RR017361 and in part by the Department of Veterans Affairs, Office of Research and Development. NR 41 TC 25 Z9 25 U1 2 U2 21 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD DEC PY 2011 VL 2 AR 587 DI 10.1038/ncomms1599 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 877EM UT WOS:000299159900019 PM 22158442 ER PT J AU Lyon, BR Lee, PA Bennett, JM DiTullio, GR Janech, MG AF Lyon, Barbara R. Lee, Peter A. Bennett, Jennifer M. DiTullio, Giacomo R. Janech, Michael G. TI Proteomic Analysis of a Sea-Ice Diatom: Salinity Acclimation Provides New Insight into the Dimethylsulfoniopropionate Production Pathway SO PLANT PHYSIOLOGY LA English DT Article ID PHOTOSYNTHETIC ENERGY-CONVERSION; ALDEHYDE DEHYDROGENASE GENE; SALT STRESS; MARINE-ALGAE; PHAEODACTYLUM-TRICORNUTUM; BINDING PROTEINS; FRAGILARIOPSIS-CYLINDRUS; BIOSYNTHETIC-PATHWAY; ARABIDOPSIS-THALIANA; LIPID-PEROXIDATION AB Dimethylsulfoniopropionate (DMSP) plays important roles in oceanic carbon and sulfur cycling and may significantly impact climate. It is a biomolecule synthesized from the methionine (Met) pathway and proposed to serve various physiological functions to aid in environmental stress adaptation through its compatible solute, cryoprotectant, and antioxidant properties. Yet, the enzymes and mechanisms regulating DMSP production are poorly understood. This study utilized a proteomics approach to investigate protein changes associated with salinity-induced DMSP increases in the model sea-ice diatom Fragilariopsis cylindrus (CCMP 1102). We hypothesized proteins associated with the Met-DMSP biosynthesis pathway would increase in relative abundance when challenged with elevated salinity. To test this hypothesis axenic log-phase cultures initially grown at a salinity of 35 were gradually shifted to a final salinity of 70 over a 24-h period. Intracellular DMSP was measured and two-dimensional gel electrophoresis was used to identify protein changes at 48 h after the shift. Intracellular DMSP increased by approximately 85% in the hypersaline cultures. One-third of the proteins increased under high salinity were associated with amino acid pathways. Three protein isoforms of S-adenosylhomo-cysteine hydrolase, which synthesizes a Met precursor, increased 1.8- to 2.1-fold, two isoforms of S-adenosyl Met synthetase increased 1.9- to 2.5-fold, and S-adenosyl Met methyltransferase increased by 2.8-fold, suggesting active methyl cycle proteins are recruited in the synthesis of DMSP. Proteins from the four enzyme classes of the proposed algal Met transaminase DMSP pathway were among the elevated proteins, supporting our hypothesis and providing candidate genes for future characterization studies. C1 [Janech, Michael G.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Lyon, Barbara R.; Lee, Peter A.; Bennett, Jennifer M.; DiTullio, Giacomo R.] Hollings Marine Lab, Charleston, SC 29412 USA. [Lyon, Barbara R.] Med Univ S Carolina, Marine Biomed & Environm Sci Ctr, Charleston, SC 29412 USA. [Lee, Peter A.; Bennett, Jennifer M.; DiTullio, Giacomo R.] Coll Charleston, Grice Marine Lab, Charleston, SC 29412 USA. [Janech, Michael G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Janech, MG (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. EM janechmg@musc.edu OI Janech, Michael/0000-0002-3202-4811 FU National Science Foundation [ANT-0739597, ANT-0739446, OPP0338097] FX This work was supported by the National Science Foundation (grant nos. ANT-0739597 to M. G. J., ANT-0739446 to P. A. L. and G. R. D., and OPP0338097 to G.R.D.). NR 92 TC 19 Z9 21 U1 3 U2 39 PU AMER SOC PLANT BIOLOGISTS PI ROCKVILLE PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA SN 0032-0889 EI 1532-2548 J9 PLANT PHYSIOL JI Plant Physiol. PD DEC PY 2011 VL 157 IS 4 BP 1926 EP 1941 DI 10.1104/pp.111.185025 PG 16 WC Plant Sciences SC Plant Sciences GA 866JC UT WOS:000298375600026 PM 22034629 ER PT J AU Hebert, PL Taylor, LT Wang, JJ Bergman, MA AF Hebert, Paul L. Taylor, Leslie T. Wang, Jason J. Bergman, Margo A. TI Methods for Using Data Abstracted from Medical Charts to Impute Longitudinal Missing Data in a Clinical Trial SO VALUE IN HEALTH LA English DT Article DE blood pressure; clinical trials; imputation; longitudinal data; missing data ID CARE OUTCOME ANALYSES; MULTIPLE IMPUTATION; VALUES; ATTRITION AB Objective: To describe a method for imputing missing follow-up blood pressure data in a clinical hypertension trial using blood pressures abstracted from medical charts. Methods: We tested a two-step method. In the first, a longitudinal mixed-effects model was estimated on blood pressures abstracted from medical charts. In the second, the patient-specific fitted values from this model at follow-up were used to impute blood pressures missing at follow-up in the trial. Simulations that imposed alternative missing data mechanisms on observed trial data were used to compare this approach to imputation approaches that do not incorporate data from charts. Results: For data that are missing at random, incorporating the fitted values from chart-based longitudinal models leads to estimates of the trial-based blood pressures that are unbiased and have lower mean squared deviation than do blood pressures imputed without the chart-based data. For data that are missing not at random, incorporating fitted values ameliorates but does not eliminate the inherent missing data bias. Conclusions: Incorporating chart data into an imputation algorithm via the use of longitudinal mixed-effects model is an efficient way to impute longitudinal data that are missing from a randomized trial. C1 [Hebert, Paul L.; Taylor, Leslie T.; Bergman, Margo A.] NW Ctr Outcomes Res Older Adults, VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA USA. [Wang, Jason J.] Primary Care Informat Project, Dept Hlth & Mental Hyg, New York, NY USA. [Hebert, Paul L.] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY USA. RP Hebert, PL (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Paul.Hebert2@va.gov FU National Institutes of Health, National Center for Minority Health and Health Disparities [1P60MD000270-01] FX Source of financial support: This work was funded by a grant from the National Institutes of Health, National Center for Minority Health and Health Disparities (1P60MD000270-01). The views expressed herein are those of the authors and do not necessarily represent the views of the National Institutes of Health and other affiliated institutions. NR 17 TC 2 Z9 2 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD DEC PY 2011 VL 14 IS 8 BP 1085 EP 1091 DI 10.1016/j.jval.2011.05.049 PG 7 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 876BM UT WOS:000299081900015 PM 22152178 ER PT J AU Hwang, U Weber, EJ Richardson, LD Sweet, V Todd, K Abraham, G Ankel, F AF Hwang, Ula Weber, Ellen J. Richardson, Lynne D. Sweet, Vicki Todd, Knox Abraham, Gallane Ankel, Felix TI A Research Agenda to Assure Equity During Periods of Emergency Department Crowding SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID HEALTH-CARE DISPARITIES; UNITED-STATES; LANGUAGE BARRIERS; CHEST-PAIN; RACIAL DISPARITIES; ETHNIC DISPARITIES; ELDERLY-PATIENTS; TRAUMA; MANAGEMENT; ACCESS AB The effect of emergency department (ED) crowding on equitable care is the least studied of the domains of quality as defined by the Institute of Medicine (IOM). Inequities in access and treatment throughout the health care system are well documented in all fields of medicine. While there is little evidence demonstrating that inequity is worsened by crowding, theory and evidence from social science disciplines, as well as known barriers to care for vulnerable populations, would suggest that crowding will worsen inequities. To design successful interventions, however, it is important to first understand how crowding can result in disparities and base interventions on these mechanisms. A research agenda is proposed to understand mechanisms that may threaten equity during periods of crowding and design and test potential interventions that may ensure the equitable aspect of quality of care. C1 [Hwang, Ula; Richardson, Lynne D.; Abraham, Gallane] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. [Hwang, Ula] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Richardson, Lynne D.] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA. [Hwang, Ula] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Weber, Ellen J.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA. [Sweet, Vicki] Emergency Serv & PreHosp Care, St Jude Med Ctr, Fullerton, CA USA. [Todd, Knox] Univ Texas MD Anderson Canc Ctr, Dept Emergency Med, Houston, TX 77030 USA. [Ankel, Felix] Univ Minnesota, Sch Med, Dept Emergency Med, Minneapolis, MN 55455 USA. RP Hwang, U (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. EM ula.hwang@mountsinai.org OI Weber, Ellen/0000-0002-0094-1973 FU Agency for Healthcare Research and Quality (AHRQ) [1R13HS020139-01]; Robert Wood Johnson Foundation FX Funding for this conference was made possible (in part) by 1R13HS020139-01 from the Agency for Healthcare Research and Quality (AHRQ). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the U. S. Government. This issue of Academic Emergency Medicine is funded by the Robert Wood Johnson Foundation. NR 53 TC 5 Z9 5 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD DEC PY 2011 VL 18 IS 12 SI SI BP 1318 EP 1323 DI 10.1111/j.1553-2712.2011.01233.x PG 6 WC Emergency Medicine SC Emergency Medicine GA 861IQ UT WOS:000298013000015 PM 22168197 ER PT J AU Silverman, S Cates, M Saunders, G AF Silverman, ShienPei Cates, Megan Saunders, Gabrielle TI Is Measured Hearing Aid Benefit Affected by Seeing Baseline Outcome Questionnaire Responses? SO AMERICAN JOURNAL OF AUDIOLOGY LA English DT Article DE outcomes; hearing aids; audiologic rehabilitation ID TEST-RETEST RELIABILITY; QUALITY-OF-LIFE; HANDICAP INVENTORY; SATISFACTION; DISEASE; ADULTS; TRIAL AB Purpose: To determine whether hearing aid outcome measured by the Hearing Handicap Inventory (HHI) for the Elderly/Adults (Newman, Weinstein, Jacobson, & Hug, 1990; Ventry & Weinstein, 1982) is differentially affected by informed vs. blind administration of the postfitting questionnaire. Method: Participants completed the HHI at their hearing aid evaluation and again at their hearing aid follow-up visit. At follow-up, half received a clean HHI form (blind administration), whereas the remainder responded on their original form (informed administration) and could thus base their follow-up responses on those they gave at the hearing aid evaluation. Results: The data show that for the population examined here, informed administration of the follow-up HHI did not yield a different outcome to blind administration of the follow-up HHI. This was not influenced by past hearing aid use, age of the participant, or the duration of time between baseline questionnaire completion and follow-up completion. Conclusion: These data suggest that completion of follow-up questionnaires in either informed or blind format will have little impact on HHI responses, most likely because of the many other factors that combined to influence hearing aid outcome. C1 [Silverman, ShienPei; Saunders, Gabrielle] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA. [Cates, Megan] Univ Arkansas, Univ Arkansas Med Sci, Little Rock, AR 72204 USA. RP Saunders, G (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA. EM gabrielle.saunders@va.gov FU National Institutes of Health [T35 DC008764]; VA Rehabilitation Research & Development Grant [C4844C] FX Support was provided by National Institutes of Health Pre-doctoral Training Grant T35 DC008764 and by VA Rehabilitation Research & Development Grant C4844C awarded to the VA RR&D National Center for Rehabilitative Auditory Research. We thank Portland VAMC Audiology clinic staff for their participation and assistance with data collection. NR 36 TC 0 Z9 1 U1 0 U2 3 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1059-0889 J9 AM J AUDIOL JI Am. J. Audiol. PD DEC PY 2011 VL 20 IS 2 BP 90 EP 99 DI 10.1044/1059-0889(2011/10-0003) PG 10 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 865ZJ UT WOS:000298349100003 PM 21940983 ER PT J AU Peron, EP Gray, SL Hanlon, JT AF Peron, Emily P. Gray, Shelly L. Hanlon, Joseph T. TI Medication Use and Functional Status Decline in Older Adults: A Narrative Review SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Review DE activities of daily living; aged; drug use ID RANDOMIZED CONTROLLED-TRIAL; DRUG BURDEN INDEX; FRAIL ELDERLY POPULATION; LOWER-EXTREMITY FUNCTION; NURSING-HOME RESIDENTS; PHYSICAL FUNCTION; VITAMIN-D; GROWTH-HORMONE; HIP-FRACTURE; CALCIUM SUPPLEMENTATION AB Background: Functional status is the cornerstone of geriatric care and serves as an indicator of general well-being. A decline in function can increase health care use, worsen quality of life, threaten independence, and increase the risk of mortality. One of several risk factors for decline in functional status is medication use. Objective: Our aim was to critically review published articles that have examined the relationship between medication use and functional status decline in the elderly. Methods: The MEDLINE and EMBASE databases were searched for English-language articles published from January 1986 to June 2011. Search terms included aged, humans, drug utilization, polypharmacy, inappropriate prescribing, anticholinergics, psychotropics, antihypertensives, drug burden index, functional status, function change or decline, activities of daily living, gait, mobility limitation, and disability. A manual search of the reference lists of the identified articles and the authors' article files, book chapters, and recent reviews was conducted to retrieve additional publications. Only articles that used rigorous observational or interventional designs were included. Cross-sectional studies and case series were excluded from this review. Results: Nineteen studies met the inclusion criteria. Five studies addressed the impact of suboptimal prescribing on function, 3 of which found an increased risk of worse function in community-dwelling subjects receiving polypharmacy. Three of the 4 studies that assessed benzodiazepine use and functional status decline found a statistically significant association. One cohort study identified no relationship between antidepressant use and functional status, whereas a randomized trial found that amitriptyline, but not desipramine or paroxetine, impaired certain measures of gait. Two studies found that increasing anticholinergic burden was associated with worse functional status. In a study of hospitalized rehabilitation patients, users of hypnotics/anxiolytics (eg, phenobarbital, zolpidem) had lower relative Functional Independence Measure motor gains than nonusers. Use of multiple central nervous system (CNS) drugs (using different definitions) was linked to greater declines in self-reported mobility and Short Physical Performance Battery (SPPB) scores in 2 community-based studies. Another study of nursing home patients did not report a significant decrease in SPPB scores in those taking multiple CNS drugs. Finally, 2 studies found mixed effects between antihypertensive use and functional status in the elderly. Conclusions: Benzodiazepines and anticholinergics have been consistently associated with impairments in functional status in the elderly. The relationships between suboptimal prescribing, antidepressants, and antihypertensives and functional status decline were mixed. Further research using established measures and methods is needed to better describe the impact of medication use on functional status in older adults. (Am J Geriatr Pharmacother. 2011;9: 378-391) (C) 2011 Elsevier HS Journals, Inc. All rights reserved. C1 [Peron, Emily P.; Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Gray, Shelly L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] VA Pittsburgh Hlth Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Peron, EP (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA. EM emp56@pitt.edu FU National Institute on Aging [U01 AG00678121, R01 AG027017, P30 AG024827, T32 AG021885, K07 AG033174, R56 AG027017, R01 AG034056]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [R01 HS017695, R01 HS018721, K12 HS019461]; VA Health Services [IIR-06-062] FX This study was primarily supported by National Institute on Aging grants and contracts (U01 AG00678121, R01 AG027017, P30 AG024827, T32 AG021885, K07 AG033174, R56 AG027017, R01 AG034056), a National Institute of Mental Health grant (R34 MH082682), a National Institute of Nursing Research grant (R01 NR010135), an Agency for Healthcare Research and Quality grants (R01 HS017695, R01 HS018721, K12 HS019461), and a VA Health Services Research grant (IIR-06-062). NR 97 TC 36 Z9 37 U1 3 U2 27 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD DEC PY 2011 VL 9 IS 6 BP 378 EP 391 DI 10.1016/j.amjopharm.2011.10.002 PG 14 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 869BM UT WOS:000298570700003 PM 22057096 ER PT J AU Linnebur, SA Fish, DN Ruscin, JM Radcliff, TA Oman, KS Fink, R Van Dorsten, B Liebrecht, D Fish, R McNulty, M Hutt, E AF Linnebur, Sunny A. Fish, Douglas N. Ruscin, J. Mark Radcliff, Tiffany A. Oman, Kathy S. Fink, Regina Van Dorsten, Brent Liebrecht, Debra Fish, Ron McNulty, Monica Hutt, Evelyn TI Impact of a Multidisciplinary Intervention on Antibiotic Use for Nursing Home-Acquired Pneumonia SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Article DE academic detailing; antibacterial agents; guideline adherence; nursing homes; physician practice patterns; pneumonia ID RANDOMIZED CONTROLLED-TRIAL; TERM-CARE FACILITIES; GUIDELINES; PREVENTION; MANAGEMENT; RESIDENTS; ADHERENCE; COMMUNITY; EDUCATION; THERAPY AB Background: Academic detailing in nursing homes (NHs) has been shown to improve drug use patterns and adherence to guidelines. Objective: The purpose of this study was to evaluate the impact of a multidisciplinary intervention that included academic detailing on adherence to national nursing home acquired pneumonia (NHAP) guidelines related to use of antibiotics. Methods: This quasi-experimental study evaluated the effects of a 2-year multifaceted and multidisciplinary intervention targeting implementation of national evidence-based guidelines for NHAP. Interventions took place in 8 NHs in Colorado; 8 NHs in Kansas and Missouri served as controls. Interventions included (1) educational sessions for nurses to improve recognition and timely treatment of NHAP symptoms and (2) academic detailing to clinicians by pharmacists regarding diagnostic and prescribing practices. Differences in antibiotic use between groups were compared after 2 intervention years relative to baseline. Results: A total of 549 episodes of NHAP were evaluated in the intervention group and 574 in the control group. Compared with baseline, 1 facility in the intervention group significantly improved in guideline adherence for optimal antibiotic use (P = 0.007), whereas no facilities in the control group improved. The mean adherence score for optimal antibiotic use in intervention NHs increased from 60% to 66%, whereas the control NHs increased from 32% to 39% (P = 0.3). Mean adherence to guidelines recommending antibiotic use within 4 hours of NHAP diagnosis increased from 57% to 75% in intervention NHs but decreased from 38% to 31% in control NHs (P = 0.0003 for difference). There was no difference between intervention and control NHs for guideline adherence regarding optimal duration of antibiotic use. Conclusions: The ability of this multifaceted study to repeatedly remind nursing staff of the importance of timely antibiotic administration contrasts with its limited academic detailing interaction with clinicians. This difference within the intervention may explain the differential impact of the intervention on antibiotic guideline adherence. (Am J Geriatr Pharmacother. 2011;9:442-450) (C) 2011 Elsevier HS Journals, Inc. All rights reserved. C1 [Linnebur, Sunny A.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO 80045 USA. [Ruscin, J. Mark] So Illinois Univ, Sch Pharm, Edwardsville, IL 62026 USA. [Radcliff, Tiffany A.; Hutt, Evelyn] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Linnebur, SA (reprint author), Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus,12850 E Montview Blvd,Campus, Aurora, CO 80045 USA. EM sunny.linnebur@ucdenver.edu FU Agency for Health Care Research and Quality [RO1 HS13618-01A1] FX This study was supported by an investigator-initiated research grant from the Agency for Health Care Research and Quality (RO1 HS13618-01A1). The authors have indicated that they have no other conflicts of interest regarding the content of this article. NR 30 TC 13 Z9 14 U1 2 U2 6 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD DEC PY 2011 VL 9 IS 6 BP 442 EP 450 DI 10.1016/j.amjopharm.2011.09.009 PG 9 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 869BM UT WOS:000298570700009 PM 22055208 ER PT J AU Chopra, P Verma, P Klaustermeyer, WB AF Chopra, Preet Verma, Prashant Klaustermeyer, William B. TI SUCCESSFUL USE OF PRASUGREL, AN ALTERNATIVE ANTIPLATELET AGENT, IN A PATIENT WITH CLOPIDOGREL ALLERGY SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Letter C1 [Chopra, Preet; Verma, Prashant; Klaustermeyer, William B.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare, Dept Allergy Immunol, Los Angeles, CA 90095 USA. RP Chopra, P (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare, Dept Allergy Immunol, Los Angeles, CA 90095 USA. EM preetichopra14@gmail.com NR 8 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD DEC PY 2011 VL 107 IS 6 BP 541 EP 542 DI 10.1016/j.anai.2011.08.003 PG 2 WC Allergy; Immunology SC Allergy; Immunology GA 862EN UT WOS:000298072700014 PM 22123386 ER PT J AU Gabayan, GZ Derose, SF Asch, SM Yiu, S Lancaster, EM Poon, KT Hoffman, JR Sun, BC AF Gabayan, Gelareh Z. Derose, Stephen F. Asch, Steven M. Yiu, Sau Lancaster, Elizabeth M. Poon, K. Trudy Hoffman, Jerome R. Sun, Benjamin C. TI Patterns and Predictors of Short-Term Death After Emergency Department Discharge SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID STAGE RENAL-DISEASE; AFTER-DISCHARGE; CARDIOVASCULAR-DISEASE; OLDER-ADULTS; DATA SYSTEM; ALL-CAUSE; MORTALITY; COMORBIDITY; DIAGNOSIS; SURVIVAL AB Study objective: The emergency department (ED) is an inherently high-risk setting. Early death after an ED evaluation is a rare and devastating outcome; understanding it can potentially help improve patient care and outcomes. Using administrative data from an integrated health system, we describe characteristics and predictors of patients who experienced 7-day death after ED discharge. Methods: Administrative data from 12 hospitals were used to identify death after discharge in adults aged 18 year or older within 7 days of ED presentation from January 1, 2007, to December 31, 2008. Patients who were nonmembers of the health system, in hospice care, or treated at out-of-network EDs were excluded. Predictors of 7-day postdischarge death were identified with multivariable logistic regression. Results: The study cohort contained a total of 475,829 members, with 728,312 discharges from Kaiser Permanente Southern California EDs in 2007 and 2008. Death within 7 days of discharge occurred in 357 cases (0.05%). Increasing age, male sex, and number of preexisting comorbidities were associated with increased risk of death. The top 3 primary discharge diagnoses predictive of 7-day death after discharge included noninfectious lung disease (odds ratio [OR] 7.1; 95% confidence interval [Cl] 2.9 to 17.4), renal disease (OR 5.6; 95% Cl 2.2 to 14.2), and ischemic heart disease (OR 3.8; 95% Cl 1.0 to 13.6). Conclusion: Our study suggests that 50 in 100,000 patients in the United States die within 7 days of discharge from an ED. To our knowledge, our study is the first to identify potentially "high-risk" discharge diagnoses in patients who experience a short-term death after discharge. [Ann Emerg Med. 2011;58:551-558.] C1 [Gabayan, Gelareh Z.; Asch, Steven M.; Sun, Benjamin C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Gabayan, Gelareh Z.; Asch, Steven M.; Sun, Benjamin C.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Med, Los Angeles, CA USA. [Gabayan, Gelareh Z.; Lancaster, Elizabeth M.] Ronald Reagan UCLA, Ctr Emergency Med, Los Angeles, CA USA. [Derose, Stephen F.; Yiu, Sau; Lancaster, Elizabeth M.; Poon, K. Trudy] Kaiser Permanente So Calif, Div Res & Evaluat, Pasadena, CA USA. [Hoffman, Jerome R.] Univ So Calif, Dept Emergency Med, Los Angeles, CA USA. RP Gabayan, GZ (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. EM gelareh@gabayan.com FU Kaiser Permanente Southern California; UCLA Oppenheimer Foundation; Greater Los Angeles Veterans Affairs Department of Health Services Research and Development; UCLA Older Americans Independence Center, NIH/NIA [P30-AG028748]; Emergency Medicine Foundation [59668] FX By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This research was supported by Kaiser Permanente Southern California and the UCLA Oppenheimer Foundation. During the initial phase of this project Dr. Gabayan received support from the Greater Los Angeles Veterans Affairs Department of Health Services Research and Development. Continued support was obtained from the Emergency Medicine Foundation Career Development Award (59668: G. Gabayan). Dr. Sun received support from the UCLA Older Americans Independence Center, NIH/NIA grant P30-AG028748, and the content does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health. NR 34 TC 18 Z9 18 U1 2 U2 12 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD DEC PY 2011 VL 58 IS 6 BP 551 EP 558 DI 10.1016/j.annemergmed.2011.07.001 PG 8 WC Emergency Medicine SC Emergency Medicine GA 864GI UT WOS:000298224600012 PM 21802775 ER PT J AU Asgari, MM Warton, EM Neugebauer, R Chren, MM AF Asgari, Maryam M. Warton, E. Margaret Neugebauer, Romain Chren, Mary-Margaret TI Predictors of Patient Satisfaction With Mohs Surgery Analysis of Preoperative, Intraoperative, and Postoperative Factors in a Prospective Cohort SO ARCHIVES OF DERMATOLOGY LA English DT Article ID CAUSAL DIAGRAMS; BREAST-CANCER; SKIN-CANCER; LIFE; CARE; MORBIDITY; KNOWLEDGE; OUTCOMES AB Objective: To identify preoperative, intraoperative, and postoperative variables that predict higher short-and long-term patient satisfaction with Mohs surgery. Design: Prospective cohort study. Setting: A university-based dermatology practice and the affiliated Veterans Affairs medical center dermatology clinic. Patients: A total of 339 consecutive patients treated with Mohs surgery in 1999 and 2000. Main Outcome Measures: Short-term satisfaction at 1 week and long-term satisfaction at 1 year. We used directed acyclic graphs to determine appropriate confounding adjustment for preoperative, intraoperative, and postoperative variables that influence satisfaction with Mohs surgery in logistic regression models. Results: Better preoperative skin-related quality of life (measured using Skindex) and more intraoperative Mohs stages were the most salient predictors of higher short-and long-term satisfaction; these odds ratios (ORs) were 2.33 (95% CI, 1.01-5.35) and 5.19 (1.66-16.29), respectively, for preoperative skin-related quality of life and 7.06 (2.02-24.67) and 5.30 (1.24-22.64), respectively, for more intraoperative Mohs stages. Patients not bothered by postoperative bleeding were more likely to be satisfied short term (OR, 2.25; 95% CI, 1.25-4.05), as were those who considered themselves involved in decision making about their treatment (3.05; 1.52-6.10). Higher long-term satisfaction with Mohs surgery was observed among patients who were married (2.36; 1.10-5.09). Conclusions: Higher short-and long-term satisfaction with Mohs surgery is predicted by better preoperative skin-related quality of life and by more intraoperative Mohs stages. The effect of postoperative variables wanes over time, suggesting that factors influencing satisfaction can vary depending on the time frame when satisfaction is measured. Our results may help clinicians identify patients who are at higher risk of dissatisfaction following Mohs surgery. C1 [Asgari, Maryam M.; Warton, E. Margaret; Neugebauer, Romain] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. [Asgari, Maryam M.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. RP Asgari, MM (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM maryam.m.asgari@kp.org RI Asgari, Maryam/O-4947-2016 FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23 AR 051037, K24 AR052667]; Health Services Research and Development Service, Department of Veterans Affairs [IIR 04-043-3] FX This study was supported in part by grants K23 AR 051037 (Dr Asgari) and K24 AR052667 (Dr Chren) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and by grant IIR 04-043-3 (Dr Chren) from the Health Services Research and Development Service, Department of Veterans Affairs. NR 35 TC 6 Z9 6 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD DEC PY 2011 VL 147 IS 12 BP 1387 EP 1394 PG 8 WC Dermatology SC Dermatology GA 864QV UT WOS:000298255800005 PM 22184760 ER PT J AU Lawson, EH Gibbons, MM Ingraham, AM Shekelle, PG Ko, CY AF Lawson, Elise H. Gibbons, Melinda Maggard Ingraham, Angela M. Shekelle, Paul G. Ko, Clifford Y. TI Appropriateness Criteria to Assess Variations in Surgical Procedure Use in the United States SO ARCHIVES OF SURGERY LA English DT Review ID BYPASS GRAFT-SURGERY; UPPER GASTROINTESTINAL ENDOSCOPY; ACADEMIC MEDICAL-CENTERS; HEALTH-CARE SERVICES; NEW-YORK-STATE; CAROTID-ENDARTERECTOMY; CORONARY REVASCULARIZATION; PHYSICIAN RATINGS; CARDIAC REVASCULARIZATION; PRACTICE GUIDELINES AB Objectives: To systematically describe appropriateness criteria (AC) developed in the United States for surgical procedures and to summarize how these criteria have been applied to identify overuse and underuse of procedures in US populations. Data Sources: MEDLINE literature search performed in February 2010 and May 2011. Study Selection: Studies were included if they addressed the appropriateness of a surgical procedure using the RAND-UCLA Appropriateness Method. Non-US studies were excluded. Data Extraction: Information was abstracted on study design, surgical procedure, and reported rates of appropriate use, overuse, and underuse. Identified AC were cross-referenced with lists of common procedures from the Nationwide Inpatient Sample and the State Ambulatory Surgery databases. Data Synthesis: A total of 1601 titles were identified; 39 met the inclusion criteria. Of these, 17 developed AC and 27 applied AC to US populations. Appropriateness criteria have been developed for 16 surgical procedures. Underuse has only been studied for coronary artery bypass graft surgery, and rates range from 24% to 57%. Overuse has been more broadly studied, with rates ranging from 9% to 53% for carotid endarterectomy, 0% to 14% for coronary artery bypass graft, 11% to 24% for upper gastrointestinal tract endoscopy, and 16% to 70% for hysterectomy. Appropriateness criteria exist for 10 of the 25 most common inpatient procedures and 6 of the 15 top ambulatory procedures in the United States. Most studies are more than 5 years old. Conclusions: Most existing AC are outdated, and AC have never been developed for most common surgical procedures. A broad and coordinated effort to develop and maintain AC would be required to implement this tool to address variation in the use of surgical procedures. C1 [Lawson, Elise H.] Univ Calif Los Angeles, Med Ctr, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Lawson, Elise H.; Ingraham, Angela M.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Gibbons, Melinda Maggard] Olive View UCLA Univ Calif Los Angeles, Dept Surg, Med Ctr, Sylmar, CA USA. [Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Shekelle, Paul G.] RAND Hlth, Santa Monica, CA USA. [Shekelle, Paul G.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Surg, David Geffen Sch Med, CHS 72-215,10833 LeConte Ave, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU Robert Wood Johnson Foundation through the American College of Surgeons FX Dr Lawson's time was supported by the Robert Wood Johnson Foundation Clinical Scholars Program through the American College of Surgeons. NR 60 TC 22 Z9 22 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD DEC PY 2011 VL 146 IS 12 BP 1433 EP 1440 PG 8 WC Surgery SC Surgery GA 864RF UT WOS:000298256900025 PM 22184308 ER PT J AU Thase, ME Larsen, KG Kennedy, SH AF Thase, Michael E. Larsen, Klaus G. Kennedy, Sidney H. TI Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID ESCITALOPRAM; SEVERITY; TRIALS; TRAJECTORIES; METAANALYSIS; EFFICACY AB Background There is controversy about the implications of relatively small average drug-placebo differences observed in randomised controlled trials of antidepressant medications. Aims To investigate whether efficacy is better understood as a large effect in a subgroup of patients. Method The mixture model was used to identify patient subgroups (patients benefiting or not benefiting from treatment) to directly model the skewness of Montgomery-Asberg Depression Rating Scale (MADRS) scores at week 8. Results The MADRS scores improved by 15.9 points (95% CI 15.2-16.6) among patients who benefited from treatment. The proportion of patients who benefited from escitalopram and not from placebo treatment was 19.5%, corresponding to a number needed to treat of 5. Conclusions This model gave a considerably better fit to the data than the analysis of covariance model in which all patients were assumed to benefit from treatment. The small average antidepressant-placebo difference obscures a much larger effect in a clinically meaningful subgroup of patients. C1 [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Larsen, Klaus G.] H Lundbeck & Co AS, Copenhagen, Denmark. [Kennedy, Sidney H.] Univ Toronto, Toronto, ON, Canada. RP Thase, ME (reprint author), Univ Penn, Sch Med, Suite 689,3535 Market St, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu FU Agency for Healthcare Research and Quality; Aldolor; Alkermes; AstraZeneca; Bristol-Myers Squibb; Cephalon; Cyberonics; Dey Pharmaceuticals; Eli Lilly; GlaxoSmithKline; Janssen Pharmaceutica; MedAvante; Merck FX M.E.T. is an advisor/consultant for H. Lundbeck A/S. During the past 5 years has been advisor/consultant for, and/or received research funding and/or honoraria for talks from: the Agency for Healthcare Research and Quality, Aldolor, Alkermes, AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Dey Pharmaceuticals, Eli Lilly, Forest Laboratories (including PGx), GlaxoSmithKline, Janssen Pharmaceutica, MedAvante, Merck (including Organon and Schering-Plough), National Institute of Mental Health, Neuronetics, Novartis, Otsuka, PamLab, Pfizer (including Wyeth), Rexahn, Sanofi Aventis, Sepracor, Shire US, Takeda and Transcept. He has equity holdings in MedAvante and has received income from royalties from American Psychiatric Publishing, Guilford Publications and Herald House. S.H.K has received grant funding and consulting honoraria from H. Lundbeck A/S. In the past 5 years he has also received grant funding or consulting honoraria from AstraZeneca, Biovail, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen-Ortho, Merck-Frosst, Organon, Pfizer, Servier and St Jude Medical. K.G.L. is an employee of H. Lundbeck A/S. NR 29 TC 27 Z9 27 U1 1 U2 7 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND SN 0007-1250 EI 1472-1465 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD DEC PY 2011 VL 199 IS 6 BP 501 EP 507 DI 10.1192/bjp.bp.111.093336 PG 7 WC Psychiatry SC Psychiatry GA 867FO UT WOS:000298440500014 PM 22130749 ER PT J AU Park, LS Tate, JP Justice, AC Lo Re, V Lim, JK Brau, N Brown, ST Butt, AA Gibert, C Goetz, MB Rimland, D Rodriguez-Barradas, MC Dubrow, R AF Park, Lesley S. Tate, Janet P. Justice, Amy C. Lo Re, Vincent, III Lim, Joseph K. Braeu, Norbert Brown, Sheldon T. Butt, Adeel A. Gibert, Cynthia Goetz, Matthew Bidwell Rimland, David Rodriguez-Barradas, Maria C. Dubrow, Robert TI FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID C VIRUS-INFECTION; DIABETES-MELLITUS; UNITED-STATES; HEPATITIS; EPIDEMIOLOGY; COINFECTION; MORTALITY; CIRRHOSIS; FIBROSIS; OBESITY AB Background: Chronic inflammation caused by hepatitis B virus infection, hepatitis Cvirus infection, and/or heavy alcohol use can lead to fibrosis, cirrhosis, and eventually hepatocellular carcinoma (HCC). FIB-4 is an index score calculated from platelet count, alanine transaminase, aspartate transaminase, and age that predicts fibrosis and cirrhosis. We hypothesized that high FIB-4 would be associated with development of HCC in HIV infected persons, who are at high risk due to high prevalence of viral hepatitis and alcohol consumption, and possibly due to HIV infection itself. Methods: Using proportional hazards models, we tested this hypothesis among 22,980 HIV-infected men from the Veterans Aging Cohort Study. We identified incident HCC cases from the Veterans Affairs Central Cancer Registry. Results: During follow-up, there were 112 incident HCC diagnoses. The age-and race/ethnic group adjusted HR was 4.2 [95% confidence interval (CI), 2.4-7.4] for intermediate FIB-4 and 13.0 (95% CI, 7.2-23.4) for high FIB-4, compared with low FIB-4. After further adjustment for enrollment year, CD4 count, HIV-1 RNA level, antiretroviral therapy use, hepatitis B and C virus infection, alcohol abuse/dependency, and diabetes, FIB-4 remained a strong, significant, independent risk factor for HCC. The multivariate-adjusted HR was 3.6 (95% CI, 2.1-6.4) for intermediate FIB-4 and 9.6 (95% CI, 5.2-17.4) for high FIB-4. Conclusions: Calculated from routine, noninvasive laboratory tests, FIB-4 is a strong, independent HCC risk factor in HIV-infected patients. Impact: FIB-4 might prove valuable as an easily measured index to identify those at highest risk for HCC, even prior to development of clinical cirrhosis. Cancer Epidemiol Biomarkers Prev; 20(12); 2512-7. (C) 2011 AACR. C1 [Park, Lesley S.; Tate, Janet P.; Justice, Amy C.; Lim, Joseph K.; Dubrow, Robert] Yale Univ, Sch Med, West Haven, CT 06516 USA. [Dubrow, Robert] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Tate, Janet P.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Lo Re, Vincent, III] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Lo Re, Vincent, III] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Braeu, Norbert; Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA. [Gibert, Cynthia] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Goetz, Matthew Bidwell] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. RP Park, LS (reprint author), Yale Univ, Sch Med, 950 Campbell Ave,Bldg 35A, West Haven, CT 06516 USA. EM lesley.park@yale.edu RI Lo Re, Vincent/N-7817-2015 OI Goetz, Matthew/0000-0003-4542-992X FU NIH: National Institute on Alcohol Abuse and Alcoholism [U01-AA13566]; National Institute on Aging [R01-AG029154]; National Heart, Lung, and Blood Institute [R01-HL095136, R01-HL090342, RCI-HL100347]; National Institute of Allergy and Infectious Diseases [U01-AI069918]; National Institute of Mental Health [P30-MH062294]; Veterans Health Administration Office of Research and Development [VA REA 08-266]; Office of Academic Affiliations FX This work was supported by NIH: National Institute on Alcohol Abuse and Alcoholism (U01-AA13566); National Institute on Aging (R01-AG029154); National Heart, Lung, and Blood Institute (R01-HL095136, R01-HL090342, RCI-HL100347); National Institute of Allergy and Infectious Diseases (U01-AI069918); National Institute of Mental Health (P30-MH062294); and the Veterans Health Administration Office of Research and Development (VA REA 08-266) and Office of Academic Affiliations (Medical Informatics Fellowship). NR 22 TC 21 Z9 21 U1 1 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD DEC PY 2011 VL 20 IS 12 BP 2512 EP 2517 DI 10.1158/1055-9965.EPI-11-0582 PG 6 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 864JA UT WOS:000298234900006 PM 22028407 ER PT J AU Stott-Miller, M Houck, JR Lohavanichbutr, P Mendez, E Upton, MP Futran, ND Schwartz, SM Chen, C AF Stott-Miller, Marni Houck, John R. Lohavanichbutr, Pawadee Mendez, Eduardo Upton, Melissa P. Futran, Neal D. Schwartz, Stephen M. Chen, Chu TI Tumor and Salivary Matrix Metalloproteinase Levels Are Strong Diagnostic Markers of Oral Squamous Cell Carcinoma SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID SINGLE NUCLEOTIDE POLYMORPHISM; GENE-EXPRESSION; HUMAN-PAPILLOMAVIRUS; POTENTIAL BIOMARKERS; OROPHARYNGEAL CANCER; CDNA MICROARRAY; RISK-FACTOR; HEAD; NECK; PROGRESSION AB Background: The matrix metalloproteinases (MMP) cause degradation of the extracellular matrix and basement membranes, and thus may play a key role in cancer development. Methods: In our search for biomarkers for oral squamous cell carcinomas (OSCC), we compared primary OSCC, oral dysplasia and control subjects with respect to: (i) expression of MMP1, MMP3, MMP10, and MMP12 in oral epithelial tissue using Affymetrix U133 2.0 Plus GeneChip arrays, followed by quantitative reverse transcription-PCR (qRT-PCR) for MMP1, and (ii) determination of MMP1 and MMP3 concentrations in saliva. Results: MMP1 expression in primary OSCC (n = 119) was > 200-fold higher (P 7.16 x 10(-40)) compared with expression levels in nonneoplastic oral epithelium from controls (n 35). qRT-PCR results on 30 cases and 22 controls confirmed this substantial differential expression. The exceptional discriminatory power to separate OSCC from controls was validated in two independent testing sets (AUC% 100; 95% CI: 100-100 and AUC% 98.4; 95% CI: 95.6-100). Salivary concentrations of MMP1 and MMP3 in OSCC patients (33 stage I/II, 26 stage III/IV) were 6.2 times (95% CI: 3.32-11.73) and 14.8 times (95% CI: 6.75-32.56) higher, respectively, than in controls, and displayed an increasing trend with higher stage disease. Conclusion: Tumor and salivary MMPs are robust diagnostic biomarkers of OSCC. Impact: The capacity of MMP gene expression to identify OSCC provides support for further investigation into MMPs as potential markers for OSCC development. Detection of MMP proteins in saliva in particular may provide a promising means to detect and monitor OSCC noninvasively. Cancer Epidemiol Biomarkers Prev; 20(12); 2628-36. (C) 2011 AACR. C1 [Stott-Miller, Marni; Houck, John R.; Lohavanichbutr, Pawadee; Mendez, Eduardo; Schwartz, Stephen M.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA. [Stott-Miller, Marni; Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Mendez, Eduardo; Futran, Neal D.; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Program Epidemiol, 1100 Fairview Ave N,M5-C800,POB 19024, Seattle, WA 98109 USA. EM cchen@fhcrc.org FU U.S. NIH (from the National Cancer Institute) [R01CA095419]; NIH [5T32DE007132-28]; Fred Hutchinson Cancer Research Center FX U.S. NIH (R01CA095419 from the National Cancer Institute), NIH 5T32DE007132-28 (Comprehensive training in inter-disciplinary oral health research), and institutional funds from the Fred Hutchinson Cancer Research Center. NR 49 TC 15 Z9 15 U1 0 U2 8 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD DEC PY 2011 VL 20 IS 12 BP 2628 EP 2636 DI 10.1158/1055-9965.EPI-11-0503 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 864JA UT WOS:000298234900019 PM 21960692 ER PT J AU Jones, JA Stroud, RE O'Quinn, EC Black, LE Barth, JL Elefteriades, JA Bavaria, JE Gorman, JH Gorman, RC Spinale, FG Ikonomidis, JS AF Jones, Jeffrey A. Stroud, Robert E. O'Quinn, Elizabeth C. Black, Laurel E. Barth, Jeremy L. Elefteriades, John A. Bavaria, Joseph E. Gorman, Joseph H., III Gorman, Robert C. Spinale, Francis G. Ikonomidis, John S. TI Selective MicroRNA Suppression in Human Thoracic Aneurysms Relationship of miR-29a to Aortic Size and Proteolytic Induction SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE aneurysm; thoracic aorta; microRNA; MMP; remodeling ID CARDIOVASCULAR-DISEASE ENTERPRISES; IN-SITU LOCALIZATION; MATRIX METALLOPROTEINASES; ENDOGENOUS INHIBITORS; MAJOR SHAREHOLDERS; MARFAN-SYNDROME; IV COLLAGENASE; MURINE MODEL; EXPRESSION; MATRIX-METALLOPROTEINASE-9 AB Background-Increasing evidence points to a direct role for altered microRNA (miRNA or miR) expression levels in cardiovascular remodeling and disease progression. Although alterations in miR expression levels have been directly linked to cardiac hypertrophy, fibrosis, and remodeling, their role in regulating gene expression during thoracic aortic aneurysm (TAA) development has yet to be explored. Methods and Results-The present study examined miR expression levels in aortic tissue specimens collected from patients with ascending TAAs by quantitative real-time PCR, and observed decreased miR expression (miRs -1, -21, -29a, -133a, and -486) as compared with normal aortic specimens. A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified; as aortic diameter increased, miR expression decreased. Through the use of a bioinformatics approach, members of the matrix metalloproteinase (MMP) family, proteins involved in TAA development, were examined for putative miR binding sites. MMP-2 and MMP-9 were identified as potential targets for miR-29a and miR-133a, respectively, and MMP-2 was subsequently verified as a miR-29a target in vitro. A significant inverse relationship between miR-29a and total MMP-2 was then identified in the clinical TAA specimens. Conclusions-These findings demonstrate altered miR expression patterns in clinical TAA specimens, suggesting that the loss of specific miR expression may allow for the elaboration of specific MMPs capable of driving aortic remodeling during TAA development. Importantly, these data suggest that these miRs have biological and clinical relevance to the behavior of TAAs and may provide significant targets for therapeutic and diagnostic applications. (Circ Cardiovasc Genet. 2011;4:605-613.) C1 [Ikonomidis, John S.] Med Univ S Carolina, Div Cardiothorac Surg, S Carolina Heart Valve Ctr, Charleston, SC 29425 USA. [Jones, Jeffrey A.; Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Barth, Jeremy L.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Elefteriades, John A.] Yale Univ, Sch Med, Dept Cardiothorac Surg, New Haven, CT USA. [Bavaria, Joseph E.; Gorman, Joseph H., III; Gorman, Robert C.] Univ Penn, Gorman Cardiovasc Res Grp, Glenolden Res Lab, Glenolden, PA USA. RP Ikonomidis, JS (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, S Carolina Heart Valve Ctr, 25 Courtenay Dr,Suite 7030, Charleston, SC 29425 USA. EM ctsxresearch@musc.edu FU Department of Veterans Affairs; National Institutes of Health; NIH/NCRR [RR16434, RR16461]; [NHLBI/R01s HL057952-08]; [HL059165-09]; [NHLBI/R21 HL089170-01A1]; [R01 HL102121-01A1] FX This work was supported by the Department of Veterans Affairs: Career Development Award (CDA-2) and a Merit Award to Dr Jones and a Merit Award to Dr Spinale; National Institutes of Health grants NIH/NCRR RR16434 and RR16461 to Dr Barth; NHLBI/R01s HL057952-08 and HL059165-09 to Dr Spinale; and NHLBI/R21 HL089170-01A1 and R01 HL102121-01A1 to Dr Ikonomidis. NR 35 TC 41 Z9 43 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD DEC PY 2011 VL 4 IS 6 BP 605 EP U264 DI 10.1161/CIRCGENETICS.111.960419 PG 15 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 866VR UT WOS:000298414800006 PM 22010139 ER PT J AU Zile, MR Mehurg, SM Arroyo, JE Stroud, RE DeSantis, SM Spinale, FG AF Zile, Michael R. Mehurg, Shannon M. Arroyo, Jazmine E. Stroud, Robert E. DeSantis, Stacia M. Spinale, Francis G. TI Relationship Between the Temporal Profile of Plasma microRNA and Left Ventricular Remodeling in Patients After Myocardial Infarction SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE myocardial infarction; remodeling; microRNA ID CIRCULATING MICRORNAS; DISEASE; EXPRESSION; BIOMARKERS; HEART; FIBROSIS; MARKERS; CANCER; OCCURS; BLOOD AB Background-microRNAs (miRs) are small noncoding RNAs that recognize and bind to mRNAs and inhibit protein translation or degrade mRNA. Studies in animal models have suggested that miRs play a translational or posttranslational regulatory role in myocardial growth, fibrosis, viability, and remodeling. However, whether specific temporal changes in miRs occur in patients during the left ventricular (LV) remodeling process that follows a myocardial infarction (post-MI) remains unknown. The current pilot study tested the hypotheses that plasma miRs could be reliably measured in post-MI patients and that there is a relationship between temporal changes in specific miRs and post-MI LV structural remodeling. Methods and Results-LV end-diastolic volume (echocardiography) and plasma miR were measured in age-matched referent controls (CTLs, n = 12) and post-MI patients (n = 12) from day 2 through day 90 post-MI. Selected miRs (miR-1, miR-21, miR-29a, miR-133a, and miR-208) were measured using quantitative reverse transcription-polymerase chain reaction and normalized for endogenous small nuclear RNA U6. After MI, LV end-diastolic volume increased progressively compared with CTL; this was accompanied by time-dependent changes in specific miRs. For example, miR-21 initially decreased 2 days post-MI (0.3 +/- 0.1-fold versus CTL; P<0.05), increased 5 days post-MI (2 +/- 1-fold versus CTL; P<0.05), and returned to CTL values at later post-MI time points. In contrast, miR-29a increased 5 days post-MI (4 +/- 1-fold versus CTL; P<0.05) and then decreased to CTL at later time points. miR-208 increased 5 days post-MI (3 +/- 1-fold versus CTL; P<0.05) and remained elevated up to 90 days post-MI. Conclusions-A time-dependent change in miRs occurred in post-MI patients, including an early and robust increase in miRs that has affected myocardial growth, fibrosis, and viability. Thus, serially profiling miRs in the plasma of post-MI patients may hold both mechanistic and prognostic significance. (Circ Cardiovasc Genet. 2011;4:614-619.) C1 [Zile, Michael R.; Mehurg, Shannon M.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Arroyo, Jazmine E.; Stroud, Robert E.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Dept Surg, Charleston, SC 29425 USA. [DeSantis, Stacia M.] Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. [DeSantis, Stacia M.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. RP Zile, MR (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Ashley River Towers,25 Courtenay Dr,Room 7067, Charleston, SC 29425 USA. EM zilem@musc.edu FU Doris Duke Foundation and Health Sciences of South Carolina; Research Service of the Department of Veterans Affairs; National Institutes of Health [HL057952, HL059165, HL095608] FX This study was supported by the Doris Duke Foundation and Health Sciences of South Carolina (Dr Zile); the Research Service of the Department of Veterans Affairs (Drs Zile and Spinale); grants HL057952, HL059165, and HL095608 from the National Institutes of Health (Dr Spinale). NR 24 TC 61 Z9 66 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD DEC PY 2011 VL 4 IS 6 BP 614 EP 619 DI 10.1161/CIRCGENETICS.111.959841 PG 6 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 866VR UT WOS:000298414800007 PM 21956146 ER PT J AU O'Leary, TJ AF O'Leary, Timothy J. TI "Research Use Only" Reagents: Is There an Imperative for Increased FDA Oversight? SO CLINICAL CHEMISTRY LA English DT Article C1 Vet Hlth Adm, Off Res & Dev, US Dept Vet Affairs, Washington, DC 20420 USA. RP O'Leary, TJ (reprint author), Vet Hlth Adm, Off Res & Dev, US Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA. EM timothy.oleary@va.gov NR 3 TC 1 Z9 1 U1 0 U2 2 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD DEC PY 2011 VL 57 IS 12 BP 1681 EP 1683 DI 10.1373/clinchem.2011.174268 PG 3 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 862UM UT WOS:000298119600009 PM 21998341 ER PT J AU Mukete, BN Atlas, SA AF Mukete, Bertrand N. Atlas, Steven A. TI Implications of Changes in Plasma Asymmetric Dimethylarginine During Treatment of Hypertension SO CURRENT HYPERTENSION REPORTS LA English DT Editorial Material DE Dimethylarginine; Hypertension; Treatment; Clinical trial; Nebivolol; Metoprolol; Beta-blockers; Nitric oxide synthase; Arginine; Antihypertensive agents ID BETA(3)-ADRENOCEPTOR AGONISTS; NEBIVOLOL; DRUGS C1 [Mukete, Bertrand N.; Atlas, Steven A.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Mukete, Bertrand N.; Atlas, Steven A.] Mt Sinai Sch Med, New York, NY 10028 USA. RP Atlas, SA (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM steven.atlas@va.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1522-6417 J9 CURR HYPERTENS REP JI Curr. Hypertens. Rep. PD DEC PY 2011 VL 13 IS 6 BP 406 EP 408 DI 10.1007/s11906-011-0233-8 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 874ZA UT WOS:000298996300004 PM 22045470 ER PT J AU Egede, LE Gebregziabher, M Lynch, CP Gilbert, GE Echols, C AF Egede, Leonard E. Gebregziabher, Mulugeta Lynch, Cheryl P. Gilbert, Gregory E. Echols, Carrae TI Longitudinal ethnic differences in multiple cardiovascular risk factor control in a cohort of US adults with diabetes SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Diabetes; Cardiovascular disease; Risk factor control; Ethnicity; Veterans ID OF-VETERANS-AFFAIRS; HEALTH-CARE-SYSTEM; INTERMEDIATE OUTCOMES; DISEASE RISK; PREVENTION; POPULATION; PREVALENCE; QUALITY; TRIAD AB Aim: To examine longitudinal differences in multiple cardiovascular risk factor control (glycemia, blood pressure, and lipids) by race/ethnicity. Methods: Data were analyzed on a cohort of 11,203 veterans with type 2 diabetes. Primary outcome was odds of none of the risk factors out of control vs. having at least one out of control (HbA1c > 8.0%, BP > 140/90 mmHg, and LDL > 100 mg/dL). Secondary outcome was odds of having none out of control vs. having one, two or three risk factors out of control, respectively. Generalized linear mixed models assessed the relationship between race/ethnicity and multiple risk factor control adjusted for covariates. Results: Adjusted models for primary outcome showed that NHB had two-fold (95% CI 1.8-2.3) and Hispanics had 48% higher (95% CI 1.3-1.7) odds of multiple risk factors out of control over time compared to NHW. Adjusted models for secondary outcome showed that NHB and Hispanics also had higher odds of having one, two, and three risk factors out of control over time compared to NHW. Conclusions: Ethnic minority veterans with diabetes are less likely to have multiple cardiovascular risk factor control over time compared to whites. Thus, greater risk reduction efforts are needed to reduce the heavier disease burden among ethnic minorities. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Egede, Leonard E.; Gebregziabher, Mulugeta; Lynch, Cheryl P.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Egede, Leonard E.; Lynch, Cheryl P.; Gilbert, Gregory E.; Echols, Carrae] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu RI Gilbert, Gregory/C-7735-2016 OI Gilbert, Gregory/0000-0003-0879-5496; Gebregziabher, Mulugeta/0000-0002-4826-481X FU Center for Disease Prevention and Health Interventions for Diverse Populations [REA 08-261]; Veterans Affairs Health Services Research and Development (PI - Leonard Egede) FX This study was supported by Grant # REA 08-261, Center for Disease Prevention and Health Interventions for Diverse Populations funded by Veterans Affairs Health Services Research and Development (PI - Leonard Egede). NR 31 TC 13 Z9 13 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD DEC PY 2011 VL 94 IS 3 BP 385 EP 394 DI 10.1016/j.diabres.2011.08.003 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 863EA UT WOS:000298144400019 PM 21903291 ER PT J AU Nett, JE Sanchez, H Cain, MT Ross, KM Andes, DR AF Nett, Jeniel E. Sanchez, Hiram Cain, Michael T. Ross, Kelly M. Andes, David R. TI Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity Regulation SO EUKARYOTIC CELL LA English DT Article ID ANTIFUNGAL AGENTS; SACCHAROMYCES-CEREVISIAE; FLUCONAZOLE RESISTANCE; GENE DISRUPTION; BETA-GLUCANS; EFFLUX PUMPS; IN-VIVO; SUSCEPTIBILITY; INFECTIONS; PATHWAY AB Candida albicans frequently infects medical devices by growing as a biofilm, i.e., a community of adherent organisms entrenched in an extracellular matrix. During biofilm growth, Candida spp. acquire the ability to resist high concentrations of antifungal drugs. One recently recognized biofilm resistance mechanism involves drug sequestration by matrix beta-1,3 glucan. Using a candidate gene approach, we investigated potential C. albicans beta-1,3-glucan regulators, based on their homology to Saccharomyces cerevisiae, including SMI1 and protein kinase C (PKC) pathway components. We identified a role for the SMI1 in biofilm matrix glucan production and development of the associated drug resistance phenotype. This pathway appears to act through transcription factor Rlmp and glucan synthase Fks1p. The phenotypes of these mutant biofilms mimicked those of the smi1 Delta/smi1 Delta biofilm, and overexpression of FKS1 in the smi1 Delta/smi1 Delta mutant restored the biofilm resistant phenotype. However, control of this pathway is distinct from that of the upstream PKC pathway because the pkc1 Delta/pkc1 Delta, bck1 Delta/bck1 Delta, mkk2 Delta/mkk2 Delta, and mkc1 Delta/mkc1 Delta biofilms retained the resistant phenotype of the parent strain. In addition, resistance to cell-perturbing agents and gene expression data do not support a significant role for the cell wall integrity pathway during the biofilm formation. Here we show that Smi1p functions in conjunction with Rlm1p and Fks1p to produce drug-sequestering biofilm beta-glucan. Our work provides new insight into how the C. albicans biofilm matrix production and drug resistance pathways intersect with the planktonic cell wall integrity pathway. This novel connection helps explain how pathogens in a multicellular biofilm community are protected from anti-infective therapy. C1 [Nett, Jeniel E.; Sanchez, Hiram; Cain, Michael T.; Ross, Kelly M.; Andes, David R.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Andes, David R.] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53705 USA. [Nett, Jeniel E.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Andes, DR (reprint author), Univ Wisconsin, Dept Med, 5211 UW Med Fdn Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA. EM dra@medicine.wisc.edu FU National Institutes of Health [RO1 AI073289-01]; Veteran Women's Health Fellowship FX This work was supported by the National Institutes of Health (grant RO1 AI073289-01) and the Veteran Women's Health Fellowship. NR 52 TC 45 Z9 53 U1 1 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1535-9778 J9 EUKARYOT CELL JI Eukaryot. Cell PD DEC PY 2011 VL 10 IS 12 BP 1660 EP 1669 DI 10.1128/EC.05126-11 PG 10 WC Microbiology; Mycology SC Microbiology; Mycology GA 863HN UT WOS:000298153500007 PM 21666076 ER PT J AU Pantaleo, MA Astolfi, A Nannini, M Ceccarelli, C Formica, S Santini, D Heinrich, MC Corless, C Dei Tos, AP Paterini, P Catena, F Maleddu, A Saponara, M Di Battista, M Biasco, G AF Pantaleo, Maria A. Astolfi, Annalisa Nannini, Margherita Ceccarelli, Claudio Formica, Serena Santini, Donatella Heinrich, Michael C. Corless, Christopher Dei Tos, Angelo Paolo Paterini, Paola Catena, Fausto Maleddu, Alessandra Saponara, Maristella Di Battista, Monica Biasco, Guido TI Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours SO HISTOPATHOLOGY LA English DT Article DE gene expression profiling; GIST; ICC; ICC mature; ICC precursor; IGF1R; KIT; PDGFRA ID INTERSTITIAL-CELLS; C-KIT; THERAPEUTIC TARGET; MUTATIONS; CAJAL; GISTS; STOMACH; COMMON; RECEPTOR; SIZE AB Aims: To compare the genomic signatures of wildtype (WT) and mutated GISTs and the murine interstitial cells of Cajal (ICCs) to find markers of cell differentiation and other functions that may identify cells that give rise to WT tumours. Methods and results: We analysed the gene expression profiles of a total of 30 tumour samples (four WT GISTs and 26 mutated GISTs), selected the genes most differentially expressed (P < 0.001: 448 probe sets) and validated these results by quantitative polymerase chain reaction (PCR) and immunohistochemistry. In addition, we conducted a meta-analysis merging data from human GISTs with a genomic data set from murine ICCs. The gene expression profiles of WT and mutated GISTs differed profoundly, especially in the expression of those genes restricted primarily to neural tissues. We found that mature ICCs are more similar to mutated GISTs than WT GISTs. Conclusions: WT GISTs have different genomic profiles from both mutated GISTs and murine mature ICCs. Considering that IGF1R expression is common to both WT GISTs and putative precursor ICCs, this study suggests that WT GISTs may derive either from ICCs at a different step of differentiation or from a different cell of origin. C1 [Pantaleo, Maria A.; Nannini, Margherita; Maleddu, Alessandra; Saponara, Maristella; Di Battista, Monica; Biasco, Guido] Univ Bologna, S Orsola Malpighi Hosp, Dept Hematol & Oncol Sci LA Seragnoli, I-40138 Bologna, Italy. [Pantaleo, Maria A.; Astolfi, Annalisa; Formica, Serena; Paterini, Paola; Biasco, Guido] Univ Bologna, Interdept Ctr Canc Res G Prodi, I-40138 Bologna, Italy. [Ceccarelli, Claudio; Santini, Donatella] Univ Bologna, S Orsola Malpighi Hosp, Dept Radiol & Histopathol Sci, Surg Pathol Unit, I-40138 Bologna, Italy. [Heinrich, Michael C.; Corless, Christopher] Portland VA Med Ctr, Dept Med, Portland, OR USA. [Heinrich, Michael C.; Corless, Christopher] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Dei Tos, Angelo Paolo] Gen Hosp Treviso, Dept Oncol, Treviso, Italy. [Catena, Fausto] Univ Bologna, S Orsola Malpighi Hosp, Emergency Surg & Transplant Dept, I-40138 Bologna, Italy. RP Pantaleo, MA (reprint author), Univ Bologna, S Orsola Malpighi Hosp, Dept Hematol & Oncol Sci LA Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy. EM maria.pantaleo@unibo.it RI Saponara, Maristella/J-9904-2016; nannini, margherita/J-9866-2016 OI Saponara, Maristella/0000-0003-0715-171X; PANTALEO, MARIA ABBONDANZA/0000-0002-0177-6957; DEI TOS, ANGELO/0000-0002-1228-8940; Ceccarelli, Claudio/0000-0003-0743-2087; NANNINI, MARGHERITA/0000-0002-2103-1960; astolfi, annalisa/0000-0002-2732-0747 FU Fondazione Cassa di Risparmio of Bologna (CARISBO), Italy; Fondazione Giuseppe Alazio; Palermo Italy; Fondazione Vanini-Cavagnino, Bologna, Italy FX Research programmes on GIST are supported by Fondazione Cassa di Risparmio of Bologna (CARISBO), Italy, Fondazione Giuseppe Alazio, Palermo Italy and Fondazione Vanini-Cavagnino, Bologna, Italy. NR 30 TC 10 Z9 10 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0309-0167 J9 HISTOPATHOLOGY JI Histopathology PD DEC PY 2011 VL 59 IS 6 BP 1071 EP 1080 DI 10.1111/j.1365-2559.2011.04071.x PG 10 WC Cell Biology; Pathology SC Cell Biology; Pathology GA 866CT UT WOS:000298358000005 PM 22175887 ER PT J AU Lai, YY Chen, B Shi, JB Palmer, JN Kennedy, DW Cohen, NA AF Lai, Yinyan Chen, Bei Shi, Jianbo Palmer, James N. Kennedy, David W. Cohen, Noam A. TI Inflammation-mediated upregulation of centrosomal protein 110, a negative modulator of ciliogenesis, in patients with chronic rhinosinusitis SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Chronic rhinosinusitis; ciliated epithelial cell; ciliogenesis; cytokine; inflammation; centrosomal protein 110 ID LIQUID INTERFACE CULTURES; CHRONIC SINUSITIS; NASAL POLYPOSIS; PSEUDOMONAS-AERUGINOSA; HUMAN-CELLS; EXPRESSION; CILIA; CENTRIOLE; INTERLEUKIN-5; EPITHELIUM AB Background: Sinonasal mucosa in patients with chronic rhinosinusitis (CRS) is often devoid of motile cilia. This defect is presumed to result from prolonged inflammation, infection, or both. However, the mechanism underlying this observation is unknown. Recently, centrosomal protein 110 (Cp110) was shown to prevent the terminal step in ciliary maturation (ie, elongation), suggesting that Cp110 might be involved in pathological states in which ciliation is abnormal. Objectives: First, we sought to investigate the expression of Cp110 in sinonasal mucosa from patients with CRS and control subjects. Second, we sought to determine the extent that inflammatory cytokines modulate Cp110 expression and ciliary maturation in vitro. Methods: Sinonasal mucosal specimens from patients with and without CRS were analyzed for Cp110 mRNA and protein expression. Furthermore, human and murine nasal respiratory epithelial cultures were used to investigate Cp110 expression under normal growth conditions and in the presence of exogenous proinflammatory cytokines. Results: Increased Cp110 mRNA and protein expression was found in sinonasal mucosal specimens from patients with CRS compared with that seen in control specimens. During ciliogenesis in vitro, the expression of Cp110 gradually decreased in cultures derived from patients without CRS but remained increased in cultures derived from patients with CRS. Furthermore, cultures grown in the presence of proinflammatory cytokines demonstrated increased levels of Cp110 expression with concomitant inhibition of ciliogenesis. Conclusion: Increased Cp110 expression in mucosa from patients with CRS might contribute to the poor ciliation observed in patients with CRS. Exogenous cytokine exposure maintains increased levels of Cp110 expression. Regulation of Cp110 expression by inflammation warrants additional investigation because it might offer a novel target in the management of respiratory tract diseases. (J Allergy Clin Immunol 2011;128:1207-15.) C1 [Lai, Yinyan; Chen, Bei; Palmer, James N.; Kennedy, David W.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Lai, Yinyan; Shi, Jianbo] Sun Yat Sen Univ, Otorhinolaryngol Hosp, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China. [Palmer, James N.; Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Div Otolaryngol, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM cohenn@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 FU China Scholarship Council; Flight Attendant Medical Research Institute [082478] FX Supported by the China Scholarship Council and the Flight Attendant Medical Research Institute Clinical Innovator Award (082478; to N.A.C.). NR 42 TC 31 Z9 33 U1 1 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD DEC PY 2011 VL 128 IS 6 BP 1207 EP U526 DI 10.1016/j.jaci.2011.09.001 PG 10 WC Allergy; Immunology SC Allergy; Immunology GA 865WX UT WOS:000298342700008 PM 21982113 ER PT J AU Udelson, JE Bilsker, M Hauptman, PJ Sequeira, R Thomas, I O'Brien, T Zimmer, C Orlandi, C Konstam, MA AF Udelson, James E. Bilsker, Martin Hauptman, Paul J. Sequeira, Rafael Thomas, Ignatius O'Brien, Terrence Zimmer, Christopher Orlandi, Cesare Konstam, Marvin A. TI A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Tolvaptan Monotherapy Compared to Furosemide and the Combination of Tolvaptan and Furosemide in Patients With Heart Failure and Systolic Dysfunction SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; diuretics; vasopressin ID LEFT-VENTRICULAR DYSFUNCTION; NEONATAL-RAT CARDIOMYOCYTE; VASOPRESSIN ANTAGONIST; RENAL-FUNCTION; RECEPTOR ANTAGONIST; PROTEIN-SYNTHESIS; DIURETIC THERAPY; ACTIVATION; SODIUM; TRIAL AB Background: Increased vasopressin levels may be present in patient with chronic heart failure (HF) and contribute to pathophysiology through effects on the vasopressin V2 receptor. The presence of background diuretic therapy may confound evaluations of vasopressin receptor antagonists (VRA). Methods and Results: Eligible patients had FIF (New York Heart Association Class 11411), systolic dysfunction (left ventricular ejection fraction <= 0.40) and signs of congestion (eg, edema, rales). At screening, patients were removed from baseline diuretic therapy and placed on a low-sodium diet (2 g/day). After a 2-day run-in period, 83 patients were randomized to placebo (n = 21), monotherapy with the vasopressin V2 receptor antagonist tolvaptan (TLV) 30 mg (n = 20), monotherapy with furosernide 80 mg (FURO, n = 22) or both TLV 30 mg and FURO 80 mg (n = 20) once daily for 7 days. Patients were on standard background therapy and not fluid-restricted throughout the study. A decrease in body weight of -1.37 +/- 1.61, -0.54 +/- 1.59, and -1.13 +/- 1.49 kg was observed versus baseline for TLV, FURO, and TLV+FURO, respectively, at day 8. At the same point, the placebo group showed a body weight increase of +0.72 +/- 2.42 kg versus baseline (P = .0006 for TLV versus placebo). Increases in urine volume from baseline were greater with TLV alone (2646 +/- 1503 mL/24 hours) than with FURO (894 +/- 853 mL/24 hours, P < .001), or PLC (423 +/- 786 mL/24 hours, P < .001), and similar to TLV+FURO (2585 2119 mL/24 hours). An increase in serum sodium within the normal range was also observed in TLV-treated patients (P < .02 versus placebo; P < .01 versus FURO). No changes in serum potassium, other laboratory values, or blood pressure were observed. TLV therapy was well tolerated. Conclusions: In patients with HF and signs of volume overload, TLV monotherapy without concomitant loop diuretic therapy reduced body weight when compared to placebo without adverse changes in serum electrolytes, during a sodium restricted diet while on background medications including angiotensin-converting enzyme inhibitors and beta-blockers. (J Cardiac Fail 2011;17:973-981) C1 [Udelson, James E.; Konstam, Marvin A.] Tufts Med Ctr, Div Cardiol, Boston, MA 02111 USA. [Udelson, James E.; Konstam, Marvin A.] Tufts Med Ctr, CardioVasc Ctr, Boston, MA 02111 USA. [Bilsker, Martin; Sequeira, Rafael] Univ Miami, Jackson Mem Hosp, Div Cardiol, Miami, FL 33136 USA. [Hauptman, Paul J.] St Louis Univ, Sch Med, St Louis, MO USA. [Thomas, Ignatius] Med Res Inst, Slidell, LA USA. [O'Brien, Terrence] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Zimmer, Christopher; Orlandi, Cesare] Otsuka Maryland Res Inst, Rockville, MD USA. RP Udelson, JE (reprint author), Tufts Med Ctr, Div Cardiol, 750 Washington St,Box 70, Boston, MA 02111 USA. EM JUdelson@tuftsmedicalcenter.org NR 32 TC 22 Z9 24 U1 1 U2 5 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD DEC PY 2011 VL 17 IS 12 BP 973 EP 981 DI 10.1016/j.cardfail.2011.08.005 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 864AB UT WOS:000298208300001 PM 22123358 ER PT J AU Goedecke, JH Evans, J Keswell, D Stimson, RH Livingstone, DEW Hayes, P Adams, K Dave, JA Victor, H Levitt, NS Lambert, EV Walker, BR Seckl, JR Olsson, T Kahn, SE AF Goedecke, Julia H. Evans, Juliet Keswell, Dheshnie Stimson, Roland H. Livingstone, Dawn E. W. Hayes, Philip Adams, Kevin Dave, Joel A. Victor, Hendriena Levitt, Naomi S. Lambert, Estelle V. Walker, Brian R. Seckl, Jonathan R. Olsson, Tommy Kahn, Steven E. TI Reduced Gluteal Expression of Adipogenic and Lipogenic Genes in Black South African Women Is Associated with Obesity-Related Insulin Resistance SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID ADIPOSE-TISSUE; IMPAIRED ADIPOGENESIS; BODY-FAT; DIFFERENTIATION; SENSITIVITY; PROFILE; PREADIPOCYTES; INFLAMMATION; HEALTH; MUSCLE AB Context: Black South African women are less insulin sensitive than their White counterparts, despite less central and greater peripheral fat deposition. We hypothesized that this paradox may be explained, in part, by differences in the adipogenic capacity of sc adipose tissue (SAT). Objective: Our objective was to measure adipogenic and lipogenic gene expression in abdominal and gluteal SAT depots and determine their relationships with insulin sensitivity (S(I)) in South African women. Participants and Design: Fourteen normal-weight [body mass index (BMI) <25 kg/m(2)] Black, 13 normal-weight White, 14 obese (BMI >30 kg/m(2)) Black, and 13 obese White premenopausal South African women participated in this cross-sectional study. Main outcomes: S(I) (frequently sampled iv glucose tolerance test) in relation to expression of adipogenic and lipogenic genes in abdominal and gluteal SAT depots. Results: With increasing BMI, Black women had less visceral fat (P = 0.03) and more abdominal (P = 0.017) and gynoid (P = 0.041) SAT but had lower S(I) (P < 0.01) than White women. The expression of adipogenic and lipogenic genes was proportionately lower with obesity in Black but not White women in the gluteal and deep SAT depots (P < 0.05 for ethnicity x BMI effect). In Black women only, the expression of these genes correlated positively with S(I) (all P < 0.05), independently of age and fat mass. Conclusions: Obese Black women have reduced SAT expression of adipogenic and lipogenic genes compared with White women, which associates with reduced S(I). These findings suggest that obesity in Black women impairs SAT adipogenesis and storage, potentially leading to insulin resistance and increased risk of type 2 diabetes. (J Clin Endocrinol Metab 96: E2029-E2033, 2011) C1 [Goedecke, Julia H.; Evans, Juliet; Keswell, Dheshnie; Victor, Hendriena; Lambert, Estelle V.] Univ Cape Town, Med Res Council Res Unit Exercise Sci & Sports Me, ZA-7725 Newlands, South Africa. [Hayes, Philip; Adams, Kevin] Univ Cape Town, Dept Human Biol, ZA-7725 Newlands, South Africa. [Dave, Joel A.; Levitt, Naomi S.] Univ Cape Town, Plast Surg Units, Dept Med, ZA-7725 Newlands, South Africa. [Dave, Joel A.; Levitt, Naomi S.] Univ Cape Town, Endocrine Units, Dept Med, ZA-7725 Newlands, South Africa. [Goedecke, Julia H.] S African MRC, ZA-7505 Tygerberg, South Africa. [Stimson, Roland H.; Livingstone, Dawn E. W.; Walker, Brian R.; Seckl, Jonathan R.] Univ Edinburgh, Endocrinol Unit, Univ British Heart Fdn Ctr Cardiovasc Sci, Edinburgh EH16 4TJ, Midlothian, Scotland. [Olsson, Tommy] Umea Univ, Dept Med, SE-90187 Umea, Sweden. [Kahn, Steven E.] Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98108 USA. [Kahn, Steven E.] Univ Washington, Div Metab Endocrinol & Nutr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Goedecke, JH (reprint author), Univ Cape Town, Med Res Council Res Unit Exercise Sci & Sports Me, 3rd Floor Sports Sci Inst S Africa,POB 115, ZA-7725 Newlands, South Africa. EM julia.goedecke@uct.ac.za RI Seckl, Jonathan/C-3555-2013; Goedecke, Julia/J-8628-2013; Goedecke, Julia/E-1820-2016 OI Goedecke, Julia/0000-0001-6795-4771; Goedecke, Julia/0000-0001-6795-4771; Olsson, Tommy/0000-0001-7768-1076; Kahn, Steven/0000-0001-7307-9002 FU South African Medical Research Council; International Atomic Energy Agency; National Research Foundation of South Africa; Royal Society SA-UK; University of Cape Town; British Heart Foundation; Wellcome Trust; U.S. Department of Veterans Affairs FX This work was supported by the South African Medical Research Council, International Atomic Energy Agency, National Research Foundation of South Africa and Royal Society SA-UK Science Networks Program, University of Cape Town, British Heart Foundation, Wellcome Trust, and U.S. Department of Veterans Affairs. NR 20 TC 11 Z9 11 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD DEC PY 2011 VL 96 IS 12 BP E2029 EP E2033 DI 10.1210/jc.2011-1576 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 865FA UT WOS:000298295200016 PM 21956425 ER PT J AU Schafer, AL Sellmeyer, DE Schwartz, AV Rosen, CJ Vittinghoff, E Palermo, L Bilezikian, JP Shoback, DM Black, DM AF Schafer, Anne L. Sellmeyer, Deborah E. Schwartz, Ann V. Rosen, Clifford J. Vittinghoff, Eric Palermo, Lisa Bilezikian, John P. Shoback, Dolores M. Black, Dennis M. TI Change in Undercarboxylated Osteocalcin Is Associated with Changes in Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH Study) SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID VITAMIN-K STATUS; SERUM OSTEOCALCIN; PLASMA-GLUCOSE; METABOLISM; PROTEIN; MEN AB Context: The undercarboxylated form of the osteoblast-secreted protein osteocalcin has favorable effects on fat and glucose metabolism in mice. In human subjects, cross-sectional studies suggest a relevant association. Objective: We investigated whether changes in undercarboxylated osteocalcin (ucOC) during osteoporosis treatment are associated with changes in metabolic parameters. Design, Setting, Participants, and Interventions: We measured ucOC in sera from a subset of osteoporotic postmenopausal women who were treated with PTH(1-84) or alendronate (n = 64 and n = 33, respectively) during the Parathyroid Hormone and Alendronate study. Main Outcome Measures: We measured serum adiponectin, leptin, and insulin and analyzed existing data on body weight, fat mass, and serum glucose concentration. Three-month changes in ucOC levels were evaluated as predictors of 12-month changes in indices of fat and glucose metabolism. Results: ucOC levels increased with PTH(1-84) and decreased with alendronate administration (P <= 0.01 for both treatment groups). Three-month change in ucOC was inversely associated with 12-month changes in body weight (standardized beta = -0.25, P = 0.04) and fat mass (beta = -0.23, P = 0.06), after adjustment for the treatment group. Three-month change in ucOC was positively associated with a 12-month change in adiponectin (beta = 0.30, P = 0.01), independent of change in fat mass. There were no interactions between treatment and change in ucOC on changes in weight, fat mass, or adiponectin. Conclusions: PTH(1-84) increases and alendronate decreases ucOC levels. Changes in ucOC induced by PTH(1-84) and alendronate are associated with changes in metabolic indices. These associations are consistent with observations from animal models and support a role for ucOC in the skeletal regulation of energy metabolism in humans. (J Clin Endocrinol Metab 96: E1982-E1989, 2011) C1 [Schafer, Anne L.; Shoback, Dolores M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Schwartz, Ann V.; Vittinghoff, Eric; Palermo, Lisa; Black, Dennis M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Schafer, Anne L.; Shoback, Dolores M.] San Francisco VA Med Ctr, Med Serv, Endocrine Res Unit, San Francisco, CA 94121 USA. [Sellmeyer, Deborah E.] Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA. [Rosen, Clifford J.] Maine Med Ctr, Res Inst, Scarborough, ME 04074 USA. [Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA. RP Schafer, AL (reprint author), 4150 Clement St,Box 111N, San Francisco, CA 94121 USA. EM anne.schafer@ucsf.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [NIAMS-045, N01-AR-9-2245]; Veterans Affairs; Department of Veterans Affairs; Amgen; Novartis; Merck; Roche FX The PaTH study was supported by a contract with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS-045, N01-AR-9-2245; to D.M.B.). The study drugs were supplied by NPS Pharmaceuticals, Inc. [PTH(1-84)] and Merck & Co., Inc. (alendronate). The authors have full control of all primary data. This ancillary study was supported by the Veterans Affairs Research Enhancement Award Program. Additional support for A.L.S. came from the Department of Veterans Affairs, through a Health Issues of Women Veterans Fellowship and a Career Development Award.; D.E.S. has received research support from Amgen and Novartis. A.V.S. has received research support from Merck. L.P. has consulted for NPS Pharmaceuticals, Inc. and Nycomed. D.M.B. has received research support from Amgen, Merck, Novartis, and Roche and has consulted for Nycomed. NR 20 TC 56 Z9 60 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD DEC PY 2011 VL 96 IS 12 BP E1982 EP E1989 DI 10.1210/jc.2011-0587 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 865FA UT WOS:000298295200009 PM 21994958 ER PT J AU Bloch, MJ Basile, JN AF Bloch, Michael J. Basile, Jan N. TI UK Guidelines Call for Routine 24-Hour Ambulatory Blood Pressure Monitoring in All Patients to Make the Diagnosis of HypertensionuNot Ready for Prime Time in the United States SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material C1 [Bloch, Michael J.] St Marys Reg Med Ctr, Risk Reduct Ctr, Reno, NV 89503 USA. [Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA. [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. RP Bloch, MJ (reprint author), St Marys Reg Med Ctr, Risk Reduct Ctr, 645 N Arlington St,Suite 460, Reno, NV 89503 USA. EM mbloch@aol.com NR 1 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD DEC PY 2011 VL 13 IS 12 BP 871 EP 872 DI 10.1111/j.1751-7176.2011.00551.x PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 859DJ UT WOS:000297854700003 PM 22142345 ER PT J AU Patel, M Gonzalez, R Halford, C Lewinski, MA Landaw, EM Churchill, BM Haake, DA AF Patel, Mayank Gonzalez, Rodrigo Halford, Colin Lewinski, Michael A. Landaw, Elliot M. Churchill, Bernard M. Haake, David A. TI Target-Specific Capture Enhances Sensitivity of Electrochemical Detection of Bacterial Pathogens SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID GENOMIC DNA; URINE; UROPATHOGENS; GUIDELINES; SPECIMENS; DIAGNOSIS; WOMEN AB We report the concentration and purification of bacterial 16S rRNA by the use of a biotinylated DNA target-specific capture (TSC) probe. For both cultivated bacterial and urine specimens from urinary tract infection patients, TSC resulted in a 5- to 8-fold improvement in the sensitivity of bacterial detection in a 16S rRNA electrochemical sensor assay. C1 [Haake, David A.] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. [Patel, Mayank; Halford, Colin; Churchill, Bernard M.; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Landaw, Elliot M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. [Lewinski, Michael A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. RP Haake, DA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Infect Dis, 111F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM DHAAKE@UCLA.EDU FU National Institute of Allergy and Infectious Diseases [AI075565]; Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research FX This study was supported by Cooperative Agreement Award AI075565 (to D.A.H.) from the National Institute of Allergy and Infectious Diseases and by the Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research. B.M.C. is the Judith and Robert Winston Chair in Pediatric Urology. NR 15 TC 5 Z9 5 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2011 VL 49 IS 12 BP 4293 EP 4296 DI 10.1128/JCM.01261-11 PG 4 WC Microbiology SC Microbiology GA 862SC UT WOS:000298113400043 PM 21940468 ER PT J AU Peters, ME Vaidya, V Drye, LT Rosenberg, PB Martin, BK Porsteinsson, AP Frangakis, CE Mintzer, J Weintraub, D Schneider, LS Rabins, PV Munro, CA Meinert, CL Lyketsos, CG Dimitri, A AF Peters, Matthew E. Vaidya, Vijay Drye, Lea T. Rosenberg, Paul B. Martin, Barbara K. Porsteinsson, Anton P. Frangakis, Constantine E. Mintzer, Jacobo Weintraub, Daniel Schneider, Lon S. Rabins, Peter V. Munro, Cynthia A. Meinert, Curtis L. Lyketsos, Constantine G. Dimitri, Avramopoulos CA DIADS-2 Res Grp TI Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic Influences SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE Alzheimer disease; sertraline; depression; randomized trial; dementia; antidepressant ID DOUBLE-BLIND; NEUROPSYCHIATRIC SYMPTOMS; CLINICAL-TRIAL; POLYMORPHISM; DEMENTIA; PREVALENCE; PSYCHOSIS; EFFICACY; CRITERIA AB Objective. To assess the potential for genetic influences on sertraline treatment efficacy for depression of Alzheimer disease (dAD). Four functional genetic variants were studied: 2 serotonin receptors (HTR2A-T102C and HTR2C-Cys23Ser), the serotonin transporter (5HTT-LPR), and brain-derived neurotrophic factor (BDNF-Val66Met). Treatment response by genotype was measured by (1) the modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change, (2) the Cornell scale for Depression in Dementia, and (3) remission of depression. Methods. We utilized data from the Depression in Alzheimer's Disease Study 2 (DIADS-2), a 24-week, randomized, multicenter trial showing no significant treatment effect of sertraline on dAD. Proportional odds logistic regression and mixed effects models were used to examine the above mentioned outcome measures. Results. No significant interactions were seen between any of the genetic polymorphisms and the selected outcomes above at 12 or 24 weeks. Discussion. Treatment outcomes in the DIADS-2 trial were not significantly influenced by genetic variation at the loci that were assessed. Future studies should continue to examine the interaction of depression-related genetic variants with antidepressant treatment in Alzheimer disease patients with depression. C1 [Peters, Matthew E.; Rosenberg, Paul B.; Rabins, Peter V.; Munro, Cynthia A.; Lyketsos, Constantine G.; Dimitri, Avramopoulos] Johns Hopkins Univ, Baltimore, MD 21224 USA. [Vaidya, Vijay; Drye, Lea T.; Martin, Barbara K.; Frangakis, Constantine E.; Meinert, Curtis L.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Porsteinsson, Anton P.] Univ Rochester, Rochester, NY USA. [Mintzer, Jacobo] Med Univ S Carolina, Charleston, SC 29425 USA. [Mintzer, Jacobo] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Weintraub, Daniel] Univ Penn, Philadelphia, PA 19104 USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. RP Lyketsos, CG (reprint author), Johns Hopkins Univ, 5300 Alpha Commons Dr, Baltimore, MD 21224 USA. EM kostas@jhmi.edu OI Drye, Lea/0000-0002-2964-1878 FU National Institute of Mental Health [1U01MH066136, 1U01MH068014, 1U01MH066174, 1U01MH066175, 1U01MH066 176, 1U01MH066177]; National Institutes of Health; Michael J. Fox Foundation for Parkinson's Research; Baxter; Bristol-Myers Squibb; Elan Pharmaceuticals; Janssen Alzheimer Initiative; Medivation Inc; Pfizer Inc; Toyama; Eisai Inc; Eli Lilly; Forest Laboratories; Janssen; GlaxoSmithKline; Merck; Mitsubishi; Myriad; Neurochem; Ono Pharma; Wyeth; Alzheimer's Disease Cooperative Study Group [NIA-U01AG10483]; Alzheimer's Disease Neuroimaging Initiative [NIA-U01AG024904]; ADAPT-FS [NIA-U01AG15477]]; CitAD [NIMH-R01AG031348]; DIADS-2 [NIMH-U01MH066177]; NIA; Pfizer; Janssen Alzheimer's Immunotherapy; Genentech; NIMH; Associated Jewish Federation of Baltimore; Weinberg Foundation; Forest; Eisai; Astra-Zeneca; Lilly; Ortho-McNeil; BristolMyers; Novartis; National Football League; Elan FX The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by National Institute of Mental Health, 1U01MH066136, 1U01MH068014, 1U01MH066174, 1U01MH066175, 1U01MH066 176, 1U01MH066177. DW has received grants or research funding from National Institutes of Health and the Michael J. Fox Foundation for Parkinson's Research. APP received research support from Baxter, Bristol-Myers Squibb, Elan Pharmaceuticals, Janssen Alzheimer Initiative, Medivation Inc, Pfizer Inc, Toyama, Eisai Inc, Eli Lilly, Forest Laboratories, Janssen, GlaxoSmithKline, Merck, Mitsubishi, Myriad, Neurochem, Ono Pharma, Wyeth, the Alzheimer's Disease Cooperative Study Group (NIA-U01AG10483), Alzheimer's Disease Neuroimaging Initiative NIA-U01AG024904, ADAPT-FS (NIA-U01AG15477], CitAD study (NIMH-R01AG031348), and DIADS-2 study (NIMH-U01MH066177). JM received research support from NIA, Eli Lilly, Pfizer, Janssen Alzheimer's Immunotherapy, and Genentech. CGL received grant support (research or CME) from NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, BristolMyers, Novartis, National Football League, and Elan. NR 34 TC 6 Z9 7 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 EI 1552-5708 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD DEC PY 2011 VL 24 IS 4 BP 222 EP 228 DI 10.1177/0891988711422527 PG 7 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 873BJ UT WOS:000298855400007 PM 22228829 ER PT J AU Forrest, GN Arnold, RS Gammie, JS Gilliam, BL AF Forrest, Graeme N. Arnold, Ryan S. Gammie, James S. Gilliam, Bruce L. TI Single center experience of a vancomycin resistant enterococcal endocarditis cohort SO JOURNAL OF INFECTION LA English DT Article DE Vancomycin resistant enterococci; Hemodialysis; Organ transplantation; Endocarditis ID INFECTIVE ENDOCARDITIS; STAPHYLOCOCCUS-AUREUS; RISK-FACTORS; ANTIMICROBIAL THERAPY; BACTEREMIA; FAECALIS; SAFETY; SURVEILLANCE; DAPTOMYCIN; DIAGNOSIS AB Objectives: Vancomycin resistant enterococcus (VRE) infective endocarditis (IE) is an increasing nosocomial problem. We describe the clinical management and outcomes of a cohort of patients with VRE IE at a tertiary endocarditis referral center. Methods: Retrospective review of all proven cases of VRE IE, from July 2000 through January 2008 was performed. Demographics, comorbidities and therapeutic details were collected and analyzed to assess for risk factors and clinical outcomes. Results: Fifty cases of VRE IE were identified: 26 (52%) were Enterococcus faecium and 24 were Enterococcus faecalis. Vancomycin resistant E. faecalis IE was associated with the presence of a central venous line, liver transplantation, and mitral valve infection while VR E. faecium IE was significantly associated with tricuspid valve infection (p = 0.03). The median duration of bacteremia was 14 days for E. faecium and 4 days for E. faecalis, respectively (p = 0.002). Factors associated with mortality on bivariate analysis were hemodialysis via a catheter with VR E. faecium (OR = 11.7. CI 1.1-122, p = 0.02) and liver transplantation with both species. Combination antimicrobial therapy (OR = 0.5 CI = 0.06-3.2, p = 0.1) and valve surgery (OR 1.3 CI 0.8-20, p = 0.02) trended toward improved survival with E. faecalis on bivariate analysis. On multivariate analysis, none of the associations were significant. Conclusions: Hemodialysis and liver transplantation were factors associated with acquisition of VRE IE. There was a higher mortality and prolonged bacteremia with VR E. faecium IE than VR E. faecalis IE. Although not significant, combination antimicrobial therapy and surgical intervention trended toward improved survival. Published by Elsevier Ltd on behalf of The British Infection Association. C1 [Forrest, Graeme N.] Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA. [Arnold, Ryan S.] Univ Maryland, Sch Med, Div Infect Dis, Baltimore, MD 21201 USA. [Gammie, James S.] Univ Maryland, Sch Med, Div Cardiac Surg, Baltimore, MD 21201 USA. [Gilliam, Bruce L.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. RP Forrest, GN (reprint author), Portland VA Med Ctr, Div Infect Dis, 3710 SW US Vet Hosp Rd,P3-ID, Portland, OR 97239 USA. EM forrestg@ohsu.edu FU Cubist Pharmaceuticals, Inc. FX Graeme Forrest has received research funding from Cubist Pharmaceuticals, Inc. Bruce Gilliam has been a speaker for Cubist Pharmaceuticals, Inc. NR 26 TC 9 Z9 10 U1 0 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 J9 J INFECTION JI J. Infect. PD DEC PY 2011 VL 63 IS 6 BP 420 EP 428 DI 10.1016/j.jinf.2011.08.014 PG 9 WC Infectious Diseases SC Infectious Diseases GA 869GP UT WOS:000298586100187 PM 21920382 ER PT J AU Harder, LH Chen, S Baker, DG Chow, B McFall, M Saxon, A Smith, MW AF Harder, Laura H. Chen, Shuo Baker, Dewleen G. Chow, Bruce McFall, Miles Saxon, Andrew Smith, Mark W. TI The Influence of Posttraumatic Stress Disorder Numbing and Hyperarousal Symptom Clusters in the Prediction of Physical Health Status in Veterans With Chronic Tobacco Dependence and Posttraumatic Stress Disorder SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Health-related quality of life; PTSD; numbing; hyperarousal; avoidance; smoking; tobacco; SF-36 ID QUALITY-OF-LIFE; ADMINISTERED PTSD SCALE; WAR VETERANS; PRIMARY-CARE; NICOTINE DEPENDENCE; VIETNAM VETERANS; FEMALE VETERANS; OLDER-ADULTS; SMOKING; RISK AB Smoking and PTSD are predictors of poor physical health status. This study examined the unique contribution of PTSD symptoms in the prediction of the SF-36 physical health status subscales accounting for cigarette smoking, chronic medical conditions, alcohol and drug use disorders, and depression. This study examined baseline interview and self-report data from a national tobacco cessation randomized, controlled trial (Veterans Affairs Cooperative Study 519) that enrolled tobacco-dependent veterans with chronic PTSD (N = 943). A series of blockwise multiple regression analyses indicated that PTSD numbing and hyperarousal symptom clusters explained a significant proportion of the variance across all physical health domains except for the Physical Functioning subscale, which measures impairments in specific physical activities. Our findings further explain the impact of PTSD on health status by exploring the way PTSD symptom clusters predict self-perceptions of health, role limitations, pain, and vitality. C1 [Harder, Laura H.; Baker, Dewleen G.] VA San Diego Healthcare Syst, San Diego, CA 92161 USA. [Chen, Shuo; Smith, Mark W.] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA. [Baker, Dewleen G.] VA San Diego, Vet Affairs Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Chow, Bruce] Vet Affairs Palo Alto Hlth Care Syst, Cooperat Studies Program, Mountain View, CA USA. [McFall, Miles; Saxon, Andrew] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [McFall, Miles; Saxon, Andrew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Smith, Mark W.] Stanford Med Sch, Ctr Primary Care & Outcomes Res, Stanford, CA USA. RP Harder, LH (reprint author), VA San Diego Healthcare Syst, 3350 La Jolla Village Dr 151, San Diego, CA 92161 USA. EM Laura.Harder@va.gov RI Smith, Mark/G-1522-2012; Schueter, nicos/A-3625-2014 OI Smith, Mark/0000-0002-4582-9088; FU Clinical Science Research and Development Service, US Department of Veterans Affairs [519, NCT00118534]; Tobacco-Related Disease Research Program [19DT-0003]; Department of Defense (Navy BUMED) [CDMRP PTO 090738]; DVA [HSRD SDR09-128]; VA Center of Excellence for Stress and Mental Health; VA Merit [821]; NIAAA [1 P20 AA017839-01]; NIDA [5 U10 DA013714-08]; TRA [05-081]; CPS [636F4574119] FX This study was supported by the Cooperative Studies Program of the Clinical Science Research and Development Service, US Department of Veterans Affairs (DVA; CSP #519, NCT00118534). Ms. Harder is supported in part by the Tobacco-Related Disease Research Program 19DT-0003. Dr. Baker receives research support from the Department of Defense (Navy BUMED and CDMRP PTO 090738) and the DVA (HSR&D SDR09-128) and is supported in part by the VA Center of Excellence for Stress and Mental Health. Dr. McFall receives research support from VA Merit #821 and DVA. Dr. Saxon receives research support from NIAAA (1 P20 AA017839-01) and NIDA (5 U10 DA013714-08). Dr. Smith is supported in part by TRA 05-081 and CPS #636F4574119. NR 43 TC 11 Z9 11 U1 3 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD DEC PY 2011 VL 199 IS 12 BP 940 EP 945 DI 10.1097/NMD.0b013e3182392bfb PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 863CD UT WOS:000298139500008 PM 22134452 ER PT J AU Bekelman, DB Nowels, CT Retrum, JH Allen, LA Shakar, S Hutt, E Heyborne, T Main, DS Kutner, JS AF Bekelman, David B. Nowels, Carolyn T. Retrum, Jessica H. Allen, Larry A. Shakar, Simon Hutt, Evelyn Heyborne, Theresa Main, Deborah S. Kutner, Jean S. TI Giving Voice to Patients' and Family Caregivers' Needs in Chronic Heart Failure: Implications for Palliative Care Programs SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID PHYSICAL IMPAIRMENT; COLLABORATIVE CARE; CHRONIC ILLNESS; DEPRESSION; CANCER; ASSOCIATION; MANAGEMENT; STATEMENT; AMERICAN; SERVICES AB Background: The American College of Cardiology Foundation/American Heart Association (ACC/AHA) Guidelines for the Management of Heart Failure recommend palliative care in the context of Stage D HF or at the end of life. Previous studies related to heart failure (HF) palliative care provide useful information about patients' experiences, but they do not provide concrete guidance for what palliative care needs are most important and how a palliative care program should be structured. Objectives: Describe HF patients' and their family caregivers' major concerns and needs. Explore whether, how, and when palliative care would be useful to them. Design and participants: Qualitative study using in-depth interviews of 33 adult outpatients with symptomatic HF identified using purposive sampling and 20 of their family caregivers. Approach: Interviews were transcribed verbatim and analyzed using the constant comparative method. Key results: Overall, patients and caregivers desired early support adjusting to the limitations and future course of illness, relief of a number of diverse symptoms, and the involvement of family caregivers using a team approach. A diverse group of participants desired these elements of palliative care early in illness, concurrent with their disease-specific care, coordinated by a provider who understood their heart condition and knew them well. Some diverging needs and preferences were found based on health status and age. Conclusions: HF patients and their family caregivers supported early integration of palliative care services, particularly psychosocial support and symptom control, using a collaborative team approach. Future research should test the feasibility and effectiveness of integrating such a program into routine HF care. C1 [Bekelman, David B.; Hutt, Evelyn] Dept Vet Affairs Med Ctr, Res Sect, Denver, CO USA. [Bekelman, David B.; Hutt, Evelyn] Dept Vet Affairs Med Ctr, Genet Sect, Denver, CO USA. [Bekelman, David B.; Nowels, Carolyn T.; Hutt, Evelyn; Kutner, Jean S.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO USA. [Bekelman, David B.; Allen, Larry A.] Colorado Cardiovasc Outcomes Res, Denver, CO USA. [Retrum, Jessica H.] Univ Colorado, Sch Publ Affairs, Denver, CO 80202 USA. [Allen, Larry A.; Shakar, Simon] Univ Colorado, Sch Med, Dept Med, Div Cariol, Aurora, CO USA. [Main, Deborah S.] Univ Colorado, Dept Hlth & Behav Sci, Denver, CO 80202 USA. RP Bekelman, DB (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM david.bekelman@va.gov FU University of Colorado Denver Hartford/Jahnigen Center for Excellence in Geriatric Medicine; Mordecai Palliative Care Grants Fund; Department of Veterans Affairs [HSRD CDA 08-022] FX This research was funded by the University of Colorado Denver Hartford/Jahnigen Center for Excellence in Geriatric Medicine and the Mordecai Palliative Care Grants Fund. Dr. Bekelman is funded by a Department of Veterans Affairs Career Development Award (HSR&D CDA 08-022). The funding organizations had no role in any part of the study. We thank Sheldon Gottlieb, MD, for contributing to the title, and Traci Yamashita, MA, for assistance with survey data. The views in this article are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 40 TC 34 Z9 34 U1 0 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2011 VL 14 IS 12 BP 1317 EP 1324 DI 10.1089/jpm.2011.0179 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 863EO UT WOS:000298145800010 PM 22107107 ER PT J AU Krimshtein, NS Luhrs, CA Puntillo, KA Cortez, TB Livote, EE Penrod, JD Nelson, JE AF Krimshtein, Nina S. Luhrs, Carol A. Puntillo, Kathleen A. Cortez, Therese B. Livote, Elayne E. Penrod, Joan D. Nelson, Judith E. TI Training Nurses for Interdisciplinary Communication with Families in the Intensive Care Unit: An Intervention SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; PALLIATIVE CARE; CRITICALLY-ILL; MORAL DISTRESS; FOLLOW-UP; END; SKILLS; PHYSICIANS; EFFICACY; MEETINGS AB Background: Critical care nurse communication training has largely been limited to didactic materials, interactive training for nurse supervisors, or brief participatory learning programs within the context of comprehensive end-of-life care educational seminars. Preliminary evidence suggests that an interactive approach can also be effective in communication skills training for intensive care unit (ICU) nurses. Methods: We implemented a 1-day educational intervention in five acute care hospitals within Veterans Integrated Service Network (VISN) 3 (New York-New Jersey region) of the Department of Veterans Affairs and focused solely on communication skills and targeted specifically to nurses providing bedside care for critically ill patients. A "learner centered'' approach to skills training that has several integral components was employed. Among these are: a cognitive, evidence-based foundation upon which to build new skills; a method such as role-play that allows participants to practice newly learned skills; and an affective component, during which trainees can freely discuss their impressions of the exercise or explore difficulties that may have been encountered. Before and after the program we conducted a detailed assessment of participants' self-rated communication skills and of the techniques and materials we used. Results and conclusions: Post-program responses documented significant improvement in self-evaluated skills for each of the core tasks we assessed. Evidence suggests that communication with patients and families in the ICU can be most effectively approached in an interdisciplinary way. For nurses to fully realize their potential for optimal communication as members of the multidisciplinary team, they must be equipped with the necessary skills. We believe this new program helps to expand the range of approaches for training nurses in essential communication skills. C1 [Krimshtein, Nina S.; Nelson, Judith E.] Mt Sinai Sch Med, Div Pulm & Crit Care, New York, NY 10029 USA. [Luhrs, Carol A.; Cortez, Therese B.] New York Harbor Healthcare Syst, Dept Vet Affairs, Brooklyn, NY USA. [Puntillo, Kathleen A.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA. [Livote, Elayne E.; Penrod, Joan D.] James J Peters VA Med Ctr, Bronx, NY USA. RP Nelson, JE (reprint author), Mt Sinai Sch Med, Div Pulm & Crit Care, 1 Gustave Levy Pl, New York, NY 10029 USA. EM judith.nelson@mountsinai.org FU Veterans Integrated Service Network (VISN); Center for the Study of Health Care Across Systems and Sites of Care at the James J. Peters VA Medical Center, Bronx, New York; National Institute on Aging [AG04234] FX This project was supported by the Veterans Integrated Service Network (VISN) 3 Palliative Care Program and by the Center for the Study of Health Care Across Systems and Sites of Care at the James J. Peters VA Medical Center, Bronx, New York. Additional organizational support for the program was provided by nursing leadership within the hospitals participating in the program. Dr. Nelson is the recipient of a K07 Academic Career Leadership Award (AG04234) from the National Institute on Aging. NR 41 TC 32 Z9 32 U1 3 U2 17 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2011 VL 14 IS 12 BP 1325 EP 1332 DI 10.1089/jpm.2011.0225 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 863EO UT WOS:000298145800011 PM 22132740 ER PT J AU Stone, SC Mohanty, S Grudzen, CR Shoenberger, J Asch, S Kubricek, K Lorenz, KA AF Stone, Susan C. Mohanty, Sarita Grudzen, Corita R. Shoenberger, Jan Asch, Steve Kubricek, Katrina Lorenz, Karl A. TI Emergency Medicine Physicians' Perspectives of Providing Palliative Care in an Emergency Department SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID CONTROLLED-TRIAL; OF-LIFE; CONSULTATION; COST AB This study describes emergency physicians' perspectives on the challenges and benefits to providing palliative care in an academic, urban, public hospital in Los Angeles. Participants underwent a semi-structured interview on their training and experiences related to palliative care, perceptions of providing palliative care, and their recommendations for education and training in this area. Overall, respondents felt that palliative care is not prioritized appropriately, leading patients to be unaware of their options for end-of-life care. Providing educational materials and courses that have been developed from the ED perspective should be included in ongoing continuing medical education. Having a palliative care team that is responsive to the needs of the ED will further enhance collaboration with the ED. Future research should focus on understanding the range of benefits to having palliative care in the ED. C1 [Stone, Susan C.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Lorenz, Karl A.] Univ Calif Los Angeles, W Los Angeles VA, Los Angeles, CA 90048 USA. [Shoenberger, Jan] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Grudzen, Corita R.] Mt Sinai Sch Med, New York, NY USA. [Asch, Steve] Stanford Univ, Sch Med, Palo Alto VA, Stanford, CA 94305 USA. [Kubricek, Katrina] Childrens Hosp Los Angeles, Los Angeles, CA USA. RP Stone, SC (reprint author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, 8700 Beverly Blvd, Los Angeles, CA 90048 USA. EM sstone.90064@yahoo.com OI Grudzen, Corita/0000-0003-3039-8497 FU Archstone Foundation FX This study was funded by the Archstone Foundation. NR 15 TC 20 Z9 20 U1 1 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2011 VL 14 IS 12 BP 1333 EP 1338 DI 10.1089/jpm.2011.0106 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 863EO UT WOS:000298145800012 PM 22136262 ER PT J AU Moore, MS AF Moore, Mary S. TI Re: A Simple Thank You SO JOURNAL OF PERIANESTHESIA NURSING LA English DT Letter C1 S Texas Vet Healthcare Syst, San Antonio, TX USA. RP Moore, MS (reprint author), S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1089-9472 J9 J PERIANESTH NURS JI J. PeriAnesthesia Nurs. PD DEC PY 2011 VL 26 IS 6 BP 370 EP 370 DI 10.1016/j.jopan.2011.09.010 PG 1 WC Nursing SC Nursing GA 864WM UT WOS:000298271200002 PM 22099126 ER PT J AU Mikuls, TR LeVan, TD Sayles, H Yu, F Caplan, L Cannon, GW Kerr, GS Reimold, AM Johnson, DS Thiele, GM AF Mikuls, Ted R. LeVan, Tricia D. Sayles, Harlan Yu, Fang Caplan, Liron Cannon, Grant W. Kerr, Gail S. Reimold, Andreas M. Johnson, Dannette S. Thiele, Geoffrey M. TI Soluble CD14 and CD14 Polymorphisms in Rheumatoid Arthritis SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE SOLUBLE CD14; RHEUMATOID ARTHRITIS; ACUTE-PHASE RESPONSE; DISEASE SEVERITY; DISEASE ACTIVITY; POLYMORPHISMS ID SINGLE-NUCLEOTIDE POLYMORPHISMS; DISEASE-ACTIVITY; LIPOPOLYSACCHARIDE; ASSOCIATION; PERIODONTITIS; PROTEIN; PLASMA; LPS; VALIDATION; ACTIVATION AB Objective. Soluble CD14 (sCD14) is involved in innate immune responses and has been implicated to play a pathogenic role in inflammatory diseases including rheumatoid arthritis (RA). No studies have identified the specific factors that influence sCD14 expression in RA. We used cross-sectional data to evaluate the relationship of sCD14 concentrations in RA with measures of disease activity and severity. We hypothesized that sCD14 concentrations would be elevated in subjects with greater RA disease severity and markers of disease activity, compared to subjects with lower disease activity. We also examined whether well-defined polymorphisms in CD14 are associated with sCD14 expression in RA. Methods. Soluble CD14 concentrations were measured using banked serum from patients with RA (n = 1270) and controls (n = 186). Associations of patient factors including demographics, measures of RA disease activity/severity, and select CD14 single-nucleotide polymorphisms (SNP) with sCD14 concentration were examined in patients with RA using ordinal logistic regression. Results. Circulating concentrations of sCD14 were higher in patients with RA compared to controls (p < 0.0001). Factors significantly and independently associated with higher sCD14 levels in patients with RA included older age, being white (vs African American), lower body mass index, elevated high sensitivity C-reactive protein, and higher levels of disease activity based on the Disease Activity Score (DAS28). There were no significant associations of CD14 tagging SNP with sCD14 level in either univariate or multivariable analyses. Conclusion. Circulating levels of sCD14 are increased in RA and are highest in patients with increased levels of RA disease activity. In the context of RA, sCD14 concentrations also appear to be strongly influenced by specific patient factors including older age and race but not by genetic variation in CD14. (First Release Sept 15 2011; J Rheumatol 2011;38:2509-16; doi:10.3899/jrheum.110378) C1 [Mikuls, Ted R.] Omaha VA Med Ctr, Dept Med, Div Rheumatol & Immunol, Omaha, NE USA. [LeVan, Tricia D.] Omaha VA Med Ctr, Dept Epidemiol, Omaha, NE USA. [Sayles, Harlan] Omaha VA Med Ctr, Dept Biostat, Omaha, NE USA. [Caplan, Liron] Denver VAMC, Denver, CO USA. [Caplan, Liron] Univ Colorado, Boulder, CO 80309 USA. [Cannon, Grant W.] Salt Lake City VAMC, Salt Lake City, UT USA. [Kerr, Gail S.] VAMC, Georgetown, Guyana. [Kerr, Gail S.] Howard Univ Hosp, Washington, DC 20059 USA. [Reimold, Andreas M.] Dallas VAMC, Dallas, TX USA. [Reimold, Andreas M.] Univ Texas SW Med Ctr, Dallas, TX USA. [Johnson, Dannette S.] Sonny Montgomery VAMC, Montgomery, AL USA. RP Mikuls, TR (reprint author), Omaha VA Med Ctr, Dept Med, Div Rheumatol & Immunol, Omaha, NE USA. EM tmikuls@unmc.edu RI Yu, Fang/B-9874-2013 OI Thiele, Geoffrey/0000-0001-5688-8596 FU VA CSRD; VA HSRD Program FX Supported by a Merit Grant from VA CSR&D. The Veterans Affairs Rheumatoid Arthritis registry has received research support from the VA HSR&D Program. NR 47 TC 10 Z9 10 U1 0 U2 2 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD DEC PY 2011 VL 38 IS 12 BP 2509 EP 2516 DI 10.3899/jrheum.110378 PG 8 WC Rheumatology SC Rheumatology GA 868NU UT WOS:000298530800004 PM 21921097 ER PT J AU Kong, A Beresford, SAA Alfano, CM Foster-Schubert, KE Neuhouser, ML Johnson, DB Duggan, C Wang, CY Xiao, LR Bain, CE McTiernan, A AF Kong, Angela Beresford, Shirley A. A. Alfano, Catherine M. Foster-Schubert, Karen E. Neuhouser, Marian L. Johnson, Donna B. Duggan, Catherine Wang, Ching-Yun Xiao, Liren Bain, Carolyn E. McTiernan, Anne TI Associations between Snacking and Weight Loss and Nutrient Intake among Postmenopausal Overweight to Obese Women in a Dietary Weight-Loss Intervention SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID LOOK-AHEAD ACTION; ENERGY-INTAKE; FOOD-INTAKE; EATING OCCASIONS; US ADULTS; PATTERNS; HEALTH; FREQUENCY; MEAL; BMI AB Snacking may play a role in weight control. The associations of timing and frequency of snacking with observed weight change and nutrient intake were assessed in an ancillary study to a 12-month randomized controlled trial in Seattle, WA. Overweight-to-obese postmenopausal women (n=123) enrolled in the two dietary weight-loss arms from 2007 to 2008 with complete data at 12 months were included in these analyses.. Generalized linear models were used to test the associations between snacking and weight loss (percent) and nutrient intake at the 12-month time point. Participants were, on average, 58 years old and mainly non-Hispanic white (84%). Ninety-seven percent reported one or more snacks per day. Weight loss (percent) was significantly lower among mid-morning (10:30 AM to 11:29 Am) snackers (7.0%, 95% confidence interval: 4.3 to 9.7) compared to non mid-morning snackers (11.4%, 95% confidence interval: 10.2 to 12.6; P=0.005). A higher proportion of mid-morning snackers reported more than one snack per day (95.7%), compared to afternoon (82.8%) and evening (80.6%) snackers, although differences were not statistically significant (P>0.05). Women who reported two or more snacks per day vs one or no snacks per day had higher fiber intake (P=0.027). Afternoon snackers had higher fruit and vegetable intake compared to non-afternoon-snackers (P=0.035). These results suggest that snack meals can be a source for additional fruits, vegetables, and fiber-rich foods; however, snacking patterns might also reflect unhealthy eating habits and impede weight-loss progress. Future dietary weight-loss interventions should evaluate the effects of timing, frequency, and quality of snacks on weight loss. J Am Diet Assoc. 2011;111:1898-1903. C1 [McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Prevent Ctr, Seattle, WA 98109 USA. [Kong, Angela] Univ Illinois, Inst Hlth Res & Policy, Canc Educ & Career Dev Program, Chicago, IL USA. [Beresford, Shirley A. A.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA. [Alfano, Catherine M.] NCI, Off Canc Survivorship, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Foster-Schubert, Karen E.] Univ Washington, VA Puget Sound Hlth Care, Seattle, WA 98195 USA. [Duggan, Catherine] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98109 USA. [Johnson, Donna B.] Univ Washington, Ctr Publ Hlth Nutr, Seattle, WA 98195 USA. RP McTiernan, A (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Prevent Ctr, 1100 Fairview Ave N,M4-B874,POB 19024, Seattle, WA 98109 USA. EM amctiern@fhcrc.org RI Duggan, Catherine/F-9414-2015 OI Duggan, Catherine/0000-0001-7369-4021 FU National Cancer Institute (NCI) National Institutes of Health (NIH) [R01 CA105204-01A1, U54-CA116847]; NIH [5KL2RR025015-03]; NCI [R25CA094880, 2R25CA057699-16] FX This study was funded by National Cancer Institute (NCI) National Institutes of Health (NIH) grants R01 CA105204-01A1 and U54-CA116847 (Transdisciplinary Research on Energetics and Cancer). K.E.F.-S. received support from NIH 5KL2RR025015-03 and A.K. was supported by NCI R25CA094880 at the time of this study and is currently supported by NCI 2R25CA057699-16. NR 32 TC 6 Z9 6 U1 2 U2 6 PU AMER DIETETIC ASSOC PI CHICAGO PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD DEC PY 2011 VL 111 IS 12 BP 1898 EP 1903 DI 10.1016/j.jada.2011.09.012 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 872RY UT WOS:000298828200016 PM 22117666 ER PT J AU Burgio, KL Goode, PS Johnson, TM Hammontree, L Ouslander, JG Markland, AD Colli, J Vaughan, CP Redden, DT AF Burgio, Kathryn L. Goode, Patricia S. Johnson, Theodore M., II Hammontree, Lee Ouslander, Joseph G. Markland, Alayne D. Colli, Janet Vaughan, Camille P. Redden, David T. TI Behavioral Versus Drug Treatment for Overactive Bladder in Men: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Urological-Association CY JUN 06, 2010 CL San Francisco, CA SP Amer Urol Assoc DE overactive bladder; behavioral treatment; drug therapy; lower urinary tract symptoms; urinary incontinence ID URINARY-TRACT SYMPTOMS; BENIGN PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED-TRIAL; SIDED TESTS PROCEDURE; OLDER WOMEN; INCONTINENT WOMEN; MANAGEMENT; THERAPY; COMBINATION; EFFICACY AB OBJECTIVES: To compare the effectiveness of behavioral treatment with that of antimuscarinic therapy in men without bladder outlet obstruction who continue to have overactive bladder (OAB) symptoms with alpha-blocker therapy. DESIGN: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial was a two-site randomized, controlled, equivalence trial with 4-week alpha-blocker run-in. SETTING: Veterans Affairs Medical Center outpatient clinics. PARTICIPANTS: Volunteer sample of 143 men aged 42 to 88 who continued to have urgency and more than eight voids per day, with or without incontinence, after run-in. INTERVENTIONS: Participants were randomized to 8 weeks of behavioral treatment (pelvic floor muscle exercises, urge suppression techniques, delayed voiding) or drug therapy (individually titrated, extended-release oxybutynin, 5-30 mg/d). MEASUREMENTS: Seven-day bladder diaries and a validated urgency scale were used to calculate changes in 24-hour voiding frequency, nocturia, urgency, and incontinence. Secondary outcomes were global patient ratings and American Urological Association Symptom Index. RESULTS: Mean voids per day decreased from 11.3 to 9.1 (- 18.8%) with behavioral treatment and 11.5 to 9.5 (- 16.9%) with drug therapy. Equivalence analysis indicated that posttreatment means were equivalent (P <.01). After treatment, 85% of participants rated themselves as much better or better; more than 90% were completely or somewhat satisfied, with no betweengroup differences. The behavioral group showed greater reductions in nocturia (mean = -0.70 vs - 0.32 episodes/ night; P =.05). The drug group showed greater reductions in maximum urgency scores (mean = -0.44 vs -0.12; P =.02). Other between-group differences were nonsignificant. CONCLUSION: Behavioral and antimuscarinic therapy are effective when added to alpha-blocker therapy for OAB in men without outlet obstruction. Behavioral treatment is at least as effective as antimuscarinic therapy. J Am Geriatr Soc 59: 2209-2216, 2011. C1 [Burgio, Kathryn L.; Goode, Patricia S.; Johnson, Theodore M., II; Hammontree, Lee; Markland, Alayne D.; Colli, Janet; Vaughan, Camille P.; Redden, David T.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Birmingham, AL USA. [Burgio, Kathryn L.; Goode, Patricia S.; Markland, Alayne D.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Hammontree, Lee; Colli, Janet] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. [Redden, David T.] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Johnson, Theodore M., II; Vaughan, Camille P.] Emory Univ, Atlanta, GA 30322 USA. [Ouslander, Joseph G.] Florida Atlantic Univ, Charles E Schmidt Coll Biomed Sci, Dept Clin Biomed Sci, Miami, FL USA. RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, 11G,700 S 19th St, Birmingham, AL 35233 USA. EM kburgio@aging.uab.edu RI Vaughan, Camille/I-3758-2014 NR 39 TC 35 Z9 35 U1 3 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2011 VL 59 IS 12 BP 2209 EP 2216 DI 10.1111/j.1532-5415.2011.03724.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 869LU UT WOS:000298600300003 PM 22092152 ER PT J AU Blackwell, T Yaffe, K Ancoli-Israel, S Redline, S Ensrud, KE Stefanick, ML Laffan, A Stone, KL AF Blackwell, Terri Yaffe, Kristine Ancoli-Israel, Sonia Redline, Susan Ensrud, Kristine E. Stefanick, Marcia L. Laffan, Alison Stone, Katie L. CA Osteoporotic Fractures Men Study TI Associations Between Sleep Architecture and Sleep-Disordered Breathing and Cognition in Older Community-Dwelling Men: The Osteoporotic Fractures in Men Sleep Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE sleep architecture; sleep-disordered breathing; cognitive function; hypoxemia ID APNEA SYNDROME; ALZHEIMERS-DISEASE; CPAP TREATMENT; HEART HEALTH; REM-SLEEP; MEMORY; DYSFUNCTION; CONSOLIDATION; PERFORMANCE; IMPROVEMENT AB OBJECTIVES: To examine the association between sleep architecture, sleep-disordered breathing, and cognition in older men. DESIGN: Population-based cross-sectional study. SETTING: Six clinical sites in the United States. PARTICIPANTS: Two thousand nine hundred nine community- dwelling men aged 67 and older who were not selected on the basis of sleep problems or cognitive impairment. MEASUREMENTS: Predictors were measured using in-home polysomnography: sleep architecture, nocturnal hypoxemia (any sleep time with arterial oxygen saturation < 80%), apnea-hypopnea index (AHI), and arousal index. Cognitive outcomes were measured using the modified Mini-Mental State Examination (3MS), Trail-Making Test Part B (TMT-B), and the Digit Vigilance Test (DVT). RESULTS: Analyses adjusted for age, race, education, body mass index, lifestyle, comorbidities, and medication use showed that participants who spent less percentage of time in rapid eye movement (REM) sleep had lower levels of cognition; participants in the lowest quartile (< 14.8%) took an average of 5.9 seconds longer on the TMT-B and 20.1 seconds longer on the DVT than those in the highest quartile (>= 23.7%). Similarly, greater percentage of time spent in Stage 1 sleep was related to poorer cognitive function. Participants in the highest quartile of Stage 1 sleep (>= 8.6%) had worse cognitive scores on average than those in the lowest quartile (< 4.0%). Those with nocturnal hypoxemia took an average of 22.3 seconds longer to complete the DVT than those without, but no associations were found with 3MS or the TMT-B. CONCLUSION: Spending less percentage of time in REM sleep and greater percentage of time in Stage 1 sleep and having higher levels of nocturnal hypoxemia were associated with poorer cognition in older men. Further studies are needed to clarify the direction of these associations and to explore potential mechanisms. J Am Geriatr Soc 59: 2217-2225, 2011. C1 [Blackwell, Terri; Laffan, Alison; Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA. [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Ensrud, Kristine E.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA. [Stefanick, Marcia L.] Stanford Univ, Dept Med, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA. RP Blackwell, T (reprint author), San Francisco Coordinating Ctr, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA. EM tblackwell@sfcc-cpmc.net FU National Institutes of Health (NIH); National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Aging; National Cancer Institute; National Center for Research Resources; NIH Roadmap for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140, AG08415]; National Heart, Lung, and Blood Institute [R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, R01 HL070839]; Sepracor; Litebook FX Conflict of Interest: MrOS is supported by National Institutes of Health (NIH) funding. The following institutes provide support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the National Cancer Institute, the National Center for Research Resources, and NIH Roadmap for Medical Research under Grants U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140, and AG08415.; The National Heart, Lung, and Blood Institute provides funding for the MrOS Sleep ancillary study "Out-comes of Sleep Disorders in Older Men" under Grants R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and R01 HL070839. Dr. Yaffe received funding from K 24 grant AG031155.; Dr. Ancoli-Israel has consulted for or is on the advisory board of Ferring Pharmaceuticals, GlaxoSmithKline, Merck, NeuroVigil, Pfizer, Philips Respironics, Sanofi-Aventis, Sepracor, Scherling-Plough, and Perdue, and has received research support from Sepracor and Litebook. NR 50 TC 37 Z9 37 U1 3 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2011 VL 59 IS 12 BP 2217 EP 2225 DI 10.1111/j.1532-5415.2011.03731.x PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 869LU UT WOS:000298600300004 PM 22188071 ER PT J AU Gray, SL Boudreau, RM Newman, AB Studenski, SA Shorr, RI Bauer, DC Simonsick, EM Hanlon, JT AF Gray, Shelly L. Boudreau, Robert M. Newman, Anne B. Studenski, Stephanie A. Shorr, Ronald I. Bauer, Douglas C. Simonsick, Eleanor M. Hanlon, Joseph T. CA Hlth Aging Body Composition Study TI Angiotensin-Converting Enzyme Inhibitor and Statin Use and Incident Mobility Limitation in Community-Dwelling Older Adults: The Health, Aging and Body Composition Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE medications; mobility; pharmacoepidemiology ID PERIPHERAL ARTERIAL-DISEASE; RANDOMIZED CONTROLLED-TRIAL; LOWER-EXTREMITY FUNCTION; C-REACTIVE PROTEIN; WOMEN AGED 65; PHYSICAL FUNCTION; WALKING PERFORMANCE; VASCULAR-DISEASE; PRAVASTATIN; ATORVASTATIN AB OBJECTIVES: To evaluate whether the use of angiotensin- converting enzyme (ACE) inhibitors and statins is associated with a lower risk of incident mobility limitation in older community dwelling adults. DESIGN: Longitudinal cohort study. SETTING: Health, Aging and Body Composition (Health ABC) study. PARTICIPANTS: Three thousand fifty-five participants who were well functioning at baseline (no mobility limitations). MEASUREMENTS: Summated standardized daily doses (low, medium, high) and duration of ACE inhibitor and statin use were computed. Mobility limitation (two consecutive self-reports of having any difficulty walking onequarter of a mile or climbing 10 steps without resting) was assessed every 6 months after baseline. Multivariable Cox proportional hazards analyses were conducted, adjusting for demographics, health status, and health behaviors. RESULTS: At baseline, 15.2% used ACE inhibitors and 12.9% used statins; use of both was greater than 25% by Year 6. Over 6.5 years of follow-up, 49.8% had developed mobility limitation. In separate multivariable models, neither ACE inhibitor (multivariate hazard ratio (HR) = 0.95, 95% confidence interval (CI) = 0.82-1.09) nor statin use (multivariate HR = 1.02, 95% CI = 0.87-1.17) was associated with lower risk of mobility limitation. Similar findings were seen in analyses examining dose-response and duration-response relationships and a sensitivity analysis restricted to those with hypertension. CONCLUSION: ACE inhibitors and statins widely prescribed to treat hypertension and hypercholesterolemia, respectively, do not lower risk of mobility limitation, an important indicator of quality of life. J Am Geriatr Soc 59: 2226-2232, 2011. C1 [Gray, Shelly L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Boudreau, Robert M.; Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Newman, Anne B.; Studenski, Stephanie A.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Studenski, Stephanie A.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Geriatr Res Educ, Pittsburgh, PA USA. [Studenski, Stephanie A.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Clin, Pittsburgh, PA USA. [Shorr, Ronald I.] N Florida S Georgia Vet Hlth Syst, Geriatr Res Educ & Clin Ctr, Gainesville, FL USA. [Bauer, Douglas C.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. RP Gray, SL (reprint author), Univ Washington, Sch Pharm, Box 357630, Seattle, WA 98195 USA. EM slgray@u.washington.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Boudreau, Robert/0000-0003-0162-5187 FU National Institutes of Health, National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R56AG027017, R01AG034056]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [R01 HS017695, R01 HS018721, K12 HS019461]; Veterans Affairs Health Services Research [IIR-06-062]; Merck; Novartis; GTX; Hazzard Text McGraw Hill FX This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging (NIA) and Contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106. The authors were also supported by NIA Grants and Contracts R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R56AG027017, and R01AG034056; National Institute of Mental Health Grant R34 MH082682; National Institute of Nursing Research Grant R01 NR010135; Agency for Healthcare Research and Quality Grants R01 HS017695, R01 HS018721, and K12 HS019461; and Veterans Affairs Health Services Research Grant IIR-06-062.; Dr. Studenski received institutional grant support, travel expenses, and consultancy fees from Merck; consultancy fees from Novartis and GTX; and royalties from Hazzard Text McGraw Hill. NR 37 TC 14 Z9 14 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2011 VL 59 IS 12 BP 2226 EP 2232 DI 10.1111/j.1532-5415.2011.03721.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 869LU UT WOS:000298600300005 PM 22092102 ER PT J AU Feil, DG Rajan, M Soroka, O Tseng, CL Miller, DR Pogach, LM AF Feil, Denise G. Rajan, Mangala Soroka, Orysya Tseng, Chin-Lin Miller, Donald R. Pogach, Leonard M. TI Risk of Hypoglycemia in Older Veterans with Dementia and Cognitive Impairment: Implications for Practice and Policy SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE diabetes mellitus; dementia; cognitive impairment; glycemic control; hypoglycemia ID TYPE-2 DIABETES-MELLITUS; BLOOD-GLUCOSE CONTROL; ADVERSE DRUG EVENTS; GLYCEMIC CONTROL; CARE; PERFORMANCE; INSULIN; HEALTH; COMPLICATIONS; SULFONYLUREAS AB OBJECTIVES: To examine the relationship between management of diabetes mellitus and hypoglycemia in older adults with and without dementia and cognitive impairment. DESIGN: Cross-sectional database analysis of veterans aged 65 years and older stratified according to dementia, cognitive impairment, age, antiglycemic medications, and glycosylated hemoglobin (Hba1c) level. SETTING: Research database with linked clinical, laboratory, pharmacy, and International Classification of Diseases, Ninth Revision, Clinical Modification, codes. PARTICIPANTS: Four hundred ninety-seven thousand nine hundred veterans aged 65 and older with diabetes mellitus who obtained services from the Department of Veterans Affairs in fiscal years (FYs) 2002 and 2003. MEASUREMENTS: Hypoglycemia, the outcome variable, was identified from outpatient visits, emergency department and inpatient admission codes in FY2003. Independent variables (FY2002-03) included dementia and cognitive impairment, comorbid conditions, extended care and nursing home stays, demographics, antiglycemic medication, and HbA1c levels. RESULTS: Prevalence of combined dementia and cognitive impairment was 13.1% for individuals aged 65 to 74 and 24.2% for those aged 75 and older. Mean HbA1c levels were 7.0 +/- 1.3% for all participants and 6.9 +/- 1.3% for those with dementia. The proportion of participants taking insulin was higher in those with dementia or cognitive impairment (30%) than in those with neither condition (24%). Of all participants taking insulin, more with dementia (26.5%) and cognitive impairment (19.5%) were hypoglycemic than of those with neither condition (14.4%). For all participants, unadjusted odds ratios (ORs) for hypoglycemia were 2.42 (95% confidence interval (CI) = 2.36-2.48) for dementia and 1.72 (95% CI = 1.65-1.79) for cognitive impairment; adjusted ORs were 1.58 (95% CI = 1.53-1.62) for dementia and 1.13 (95% CI = 1.08-1.18) for cognitive impairment. CONCLUSION: Diabetes mellitus was managed more intensively in older veterans with dementia and cognitive impairment, and dementia and cognitive impairment were independently associated with greater risk of hypoglycemia. J Am Geriatr Soc 59: 2263-2272, 2011. C1 [Feil, Denise G.] Univ Calif Los Angeles, Div Geriatr Psychiat, W Los Angeles Vet Affairs Healthcare Ctr, Los Angeles, CA USA. [Feil, Denise G.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Rajan, Mangala; Soroka, Orysya; Tseng, Chin-Lin; Pogach, Leonard M.] Ctr Healthcare Knowledge Management, Dept Vet Affairs New Jersey Healthcare Syst, E Orange, NJ USA. [Miller, Donald R.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Miller, Donald R.] Bedford Vet Affairs Med Ctr Hlth Qual Outcomes &, Bedford, MA USA. [Tseng, Chin-Lin; Pogach, Leonard M.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. RP Pogach, LM (reprint author), VA New Jersey Healthcare Syst, VA HSR&D Ctr Healthcare Knowledge Management Res, 385 Tremont Ave, E Orange, NJ 07018 USA. EM leonard.pogach@va.gov FU VA Health Services Research and Development (HSRD); VA HSRD Diabetes Quality Enhancement Research Initiative FX Dr. Feil received grant support from a VA Health Services Research and Development (HSRD) Career Development Award. Dr. Pogach and Dr. Miller report funding from the VA HSRD Diabetes Quality Enhancement Research Initiative. NR 51 TC 36 Z9 36 U1 4 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2011 VL 59 IS 12 BP 2263 EP 2272 DI 10.1111/j.1532-5415.2011.03726.x PG 10 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 869LU UT WOS:000298600300010 PM 22150156 ER PT J AU Kelley, AS Ettner, SL Wenger, NS Sarkisian, CA AF Kelley, Amy S. Ettner, Susan L. Wenger, Neil S. Sarkisian, Catherine A. TI Determinants of Death in the Hospital Among Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hospital use; end-of-life care; health services ID OF-LIFE CARE; TERMINALLY-ILL PATIENTS; TREATMENT INTENSITY; ETHNIC-DIFFERENCES; FAMILY-MEMBERS; END; PLACE; PREFERENCES; CANCER; QUALITY AB OBJECTIVES: To investigate patient-level determinants of in-hospital death, adjusting for patient and regional characteristics. DESIGN: Using multivariable regression, the relationship between in-hospital death and participants' social, functional, and health characteristics was investigated, controlling for regional Hospital Care Intensity Index (HCI) from the Dartmouth Atlas of Health Care. SETTING: The Health and Retirement Study, a longitudinal nationally representative cohort of older adults. PARTICIPANTS: People aged 67 and older who died between 2,000 and 2,006 (N = 3,539) were sampled. MEASUREMENTS: In-hospital death. RESULTS: Thirty-nine percent (n = 1,380) of participants died in the hospital (range 34% in Midwest to 45% in Northeast). Nursing home residence, functional dependence, and cancer or dementia diagnosis, among other characteristics, were associated with lower adjusted odds of in-hospital death. Being black or Hispanic, living alone, and having more medical comorbidities were associated with greater adjusted odds, as was higher HCI. Sex, education, net worth, and completion of an advance directive did not correlate with in-hospital death. CONCLUSION: Black race, Hispanic ethnicity, and other functional and social characteristics are correlates of inhospital death, even after controlling for the role of HCI. Further work must be done to determine whether preferences, provider characteristics and practice patterns, or differential access to medical and community services drive this difference. J Am Geriatr Soc 59: 2321-2325, 2011. C1 [Kelley, Amy S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Ettner, Susan L.; Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Sarkisian, Catherine A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Los Angeles, CA USA. RP Kelley, AS (reprint author), 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM amy.kelley@mssm.edu FU Univeristy of California at Los Angeles; Veterans Affairs Greater Los Angeles Healthcare System Geriatric Research Education Clinical Center FX The authors report no financial or personal conflicts of interest. While conducting this work, Dr. Kelley was supported by the National Research Service Award Fellowship Program at the Univeristy of California at Los Angeles and the Brookdale Leadership in Aging Fellowship. Dr. Sarkisian is supported by the Veterans Affairs Greater Los Angeles Healthcare System Geriatric Research Education Clinical Center. NR 23 TC 9 Z9 9 U1 1 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2011 VL 59 IS 12 BP 2321 EP 2325 DI 10.1111/j.1532-5415.2011.03718.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 869LU UT WOS:000298600300017 PM 22092014 ER PT J AU Afaq, F Katiyar, SK AF Afaq, F. Katiyar, S. K. TI Polyphenols: Skin Photoprotection and Inhibition of Photocarcinogenesis SO MINI-REVIEWS IN MEDICINAL CHEMISTRY LA English DT Review DE Polyphenols; photoprotection; photocarcinogenesis; proliferation; skin cancer; inflammation; immunosuppression; DNA repair; cellular signaling pathway; reactive oxygen species; ultraviolet radiation ID GREEN TEA POLYPHENOLS; SKH-1 HAIRLESS MICE; FACTOR-KAPPA-B; HUMAN EPIDERMAL-KERATINOCYTES; ACTIVATED PROTEIN-KINASES; INDUCED OXIDATIVE STRESS; RADIATION-INDUCED IMMUNOSUPPRESSION; INDUCED IMMUNE SUPPRESSION; UV-INDUCED IMMUNOSUPPRESSION; HUMAN RECONSTITUTED SKIN AB Polyphenols are a large family of naturally occurring plant products and are widely distributed in plant foods, such as, fruits, vegetables, nuts, flowers, bark and seeds, etc. These polyphenols contribute to the beneficial health effects of dietary products. Clinical and epidemiological studies suggest that exposure of the skin to environmental factors/pollutants, such as solar ultraviolet (UV) radiation induce harmful effects and leads to various skin diseases including the risk of melanoma and non-melanoma skin cancers. The incidence of non-melanoma skin cancer, comprising of squamous cell carcinoma and basal cell carcinoma, is a significant public health concern world-wide. Exposure of the skin to solar UV radiation results in inflammation, oxidative stress, DNA damage, dysregulation of cellular signaling pathways and immunosuppression thereby resulting in skin cancer. The regular intake of natural plant products, especially polyphenols, which are widely present in fruits, vegetables, dry legumes and beverages have gained considerable attention as protective agents against the adverse effects of UV radiation. In this article, we first discussed the impact of polyphenols on human health based on their structure-activity relationship and bioavailability. We then discussed in detail the photoprotective effects of some selected polyphenols on UV-induced skin inflammation, proliferation, immunosuppression, DNA damage and dysregulation of important cellular signaling pathways and their implications in skin cancer management. The selected polyphenols include: green tea polyphenols, pomegranate fruit extract, grape seed proanthocyanidins, resveratrol, silymarin, genistein and delphinidin. The new information on the mechanisms of action of these polyphenols supports their potential use in skin photoprotection and prevention of photocarcinogenesis in humans. C1 [Afaq, F.; Katiyar, S. K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, S. K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Afaq, F (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM fafaq@uab.edu; skatiyar@uab.edu FU National Institutes of Health [R21 AT002429-02, CA104428, CA140832, AT002536]; Veterans Administration FX This work was supported by funds from the National Institutes of Health [(R21 AT002429-02, F.A.) (CA104428, CA140832, AT002536, S.K.K.)] and Veterans Administration Merit Review Award (S.K.K.). The content of this article does not necessarily reflect the views or policies of the funding agencies. NR 109 TC 58 Z9 60 U1 3 U2 43 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1389-5575 J9 MINI-REV MED CHEM JI Mini-Rev. Med. Chem. PD DEC PY 2011 VL 11 IS 14 BP 1200 EP 1215 PG 16 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 869YH UT WOS:000298635800004 PM 22070679 ER PT J AU Cloninger, C Bernath, A Bashir, T Holmes, B Artinian, N Ruegg, T Anderson, L Masri, J Lichtenstein, A Gera, J AF Cloninger, Cheri Bernath, Andrew Bashir, Tariq Holmes, Brent Artinian, Nicholas Ruegg, Teresa Anderson, Lauren Masri, Janine Lichtenstein, Alan Gera, Joseph TI Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; NUCLEAR RIBONUCLEOPROTEIN A1; SIGNAL-REGULATING KINASE-1; ENDOTHELIAL GROWTH-FACTOR; MAMMALIAN TARGET; CYCLIN D1; MULTIPLE-MYELOMA; AKT ACTIVITY; RAPAMYCIN AB A variety of mechanisms confer hypersensitivity of tumor cells to the macrolide rapamycin, the prototypic mTORC1 inhibitor. Several studies have shown that the status of the AKT kinase plays a critical role in determining hypersensitivity. Cancer cells in which AKT activity is elevated are exquisitely sensitive to mTORC1 inhibitors while cells in which the kinase is quiescent are relatively resistant. Our previous work has shown that a transcript-specific protein synthesis salvage pathway is operative in cells with quiescent AKT levels, maintaining the translation of crucial mRNAs involved in cell-cycle progression in the face of global eIF-4E-mediated translation inhibition. The activation of this salvage pathway is dependent on SAPK2/p38-mediated activation of IRES-dependent initiation of the cyclin D1 and c-MYC mRNAs, resulting in the maintenance of their protein expression levels. Here, we show that both genetic and pharmacologic inhibition of SAPK2/p38 in glioblastoma multiforme cells significantly reduces rapamycin-induced IRES-mediated translation initiation of cyclin D1 and c-MYC, resulting in increased G(1) arrest in vitro and inhibition of tumor growth in xenografts. Moreover, we observed that the AKT-dependent signaling alterations seen in vitro are also displayed in engrafted tumors cells and were able to show that combined inhibitor treatments markedly reduced the mRNA translational state of cyclin D1 and c-MYC transcripts in tumors isolated from mice. These data support the combined use of SAPK2/p38 and mTORC1 inhibitors to achieve a synergistic antitumor therapeutic response, particularly in rapamycin-resistant quiescent AKT-containing cells. Mol Cancer Ther; 10(12); 2244-56. (C)2011 AACR. C1 [Cloninger, Cheri; Bernath, Andrew; Bashir, Tariq; Holmes, Brent; Artinian, Nicholas; Ruegg, Teresa; Anderson, Lauren; Masri, Janine; Lichtenstein, Alan; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA USA. [Lichtenstein, Alan; Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Lichtenstein, Alan; Gera, Joseph] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. [Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. RP Gera, J (reprint author), Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, 16111 Plummer St 151, Sepulveda, CA 91343 USA. EM jgera@mednet.ucla.edu FU NIH [CA16042, AI28697, R01CA111448, R01CA109312]; Jonsson Comprehensive Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at UCLA; Veterans Administration FX We thank members of the Lichtenstein and Gera labs for helpful discussions and Dr. Robert Nishimura for comments on the manuscript. We also thank Alex Funk and Jonathan Li for technical assistance. Flow cytometry was performed in the UCLA Jonsson Comprehensive Cancer Center and Center for AIDS Research, Janis Giorgi Flow Cytometry Core Facility (supported by NIH grants CA16042 and AI28697 and by the Jonsson Comprehensive Cancer Center, the UCLA AIDS Institute and the David Geffen School of Medicine at UCLA). We thank Ardella Sherwood for excellent administrative assistance.; This work was supported, in whole or in part, by NIH grants R01CA111448 (A. Lichtenstein), R01CA109312 (J. Gera), and funds from the Veterans Administration. NR 41 TC 8 Z9 8 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2011 VL 10 IS 12 BP 2244 EP 2256 DI 10.1158/1535-7163.MCT-11-0478 PG 13 WC Oncology SC Oncology GA 865XO UT WOS:000298344400004 PM 21911485 ER PT J AU Jin, JF Samuvel, DJ Zhang, XM Li, YC Lu, ZY Lopes-Virella, MF Huang, Y AF Jin, Junfei Samuvel, Devadoss J. Zhang, Xiaoming Li, Yanchun Lu, Zhongyang Lopes-Virella, Maria F. Huang, Yan TI Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells SO MOLECULAR IMMUNOLOGY LA English DT Article DE Toll-like receptor; Interleukin 6; p38 mitogen-activated protein kinase; Inflammation ID ACTIVATED PROTEIN-KINASE; TOLL-LIKE RECEPTOR-2; NF-KAPPA-B; P38 MAPK; ASP299GLY POLYMORPHISM; SIGNALING PATHWAYS; INSULIN-RESISTANCE; MMP-1 EXPRESSION; DENDRITIC CELLS; TNF-ALPHA AB Studies have demonstrated that TLR4 and TLR2 expression by monocytes and the blood levels of TLR4 and TLR2 ligand in diabetic patients are significantly incased compared to nondiabetic patients, indicating that more monocytes in diabetic patients may have coactivation of TLR4 and TLR2. Although it has been shown that either TLR4 or TLR2 activation leads to increased expression of proinflammatory cytokines, the effect of coactivation of TLR2 and TLR4 in mononuclear cells on proinflammatory cytokine expression and the underlying molecular mechanisms remain largely unknown. In this study, we found that while TLR1, TLR2, TLR4 and TLR6 were expressed by U937 mononuclear cells, TLR4 was expressed at the highest level. Interestingly, results showed that while activation of either TLR4 or TLR2/6 (TLR2dimerized with TLR6), but not TLR2/1 (TLR2dimerized with TLR1), significantly increased IL-6 expression by U937 mononuclear cells, coactivation of TLR4 and TLR2/6, but not TLR4 and TLR2/1, led to a further augmentation on IL-6 expression by increasing IL-6 transcriptional activity, but not mRNA stability. To explore the signaling mechanisms involved in the augmentation, we found that p38MAPK and NF kappa B pathways, but not ERK and JNK pathways, were required for the augmentation of IL-6 expression by coactivation of TLR4 and TLR2/6. Furthermore, we found that coactivation of TLR4 and TLR2/6 increased p38 phosphorylation, but not NFkB activity, as compared to activation of TLR4or TLR2/6 alone. Taken together, this study showed that coactivation of TLR4 and TLR2/6 coordinates an additive augmentation of IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells. Published by Elsevier Ltd. C1 [Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Jin, Junfei; Samuvel, Devadoss J.; Zhang, Xiaoming; Li, Yanchun; Lu, Zhongyang; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29425 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU NIH [DE016353]; Department of Veterans Affairs FX This work was supported by NIH grant DE016353 and a Merit Review Grant from Department of Veterans Affairs (to Y.H.). NR 52 TC 16 Z9 16 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD DEC PY 2011 VL 49 IS 3 BP 423 EP 432 DI 10.1016/j.molimm.2011.08.026 PG 10 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 872AV UT WOS:000298779700002 PM 22030478 ER PT J AU Pelak, VS Smyth, SF Boyer, PJ Filley, CM AF Pelak, Victoria S. Smyth, Shawn F. Boyer, Philip J. Filley, Christopher M. TI Computerized visual field defects in posterior cortical atrophy SO NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; DEMENTIA; CONSORTIUM; DIAGNOSIS; SERIES AB Background and objective: Posterior cortical atrophy (PCA) is a progressive neurodegenerative syndrome that presents with cortical visual dysfunction and relatively preserved memory. Although higher cortical visual syndromes are well known in PCA, visual field defects detected by computerized visual field (CVF) perimetry have not been systematically described. The objective of this study was to describe CVF defects measured by threshold perimetry in PCA. Methods: This was a retrospective case series of patients meeting proposed PCA diagnostic criteria seen in the Neuro-ophthalmology and Neurobehavior Clinics at the University of Colorado during 2002 to 2006. History, examination, neuroimaging, autopsy, and CVF studies were analyzed. Results: Nine of 11 patients who met the criteria for PCA and had CVF testing were included. Seven of the 9 patients had homonymous hemianopia or quadrantanopia, and 2 had bilateral constriction. All patients progressed to dementia. Criteria were met for probable Alzheimer disease (AD) in 7, definite AD in 1, and definite dementia with Lewy bodies associated with AD pathology in 1. Seven of 9 patients had early and prominent complaints of difficulty driving. Conclusions: CVF defects were characterized by homonymous visual field defects or bilateral constriction. Eight of 9 patients progressed to probable or definite AD, but the CVF defects were distinctly different from those in typical AD. This observation probably reflects a posterior shift of cortical pathology to the primary and early secondary visual cortices in PCA. CVF testing should be considered in older patients with unexplained visual complaints, particularly when associated with difficulty driving, which may indicate the possibility of PCA and prompt early neurobehavioral evaluation. Neurology (R) 2011; 77:2119-2122 C1 [Pelak, Victoria S.; Smyth, Shawn F.; Filley, Christopher M.] Univ Colorado Denver Sch Med, Dept Neurol, Denver, CO USA. [Boyer, Philip J.] Univ Colorado Denver Sch Med, Dept Pathol, Denver, CO USA. [Pelak, Victoria S.] Univ Colorado Denver Sch Med, Dept Ophthalmol, Denver, CO USA. [Filley, Christopher M.] Univ Colorado Denver Sch Med, Dept Psychiat, Denver, CO USA. [Pelak, Victoria S.; Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Pelak, VS (reprint author), Acad Off 1,Mailstop B185,12631 E 17th Ave,Room 52, Aurora, CO 80045 USA. EM victoria.pelak@ucdenver.edu FU UpToDate, Inc.; NIH; Alzheimer's Association; University Press of Colorado; Behavioral Neurology of White Matter (Oxford University Press); University of Colorado Alzheimer's Disease and Cognition Center (ADCC); NIH/NIAMSD FX Dr. Pelak receives publishing royalties from UpToDate, Inc.; serves as a consultant for Anthem Blue Cross and Blue Shield; receives research support from the NIH and the Alzheimer's Association; and has given expert testimony in medico-legal cases. Dr. Smyth reports no disclosures. Dr. Boyer serves on the editorial board of the Journal of Pathology Informatics and has given expert testimony in medico-legal cases. Dr. Filley receives publishing royalties for Neurobehavioral Anatomy, 2nd ed.(University Press of Colorado, 2001) and The Behavioral Neurology of White Matter (Oxford University Press, 2001); receives research support from University of Colorado Alzheimer's Disease and Cognition Center (ADCC), Alzheimer's Association, and the NIH/NIAMSD; and has given expert testimony in medico-legal cases. NR 18 TC 12 Z9 12 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD DEC PY 2011 VL 77 IS 24 BP 2119 EP 2122 DI 10.1212/WNL.0b013e31823e9f2a PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 865PT UT WOS:000298323500015 PM 22131540 ER PT J AU McGinnis, KA Brandt, CA Skanderson, M Justice, AC Shahrir, S Butt, AA Brown, ST Freiberg, MS Gibert, CL Goetz, MB Kim, JW Pisani, MA Rimland, D Rodriguez-Barradas, MC Sico, JJ Tindle, HA Crothers, K AF McGinnis, Kathleen A. Brandt, Cynthia A. Skanderson, Melissa Justice, Amy C. Shahrir, Shahida Butt, Adeel A. Brown, Sheldon T. Freiberg, Matthew S. Gibert, Cynthia L. Goetz, Matthew Bidwell Kim, Joon Woo Pisani, Margaret A. Rimland, David Rodriguez-Barradas, Maria C. Sico, Jason J. Tindle, Hilary A. Crothers, Kristina TI Validating Smoking Data From the Veteran's Affairs Health Factors Dataset, an Electronic Data Source SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID HIV-NEGATIVE VETERANS; INFECTION; MORTALITY; COHORT; DISEASE; SYSTEM; IMPACT AB We assessed smoking data from the Veterans Health Administration (VHA) electronic medical record (EMR) Health Factors dataset. To assess the validity of the EMR Health Factors smoking data, we first created an algorithm to convert text entries into a 3-category smoking variable (never, former, and current). We compared this EMR smoking variable to 2 different sources of patient self-reported smoking survey data: (a) 6,816 HIV-infected and -uninfected participants in the 8-site Veterans Aging Cohort Study (VACS-8) and (b) a subset of 13,689 participants from the national VACS Virtual Cohort (VACS-VC), who also completed the 1999 Large Health Study (LHS) survey. Sensitivity, specificity, and kappa statistics were used to evaluate agreement of EMR Health Factors smoking data with self-report smoking data. For the EMR Health Factors and VACS-8 comparison of current, former, and never smoking categories, the kappa statistic was .66. For EMR Health Factors and VACS-VC/LHS comparison of smoking, the kappa statistic was .61. Based on kappa statistics, agreement between the EMR Health Factors and survey sources is substantial. Identification of current smokers nationally within the VHA can be used in future studies to track smoking status over time, to evaluate smoking interventions, and to adjust for smoking status in research. Our methodology may provide insights for other organizations seeking to use EMR data for accurate determination of smoking status. C1 [McGinnis, Kathleen A.; Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Brandt, Cynthia A.; Justice, Amy C.; Sico, Jason J.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Brandt, Cynthia A.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA. [Justice, Amy C.; Pisani, Margaret A.] Yale Univ, Dept Med, New Haven, CT 06520 USA. [Shahrir, Shahida; Crothers, Kristina] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. [Butt, Adeel A.; Freiberg, Matthew S.; Tindle, Hilary A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Brown, Sheldon T.; Kim, Joon Woo] James J Peterson VAMC, Bronx, NY USA. [Gibert, Cynthia L.] VA Med Ctr, Washington, DC USA. [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VAMC, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Sico, Jason J.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. RP McGinnis, KA (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA. EM kathleen.mcginnis3@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU VAHS HSRD [RCD 04-125-1]; National Institute on Aging (NIA) [K08 AG00826]; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism [U01-13566]; NIH/NHLBI [1R01 HL090342] FX Supported by VAHS HSR&D RCD 04-125-1, NIA K08 AG00826, an interagency agreement between the National Institute on Aging and the National Institute of Mental Health, and the National Institute on Alcohol Abuse and Alcoholism (Grant No. U01-13566; ACJ); NIH/NHLBI 1R01 HL090342 (KC). NR 23 TC 37 Z9 37 U1 1 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD DEC PY 2011 VL 13 IS 12 BP 1233 EP 1239 DI 10.1093/ntr/ntr206 PG 7 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 852RY UT WOS:000297376400009 PM 21911825 ER PT J AU Matlock, DD Nowels, CT Masoudi, FA Sauer, WH Bekelman, DB Main, DS Kutner, JS AF Matlock, Dan D. Nowels, Carolyn T. Masoudi, Frederick A. Sauer, William H. Bekelman, David B. Main, Deborah S. Kutner, Jean S. TI Patient and Cardiologist Perceptions on Decision Making for Implantable Cardioverter-Defibrillators: A Qualitative Study SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE Implantable cardioverter-defibrillators; qualitative research; medical decision making ID HEART-FAILURE; OF-LIFE; PROPHYLACTIC IMPLANTATION; CARE; DEACTIVATION; CONSEQUENCES; AMIODARONE; MANAGEMENT; THERAPY; CHOICE AB Background: Although implantable cardioverter-defibrillators (ICDs) reduce mortality in selected patients, they are also associated with potential risks. Periprocedural decision making requires understanding both benefits and risks. Methods: This qualitative study aims to understand cardiologists' and patients' perspectives about decision making surrounding ICD implantation using semi-structured, in-depth interviews. We interviewed 11 cardiologists (including four electrophysiologists) and 20 patients (14 with ICDs; six who declined ICDs). The data were analyzed through the theoretical lens of patient-centered care using the constant comparative method. Results: Cardiologists emphasized the benefits of ICD therapy but varied substantially in the extent to which they emphasized the various risks associated with ICD implantation with patients. Cardiologists indicated that they were influenced by the benefits of therapy as presented in published guidelines. Many patients who chose to receive an ICD indicated that they followed the advice of their physician without questioning the risks and benefits of the device. Some ICD recipients described not learning many of the risks until after device implantation or when they experienced these side effects. Patients who declined ICD implantation were concerned that the ICD was unnecessary or believed that the risks related to sudden death without an ICD did not apply to them. Only one patient considered the trade-off between dying quickly versus living longer with progressive heart failure. Conclusions: In our sample, cardiologists' desire to adhere to published guidelines appears to inhibit shared decision making. The marked variability in the discussions surrounding ICD decisions highlights a need for an improved process of ICD decision making. (PACE 2011; 34: 1634-1644) C1 [Matlock, Dan D.] Univ Colorado, Acad Off 1, Dept Med, Div Gen Internal Med,Sch Med, Aurora, CO 80045 USA. [Matlock, Dan D.; Masoudi, Frederick A.; Bekelman, David B.] Univ Colorado, Colorado Cardiovasc Outcomes Res Grp, Denver, CO 80202 USA. [Matlock, Dan D.; Masoudi, Frederick A.] Univ Colorado, Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80202 USA. [Bekelman, David B.] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80202 USA. [Main, Deborah S.] Univ Colorado, Dept Hlth & Behav Sci, Denver, CO 80202 USA. RP Matlock, DD (reprint author), Univ Colorado, Acad Off 1, Dept Med, Div Gen Internal Med,Sch Med, 12631 E 17th Ave,Campus Box B-180, Aurora, CO 80045 USA. EM daniel.matlock@ucdenver.edu FU Foundation for Informed Medical Decision Making (FIMDM) FX Financial support for this study was provided by a George Bennett Postdoctoral Research Grant from the Foundation for Informed Medical Decision Making (FIMDM) awarded to Dr. Matlock. The views in this article are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 38 TC 25 Z9 26 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD DEC PY 2011 VL 34 IS 12 BP 1634 EP 1644 DI 10.1111/j.1540-8159.2011.03237.x PG 11 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 860HZ UT WOS:000297940700013 PM 21972983 ER PT J AU Naik, AD Teal, CR Rodriguez, E Haidet, P AF Naik, Aanand D. Teal, Cayla R. Rodriguez, Elisa Haidet, Paul TI Knowing the ABCs: A comparative effectiveness study of two methods of diabetes education SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Diabetes education; Self-management; Patient empowerment; Team-based learning; Group clinics ID SELF-MANAGEMENT EDUCATION; GLYCEMIC CONTROL; HYPERTENSION CONTROL; PATIENT EMPOWERMENT; VULNERABLE PATIENTS; CARE; A1C; KNOWLEDGE; OUTCOMES; ADULTS AB Objective: To test an active-learning, empowerment approach to teaching patients about the "diabetes ABCs" (hemoglobin A(1)C, systolic blood pressure, and low density lipoprotein cholesterol). Methods: 84 (97%) diabetic patients who participated in a randomized effectiveness trial of two clinic-based group educational methods and completed a post-intervention assessment. The empowerment arm participated in a group session that incorporated two educational innovations (a conceptual metaphor to foster understanding, and team-based learning methods to foster active learning). The traditional diabetes education arm received a didactic group session focused on self-management and educational materials about the diabetes ABCs. Participants in both arms received individual review of their current ABC values. Results: A questionnaire evaluated knowledge, understanding, and recall of the diabetes ABCs was administered three months after enrollment in the study. At three months, participants in the empowerment group demonstrated greater understanding of the diabetes ABCs (P < 0.0001), greater knowledge of their own values (P < 0.0001), and greater knowledge of guideline-derived target goals for the ABCs compared with participants in the traditional arm (P < 0.0001). Conclusion: An active-learning, empowerment-based approach applied to diabetes education can lead to greater understanding and knowledge retention. Practice implications: An empowerment approach to education can facilitate informed, activated patients and increase performance of self-management behaviors. Published by Elsevier Ireland Ltd. C1 [Naik, Aanand D.; Rodriguez, Elisa] Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA. [Naik, Aanand D.; Teal, Cayla R.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Haidet, Paul] Penn State Univ, Coll Med, Off Med Educ, Hershey, PA USA. [Haidet, Paul] Penn State Univ, Coll Med, Dept Med, Hershey, PA USA. [Haidet, Paul] Penn State Univ, Coll Med, Dept Humanities, Hershey, PA USA. [Naik, Aanand D.; Rodriguez, Elisa; Haidet, Paul] Houston Ctr Res & Educ Therapeut, Houston, TX USA. [Teal, Cayla R.] Baylor Coll Med, Off Undergrad Med Educ, Houston, TX 77030 USA. RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr 152, Houston Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM anaik@bcm.edu RI Herring, Anna/L-7859-2014 FU Agency for Healthcare Research and Quality [U18HS016093]; Centers for Research and Education on Therapeutics (Houston CERT. Suarez-Almazor, PI); Doris Duke Charitable Foundation; National Institute on Aging [K23AG027144] FX This work was supported by a grant from the Agency for Healthcare Research and Quality (#U18HS016093), Centers for Research and Education on Therapeutics (Houston CERT. Suarez-Almazor, PI). The authors acknowledge additional project support from a Clinical Scientist Development Award from the Doris Duke Charitable Foundation and resources in the preparation of this manuscript from the Houston Health Services Research and Development Center of Excellence (HFP90-020) at the Michael E. DeBakey VA Medical Center. Dr. Naik receives additional support from the National Institute on Aging (K23AG027144). These sources had no role in the preparation, review, or approval of the manuscript. The authors thank Andrea Price, BA, and Donna Rochon, PhD, for their assistance with patient recruitment, retention and project support, Teresa Zhang, PhD, and Annette Walder, MS with data analysis. NR 29 TC 6 Z9 6 U1 0 U2 13 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD DEC PY 2011 VL 85 IS 3 BP 383 EP 389 DI 10.1016/j.pec.2011.01.010 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 864EM UT WOS:000298219800008 PM 21300516 ER PT J AU Naik, AD Street, RL Castillo, D Abraham, NS AF Naik, Aanand D. Street, Richard L., Jr. Castillo, Diana Abraham, Neena S. TI Health literacy and decision making styles for complex antithrombotic therapy among older multimorbid adults SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Aging; Drugs; Prevention; Literacy; Doctor-patient relationship ID PATIENT PARTICIPATION; IDENTIFY PATIENTS; COMMUNICATION; PREFERENCES; QUESTIONS; ENCOUNTER; OUTCOMES; CANCER; RISK AB Objectives: To evaluate the effect of functional health literacy (FHL) on preferences for decision-making; and among those initially preferring a passive decision-making role, to explore how preferences change if their physician actively encourages their involvement. Methods: Consecutive older adults with cardiovascular disease receiving complex antithrombotic therapy completed a comprehensive assessment including measures of FHL and preferences for shared decision making. Results: Half of all participants had inadequate or marginal FHL. Those with inadequate FHL were more likely (P = 0.01) to prefer passive rather than active decision making styles even after controlling for age, education, and numeracy. However, 40% of patients preferring passive styles had adequate FHL and these patients were significantly more likely to change their preference to more active styles (odds ratio = 7.17, P < .01) if their physician "was more supportive or encouraged participation". Conclusions: Screening FHL can provide insight into patients' preferences for active participation in decision making. Clinicians' encouragement of participation can increase engagement by patients with adequate FHL. Practice implications: We propose an algorithm for screening FHL and preferences for participating in decisions about complex medication regimens. Published by Elsevier Ireland Ltd. C1 [Naik, Aanand D.; Street, Richard L., Jr.; Castillo, Diana; Abraham, Neena S.] Michael E DeBakey VA Med Ctr, Houston HSR&D Ctr Excellence, Houston, TX USA. [Naik, Aanand D.; Abraham, Neena S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Street, Richard L., Jr.] Texas A&M Univ, Dept Commun, College Stn, TX USA. RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM anaik@bcm.tmc.edu FU Houston Veterans Affairs Health Sciences Research and Development Center of Excellence [HFP90-020]; National Institute on Aging [K23AG027144]; Doris Duke Charitable Foundation; American Gastroenterological Association Foundation-Sucampo-Association; Department of Veterans Affairs [VA IIR 08-028] FX This study was supported by a locally funded pilot grant and use of facilities at the Houston Veterans Affairs Health Sciences Research and Development Center of Excellence (HFP90-020). Dr. Naik is also supported by a National Institute on Aging Career Development Award (K23AG027144) and a Doris Duke Charitable Foundation Clinical Scientist Development Award. Dr. Abraham is supported by an American Gastroenterological Association Foundation-Sucampo-Association of Specialty Professors Designated Research Award in Geriatric Gastroenterology and by a Merit Review Award from the Department of Veterans Affairs (VA IIR 08-028). No funding agencies had a role in the design and conduct of the study, analysis and interpretation of data, or preparation and approval of the manuscript. The views expressed herein are those of the authors and do not necessarily reflect those of the Department of Veterans Affairs or Baylor College of Medicine. NR 32 TC 18 Z9 18 U1 3 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD DEC PY 2011 VL 85 IS 3 BP 499 EP 504 DI 10.1016/j.pec.2010.12.015 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 864EM UT WOS:000298219800025 PM 21251788 ER PT J AU Arjomandi, M Galanter, JM Choudhry, S Eng, C Hu, DL Beckman, K Chapela, R Rodriguez-Santana, JR Rodriguez-Cintron, W Ford, J Avila, PC Burchard, EG AF Arjomandi, Mehrdad Galanter, Josh M. Choudhry, Shweta Eng, Celeste Hu, Donglei Beckman, Kenneth Chapela, Rocio Rodriguez-Santana, Jose R. Rodriguez-Cintron, William Ford, Jean Avila, Pedro C. Burchard, Esteban G. TI Polymorphism in Osteopontin Gene (SPP1) Is Associated with Asthma and Related Phenotypes in a Puerto Rican Population SO PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY LA English DT Article ID MURINE MODEL; MICE LACKING; EXPRESSION; DISEASE; RISK; TNF-ALPHA-308; EPIDEMIOLOGY; EOSINOPHILS; MACROPHAGES; ACTIVATION AB Recent studies have shown that osteopontin, a cytokine with suggested immunoregulatory functions, may contribute to pathogenesis of asthma. To determine whether single-nucleotide polymorphisms (SNPs) in SPP1, the gene encoding osteopontin, are associated with risk of asthma, we genotyped 6 known SNPs in SPP1 in the well-characterized Genetics of Asthma in Latino Americans population of 294 Mexican and 365 Puerto Rican parent-child asthma trios. The associations between SNPs and asthma or asthma-related phenotypes were examined by transmission disequilibrium tests as implemented in the family-based association test program. Three polymorphisms, 1 in exon 7 (rs1126616C) and 2 in the 3'-untranslated region (rs1126772A and rs9138A) of SPP1, were associated with diagnosis of asthma, severity of asthma, asthma in subjects with elevated immunoglobulin E (IgE) (IgE > 100 IU/mL), and postbronchodilator FEV(1) in Puerto Ricans (P values = 0.00007-0.04). The CC genotype of rs1126616 conferred an odds ratio of 1.7 (95% CI = [1.3, 2.3], P value adjusted for multiple comparisons = 0.001) for asthma compared with the CT and TT genotypes. Furthermore, haplotype analysis identified rs1126616C-rs1126772A-rs9138A to be associated with an increased risk for asthma, severity of asthma, and asthma in subjects with elevated IgE (P = 0.03). There was no association between the SPP1 SNPs and asthma outcomes in Mexicans. Our findings suggest that the SPP1 gene is a risk factor for asthma and asthma-related phenotypes in Puerto Ricans, and are consistent with previous animal and human studies on the role of osteopontin in pathogenesis of asthma. C1 [Arjomandi, Mehrdad] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Arjomandi, Mehrdad] Univ Calif San Francisco, Human Exposure Lab, San Francisco, CA 94121 USA. [Galanter, Josh M.; Choudhry, Shweta; Eng, Celeste; Hu, Donglei; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, Lung Biol Ctr, San Francisco, CA 94121 USA. [Choudhry, Shweta; Eng, Celeste; Hu, Donglei; Burchard, Esteban G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Inst Human Genet, San Francisco, CA 94121 USA. [Beckman, Kenneth] Univ Minnesota, Biomed Genom Ctr, Minneapolis, MN USA. [Chapela, Rocio] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico. [Rodriguez-Santana, Jose R.; Rodriguez-Cintron, William] CSP, Ctr Neumol Pediat, San Juan, PR USA. [Ford, Jean] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Avila, Pedro C.] Northwestern Univ, Div Allergy Immunol, Chicago, IL 60611 USA. [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94121 USA. RP Arjomandi, M (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Vet Affairs Med Ctr, Bldg 203,Room 3A-128,Mailstop 111-D,4150 Clement, San Francisco, CA 94121 USA. EM mehrdad.arjomandi@ucsf.edu FU NIH/NHLBI [HL083099]; GALA [HL078885, HL088133]; tobacco-related disease research program (TRDRP) (GALA) [15KT-0008]; Northern California Institute for Research and Education (Arjomandi); University of California San Francisco Cardiovascular Research Institute Faculty (Arjomandi) FX This study was supported by NIH/NHLBI HL083099 (Arjomandi K23 award), HL078885, and HL088133 (GALA funding), tobacco-related disease research program (TRDRP) 15KT-0008 (GALA funding), Northern California Institute for Research and Education (Arjomandi), and University of California San Francisco Cardiovascular Research Institute Faculty Development Funds (Arjomandi). NR 51 TC 9 Z9 11 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2151-321X J9 PEDIAT ALLER IMM PUL JI Pediatr. Allergy Immunol. Pulmonol. PD DEC PY 2011 VL 24 IS 4 BP 207 EP 214 DI 10.1089/ped.2011.0095 PG 8 WC Allergy; Immunology; Pediatrics; Respiratory System SC Allergy; Immunology; Pediatrics; Respiratory System GA 864IT UT WOS:000298234100005 ER PT J AU Baca, CB Vickrey, BG Caplan, R Vassar, SD Berg, AT AF Baca, Christine B. Vickrey, Barbara G. Caplan, Rochelle Vassar, Stefanie D. Berg, Anne T. TI Psychiatric and Medical Comorbidity and Quality of Life Outcomes in Childhood-Onset Epilepsy SO PEDIATRICS LA English DT Article DE epilepsy; psychiatric comorbidity; quality of life; Child Health Questionnaire; child and adolescent health ID WELL-CONTROLLED EPILEPSY; NEWLY-DIAGNOSED EPILEPSY; LONG-TERM PROGNOSIS; PEDIATRIC EPILEPSY; DEPRESSIVE SYMPTOMS; SPECTRUM DISORDER; CHILDREN; HEALTH; ADOLESCENTS; SEIZURE AB OBJECTIVE: We compared associations of epilepsy remission status and severity as well as psychiatric and other comorbidities with child and parent-proxy reports of health-related quality of life (HRQoL) in adolescents previously diagnosed with epilepsy. METHODS: In a prospective, community-based study of newly diagnosed childhood epilepsy, HRQoL of 277 children was assessed 8 to 9 years after diagnosis by using child and parent-proxy versions of the Child Health Questionnaire (CHQ). Multiple linear regression models adjusted for age and gender were used to compare associations of epilepsy remission and "complicated" epilepsy (secondary to an underlying neurologic insult or epileptic encephalopathy) status and psychiatric and other comorbidities with HRQoL. RESULTS: Mean age of epilepsy onset was 4.4 years (SD: 2.6). At the 9-year reassessment, children were, on average, 13.0 years old (SD: 2.6); 64% were seizure-free for 5 years, 31% were taking antiepileptic drugs, and 19% had a complicated epilepsy. Prevalence of comorbidities at follow-up were 26% psychiatric diagnosis; 39% neurodevelopmental spectrum disorder (NDSD); 24% chronic medical illness; and 15% migraine. In multivariable analysis, having a psychiatric disorder was broadly associated with child (6 of 11 scales) and parent-proxy (7 of 12 scales) HRQoL (P <= .0125). Five-year remission and complicated epilepsy status had few or no associations with HRQoL. Although parent-proxy HRQoL was strongly associated with NDSD (6 of 11 scales), child-reported HRQoL was not (2 of 11 scales). CONCLUSIONS: Psychiatric comorbidities are strongly associated with long-term HRQoL in childhood-onset epilepsy, which suggests that comprehensive epilepsy care must include screening and treatment for these conditions, even if seizures remit. Pediatrics 2011;128:e1532-e1543 C1 [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. [Caplan, Rochelle] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Berg, Anne T.] NW Childrens Hosp, Chicago, IL USA. RP Baca, CB (reprint author), Univ Calif Los Angeles, Dept Neurol, Box 951769,C-239 RNRC, Los Angeles, CA 90095 USA. EM cbower@mednet.ucla.edu FU National Institutes of Health (NIH); National Institutes of Health, National Institute of Neurological Disorders and Stroke [R37-NS31146]; Robert Wood Johnson Foundation [59982] FX Funded by the National Institutes of Health (NIH).; This work was supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke grant R37-NS31146 (principal investigator Dr Berg). Dr Baca was supported by Robert Wood Johnson Foundation Clinical Scholars Program grant 59982. NR 77 TC 57 Z9 58 U1 2 U2 13 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD DEC PY 2011 VL 128 IS 6 BP E1532 EP E1543 DI 10.1542/peds.2011-0245 PG 12 WC Pediatrics SC Pediatrics GA 862ZA UT WOS:000298131400021 PM 22123895 ER PT J AU Broyles, LM Rodriguez, KL Price, PA Bayliss, NK Sevick, MA AF Broyles, Lauren Matukaitis Rodriguez, Keri L. Price, Patrice A. Bayliss, Nichole K. Sevick, Mary Ann TI Overcoming Barriers to the Recruitment of Nurses as Participants in Health Care Research SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE alcohol / alcoholism; focus groups; health care; health care, acute / critical; nursing; relationships, research; research participation; research, access to participants; research, qualitative; sensitive topics ID QUALITY-OF-LIFE; NURSING-RESEARCH; FOCUS GROUPS; PERCEPTIONS; EXPERIENCES; INTERVIEWS; STRATEGIES; PROVIDERS; EMPLOYEES; HEART AB Adequate participant recruitment is critical for the successful execution of research studies involving human subjects. Participant recruitment can be particularly challenging when the intended study participants are health care providers as opposed to patients. Discussions of the challenges and successful strategies associated with provider recruitment are limited, particularly regarding providers other than physicians and settings outside of primary care. Using a case study format, we present our experiences recruiting inpatient nurses into a study which involved focus group methodology at a United States Veterans Health Administration facility. We describe the initial logistical and ethical issues involved, various challenges we encountered, and five successful action strategies used during a second recruitment wave addressing logistical issues; on-site recruitment; increased scheduling flexibility and peer-to-peer recruitment; attention to the sensitive nature of the research topic; and increased involvement of stakeholders. In conclusion, we advocate for multimodal recruitment strategies that facilitate ongoing investigator-clinician partnerships. C1 [Broyles, Lauren Matukaitis; Rodriguez, Keri L.; Bayliss, Nichole K.; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Broyles, Lauren Matukaitis] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. [Rodriguez, Keri L.; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. [Price, Patrice A.] VA Pittsburgh Healthcare Syst, Crit Care Serv Line, Pittsburgh, PA 15206 USA. RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA. EM Lauren.Broyles@va.gov NR 53 TC 7 Z9 7 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 J9 QUAL HEALTH RES JI Qual. Health Res. PD DEC PY 2011 VL 21 IS 12 BP 1705 EP 1718 DI 10.1177/1049732311417727 PG 14 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA 854VJ UT WOS:000297522600009 PM 21844286 ER PT J AU Thompson, GR Wickes, BL Herrera, ML Haman, TC Lewis, JS Jorgensen, JH AF Thompson, G. R., III Wickes, B. L. Herrera, M. L. Haman, T. C. Lewis, J. S., II Jorgensen, J. H. TI Disseminated Burkholderia gladioli infection in a lung transplant recipient with underlying hypocomplementemic urticarial vasculitis SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE hypocomplementemic urticarial vasculitis; Burkholderia gladioli; Burkholderia; lung transplantation ID CHRONIC GRANULOMATOUS-DISEASE; CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; IDENTIFICATION; CEPACIA; ANTIBODIES; PCR AB Burkholderia gladioli is difficult to definitively identify within the laboratory using phenotypic testing alone. We describe a case of recurrent B. gladioli infection in a lung transplant recipient with underlying hypocomplementemic urticarial vasculitis syndrome, discuss the difficulties encountered with laboratory identification, provide a review of the methodology required for definitive identification, and discuss potential pathophysiologic mechanisms in this patient responsible for the difficulty in treatment. C1 [Thompson, G. R., III] Univ Calif Davis, Coccidioidomycosis Serol Lab, Dept Med Microbiol & Immunol, Davis, CA 95616 USA. [Thompson, G. R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Davis, CA 95616 USA. [Wickes, B. L.; Herrera, M. L.; Jorgensen, J. H.] Univ Texas San Antonio, Dept Microbiol, Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Haman, T. C.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Lewis, J. S., II] Univ Hlth Syst, Dept Pharm, San Antonio, TX USA. RP Thompson, GR (reprint author), Univ Calif Davis, Coccidioidomycosis Serol Lab, Dept Med Microbiol & Immunol, 1 Shields Ave,Tupper Hall, Davis, CA 95616 USA. EM george.thompson@ucdmc.ucdavis.edu NR 24 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-2273 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD DEC PY 2011 VL 13 IS 6 BP 641 EP 645 DI 10.1111/j.1399-3062.2011.00638.x PG 5 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 865RL UT WOS:000298327900013 PM 21504528 ER PT J AU Chin, CT Weintraub, WS Dai, D Mehta, RH Rumsfeld, JS Anderson, HV Messenger, JC Kutcher, MA Peterson, ED Brindis, RG Rao, SV AF Chin, Chee Tang Weintraub, William S. Dai, David Mehta, Rajendra H. Rumsfeld, John S. Anderson, H. Vernon Messenger, John C. Kutcher, Michael A. Peterson, Eric D. Brindis, Ralph G. Rao, Sunil V. TI Trends and predictors of length of stay after primary percutaneous coronary intervention: A report from the CathPCI Registry SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR DATA REGISTRY; EARLY DISCHARGE; PRIMARY ANGIOPLASTY; COST-EFFECTIVENESS; MORTALITY; OUTCOMES AB Background Post hoc analyses of clinical trials suggest that certain patients are eligible for early discharge after ST-segment elevation myocardial infarction. The extent to which ST-segment elevation myocardial infarction patients are discharged early after primary percutaneous coronary intervention (PPCI) in current practice is unknown. Methods We examined 115,113 patients in the CathPCI Registry to assess temporal trends in length of stay (LOS) after PPCI. Baseline characteristics were compared between patients with LOS <= 2 and >2 days. Predictors of LOS >2 days were determined by logistic regression and adjusted for clustering among centers. Patterns of discharge within 2 days for low-risk patients with no inhospital complications were examined. Results From January 2005 through March 2009, mean LOS (4.0 +/- 3.0 to 3.6 +/- 2.7 days) (P for trend <.001) and the proportion of patients discharged after 2 days decreased (72.0%-65.9%), while predicted inhospital mortality risk remained unchanged. Patients with LOS >2 days (n = 77,471; 67.3%) were older and more likely to have had an intra-aortic balloon pump, cardiogenic shock, transfusions, and post-PPCI complications. Of 958 hospitals, 437 (45.6%) discharged at least half of their low-risk patients with no inhospital complications within 2 days. Conclusions While the predicted risk profile has remained stable, there has been a significant decrease in LOS after PPCI. Nevertheless, hospitals vary in discharging low-risk and uncomplicated patients early. Discharge within 2 days was associated with specific patient, procedure, and hospital factors. Further study is needed to determine the safety of early discharge among patients undergoing PPCI. (Am Heart J 2011;162:1052-61.) C1 [Chin, Chee Tang] Natl Heart Ctr Singapore, Singapore 168752, Singapore. [Chin, Chee Tang; Dai, David; Mehta, Rajendra H.; Peterson, Eric D.; Rao, Sunil V.] Duke Clin Res Inst, Durham, NC USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Anderson, H. Vernon] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA. [Messenger, John C.] Univ Colorado, Denver Sch Med, Aurora, CO USA. [Kutcher, Michael A.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Brindis, Ralph G.] No Calif Kaiser Permanente, Oakland, CA USA. RP Chin, CT (reprint author), Natl Heart Ctr Singapore, 17 3rd Hosp Ave, Singapore 168752, Singapore. EM chin.chee.tang@nhcs.com.sg FU Agency for Healthcare Research and Quality (AHRQ) [U18HS016964] FX This project was supported by grant number U18HS016964 from the Agency for Healthcare Research and Quality (AHRQ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the AHRQ. The funding source had no role in the design or implementation of the study, or in the decision to seek publication. NR 16 TC 10 Z9 10 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD DEC PY 2011 VL 162 IS 6 BP 1052 EP 1061 DI 10.1016/j.ahj.2011.09.008 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 861QC UT WOS:000298033300013 PM 22137079 ER PT J AU Donohue, JM Zhang, YT Men, AM Perera, S Lave, JR Hanlon, JT Reynolds, CF AF Donohue, Julie M. Zhang, Yuting Men, Aiju Perera, Subashan Lave, Judith R. Hanlon, Joseph T. Reynolds, Charles F. TI Impact of Medicare Part D on Antidepressant Treatment, Medication Choice, and Adherence Among Older Adults With Depression SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Adherence; depression; insurance coverage; medicare ID PRIMARY-CARE PATIENTS; MAJOR DEPRESSION; HEALTH-SERVICES; DRUG; SYMPTOMS; COST; NONADHERENCE; BENEFICIARIES; MORTALITY; TRIAL AB Objectives: Depression in older adults is often undertreated due, in part, to medication costs. We examined the impact of improved prescription drug coverage under Medicare Part D on use of antidepressants, medication choice, and adherence. Design, Setting and Participants: Observational claims-based study of older adults with depression (ICD-9: 296.2, 296.3, 311, 300.4) continuously enrolled in a Medicare managed care plan between 2004 and 2007. Three groups with limited ($ 150 or $ 350 quarterly caps) or no drug coverage in 2004-2005 obtained Part D benefits in 2006. A comparison group had stable employer-sponsored coverage throughout. Measurements: Any antidepressant prescription fill, antidepressant choice (tricyclics or monoamine oxidase inhibitors versus newer antidepressants), and adherence (80% of days covered) in the first 6 months of treatment. Results: Part D was associated with increased odds of any antidepressant use among those who previously lacked coverage (odds ratio [OR] 1.61, 95% confidence interval [CI] 1.41-1.85) but odds of use did not change among those with limited prior coverage. Use of older antidepressant agents did not change with Part D. All three groups whose coverage improved with Part D had significantly higher odds of 80% of days covered with an antidepressant (OR = 1.86 [95% CI: 1.44-2.39] for no coverage, 1.74 [95% CI: 1.25% 3.42] for $ 150 cap; and 1.19 [95% CI: 1.06-1.34] for the $ 350 cap groups). Conclusions: Medicare Part D was associated with improvements in antidepressant use and adherence in depressed older adults who previously had no or limited drug coverage but not with changes in use of older agents. use and adherence in depressed older adults who previously had no or limited drug coverage but not with changes in use of older agents. (Am J Geriatr Psychiatry 2011; 19:989-997) C1 [Donohue, Julie M.; Zhang, Yuting; Lave, Judith R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA. [Donohue, Julie M.; Reynolds, Charles F.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA. [Perera, Subashan; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Geriatr Med, Pittsburgh, PA 15261 USA. [Perera, Subashan; Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Ctr Hlth Equ Res, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Ctr Geriatr Res Educ & Clin, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Donohue, Julie M.; Reynolds, Charles F.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. RP Donohue, JM (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A613, Pittsburgh, PA 15261 USA. EM jdonohue@pitt.edu RI Perera, Subashan/D-7603-2014 OI Donohue, Julie/0000-0003-2418-6017; Zhang, Yuting/0000-0002-6460-6779 FU National Center for Research Resources, National Institutes of Health (NIH) [KL2 RR-024154-04]; Agency for Healthcare Research and Quality [R01HS017695]; NIH [R34 MH082682, R01AG027017, P30AG024827, P30MH71944, T32AG021885, K07AG033174, R01AG034056]; Veterans Administration Health Services Research and Development Service [IIR-06-062]; UPMC endowment in geriatric psychiatry; John A. Hartford Foundation FX This publication was supported by the National Center for Research Resources, National Institutes of Health (NIH) (KL2 RR-024154-04), Agency for Healthcare Research and Quality (R01HS017695), NIH grants (R34 MH082682, R01AG027017, P30AG024827, P30MH71944, T32AG021885, K07AG033174, R01AG034056), the Veterans Administration Health Services Research and Development Service (IIR-06-062), the UPMC endowment in geriatric psychiatry, and John A. Hartford Foundation. NR 32 TC 16 Z9 16 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD DEC PY 2011 VL 19 IS 12 BP 989 EP 997 DI 10.1097/JGP.0b013e3182051a9b PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 857ES UT WOS:000297699600002 PM 22123272 ER PT J AU Jack, CR Vemuri, P Wiste, HJ Weigand, SD Aisen, PS Trojanowski, JQ Shaw, LM Bernstein, MA Petersen, RC Weiner, MW Knopman, DS AF Jack, Clifford R., Jr. Vemuri, Prashanthi Wiste, Heather J. Weigand, Stephen D. Aisen, Paul S. Trojanowski, John Q. Shaw, Leslie M. Bernstein, Matthew A. Petersen, Ronald C. Weiner, Michael W. Knopman, David S. CA Alzheimer's Dis Neuroimaging Initi TI Evidence for Ordering of Alzheimer Disease Biomarkers SO ARCHIVES OF NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; CEREBROSPINAL-FLUID A-BETA(42); NORMAL OLDER-ADULTS; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; CSF BIOMARKERS; A-BETA; AMYLOID DEPOSITION AB Objective: To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner. Design: Validation sample. Setting: Multisite, referral centers. Participants: A total of 401 elderly participants in the Alzheimer's Disease Neuroimaging Initiative who were cognitively normal, who had mild cognitive impairment, or who had AD dementia. We compared the proportions of 3 AD biomarker values (the A beta 42 level in cerebrospinal fluid [CSF], the total tau level in CSF, and the hippocampal volume adjusted for intracranial volume [hereafter referred to as the adjusted hippocampal volume]) that were abnormal as cognitive impairment worsened. Cut points demarcating normal vs abnormal for each biomarker were established by maximizing diagnostic accuracy in independent autopsy samples. Main Outcome Measures: Three AD biomarkers (ie, the CSF A beta 42 level, the CSF total tau level, and the adjusted hippocampal volume). Results: Within each clinical group of the entire sample (n=401), the CSF A beta 42 level was abnormal more often than was the CSF total tau level or the adjusted hippocampal volume. Among the 298 participants with both baseline and 12-month data, the proportion of participants with an abnormal A beta 42 level did not change from baseline to 12 months in any group. The proportion of participants with an abnormal total tau level increased from baseline to 12 months in cognitively normal participants (P=.05) but not in participants with mild cognitive impairment or AD dementia. For 209 participants with an abnormal CSF A beta 42 level at baseline, the percentage with an abnormal adjusted hippocampal volume but normal CSF total tau level increased from baseline to 12 months in participants with mild cognitive impairment. No change in the percentage of MCI participants with an abnormal total tau level was seen between baseline and 12 months. Conclusions: A reduction in the CSF A beta 42 level denotes a pathophysiological process that significantly departs from normality (ie, becomes dynamic) early, whereas the CSF total tau level and the adjusted hippocampal volume are biomarkers of downstream pathophysiological processes. The CSF total tau level becomes dynamic before the adjusted hippocampal volume, but the hippocampal volume is more dynamic in the clinically symptomatic mild cognitive impairment and AD dementia phases of the disease than is the CSF total tau level. Arch Neurol. 2011; 68(12): 1526-1535. Published online August 8, 2011. doi:10.1001/archneurol.2011.183 C1 [Jack, Clifford R., Jr.; Vemuri, Prashanthi; Bernstein, Matthew A.] Mayo Clin & Mayo Fdn Med Educ & Res, Dept Radiol, Rochester, MN 55905 USA. [Wiste, Heather J.; Weigand, Stephen D.] Mayo Clin & Mayo Fdn Med Educ & Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA. [Petersen, Ronald C.; Knopman, David S.] Mayo Clin & Mayo Fdn Med Educ & Res, Dept Neurol, Rochester, MN 55905 USA. [Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Weiner, Michael W.] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Trojanowski, John Q.; Shaw, Leslie M.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Trojanowski, John Q.; Shaw, Leslie M.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA. RP Jack, CR (reprint author), Mayo Clin & Mayo Fdn Med Educ & Res, Dept Radiol, 200 1st St SW, Rochester, MN 55905 USA. EM jack.clifford@mayo.edu RI Jack, Clifford/F-2508-2010; Vemuri, Prashanthi/K-7030-2012 OI Jack, Clifford/0000-0001-7916-622X; Bernstein, Matt/0000-0003-3770-0441 FU Pfizer; Baxter International Inc; Merck; Avid; Elan Pharmaceuticals; Forest Pharmaceuticals; Baxter Healthcare; National Institutes of Health [AG11378]; ADNI FX Dr Aisen serves on a scientific advisory board for NeuroPhage; serves as a consultant to Elan Corporation, Wyeth, Eisai Inc, Bristol-Myers Squibb, Eli Lilly and Company, NeuroPhage, Merck, Roche, Amgen, Abbott, Pfizer, Novartis, Bayer, Astellas, Dainippon, Biomarin, Solvay, Otsuka, Daiichi, AstraZeneca, Janssen, and Medivation Inc; receives research support from Pfizer and Baxter International Inc; and has received stock options from Medivation Inc and NeuroPhage. Dr Petersen reports serving as a consultant for Elan Pharmaceuticals and GE Healthcare and serving on data monitoring committees for Pfizer and Janssen Alzheimer Immunotherapy. Dr Weiner reports serving on the advisory boards of Elan/Wyeth, Novartis, Banner, Lilly, VACO, Biogen Idec, Araclon, and Pfizer. He serves as a consultant to Elan/Wyeth, Novartis, Forest, Ipsen, Daiichi Sankyo Inc, AstraZeneca, Araclon, Pfizer, TauRx Therapeutics, Bayer, Biogen Idec, Exonhit Therapeutics, Servier, and Synarc. He has received honoraria from the American Academy of Neurology, Ipsen, NeuroVigil Inc, and the Institut Catala de Neurociencies Aplicades. He receives research funding from Merck and Avid. He owns stock in Synarc and Elan. He serves on the editorial advisory board for Alzheimer's & Dementia and the Journal of Magnetic Resonance Imaging. Dr Knopman reports that he serves on a Data Safety Monitoring Board for Lilly Pharmaceuticals and is an investigator for clinical trials sponsored by Elan Pharmaceuticals, Forest Pharmaceuticals, and Baxter Healthcare. He is deputy editor of Neurology and receives compensation for editorial services.; This work was support by the National Institutes of Health (grant AG11378) and the ADNI. Online-Only Material: The eTables and eFigures are available at http://www.archneurol.com. NR 86 TC 105 Z9 105 U1 3 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD DEC PY 2011 VL 68 IS 12 BP 1526 EP 1535 DI 10.1001/archneurol.2011.183 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 861BJ UT WOS:000297993500005 PM 21825215 ER PT J AU Weintraub, D Doshi, J Koka, D Davatzikos, C Siderowf, AD Duda, JE Wolk, DA Moberg, PJ Xie, SX Clark, CM AF Weintraub, Daniel Doshi, Jimit Koka, Deepthi Davatzikos, Christos Siderowf, Andrew D. Duda, John E. Wolk, David A. Moberg, Paul J. Xie, Sharon X. Clark, Christopher M. TI Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease SO ARCHIVES OF NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; LEWY BODIES; PATTERN-CLASSIFICATION; ELASTIC REGISTRATION; BRAIN ATROPHY; MCI PATIENTS; DEMENTIA; IMPAIRMENT; HIPPOCAMPAL; MRI AB Objective: To assess regions and patterns of brain atrophy in patients with Parkinson disease (PD) with normal cognition (PD-NC), mild cognitive impairment (PD-MCI), and dementia-level cognitive deficits (PDD). Design: Images were quantified using a region-ofinterest approach and voxel-based morphometry analysis. We used a high-dimensional pattern classification approach to delineate brain regions that collectively formed the Spatial Pattern of Abnormalities for Recognition of PDD. Setting: The Parkinson's Disease and Movement Disorders Center at the University of Pennsylvania. Subjects: Eighty-four PD patients (61 PD-NC, 12 PD-MCI, and 11 PDD) and 23 healthy control subjects (HCs) underwent magnetic resonance imaging of the brain. Results: The PD-NC patients did not demonstrate significant brain atrophy compared with HCs. Compared with PD-NC patients, PD-MCI patients had hippocam-pal atrophy (beta=-0.37; P=.001), and PDD patients demonstrated hippocampal (beta=-0.32; P=.004) and additional medial temporal lobe atrophy (beta=-0.36; P=.003). The PD-MCI patients had a different pattern of atrophy compared with PD-NC patients (P=.04) and a similar pattern to that of PDD patients (P=.81), characterized by hippocampal, prefrontal cortex gray and white matter, occipital lobe gray and white matter, and parietal lobe white matter atrophy. In nondemented PD patients, there was a correlation between memory-encoding performance and hippocampal volume. Conclusions: Hippocampal atrophy is a biomarker of initial cognitive decline in PD, including impaired memory encoding and storage, suggesting heterogeneity in the neural substrate of memory impairment. Use of a pattern classification approach may allow identification of diffuse regions of cortical gray and white matter atrophy early in the course of cognitive decline. Arch Neurol. 2011; 68(12):1562-1568 C1 [Weintraub, Daniel; Moberg, Paul J.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Siderowf, Andrew D.; Duda, John E.; Wolk, David A.; Clark, Christopher M.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Doshi, Jimit; Koka, Deepthi; Davatzikos, Christos] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Duda, John E.; Moberg, Paul J.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Clark, Christopher M.] Avid Radiopharmaceut, Philadelphia, PA USA. RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, 3615 Chestnut St,Ste 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Department of Health of the Commonwealth of Pennsylvania [SAP4100027296]; National Institute of Neurological Disorders and Stroke (Penn Udall Center) [P50 NS053488]; National Institute on Aging [R01-14971, P30-AG10124] FX This study was supported by health research grant SAP4100027296 from the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 200177; by P50 NS053488 from the National Institute of Neurological Disorders and Stroke (Penn Udall Center); and by grants R01-14971 and P30-AG10124 from the National Institute on Aging. NR 52 TC 78 Z9 79 U1 2 U2 13 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD DEC PY 2011 VL 68 IS 12 BP 1562 EP 1568 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 861BJ UT WOS:000297993500010 PM 22159053 ER PT J AU Wang, V Liu, CF Bryson, CL Sharp, ND Maciejewski, ML AF Wang, Virginia Liu, Chuan-Fen Bryson, Christopher L. Sharp, Nancy D. Maciejewski, Matthew L. TI Does Medication Adherence Following a Copayment Increase Differ by Disease Burden? SO HEALTH SERVICES RESEARCH LA English DT Article DE Cost sharing; medication adherence; diabetes; hypertension; veterans ID ACUTE MYOCARDIAL-INFARCTION; MANAGED CARE; PRESCRIPTION DRUGS; PHARMACY BENEFITS; STATIN THERAPY; RETROSPECTIVE COHORT; HEALTH-INSURANCE; RISK ADJUSTMENT; CHRONICALLY ILL; PART-D AB Objectives. To compare changes in medication adherence between patients with high- or low-comorbidity burden after a copayment increase. Methods. We conducted a retrospective observational study at four Veterans Affairs (VA) medical centers by comparing veterans with hypertension or diabetes required to pay copayments with propensity score-matched veterans exempt from copayments. Disease cohorts were stratified by Diagnostic Cost Group risk score: low-(<1) and high-comorbidity (>1) burden. Medication adherence from February 2001 to December 2003, constructed from VA pharmacy claims data based on the ReComp algorithm, were assessed using generalized estimating equations. Results. Veterans with lower comorbidity were more responsive to a U.S.$5 copayment increase than higher comorbidity veterans. In the lower comorbidity groups, veterans with diabetes had a greater reduction in adherence than veterans with hypertension. Adherence trends were similar for copayment-exempt and nonexempt veterans with higher comorbidity. Conclusion. Medication copayment increases are associated with different impacts for low- and high-risk patients. High-risk patients incur greater out-of-pocket costs from continued adherence, while low- risk patients put themselves at increased risk for adverse health events due to greater nonadherence. C1 [Wang, Virginia] Duke Univ, Ctr Hlth Serv Res Primary Care, Durham VA Med Ctr, Dept Med,Div Gen Internal Med, Durham, NC 27705 USA. [Liu, Chuan-Fen; Bryson, Christopher L.; Sharp, Nancy D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Liu, Chuan-Fen; Bryson, Christopher L.; Sharp, Nancy D.] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA. [Maciejewski, Matthew L.] Duke Univ, Div Gen Internal Med, Dept Med, Durham, NC 27706 USA. [Maciejewski, Matthew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. RP Wang, V (reprint author), Duke Univ, Ctr Hlth Serv Res Primary Care, Durham VA Med Ctr, Dept Med,Div Gen Internal Med, 508 Fulton St 152, Durham, NC 27705 USA. EM virginia.wang@duke.edu FU Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs [IIR 03-200]; Department of Veteran Affairs Office of Academic Affiliations; AHRQ [K12 HS 019479] FX This research was supported by Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs, project number IIR 03-200, Department of Veteran Affairs Office of Academic Affiliations, and AHRQ grant number K12 HS 019479. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veteran Affairs, AHRQ, University of Washington, or Duke University Health System. NR 73 TC 10 Z9 10 U1 5 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD DEC PY 2011 VL 46 IS 6 BP 1963 EP 1985 DI 10.1111/j.1475-6773.2011.01286.x PN 1 PG 23 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 851BT UT WOS:000297244000015 PM 21689097 ER PT J AU Larsen, GK Evans, J Lambert, WE Chen, YY Raitt, MH AF Larsen, Gail K. Evans, John Lambert, William E. Chen, Yiyi Raitt, Merritt H. TI Shocks burden and increased mortality in implantable cardioverter-defibrillator patients SO HEART RHYTHM LA English DT Article DE Implantable cardioverter-defibrillator; Shocks; Antitachycardia pacing; Ventricular arrhythmia; Death ID SUDDEN CARDIAC DEATH; HEART-FAILURE; VENTRICULAR-ARRHYTHMIA; MADIT-II; THERAPY; CARDIOMYOPATHY; PREVENTION; SURVIVAL AB BACKGROUND Implantable cardioverter-defibrillator (ICD) shocks are associated with an increased risk of death. It is unclear whether ICD shocks are detrimental per se or a marker of higher risk patients. OBJECTIVE We aimed to assess the association between ICD shocks and time to death after correction for baseline mortality based on the Seattle Heart Failure Model (SHFM). METHODS The primary analysis compared time-to-death between patients receiving no shocks and patients receiving shocks of any type adjusted for SHFM score at time of implantation and other comorbidities. Subgroup analyses were performed to further describe the relationship between shocks and mortality risk. RESULTS Over a median follow-up of 41 months (interquartile range 23-64), one or more shock episodes occurred in 59% of 425 patients and 40% of the patients died. Patients receiving shocks of any type had increased risk of death (hazard ratio 1.55; 95% confidence interval 1.07-2.23; P = .02) versus patients receiving no shocks. While patients with 1-5 days with shock (shock days) did not show evidence of increased risk of death (1.30 [0.88-.94]; P = 0.19), those with 6-10 shock days (2.22 [1.21-4.08]; P <.01) and >10 shock days (3.66 [1.86 -7.19]; P <.01) had increasingly higher risk. There was no increased hazard for death (0.73 [0.34 -1.57]; P = .41) in patients treated only with antitachycardia pacing (ATP). CONCLUSION ICD shocks were associated with increased mortality risk after adjustment for SHFM-predicted mortality, and the burden of shocks played a role in this association. ATP did not increase mortality risk, suggesting that shocks may themselves be detrimental. C1 [Raitt, Merritt H.] Portland VA Med Ctr, Portland, OR 97239 USA. [Larsen, Gail K.; Lambert, William E.; Chen, Yiyi; Raitt, Merritt H.] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Evans, John] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Raitt, MH (reprint author), Portland VA Med Ctr, 3710 SW US Vet Rd, Portland, OR 97239 USA. EM merritt.raitt@va.gov OI Raitt, Merritt/0000-0001-5638-7732 NR 18 TC 48 Z9 49 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD DEC PY 2011 VL 8 IS 12 BP 1881 EP 1886 DI 10.1016/j.hrthm.2011.07.036 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 863CE UT WOS:000298139600011 PM 21816127 ER PT J AU El-Shewy, HM Abdel-Samie, SA Al Qalam, AM Lee, MH Kitatani, K Anelli, V Jaffa, AA Obeid, LM Luttrell, LM AF El-Shewy, Hesham M. Abdel-Samie, Souzan A. Al Qalam, Abdelmohsen M. Lee, Mi-Hye Kitatani, Kazuyuki Anelli, Viviana Jaffa, Ayad A. Obeid, Lina M. Luttrell, Louis M. TI Phospholipase C and Protein Kinase C-beta 2 Mediate Insulin-Like Growth Factor II-Dependent Sphingosine Kinase 1 Activation SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID HETEROTRIMERIC G-PROTEINS; G-ALPHA-Q; FACTOR-II/MANNOSE-6-PHOSPHATE RECEPTOR; RECYCLING ENDOSOMES; PLASMA-MEMBRANE; ADULT-RAT; CELLS; EXPRESSION; TRANSLOCATION; PKC AB We recently reported that IGF-II binding to the IGF-II/mannose-6-phosphate (M6P) receptor activates the ERK1/2 cascade by triggering sphingosine kinase 1 (SK1)-dependent transactivation of G protein-coupled sphingosine 1-phosphate (S1P) receptors. Here, we investigated the mechanism of IGF-II/M6P receptor-dependent sphingosine kinase 1 (SK1) activation in human embryonic kidney 293 cells. Pretreating cells with protein kinase C (PKC) inhibitor, bisindolylmaleimide-I, abolished IGF-II-stimulated translocation of green fluorescent protein (GFP)-tagged SK1 to the plasma membrane and activation of endogenous SK1, implicating PKC as an upstream regulator of SK1. Using confocal microscopy to examine membrane translocation of GFP-tagged PKC alpha, beta 1, beta 2, delta, and zeta, we found that IGF-II induced rapid, transient, and isoform-specific translocation of GFP-PKC beta 2 to the plasma membrane. Immunoblotting of endogenous PKC phosphorylation confirmed PKC beta 2 activation in response to IGF-II. Similarly, IGF-II stimulation caused persistent membrane translocation of the kinase-deficient GFP-PKC beta 2 (K371R) mutant, which does not dissociate from the membrane after translocation. IGF-II stimulation increased diacylglycerol (DAG) levels, the established activator of classical PKC. Interestingly, the polyunsaturated fraction of DAG was increased, indicating involvement of phosphatidyl inositol/phospholipase C (PLC). Pretreating cells with the PLC inhibitor, U73122, attenuated IGF-II-dependent DAG production and PKC beta 2 phosphorylation, blocked membrane translocation of the kinase-deficient GFP-PKC beta 2 (K371R) mutant, and reduced sphingosine 1-phosphate production, suggesting that PLC/PKC beta 2 are upstream regulators of SK1 in the pathway. Taken together, these data provide evidence that activation of PLC and PKC beta 2 by the IGF-II/M6P receptor are required for the activation of SK1. (Molecular Endocrinology 25:2144-2156, 2011) C1 [El-Shewy, Hesham M.] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29425 USA. [Abdel-Samie, Souzan A.; Kitatani, Kazuyuki; Anelli, Viviana; Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.; Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP El-Shewy, HM (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St,MSC 776, Charleston, SC 29425 USA. EM elshewy@musc.edu FU South Carolina Center for Biomedical Research Excellence in Lipidomics and Pathology; National Institutes of Health (NIH) [DK55524]; NIH/NCRR [P20 RR17677, HL087986, HL077192]; Department of Veterans Affairs; Veteran Affairs Merit Award FX This work was supported by a grant from South Carolina Center for Biomedical Research Excellence in Lipidomics and Pathology (to H. M. E.), National Institutes of Health (NIH) Grants DK55524 (to L.M.L.) and NIH/NCRR P20 RR17677 (to L.M.O.), HL087986 and HL077192 (to A.A.J.), Department of Veterans Affairs Research Enhancement Award (L.M.L.), and Veteran Affairs Merit Award (to L.M.O.). NR 44 TC 11 Z9 11 U1 0 U2 16 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD DEC PY 2011 VL 25 IS 12 BP 2144 EP 2156 DI 10.1210/me.2011-0101 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 861YB UT WOS:000298055800015 PM 22016563 ER PT J AU Nair, G Pardue, MT Kim, M Duong, TQ AF Nair, Govind Pardue, Machelle T. Kim, Moon Duong, Timothy Q. TI Manganese-Enhanced MRI Reveals Multiple Cellular and Vascular Layers in Normal and Degenerated Retinas SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE magnetic resonance imaging; MEMRI; retinal degeneration; high resolution imaging; MRI microscopy; RCS ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL PATHWAY; FUNCTIONAL MRI; RAT RETINA; RCS RAT; BRAIN; RESOLUTION; CLEARANCE; TRANSPORT; CONTRAST AB Purpose: To use manganese-enhanced magnetic resonance imaging (MEMRI) at 25 x 25 x 800 mu m(3) to image different retinal and vascular layers in the rat retinas. Materials and Methods: Manganese-chloride was injected intraocularly in normal (n = 5) and Royal College of Surgeons (RCS, an model of photoreceptor degeneration) (n = 5) rats at postnatal day 90. MEMRI at 4.7 T was performed 24 hours later. MRI was repeated following intravenous Gd-DTPA in the same animals to highlight the vasculatures. Layer assignment and thickness were compared to histology. Results: MEMRI 24 hours after intravitreal manganese-chloride injection revealed seven bands of alternating hyper- and hypointensities, corresponding histologically to the ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, photoreceptor-segment layer, and choroidal vascular layer. Intravenous Gd-DTPA-which does not cross the blood-retinal barrier and the retinal pigment epithelium-further enhanced the two layers bounding the retina, corresponding to the retinal and choroidal vascular layers, but not the avascular outer nuclear layer and the photoreceptor-segment layer. MEMRI of the RCS retinas revealed the loss of the outer plexiform layer, outer nuclear layer, and photoreceptor-segment layer. Histological analysis corroborated the MRI laminar assignments and thicknesses. Conclusion: Lamina-specific retinal structures neurodegenerative changes to structure in retinal diseases can be detected using MEMRI. C1 [Duong, Timothy Q.] UTHSCSA, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] UTHSCSA, Res Imaging Inst, Dept Physiol, San Antonio, TX 78229 USA. [Nair, Govind] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Worcester, MA USA. [Nair, Govind] Worcester Polytech Inst, Worcester, MA 01609 USA. [Nair, Govind] Emory Univ, Yerkes Imaging Ctr, Neurosci Div, Atlanta, GA 30322 USA. [Pardue, Machelle T.; Kim, Moon] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Pardue, Machelle T.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA. [Duong, Timothy Q.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Duong, TQ (reprint author), UTHSCSA, Res Imaging Inst, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008 FU NEI NIH HHS [R01 EY018855, R01 EY014211] NR 33 TC 12 Z9 12 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD DEC PY 2011 VL 34 IS 6 BP 1422 EP 1429 DI 10.1002/jmri.22719 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 851VG UT WOS:000297298800020 PM 21964629 ER PT J AU Liang, HY Ward, WF Jang, YC Bhattacharya, A Bokov, AF Li, Y Jernigan, A Richardson, A Van Remmen, H AF Liang, Huiyun Ward, Walter F. Jang, Youngmok C. Bhattacharya, Arunabh Bokov, Alex F. Li, Yan Jernigan, Amanda Richardson, Arlan Van Remmen, Holly TI PGC-1 alpha PROTECTS NEURONS AND ALTERS DISEASE PROGRESSION IN AN AMYOTROPHIC LATERAL SCLEROSIS MOUSE MODEL SO MUSCLE & NERVE LA English DT Article DE amyotrophic lateral sclerosis; excitatory amino acid transporter protein 2 (EAAT2); motor neuron; neuromuscular junction; PGC-1 alpha transgenic mice ID CU,ZN SUPEROXIDE-DISMUTASE; OXYGEN SPECIES PRODUCTION; ACETYLCHOLINE-RECEPTOR; MITOCHONDRIAL BIOGENESIS; CALORIC RESTRICTION; SKELETAL-MUSCLE; TRANSGENIC MICE; TRANSCRIPTIONAL COACTIVATOR; NEUROMUSCULAR-JUNCTION; RADICAL GENERATION AB Introduction: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. We sought to determine whether peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) would have a beneficial effect on this disease. Methods: PGC-1 alpha transgenic mice were crossed with SOD1 mutant G93A DL mice. Results: We observed a moderate but non-significant increase in average lifespan in PGC-1 alpha/G93A DL mice, as compared with G93A DL mice (292 +/- 3 days vs. 274 +/- 7 days). Although the onset of ALS was not altered, progression of the disease was significantly slower (similar to 34% increase in duration) in the PGC-1 alpha/G93A DL mice. These mice also exhibited markedly improved performance on the rotarod test, and the improved motor activity was associated with a decreased loss of motor neurons and less degeneration of neuromuscular junctions. Conclusion: A sustained level of excitatory amino acid transporter protein 2 (EAAT2) in astrocytes of the PGC-1 alpha/G93A DL mice may contribute to neuronal protection. Muscle Nerve 44: 947-956, 2011 C1 [Liang, Huiyun; Ward, Walter F.; Jang, Youngmok C.; Bhattacharya, Arunabh; Bokov, Alex F.; Li, Yan; Jernigan, Amanda; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ward, Walter F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Bokov, Alex F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat & Epidemiol, San Antonio, TX 78229 USA. [Bhattacharya, Arunabh; Richardson, Arlan; Van Remmen, Holly] Univ Texas San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM vanremmen@uthscsa.edu FU Muscular Dystrophy Association [MDA 69814, 10047]; VA Merit grant FX The authors thank Dr. Florian Muller for his helpful input for this study. This work was supported by Muscular Dystrophy Association grants MDA 69814 (to H.L.) and 10047 (to H.v.R.), and a VA Merit grant (to H.v.R.). NR 59 TC 39 Z9 39 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD DEC PY 2011 VL 44 IS 6 BP 947 EP 956 DI 10.1002/mus.22217 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 860HG UT WOS:000297938800017 PM 22102466 ER PT J AU Baddley, JW Pappas, PG AF Baddley, John W. Pappas, Peter G. TI Pulmonary Fungal Infections PREFACE SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material C1 [Baddley, John W.; Pappas, Peter G.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Baddley, JW (reprint author), Univ Alabama, Dept Med, Div Infect Dis, Tinsley Harrison Tower 229,1530 3rd Ave S, Birmingham, AL 35294 USA. EM jbaddley@uab.edu NR 0 TC 1 Z9 1 U1 0 U2 1 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD DEC PY 2011 VL 32 IS 6 BP 661 EP 662 DI 10.1055/s-0031-1295713 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 860OZ UT WOS:000297958900001 PM 22167393 ER PT J AU Thompson, GR Patterson, TF AF Thompson, George R., III Patterson, Thomas F. TI Pulmonary Aspergillosis: Recent Advances SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE Aspergillosis; chronic cavitary aspergillosis; aspergilloma ID STEM-CELL TRANSPLANTATION; CRITICALLY-ILL PATIENTS; BETA-GLUCAN RECEPTOR; INVASIVE MOLD INFECTION; AMPHOTERICIN-B THERAPY; ANTIFUNGAL THERAPY; NEUTROPENIC PATIENTS; CANCER-PATIENTS; FUMIGATUS; POSACONAZOLE AB Aspergillosis remains a significant cause of morbidity and mortality. The spectrum of disease is diverse and ranges from noninvasive disease with an excessive immune response, such as in allergic bronchopulmonary aspergillosis (ABPA), to a lack of an immune response as seen in patients with quantitative or qualitative granulocyte deficits and subsequent invasive pulmonary aspergillosis. Noninvasive diagnostic testing has improved the time to initiation of effective antifungal therapy, and numerous agents in different therapeutic classes are now available as treatment options. Voriconazole remains the preferred agent in the treatment of invasive pulmonary aspergillosis, and recent data have increased interest in the potential of combination therapy against this often lethal infection. The role of host genetics in selecting patients that may benefit from more aggressive antifungal prophylaxis or treatment practices remains unclear but is likely to guide therapeutic choices as newer data become available. C1 [Thompson, George R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Davis, CA 95616 USA. [Thompson, George R., III] Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Thompson, GR (reprint author), Univ Calif Davis, Dept Internal Med, Div Infect Dis, 1 Shields Ave,Tupper Hall,Rm 3146, Davis, CA 95616 USA. EM grthompson@ucdavis.edu NR 74 TC 18 Z9 18 U1 1 U2 5 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD DEC PY 2011 VL 32 IS 6 BP 673 EP 681 DI 10.1055/s-0031-1295715 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 860OZ UT WOS:000297958900003 PM 22167395 ER PT J AU Brizendine, KD Baddley, JW Pappas, PG AF Brizendine, Kyle D. Baddley, John W. Pappas, Peter G. TI Pulmonary Cryptococcosis SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE Cryptococcus; pulmonary; cryptococcosis; cryptococcal; pneumonia ID HUMAN-IMMUNODEFICIENCY-VIRUS; INVASIVE FUNGAL-INFECTIONS; ACTIVE ANTIRETROVIRAL THERAPY; BRONCHOALVEOLAR LAVAGE FLUID; ORGAN TRANSPLANT RECIPIENTS; NECROSIS-FACTOR-ALPHA; NEOFORMANS INFECTION; IMMUNOCOMPETENT PATIENTS; MAINTENANCE THERAPY; NEGATIVE PATIENTS AB Cryptococcosis is an invasive fungal infection (IFI), caused predominantly by Cryptococcus neoformans or Cryptococcus gattii, that affects both immunocompromised (IC) and non-IC patients. Although the most serious disease manifestation is meningoencephalitis, cryptococcal pneumonia is underdiagnosed and may disseminate to the central nervous system (CNS) and other sites depending upon host defenses and administration of appropriate antifungal therapy. The clinical presentation of pulmonary cryptococcosis varies along a spectrum from asymptomatic infection to severe pneumonia and respiratory failure, and the radiological presentation can be characterized by an array of findings, including nodules, consolidation, cavitary lesions, and a diffuse interstitial pattern. Diagnosis most often relies upon isolation of Cryptococcus from a pulmonary specimen in the appropriate clinical and radiological context. Treatment recommendations include induction therapy with an amphotericin B preparation and flucytosine for IC patients and those with severe disease and fluconazole for mild-to-moderate, localized disease. Knowledge of the pathophysiology, epidemiology, clinical presentation, and treatment of pulmonary cryptococcosis may lead to greater recognition of this underdiagnosed IFI and improved outcomes. C1 [Brizendine, Kyle D.; Baddley, John W.; Pappas, Peter G.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Pappas, PG (reprint author), Univ Alabama, Dept Med, Div Infect Dis, Tinsley Harrison Tower 229,1530 3rd Ave S, Birmingham, AL 35294 USA. EM pappas@uab.edu NR 71 TC 19 Z9 22 U1 1 U2 10 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD DEC PY 2011 VL 32 IS 6 BP 727 EP 734 DI 10.1055/s-0031-1295720 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 860OZ UT WOS:000297958900008 PM 22167400 ER PT J AU Howard, G Cushman, M Kissela, BM Kleindorfer, DO McClure, LA Safford, MM Rhodes, JD Soliman, EZ Moy, CS Judd, SE Howard, VJ AF Howard, George Cushman, Mary Kissela, Brett M. Kleindorfer, Dawn O. McClure, Leslie A. Safford, Monika M. Rhodes, J. David Soliman, Elsayed Z. Moy, Claudia S. Judd, Suzanne E. Howard, Virginia J. CA REGARDS Investigators TI Traditional Risk Factors as the Underlying Cause of Racial Disparities in Stroke Lessons From the Half-Full (Empty?) Glass SO STROKE LA English DT Article DE stroke; risk factors; hypertension; diabetes mellitus; mediation analysis ID SOUTHEASTERN UNITED-STATES; CARDIOVASCULAR-DISEASES; BLOOD-PRESSURE; FOLLOW-UP; HYPERTENSION; AWARENESS; ASSOCIATION; PREVALENCE; MORTALITY; REASONS AB Background and Purpose-Black/white disparities in stroke incidence are well documented, but few studies have assessed the contributions to the disparity. Here we assess the contribution of "traditional" risk factors. Methods-A total of 25 714 black and white men and women, aged >= 45 years and stroke-free at baseline, were followed for an average of 4.4 years to detect stroke. Mediation analysis using proportional hazards analysis assessed the contribution of traditional risk factors to racial disparities. Results-At age 45 years, incident stroke risk was 2.90 (95% CI: 1.72-4.89) times more likely in blacks than in whites and 1.66 (95% CI: 1.34-2.07) times at age 65 years. Adjustment for risk factors attenuated these excesses by 40% and 45%, respectively, resulting in relative risks of 2.14 (95% CI: 1.25-3.67) and 1.35 (95% CI: 1.08-1.71). Approximately one half of this mediation is attributable to systolic blood pressure. Further adjustment for socioeconomic factors resulted in total mediation of 47% and 53% to relative risks of 2.01 (95% CI: 1.16-3.47) and 1.30 (1.03-1.65), respectively. Conclusions-Between ages 45 to 65 years, approximately half of the racial disparity in stroke risk is attributable to traditional risk factors (primarily systolic blood pressure) and socioeconomic factors, suggesting a critical need to understand the disparity in the development of these traditional risk factors. Because half of the excess stroke risk in blacks is not attributable to traditional risk factors and socioeconomic factors, differential impact of risk factors, residual confounding, or nontraditional risk factors may also play a role. (Stroke. 2011;42:3369-3375.) C1 [Howard, George; McClure, Leslie A.; Rhodes, J. David; Judd, Suzanne E.] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [Howard, Virginia J.] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Safford, Monika M.] Univ Alabama, Deep S Ctr Effectiveness, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Safford, Monika M.] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Cushman, Mary] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA. [Kissela, Brett M.; Kleindorfer, Dawn O.] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA. [Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA. [Moy, Claudia S.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA. RP Howard, G (reprint author), Univ Alabama, Sch Publ Hlth, Dept Biostat, 1665 Univ Blvd, Birmingham, AL 35294 USA. EM ghoward@uab.edu RI McClure, Leslie/P-2929-2015 OI Kissela, Brett/0000-0002-9773-4013 FU National Institute of Neurological Disorders and Stroke [NS 041588] FX The research reported in this article was supported by cooperative agreement NS 041588 from the National Institute of Neurological Disorders and Stroke. NR 29 TC 56 Z9 57 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD DEC PY 2011 VL 42 IS 12 BP 3369 EP 3375 DI 10.1161/STROKEAHA.111.625277 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 860IH UT WOS:000297941500017 PM 21960581 ER PT J AU Green, SM Selzer, F Mulukutla, SR Tadajweski, EJ Green, JA Wilensky, RL Laskey, WK Cohen, HA Rao, SV Weisbord, SD Lee, JS Reis, SE Kip, KE Kelsey, SF Williams, DO Marroquin, OC AF Green, Sandy M. Selzer, Faith Mulukutla, Suresh R. Tadajweski, Edward J. Green, Jamie A. Wilensky, Robert L. Laskey, Warren K. Cohen, Howard A. Rao, Sunil V. Weisbord, Steven D. Lee, Joon S. Reis, Steven E. Kip, Kevin E. Kelsey, Sheryl F. Williams, David O. Marroquin, Oscar C. TI Comparison of Bare-Metal and Drug-Eluting Stents in Patients with Chronic Kidney Disease (from the NHLBI Dynamic Registry) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID PERCUTANEOUS CORONARY INTERVENTION; GLOMERULAR-FILTRATION-RATE; RENAL-INSUFFICIENCY; ARTERY-DISEASE; CARDIOVASCULAR OUTCOMES; MYOCARDIAL-INFARCTION; THROMBOSIS; ANGIOPLASTY; EVENTS; ERA AB Patients with chronic kidney disease (CKD) have a disproportionate burden of coronary artery disease and commonly undergo revascularization. The role and safety of percutaneous coronary intervention (PCI) using drug-eluting stents (DESs) verses bare-metal stents in patients with CKD not on renal replacement therapy has not been fully evaluated. This study investigated the efficacy and safety of DES in patients with CKD not on renal replacement therapy. Patients were drawn from the National Heart, Lung, and Blood Institute Dynamic Registry and were stratified by renal function based on estimated glomerular filtration rate (GFR). Of the 4,157 participants, 1,108 had CKD ("low GFR" <60 ml/min/1.73 m(2)), whereas 3,049 patients had normal renal function ("normal GFR" >= 60 ml/min/1.73 m(2)). For each stratum of renal function we compared risk of death, myocardial infarction, or repeat revascularization between subjects who received DESs and bare-metal stents at the index procedure. Patients with low GFR had higher 1-year rates of death and myocardial infarction and a decreased rate of repeat revascularization compared to patients with normal GFR. Use of DESs was associated with a decreased need for repeat revascularization in the normal-GFR group (adjusted hazard ratio 0.63, 95% confidence interval 0.50 to 0.79, p <0.001) but not in the low-GFR group (hazard ratio 0.69, 95% confidence interval 0.45 to 1.06, p = 0.09). Risks of death and myocardial infarction were not different between the 2 stents in either patient population. In conclusion, presence of CKD predicted poor outcomes after PCI with high rates of mortality regardless of stent type. The effect of DES in decreasing repeat revascularization appeared to be attenuated in these patients. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:1658-1664) C1 [Green, Sandy M.; Mulukutla, Suresh R.; Tadajweski, Edward J.; Green, Jamie A.; Weisbord, Steven D.; Lee, Joon S.; Reis, Steven E.; Marroquin, Oscar C.] Univ Pittsburgh, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA 15260 USA. [Wilensky, Robert L.] Univ Penn Hlth Syst, Philadelphia, PA USA. [Laskey, Warren K.] Univ New Mexico, Albuquerque, NM USA. [Cohen, Howard A.] Lenox Hill Heart & Vasc Inst, New York, NY USA. [Rao, Sunil V.] Duke Univ, Med Ctr, Durham, NC USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kip, Kevin E.] Univ S Florida, Tampa, FL USA. [Williams, David O.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Selzer, Faith; Mulukutla, Suresh R.; Kelsey, Sheryl F.; Marroquin, Oscar C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Marroquin, OC (reprint author), Univ Pittsburgh, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA 15260 USA. EM marroquinoc@upmc.edu RI Reis, Steven/J-3957-2014; Marroquin, Oscar/F-2214-2015 OI Marroquin, Oscar/0000-0002-0909-0319 FU National Heart, Lung, and Blood Institute, Bethesda, Maryland [HL033292] FX This study was supported in part by Grant HL033292 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland. NR 30 TC 12 Z9 12 U1 1 U2 4 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD DEC 1 PY 2011 VL 108 IS 11 BP 1658 EP 1664 DI 10.1016/j.amjcard.2011.07.029 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 859MH UT WOS:000297880000022 PM 21890077 ER PT J AU Au, DH AF Au, David H. TI Health Care Reform and Comparative Effectiveness Research in Critical Care Medicine SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID COSTS C1 [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. NR 15 TC 0 Z9 0 U1 0 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD DEC 1 PY 2011 VL 184 IS 11 BP 1219 EP 1220 DI 10.1164/rccm.201107-1354ED PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 855NU UT WOS:000297572100003 PM 22162878 ER PT J AU Cannon, GW Mikuls, TR Hayden, CL Ying, J Curtis, JR Reimold, AM Caplan, L Kerr, GS Richards, JS Johnson, DS Sauer, BC AF Cannon, Grant W. Mikuls, Ted R. Hayden, Candace L. Ying, Jian Curtis, Jeffrey R. Reimold, Andreas M. Caplan, Liron Kerr, Gail S. Richards, J. Steuart Johnson, Dannette S. Sauer, Brian C. TI Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice SO ARTHRITIS CARE & RESEARCH LA English DT Article ID MODIFYING ANTIRHEUMATIC DRUGS; HEALTH-ASSESSMENT QUESTIONNAIRE; MEDICATION ADHERENCE; PREDICTORS; NONADHERENCE; PATIENT; CARE; PERSISTENCE; MANAGEMENT; DATABASES AB Objective The Veterans Affairs (VA) Rheumatoid Arthritis (VARA) registry and the VA Pharmacy Benefits Management database were linked to determine the association of methotrexate (MTX) adherence with rheumatoid arthritis (RA) disease activity. Methods. For each patient, the medication possession ratio (MPR) was calculated for the first episode of MTX exposure of a duration of > 12 weeks for both new and established MTX users. High MTX adherence was defined as an MPR > 0.80 and low MTX adherence was defined as an MPR < 0.80. For each patient, the mean Disease Activity Score with 28 joints (DAS28) score, erythrocyte sedimentation rate (ESR), and C-reaction protein (CRP) level observed during registry followup were compared in high-versus low-adherence groups. Results. In 455 RA patients, the prescribed doses of MTX (mean +/- SD 16 +/- 4 mg versus 16 +/- 4 mg; P = 0.6) were similar in high-adherence patients (n = 370) in comparison to low-adherence patients (n = 85). However, the actual observed MTX doses taken by patients were significantly higher in the high-adherence group (mean +/- SD 16 +/- 5 mg versus 11 +/- 3 mg; P < 0.001). DAS28 (mean +/- SD 3.6 +/- 1.2 versus 3.9 +/- 1.5; P < 0.02), ESR (mean +/- SD 24 +/- 18 versus 29 +/- 24 mm/hour; P = 0.05), and CRP level (mean +/- SD 1.2 +/- 1.3 versus 1.6 +/- 1.5 mg/dl; P < 0.03) were lower in the high-adherence group compared to those with low MTX adherence. These variances were not explained by differences in baseline demographic features, concurrent treatments, or whether MTX was initiated before or after VARA enrollment. Conclusion. High MTX adherence was associated with improved clinical outcomes in RA patients treated with MTX. Adjustment for potential confounders did not alter the estimated effect of adherence. These results demonstrate the advantages of being able to merge clinical observations with pharmacy databases to evaluate antirheumatic drugs in clinical practice. C1 [Cannon, Grant W.; Hayden, Candace L.; Sauer, Brian C.] George E Wahlen VA Med Ctr, Salt Lake City, UT 84148 USA. [Cannon, Grant W.; Hayden, Candace L.; Ying, Jian; Sauer, Brian C.] Univ Utah, Salt Lake City, UT USA. [Mikuls, Ted R.] Omaha VA Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL USA. [Reimold, Andreas M.] VA Med Ctr, Dallas, TX USA. [Reimold, Andreas M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Caplan, Liron] Denver VA Med Ctr, Aurora, CO USA. [Caplan, Liron] Univ Colorado, Aurora, CO USA. [Kerr, Gail S.] Georgetown Univ, VA Med Ctr, Washington, DC USA. [Kerr, Gail S.] Howard Univ, Washington, DC 20059 USA. [Johnson, Dannette S.] Montgomery VA Med Ctr, Jackson, VA USA. [Johnson, Dannette S.] Univ Mississippi, Jackson, MS 39216 USA. RP Cannon, GW (reprint author), George E Wahlen VA Med Ctr, 500 Foothill Blvd, Salt Lake City, UT 84148 USA. EM grant.cannon@va.gov FU VA Health Services [SHP-08-172]; VA; NIH [K23, AR053351]; Agency for Healthcare Research and Quality [R01-HS-018517]; VA Career Development Awards [RCD-06-300-2, CDA-07-221] FX Supported by a VA Health Services Research & Development grant (SHP-08-172). Dr. Mikuls's work was supported by a VA Clinical Science Research & Development Merit award. Dr. Curtis's work was supported by the NIH (grants K23 and AR053351) and the Agency for Healthcare Research and Quality (grant R01-HS-018517). Drs. Caplan and Sauer's work was supported by VA Career Development Awards (RCD-06-300-2 and CDA-07-221). NR 40 TC 26 Z9 26 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD DEC PY 2011 VL 63 IS 12 BP 1680 EP 1690 DI 10.1002/acr.20629 PG 11 WC Rheumatology SC Rheumatology GA 853WV UT WOS:000297457300006 PM 21905260 ER PT J AU LaBode, V Sher, L AF LaBode, Vanessa Sher, Leo TI Suicide prevention in older men: do medical professionals know enough? SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter C1 [LaBode, Vanessa] James J Peters Vet Adm Med Ctr, New York, NY USA. Mt Sinai Sch Med, New York, NY USA. RP LaBode, V (reprint author), James J Peters Vet Adm Med Ctr, New York, NY USA. NR 5 TC 1 Z9 1 U1 0 U2 3 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0004-8674 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD DEC PY 2011 VL 45 IS 12 BP 1094 EP 1094 DI 10.3109/00048674.2011.613066 PG 1 WC Psychiatry SC Psychiatry GA 854BK UT WOS:000297469300014 PM 22014105 ER PT J AU Sacks, HS Fain, JN AF Sacks, Harold S. Fain, John N. TI Human epicardial fat: what is new and what is missing? SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY LA English DT Article DE adipokines; coronary atherosclerosis; epicardial fat; genes; inflammation ID CORONARY-ARTERY-DISEASE; PERIVASCULAR ADIPOSE-TISSUE; PERICARDIAL FAT; CARDIOVASCULAR-DISEASE; NONDIABETIC PATIENTS; COMPUTED-TOMOGRAPHY; SURROUNDING TISSUE; INSULIN-RESISTANCE; METABOLIC SYNDROME; BARIATRIC SURGERY AB 1. Putative physiological functions of human epicardial adipose tissue (EAT) include: (i) lipid storage for the energy needs of the myocardium; (ii) thermoregulation, whereby brown fat components of EAT generate heat by non-shivering thermogenesis in response to core cooling; (iii) neuroprotection of the cardiac autonomic ganglia and nerves; and (iv) regulation of vasomotion and luminal size of the coronary arteries. Under pathophysiological circumstances, EAT may play an adverse paracrine role in cardiac arrhythmias and in lipotoxic cardiomyopathy, but of major current interest is its hypothetical role as an immunological organ contributing to inflammation around coronary artery disease (CAD). C1 [Sacks, Harold S.] VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div 111D, Los Angeles, CA 90073 USA. [Fain, John N.] Univ Tennessee, Dept Mol Sci, Hlth Sci Ctr, Memphis, TN USA. RP Sacks, HS (reprint author), VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM hsacks@hotmail.com FU van Vleet Chair of Excellence (University of Tennessee); Baptist Heart Institute and Foundation (Memphis, TN, USA); Cardiometabolic Disease Research Foundation (Memphis, TN, USA) FX The authors' work reported herein was supported by the van Vleet Chair of Excellence (University of Tennessee), The Baptist Heart Institute and Foundation (Memphis, TN, USA) and The Cardiometabolic Disease Research Foundation (Memphis, TN, USA). Both authors contributed equally to this work and the authors have no conflicts of interest to declare. NR 75 TC 38 Z9 40 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0305-1870 J9 CLIN EXP PHARMACOL P JI Clin. Exp. Pharmacol. Physiol. PD DEC PY 2011 VL 38 IS 12 BP 879 EP 887 DI 10.1111/j.1440-1681.2011.05601.x PG 9 WC Pharmacology & Pharmacy; Physiology SC Pharmacology & Pharmacy; Physiology GA 853GE UT WOS:000297413400015 PM 21895738 ER PT J AU Leung, FW AF Leung, Felix W. TI Water Exchange May Be Superior to Water Immersion for Colonoscopy SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID US VETERANS; SEDATION; IMPACT C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. NR 15 TC 20 Z9 20 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2011 VL 9 IS 12 BP 1012 EP 1014 DI 10.1016/j.cgh.2011.09.007 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857WJ UT WOS:000297754100009 PM 21946120 ER PT J AU Foster, T Hon, HM Kanwal, F Han, S Spiegel, B AF Foster, Temitope Hon, Huiming Kanwal, Fasiha Han, Steven Spiegel, Brennan TI Screening High Risk Individuals for Hepatitis B: Physician Knowledge, Attitudes, and Beliefs SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Hepatitis B; Vaccines; Screening; Guideline adherence ID ACUTE VIRAL-HEPATITIS; VIRUS INFECTION; UNITED-STATES; RECOMMENDATIONS; PREVENTION; IMMUNIZATION; SURVEILLANCE; IMMUNITY; ADULTS AB Background Although the overall incidence of hepatitis B virus (HBV) has declined since the introduction of universal vaccine guidelines, the incidence remains elevated in high risk groups. Recent guidelines from the Centers for Disease Control (CDC) have underscored the importance of vaccination against HBV in high risk individuals. However, the incidence of HBV in this group remains elevated, suggesting underuse of vaccinations by healthcare providers. Aim The purpose of this study was to measure practice patterns of HBV vaccination, and identify predictors of vaccination underuse. Methods We created a survey with four vignettes describing patients at high risk for contracting HBV, followed by questions regarding knowledge, attitudes, and beliefs (KAB) of HBV screening and vaccination. A random sample of 1,000 physicians, including internists, family medicine, OB/GYN, gastroenterologists, and experts in HBV epidemiology were surveyed. Regression analysis on composite guideline adherence scores identified KAB profiles that predict scores. Results On average, responders endorsed 71% of the CDC HBV vaccination guidelines. There were three predictors of diminished screening proclivity: (1) younger provider age (P = 0.028), (2) lower awareness that adult HBV is contracted primarily through heterosexual sex (P = 0.023), and (3) being a provider other than a gastroenterologist (P = 0.009). Conclusions Respondents endorsed most-but not all-CDC supported HBV screening practices. Lower adherence was predicted by specific and modifiable KAB profiles, and by younger age. Future efforts to improve adherence should target trainees, emphasize the importance of obtaining sexual histories in high risk patients, and inform that HBV is predominantly a heterosexually transmitted infection. C1 [Foster, Temitope; Hon, Huiming] Emory Univ, Sch Med, Div Digest Dis, Atlanta, GA 30303 USA. [Kanwal, Fasiha] St Louis Univ, St Louis, MO 63103 USA. [Han, Steven; Spiegel, Brennan] Univ Calif Los Angeles, Los Angeles, CA USA. [Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Spiegel, Brennan] CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Spiegel, Brennan] UCLA VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA. RP Foster, T (reprint author), Emory Univ, Sch Med, Div Digest Dis, 49 Jesse Hill Jr Dr SE,Rm 437, Atlanta, GA 30303 USA. EM tyfoste@emory.edu FU Ruth L. Kirschstein-National Service [T32 DK 07180-34]; Bristol-Meyers Squibb FX Dr. Foster was supported by a Ruth L. Kirschstein-National Service Research Award (T32 DK 07180-34). This study was supported by an investigator-initiated research grant by Bristol-Meyers Squibb. NR 20 TC 4 Z9 4 U1 1 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD DEC PY 2011 VL 56 IS 12 BP 3471 EP 3487 DI 10.1007/s10620-011-1928-z PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857UM UT WOS:000297747300010 PM 22001940 ER PT J AU Yan, W Ding, P Geng, Z Zhou, XH AF Yan, Wei Ding, Peng Geng, Zhi Zhou, Xiaohua TI Identifiability of causal effects on a binary outcome within principal strata SO FRONTIERS OF MATHEMATICS IN CHINA LA English DT Article DE Causal inference; identifiability; principal effect; multi-component intervention ID INFERENCE; STRATIFICATION; STATISTICS AB Principal strata are defined by the potential values of a post-treatment variable, and a principal effect is a causal effect within a principal stratum. Identifying the principal effect within every principal stratum is quite challenging. In this paper, we propose an approach for identifying principal effects on a binary outcome via a pre-treatment covariate. We prove the identifiability with single post-treatment intervention under the monotonicity assumption. Furthermore, we discuss the local identifiability with multicomponent intervention. Simulations are performed to evaluate our approach. We also apply it to a real data set from the Improving Mood-Promoting Access to Collaborate Treatment program. C1 [Yan, Wei; Ding, Peng; Geng, Zhi] Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China. [Zhou, Xiaohua] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China. [Zhou, Xiaohua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiaohua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Biostat Unit, Seattle, WA 98101 USA. RP Geng, Z (reprint author), Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China. EM zgeng@math.pku.edu.cn FU NIH [R03 TW007197]; National Natural Science Foundation of China [10721403, 10931002] FX The authors would like to thank the referees for their valuable comments and suggestions. The authors are grateful to Dr. Unutzer and the IMPACT study team for making their data available. This work was supported by NIH R03 TW007197 and the National Natural Science Foundation of China (Grant Nos. 10721403, 10931002). NR 10 TC 1 Z9 1 U1 0 U2 6 PU HIGHER EDUCATION PRESS PI BEIJING PA SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA SN 1673-3452 J9 FRONT MATH CHINA JI Front. Math. China PD DEC PY 2011 VL 6 IS 6 BP 1249 EP 1263 DI 10.1007/s11464-011-0127-8 PG 15 WC Mathematics SC Mathematics GA 856MT UT WOS:000297647000013 ER PT J AU Lemonovich, TL Haynes, K Lautenbach, E Amorosa, VK AF Lemonovich, T. L. Haynes, K. Lautenbach, E. Amorosa, V. K. TI Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study SO INFECTION LA English DT Article ID ANTIMICROBIAL THERAPY; RISK-FACTORS; PROSPECTIVE MULTICENTER; INFECTIVE ENDOCARDITIS; BACTERIAL-ENDOCARDITIS; GENTAMICIN; MORTALITY; CARE; PREDICTORS; DIAGNOSIS AB Purpose Although limited data exist on the efficacy and potential risk of synergistic aminoglycoside therapy for persistent Staphylococcus aureus bacteremia and endocarditis, aminoglycosides are frequently used in clinical practice. Methods As our study population, we included subjects fulfilling the modified Duke criteria for S. aureus endocarditis and/or having greater than 72 h of S. aureus bacteremia. Among these subjects, we compared patients who did and did not receive aminoglycoside therapy for their S. aureus bloodstream infection. These groups were compared for the primary outcome of recurrent bacteremia, as well as for the duration of bacteremia, mortality, complication rate, and incident renal failure. Results Eighty-seven subjects fulfilled the inclusion criteria. Of these, 49 received aminoglycoside therapy, whereas 38 did not. There were no significant differences in the baseline characteristics when comparing groups who did or did not receive aminoglycoside therapy. Four (8.2%) subjects treated with aminoglycoside therapy experienced recurrent bacteremia versus nine (23.7%) who did not receive aminoglycoside therapy [relative risk and 95% confidence interval [RR (95% CI)] = 0.51 (0.22-1.17), p = 0.04]. In multivariable analyses, aminoglycoside use remained significantly associated with a decrease in recurrent bacteremia [adjusted odds ratio (OR) (95% CI) = 0.26 (0.07-0.98), p = 0.046]. No significant differences were seen between groups treated with and without an aminoglycoside in terms of the 6-month all-cause mortality (51.0 vs. 42.1%, p = 0.41), complication rate (71.4 vs. 73.7%, p = 0.82), or incident renal failure (54.5 vs. 46.9%, p = 0.54). Conclusions The use of combination therapy with an aminoglycoside in persistent S. aureus bacteremia and/or endocarditis may be associated with a lower rate of recurrent bacteremia without significant differences in the incident renal failure. C1 [Lemonovich, T. L.] Case Western Reserve Univ, Div Infect Dis & HIV Med, Dept Med, Cleveland, OH 44106 USA. [Haynes, K.; Lautenbach, E.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Lautenbach, E.; Amorosa, V. K.] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA. [Lautenbach, E.] Univ Penn, Sch Med, Ctr Educ, Philadelphia, PA 19104 USA. [Lautenbach, E.] Univ Penn, Sch Med, Ctr Res Therapeut, Philadelphia, PA 19104 USA. [Amorosa, V. K.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Lemonovich, TL (reprint author), Case Western Reserve Univ, Div Infect Dis & HIV Med, Dept Med, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM tracy.lemonovich@UHhospitals.org FU Merck; Ortho-McNeil; AstraZeneca FX Ebbing Lautenbach has received research funding from Merck, Ortho-McNeil, and AstraZeneca. All other authors have no conflicts. NR 32 TC 4 Z9 4 U1 0 U2 1 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8126 EI 1439-0973 J9 INFECTION JI Infection PD DEC PY 2011 VL 39 IS 6 BP 549 EP 554 DI 10.1007/s15010-011-0189-2 PG 6 WC Infectious Diseases SC Infectious Diseases GA 855RX UT WOS:000297583200009 PM 21898120 ER PT J AU Sonnenberg, A Melton, SD Genta, RM Lewis, AD AF Sonnenberg, Amnon Melton, Shelby D. Genta, Robert M. Lewis, Anne D. TI Absence of Focally Enhanced Gastritis in Macaques with Idiopathic Colitis SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE etiology of inflammatory bowel disease; focally enhanced gastritis; gastritis; idiopathic chronic colitis of macaques; infectious organisms in inflammatory bowel disease; rhesus macaques (Macaca mulatta) ID RHESUS MACAQUES; CROHNS-DISEASE; HELICOBACTER-PYLORI; CHRONIC DIARRHEA; MACACA-MULATTA; MONKEYS; BIOPSIES; MODEL AB Background: Focally enhanced gastritis has been described in association with Crohn's disease and ulcerative colitis, but is rare in the general population. The study aim was to test whether idiopathic colitis in macaques was associated with any characteristic changes of the gastric mucosa resembling similar changes in humans. Methods: The presence or absence of idiopathic colitis was established by gross and microscopic examination of the colons of rhesus macaques (Macaca mulatta), which died at the Oregon National Primate Research Center. Gastric tissue specimens were compared between a case population of 26 macaques with idiopathic colitis and a control population of 21 macaques without colitis. The specimens were histologically assessed by two independent pathologists blinded to the presence or absence of idiopathic colitis. Differences between cases and controls were compared using a two-sided Fisher's exact test. Results: Of the 26 cases of macaques with colitis, 11 animals (42%) harbored signs of chronic gastritis. Of the 21 control macaques without colitis, nine animals (43%) harbored signs of chronic gastritis, P = 1.0000. Of all animals with gastritis, 1/11 animals with colitis and 2/9 control animals showed rare active gastritis as evidenced by the presence of neutrophils, P = 0.5658. Lymphocytic infiltrates of the gastric mucosa were seen in 4/11 colitis cases and 0/9 controls, P = 0.0942. No gastric specimens with focally enhanced gastritis were found among any of the case or control animals. Conclusions: Unlike chronic inflammatory bowel disease in humans, idiopathic colitis in macaques is not associated with focally enhanced gastritis or any other type of specific gastritis. (Inflamm Bowel Dis 2011;17:2456-2461) C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon; Lewis, Anne D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Melton, Shelby D.; Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Melton, Shelby D.; Genta, Robert M.] Caris Diagnost, Dallas, TX USA. [Melton, Shelby D.; Genta, Robert M.] Dallas VA Med Ctr, Dallas, TX USA. [Lewis, Anne D.] Oregon Natl Primate Res Ctr, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu FU Takeda Pharmaceuticals; Oregon National Primate Research Center NCRR [RR000163] FX The authors have no potential conflicts of interest to declare. Amnon Sonnenberg has been supported by a grant from Takeda Pharmaceuticals. Anne D. Lewis has been supported by the Oregon National Primate Research Center NCRR base grant RR000163. NR 17 TC 4 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2011 VL 17 IS 12 BP 2456 EP 2461 DI 10.1002/ibd.21696 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857QP UT WOS:000297734000013 PM 21425215 ER PT J AU Hage, FG Dean, P Iqbal, F Heo, J Iskandrian, AE AF Hage, Fadi G. Dean, Phillip Iqbal, Fahad Heo, Jaekyeong Iskandrian, Ami E. TI A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Regadenoson; heart rate response; myocardial perfusion imaging; risk stratification ID DIABETES-MELLITUS; ADENOSINE; STRESS; RECLASSIFICATION; PREDICTOR; MORTALITY; AGONIST; TRIAL; AGE AB Regadenoson myocardial perfusion imaging (MPI) is a useful method for risk assessment. We hypothesized that the heart rate response (HRR) to regadenoson carries incremental prognostic information to that derived from perfusion pattern and left ventricular (LV) ejection fraction (EF). The study population included 1,156 (60 +/- A 13 years, 46% women, 40% diabetes mellitus, 53% chronic kidney disease) patients. During a follow-up period of 22 +/- A 5 months, 103 patients died (9%). Independent determinants of the HRR included age, gender, race, diabetes mellitus, coronary revascularization, LVEF, use of insulin and aldosterone antagonists. Decreasing HRR was associated with stepwise increase in mortality (log-rank P < .0001). In a Cox proportional model for mortality that adjusted for age, gender, diabetes mellitus, renal disease, and MPI findings, HRR in the lowest quartile was independently associated with fivefold increase in mortality compared to the highest quartile [HR 5.2, 95% CI 2.3-12.0, P < .0001]. Patients with a normal HRR had a relatively low annualized total mortality despite the presence of risk factors. The addition of HRR to traditional MPI findings had a net reclassification improvement of 15%, P = .02. A blunted HRR to regadenoson is an independent predictor of poor outcome, adds incremental value to MPI, and helps in better risk stratification. C1 [Hage, Fadi G.; Iqbal, Fahad; Heo, Jaekyeong; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Dean, Phillip] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama, Div Cardiovasc Dis, ZRB 1024,1530 3rd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 FU Astellas FX Ami Iskandrian has received research funds from Astellas and served as consultant for Gilead. NR 25 TC 24 Z9 24 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD DEC PY 2011 VL 18 IS 6 BP 1086 EP 1094 DI 10.1007/s12350-011-9429-1 PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 856GK UT WOS:000297626600016 PM 21785922 ER PT J AU Goreshi, R Chock, M Foering, K Feng, R Okawa, J Rose, M Fiorentino, D Werth, V AF Goreshi, Renato Chock, Monika Foering, Kristen Feng, Rui Okawa, Joyce Rose, Matt Fiorentino, David Werth, Victoria TI Quality of life in dermatomyositis SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE autoimmune disease; clinical research; connective tissue disease; cutaneous lupus; dermatomyositis; itch; pruritus; quality of life ID HEALTH SURVEY SF-36; PSYCHIATRIC-DISORDERS; SKIN-DISEASE; DERMATOLOGICAL OUTPATIENTS; PSYCHOLOGICAL DISTRESS; VALIDITY; RELIABILITY; MORBIDITY; PSORIASIS; PRURITUS AB Background: Quality of life (QoL) for patients with inflammatory skin disease can he significant, but has been evaluated in just one study in dermatomyositis (DM). Objective: We sought to examine the relationship between the Cutaneous Dermatomyositis Area (CDASI) and Severity Index, a DM-specific cutaneous severity instrument. and various QoL study instruments and to determine the impact of DM on QoL. Methods: Skin-specific QoL instruments, the Skindex and the Dermatology Life Quality Index, and global medical QoL instruments, the Short Form 36 and the Health Assessment Questionnaire-Disability Index, were used. Pruritus was evaluated by a visual analog scale and a 0-to-10 scale in DM and cutaneous lupus erythematosus (CLE) populations, respectively. Results: There was a significant correlation between the CDASI and all skin-specific QoL scores (lowest P = .0377). Using the Short Form 36, DM population was found to have significantly worse QoL scores than the general population with the exception of bodily pain (all subscore P values < .01). Furthermore, DM had a significantly lower vitality score, representing energy level, compared with CLE, hypertension, diabetes, and recent myocardial infarction scores (lowest P = .003). There was a significantly lower mental health score, representing overall mood, to all compared diseases except CLE and clinical depression (P values < .01 when significant). We found that DM produces more pruritus than CLE (P < .0001). Limitations: A larger patient population needs to be studied to further assess QoL in patients with DM. Conclusion: We conclude that DM has a large impact on QoL, even when compared with other diseases, and that DM skin disease activity correlates with a poorer QoL. (J Am Acad Dermatol 2011;65:1107-16.) C1 [Goreshi, Renato; Foering, Kristen; Okawa, Joyce; Rose, Matt; Werth, Victoria] Philadelphia Dept Vet Affairs Med Ctr, Philadelphia, PA USA. [Goreshi, Renato; Foering, Kristen; Okawa, Joyce; Rose, Matt; Werth, Victoria] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Chock, Monika; Fiorentino, David] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Feng, Rui] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Werth, V (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu OI Fiorentino, David/0000-0001-7951-3674 FU National Institutes of Health (NIH) [NIH K24-AR 02207, NIH 5-R25-HL084665-04]; Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; Centocor; Abbott Laboratories; Amgen FX This material is based on work supported by the National Institutes of Health (NIH), including NIH K24-AR 02207 (Dr Werth) and training grant NIH 5-R25-HL084665-04 (Dr Goreshi). This work was also partially supported by a Merit Review Grant from the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development.; Dr Fiorentino received honoraria from Amgen, Centocor, Chemocentryx, and MedImmune; received grants from Centocor, Abbott Laboratories, and Amgen; and filed a patent (US patent application serial number 12/694,980 for "Profiling for Determination of Response to Treatment for Inflammatory Disease" filed on January 27, 2010). Drs Goreshi, Chock, Feng, and Werth, Ms Foering, Ms Okawa, and Mr Rose have no conflicts of interest to declare. NR 53 TC 23 Z9 24 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD DEC PY 2011 VL 65 IS 6 BP 1107 EP 1116 DI 10.1016/j.jaad.2010.10.016 PG 10 WC Dermatology SC Dermatology GA 857KK UT WOS:000297717200004 PM 21722989 ER PT J AU Asgari, MM Chren, MM Warton, EM Friedman, GD White, E AF Asgari, Maryam M. Chren, Mary-Margaret Warton, E. Margaret Friedman, Gary D. White, Emily TI Supplement use and risk of cutaneous squamous cell carcinoma SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE antioxidant; epidemiology; skin cancer; squamous cell carcinoma; supplement; vitamin ID NONMELANOMA SKIN-CANCER; ORAL VITAMIN-E; GRAPE SEED; ALPHA-TOCOPHEROL; CONTROLLED-TRIAL; BETA-CAROTENE; BASAL-CELL; IN-VITRO; POLYPHENOLIC FRACTION; DIETARY FACTORS AB Background: Laboratory and epidemiologic studies suggest that certain dietary supplements may alter risk of cutaneous squamous cell carcinoma (SCC). Objective: We sought to examine the association between supplement use and SCC risk. Methods: Cases (n = 415) were defined as Kaiser Permanente Northern California members with a pathology-verified SCC in 2004 and control subjects (n = 415) were age-, sex-, and race-matched members with no history of skin cancer. Supplement use and SCC risk factors were ascertained by questionnaire. Associations of SCC with use of multivitamins; vitamins A, C, D, and E; and grape seed extract were estimated as odds ratios and 95% confidence intervals using conditional logistic regression. Models were adjusted for SCC risk factors and other supplement use. Results: Grape seed extract users had a significantly decreased risk of cutaneous SCC (adjusted odds ratio 0.26, confidence interval 0.08-0.89, P = .031). Multivitamin use was associated with a borderline significant reduction in SCC risk (adjusted odds ratio 0.71, confidence interval 0.51-1.00, P = .049). Use of vitamins A, C, 0, and E was not associated with SCC risk. Limitations: The data may be prone to recall and selection bias because of the case-control design. No information was obtained on dose or duration of supplement use. Conclusions: Use of grape seed extract may be associated with a decreased risk of cutaneous SCC. The other supplements included in our study did not reveal clear associations with SCC risk. (J Am Acad Dermatol 2011;65:1145-51.) C1 [Asgari, Maryam M.; Warton, E. Margaret; Friedman, Gary D.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. [Asgari, Maryam M.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. [Friedman, Gary D.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [White, Emily] Univ Washington, Med Ctr, Dept Epidemiol, Seattle, WA 98195 USA. [White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. RP Asgari, MM (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM maryam.m.asgari@kp.org RI Asgari, Maryam/O-4947-2016 FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23 AR 051037, K24 AR 052667]; National Cancer Institute [R01 CA 098838, K05CA154337] FX Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23 AR 051037 to Dr Asgari, K24 AR 052667 to Dr Chren) and by the National Cancer Institute (R01 CA 098838 to Dr Friedman, K05CA154337 to Dr White). NR 47 TC 6 Z9 6 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD DEC PY 2011 VL 65 IS 6 BP 1145 EP 1151 DI 10.1016/j.jaad.2010.09.009 PG 7 WC Dermatology SC Dermatology GA 857KK UT WOS:000297717200008 PM 21664718 ER PT J AU Sacks, HS Fain, JN Cheema, P Bahouth, SW Garrett, E Wolf, RY Wolford, D Samaha, J AF Sacks, Harold S. Fain, John N. Cheema, Paramjeet Bahouth, Suleiman W. Garrett, Edward Wolf, Rodney Y. Wolford, David Samaha, Joseph TI Depot-Specific Overexpression of Proinflammatory, Redox, Endothelial Cell, and Angiogenic Genes in Epicardial Fat Adjacent to Severe Stable Coronary Atherosclerosis SO METABOLIC SYNDROME AND RELATED DISORDERS LA English DT Article ID ADIPOSE-TISSUE; ARTERY-DISEASE; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; OXIDATIVE STRESS; EXPRESSION; MEDIATORS AB Background: Pro- and antiinflammatory genes are expressed in epicardial adipose tissue (EAT). Our objectives were to characterize genes in EAT that may contribute specifically to coronary atherogenesis and to measure circulating adipokines matched to their messenger RNAs (mRNAs) in EAT. We hypothesized that severe coronary atherosclerosis (CAD) would preferentially affect gene expression in EAT as compared to substernal fat or subcutaneous thoracic adipose tissue (SAT), as well as circulating levels of adipokines. Methods: Fat mRNA was quantified using reverse transcription polymerase chain reaction (RT-PCR), and circulating adipokines were measured by enzyme-linked immunosorbent assays (ELISAs) in patients with severe stable CAD and controls without severe CAD undergoing open heart surgery. Results: A total of 39 of 70 mRNAs in EAT were significantly increased in CAD. Only 4 and 3 of these mRNAs were increased in substernal fat and SAT, respectively. Of the mRNAs increased in EAT, 17 were either inflammatory adipokines or proteins known to be involved in inflammatory processes, 7 were involved in oxidative stress and or oxygen species regulation, whereas 15 were proteins involved in metabolism and regulation of gene transcription or proteins unique to fat cells. The largest increases, over three-fold, were seen in GPX3, gp91 phox, p47phox, heme oxygenase, and interleukin-8 (IL-8). Tpl2 mRNA was uniquely elevated in all three fat depots from CAD patients, and its expression in SAT, but not in EAT or substernal fat, was directly correlated with homeostasis model assessment of insulin resistance (HOMA-IR) values. Compared to controls, there were no associations between circulating levels of IL-8, lipocalin-2, nerve growth factor (NGF), RANTES, CD-163, GPX-3, monocyte chemotactic protein-1 (MCP-1)/CCL2, leptin, soluble vascular endothelial growth factor receptor-1 (sFLT1), fatty acid binding protein-4 (FABP-4), and plasminogen activator inhibitor-1 (PAI-1) and increases in their gene expression in EAT adjacent to CAD. Conclusions: Expression of proinflammatory, redox, endothelial cell, and angiogenic genes in EAT is depot specific and supports the hypothesis that pathophysiologically EAT contributes locally to CAD. CAD links with these fat depots might involve Tpl2 as a primary response indicator. C1 [Sacks, Harold S.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Med, Memphis, TN USA. [Fain, John N.; Cheema, Paramjeet] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Mol Sci, Memphis, TN USA. [Bahouth, Suleiman W.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Pharmacol, Memphis, TN USA. [Sacks, Harold S.; Garrett, Edward; Wolf, Rodney Y.; Wolford, David; Samaha, Joseph] Baptist Mem Hosp, Baptist Heart Inst, Memphis, TN 38146 USA. RP Sacks, HS (reprint author), VA Greater Angeles Healthcare Syst, Endocrinol & Diabet Div, 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM hsacks@hotmail.com FU Van Vleet Chair of Excellence, University of Tennessee; Baptist Heart Institute and Foundation, Memphis, TN; Cardiometabolic Disease Research Foundation, Memphis, TN FX This study was supported by the Van Vleet Chair of Excellence, University of Tennessee; the Baptist Heart Institute and Foundation, Memphis, TN; and the Cardiometabolic Disease Research Foundation, Memphis, TN. NR 28 TC 17 Z9 17 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-4196 J9 METAB SYNDR RELAT D JI Metab. Syndr. Relat. Disord. PD DEC PY 2011 VL 9 IS 6 BP 433 EP 439 DI 10.1089/met.2011.0024 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 859BL UT WOS:000297849000004 PM 21679057 ER PT J AU Vogel, KS Perez, M Momand, JR Acevedo-Torres, K Hildreth, K Garcia, RA Torres-Ramos, CA Ayala-Torres, S Prihoda, TJ McMahan, CA Walter, CA AF Vogel, Kristine S. Perez, Marissa Momand, Jamila R. Acevedo-Torres, Karina Hildreth, Kim Garcia, Rebecca A. Torres-Ramos, Carlos A. Ayala-Torres, Sylvette Prihoda, Thomas J. McMahan, C. Alex Walter, Christi A. TI Age-Related Instability in Spermatogenic Cell Nuclear and Mitochondrial DNA Obtained From Apex1 Heterozygous Mice SO MOLECULAR REPRODUCTION AND DEVELOPMENT LA English DT Article ID BASE EXCISION-REPAIR; HUMAN APURINIC ENDONUCLEASE; INDUCED SPECIFIC-LOCUS; POLYMERASE-BETA; OXIDATIVE STRESS; MAMMALIAN-CELLS; HUMAN SPERM; OLD MICE; SPERMATOZOAL CHROMATIN; SPONTANEOUS MUTATION AB The prevalence of spontaneous mutations increases with age in the male germline; consequently, older men have an increased risk of siring children with genetic disease due to de novo mutations. The lacI transgenic mouse can be used to study paternal age effects, and in this system, the prevalence of de novo mutations increases in the male germline at old ages. Mutagenesis is linked with DNA repair capacity, and base excision repair (BER), which can ameliorate spontaneous DNA damage, decreases in nuclear extracts of spermatogenic cells from old mice. Mice heterozygous for a null allele of the Apex1 gene, which encodes apurinic/apyrimidinic endonuclease I (APEN), an essential BER enzyme, display an accelerated increase in spontaneous germline mutagenesis early in life. Here, the consequences of lifelong reduction of APEN on genetic instability in the male germline were examined, for the first time, at middle and old ages. Mutant frequency increased earlier in spermatogenic cells from Apex1(+/-) mice (by 6 months of age). Nuclear DNA damage increased with age in the spermatogenic lineage for both wild-type and Apex1(+/-) mice. By old age, mutant frequencies were similar for wild-type and APEN-deficient mice. Mitochondrial genome-repair also depends on APEN, and novel analysis of mitochondrial-DNA(mtDNA) damage revealed an increase in the Apex1(+/-) spermatogenic cells by middle age. Thus, Apex1 heterozygosity results in accelerated damage to mtDNA and spontaneous mutagenesis, consistent with an essential role for APEN in maintaining nuclear and mtDNA integrity in spermatogenic cells throughout life. C1 [Vogel, Kristine S.; Perez, Marissa; Momand, Jamila R.; Hildreth, Kim; Garcia, Rebecca A.; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Acevedo-Torres, Karina; Torres-Ramos, Carlos A.] Univ Puerto Rico, Dept Physiol, San Juan, PR 00936 USA. [Ayala-Torres, Sylvette] Univ Puerto Rico, Dept Pharmacol, San Juan, PR 00936 USA. [Prihoda, Thomas J.; McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Walter, Christi A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walter@uthscsa.edu FU NIH-NIA [AG0211663, AG024364]; NIH-NCI [CCSG CA054174]; NIH-NINDS [5U54NS039408]; NIH-NIGMS [NIH-NCRR-G12RR03051, 5SC3GM084759, 5R25GM061838] FX The authors would like to thank Roderick Haesevoets, DNA Sequencing Facility, Centre for Biomedical Research at the University of Victoria, for lacI sequencing and mutation spectrum data. This work was supported by grants AG0211663 and AG024364 (NIH-NIA) to C.A.W., the CCSG CA054174 (NIH-NCI) to UTHSCSA, and by grants 5U54NS039408 (NIH-NINDS), NIH-NCRR-G12RR03051, 5SC3GM084759 (NIH-NIGMS), and 5R25GM061838 (NIH-NIGMS) to C.A.T.-R. NR 68 TC 10 Z9 10 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1040-452X J9 MOL REPROD DEV JI Mol. Reprod. Dev. PD DEC PY 2011 VL 78 IS 12 BP 906 EP 919 DI 10.1002/mrd.21374 PG 14 WC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology; Reproductive Biology SC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology; Reproductive Biology GA 855EU UT WOS:000297547400004 PM 21919107 ER PT J AU Kim, E Cameron, M Lovera, J Schaben, L Bourdette, D Whitham, R AF Kim, E. Cameron, M. Lovera, J. Schaben, L. Bourdette, D. Whitham, R. TI American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE clinical trial; complementary therapies; fatigue; ginseng; Panax; multiple sclerosis ID MODAFINIL; IMPACT; SCALE AB This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo. C1 [Kim, E.; Cameron, M.; Bourdette, D.; Whitham, R.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Kim, E.; Cameron, M.; Bourdette, D.; Whitham, R.] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. [Kim, E.; Cameron, M.; Bourdette, D.; Whitham, R.] Portland VA Med Ctr, MS Ctr Excellence W, Portland, OR USA. [Lovera, J.] Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA USA. [Schaben, L.] Bend Neurol Associates, Bend, OR USA. RP Cameron, M (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,CR120, Portland, OR 97239 USA. EM cameromi@ohsu.edu FU Department of Veterans Affairs; Department of Veterans Affairs, Rehabilitation Research and Development Service; National MS Society [PP1307, CA 1055-A-3]; PHS [5 M01 RR000334]; Medical Research Foundation; Nancy Davis Center without Walls; Oregon Clinical and Translational Research Institute (OCTRI); National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1 RR024140]; NIH Roadmap for Medical Research FX Dr Kim and Dr Schaben were Multiple Sclerosis Fellows supported by the Department of Veterans Affairs. Dr Cameron was supported by a Career Development Award from the Department of Veterans Affairs, Rehabilitation Research and Development Service. Ginseng and placebo products were donated by Afexa Life Sciences Inc. (Edmonton, Canada).; This study was supported by National MS Society grants PP1307 (Pilot Project Award) and CA 1055-A-3 (Collaborative MS Research Center Award); PHS Grant 5 M01 RR000334; the Medical Research Foundation; and the Nancy Davis Center without Walls. This publication was made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NR 10 TC 5 Z9 5 U1 0 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER J JI Mult. Scler. J. PD DEC PY 2011 VL 17 IS 12 BP 1523 EP 1526 DI 10.1177/1352458511412062 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 854UZ UT WOS:000297521400018 PM 21803872 ER PT J AU Corless, CL Barnett, CM Heinrich, MC AF Corless, Christopher L. Barnett, Christine M. Heinrich, Michael C. TI Gastrointestinal stromal tumours: origin and molecular oncology SO NATURE REVIEWS CANCER LA English DT Review ID FACTOR-RECEPTOR-ALPHA; C-KIT GENE; OF-FUNCTION MUTATIONS; POSITRON-EMISSION-TOMOGRAPHY; CYCLE REGULATORY PROTEINS; TYROSINE KINASE INHIBITOR; V600E BRAF MUTATIONS; TERM-FOLLOW-UP; IMATINIB MESYLATE; INTERSTITIAL-CELLS AB Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of personalized treatment for cancer patients. The nearly simultaneous discovery of a biomarker that is reflective of their origin and the presence of gain-of-function kinase mutations in these tumours set the stage for more accurate diagnosis and the development of kinase inhibitor therapy. Subsequent studies of genotype and phenotype have led to a molecular classification of GIST and to treatment optimization on the basis of molecular subtype. The study of drug-resistant tumours has advanced our understanding of kinase biology, enabling the development of novel kinase inhibitors. Further improvements in GIST treatment may require targeting GIST stem cell populations and/or additional genomic events. C1 [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Haematol & Oncol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Pathol, Portland VA Med Ctr, Portland, OR 97239 USA. RP Heinrich, MC (reprint author), Oregon Hlth & Sci Univ, Knight Canc Inst, Div Haematol & Oncol, Portland, OR 97239 USA. EM heinrich@ohsu.edu FU GIST; BP Lester Foundation; LifeRaft Group; Department of Veterans Affairs FX The authors wish to acknowledge all of the members of their laboratories for their continuing efforts on gastrointestinal stromal tumour (GIST) research. Some of the work referenced in this article was supported by generous donations from the GIST Cancer Research Fund and the BP Lester Foundation, and by grant support from the LifeRaft Group. In addition, M. C. H. received research grant funding from the Department of Veterans Affairs (Merit Review Award). NR 194 TC 238 Z9 253 U1 5 U2 33 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-175X J9 NAT REV CANCER JI Nat. Rev. Cancer PD DEC PY 2011 VL 11 IS 12 BP 865 EP 878 DI 10.1038/nrc3143 PG 14 WC Oncology SC Oncology GA 859DC UT WOS:000297853900013 PM 22089421 ER PT J AU Tregellas, JR Wylie, KP Rojas, DC Tanabe, J Martin, J Kronberg, E Cordes, D Cornier, MA AF Tregellas, Jason R. Wylie, Korey P. Rojas, Donald C. Tanabe, Jody Martin, Jesse Kronberg, Eugene Cordes, Dietmar Cornier, Marc-Andre TI Altered Default Network Activity in Obesity SO OBESITY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; VISUAL FOOD CUES; HUMAN BRAIN; RESTING STATE; NEURONAL RESPONSE; NEURAL RESPONSES; FUNCTIONAL MRI; LIQUID-MEAL; REWARD; FMRI AB The regulation of energy intake is a complex process involving the integration of homeostatic signals and both internal and external sensory inputs. To better understand the neurobiology of this process and how it may be dysfunctional in obesity, this study examined activity of the brain's "default network" in reduced-obese (RO) as compared to lean individuals. The default network is a group of functionally connected brain regions thought to play an important role in internally directed cognitive activity and the interplay between external and internal sensory processing. Functional magnetic resonance imaging was performed in 24 lean and 18 RO individuals in the fasted state after 2 days of eucaloric energy intake and after 2 days of 30% overfeeding in a counterbalanced design. Scanning was performed while subjects passively viewed images of food and nonfood objects. Independent component analysis was used to identify the default network component. In the eucaloric state, greater default network activity was observed in RO compared to lean individuals in the lateral inferior parietal and posterior cingulate cortices. Activity was positively correlated with appetite. Overfeeding resulted in increased default network activity in lean but not RO individuals. These findings suggest that the function of the default network, a major contributor to intrinsic neuronal activity, is altered in obesity and/or obese-prone individuals. Future studies of the network's function and its relationship to other brain networks may improve our understanding of the mechanisms and treatment of obesity. C1 [Tregellas, Jason R.; Wylie, Korey P.; Rojas, Donald C.; Tanabe, Jody; Martin, Jesse; Kronberg, Eugene; Cordes, Dietmar] Denver VA Med Ctr, Dept Psychiat, Aurora, CO USA. [Cornier, Marc-Andre] Univ Colorado Denver, Div Endocrinol, Dept Med, Aurora, CO USA. [Tanabe, Jody; Cordes, Dietmar] Univ Colorado, Dept Radiol, Denver, CO 80202 USA. RP Tregellas, JR (reprint author), Denver VA Med Ctr, Dept Psychiat, Aurora, CO USA. EM Jason.tregellas@ucdenver.edu RI Rojas, Don/F-4296-2012; Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616 FU NIH/NCRR Colorado CTSI [UL1 RR025780]; NIH/NIDDK Clinical Nutrition Research Unit [DK48520]; NIH/NCRR [RR016185, R01DK072174, R01DK089095] FX This study was supported by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780, NIH/NIDDK Clinical Nutrition Research Unit Grant Number DK48520, and NIH/NCRR Grant Numbers RR016185, R01DK072174 and R01DK089095. NR 46 TC 29 Z9 29 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD DEC PY 2011 VL 19 IS 12 BP 2316 EP 2321 DI 10.1038/oby.2011.119 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 853EM UT WOS:000297409000005 PM 21633398 ER PT J AU Martin, JL Fiorentino, L Jouldjian, S Mitchell, M Josephson, KR Alessi, CA AF Martin, Jennifer L. Fiorentino, Lavinia Jouldjian, Stella Mitchell, Michael Josephson, Karen R. Alessi, Cathy A. TI Poor Self-Reported Sleep Quality Predicts Mortality within One Year of Inpatient Post-Acute Rehabilitation among Older Adults SO SLEEP LA English DT Article DE Aging; rehabilitation; mortality ID ILLNESS RATING-SCALE; FOLLOW-UP; DAYTIME SLEEPINESS; POPULATION; DISTURBANCES; VALIDATION; RECOVERY; DISEASE; PEOPLE; MODEL AB Study Objective: To evaluate the association between self-reported sleep quality among older adults during inpatient post-acute rehabilitation and one-year survival. Design: Prospective, observational cohort study. Setting: Two inpatient post-acute rehabilitation sites (one community and one Veterans Administration). Participants: Older patients (aged >= 65 years, n = 245) admitted for inpatient post-acute rehabilitation. Interventions: None. Measurements and Results: Within one year of post-acute rehabilitation, 57 participants (23%) were deceased. Cox proportional hazards models showed that worse Pittsburgh Sleep Quality Index (PSQI) total scores during the post-acute care stay were associated with increased mortality risk when controlling for amount of rehabilitation therapy received, comorbidities, and cognitive functioning (Hazard ratio [95% CI] = 1.11 [1.02-1.20]). Actigraphically estimated sleep was unrelated to mortality risk. Conclusions: Poorer self-reported sleep quality, but not objectively estimated sleep parameters, during post-acute rehabilitation was associated with shorter survival among older adults. This suggests self-reported poor sleep may be an important and potentially modifiable risk factor for negative outcomes in these vulnerable older adults. Studies of interventions to improve sleep quality during inpatient rehabilitation should therefore be undertaken, and the long-term health benefits of improved sleep should be explored. C1 [Martin, Jennifer L.; Alessi, Cathy A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, Jennifer L.; Jouldjian, Stella; Mitchell, Michael; Josephson, Karen R.; Alessi, Cathy A.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Fiorentino, Lavinia] Univ Calif San Diego, Dept Psychiat, Div Geriatr Mental Hlth, San Diego, CA 92103 USA. RP Martin, JL (reprint author), VA GRECC 11E, 16111 Plummer St, North Hills, CA 91007 USA. EM Jennifer.Martin@va.gov FU NIA [K23 AG028452]; VA HSRD [IIR-01-053-1, IIR 04-321-2, AIA-03-047]; NIMH [T32 MH 019925-11, T32 MH019934]; VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center (GRECC) FX The authors thank the participating facilities and their staff, and the members of the research team who made this study possible. In particular, the authors thank Terry Vandenberg, MA, Sergio Martinez, Maryanne Devereaux, Christina Kurtz, RN, Rebecca Saia, Crystal Barker, RN, Jae Lee, MD, David Kim, PA, and Adam Webber, BSc(Hons), MRCP (UK). This study was supported by NIA K23 AG028452; VA HSR&D (IIR-01-053-1; IIR 04-321-2; AIA-03-047), NIMH T32 MH 019925-11, NIMH T32 MH019934, and VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center (GRECC). NR 28 TC 17 Z9 17 U1 2 U2 6 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD DEC 1 PY 2011 VL 34 IS 12 BP 1715 EP 1721 DI 10.5665/sleep.1444 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 857BT UT WOS:000297689800018 PM 22131610 ER PT J AU Barton, C Morris, R Rothlind, J Yaffe, K AF Barton, Cynthia Morris, Rebecca Rothlind, Johannes Yaffe, Kristine TI Video-Telemedicine in a Memory Disorders Clinic: Evaluation and Management of Rural Elders with Cognitive Impairment SO TELEMEDICINE AND E-HEALTH LA English DT Article DE telemedicine; telehealth; telecommunications ID DEMENTIA; DIAGNOSIS; TELEHEALTH; CONSULTATION; ASSESSMENTS AB Objective: Telemedicine is increasingly being used to provide consultation for healthcare in rural areas. Little work has been done with dementia although preliminary research suggests that clinical diagnosis performed via telemedicine consultation is valid. We implemented a program to provide multidisciplinary, state-of-the-art diagnosis of cognitive impairment by video-telemedicine (VTM) integrated into a clinical setting. Methods: Patients at a rural veteran's community clinic were referred by their local provider for evaluation of memory complaints by the multidisciplinary team of the San Francisco Veterans Administration (SFVA) Memory Disorders Clinic (MDC). The evaluation was integrated into the usual clinic structure and included a neurological evaluation and neuropsychological testing by the MDC team via video assisted by a remote clinician at the community clinic. Results: We evaluated 15 new patients referred to our multidisciplinary clinic. In each case, the VTM format permitted the MDC team to arrive at a working diagnosis; 12 patients with dementia, two with mild cognitive impairment, and one cognitively normal. Relevant treatment recommendations were made to the patients and caregivers. The evaluation results were discussed with providers who joined the MDC postclinic conference via VTM. In the majority of cases, recommendations were followed and there was satisfaction with VTM by providers and patients. Conclusions: VTM is emerging as an effective way to provide consultation and care to rural residents who may not have access to specialty services and can be integrated into current clinical settings. C1 [Barton, Cynthia; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Barton, Cynthia; Rothlind, Johannes; Yaffe, Kristine] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Morris, Rebecca] Vet Adm Community Based Clin, Eureka, CA USA. [Rothlind, Johannes; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Barton, C (reprint author), San Francisco VAMC Memory Disorders Clin, UCSF Memory & Aging Ctr, 4150 Clement St,Box 127, San Francisco, CA 94121 USA. EM cbarton@memory.ucsf.edu NR 23 TC 14 Z9 15 U1 2 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED E-HEALTH JI Telemed. e-Health PD DEC PY 2011 VL 17 IS 10 BP 789 EP 793 DI 10.1089/tmj.2011.0083 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 860BD UT WOS:000297919800008 PM 22023458 ER PT J AU Lee, JS Primack, BA Mor, MK Stone, RA Obrosky, DS Yealy, DM Fine, MJ AF Lee, Jonathan S. Primack, Brian A. Mor, Maria K. Stone, Roslyn A. Obrosky, D. Scott Yealy, Donald M. Fine, Michael J. TI Processes of Care and Outcomes for Community-Acquired Pneumonia SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Pneumonia; Processes of care; Quality of care ID CHI-SQUARED TESTS; QUALITY-OF-CARE; MYOCARDIAL-INFARCTION; ELDERLY-PATIENTS; RISK PATIENTS; GUIDELINES; MANAGEMENT; THERAPY; IMPROVEMENT; MORTALITY AB BACKGROUND: Although processes of care are common proxies for health care quality, their associations with medical outcomes remain uncertain. METHODS: For 2076 patients hospitalized with pneumonia from 32 emergency departments, we used multilevel logistic regression modeling to assess independent associations between patient outcomes and the performance of 4 individual processes of care (assessment of oxygenation, blood cultures, and rapid initiation [<4 hours] and appropriate selection of antibiotic therapy) and the cumulative number of processes of care performed. RESULTS: Overall, 141 patients (6.8%) died. Mortality was 0.3% to 1.7% lower for patients who had each of the individual processes of care performed (P >= .13 for each comparison); mortality was 7.5% for patients who had 0 to 2 processes of care, 7.2% for those with 3 processes of care, and 5.8% for those with all 4 processes of care performed (P = .39). Mortality was not significantly associated with either individual or cumulative process measures in multivariable models. CONCLUSION: Neither the individual processes of care nor the cumulative number performed is associated with short-term mortality for pneumonia. Published by Elsevier Inc. The American Journal of Medicine (2011) 124, 1175.e9-1175.e17 C1 [Lee, Jonathan S.; Primack, Brian A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Primack, Brian A.; Stone, Roslyn A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15261 USA. [Yealy, Donald M.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA. [Mor, Maria K.; Stone, Roslyn A.; Obrosky, D. Scott; Fine, Michael J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Mor, Maria K.; Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. RP Fine, MJ (reprint author), Vet Adm Pittsburgh Healthcare Syst 151 C H, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Room 4059E, Pittsburgh, PA 15206 USA. EM Michael.Fine@va.gov FU Agency for Healthcare Research and Quality [R01-HS10049]; National Institute of Allergy and Infectious Diseases [K24-AI001769]; Robert Wood Johnson Foundation; National Cancer Institute [K07-CA114315] FX Grant R01-HS10049 from the Agency for Healthcare Research and Quality. Dr Fine was supported in part from a career development award from the National Institute of Allergy and Infectious Diseases (Grant Number K24-AI001769). Dr Primack was supported in part by a Physician Faculty Scholar Award from the Robert Wood Johnson Foundation and a career development award from the National Cancer Institute (K07-CA114315). NR 32 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD DEC PY 2011 VL 124 IS 12 AR 1175.e9 DI 10.1016/j.amjmed.2011.05.029 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 853CZ UT WOS:000297405100027 PM 22000624 ER PT J AU Finlayson, E Wang, L Landefeld, CS Dudley, RA AF Finlayson, Emily Wang, Li Landefeld, C. Seth Dudley, R. Adams TI Major Abdominal Surgery in Nursing Home Residents A National Study SO ANNALS OF SURGERY LA English DT Article ID ACUTE APPENDICITIS; SURGICAL OUTCOMES; OLDER; OCTOGENARIANS; CANCER AB Objective: To determine surgical risk in nursing home residents undergoing major abdominal surgery. Background: Recent studies suggest that surgery can be performed safely in the very old. Surgical risk in nursing home residents is poorly understood. Methods: We used national Medicare claims and the nursing home Minimum Data Set (1999-2006) to identify nursing home residents undergoing surgery (surgery for bleeding duodenal ulcer, cholecystectomy, appendectomy, and colectomy, n = 70,719). We compared operative mortality and use of invasive interventions (mechanical ventilation, intravascular hemodynamic monitoring, feeding tube placement, tracheostomy, and vena cava filters) among nursing home residents to rates among noninstitutionalized Medicare enrollees age 65 and older undergoing the same procedures. (n = 1,060,389). We adjusted for patient characteristics using logistic regression. Results: Operative mortality among nursing home residents was substantially higher than among noninstitutionalized Medicare enrollees for all procedures (surgery for bleeding duodenal ulcer, 42% versus 26%, adjusted odds ratio (AOR) 1.79; colectomy, 32% versus 13%, AOR 2.06; appendectomy, 12% versus 2%, AOR 3.27; cholecystectomy, 11% versus 3%, AOR 2.65; P < 0.001 for all comparisons). Overall, invasive interventions were more common among nursing home residents than controls (ranging from 18% and 5%, respectively, for cholecystectomy to 55% and 43%, respectively, for surgery for bleeding duodenal ulcer, P < 0.0001 for all comparisons). Conclusions: Nursing home residents experience substantially higher rates of mortality and invasive interventions after major surgery than other Medicare beneficiaries that are independent of age and measured comorbidities. Our data suggest that the risks of major surgery are substantially higher in nursing home residents and this information should inform decisions of physicians and patients and their families. C1 [Finlayson, Emily; Dudley, R. Adams] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA. [Finlayson, Emily] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94118 USA. [Wang, Li] StatinMed, Ann Arbor, MI USA. [Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94118 USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA. [Dudley, R. Adams] Univ Calif San Francisco, Dept Med, San Francisco, CA 94118 USA. RP Finlayson, E (reprint author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 3333 Calif St,Suite 265, San Francisco, CA 94118 USA. EM emily.finlayson@ucsfmedctr.org FU National Institute on Aging [5K08AG028965]; Robert Wood Johnson Foundation FX Supported by a National Institute on Aging/Paul B. Beeson Clinical Scientist Development Award in Aging (5K08AG028965). Dr. Dudley's work was supported by an Investigator Award in Health Policy from the Robert Wood Johnson Foundation. NR 15 TC 15 Z9 15 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD DEC PY 2011 VL 254 IS 6 BP 921 EP 926 DI 10.1097/SLA.0b013e3182383a78 PG 6 WC Surgery SC Surgery GA 852RM UT WOS:000297375200013 PM 22020197 ER PT J AU Chu, D Bakaeen, FG AF Chu, Danny Bakaeen, Faisal G. TI Hypoalbuminemia as a Contributor to the Progression of Cardiovascular Diseases Reply SO ANNALS OF THORACIC SURGERY LA English DT Letter C1 [Chu, Danny; Bakaeen, Faisal G.] Baylor Coll Med, Div Cardiothorac Surg, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Chu, D (reprint author), Baylor Coll Med, Div Cardiothorac Surg, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM dchu@bcm.edu NR 2 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD DEC PY 2011 VL 92 IS 6 BP 2305 EP 2306 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 852EL UT WOS:000297333300080 ER PT J AU Bhargava, P Vaidya, S Kolokythas, O Katz, DS Dighe, M AF Bhargava, P. Vaidya, S. Kolokythas, O. Katz, D. S. Dighe, M. TI Hepatic vascular shunts: embryology and imaging appearances SO BRITISH JOURNAL OF RADIOLOGY LA English DT Review ID HEREDITARY HEMORRHAGIC TELANGIECTASIA; PORTOSYSTEMIC VENOUS SHUNT; HEPATOCELLULAR-CARCINOMA; CT; SONOGRAPHY; CIRRHOSIS AB The purpose of this pictorial review is to understand the embryological basis of the development of congenital hepatic vascular shunts and to review the multimodality imaging appearances of congenital and acquired hepatic vascular shunts. Hepatic vascular shunts are commonly seen in imaging. Familiarity with their characteristic appearances is important in order to accurately characterise these shunts and diagnose the underlying disorders. C1 [Bhargava, P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Ctr, Sch Med, Dept Radiol, Seattle, WA 98108 USA. [Bhargava, P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Katz, D. S.] Winthrop Univ Hosp, Dept Radiol, Mineola, NY 11501 USA. RP Bhargava, P (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Ctr, Sch Med, Dept Radiol, Mail Box 358280,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 17 TC 4 Z9 5 U1 0 U2 2 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0007-1285 J9 BRIT J RADIOL JI Br. J. Radiol. PD DEC PY 2011 VL 84 IS 1008 BP 1142 EP 1152 DI 10.1259/bjr/82649468 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 851IZ UT WOS:000297263000018 PM 22101582 ER PT J AU Marks, G Gardner, LI Craw, J Giordano, TP Mugavero, MJ Keruly, JC Wilson, TE Metsch, LR Drainoni, ML Malitz, F AF Marks, Gary Gardner, Lytt I. Craw, Jason Giordano, Thomas P. Mugavero, Michael J. Keruly, Jeanne C. Wilson, Tracey E. Metsch, Lisa R. Drainoni, Mari-Lynn Malitz, Faye TI The Spectrum of Engagement in HIV Care: Do More Than 19% of HIV-Infected Persons in the US Have Undetectable Viral Load? SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Marks, Gary; Gardner, Lytt I.; Craw, Jason] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Giordano, Thomas P.] Baylor Coll Med, Thomas St Hlth Ctr, Houston, TX 77030 USA. [Giordano, Thomas P.] DeBakey VA Med Ctr, Houston, TX USA. [Mugavero, Michael J.] Univ Alabama Birmingham UAB, UAB Ctr AIDS Res, Birmingham, AL USA. [Mugavero, Michael J.] UAB 1917 Clin, Birmingham, AL USA. [Keruly, Jeanne C.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Wilson, Tracey E.] Suny Downstate Med Ctr, Sch Publ Hlth, Brooklyn, NY 11203 USA. [Metsch, Lisa R.] Univ Miami, Miller Sch Med, Dev Ctr AIDS Res, Coral Gables, FL 33124 USA. [Drainoni, Mari-Lynn] Boston Univ, Dept Hlth Policy & Management, Sch Publ Hlth, Sect Infect Dis,Dept Med,Sch Med, Boston, MA 02215 USA. [Malitz, Faye] Hlth Resources & Serv Adm, HIV AIDS Bur, Rockville, MD USA. RP Marks, G (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM gmarks@cdc.gov NR 4 TC 16 Z9 16 U1 0 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2011 VL 53 IS 11 BP 1168 EP U154 DI 10.1093/cid/cir678 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 851OH UT WOS:000297279900025 PM 21976466 ER PT J AU Mendez, MF Shapira, JS AF Mendez, Mario F. Shapira, Jill S. TI Loss of emotional insight in behavioral variant frontotemporal dementia or "frontal anosodiaphoria" SO CONSCIOUSNESS AND COGNITION LA English DT Article DE Insight; Anosognosia; Anosodiaphoria; Dementia; Frontotemporal dementia; Alzheimer's disease ID ALZHEIMERS-DISEASE; SELF-AWARENESS; COGNITIVE IMPAIRMENT; DIAGNOSTIC-CRITERIA; PREFRONTAL CORTEX; ANOSOGNOSIA; DEFICITS; UNAWARENESS; DEGENERATION; RECOGNITION AB Loss of insight is a prominent clinical manifestation of behavioral variant frontotemporal dementia (bvFTD), but its characteristics are poorly understood. Twelve bvFTD patients were compared with 12 Alzheimer's disease (AD) patients on a structured insight interview of cognitive insight (awareness of having a disorder) and emotional insight (concern over having a disorder). Compared to the AD patients, the bvFTD patients were less aware and less concerned about their disorder, and they had less appreciation of its effects on themselves and on others. After corrective feedback ("updating"), the bvFTD patients were just as aware of their disorder as the AD patients but remained unconcerned and unappreciative of its effects. These findings suggest that lack of insight in bvFTD is not due to "anosognosia," or impaired cognitive and executive awareness of disease, but to "frontal anosodiaphoria," or lack of emotional concern over having bvFTD and its impact on themselves and others. Published by Elsevier Inc. C1 [Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU NIA NIH HHS [R01 AG034499, R01 AG034499-03, R01AG034499-02] NR 66 TC 22 Z9 23 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8100 J9 CONSCIOUS COGN JI Conscious. Cogn. PD DEC PY 2011 VL 20 IS 4 SI SI BP 1690 EP 1696 DI 10.1016/j.concog.2011.09.005 PG 7 WC Psychology, Experimental SC Psychology GA 851NP UT WOS:000297278100066 PM 21959203 ER PT J AU Samuvel, DJ Jin, JF Sundararaj, KP Li, YC Zhang, XM Lopes-Virella, MF Huang, Y AF Samuvel, Devadoss J. Jin, Junfei Sundararaj, Kamala P. Li, Yanchun Zhang, Xiaoming Lopes-Virella, Maria F. Huang, Yan TI TLR4 Activation and IL-6-Mediated Cross Talk between Adipocytes and Mononuclear Cells Synergistically Stimulate MMP-1 Expression SO ENDOCRINOLOGY LA English DT Article ID ADIPOSE-TISSUE DEVELOPMENT; LOW-GRADE INFLAMMATION; DIET-INDUCED OBESITY; NF-KAPPA-B; INSULIN-RESISTANCE; MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTOR; ACID; ANGIOGENESIS; INHIBITION AB Obesity is associated with increased monocyte infiltration into adipose tissue and hence increased interaction between adipocytes and monocytes. Although it has been shown that matrix metalloproteinases (MMP) play a critical role in adipose tissue development, the effect of adipocyte and monocyte interaction on MMP production remains largely unknown. Furthermore, although it has been shown that Toll-like receptor 4 (TLR4), a receptor mediating innate immune response, plays an important role in the obesity-associated inflammation and insulin resistance, the effect of TLR4 activation in coculture of adipocytes and monocytes on MMP production has not been investigated. In this study, we cocultured adipocytes with U937 mononuclear cells in a Transwell coculture system and activated TLR4 with lipopolysaccharide or palmitic acid. We found that TLR4 activation and the coculture had a synergistic effect on MMP-1 production. In our further investigation on the underlying mechanisms, it was indicated that adipocyte-derived IL-6 and TLR4 activation acted in concert to synergistically stimulate MMP-1 expression by U937 cells. Taken together, this study has uncovered a novel mechanism potentially involved in MMP-1 up-regulation in adipose tissue, which may facilitate adipose tissue development and obesity. (Endocrinology 152: 4662-4671, 2011) C1 [Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Samuvel, Devadoss J.; Jin, Junfei; Sundararaj, Kamala P.; Li, Yanchun; Zhang, Xiaoming; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Samuvel, Devadoss J.; Jin, Junfei; Sundararaj, Kamala P.; Li, Yanchun; Zhang, Xiaoming; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU Department of Veterans Affairs; National Institutes of Health [DE16353] FX This work was supported by a Merit Review Grant from Department of Veterans Affairs and National Institutes of Health Grant DE16353 (to Y.H.). NR 36 TC 6 Z9 6 U1 0 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD DEC PY 2011 VL 152 IS 12 BP 4662 EP 4671 DI 10.1210/en.2011-1026 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 852RZ UT WOS:000297376500022 PM 21952248 ER PT J AU Carrithers, LM Hulseberg, P Sandor, M Carrithers, MD AF Carrithers, Lisette M. Hulseberg, Paul Sandor, Matyas Carrithers, Michael D. TI The human macrophage sodium channel NaV1.5 regulates mycobacteria processing through organelle polarization and localized calcium oscillations SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY LA English DT Article DE macrophage; phagocytosis; voltage-gated sodium channel; calcium signaling ID INTRACELLULAR CA2+ STORES; HUMAN NEUTROPHILS; PHAGOCYTOSIS; PROTEIN; CELLS; TUBERCULOSIS; INHIBITION; PHAGOSOME; DYNAMICS; RELEASE AB Phagocytosis and intracellular processing of mycobacteria by macrophages are complex cellular processes that require spatial and temporal coordination of particle uptake, organelle movement, activation of signaling pathways, and channel-mediated ionic flux. Recent work demonstrated that human macrophage NaV1.5, an intracellular voltage-gated sodium channel expressed on late endosomes, enhances endosomal acidification and phagocytosis. Here, using bacillus Camille-Guerin (BCG) as a model of mycobacterial infection, we examined how this channel regulates phagocytosis and phagosome maturation in human macrophages. Knockdown of NaV1.5 reduced high capacity uptake of labeled BCG. BCG-containing, NaV1.5-expressing cells demonstrated localization of NaV1.5 and Rab-7 positive endosomes and mitochondria to periphagosome regions that was not observed in NaV1.5-deficient cells. Knockdown of the channel reduced the initial calcium response following bacterial challenge and prevented the generation of prolonged and localized calcium oscillations during phagosome maturation. Inhibition of the mitochondrial Na+/Ca2+ exchanger also prevented prolonged calcium oscillations during phagosome maturation. These results suggest that NaV1.5 and mitochondrial-dependent calcium signaling regulate mycobacteria phagocytosis and phagosome maturation in human macrophages through spatial-temporal coordination of calcium signaling within a unique subcellular region. C1 [Carrithers, Lisette M.; Carrithers, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53706 USA. [Hulseberg, Paul; Sandor, Matyas] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol, Madison, WI 53706 USA. Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Carrithers, Michael D.] William S Middleton Mem Vet Adm Med Ctr, Neurol Serv, Madison, WI USA. RP Carrithers, MD (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, 1300 Univ Ave,Room 2679, Madison, WI 53706 USA. EM carrithers@neurology.wisc.edu FU University of Wisconsin; VA Merit Award (BLRD) FX This work is supported by the University of Wisconsin and a VA Merit Award (BLR&D) to M.D.C. NR 27 TC 23 Z9 23 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0928-8244 J9 FEMS IMMUNOL MED MIC JI FEMS Immunol. Med. Microbiol. PD DEC PY 2011 VL 63 IS 3 BP 319 EP 327 DI 10.1111/j.1574-695X.2011.00853.x PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 850PH UT WOS:000297207200002 PM 22092558 ER PT J AU Wiren, KM Hashimoto, JG Zhang, XW AF Wiren, Kristine M. Hashimoto, Joel G. Zhang, Xiao-Wei TI Stem Cell Activation in Adults Can Reverse Detrimental Changes in Body Composition to Reduce Fat and Increase Lean Mass in Both Sexes SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE STEM CELL; AGING; TESTOSTERONE; ANDROGEN RECEPTOR; LEAN MASS; FAT MASS; NEURAL CREST ID ANDROGEN REPLACEMENT THERAPY; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; TRANSDERMAL TESTOSTERONE; METABOLIC SYNDROME; HYPOGONADAL MEN; SEXUAL FUNCTION; DOUBLE-BLIND; RECEPTOR; MICE AB Detrimental changes in body composition are often associated with declining levels of testosterone. Here, we evaluated the notion that multipotent mesenchymal stem cells, that give rise to both fat and muscle tissue, can play a significant role to alter existing body composition in the adult. Transgenic mice with targeted androgen receptor (AR) overexpression in stem cells were employed. Wild-type littermate and AR-transgenic male and female mice were gonadectomized and left untreated for 2 months. After the hypogonadal period, mice were then treated with 5 alpha-dihydrotestosterone (DHT) for 6 weeks. After orchidectomy (ORX), wild-type males have reduced lean mass and increased fat mass compared to shams. DHT treatment was beneficial to partially restore body composition. In wild-type females, ovariectomy (OVX) produced a similar change but there was no improvement with DHT. In targeted AR transgenic mice, DHT treatment increased lean and reduced fat mass to sham levels. In contrast to wild-type females, DHT treatment in female transgenic mice significantly ameliorated the increased fat and decreased lean mass changes that result after OVX. Our results show that DHT administration reduces fat mass and increases lean mass in wildtype males but not females, indicating that wild-type females are not as sensitive to androgen treatment. Because both male and female transgenic mice are more responsive than wild-type, results suggest that body composition remains linked to stem cell fate in the adult and that targeted androgen signaling in stem cells can play a significant role to reverse detrimental changes in body composition in both sexes. J. Cell. Biochem. 112: 3638-3647, 2011. (C) 2011 Wiley Periodicals, Inc. C1 [Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, Res Serv P3 R&D39, Portland, OR 97239 USA. [Wiren, Kristine M.; Hashimoto, Joel G.; Zhang, Xiao-Wei] Vet Affairs Med Ctr, Res Serv, Portland, OR 97239 USA. [Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland VA Med Ctr, Res Serv P3 R&D39, Portland, OR 97239 USA. RP Wiren, KM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, Res Serv P3 R&D39, 3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM wirenk@ohsu.edu OI Wiren, Kristine/0000-0002-6159-4450 FU National Institute of Diabetes, Digestive and Kidney Disease [R01 DK067541]; Department of Defense; United States Army [W81XWH-05-1-0086] FX Grant sponsor: National Institute of Diabetes, Digestive and Kidney Disease; Grant number: R01 DK067541; Grant sponsor: Department of Defense; United States Army Research Acquisition Activity Award No.; Grant number: W81XWH-05-1-0086. NR 48 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD DEC PY 2011 VL 112 IS 12 BP 3638 EP 3647 DI 10.1002/jcb.23288 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 851YV UT WOS:000297309600018 PM 21793043 ER PT J AU Gahramanov, S Muldoon, LL Li, X Neuwelt, EA AF Gahramanov, Seymur Muldoon, Leslie L. Li, Xin Neuwelt, Edward A. TI Improved Perfusion MR Imaging Assessment of Intracerebral Tumor Blood Volume and Antiangiogenic Therapy Efficacy in a Rat Model with Ferumoxytol SO RADIOLOGY LA English DT Article ID CONTRAST-ENHANCED MR; BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; GLIOMA MODEL; GRADE; PROGRESSION; SURVIVAL; AGENT; MAPS; BEVACIZUMAB AB Purpose: To evaluate the consistency of tumor blood volume measurements and antiangiogenic therapy efficacy assessments with a low-molecular-weight gadolinium-based contrast agent (GBCA, gadodiamide) versus an iron oxide nanoparticle (ferumoxytol) in the presence or absence of a loading dose of contrast agent before perfusion magnetic resonance (MR) imaging (preload method). Materials and Methods: The protocol was approved by the institutional animal care and use committee. U87MG tumor cells were implanted intracerebrally in 13 rats. All 13 rats underwent 11.75-T MR imaging with gadodiamide (60 mu L) 13 days after tumor implantation. The next day, nine rats underwent MR imaging with ferumoxytol (60 mu L). Immediately after ferumoxytol imaging, six rats received bevacizumab (45 mg/kg). MR imaging was repeated 48 hours after bevacizumab treatment with gadodiamide and 72 hours after treatment with ferumoxytol. Each study included three consecutive dynamic susceptibility-weighted contrast material-enhanced (DSC) MR acquisitions, which were performed without preload, with single-dose preload, and with double-dose preload. Tumor relative cerebral blood volume (rCBV) was estimated from each DSC MR acquisition. Two-way repeated measures analysis of variance was performed to test for differences between groups with both contrast agents. Results: DSC MR imaging with gadodiamide and without preload showed low rCBV (<= 1.75) in nine of the 13 tumors; estimated rCBV increased progressively with both single- and double-dose preloads (P < .001). Conversely, rCBVs obtained with ferumoxytol were high (>1.75) and remained constant with all three acquisitions. The magnitude of rCBV decrease after bevacizumab administration was dependent: on the dose of gadodiamide preload, whereas the magnitude of rCBV decrease with ferumoxytol was constant regardless of whether contrast agent preload was used. Conclusion: With GBCA, tumor rCBV can be underestimated without preload and becomes dose dependent with preload correction. Conversely, ferumoxytol provides consistent assessment of tumor rCBV and antiangiogenic therapy efficacy. (C) RSNA, 2011 C1 [Gahramanov, Seymur; Muldoon, Leslie L.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97239 USA. [Li, Xin] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,Room L603, Portland, OR 97239 USA. EM neuwelte@ohsu.edu FU Veterans Administration; National Institutes of Health [NS053468, CA137488, NS044687]; AMAG Pharmaceuticals FX Supported by a Veterans Administration Merit Review grant.; This study was supported by the National Institutes of Health (grants NS053468, CA137488, and NS044687).; Disclosures of Potential Conflicts of Interest: S.G. No potential conflicts of interest to disclose. L.L.M. No potential conflicts of interest to disclose. X.I.. No potential conflicts of interest, to disclose. E.A.N. Financial activities related to the present article: ferumoxytol ultrasmall superparamagnetic iron oxide nanoparticles were donated by AMAG Pharmaceuticals. Financial activities not, related to the present article: has a sponsored research agreement with AMAG Pharmaceuticals. Other relationships: none to disclose. NR 38 TC 25 Z9 25 U1 0 U2 10 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD DEC PY 2011 VL 261 IS 3 BP 796 EP 804 DI 10.1148/radiol.11103503 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 849PR UT WOS:000297138100016 PM 21940504 ER PT J AU Alley, DE Lloyd, J Pagan, JA Pollack, CE Shardell, M Cannuscio, C AF Alley, Dawn E. Lloyd, Jennifer Pagan, Jose A. Pollack, Craig E. Shardell, Michelle Cannuscio, Carolyn TI Mortgage Delinquency and Changes in Access to Health Resources and Depressive Symptoms in a Nationally Representative Cohort of Americans Older Than 50 Years SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID US ELDERLY PERSONS; SOCIOECONOMIC DISPARITIES; FOOD INSECURITY; UNITED-STATES; MORTALITY; HOME; PEOPLE; CONSEQUENCES; ASSOCIATION; COMMUNITY AB Objectives. We evaluated associations between mortgage delinquency and changes in health and health-relevant resources over 2 years, with data from the Health and Retirement Study, a longitudinal survey representative of US adults older than 50 years. Methods. In 2008, participants reported whether they had fallen behind on mortgage payments since 2006 (n=2474). We used logistic regression to compare changes in health (incidence of elevated depressive symptoms, major declines in self-rated health) and access to health-relevant resources (food, prescription medications) between participants who fell behind on their mortgage payments and those who did not. Results. Compared with nondelinquent participants, the mortgage-delinquent group had worse health status and less access to health-relevant resources at baseline. They were also significantly more likely to develop incident depressive symptoms (odds ratio [OR]=8.60; 95% confidence interval [CI]=3.38, 21.85), food insecurity (OR=7.53; 95% CI=3.01, 18.84), and cost-related medication nonadherence (OR=8.66; 95% CI=3.72, 20.16) during follow-up. Conclusions. Mortgage delinquency was associated with significant elevations in the incidence of mental health impairments and health-relevant material disadvantage. Widespread mortgage default may have important public health implications. (Am J Public Health. 2011;101:2293-2298. doi:10.2105/AJPH.2011.300245) C1 [Alley, Dawn E.; Lloyd, Jennifer; Shardell, Michelle] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. [Pagan, Jose A.] Univ N Texas Hlth Sci Ctr, Sch Publ Hlth, Dept Hlth Management & Policy, Ft Worth, TX USA. [Pollack, Craig E.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Cannuscio, Carolyn] Dept Vet Affairs Med Ctr, Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Alley, DE (reprint author), 660 W Redwood St,221B, Baltimore, MD 21201 USA. EM dalley@epi.umaryland.edu RI Cannuscio, Carolyn/A-1123-2007 FU National Institutes of Health [T32AG000262, K12HC043489]; Philadelphia Veterans Affairs Medical Center; Organized Research Center on Aging at the University of Maryland, Baltimore FX This study was supported by the National Institutes of Health (grants T32AG000262 and K12HC043489). It was conducted with support, resources, and use of facilities from the Philadelphia Veterans Affairs Medical Center in conjunction with the Organized Research Center on Aging at the University of Maryland, Baltimore NR 38 TC 32 Z9 32 U1 2 U2 11 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2011 VL 101 IS 12 BP 2293 EP 2298 DI 10.2105/AJPH.2011.300245 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 849QT UT WOS:000297140900022 PM 22021301 ER PT J AU Doherty-King, B Bowers, B AF Doherty-King, Barbara Bowers, Barbara TI How Nurses Decide to Ambulate Hospitalized Older Adults: Development of a Conceptual Model SO GERONTOLOGIST LA English DT Article DE Conceptual development; Grounded theory; Hospital; ambulatory care; Nursing studies; Function (physical; mental) ID FUNCTIONAL DECLINE; LOW MOBILITY; CARE; OUTCOMES AB Adults over the age of 65 years account for 60% of all hospital admissions and experience consequential negative outcomes directly related to hospitalization. Negative outcomes include falls, delirium, loss in ability to perform basic activities of daily living, and new walking dependence. New walking dependence, defined as the loss in ability to walk independently, occurs in 16%--59% of hospitalized older patients. Nurses are pivotal in promoting functional walking independence in hospitalized patients. However, little is known about how nurses make decisions about whether, when, and how to ambulate older patients. A qualitative study using grounded dimensional analysis was conducted to further explore how nurses make decisions about ambulating hospitalized older adults. Twenty-five registered nurses participated in in-depth interviews lasting 30--60 min. Open, axial, and selective coding was used during the analysis. A conceptual model, which is grounded in how nurses experience ambulating patients, was developed. Multiple categories and dimensions interact and produce an action by the nurse to either restrict mobilization to the level of the bed or progress the patient to ambulation in the hallway. Factors that seemed to have a greater impact on nurses' decisions on whether, when, and how to ambulate were the risk/opportunity assessment, preventing complications, and the presence of a unit expectation to ambulate patients. C1 [Doherty-King, Barbara] William S Middleton Mem Vet Adm Med Ctr, GRECC, Geriatr Educ Res & Clin Ctr, Madison, WI 53705 USA. [Doherty-King, Barbara; Bowers, Barbara] Univ Wisconsin, Sch Nursing, Madison, WI 53706 USA. RP Doherty-King, B (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, Geriatr Educ Res & Clin Ctr, 2500 Overlook Terrace G11, Madison, WI 53705 USA. EM Barbara.king4@va.gov OI King, Barbara/0000-0003-0577-9028; Bowers, Barbara/0000-0002-3226-0718 NR 20 TC 13 Z9 13 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD DEC PY 2011 VL 51 IS 6 BP 786 EP 797 DI 10.1093/geront/gnr044 PG 12 WC Gerontology SC Geriatrics & Gerontology GA 851BD UT WOS:000297242400007 PM 22024979 ER PT J AU Davis, MM Bond, LA Howard, A Sarkisian, CA AF Davis, Melinda M. Bond, Lynne A. Howard, Alan Sarkisian, Catherine A. TI Primary Care Clinician Expectations Regarding Aging SO GERONTOLOGIST LA English DT Article DE Attitudes toward aging; Successful aging; Expectations regarding aging ID OLDER-ADULTS; SELF-PERCEPTIONS; HEALTH; DEPRESSION; ATTITUDES; AGEISM AB Purpose: Expectations regarding aging (ERA) in community-dwelling older adults are associated with personal health behaviors and health resource usage. Clinicians' age expectations likely influence patients' expectations and care delivery patterns; yet, limited research has explored clinicians' age expectations. The Expectations Regarding Aging Survey (ERA-12) was used to assess (a) age expectations in a sample of primary care clinicians practicing in the United States and (b) clinician characteristics associated with ERA-12 scores. Design and Methods: This study was a cross-sectional survey of primary care clinicians affiliated with 5 practice-based research networks, October 2008 to June 2009. A total of 374 of the 1,510 distributed surveys were returned (24.8% response rate); 357 analyzed. Mean respondent age was 48.6 years (SD = 11.6; range 23-87 years); 88.0% physicians, 96.0% family medicine, 94.9% White, and 61.9% male. Results: Female clinicians reported higher ERA-12 scores; clinicians' age expectations decreased with greater years in practice. Among the clinicians, higher ERA-12 scores were associated with higher clinician ratings of the importance of and personal skill in administering preventive counseling and the importance of delivering preventive services. Agreement with individual ERA-12 items varied widely. Implications: Unrealistically high or low ERA could negatively influence the quality of care provided to patients and patients' own age expectations. Research should examine the etiology of clinicians' age expectations and their association with older adult diagnoses and treatment. Medical education must incorporate strategies to promote clinician attitudes that facilitate successful patient aging. C1 [Davis, Melinda M.] Oregon Hlth & Sci Univ, Dept Family Med, Oregon Rural Practice Based Res Network, Portland, OR 97239 USA. [Bond, Lynne A.] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. [Howard, Alan] Univ Vermont, Acad Comp Serv, Burlington, VT 05405 USA. [Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sarkisian, Catherine A.] Univ Calif Los Angeles, Dept Med, Div Geriatr, Geriatr Res Educ Clin Ctr, Los Angeles, CA USA. RP Davis, MM (reprint author), Oregon Hlth & Sci Univ, Dept Family Med, Oregon Rural Practice Based Res Network, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM davismel@ohsu.edu FU NCRR NIH HHS [1U1 RR02414-01] NR 39 TC 6 Z9 6 U1 2 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD DEC PY 2011 VL 51 IS 6 BP 856 EP 866 DI 10.1093/geront/gnr017 PG 11 WC Gerontology SC Geriatrics & Gerontology GA 851BD UT WOS:000297242400013 PM 21430129 ER PT J AU Deo, R Katz, R Shlipak, MG Sotoodehnia, N Psaty, BM Sarnak, MJ Fried, LF Chonchol, M de Boer, IH Enquobahrie, D Siscovick, D Kestenbaum, B AF Deo, Rajat Katz, Ronit Shlipak, Michael G. Sotoodehnia, Nona Psaty, Bruce M. Sarnak, Mark J. Fried, Linda F. Chonchol, Michel de Boer, Ian H. Enquobahrie, Daniel Siscovick, David Kestenbaum, Bryan TI Vitamin D, Parathyroid Hormone, and Sudden Cardiac Death Results From the Cardiovascular Health Study SO HYPERTENSION LA English DT Article DE sudden cardiac death; vitamin D; parathyroid hormone; elderly; risk factors ID SMOOTH-MUSCLE-CELLS; D DEFICIENCY; MYOCARDIAL-INFARCTION; CORONARY-ANGIOGRAPHY; SEASONAL-VARIATION; RISK; HYPERTROPHY; MORTALITY; POPULATION; 25-HYDROXYVITAMIN-D AB Recent studies have demonstrated greater risks of cardiovascular events and mortality among persons who have lower 25-hydroxyvitamin D (25-OHD) and higher parathyroid hormone (PTH) levels. We sought to evaluate the association between markers of mineral metabolism and sudden cardiac death (SCD) among the 2312 participants from the Cardiovascular Health Study who were free of clinical cardiovascular disease at baseline. We estimated associations of baseline 25-OHD and PTH concentrations individually and in combination with SCD using Cox proportional hazards models after adjustment for demographics, cardiovascular risk factors, and kidney function. During a median follow-up of 14 years, there were 73 adjudicated SCD events. The annual incidence of SCD was greater among subjects who had lower 25-OHD concentrations, 2 events per 1000 for 25-OHD >= 20 ng/mL and 4 events per 1000 for 25-OHD <20 ng/mL. Similarly, SCD incidence was greater among subjects who had higher PTH concentrations, 2 events per 1000 for PTH <65 pg/mL and 4 events per 1000 for PTH >= 65 pg/mL. Multivariate adjustment attenuated associations of 25-OHD and PTH with SCD. Finally, 267 participants (11.7% of the cohort) had high PTH and low 25-OHD concentrations. This combination was associated with a >2-fold risk of SCD after adjustment (hazard ratio: 2.19 [95% CI: 1.17-4.10]; P=0.017) compared with participants with normal levels of PTH and 25-OHD. The combination of lower 25-OHD and higher PTH concentrations appears to be associated independently with SCD risk among older adults without cardiovascular disease. (Hypertension. 2011;58:1021-1028.) C1 [Deo, Rajat] Univ Penn, Sect Electrophysiol, Div Cardiovasc Med, Philadelphia, PA 19104 USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Sotoodehnia, Nona] Univ Washington, Div Cardiol, Seattle, WA 98195 USA. [Psaty, Bruce M.; Enquobahrie, Daniel; Siscovick, David] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Psaty, Bruce M.; Enquobahrie, Daniel; Siscovick, David] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Psaty, Bruce M.; Enquobahrie, Daniel; Siscovick, David] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA USA. [de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Shlipak, Michael G.] Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Fried, Linda F.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Chonchol, Michel] Univ Colorado Denver & Hlth Sci Ctr, Div Renal Dis & Hypertens, Aurora, CO USA. RP Deo, R (reprint author), Univ Penn, Sect Electrophysiol, Div Cardiovasc Med, 3400 Spruce St,9 Founders Cardiol, Philadelphia, PA 19104 USA. EM Rajat.Deo@uphs.upenn.edu FU National Institute on Aging at the National Institutes of Health [AG-023629]; National Heart, Lung, and Blood Institute at the National Institutes of Health [N01-HC-80007, N01-HC-85079, N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, U01-HL-080295]; National Institute on Aging [R01 AG-15928, R01 AG-20098, AG-027058]; National Heart, Lung, and Blood Institute [R01 HL-075366]; University of Pittsburgh Claude D. Pepper Older Americans Independence Center [P30-AG-024827]; National Institutes of Health [R01 HL084443, R01 HL088456]; [K23DK089118] FX This work was supported by the National Institute on Aging at the National Institutes of Health (grant AG-023629). The CHS was supported by contracts N01-HC-80007, N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, and U01-HL-080295 from the National Heart, Lung, and Blood Institute at the National Institutes of Health, with additional contribution from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. Additional support was provided through grants R01 AG-15928, R01 AG-20098, and AG-027058 from the National Institute on Aging; R01 HL-075366 from the National Heart, Lung, and Blood Institute; and the University of Pittsburgh Claude D. Pepper Older Americans Independence Center P30-AG-024827. R.D. was supported by K23DK089118. Additional grant support includes National Institutes of Health grants R01 HL084443 and R01 HL088456. NR 38 TC 48 Z9 49 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD DEC PY 2011 VL 58 IS 6 BP 1021 EP 1028 DI 10.1161/HYPERTENSIONAHA.111.179135 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 850TI UT WOS:000297221900015 PM 22068871 ER PT J AU Linville, D Stice, E Gau, J O'Neil, M AF Linville, Deanna Stice, Eric Gau, Jeff O'Neil, Maya TI Predictive Effects of Mother and Peer Influences on Increases in Adolescent Eating Disorder Risk Factors and Symptoms: A 3-Year Longitudinal Study SO INTERNATIONAL JOURNAL OF EATING DISORDERS LA English DT Article DE maternal and peer; eating disorders; predictive effects ID DUAL-PATHWAY MODEL; BODY DISSATISFACTION; BULIMIC PATHOLOGY; WEIGHT-LOSS; DIAGNOSTIC SCALE; GIRLS; BEHAVIORS; DEPRESSION; IMAGE; BOYS AB Objective: To investigate the relation of maternal and peer attitudes and behaviors to changes in eating disorder risk factors and symptoms in adolescent females. Method: We tested whether maternal and peer eating attitudes, behaviors, and deficits in social support at baseline predicted subsequent increases in eating disorder risk factors and symptoms among 483 late adolescent females followed over 3 years. Results: Data provide partial support for hypotheses, as eating disorder risk factors and symptoms increased over time and maternal thin ideal internalization significantly predicted a future increases in adolescent bulimic symptoms. There were no significant predictors of adolescent thin ideal internalization or body dissatisfaction. Discussion: Findings only partially support the hypothesis that unhealthy attitudes and behaviors of mothers increase risk for eating disorder symptoms in their late adolescent daughters. These results underscore why eating disorder prevention programs should be based on risk factor research that has used prospective and rigorous designs. (C) 2011 by Wiley Periodicals, Inc. C1 [Linville, Deanna] Univ Oregon, Dept Counseling Psychol & Human Serv, Eugene, OR 97403 USA. [Stice, Eric] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Gau, Jeff] Oregon Res Inst, Eugene, OR 97403 USA. [O'Neil, Maya] Portland VA Med Ctr, Hlth Serv Res & Dev Serv, Portland, OR USA. RP Linville, D (reprint author), Univ Oregon, Dept Counseling Psychol & Human Serv, 5251 Univ Oregon, Eugene, OR 97403 USA. EM Linville@uoregon.edu FU National Institutes of Health [MH01708, MH/DK61957] FX Supported by MH01708, MH/DK61957 from National Institutes of Health. NR 50 TC 11 Z9 12 U1 1 U2 19 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0276-3478 J9 INT J EAT DISORDER JI Int. J. Eating Disord. PD DEC PY 2011 VL 44 IS 8 BP 745 EP 751 DI 10.1002/eat.20907 PG 7 WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology SC Psychology; Nutrition & Dietetics; Psychiatry GA 851YS UT WOS:000297309300013 PM 21344465 ER PT J AU Kalkonde, YV Shelton, R Villarreal, M Sigala, J Mishra, PK Ahuja, SS Barea-Rodriguez, E Moretti, P Ahuja, SK AF Kalkonde, Y. V. Shelton, R. Villarreal, M. Sigala, J. Mishra, P. K. Ahuja, S. S. Barea-Rodriguez, E. Moretti, P. Ahuja, S. K. TI THE CC CHEMOKINE RECEPTOR 5 REGULATES OLFACTORY AND SOCIAL RECOGNITION IN MICE SO NEUROSCIENCE LA English DT Article DE chemokine; CC-chemokine receptor 5; CC-chemokine ligand 3; behavior; social recognition; N-methyl D-aspartate receptor 1 ID LONG-TERM-MEMORY; MOUSE MODEL; NERVOUS-SYSTEM; BRAIN; EXPRESSION; OXYTOCIN; BEHAVIOR; NEURONS; DISEASE; GENE AB Chemokines are chemotactic cytokines that regulate cell migration and are thought to play an important role in a broad range of inflammatory diseases. The availability of chemokine receptor blockers makes them an important therapeutic target. In vitro, chemokines are shown to modulate neurotransmission. However, it is not very clear if chemokines play a role in behavior and cognition. Here we evaluated the role of CC chemokine receptor 5 (CCR5) in various behavioral tasks in mice using Wt (Ccr5(+/+)) and Ccr5-null (Ccr5(-/-)) mice. Ccr5(-/-) mice showed enhanced social recognition. Administration of CC chemokine ligand 3 (CCL3), one of the CCR5-ligands, impaired social recognition. Since the social recognition task is dependent on the sense of olfaction, we tested olfactory recognition for social and non-social scents in these mice. Ccr5(-/-) mice had enhanced olfactory recognition for both these scents indicating that enhanced performance in social recognition task could be due to enhanced olfactory recognition in these mice. Spatial memory and aversive memory were comparable in Wt and Ccr5(-/-) mice. Collectively, these results suggest that chemokines/chemokine receptors might play an important role in olfactory recognition tasks in mice and to our knowledge represents the first direct demonstration of an in vivo role of CCR5 in modulating social behavior in mice. These studies are important as CCR5 blockers are undergoing clinical trials and can potentially modulate behavior. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Kalkonde, Y. V.; Shelton, R.; Sigala, J.; Ahuja, S. S.; Ahuja, S. K.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. [Kalkonde, Y. V.; Shelton, R.; Sigala, J.; Ahuja, S. S.; Ahuja, S. K.] S Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX USA. [Kalkonde, Y. V.; Shelton, R.; Sigala, J.; Ahuja, S. S.; Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Villarreal, M.; Mishra, P. K.; Barea-Rodriguez, E.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA. [Moretti, P.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. RP Kalkonde, YV (reprint author), SEARCH, PO Gadchiroli, Gadchiroli 442605, Maharashtra, India. EM yvkalkonde@gmail.com FU Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System; MERIT [R37046326]; NIH [AI043279, MH069270]; Elizabeth Glaser Scientist Award; Burroughs Wellcome Clinical Scientist Award in Translational Research FX We thank William Kuziel for providing Ccr5-/- mice on C57BL6/J background, Timothy Freeman and Carlo Condello for help with experiments and Ivan Becerra, William Pate and Harjeet Singh for help with illustrations. This work was supported by the Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System, and a MERIT (R37046326) and other awards (AI043279 and MH069270) from the NIH to S.K.A. S.K.A. is a recipient of the Elizabeth Glaser Scientist Award and the Burroughs Wellcome Clinical Scientist Award in Translational Research. The funding sources had no role NR 46 TC 6 Z9 7 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD DEC 1 PY 2011 VL 197 BP 153 EP 161 DI 10.1016/j.neuroscience.2011.09.039 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 849QR UT WOS:000297140700016 PM 21963866 ER PT J AU Xi, M Fung, SJ Sampogna, S Chase, MH AF Xi, M. Fung, S. J. Sampogna, S. Chase, M. H. TI EXCITATORY PROJECTIONS FROM THE AMYGDALA TO NEURONS IN THE NUCLEUS PONTIS ORALIS IN THE RAT: AN INTRACELLULAR STUDY SO NEUROSCIENCE LA English DT Article DE amygdala; electrical stimulation; REM sleep; synaptic potentials; nucleus pontis oralis ID EYE-MOVEMENT SLEEP; TERM SYNAPTIC PLASTICITY; REM-SLEEP; ELECTRICAL-STIMULATION; RETICULAR-FORMATION; PONTOGENICULOOCCIPITAL WAVES; PARADOXICAL SLEEP; BRAIN-STEM; FUNCTIONAL NEUROANATOMY; LUMBAR MOTONEURONS AB There is a consensus that active (REM) sleep (AS) is controlled by cholinergic projections from the laterodorsal and pedunculopontine tegmental nuclei (LDT/PPT) to neurons in the nucleus pontis oralis (NPO) that generate AS (i.e. AS-Generator neurons). The present study was designed to provide evidence that other projections to the NPO, such as those from the amygdala, are also capable of inducing AS. Accordingly, the responses of neurons, recorded intracellularly in the NPO, were examined following stimulation of the ipsilateral central nucleus of the amygdala (CNA) in urethane-anesthetized rats. Single pulse stimulation in the CNA produced an early, fast depolarizing potential (EPSP) in neurons within the NPO. The mean latency to the onset of these excitatory postsynaptic potentials (EPSPs) was 3.6 +/- 0.2 ms. A late, small-amplitude inhibitory synaptic potential (IPSP) was present following EPSPs in a portion of the NPO neurons. Following stimulation of the CNA with a train of 8-10 pulses, NPO neurons exhibited a sustained depolarization (5-10 my) of their resting membrane potential. When single subthreshold intracellular depolarizing current pulses were delivered to NPO neurons, CNA-induced EPSPs were sufficient to promote the discharge of these cells. Stimulation of the CNA with a short train of stimuli induced potent temporal facilitation of EPSPs in NPO neurons. Two forms of synaptic plasticity were revealed by the patterns of response of NPO neurons following stimulation of the CNA: paired-pulse facilitation (PPF) and post-tetanic potentiation (PIP). Six of recorded NPO neurons were identified morphologically with neurobiotin. They were medium to large, multipolar cells with diameters >20 mu M, which resemble AS-on cells in the NPO. The present results demonstrate that amygdalar projections are capable of exerting a powerful excitatory postsynaptic drive that activates NPO neurons. Therefore, we suggest that the amygdala is capable of inducing AS via direct projections to AS-Generator neurons in the NPO. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Xi, M.; Fung, S. J.; Sampogna, S.; Chase, M. H.] WebSci Int, Los Angeles, CA 90024 USA. [Xi, M.; Fung, S. J.; Chase, M. H.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90025 USA. RP Xi, M (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA. EM mxi@websciences.org FU NIH [NS 60917] FX This research was supported by NIH grant NS 60917. We are grateful to Mr. Vincent Lim. Ms. Nichole Stevens and Mr. Daniel Bronson for their excellent technical assistance. NR 61 TC 10 Z9 10 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD DEC 1 PY 2011 VL 197 BP 181 EP 190 DI 10.1016/j.neuroscience.2011.09.029 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 849QR UT WOS:000297140700019 PM 21955600 ER PT J AU Sher, L LaBode, V AF Sher, Leo LaBode, Vanessa TI TEACHING HEALTH CARE PROFESSIONALS ABOUT SUICIDE SAFETY PLANNING SO PSYCHIATRIA DANUBINA LA English DT Article DE suicide; training; public health AB The suicide safety plan is a plan of action created by the clinician and patient that essentially charts the course of what the patient should do if he/she begins to experience suicidal urges. It is important for clinicians to learn how to implement a safety plan so that they can offer this service to their patients and teach their colleagues and associates about suicide safety planning. The safety plan is a great tool employed to help patients with suicidal urges, but trainees-clinicians and clinician associates alike - should fully understand that it is not a form of treatment. However, since an effective treatment for suicidality does not exist, practitioners should definitely use suicide safety planning. Although more resources are now being provided to individuals with suicidal behavior, more research needs to be done to develop new, effective methods of treatment and prevention of suicidal behavior. C1 [Sher, Leo; LaBode, Vanessa] James J Peters Vet Adm Med Ctr, New York, NY USA. RP Sher, L (reprint author), Mt Sinai Sch Med, Dept Psychiat, Med Ctr, James J Peters Vet Adm, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu NR 12 TC 4 Z9 4 U1 0 U2 2 PU MEDICINSKA NAKLADA PI ZAGREB PA VLASKA 69, HR-10000 ZAGREB, CROATIA SN 0353-5053 J9 PSYCHIAT DANUB JI Psychiatr. Danub. PD DEC PY 2011 VL 23 IS 4 BP 396 EP 397 PG 2 WC Psychiatry SC Psychiatry GA 850YZ UT WOS:000297236800010 PM 22075742 ER PT J AU Sawyer, AM Gooneratne, NS Marcus, CL Ofer, D Richards, KC Weaver, TE AF Sawyer, Amy M. Gooneratne, Nalaka S. Marcus, Carole L. Ofer, Dafna Richards, Kathy C. Weaver, Terri E. TI A systematic review of CPAP adherence across age groups: Clinical and empiric insights for developing CPAP adherence interventions SO SLEEP MEDICINE REVIEWS LA English DT Review DE Obstructive sleep apnea; Continuous positive airway pressure; Patient compliance ID POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE-SLEEP-APNEA; QUALITY-OF-LIFE; LONG-TERM COMPLIANCE; APNOEA/HYPOPNOEA SYNDROME; NASAL CPAP; APNEA/HYPOPNEA SYNDROME; HYPOPNEA-SYNDROME; RANDOMIZED-TRIAL; BREATHING DISORDERS AB Continuous positive airway pressure (CPAP) is a highly efficacious treatment for obstructive sleep apnea (OSA) but adherence to the treatment limits its overall effectiveness across all age groups of patients. Factors that influence adherence to CPAP include disease and patient characteristics, treatment titration procedures, technological device factors and side effects, and psychological and social factors. These influential factors have guided the development of interventions to promote CPAP adherence. Various intervention strategies have been described and include educational, technological, psychosocial, pharmacological, and multi-dimensional approaches. Though evidence to date has led to innovative strategies that address adherence in CPAP-treated children, adults, and older adults, significant opportunities exist to develop and test interventions that are clinically applicable, specific to sub-groups of patients likely to demonstrate poor adherence, and address the multi-factorial nature of CPAP adherence. The translation of CPAP adherence promotion interventions to clinical practice is imperative to improve health and functional outcomes in all persons with,CPAP-treated OSA. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Gooneratne, Nalaka S.] Univ Penn, Sch Med, Div Geriatr Med, Philadelphia, PA 19104 USA. [Sawyer, Amy M.; Richards, Kathy C.] Univ Penn, Sch Nursing, Biobehav Hlth Sci Div, Philadelphia, PA 19104 USA. [Gooneratne, Nalaka S.; Marcus, Carole L.; Ofer, Dafna] Univ Penn, Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Richards, Kathy C.] Univ Penn, Sch Nursing, Ctr Integrat Sci Aging, Philadelphia, PA 19104 USA. [Sawyer, Amy M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Marcus, Carole L.; Ofer, Dafna] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Weaver, Terri E.] Univ Illinois, Coll Nursing, Chicago, IL 60612 USA. RP Sawyer, AM (reprint author), Penn State Univ, Sch Nursing, 201 HHD Bldg E, University Pk, PA 16802 USA. EM ams24@psu.edu; ngoonera@mail.med.upenn.edu; Dafna.ofer@uphs.upenn.edu; kathyr@nursing.upenn.edu; teweaver@uic.edu FU National Institutes of Health, National Institute of Nursing Research [K99NR011173] FX This work was supported by a grant from National Institutes of Health, National Institute of Nursing Research K99NR011173 (Sawyer AM). NR 94 TC 134 Z9 139 U1 3 U2 17 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1087-0792 J9 SLEEP MED REV JI Sleep Med. Rev. PD DEC PY 2011 VL 15 IS 6 BP 343 EP 356 DI 10.1016/j.smrv.2011.01.003 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 850WT UT WOS:000297231000002 PM 21652236 ER PT J AU Guirand, AS Dicianno, BE Mahajan, H Cooper, RA AF Guirand, Alcinto S. Dicianno, Brad E. Mahajan, Harshal Cooper, Rory A. TI Tuning Algorithms for Control Interfaces for Users with Upper-Limb Impairments SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Assistive Technology; Isometric Joystick; Rehabilitation; Movement Disorders; Wheelchairs ID ELECTRIC-POWERED WHEELCHAIRS; ISOMETRIC JOYSTICKS; POSITION; INDIVIDUALS AB Guirand AS, Dicianno BE, Mahajan H, Cooper RA: Tuning algorithms for control interfaces for users with upper-limb impairments. Am J Phys Med Rehabil 2011;90:992-998. Objective: Approximately 40% of Americans with disabilities cannot operate wheeled mobility devices and computers adequately because of diminished upper-limb motor control, sensory limitations, and cognitive impairments. We developed tuning software that can customize control interfaces for individuals with upper-limb impairments. This study compared the differences in each parameter among different diagnostic groups. Design: The age of the subjects ranged from 18 to 80 yrs. The participants were classified into the following groups: athetoid cerebral palsy, spastic cerebral palsy, multiple sclerosis, upper-limb spasticity, and control. We used a validated tuning software protocol to customize an isometric joystick before a virtual tracing or driving task. Tuning parameters were then compared across groups. Results: Seventy-five subjects were included. Gain, the parameter responsible for force-to-output ratios, in each directional axis (leftward gain: P = 0.018; rightward gain: P = 0.003; reverse gain: P = 0.007; forward gain: P = 0.014) was significantly different across the diagnostic groups. Post hoc analyses showed that the control group required smaller leftward gain than spastic cerebral palsy, multiple sclerosis and upper-limb spasticity groups and smaller gain in all other directions compared with spastic cerebral palsy. Conclusions: Gain may be a useful parameter in tuning by clinicians, and efforts aimed at gain customization may aid the development of commercially available tuning software packages. C1 [Guirand, Alcinto S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Guirand, Alcinto S.; Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] Highland Drive VA Med Ctr, Human Engn Res Labs, Pittsburgh, PA USA. [Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil PM&R, Pittsburgh, PA USA. [Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Associated Rehabil E, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), UPMC Dept PM&R, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA. OI Dicianno, Brad/0000-0003-0738-0192 FU NIH [K12 HD001097-09]; VA Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering [B3142C]; VA Merit Review [B3287R]; University of Pittsburgh School of Medicine FX Funded by the Rehabilitation Medicine Scientist Training Program NIH: K12 HD001097-09, the VA Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering (B3142C), VA Merit Review (B3287R), and the University of Pittsburgh School of Medicine Dean's Summer Research Stipend. NR 20 TC 4 Z9 4 U1 3 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD DEC PY 2011 VL 90 IS 12 BP 992 EP 998 DI 10.1097/PHM.0b013e318228ca9f PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 846RX UT WOS:000296922000004 PM 22019961 ER PT J AU Cadena, J Nair, S Henao-Martinez, AF Jorgensen, JH Patterson, JE Sreeramoju, PV AF Cadena, Jose Nair, Shalini Henao-Martinez, Andres F. Jorgensen, James H. Patterson, Jan E. Sreeramoju, Pranavi V. TI Dose of Trimethoprim-Sulfamethoxazole To Treat Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID SOFT-TISSUE INFECTIONS; CLINDAMYCIN; THERAPY; CEPHALEXIN; TRIAL AB We undertook this study to investigate whether treatment with a higher dose of trimethoprim-sulfamethoxazole (TMP/SMX) led to greater clinical resolution in patients with skin and soft tissue infections (SSTIs) caused by methicillin-resistant Staphylococcus aureus (MRSA). A prospective, observational cohort with nested case-control study was performed at a public tertiary health system. Among patients with MRSA SSTIs during the period from May 2008 to September 2008 who received oral monotherapy with TMP/SMX and whose clinical outcome was known, the clinical characteristics and outcomes were compared between patients treated with a high dose of TMP/SMX (320 mg/1,600 mg twice daily) for 7 to 15 days and patients treated with the standard dose of TMP/SMX (160 mg/800 mg twice daily) for 7 to 15 days. In patients with MRSA SSTIs, those treated with the high dose of TMP/SMX (n = 121) had clinical characteristics similar to those of patients treated with the standard dose of TMP/SMX (n = 170). The only exception was a higher proportion of patients with a history of trauma upon admission among the patients treated with the higher dose. The proportion of patients with clinical resolution of infection was not different in the two groups (88/121 [73%] versus 127/170 [75%]; P = 0.79). The lack of significance remained in patients with abscess upon stratified analysis by whether surgical drainage was performed. The study found that patients with MRSA SSTIs treated with the higher dose of TMP/SMX (320/1,600 mg twice daily) for 7 to 15 days had a similar rate of clinical resolution as patients treated with the standard dose of TMP/SMX (160/800 mg twice daily) for 7 to 15 days. C1 [Sreeramoju, Pranavi V.] Univ Texas SW Med Ctr Dallas, Dept Med Infect Dis, Dallas, TX 75390 USA. [Cadena, Jose; Patterson, Jan E.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Cadena, Jose; Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Infect Dis, San Antonio, TX 78229 USA. [Nair, Shalini; Henao-Martinez, Andres F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Jorgensen, James H.; Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Sreeramoju, PV (reprint author), Univ Texas SW Med Ctr Dallas, Dept Med Infect Dis, 5323 Harry Hines Blvd,MC 9113, Dallas, TX 75390 USA. EM pranavi.sreeramoju@utsouthwestern.edu OI Henao-Martinez, Andres/0000-0001-7363-8652 NR 12 TC 6 Z9 7 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD DEC PY 2011 VL 55 IS 12 BP 5430 EP 5432 DI 10.1128/AAC.00706-11 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 846RJ UT WOS:000296920600002 PM 21930870 ER PT J AU Schneider, L Giordano, S Zelickson, BR Johnson, MS Benavides, GA Ouyang, XS Fineberg, N Darley-Usmar, VM Zhang, JH AF Schneider, Lonnie Giordano, Samantha Zelickson, Blake R. Johnson, Michelle S. Benavides, Gloria A. Ouyang, Xiaosen Fineberg, Naomi Darley-Usmar, Victor M. Zhang, Jianhua TI Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE HNE; DMNQ; Oxidative stress; Cellular bioenergetics; SH-SY5Y; Free radicals ID LIPID-PEROXIDATION PRODUCTS; SPARE RESPIRATORY CAPACITY; CYTOCHROME-C-OXIDASE; IN-VITRO MODEL; HUMAN NEUROBLASTOMA; PARKINSONS-DISEASE; MITOCHONDRIAL RESPIRATION; GLUTAMATE EXCITOTOXICITY; COMPLEX-I; MEMBRANE AB Cell differentiation is associated with changes in metabolism and function. Understanding these changes during differentiation is important in the context of stem cell research, cancer, and neurodegenerative diseases. An early event in neurodegenerative diseases is the alteration of mitochondrial function and increased oxidative stress. Studies using both undifferentiated and differentiated SH-SY5Y neuroblastoma cells have shown distinct responses to cellular stressors; however, the mechanisms remain unclear. We hypothesized that because the regulation of glycolysis and oxidative phosphorylation is modulated during cellular differentiation, this would change bioenergetic function and the response to oxidative stress. To test this, we used retinoic acid (RA) to induce differentiation of SH-SY5Y cells and assessed changes in cellular bioenergetics using extracellular flux analysis. After exposure to RA, the SH-SY5Y cells had an increased mitochondrial membrane potential, without changing mitochondria! number. Differentiated cells exhibited greater stimulation of mitochondrial respiration with uncoupling and an increased bioenergetic reserve capacity. The increased reserve capacity in the differentiated cells was suppressed by the inhibitor of glycolysis 2-deoxy-D-glucose. Furthermore, we found that differentiated cells were substantially more resistant to cytotoxicity and mitochondrial dysfunction induced by the reactive lipid species 4-hydroxynonenal or the reactive oxygen species generator 2,3-dimethoxy-1,4-naphthoquinone. We then analyzed the levels of selected mitochondrial proteins and found an increase in complex IV subunits, which we propose contributes to the increase in reserve capacity in the differentiated cells. Furthermore, we found an increase in MnSOD that could, at least in part, account for the increased resistance to oxidative stress. Our findings suggest that profound changes in mitochondrial metabolism and antioxidant defenses occur upon differentiation of neuroblastoma cells to a neuron-like phenotype. (C) 2011 Elsevier Inc. All rights reserved. C1 [Schneider, Lonnie; Giordano, Samantha; Zelickson, Blake R.; Johnson, Michelle S.; Benavides, Gloria A.; Ouyang, Xiaosen; Darley-Usmar, Victor M.; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Schneider, Lonnie; Giordano, Samantha; Zelickson, Blake R.; Johnson, Michelle S.; Benavides, Gloria A.; Darley-Usmar, Victor M.; Zhang, Jianhua] Univ Alabama Birmingham, Sch Publ Hlth, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Ouyang, Xiaosen; Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA. [Fineberg, Naomi] Univ Alabama Birmingham, Dept Biostat, Sch Publ Hlth, Birmingham, AL 35294 USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Sch Publ Hlth, Birmingham, AL 35294 USA. EM zhanja@uab.edu RI zhang, jianhua/D-3404-2009 OI Zhang, Jianhua/0000-0002-2128-9574 FU Michael J. Fox Foundation; NIH [R01-NS064090]; VA merit award; [ES/HL10167]; [DK75865] FX We thank members of Dr. Zhang's and Dr. Darley-Usmar's laboratories for technical help and discussions. We thank Dr. Balu Chacko for help with confocal imaging. This work was supported by ES/HL10167 and DK75865 (to V.M.D.U.), the Michael J. Fox Foundation, NIHR01-NS064090, and a VA merit award (to J.Z.). NR 57 TC 62 Z9 62 U1 3 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD DEC 1 PY 2011 VL 51 IS 11 BP 2007 EP 2017 DI 10.1016/j.freeradbiomed.2011.08.030 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 848FR UT WOS:000297036500007 PM 21945098 ER PT J AU Estrada, CA Safford, MM Salanitro, AH Houston, TK Curry, W Williams, JH Ovalle, F Kim, Y Foster, P Allison, JJ AF Estrada, Carlos A. Safford, Monika M. Salanitro, Amanda H. Houston, Thomas K. Curry, William Williams, Jessica H. Ovalle, Fernando Kim, Yongin Foster, Pamela Allison, Jeroan J. TI A web-based diabetes intervention for physician: a cluster-randomized effectiveness trial SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE LA English DT Article DE internet; translational research; diabetes mellitus; rural health services; education; medical; continuing process assessment (Health Care) ID CONTINUING MEDICAL-EDUCATION; PRACTICE IMPROVEMENT MODULE; RE-AIM FRAMEWORK; SELF-ASSESSMENT; CARE; CME; BENEFICIARIES; MANAGEMENT; QUALITY; IMPACT AB To determine the effectiveness of a provider-based education and implementation intervention for improving diabetes control. Cluster-randomized trial with baseline and follow-up cross sections of diabetes patients in each participating physicians practice. Eleven US Southeastern states, 200608. Two hundred and five rural primary care physicians. Multi-component interactive intervention including Web-based continuing medical education, performance feedback and quality improvement tools. oAcceptable control' [hemoglobin A1c 9, blood pressure (BP) 140/90 mmHg, low-density lipoprotein cholesterol (LDL) 130 mg/dl] and ooptimal control' (A1c 7, BP 130/80 mmHg, LDL 100 mg/dl). Of 364 physicians attempting to register, 205 were randomized to the intervention (n 102) or control arms (n 103). Baseline and follow-up data were provided by 95 physicians (2127 patients). The proportion of patients with A1c 9 was similar at baseline and follow-up in both the control [adjusted odds ratio (AOR): 0.94; 95 confidence interval (CI): 0.61, 1.47] and intervention arms [AOR: 1.16 (95 CI: 0.80, 1.69)]; BP 140/90 mmHg and LDL 130 mg/dl were also similar at both measurement points (P 0.66, P 0.46; respectively). We observed no significant effect on diabetes control attributable to the intervention for any of the primary outcome measures. Intervention physicians engaged with the Website over a median of 64.7 weeks [interquartile range (IQR): 45.481.8) for a median total of 37 min (IQR: 1666). A wide-reach, low-intensity, Web-based interactive multi-component intervention did not improve control of glucose, BP or lipids for patients with diabetes of physicians practicing in the rural Southeastern US. C1 [Estrada, Carlos A.; Curry, William] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Estrada, Carlos A.] Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA. [Estrada, Carlos A.; Safford, Monika M.; Curry, William; Williams, Jessica H.; Ovalle, Fernando; Kim, Yongin] Univ Alabama, Birmingham, AL USA. [Salanitro, Amanda H.; Houston, Thomas K.] VA Tennessee Valley Healthcare Geriatr Res Educ C, Nashville, TN USA. [Salanitro, Amanda H.; Houston, Thomas K.] Vanderbilt Univ, Nashville, TN USA. [Houston, Thomas K.] Bedford Vet Affairs Med Ctr, Bedford, MA USA. [Foster, Pamela] Univ Alabama, Tuscaloosa, AL USA. [Allison, Jeroan J.] Univ Massachusetts, Sch Med, Worcester, MA USA. RP Estrada, CA (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. EM cestrada@uab.edu RI Houston, Thomas/F-2469-2013 OI Allison, Jeroan/0000-0003-4472-2112 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [5R18DK065001]; Veterans Affairs National Quality Scholars Program FX Awards by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5R18DK065001 to Dr J.J.A. Drs A. H. S and C. A. E. were supported by the Veterans Affairs National Quality Scholars Program. NR 28 TC 7 Z9 7 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1353-4505 J9 INT J QUAL HEALTH C JI Int. J. Qual. Health Care PD DEC PY 2011 VL 23 IS 6 BP 682 EP 689 DI 10.1093/intqhc/mzr053 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 848QL UT WOS:000297067900009 PM 21831967 ER PT J AU Dvorak-Ewell, MM Chen, TH Liang, N Garvey, C Liu, B Tu, CL Chang, WH Bikle, DD Shoback, DM AF Dvorak-Ewell, Melita M. Chen, Tsui-Hua Liang, Nathan Garvey, Caitlin Liu, Betty Tu, Chialing Chang, Wenhan Bikle, Daniel D. Shoback, Dolores M. TI Osteoblast Extracellular Ca2+-Sensing Receptor Regulates Bone Development, Mineralization, and Turnover SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE EXTRACELLULAR Ca2+-SENSING RECEPTOR; OSTEOBLASTS; BONE DEVELOPMENT; OSTEOBLAST DIFFERENTIATION ID CALCIUM-SENSING RECEPTOR; ALKALINE-PHOSPHATASE; CANCELLOUS BONE; SKELETAL PHENOTYPE; MC3T3-E1 CELLS; DEFICIENT MICE; MURINE BONE; DIFFERENTIATION; CASR; OSTEOPROTEGERIN AB The extracellular Ca2+-sensing receptor (CaR), a G protein-coupled receptor responsible for maintenance of calcium homeostasis, is implicated in regulation of skeletal metabolism. To discern the role of the osteoblast CaR in regulation of bone development and remodeling, we generated mice in which the CaR is excised in a broad population of osteoblasts expressing the 3.6-kb a(1)(I) collagen promoter. Conditional knockouts had abnormal skeletal histology at birth and developed progressively reduced mineralization secondary to retarded osteoblast differentiation, evident by significantly reduced numbers of osteoblasts and decreased expression of collagen I, osteocalcin, and sclerostin mRNAs. Elevated expression of ankylosis protein, ectonucleotide pyrophosphatase/phospho-diesterase 1, and osteopontin mRNAs in the conditional knockout indicate altered regulation of genes important in mineralization. Knockout of the osteoblast CaR also resulted in increased expression of the receptor activator of NF-kappa B ligand (RANKL), the major stimulator of osteoclast differentiation and function, consistent with elevated osteoclast numbers in vivo. Osteoblasts from the conditional knockouts exhibited delayed differentiation, reduced mineralizing capacity, altered expression of regulators of mineralization, and increased ability to promote osteoclastogenesis in coculture experiments. We conclude that CaR signaling in a broad population of osteoblasts is essential for bone development and remodeling and plays an important role in the regulation of differentiation and expression of regulators of bone resorption and mineralization. (C) 2011 American Society for Bone and Mineral Research. C1 [Shoback, Dolores M.] Univ Calif San Francisco, San Francisco VA Med Ctr, Endocrine Res Unit, Dept Vet Affairs Med Ctr,Dept Med, San Francisco, CA 94121 USA. RP Shoback, DM (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Endocrine Res Unit, Dept Vet Affairs Med Ctr,Dept Med, 111N,4150 Clement St, San Francisco, CA 94121 USA. EM dolores.shoback@ucsf.edu FU Veterans Affairs Merit Review; Department of Veterans Research Enhancement; NIH [RO1 AG21353, RO1 AR055888, RO1 DK054793] FX We gratefully acknowledge Dr Barbara Kream for the gift of the Col 3.6-Cre mice, as well as the technical help of Hashem Elalieh and Michelle Buttler. This work was supported by a Veterans Affairs Merit Review (DS), a Department of Veterans Research Enhancement Award Program in Bone Disease (DS, DB), NIH RO1 AG21353 (WC), NIH RO1 AR055888 (DS), and NIH RO1 DK054793 (DB). NR 39 TC 36 Z9 38 U1 0 U2 12 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD DEC PY 2011 VL 26 IS 12 BP 2935 EP 2947 DI 10.1002/jbmr.520 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 849QB UT WOS:000297139100016 PM 21956637 ER PT J AU McDonald, CC Deatrick, JA Kassam-Adams, N Richmond, TS AF McDonald, Catherine C. Deatrick, Janet A. Kassam-Adams, Nancy Richmond, Therese S. TI Community Violence Exposure and Positive Youth Development in Urban Youth SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Community violence; Family functioning; Positive youth development; Urban ID INNER-CITY ADOLESCENTS; MENTAL-HEALTH; POSTTRAUMATIC STRESS; PROTECTIVE FACTORS; SOCIAL SUPPORT; SYMPTOMS; TRAJECTORIES; BEHAVIORS; 4-H; STRATEGIES AB Youth in urban environments are exposed to community violence, yet some do well and continue on a positive developmental trajectory. This study investigated the relationships between lifetime community violence exposure (including total, hearing about, witnessing, and victimization), family functioning, and positive youth development (PYD) among 110 urban youth ages 10-16 years (54% female) using a paper and pen self-report survey. This cross-sectional study was part of an interdisciplinary community-based participatory research effort in West/Southwest Philadelphia. Almost 97% of the sample reported some type of community violence exposure. Controlling for presence of mother in the home and presence of father in the home, separate linear regression models for PYD by each type of community violence exposure indicated that gender and family functioning were significantly associated with PYD. None of the types of community violence exposure were significant in the models. Significant interactions between gender and presence of mother in the home and gender and family functioning helped better explain these relationships for some of the types of community violence exposure. Presence of mother was associated with higher PYD for girls, but not for boys. Boys with poor family functioning had lower PYD than girls with poor family functioning. This study helps to better delineate relationships between CVE and PYD by adding new knowledge to the literature on the role of family functioning. Points of intervention should focus on families, with attention to parental figures in the home and overall family functioning. C1 [McDonald, Catherine C.; Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [McDonald, Catherine C.; Kassam-Adams, Nancy; Richmond, Therese S.] Philadelphia Collaborat Violence Prevent Ctr, Philadelphia, PA 19104 USA. [Kassam-Adams, Nancy] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA. [Richmond, Therese S.] Univ Penn, Sch Nursing, Div Biobehav & Hlth Sci, Philadelphia, PA 19104 USA. RP McDonald, CC (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, 2L,418 Curie Blvd, Philadelphia, PA 19104 USA. EM mcdonalc@nursing.upenn.edu RI Kassam-Adams, Nancy/C-4091-2009 FU NCIPC CDC HHS [5 U49 CE001093, U49 CE001093]; NINR NIH HHS [F31 NR011107, F31 NR011107-02, F31NR011107] NR 48 TC 5 Z9 5 U1 3 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD DEC PY 2011 VL 36 IS 6 BP 925 EP 932 DI 10.1007/s10900-011-9391-5 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 838NV UT WOS:000296300400005 PM 21461763 ER PT J AU Brewster, LP Hall, DE Joehl, RJ AF Brewster, Luke P. Hall, Dan E. Joehl, Raymond J. TI Assessing Residents in Surgical Ethics: We Do It a Lot; We Only Know a Little SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE surgical ethics; resident education; clinical ethics ID EDUCATION; FUTURE AB Background. PGY-1 year of surgical residency brings together many persons of disparate experiences and educational backgrounds, including their exposure to ethics. We hypothesized that surgical PGY-1s would have a similar exposure to ethical scenarios but lack the confidence in practice and understanding of ethical principles compared with more senior residents. Materials and Methods. Surgical residents were invited to resident-initiated surgical ethics workshops utilizing a standardized text. Here a survey and multiple choice tests were administered to participants. The survey determined prior exposure to ethics curricula, the frequency of exposure to various ethics topics, and their comfort with these scenarios. A multiple choice test then quantified the knowledge base of participating residents. The results were collected and compared between surgical PGY-1s and more senior residents. Results. Eighteen PGY-1s and 12 senior residents completed this curriculum. Resident exposure to ethical concepts was common. Resident confidence in these topics was ranked moderate or higher for both groups. Despite frequent clinical exposure and strong confidence in their skills of addressing these topics, performance on the test was poor, with an average score of 59% for PGY-1s and 47% for more senior residents (P = 0.03). Conclusions. Despite clinical exposure to and confidence in their management of ethical topics, their knowledge base was poor and worse for more senior residents. Given the overall interest in a formal ethics curriculum and the knowledge deficit demonstrated, educational intervention and professional ethics support should be provided for surgical residents even with the current educational time constraints. (c) 2011 Elsevier Inc. All rights reserved. C1 [Brewster, Luke P.] Emory Univ Hosp, Dept Surg, Atlanta, GA 30022 USA. [Hall, Dan E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hall, Dan E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Joehl, Raymond J.] Edward J Hines Jr VA Hosp, Hines, IL USA. [Joehl, Raymond J.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. RP Brewster, LP (reprint author), Emory Univ Hosp, Dept Surg, 1364 Clifton Rd, Atlanta, GA 30022 USA. EM lukebrewst@aol.com RI Hall, Daniel/H-4843-2013 OI Hall, Daniel/0000-0001-6382-0522 NR 7 TC 2 Z9 2 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD DEC PY 2011 VL 171 IS 2 BP 395 EP 398 DI 10.1016/j.jss.2011.04.008 PG 4 WC Surgery SC Surgery GA 847FS UT WOS:000296957900018 PM 21601880 ER PT J AU Hammer, GE Turer, EE Taylor, KE Fang, CJ Advincula, R Oshima, S Barrera, J Huang, EJ Hou, B Malynn, BA Reizis, B DeFranco, A Criswell, LA Nakamura, MC Ma, A AF Hammer, Gianna Elena Turer, Emre E. Taylor, Kimberly E. Fang, Celia J. Advincula, Rommel Oshima, Shigeru Barrera, Julio Huang, Eric J. Hou, Baidong Malynn, Barbara A. Reizis, Boris DeFranco, Anthony Criswell, Lindsey A. Nakamura, Mary C. Ma, Averil TI Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis SO NATURE IMMUNOLOGY LA English DT Article ID TOLL-LIKE RECEPTORS; NF-KAPPA-B; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PATTERN-RECOGNITION RECEPTORS; GENOME-WIDE ASSOCIATION; INFLAMMATORY DISEASE; IN-VIVO; ANKYLOSING-SPONDYLITIS; PERIPHERAL TOLERANCE; ADAPTIVE IMMUNITY AB Dendritic cells (DCs), which are known to support immune activation during infection, may also regulate immune homeostasis in resting animals. Here we show that mice lacking the ubiquitin-editing molecule A20 specifically in DCs spontaneously showed DC activation and population expansion of activated T cells. Analysis of DC-specific epistasis in compound mice lacking both A20 and the signaling adaptor MyD88 specifically in DCs showed that A20 restricted both MyD88-independent signals, which drive activation of DCs and T cells, and MyD88-dependent signals, which drive population expansion of T cells. In addition, mice lacking A20 specifically in DCs spontaneously developed lymphocyte-dependent colitis, seronegative ankylosing arthritis and enthesitis, conditions stereotypical of human inflammatory bowel disease (IBD). Our findings indicate that DCs need A20 to preserve immune quiescence and suggest that A20-dependent DC functions may underlie IBD and IBD-associated arthritides. C1 [Hammer, Gianna Elena; Turer, Emre E.; Taylor, Kimberly E.; Fang, Celia J.; Advincula, Rommel; Oshima, Shigeru; Barrera, Julio; Huang, Eric J.; Malynn, Barbara A.; Criswell, Lindsey A.; Nakamura, Mary C.; Ma, Averil] Univ Calif San Francisco, Dept Med, San Francisco, CA 94080 USA. [Fang, Celia J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Huang, Eric J.; Nakamura, Mary C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Huang, Eric J.; Nakamura, Mary C.] VA Med Ctr, Pathol Serv, San Francisco, CA USA. [Hou, Baidong; DeFranco, Anthony] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA. [Reizis, Boris] Columbia Univ, Dept Microbiol & Immunol, New York, NY USA. RP Ma, A (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94080 USA. EM averil.ma@ucsf.edu RI Oshima, Shigeru/C-9865-2015 OI Oshima, Shigeru/0000-0003-1186-9177; Huang, Eric/0000-0002-5381-3801; Reizis, Boris/0000-0003-1140-7853 FU US National Institutes of Health; Crohn's and Colitis Foundation of America; Damon Runyon Cancer Research Foundation; Kenneth Rainin Foundation; UCSF Liver Center; Wellcome Trust [076113, 085475] FX This work was supported by the US National Institutes of Health (A. M.), The Crohn's and Colitis Foundation of America (A. M. and S.O.), The Damon Runyon Cancer Research Foundation (G. E. H.), the Kenneth Rainin Foundation and the UCSF Liver Center and the Wellcome Trust (076113 and 085475 to the Wellcome Trust Case-Control Consortium). A full list of investigators who contributed to this work is available from the Wellcome Trust Case-Control Consortium website. NR 56 TC 102 Z9 104 U1 0 U2 15 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD DEC PY 2011 VL 12 IS 12 BP 1184 EP U77 DI 10.1038/ni.2135 PG 11 WC Immunology SC Immunology GA 850NT UT WOS:000297202700013 PM 22019834 ER PT J AU Falowski, SM Sharan, A Reyes, BAS Sikkema, C Szot, P Van Bockstaele, EJ AF Falowski, Steven M. Sharan, Ashwini Reyes, Beverly A. S. Sikkema, Carl Szot, Patricia Van Bockstaele, Elisabeth J. TI An Evaluation of Neuroplasticity and Behavior After Deep Brain Stimulation of the Nucleus Accumbens in an Animal Model of Depression SO NEUROSURGERY LA English DT Article DE DBS; Deep brain stimulation; Dendritic plasticity; Depression; Neuroplasticity; Nucleus accumbens ID MEDIAL PREFRONTAL CORTEX; WISTAR-KYOTO RATS; NEUROPSYCHIATRIC DISORDERS; STRAIN DIFFERENCES; STRESS; SHELL; THALAMUS; ANTIDEPRESSANT; EPIDEMIOLOGY; CONVERGENCE AB BACKGROUND: Recent interest has demonstrated the nucleus accumbens (NAcc) as a potential target for the treatment of depression with deep brain stimulation (DBS). OBJECTIVE: To demonstrate that DBS of the NAcc is an effective treatment modality for depression and that chemical and structural changes associated with these behavioral changes are markers of neuroplasticity. METHODS: A deep brain stimulator was placed in the NAcc of male Wistar-Kyoto rats. Groups were divided into sham (no stimulation), intermittent (3 h/d for 2 weeks), or continuous (constant stimulation for 2 weeks). Exploratory and anxietylike behaviors were evaluated with the open-field test before and after stimulation. Tissue samples of the prefrontal cortex (PFC) were processed with Western blot analysis of markers of noradrenergic activity that included the noradrenergic synthesizing enzyme tyrosine hydroxylase. Analysis of tissue levels for catecholamines was achieved with high-performance liquid chromatography. Morphological properties of cortical pyramidal neurons were assessed with Golgi-Cox staining. RESULTS: Subjects undergoing intermittent and continuous stimulation of the NAcc exhibited an increase in exploratory behavior and reduced anxietylike behaviors. Tyrosine hydroxylase expression levels were decreased in the PFC after intermittent and continuous DBS, and dopamine and norepinephrine levels were decreased after continuous stimulation. Golgi-Cox staining indicated that DBS increased the length of apical and basilar dendrites in pyramidal neurons of the PFC. CONCLUSION: Deep brain stimulation induces behavioral improvement in and neurochemical and morphological alterations of the PFC that demonstrate changes within the circuitry of the brain different from the target area of stimulation. This observed dendritic plasticity may underlie the therapeutic efficacy of this treatment. C1 [Falowski, Steven M.; Sharan, Ashwini] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Reyes, Beverly A. S.; Van Bockstaele, Elisabeth J.] Thomas Jefferson Univ, Dept Neurosci, Farber Inst Neurosci, Philadelphia, PA 19107 USA. [Sikkema, Carl; Szot, Patricia] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. RP Falowski, SM (reprint author), Thomas Jefferson Univ, Dept Neurosurg, 909 Walnut St, Philadelphia, PA 19107 USA. EM sfalowski@gmail.com FU NIDA NIH HHS [R01 DA009082] NR 50 TC 29 Z9 30 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD DEC PY 2011 VL 69 IS 6 BP 1281 EP 1290 DI 10.1227/NEU.0b013e3182237346 PG 10 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 845AF UT WOS:000296794500033 PM 21566538 ER PT J AU Chao, LDL Abadjian, L Hlavin, J Meyerhoff, DJ Weiner, MW AF Chao, Linda L. Abadjian, Linda Hlavin, Jennifer Meyerhoff, Deiter J. Weiner, Michael W. TI Effects of low-level sarin and cyclosarin exposure and Gulf War Illness on Brain Structure and Function: A study at 4 T SO NEUROTOXICOLOGY LA English DT Article DE Magnetic resonance imaging; Morphometric analysis; Brain; Central nervous system; Cognitive functioning; Chemical warfare agents; Sarin; Cyclosarin; Gulf War veterans ID US ARMY VETERANS; NEUROBEHAVIORAL DEFICITS; PARKINSONS-DISEASE; RISK-FACTORS; MULTISYMPTOM ILLNESS; ALZHEIMER-DISEASE; MR SPECTROSCOPY; INJURY; KHAMISIYAH; DEMENTIA AB Background: More than 100,000 US troops were potentially exposed to chemical warfare agents sarin (GB) and cyclosarin (GF) when an ammunition dump at Khamisiyah, Iraq was destroyed during the 1991 Persian Gulf War (GW). We previously found reduced total gray matter (GM) volume in 40 GW veterans with suspected GB/GF exposure relative to 40 matched, unexposed GW veterans on a 1.5 T MR scanner. In this study, we reexamine the relationship between GB/GF exposure and volumetric measurements of gross neuroanatomical structures in a different cohort of GW veterans on a 4 T MR scanner. Methods: Neuropsychological and magnetic resonance imaging (MRI) data from a cross sectional study on Gulf War Illness performed between 2005 and 2010 were used in this study. 4T MRI data were analyzed using automated image processing techniques that produced volumetric measurements of gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF). Results: Binary comparisons of 64 GB/GF exposed veterans and 64 'matched', unexposed veterans revealed reduced GM (p = 0.03) and WM (p = 0.03) volumes in the exposed veterans. Behaviorally, exposed veterans committed more errors of omission (p = 0.02) and tended to have slower responses (p = 0.05) than unexposed veterans on the Continuous Performance Test (CPT), a measure sustained and selective attention. Regression analyses confirmed that GB/GF exposure status predicted GM (beta = -0.11, p = 0.02) and WM (beta = -0.14, p = 0.03) volumes, and number of CPT omission errors (beta = 0.22, p = 0.02) over and above potentially confounding demographic, clinical, and psychosocial variables. There was no dose-response relationship between estimated levels of GB/GF exposure and brain volume. However, we did find an effect of Gulf War Illness/Chronic Mulitsymptom Illness on both GM and WM volume in the GB/GF exposed veterans. Conclusions: These findings confirm previous reports by our group and others of central nervous system pathology in GW veterans with suspected exposure to low levels of GB/GF two decades after the exposure. (C) 2011 Elsevier Inc. All rights reserved. C1 [Chao, Linda L.; Abadjian, Linda; Hlavin, Jennifer; Meyerhoff, Deiter J.; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Chao, Linda L.; Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Chao, Linda L.; Meyerhoff, Deiter J.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Chao, LDL (reprint author), 4150 Clement St,114M, San Francisco, CA 94121 USA. EM linda.chao@ucsf.edu FU NIH/NCRR UCSF-CTSI [UL1 RR024131]; Department of Defense [DAMD17-01-1-0764]; US Army Medical Research and Materiel Command and a Department of Veterans Affairs [B3776]; Department of Veteran's Affairs FX This publication was supported by NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. This study was also supported by Department of Defense grant DAMD17-01-1-0764 entitled 'Magnetic Resonance and Spectroscopy of the Human Brain in Gulf War Illness', awarded to the Northern California Institute for Research and Education from the Department of Defense Gulf War Illnesses Research Program, US Army Medical Research and Materiel Command and a Department of Veterans Affairs grant VA GWI No. B3776 entitled 'Effects of Gulf War Illness on Brain Structure Function and Metabolism: MRI/MRS at 4 T', awarded to Dr. Michael Weiner. This material is the result of work supported with resources and the use of facilities at the San Francisco Veterans Affairs Medical Center. The authors acknowledge Col. Karl Friedl, US Army Medical Research and Materiel Command, Derek Flenniken for managing the database, Diana Truran Sacrey and her staff for scanning the subjects and processing the MRI data, Larry Sippos, Executive Officer to the Deputy Assistant Secretary of Defense for Force Health Protection and Readiness for providing information about the presence or absence of the research participants' units in the modeled hazard areas and the cumulative estimated GB/GF exposure levels, and the Gulf War veterans who participated in these studies.; The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or reflecting the views of the Army, Department of Defense, or Department of Veterans Affairs. Drs. Chao, Meyerhoff, and Weiner have received grant support from the Department of Defense and Dr. Weiner receives grant support from the Department of Veteran's Affairs. NR 49 TC 19 Z9 19 U1 2 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X J9 NEUROTOXICOLOGY JI Neurotoxicology PD DEC PY 2011 VL 32 IS 6 BP 814 EP 822 DI 10.1016/j.neuro.2011.06.006 PG 9 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA 847VK UT WOS:000297000400016 PM 21741405 ER PT J AU Eagan, MJ Bluth, BE Zhao, KW Brinkmann, EJ Wu, BM McAllister, DR AF Eagan, Michael J. Bluth, Benjamin E. Zhao, Ke-Wei Brinkmann, Elyse J. Wu, Benjamin M. McAllister, David R. TI The Effect of Growth and Differentiation Factor-5 on Two-Dimensional Cultures of Mouse Bone Marrow Stromal Cells SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING LA English DT Article DE GDF-5; Ligament Engineering; BMSCs; ACL ID ANTERIOR CRUCIATE LIGAMENT; MESENCHYMAL STEM-CELLS; MEDIAL COLLATERAL LIGAMENT; TGF-BETA-SUPERFAMILY; ACHILLES-TENDON; IN-VITRO; SILK SCAFFOLD; RABBIT MODEL; YOUNG-ADULTS; FIBROBLASTS AB Rupture of the anterior cruciate ligament (ACL) is one of the most common sports-related injuries. However, with its poor healing capacity, surgical reconstruction is currently required to restore its function. Due to serious complications associated with these reconstructions, the use of tissue engineering as an alternative has grown in appeal. Engineering approaches using ligament-derived fibroblasts have been promising but their slow growth rate may limit their practical application. More promising results have been being achieved using stem cells, in combination with appropriate growth factors. As a growth factor, GDF-5 has been shown to play a role in ligament and tendon formation, while bone marrow stem cells have shown promise in their repair. Combining these two parameters, previous work by our group has shown that a combination of GDF-5 and bone marrow stem cells in a 3D environment results in increased expression of several ligament tissue markers. In this study, we continue this work to explore if a dose-response relationship exists between GDF-5 and the stem cell. For this, murine bone marrow stem cells (D1 cells) were exposed to increasing doses of GDF-5 in a standard monolayer culture system and the expression of several ligament genes quantified. In contrast to our previous 3D system, exposing D1 cells to increasing doses of GDF-5 in a 2D culture system did not significantly affect the expression of these markers. Therefore, a more appropriate system for determining the effect of growth factors on stem cells may be a 3D culture system. C1 [Eagan, Michael J.; McAllister, David R.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Dept Orthopaed Surg, Los Angeles, CA 90095 USA. [Bluth, Benjamin E.; Brinkmann, Elyse J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Plast Surg, Dept Surg,Ctr Hlth Sci, Los Angeles, CA 90095 USA. [Zhao, Ke-Wei; McAllister, David R.] VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Orthopaed Tissue Engn Lab Los Angeles, Los Angeles, CA 90073 USA. [Brinkmann, Elyse J.; Wu, Benjamin M.] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Biomed Engn, Los Angeles, CA 90095 USA. RP McAllister, DR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Dept Orthopaed Surg, Los Angeles, CA 90095 USA. FU VA Rehabilitation RRD FX This study was supported by a VA Rehabilitation RR&D grant. NR 40 TC 1 Z9 1 U1 0 U2 2 PU AMER SCIENTIFIC PUBLISHERS PI VALENCIA PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA SN 2157-9083 J9 J BIOMATER TISS ENG JI J. Biomater. Tissue Eng. PD DEC PY 2011 VL 1 IS 2 BP 210 EP 214 DI 10.1166/jbt.2011.1025 PG 5 WC Cell & Tissue Engineering SC Cell Biology GA 057NP UT WOS:000312570600010 ER PT J AU Singh, H Classen, DC Sittig, DF AF Singh, Hardeep Classen, David C. Sittig, Dean F. TI Creating an Oversight Infrastructure for Electronic Health Record-Related Patient Safety Hazards SO JOURNAL OF PATIENT SAFETY LA English DT Article DE electronic health record; patient safety; surveillance AB Electronic health records (EHRs) have potential quality and safety benefits. However, reports of EHR-related safety hazards are now emerging. The Office of the National Coordinator for Health Information Technology recently sponsored an Institute of Medicine committee to evaluate how health information technology use affects patient safety. In this article, we propose the creation of a national EHR oversight program to provide dedicated surveillance of EHR-related safety hazards and to promote learning from identified errors, close calls, and adverse events. The program calls for data gathering, investigation/analysis, and regulatory components. The first 2 functions will depend on institution-level EHR safety committees that will investigate all known EHR-related adverse events and near-misses and report them nationally using standardized methods. These committees should also perform routine safety self-assessments to proactively identify new risks. Nationally, we propose the long-term creation of a centralized, nonpartisan board with an appropriate legal and regulatory infrastructure to ensure the safety of EHRs. We discuss the rationale of the proposed oversight program and its potential organizational components and functions. These include mechanisms for robust data collection and analyses of all safety concerns using multiple methods that extend beyond reporting, multidisciplinary investigation of selected high-risk safety events, and enhanced coordination with other national agencies to facilitate broad dissemination of hazards information. Implementation of this proposed infrastructure can facilitate identification of EHR-related adverse events and errors and potentially create a safer and more effective EHR-based health care delivery system. C1 [Singh, Hardeep] Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA. [Singh, Hardeep] Baylor Coll Med, Houston VA Patient Safety Ctr Inquiry, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Classen, David C.] Univ Utah, Salt Lake City, UT USA. [Classen, David C.] CSC, Salt Lake City, UT USA. [Sittig, Dean F.] Univ Texas Hlth Sci Ctr, Sch Biomed Informat, Univ Texas Mem Hermann Ctr Healthcare Qual & Safe, Houston, TX USA. RP Sittig, DF (reprint author), Univ Texas Sch Hlth Informat Sci Houston, UT Mem Hermann Ctr Healthcare Qual & Safety, 6410 Fannin St,UTPB 1100-13, Houston, TX 77030 USA. EM Dean.F.Sittig@uth.tmc.edu FU National Institutes of Health K23 career development award [K23CA125585]; VA National Center of Patient Safety, Agency for Health Care Research and Quality; Office of the National Coordinator for Health Information Technology (ONC) [10510592]; Houston VA Health Services Research and Development Service Center of Excellence [HFP90-020]; National Library of Medicine [R01-LM006942] FX Dr Singh is supported by a National Institutes of Health K23 career development award (K23CA125585), the VA National Center of Patient Safety, Agency for Health Care Research and Quality, a SHARP contract from the Office of the National Coordinator for Health Information Technology (ONC no. 10510592), and in part by the Houston VA Health Services Research and Development Service Center of Excellence (HFP90-020). Dr Sittig is supported in part by a grant from the National Library of Medicine R01-LM006942 and by a SHARP contract from the Office of the National Coordinator for Health Information Technology (ONC no. 10510592). Dr Classen is an employee of CSC, a technology services company. These sources had no role in the preparation, review, or approval of the article. NR 72 TC 17 Z9 17 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1549-8417 J9 J PATIENT SAF JI J. Patient Saf. PD DEC PY 2011 VL 7 IS 4 BP 169 EP 174 DI 10.1097/PTS.0b013e31823d8df0 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V27KQ UT WOS:000208612500001 PM 22080284 ER PT J AU Lyles, CR Karter, AJ Young, BA Spigner, C Grembowski, D Schillinger, D Adler, N AF Lyles, Courtney R. Karter, Andrew J. Young, Bessie A. Spigner, Clarence Grembowski, David Schillinger, Dean Adler, Nancy TI Provider factors and patient-reported healthcare discrimination in the Diabetes Study of California (DISTANCE) SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Race/ethnicity; Discrimination; Provider factors; Diabetes care; Managed care AB Objective: We examined provider-level factors and reported discrimination in the healthcare setting. Methods: With data from the Diabetes Study of Northern California (DISTANCE) - a race-stratified survey of diabetes patients in Kaiser Permanente Northern California - we analyzed patient-reported racial/ethnic discrimination from providers. Primary exposures were characteristics of the primary care provider (PCP, who coordinates care in this system), including specialty/type, and patient-provider relationship variables, including racial concordance. Results: Subjects (n = 12,151) included 20% black, 20% Latino, 23% Asian, 30% white, and 6% other patients, with 2-8% reporting discrimination by racial/ethnic group. Patients seeing nurse practitioners as their PCP (OR = 0.09; 95% CI: 0.01-0.67) and those rating their provider higher on communication (OR = 0.70; 95% CI: 0.66-0.74) were less likely to report discrimination, while those with more visits (OR = 1.10; 95% CI: 1.03-1.18) were more likely to report discrimination. Racial concordance was not significant once adjusting for patient race/ethnicity. Conclusions: Among diverse diabetes patients in managed care, provider type and communication were significantly related to patient-reported discrimination. Practice implications: Given potential negative impacts on patient satisfaction and treatment decisions, future studies should investigate which interpersonal aspects of the provider-patient relationship reduce patient perceptions of unfair treatment. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Lyles, Courtney R.; Karter, Andrew J.; Young, Bessie A.; Spigner, Clarence; Grembowski, David] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Karter, Andrew J.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Young, Bessie A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Schillinger, Dean; Adler, Nancy] UCSF, Dept Med Psychol, San Francisco, CA USA. [Schillinger, Dean; Adler, Nancy] UCSF, Dept Psychiat, San Francisco, CA USA. [Schillinger, Dean; Adler, Nancy] UCSF, Dept Pediat, San Francisco, CA USA. [Schillinger, Dean] UCSF, Dept Med, San Francisco, CA USA. [Schillinger, Dean] San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94110 USA. RP Lyles, CR (reprint author), Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Box 359455, Seattle, WA 98195 USA. EM crees@u.washington.edu FU National Research Service Award from the Agency for Healthcare Research and Quality [HS013853]; National Institute of Diabetes, Digestive and Kidney Diseases [R01 DK65664]; National Institute of Child Health and Human Development [R01 HD46113] FX This project was supported by a National Research Service Award, grant number HS013853 from the Agency for Healthcare Research and Quality, and funds were provided by National Institute of Diabetes, Digestive and Kidney Diseases R01 DK65664 and National Institute of Child Health and Human Development R01 HD46113. None of the authors had conflicts of interest, and the funders had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. NR 64 TC 7 Z9 7 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD DEC PY 2011 VL 85 IS 3 BP E216 EP E224 DI 10.1016/j.pec.2011.04.031 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA V41JR UT WOS:000209543000007 PM 21605956 ER PT J AU Saha, S Sanders, DS Korthuis, PT Cohn, JA Sharp, VL Haidet, P Moore, RD Beach, MC AF Saha, Somnath Sanders, David S. Korthuis, Philip Todd Cohn, Jonathan A. Sharp, Victoria L. Haidet, Paul Moore, Richard D. Beach, Mary Catherine TI The role of cultural distance between patient and provider in explaining racial/ethnic disparities in HIV care SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Physician-patient relations; Culture; HIV AB Objective: We sought to evaluate whether cultural distance between patients and providers was associated with quality of care for people living with HIV/AIDS, and whether cultural distance helped explain racial/ethnic disparities in HIV care. Methods: We surveyed 437 patients and 45 providers at 4 HIV clinics in the U.S. We examined the association of patients' perceived cultural distance from their providers with patient ratings of healthcare quality, trust in provider, receipt of antiretroviral therapy, medication adherence, and viral suppression. We also examined whether racial/ethnic disparities in these aspects of HIV care were mediated by cultural distance. Results: Greater cultural distance was associated with lower patient ratings of healthcare quality and less trust in providers. Compared to white patients, nonwhites had significantly lower levels of trust, adherence, and viral suppression. Adjusting for patient-provider cultural distance did not significantly affect any of these disparities (p-values for mediation >.10). Conclusion: Patient-provider cultural distance was negatively associated with perceived quality of care and trust but did not explain racial/ethnic disparities in HIV care. Practice implications: Bridging cultural differences may improve patient-provider relationships but may have limited impact in reducing racial/ethnic disparities, unless coupled with efforts to address other sources of unequal care. Published by Elsevier Ireland Ltd. C1 [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97239 USA. [Saha, Somnath; Korthuis, Philip Todd] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA. [Sanders, David S.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA. [Cohn, Jonathan A.] Wayne State Univ, Dept Med, Detroit, MI 48202 USA. [Sharp, Victoria L.] St Lukes Roosevelt Hosp, Ctr Comprehens Care, New York, NY USA. [Haidet, Paul] Penn State Univ, Coll Med, Hershey, PA USA. [Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, 3710 SW US Vet Hosp Rd P3HSRD, Portland, OR 97239 USA. EM sahas@ohsu.edu FU Agency for Healthcare Research and Quality [AHRQ 290-01-0012, K08 HS013903-05]; Robert Wood Johnson Foundation Generalist Physician Faculty Scholar Awards; National Institute on Drug Abuse [K23DA019809]; Department of Veterans Affairs FX This research was supported by a contract from the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). Dr. Beach was supported by the Agency for Healthcare Research and Quality (K08 HS013903-05) and both Drs. Beach and Saha were supported by Robert Wood Johnson Foundation Generalist Physician Faculty Scholar Awards. Dr. Korthuis was supported by the National Institute on Drug Abuse (K23DA019809). Dr. Saha was supported by the Department of Veterans Affairs. NR 39 TC 21 Z9 21 U1 2 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD DEC PY 2011 VL 85 IS 3 BP E278 EP E284 DI 10.1016/j.pec.2011.01.012 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA V41JR UT WOS:000209543000016 PM 21310581 ER PT J AU Vick, CC Graham, LA Henderson, WG Houston, TK Hawn, MT AF Vick, Catherine C. Graham, Laura A. Henderson, William G. Houston, Thomas K., II Hawn, Mary T. TI Translating preoperative smoking cessation interventions into routine clinical care of veterans: provider beliefs SO TRANSLATIONAL BEHAVIORAL MEDICINE LA English DT Article DE Smoking cessation; Counseling; Preoperative; Advise; Assess; Postoperative surgical complications; Primary care clinic; Anesthesia; Smoking status AB Smoking among veterans undergoing surgery is estimated to be 36%. Smoking has been linked to postoperative surgical complications including ischemia and cardiac arrhythmias, pneumonia, deep venous thrombosis, pulmonary embolism, and surgical site infection. Preoperative smoking cessation interventions, in which smokers quit at least 6weeks prior to surgery, have been shown to be effective both in smoking cessation and reduction of postoperative complications; however, little is known about physician beliefs regarding the optimal location and the responsible provider for intervention, or whether surgery should be postponed or delayed based on smoking status. Within the routine coordination from medical to surgical care, how should cessation interventions best be implemented? To better inform the translation of preoperative best practices for smoking cessation into clinical care in VA, a survey regarding preoperative smoking cessation beliefs and practices was administered to primary care physicians, surgeons, and anesthesia providers. Chi-square tests were used to examine differences in proportions by provider type. Most providers agreed that the primary care clinic is the best location for intervention, with preoperative and surgical clinics ranked by few as the optimal location (13% and 11%, respectively); most respondents (82%) reported that they would refuse or delay surgery in some cases based on smoking status. There were no differences in either beliefs on location or delay based on provider type. Primary care providers were most likely to advise (86.7%) and assess (80.0%) while anesthesia providers were least likely (59.1% and 22.7%, respectively). Taking time to counsel and the belief that dedicated resources would improve quit rates were associated with advising patients to quit smoking, while being uncomfortable with counseling, the belief that acute health takes precedence and the belief that there is not always time to counsel were identified as barriers to assessing patients for smoking cessation intervention. Primary care providers were more optimistic (100%) that patients would quit if counseled, more often (73.3%) reported having time to counsel, and were less likely to report that acute health takes precedence. Most providers believe that smoking cessation would reduce postoperative complications, with the ideal location for the intervention being the primary care clinic, and that some surgical cases should be delayed for this intervention. C1 [Vick, Catherine C.; Graham, Laura A.; Hawn, Mary T.] Birmingham VAMC, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35233 USA. [Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA. [Houston, Thomas K., II] Bedford VAMC, VA eHlth Qual Enhancement Res Initiat, Bedford, MA USA. [Houston, Thomas K., II] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci Quantitat Hlt, Worcester, MA USA. [Hawn, Mary T.] Univ Alabama Birmingham, Sch Med, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA. RP Vick, CC (reprint author), Birmingham VAMC, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35233 USA. EM catherine.vick@va.gov FU United States Department of Veterans' Affairs Health Services Research and Development grant [IAB 06-038] FX The authors would like to acknowledge Heather Coley, MPH, for assistance in development of the survey instrument and data collection. The authors would like to acknowledge Jasvinder Singh, MD, for critical revision of the manuscript. This research was funded by the United States Department of Veterans' Affairs Health Services Research and Development grant IAB 06-038. NR 25 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1869-6716 EI 1613-9860 J9 TRANSL BEHAV MED JI Transl. Behav. Med. PD DEC PY 2011 VL 1 IS 4 BP 604 EP 608 DI 10.1007/s13142-011-0096-1 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V39LJ UT WOS:000209412200016 PM 24073083 ER PT J AU Tafti, BA Shaba, W Li, YX Yevdayev, E Berenji, GR Glass, E AF Tafti, Bashir Akhavan Shaba, Wisam Li, Yuxin Yevdayev, Ella Berenji, Gholam Reza Glass, Edwin TI Detection of a Sinus of Valsalva Aneurysm by F-18 FDG PET/CT Imaging SO CLINICAL NUCLEAR MEDICINE LA English DT Editorial Material DE sinus of Valsalva; aneurysm; positron emission tomography/CT AB An echocardiographic examination performed on a 72-year-old man for assessment of left ventricular hypertrophy revealed a right atrial mass, approximately 4 cm in size, attached to the interatrial septum. Given his history of leiomyosarcoma with vascular invasion, the patient was referred for PET/CT to assess the possibility of metastatic involvement. The results suggested an aneurysmal mass of the aortic noncoronary cusp consistent with a sinus of Valsalva aneurysm. A subsequent CT angiogram and surgery confirmed the diagnosis. To the best of our knowledge, this is the first reported case of a sinus of Valsalva aneurysm detected in PET/CT images. C1 [Tafti, Bashir Akhavan; Shaba, Wisam; Li, Yuxin; Yevdayev, Ella; Berenji, Gholam Reza; Glass, Edwin] Vet Adm Greater Los Angeles Hlth Care Syst, Nucl Med Sect, Dept Radiol, Los Angeles, CA 90073 USA. RP Glass, E (reprint author), Vet Adm Greater Los Angeles Hlth Care Syst, Nucl Med Sect, Dept Radiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM edwin.glass@va.gov NR 11 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-9762 J9 CLIN NUCL MED JI Clin. Nucl. Med. PD DEC PY 2011 VL 36 IS 12 BP 1144 EP 1145 DI 10.1097/RLU.0b013e3182335f4d PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 845BC UT WOS:000296796800040 PM 22064097 ER PT J AU Guyatt, GH Oxman, AD Kunz, R Woodcock, J Brozek, J Helfand, M Alonso-Coello, P Glasziou, P Jaeschke, R Akl, EA Norris, S Vist, G Dahm, P Shukla, VK Higgins, J Falck-Ytter, Y Schunemann, HJ AF Guyatt, Gordon H. Oxman, Andrew D. Kunz, Regina Woodcock, James Brozek, Jan Helfand, Mark Alonso-Coello, Pablo Glasziou, Paul Jaeschke, Roman Akl, Elie A. Norris, Susan Vist, Gunn Dahm, Philipp Shukla, Vijay K. Higgins, Julian Falck-Ytter, Yngve Schuenemann, Holger J. CA GRADE Working Grp TI GRADE guidelines: 7. Rating the quality of evidence-inconsistency SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE GRADE; Inconsistency; Heterogeneity; Variability; Sub-group analysis; Interaction ID CLINICAL-TRIALS; METAANALYSIS; EPINEPHRINE; VASOPRESSIN AB This article deals with inconsistency of relative (rather than absolute) treatment effects in binary/dichotomous outcomes. A body of evidence is not rated up in quality if studies yield consistent results, but may be rated down in quality if inconsistent. Criteria for evaluating consistency include similarity of point estimates, extent of overlap of confidence intervals, and statistical criteria including tests of heterogeneity and I(2). To explore heterogeneity, systematic review authors should generate and test a small number of a priori hypotheses related to patients, interventions, outcomes, and methodology. When inconsistency is large and unexplained, rating down quality for inconsistency is appropriate, particularly if some studies suggest substantial benefit, and others no effect or harm (rather than only large vs. small effects). Apparent subgroup effects may be spurious. Credibility is increased if subgroup effects are based on a small number of a priori hypotheses with a specified direction; subgroup comparisons come from within rather than between studies; tests of interaction generate low P-values; and have a biological rationale. (C) 2011 Elsevier Inc. All rights reserved. C1 [Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, W Hamilton, ON L8N 3Z5, Canada. [Guyatt, Gordon H.; Jaeschke, Roman; Schuenemann, Holger J.] McMaster Univ, Dept Med, W Hamilton, ON L8N 3Z5, Canada. [Oxman, Andrew D.; Vist, Gunn] Norwegian Knowledge Ctr Hlth Serv, N-0130 Oslo, Norway. [Kunz, Regina] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland. [Woodcock, James] London Sch Hyg & Trop Med, London WC1, England. [Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Oregon Evidence Based Practice Ctr, Portland, OR 97201 USA. [Alonso-Coello, Pablo] Univ Autonoma Barcelona, Serv Epidemiol Clin & Salud Publ, Iberoamer Cochrane Ctr, Barcelona 08041, Spain. [Alonso-Coello, Pablo] Univ Autonoma Barcelona, Hosp St Pau, CIBERESP, Barcelona 08041, Spain. [Glasziou, Paul] Bond Univ, Fac Hlth Sci, Ctr Res Evidence Based Practice, Gold Coast, Qld 4229, Australia. [Akl, Elie A.] SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA. [Norris, Susan] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. [Dahm, Philipp] Univ Florida, Coll Med, Dept Urol, Gainesville, FL USA. [Shukla, Vijay K.] CADTH, Ottawa, ON K1S 5S8, Canada. [Higgins, Julian] MRC Biostat Unit, Cambridge, England. [Falck-Ytter, Yngve] Case Western Reserve Univ, Div Gastroenterol, Case Med Ctr & VA, Cleveland, OH 44106 USA. RP Guyatt, GH (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Room 2C12,1200 Main St, W Hamilton, ON L8N 3Z5, Canada. EM guyatt@mcmaster.ca RI Higgins, Julian/H-4008-2011; Glasziou, Paul/A-7832-2008 OI Higgins, Julian/0000-0002-8323-2514; Glasziou, Paul/0000-0001-7564-073X FU Medical Research Council [MC_U105285807] NR 18 TC 492 Z9 505 U1 4 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD DEC PY 2011 VL 64 IS 12 BP 1294 EP 1302 DI 10.1016/j.jclinepi.2011.03.017 PG 9 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 847TI UT WOS:000296995000007 PM 21803546 ER PT J AU Guyatt, GH Oxman, AD Kunz, R Woodcock, J Brozek, J Helfand, M Alonso-Coello, P Falck-Ytter, Y Jaeschke, R Vist, G Akl, EA Post, PN Norris, S Meerpohl, J Shukla, VK Nasser, M Schunemann, HJ AF Guyatt, Gordon H. Oxman, Andrew D. Kunz, Regina Woodcock, James Brozek, Jan Helfand, Mark Alonso-Coello, Pablo Falck-Ytter, Yngve Jaeschke, Roman Vist, Gunn Akl, Elie A. Post, Piet N. Norris, Susan Meerpohl, Joerg Shukla, Vijay K. Nasser, Mona Schuenemann, Holger J. CA GRADE Working Group TI GRADE guidelines: 8. Rating the quality of evidence-indirectness SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE GRADE; Quality of evidence; Indirectness; Indirect comparisons; Applicability; Generalizability ID RANDOMIZED CONTROLLED-TRIALS; METAANALYSIS; INTERVENTIONS; THERAPY; CANCER AB Direct evidence comes from research that directly compares the interventions in which we are interested when applied to the populations in which we are interested and measures outcomes important to patients. Evidence can be indirect in one of four ways. First, patients may differ from those of interest (the term applicability is often used for this form of indirectness). Secondly, the intervention tested may differ from the intervention of interest. Decisions regarding indirectness of patients and interventions depend on an understanding of whether biological or social factors are sufficiently different that one might expect substantial differences in the magnitude of effect. Thirdly, outcomes may differ from those of primary interest-for instance, surrogate outcomes that are not themselves important, but measured in the presumption that changes in the surrogate reflect changes in an outcome important to patients. A fourth type of indirectness, conceptually different from the first three, occurs when clinicians must choose between interventions that have not been tested in head-to-head comparisons. Making comparisons between treatments under these circumstances requires specific statistical methods and will be rated down in quality one or two levels depending on the extent of differences between the patient populations, co-interventions, measurements of the outcome, and the methods of the trials of the candidate interventions. (C) 2011 Elsevier Inc. All rights reserved. C1 [Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, W Hamilton, ON L8N 3Z5, Canada. [Guyatt, Gordon H.; Jaeschke, Roman; Schuenemann, Holger J.] McMaster Univ, Dept Med, W Hamilton, ON L8N 3Z5, Canada. [Oxman, Andrew D.; Vist, Gunn] Norwegian Knowledge Ctr Hlth Serv, N-0130 Oslo, Norway. [Kunz, Regina] Univ Basel Hosp, Acad Swiss Insurance Med, CH-4031 Basel, Switzerland. [Kunz, Regina] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland. [Woodcock, James] London Sch Hyg & Trop Med, London WC1, England. [Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Oregon Evidence Based Practice Ctr, Portland, OR 97201 USA. [Alonso-Coello, Pablo] Univ Autonoma Barcelona, Iberoamer Cochrane Ctr, Serv Epidemiol Clin & Salud Publ, Barcelona 08041, Spain. [Alonso-Coello, Pablo] Univ Autonoma Barcelona, Hosp St Pau, CIBERESP, Barcelona 08041, Spain. [Falck-Ytter, Yngve] Case Western Reserve Univ, Case & VA Med Ctr, Div Gastroenterol, Cleveland, OH 44106 USA. [Falck-Ytter, Yngve] Univ Oxford, Oxford, England. [Akl, Elie A.] SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA. [Post, Piet N.] Dutch Inst Healthcare Improvement CBO, Utrecht, Netherlands. [Norris, Susan] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. [Meerpohl, Joerg] Univ Med Ctr Freiburg, Inst Med Biometry & Med Informat, German Cochrane Ctr, D-79104 Freiburg, Germany. [Meerpohl, Joerg] Univ Med Ctr Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, D-79106 Freiburg, Germany. [Shukla, Vijay K.] CADTH, Ottawa, ON K1S 5S8, Canada. [Nasser, Mona] Inst Qual & Efficiency Hlth Care IQWiG, Dept Hlth Informat, Cologne, Germany. RP Guyatt, GH (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Room 2C12,1200 Main St, W Hamilton, ON L8N 3Z5, Canada. EM guyatt@mcmaster.ca RI Nasser, Mona/J-3601-2013; Meerpohl, Joerg/J-4224-2013 OI Meerpohl, Joerg/0000-0002-1333-5403 NR 21 TC 306 Z9 318 U1 1 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD DEC PY 2011 VL 64 IS 12 BP 1303 EP 1310 DI 10.1016/j.jclinepi.2011.04.014 PG 8 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 847TI UT WOS:000296995000008 PM 21802903 ER PT J AU Hunt, KJ Gonzalez, ME Lopez, R Haffner, SM Stern, MP Gonzalez-Villalpando, C AF Hunt, Kelly J. Elena Gonzalez, Maria Lopez, Ruy Haffner, Steve M. Stern, Michael P. Gonzalez-Villalpando, Clicerio TI Diabetes is More Lethal in Mexicans and Mexican-Americans Compared to Non-Hispanic Whites SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE World Health; Epidemiology; Mortality ID CARDIOVASCULAR RISK-FACTORS; IMPAIRED GLUCOSE-TOLERANCE; SAN-ANTONIO; MYOCARDIAL-INFARCTION; DISEASE MORTALITY; PLASMA-GLUCOSE; US ADULTS; ALL-CAUSE; CITY; PREVALENCE AB PURPOSE: To examine the mortality risk associated with diabetes in the Mexico City Diabetes Study (MCDS) and the San Antonio Heart Study (SAHS). METHODS: Prospective cohorts conducted 1990-2007 in MCDS and 1979-2000 in SAHS. Mortality risk was examined using Cox proportional hazard models in 1402 non-Hispanic whites (NHW), 1907 U.S.-born Mexican-Americans (MA), 444 Mexican-horn MA, and 2281 Mexico City residents (MCR) between the ages of 35-64. RESULTS: Age- and sex-adjusted mortality hazard ratios (FIR) comparing U.S.-born MA, Mexican-born MA, and MCR to NHW were 1.09(95% confidence interval [CI]: 0.86, 1.37), 1.23 (95% Cl: 0.86, 1.76), and 0.97 (95% Cl: 0.77, 1.23), respectively, in nondiabetic individuals; in contrast, mortality risk varied in diabetic individuals with respective HRs of 1.77 (95% Cl: 1.20, 2.61), 1.08 (95% Cl: 0.59, 1.97), and 2.27 (95% Cl: 1.53, 3.35) (interaction p = .0003). Excluding Mexican-born MA and nondiabetic individuals, controlling for medication use, insulin use, fasting glucose levels, and duration of diabetes explained a significant proportion of the mortality differential (HRs relative to NHW were 1.31 [95% Cl: 0.87, 1.981 in U.S.-born MA and 1.38(95% CI: 0.89, 2.121 in MCR). CONCLUSIONS: This study provides evidence that diabetes is more lethal in U.S.-born MA and MCR than in NHW. Ann Epidemiol 201121:899-906. (C) 2011 Elsevier Inc. All rights reserved. C1 [Hunt, Kelly J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Hunt, Kelly J.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Elena Gonzalez, Maria; Lopez, Ruy; Gonzalez-Villalpando, Clicerio] Unidad Invest Diabet, Mexico City, DF, Mexico. [Elena Gonzalez, Maria; Lopez, Ruy; Gonzalez-Villalpando, Clicerio] Riesgo Cardiovasc Inst Nacl Salud Publ, Mexico City, DF, Mexico. [Elena Gonzalez, Maria; Lopez, Ruy; Gonzalez-Villalpando, Clicerio] Ctr Estudios Diabet, Mexico City, DF, Mexico. [Haffner, Steve M.] Baylor Coll Med, Houston, TX 77030 USA. [Stern, Michael P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Hunt, KJ (reprint author), Med Univ S Carolina, 135 Cannon St,Suite 302,POB 250835, Charleston, SC 29425 USA. EM huntke@musc.edu FU Consejo Nacional de Ciencia y Tecnologia Apoyo [14502]; National Heart Lung and Blood Institute [R01-HL24799, R01-HL36820]; National Institute of Diabetes and Digestive and Kidney Diseases [K01-DK064867]; National Center on Minority Health and Health Disparities [R01-MD004251]; Office of Research and Development, Department of Veterans Affairs; Ralph H. Johnson VAMC; VA HSRD [IIR-06-219] FX This work was supported by grants from the Consejo Nacional de Ciencia y Tecnologia Apoyo (14502), the National Heart Lung and Blood Institute (R01-HL24799 and R01-HL36820), the National Institute of Diabetes and Digestive and Kidney Diseases (K01-DK064867), the National Center on Minority Health and Health Disparities (R01-MD004251), the Office of Research and Development, Department of Veterans Affairs, and the Ralph H. Johnson VAMC,. Further support was provided through VA HSR&D REAP Award (grant IIR-06-219). The funding agencies did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the U.S. Department of Veterans Affairs. NR 27 TC 9 Z9 10 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD DEC PY 2011 VL 21 IS 12 BP 899 EP 906 DI 10.1016/j.annepidem.2011.07.003 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 844NX UT WOS:000296755400005 PM 21840730 ER PT J AU Inslicht, SS Otte, C McCaslin, SE Apfel, BA Henn-Haase, C Metzler, T Yehuda, R Neylan, TC Marmar, CR AF Inslicht, Sabra S. Otte, Christian McCaslin, Shannon E. Apfel, Brigitte A. Henn-Haase, Clare Metzler, Thomas Yehuda, Rachel Neylan, Thomas C. Marmar, Charles R. TI Cortisol Awakening Response Prospectively Predicts Peritraumatic and Acute Stress Reactions in Police Officers SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Acute stress disorder; cortisol; peritraumatic dissociation; police stress; posttraumatic stress disorder ID VEHICLE ACCIDENT VICTIMS; POSTTRAUMATIC-STRESS; SALIVARY CORTISOL; SLEEP QUALITY; PTSD SYMPTOMS; PSYCHOMETRIC PROPERTIES; TRAUMA VICTIMS; HPA AXIS; DISORDER; ADULTS AB Background: The hypothalamic-pituitary-adrenal axis is a major stress response system hypothesized to be involved in the pathogenesis of posttraumatic stress disorder (PTSD). However, few studies have prospectively examined the relationships among pre-exposure hypothalamic-pituitary-adrenal activity, acute stress reactions and PTSD. Methods: Two hundred ninety-six police recruits were assessed during academy training before critical incident exposure and provided salivary cortisol at first awakening and after 30 minutes. A measure of cortisol awakening response (CAR) was computed as the change in cortisol level from the first to the second collection. At 12, 24, and 36 months following the start of active police service, officers were assessed for peritraumatic distress, peritraumatic dissociation, acute stress disorder (ASD) symptoms, and PTSD symptoms to their self-identified worst duty-related critical incident. Mixed models for repeated measures were used to analyze the effects of CAR on the outcome variables pooled across the three follow-up assessments. Results: After controlling for time of awakening, first awakening cortisol levels, and cumulative critical incident stress exposure, CAR during academy training was associated with greater peritraumatic dissociation, beta = .14, z = 3.49, p < .0001, and greater ASD symptoms during police service assessed at 12, 24, and 36 months, beta = .09, Z = 2.03, p < .05, but not with peritraumatic distress, beta = .03, z = .81, p = .42, or PTSD symptoms, beta = -.004, z = -.09, p = .93. Conclusions: These findings suggest that greater cortisol response to awakening is a pre-exposure risk factor for peritraumatic dissociation and ASD symptoms during police service. C1 [Inslicht, Sabra S.; McCaslin, Shannon E.; Apfel, Brigitte A.; Metzler, Thomas; Neylan, Thomas C.] San Francisco VA Med Ctr, PTSD Res Program, San Francisco, CA USA. [Inslicht, Sabra S.; McCaslin, Shannon E.; Apfel, Brigitte A.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Metzler, Thomas] No Calif Inst Res & Educ, San Francisco, CA USA. [Otte, Christian] Charite, Dept Psychiat & Psychotherapy, Ctr Berlin, D-13353 Berlin, Germany. [Henn-Haase, Clare; Marmar, Charles R.] NYU, Sch Med, Dept Psychiat, New York, NY USA. [Yehuda, Rachel] Mt Sinai Sch Med, Traumat Stress Div, Bronx, NY USA. James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Inslicht, SS (reprint author), Vet Affairs Med Ctr, PTSD Res Program, 4150 Clement St,116P, San Francisco, CA 94121 USA. EM Sabra.Inslicht@ucsf.edu FU National Institute of Mental Health [R01 - MH056350-06]; Veterans Affairs Clinical Science Research and Development [CDA-2-037-07F, CDA-2-032-06F] FX This research was supported by National Institute of Mental Health Grant (R01 - MH056350-06) to CRM. SSI and SEM were supported by Veterans Affairs Clinical Science Research and Development, Career Development Awards (CDA-2-037-07F and CDA-2-032-06F, respectively). NR 67 TC 21 Z9 24 U1 3 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD DEC 1 PY 2011 VL 70 IS 11 BP 1055 EP 1062 DI 10.1016/j.biopsych.2011.06.030 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 842FL UT WOS:000296578800010 PM 21906725 ER PT J AU Bendlin, BB Canu, E Willette, A Kastman, EK McLaren, DG Kosmatka, KJ Xu, G Field, AS Colman, RJ Coe, CL Weindruch, RH Alexander, AL Johnson, SC AF Bendlin, B. B. Canu, E. Willette, A. Kastman, E. K. McLaren, D. G. Kosmatka, K. J. Xu, G. Field, A. S. Colman, R. J. Coe, C. L. Weindruch, R. H. Alexander, A. L. Johnson, S. C. TI Effects of aging and calorie restriction on white matter in rhesus macaques SO NEUROBIOLOGY OF AGING LA English DT Article DE Rhesus macaque; Diffusion tensor imaging; Magnetic resonance imaging; Aging; Caloric restriction; White matter ID LATERAL GENICULATE NEURONS; PRIMARY VISUAL-CORTEX; AGE-RELATED DECLINE; DIETARY RESTRICTION; BRAIN ABNORMALITIES; ALZHEIMERS-DISEASE; MYELIN BREAKDOWN; OXIDATIVE DAMAGE; HUMAN OBESITY; IN-VIVO AB Rhesus macaques on a calorie restricted diet (CR) develop less age-related disease, have virtually no indication of diabetes, are protected against sarcopenia, and potentially live longer. Beneficial effects of caloric restriction likely include reductions in age-related inflammation and oxidative damage. Oligodendrocytes are particularly susceptible to inflammation and oxidative stress, therefore, we hypothesized that CR would have a beneficial effect on brain white matter and would attenuate age-related decline in this tissue. CR monkeys and controls underwent diffusion tensor imaging (DTI). A beneficial effect of CR indexed by DTI was observed in superior longitudinal fasciculus, fronto-occipital fasciculus, external capsule, and brainstem. Aging effects were observed in several regions, although CR appeared to attenuate age-related alterations in superior longitudinal fasciculus, frontal white matter, external capsule, right parahippocampal white matter, and dorsal occipital bundle. The results, however, were regionally specific and also suggested that CR is not salutary across all white matter. Further evaluation of this unique cohort of elderly primates to mortality will shed light on the ultimate benefits of an adult-onset, moderate CR diet for deferring brain aging. Published by Elsevier Inc. C1 [Bendlin, B. B.; Canu, E.; Kastman, E. K.; McLaren, D. G.; Kosmatka, K. J.; Xu, G.; Weindruch, R. H.; Johnson, S. C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Bendlin, B. B.; Canu, E.; Kastman, E. K.; McLaren, D. G.; Kosmatka, K. J.; Xu, G.; Weindruch, R. H.; Johnson, S. C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Willette, A.; Coe, C. L.] Univ Wisconsin, Dept Psychol, Harlow Primate Lab, Madison, WI 53706 USA. [Willette, A.; Colman, R. J.; Coe, C. L.; Weindruch, R. H.] Wisconsin Natl Primate Res Ctr, Madison, WI USA. [Field, A. S.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Alexander, A. L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Alexander, A. L.] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA. [Alexander, A. L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu RI McLaren, Donald/G-9906-2011; Kastman, Erik/N-6645-2016; Canu, Elisa/K-1423-2016 OI Kastman, Erik/0000-0001-7221-9042; Canu, Elisa/0000-0001-5804-3378; Bendlin, Barbara/0000-0002-0580-9875 FU Waisman Center, UW-Madison; NIH [AG11915, RR000167, AG000213]; NCRR [RR15459-01, RR020141-01] FX The authors gratefully acknowledge the support of researchers and staff at the Waisman Center, UW-Madison, where MR imaging took place, and the technical assistance provided by S. Baum, J. Christensen, JA. Adriansjach, and C. E. Armstrong. We also acknowledge the assistance provided by the Animal Care, Veterinary and Pathology Staff of the Wisconsin National Primate Research Center. The project was supported by funding from the NIH to the Wisconsin National Primate Research Center grants AG11915 and RR000167 and NIH grant AG000213. This research was conducted in part at a facility constructed with support from Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01 from NCRR. The project also benefited from resources and facilities at the Wm. S. Middleton Memorial Veterans Hospital. GRECC Manuscript 2010-11. NR 67 TC 2 Z9 2 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD DEC PY 2011 VL 32 IS 12 AR 2319.e1 DI 10.1016/j.neurobiolaging.2010.04.008 PG 11 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 839PJ UT WOS:000296379900030 PM 20541839 ER PT J AU Chu, SH Roeder, K Ferrell, RE Devlin, B DeMichele-Sweet, MAA Kamboh, MI Lopez, OL Sweet, RA AF Chu, Su Hee Roeder, Kathryn Ferrell, Robert E. Devlin, Bernie DeMichele-Sweet, Mary Ann A. Kamboh, M. Ilyas Lopez, Oscar L. Sweet, Robert A. TI TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease SO NEUROBIOLOGY OF AGING LA English DT Article DE Apolipoprotein E (APOE) epsilon 4; Late-onset Alzheimer disease (LOAD); Psychosis; TOMM40; Variable length poly-T repeat sequence ID DEMENTIA; HERITABILITY; ASSOCIATION; APOE AB Apolipoprotein E (APOE) epsilon 4 alleles increase the risk for late-onset Alzheimer disease (LOAD) and decrease the age of onset. Recently, sequencing the APOE region in a small sample of LOAD subjects identified a variable length poly-T repeat sequence in the nearby gene, TOMM40, which may affect age of onset. We genotyped the TOMM40 poly-T repeat using a novel statistical approach to refine the identification of allele length in 892 LOAD subjects and evaluated its effects on age of onset. Because psychosis in LOAD is a heritable phenotype which has shown conflicting associations with APOE genotype, we also evaluated the association of poly-T repeat length with psychosis. Poly-T repeat lengths had a trimodal distribution which differed between APOE genotype groups. After accounting for APOE epsilon 4 there was no association of poly-T repeat length with age of onset. Neither APOE epsilon 4 nor poly-T repeat length was associated with psychosis. Our findings do not support the association of poly-T repeat length with age of onset in LOAD. The clinical implications of this repeat length polymorphism remain to be elucidated. (C) 2011 Elsevier Inc. All rights reserved. C1 [Chu, Su Hee; Roeder, Kathryn] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA. [Ferrell, Robert E.; Kamboh, M. Ilyas] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. [Devlin, Bernie; DeMichele-Sweet, Mary Ann A.; Kamboh, M. Ilyas; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, MIRECC, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu OI Kamboh, M. Ilyas/0000-0002-3453-1438 FU National Institute on Aging (NIA) [AG 027224, AG030653, AG 05133] FX This work was supported by National Institute on Aging (NIA) grants AG 027224, AG030653, and AG 05133. NR 19 TC 6 Z9 7 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD DEC PY 2011 VL 32 IS 12 AR 2328.e1 DI 10.1016/j.neurobiolaging.2011.06.016 PG 9 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 839PJ UT WOS:000296379900053 PM 21820212 ER PT J AU Wang, J Ono, K Dickstein, DL Arrieta-Cruz, I Zhao, W Qian, XJ Lamparello, A Subnani, R Ferruzzi, M Pavlides, C Ho, L Hof, PR Teplow, DB Pasinetti, GM AF Wang, Jun Ono, Kenjiro Dickstein, Dara L. Arrieta-Cruz, Isabel Zhao, Wei Qian, Xianjuan Lamparello, Ashley Subnani, Rakesh Ferruzzi, Mario Pavlides, Constantine Ho, Lap Hof, Patrick R. Teplow, David B. Pasinetti, Giulio M. TI Carvedilol as a potential novel agent for the treatment of Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Article DE Oligomeric A beta; Cognitive function; Spatial memory; Basal neuronal transmission; Dendritic spine; Synaptic plasticity; Bioavailability ID AMYLOID-BETA-PROTEIN; LONG-TERM POTENTIATION; SCANNING MICROSCOPY IMAGES; MOUSE MODEL; SYNAPTIC PLASTICITY; DENDRITIC SPINES; IN-VIVO; COGNITIVE FUNCTION; PREFRONTAL CORTEX; NATURAL OLIGOMERS AB Oligomeric beta-amyloid (A beta) has recently been linked to synaptic plasticity deficits, which play a major role in progressive cognitive decline in Alzheimer's disease (AD). Here we present evidence that chronic oral administration of carvedilol, a nonselective beta-adrenergic receptor blocker, significantly attenuates brain oligomeric beta-amyloid content and cognitive deterioration in 2 independent AD mouse models. We found that carvedilol treatment significantly improved neuronal transmission, and that this improvement was associated with the maintenance of number of the less stable "learning" thin spines in the brains of AD mice. Our novel observation that carvedilol interferes with the neuropathologic, biochemical, and electrophysiological mechanisms underlying cognitive deterioration in AD supports the potential development of carvedilol as a treatment for AD. (C) 2011 Elsevier Inc. All rights reserved. C1 [Wang, Jun; Arrieta-Cruz, Isabel; Zhao, Wei; Qian, Xianjuan; Lamparello, Ashley; Subnani, Rakesh; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Brain Res Inst, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. [Dickstein, Dara L.; Hof, Patrick R.; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Ferruzzi, Mario] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA. [Pavlides, Constantine] Rockefeller Univ, New York, NY 10021 USA. [Ho, Lap; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1425 Madison Ave,Box 1230, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu RI Dickstein, Dara/F-3036-2013 FU NIH [UO1 AG29310]; Altschul Foundation FX This work is supported by NIH UO1 AG29310 (GMP) and funding provided by Altschul Foundation. NR 56 TC 5 Z9 6 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD DEC PY 2011 VL 32 IS 12 AR 2321.e1 DI 10.1016/j.neurobiolaging.2010.05.004 PG 12 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 839PJ UT WOS:000296379900036 PM 20579773 ER PT J AU Gupta, AO Singh, N AF Gupta, Ashish O. Singh, Nina TI Immune reconstitution syndrome and fungal infections SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE fungal infections; HIV; immune reconstitution syndrome; mycoses; transplants ID ORGAN TRANSPLANT RECIPIENTS; CRYPTOCOCCUS-NEOFORMANS INFECTION; PENICILLIUM-MARNEFFEI INFECTION; ADJUVANT CORTICOSTEROID-THERAPY; ACTIVE ANTIRETROVIRAL THERAPY; HIV-POSITIVE PATIENTS; VERSUS-HOST-DISEASE; REGULATORY T-CELLS; INFLAMMATORY SYNDROME; DISSEMINATED HISTOPLASMOSIS AB Purpose of review Fungal infections-related immune reconstitution syndrome (IRS) poses challenging diagnostic and management issues in immunocompromised hosts. This review summarizes the current state of knowledge regarding its pathophysiologic basis, presentation, and treatment strategies. Recent findings Existing evidence suggests that IRS is a state of an imbalance between protective immunity and inflammatory pathology versus anti-inflammatory responses that restrain inflammation. IRS has been observed in diverse hosts including HIV-infected patients initiating potent antiretroviral therapy, transplant recipients, pregnant women, and recipients of iatrogenic biologic agents. Among the most common fungal infections associated with IRS is cryptococcosis, although this entity has been documented during the course of invasive aspergillosis, histoplasmosis, and candidiasis. Unique risk factors for IRS have been recognized in specific hosts. Summary IRS is a culmination of immunologic sequelae of host-pathogen interaction during evolution of an opportunistic infection, and as such the development of biomarkers that differentiate it from progressive disease would represent an important advance. Optimal management of immunosuppression and immunomodulatory approaches that target precise regulatory pathways for IRS warrant future investigations. C1 [Singh, Nina] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gupta, Ashish O.] Univ Pittsburgh, Childrens Hosp, Div Hematol & Oncol, Pittsburgh, PA 15260 USA. RP Singh, N (reprint author), VA Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu FU Pfizer FX N.S. has received investigator-initiated grant support from Pfizer. NR 71 TC 15 Z9 15 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD DEC PY 2011 VL 24 IS 6 BP 527 EP 533 DI 10.1097/QCO.0b013e32834ab20a PG 7 WC Infectious Diseases SC Infectious Diseases GA 841FB UT WOS:000296496800003 PM 22025021 ER PT J AU Kraft, S Mackler, E Schlickman, P Welch, K DePestel, DD AF Kraft, Shawna Mackler, Emily Schlickman, Peter Welch, Kathy DePestel, Daryl D. TI Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Daptomycin; Linezolid; Vancomycin-resistant enterococci; Hematology; Bone marrow transplant; Bacteremia ID GRAM-POSITIVE INFECTIONS; BLOOD-STREAM INFECTION; FAECIUM BACTEREMIA; RISK-FACTORS; DAPTOMYCIN; MORTALITY; NEUTROPENIA; MULTICENTER; IMPACT AB The purpose of this study was to evaluate the risk factors associated with the treatment failure and 30-day mortality in hematology and bone marrow transplant patients treated with daptomycin or linezolid for vancomycin-resistant enterococci (VRE) bacteremia. The safety and tolerability of therapy was also assessed. This single-center, retrospective study included adult patients admitted to the hematology or bone marrow transplant service with documented vancomycin-resistant Enterococcus faecium or Enterococcus faecalis bacteremia and received at least 48 h of either linezolid or daptomycin as primary treatment. Clinical and microbiologic outcomes were assessed at day 7, 14, and 30 of hospital stay. A total of 72 patients were included in the analysis. Forty-three patients received daptomycin as primary treatment and 29 received linezolid as primary treatment. Overall success rate at day 7 was 81.9%, day 14 success rate was 79.2%, and day 30 success rate was 76.4% for all patients. Forty-one patients (57.0%) had high-grade bacteremia defined as greater than one positive blood culture for VRE. The mortality rate was significantly higher if high-grade bacteremia was present (34.1% vs. 7.0%; p = 0.009). This study suggests that linezolid and daptomycin are both reasonable options for treating VRE bacteremia in hematology and bone marrow transplant patients; however, patients with high-grade VRE bacteremia may be at increased risk for treatment failure. C1 [Kraft, Shawna; Mackler, Emily; DePestel, Daryl D.] Univ Michigan Hlth Syst, Dept Pharm, Ann Arbor, MI 48109 USA. [Schlickman, Peter] Denver VA Med Ctr, Dept Pharm, Denver, CO 80220 USA. [Welch, Kathy] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA. RP Kraft, S (reprint author), Univ Michigan Hlth Syst, Dept Pharm, Ann Arbor, MI 48109 USA. EM svandeko@umich.edu FU Cubist Pharmaceuticals FX Dr. DePestel is a consultant for Pfizer and Cubist Pharmaceuticals and has received funding for other projects from Cubist Pharmaceuticals. All other authors have nothing to disclose. NR 19 TC 24 Z9 25 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD DEC PY 2011 VL 19 IS 12 BP 1969 EP 1974 DI 10.1007/s00520-010-1038-z PG 6 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 839KA UT WOS:000296362900010 PM 21110047 ER PT J AU Jardin, BF LaRowe, SD Hall, BJ Malcolm, RJ AF Jardin, Bianca F. LaRowe, Steven D. Hall, Brian J. Malcolm, Robert J. TI The Obsessive Compulsive Cocaine Scale: Assessment of factor structure, reliability, and validity SO ADDICTIVE BEHAVIORS LA English DT Article DE Obsessive Compulsive Cocaine Scale; Cocaine; Confirmatory factor analysis; Psychometric properties ID DRINKING-SCALE; FIT INDEXES; ALCOHOL; BEHAVIOR; OCDS; QUANTIFICATION; QUESTIONNAIRE; DEPENDENCE; GOODNESS AB The present study assessed the factor structure, reliability, test retest, convergent validity, and predictive validity of the Obsessive Compulsive Cocaine Scale (OCCS), a newly developed questionnaire adapted from the Obsessive Compulsive Drinking Scale (OCDS). The questionnaire was administered to 189 cocaine-dependent individuals participating in two medication treatment trials for cocaine dependence. Confirmatory factor analysis of this measure revealed that it primarily assesses two factors, obsessions and compulsions. In addition, the data provided strong support for the internal consistency, test-retest reliability, predictive validity, and convergent validity of this two-factor measure. Overall, the data provide support for the psychometric strength of a modified version of the OCDS specifically designed to assess obsessive and compulsive cocaine use among those with cocaine dependence. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Jardin, Bianca F.; LaRowe, Steven D.; Hall, Brian J.] Charleston Consortium Psychol Internship Training, Charleston, SC 29425 USA. [LaRowe, Steven D.; Malcolm, Robert J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA. [LaRowe, Steven D.] Ralph H Johnson VAMC, Charleston, SC 29401 USA. RP Jardin, BF (reprint author), Charleston Consortium Psychol Internship Training, 67 President St, Charleston, SC 29425 USA. EM jardin@musc.edu OI Hall, Brian/0000-0001-9358-2377; LaRowe, Steven/0000-0002-7664-2451 FU NIDA [DA019903, DA016368] FX Funding for this study was provided by NIDA grants DA019903 and DA016368. NIDA had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication. NR 29 TC 2 Z9 2 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD DEC PY 2011 VL 36 IS 12 BP 1223 EP 1227 DI 10.1016/j.addbeh.2011.07.028 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 836LZ UT WOS:000296114500016 PM 21862227 ER PT J AU Paul, LA Grubaugh, AL Frueh, BC Ellis, C Egede, LE AF Paul, Lisa A. Grubaugh, Anouk L. Frueh, B. Christopher Ellis, Charles Egede, Leonard E. TI Associations between binge and heavy drinking and health behaviors in a nationally representative sample SO ADDICTIVE BEHAVIORS LA English DT Article DE Binge drinking; Heavy drinking; Health behaviors; Preventive care; BUSS ID ALCOHOL-CONSUMPTION; ADULTS; RISK; POPULATION; PATTERNS; DEFINITIONS; PREVALENCE; SERVICES; WOMEN; OLDER AB Background: Binge and heavy drinking are noted in the literature for their relatively high prevalence and adverse health-related effects. Design and participants: We used data from the 2006 Behavioral Risk Factor Surveillance Survey (BRFSS) to determine the associations between binge and heavy drinking and a wide range of health-related variables, including positive and negative health behaviors, preventive care practices, and quality of life indices in a nationally representative sample of 344,793 adults. Results: Rates of binge and heavy drinking in the current sample were 15% and 5%, respectively. Binge and heavy drinking were more common among men, younger adults, and individuals with higher incomes and at least some college education. After controlling for relevant demographic variables, binge and heavy drinking were associated with a number of adverse health-related and preventive care behaviors (e.g., smoking, failing to receive a mammogram), as well as less life satisfaction and a greater number of poor mental health days than those who did not engage in these drinking behaviors. Interestingly, binge and heavy drinking were also associated with some positive health-related variables (e.g., recent physical activity, positive perceptions of one's own health). Conclusions: The current study findings provide additional information regarding the relations between health-related attitudes and behaviors and binge and heavy drinking in the U.S. population. Implications of study findings are discussed. Published by Elsevier Ltd. C1 [Paul, Lisa A.; Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Grubaugh, Anouk L.; Ellis, Charles; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA REAP, Charleston, SC USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. [Ellis, Charles] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. RP Grubaugh, AL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, POB 250861, Charleston, SC 29425 USA. EM grubaugh@musc.edu FU NIDDK NIH HHS [K24 DK093699]; NIMH NIH HHS [T32 MH018869] NR 33 TC 18 Z9 19 U1 0 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD DEC PY 2011 VL 36 IS 12 BP 1240 EP 1245 DI 10.1016/j.addbeh.2011.07.034 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 836LZ UT WOS:000296114500019 PM 21868171 ER PT J AU Estrada, CA Krishnamoorthy, P Smith, A Staton, L Korf, MJ Allison, JJ Houston, TK AF Estrada, Carlos A. Krishnamoorthy, Periyakaruppan Smith, Ann Staton, Lisa Korf, Michele J. Allison, Jeroan J. Houston, Thomas K. TI Marketing to Increase Participation in a Web-Based Continuing Medical Education Cultural Competence Curriculum SO JOURNAL OF CONTINUING EDUCATION IN THE HEALTH PROFESSIONS LA English DT Article DE marketing; continuing medical education; Internet; Web; online; cultural competence ID ONLINE CME AB Introduction: CME providers may be interested in identifying effective marketing strategies to direct users to specific content. Online advertisements for recruiting participants into activities such as clinical trials, public health programs, and continuing medical education (CME) have been effective in some but not all studies. The purpose of this study was to compare the impact of 2 marketing strategies in the context of an online CME cultural competence curriculum (www.c-comp.org). Methods: In an interrupted time-series quasi-experimental design, 2 marketing strategies were tested: (1) wide dissemination to relevant organizations over a period of approximately 4 months, and (2) Internet paid search using Google Ads (5 consecutive 8-week periods-control 1, cultural/CME advertisement, control 2, hypertension/content advertisement, control 3). Outcome measures were CME credit requests, Web traffic (visits per day, page views, pages viewed per visit), and cost. Results: Overall, the site was visited 19,156 times and 78,160 pages were viewed. During the wide dissemination phase, the proportion of visits requesting CME credit decreased between the first (5.3%) and second (3.3%) halves of this phase (p = .04). During the Internet paid search phase, the proportion of visits requesting CME credit was highest during the cultural/CME advertisement period (control 1, 1.4%; cultural/CME ad, 4.3%; control 2, 1.5%; hypertension/content ad, 0.6%; control 3, 0.8%; p < .001). All measures of Web traffic changed during the Internet paid search phase (p < .01); however, changes were independent of the advertisement periods. The incremental cost for the cultural advertisement per CME credit requested was US$0.64. Discussion: Internet advertisement focusing on cultural competence and CME was associated with about a threefold increase in requests for CME credit at an incremental cost of under US$1; however, Web traffic changes were independent of the advertisement strategy. C1 [Estrada, Carlos A.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Div Gen Internal Med, VA Natl Qual Scholars Program, Birmingham, AL 35294 USA. [Estrada, Carlos A.] Univ Alabama, DSCE, REAP Ctr Surg Med Acute Care Res & Transit C SMAR, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Krishnamoorthy, Periyakaruppan] Univ Alabama, Div Continuing Med Educ, Birmingham, AL 35294 USA. [Smith, Ann] Univ Alabama, Div Prevent Med, UAB Minor Hlth & Hlth Dispar Res Ctr, Birmingham, AL 35294 USA. [Staton, Lisa] Univ Tennessee, Coll Med Chattanooga, Knoxville, TN 37996 USA. [Houston, Thomas K.] Univ Massachusetts, Sch Med, CHQOER, Bedford VAMC, Amherst, MA 01003 USA. [Houston, Thomas K.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Amherst, MA 01003 USA. RP Estrada, CA (reprint author), Univ Alabama, Birmingham Vet Affairs Med Ctr, Div Gen Internal Med, VA Natl Qual Scholars Program, 732 Fac Off Tower,510 20th St S, Birmingham, AL 35294 USA. EM cestrada@uab.edu RI Houston, Thomas/F-2469-2013 OI Allison, Jeroan/0000-0003-4472-2112 FU National Heart, Lung, and Blood Institute [K07 HL081373-01] FX This study was funded by a grant from the National Heart, Lung, and Blood Institute (K07 HL081373-01) to Dr. Estrada; approved by the institutional review boards of the University of Alabama at Birmingham; and presented in part at the 2009 and 2010 Southern Society of General Internal Medicine Annual Meetings, New Orleans, Louisiana. The authors report no conflict of interest. NR 23 TC 4 Z9 4 U1 0 U2 4 PU WILEY PERIODICALS, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA SN 0894-1912 J9 J CONTIN EDUC HEALTH JI J. Contin. Educ. Health Prof. PD WIN PY 2011 VL 31 IS 1 BP 21 EP 27 DI 10.1002/chp.20097 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 738AL UT WOS:000288611600004 PM 21425356 ER PT J AU Qureshi, SU Long, ME Bradshaw, MR Pyne, JM Magruder, KM Kimbrell, T Hudson, TJ Jawaid, A Schulz, PE Kunik, ME AF Qureshi, Salah U. Long, Mary E. Bradshaw, Major R. Pyne, Jeffrey M. Magruder, Kathy M. Kimbrell, Timothy Hudson, Teresa J. Jawaid, Ali Schulz, Paul E. Kunik, Mark E. TI Does PTSD Impair Cognition Beyond the Effect of Trauma? SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; SMALLER HIPPOCAMPAL VOLUME; NEUROPSYCHOLOGICAL FUNCTION; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; WORKING-MEMORY; SURVIVORS; SYMPTOMS; VETERANS; DEFICITS AB This systematic review analyzed data from studies examining memory and cognitive function in subjects with posttraumatic stress disorder (PTSD), compared with subjects exposed to trauma (but without PTSD). Based on analysis of 21 articles published in English from 1968 to 2009, the conclusion is that individuals with PTSD, particularly veterans, show signs of cognitive impairment when tested with neuropsychological instruments, more so than individuals exposed to trauma who do not have PTSD. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23:16-28) C1 [Qureshi, Salah U.; Long, Mary E.; Kunik, Mark E.] Michael E DeBakey Vet Affairs VA Med Ctr, Hlth Serv Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Qureshi, Salah U.; Schulz, Paul E.] Baylor Coll Med, Neurosensory Ctr, Houston, TX 77030 USA. [Qureshi, Salah U.; Schulz, Paul E.] Michael E DeBakey VA Med Ctr, Neurol Care Line, Houston, TX USA. [Qureshi, Salah U.; Long, Mary E.; Kimbrell, Timothy; Kunik, Mark E.] Baylor Coll Med, VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX 77030 USA. [Bradshaw, Major R.; Jawaid, Ali; Schulz, Paul E.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Pyne, Jeffrey M.; Kimbrell, Timothy; Hudson, Teresa J.] Univ Arkansas Med Sci, Ctr Mental Hlth & Outcomes Res, Cent Arkansas Vet Healthcare Syst, Coll Med, Little Rock, AR 72205 USA. [Pyne, Jeffrey M.; Kimbrell, Timothy; Hudson, Teresa J.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Little Rock, AR 72205 USA. [Magruder, Kathy M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Kunik, Mark E.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Kunik, ME (reprint author), Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe, Houston, TX 77030 USA. EM mkunik@bcm.tmc.edu RI Schueter, nicos/A-3625-2014 FU Houston Center for Quality of Care & Utilization Studies, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs [HFP90-020] FX This material is based on work supported in part by the Houston Center for Quality of Care & Utilization Studies, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs (HFP90-020).; The views expressed are those of the authors and do not necessarily reflect those of the VA or Baylor College of Medicine. NR 55 TC 49 Z9 50 U1 3 U2 16 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD WIN PY 2011 VL 23 IS 1 BP 16 EP 28 DI 10.1176/appi.neuropsych.23.1.16 PG 13 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 717VY UT WOS:000287076700028 PM 21304135 ER PT J AU Gordon, AJ Ettaro, L Rodriguez, KL Mocik, J Clark, DB AF Gordon, Adam J. Ettaro, Lorraine Rodriguez, Keri L. Mocik, John Clark, Duncan B. TI Provider, Patient, and Family Perspectives of Adolescent Alcohol Use and Treatment in Rural Settings SO JOURNAL OF RURAL HEALTH LA English DT Article DE Access to care; adolescents; alcohol abuse; geography; patient assessment ID RANDOMIZED CONTROLLED-TRIAL; HIGH-RISK DRINKING; PRIMARY-CARE; BRIEF INTERVENTION; COLLEGE-STUDENTS; SUBSTANCE-ABUSE; USE DISORDERS; SCREENING-TEST; PREVENTION; BEHAVIORS AB Purpose: We examined rural primary care providers' (PCPs) self-reported practices of screening, brief interventions, and referral to treatment (SBIRT) on adolescent alcohol use and examined PCPs', adolescents', and parents' attitudes regarding SBIRT on adolescent alcohol use in rural clinic settings. Methods: In 2007, we mailed surveys that inquired about alcohol-related knowledge, attitudes, and treatment practices of adolescent alcohol use to all PCPs in 8 counties in rural Pennsylvania who may have treated adolescents. We then conducted 7 focus groups of PCPs and their staffs (n = 3), adolescents (n = 2), and parents (n = 2) and analyzed the narratives using structured grounded theory, evaluating for consistent or discordant themes. Results: Twenty-seven PCPs from 7 counties returned the survey. While 92% of PCPs felt that routine screening for alcohol use should begin by age 14, 84% reportedly screened for alcohol use occasionally, and reportedly 32% screened all adolescent patients. The provider focus groups (n = 20 PCPs/staff) related that SBIRT for alcohol use for adolescents was not currently effective. Poor provider training, lack of alcohol screening tools, and lack of referral treatment options were identified barriers. Adolescents (n = 12) worried that physicians would not maintain confidentiality. Parents (n = 12) acknowledged a parental contribution to adolescent alcohol use. All groups indicated computer-based methods to screen for alcohol use among adolescents may facilitate PCP engagement. Conclusions: Despite awareness that rural adolescent alcohol use is a significant problem, PCPs, adolescents, and parents recognize that SBIRT for adolescent alcohol use in rural PCP settings is ineffective, but it may improve with computer-based screening and intervention techniques. C1 [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clincal Ctr, Pittsburgh, PA USA. [Gordon, Adam J.; Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gordon, Adam J.] Ctr Res Healthcare, Pittsburgh, PA USA. [Gordon, Adam J.; Ettaro, Lorraine; Mocik, John; Clark, Duncan B.] NW Penn Adolescent Alcohol Res Cooperat, Pittsburgh, PA USA. [Ettaro, Lorraine; Mocik, John] Univ Pittsburgh, Ctr Rural Hlth Practice, Bradford, PA USA. [Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Clark, Duncan B.] Pittsburgh Adolescent Alcohol Res Ctr, Pittsburgh, PA USA. [Gordon, Adam J.; Rodriguez, Keri L.; Clark, Duncan B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Gordon, AJ (reprint author), Mailcode 151-C-H,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM adam.gordon@va.gov FU National Institutes of Health (NIH), National Institute of Alcohol Abuse and Alcoholism (NIAAA) [U01AA016482, K02AA00291] FX This study was supported by the National Institutes of Health (NIH), National Institute of Alcohol Abuse and Alcoholism (NIAAA) from grants U01AA016482 (PI: Clark) and K02AA00291 (PI: Clark). The authors wish to acknowledge Margaret Krumm, BA, for her assistance in editing this manuscript. The authors affirm that they have listed everyone who has contributed significantly to the work of this manuscript. For further information, contact: Adam J. Gordon, MD, MPH, FACP, FASAM, CHERP; Mailcode 151-C-H, 7180 Highland Drive, Pittsburgh, PA 15206; e-mail adam.gordon@va.gov. NR 45 TC 12 Z9 12 U1 2 U2 12 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0890-765X J9 J RURAL HEALTH JI J. Rural Health PD WIN PY 2011 VL 27 IS 1 BP 81 EP 90 DI 10.1111/j.1748-0361.2010.00321.x PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 702JZ UT WOS:000285891700010 PM 21204975 ER PT J AU Dohgu, S Fleegal-DeMotta, MA Banks, WA AF Dohgu, Shinya Fleegal-DeMotta, Melissa A. Banks, William A. TI Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is mediated by luminal microvessel IL-6 and GM-CSF SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Blood-brain barrier; Human immunodeficiency virus type 1; Lipopolysaccharide; Interleukin-6; Granulocyte-macrophage colony-stimulating factor; Mitogen-activated protein kinase ID TUMOR-NECROSIS-FACTOR; IMMUNODEFICIENCY-VIRUS-INFECTION; JUNCTION PROTEIN EXPRESSION; ENDOTHELIAL-CELLS; IN-VITRO; ADSORPTIVE ENDOCYTOSIS; SURFACE-PROTEINS; PERMEABILITY; CYTOKINES; ACTIVATION AB Elevated levels of cytokines/chemokines contribute to increased neuroinvasion of human immunodeficiency virus type 1 (HIV-1). Previous work showed that lipopolysaccharide (LPS), which is present in the plasma of patients with HIV-1, enhanced transcellular transport of HIV-1 across the blood-brain barrier (BBB) through the activation of p38 mitogen-activated protein kinase (MAPK) signaling in brain microvascular endothelial cells (BMECs). Here, we found that LPS (100 mu g/mL, 4 hr) selectively increased interleukin (IL)-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) release from BMECs. The enhancement of HIV-1 transport induced by luminal LPS was neutralized by treatment with luminal, but not with abluminal, antibodies to IL-6 and GM-CSF without affecting paracellular permeability as measured by transendothelial electrical resistance (TEER). Luminal, but not abluminal, IL-6 or GMCSF also increased HIV-1 transport. U0126 (MAPK kinase (MEK) 1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) decreased the LPS-enhanced release of IL-6 and GM-CSF. These results show that p44/42 and p38 MAPK signaling pathways mediate the LPS-enhanced release of IL-6 and GM-CSF. These cytokines, in turn, act at the luminal surface of the BMEC to enhance the transcellular transport of HIV-1 independently of actions on paracellular permeability. C1 [Dohgu, Shinya; Fleegal-DeMotta, Melissa A.; Banks, William A.] Geriatr Res Educ & Clin Ctr St Louis, St Louis, MO USA. [Dohgu, Shinya] Fukuoka Univ, Fac Pharmaceut Sci, Dept Pharmaceut Care & Hlth Sci, Fukuoka 81401, Japan. [Dohgu, Shinya; Fleegal-DeMotta, Melissa A.; Banks, William A.] St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr Med, St Louis, MO 63103 USA. [Fleegal-DeMotta, Melissa A.] Clarke Univ, Dept Biol, Dubuque, IA USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Banks, William A.] Univ Washington, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Banks, WA (reprint author), Geriatr Res Educ & Clin Ctr St Louis, St Louis, MO USA. EM wabanks1@uw.edu FU National Cancer Institute, National Institutes of Health [N01-CO-12400]; VA Merit Review; NIH [R01NS050547, R01AG029839] FX The authors thank Dr. Maria A. Deli (Institute of Biophysics, Biological Research Centre of the Hungarian Academy of Sciences) for technical advice on primary BMEC culture and comments on this study. The virus was a kind gift the National Cancer Institute, National Institutes of Health. Funded in part with Federal funds from National Cancer Institute, National Institutes of Health, under Contract No. N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of names, commercial products, or organization imply endorsement by the U. S. government. Supported by VA Merit Review (WAB), NIH R01NS050547 (WAB), and NIH R01AG029839 (WAB). NR 53 TC 26 Z9 26 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD NOV 30 PY 2011 VL 8 AR 167 DI 10.1186/1742-2094-8-167 PG 12 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 878SK UT WOS:000299276600001 PM 22129063 ER PT J AU Li, XB Large, CH Ricci, R Taylor, JJ Nahas, Z Bohning, DE Morgan, P George, MS AF Li, Xingbao Large, Charles H. Ricci, Raffaella Taylor, Joseph J. Nahas, Ziad Bohning, Daryl E. Morgan, Paul George, Mark S. TI Using interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (fMRI) and dynamic causal modeling to understand the discrete circuit specific changes of medications: Lamotrigine and valproic acid changes in motor or prefrontal effective connectivity SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Transcranial magnetic stimulation; Neuroimaging; Dynamic causal modeling; Network; Lamotrigine; Valproic acid ID ANTIEPILEPTIC DRUGS; BIPOLAR DISORDER; CORTICAL EXCITABILITY; TMS; CORTEX; MECHANISMS; SYSTEM; MOOD; MRI; DEPRESSION AB The purpose of this study was to use interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (TMS/fMRI) to investigate the effects of lamotrigine (LTG) and valproic acid (VPA) on effective connectivity within motor and corticolimbic circuits. In this randomized, double-blind, crossover trial, 30 healthy volunteers received either drug or placebo 3.5 h prior to interleaved TMS/fMRI. We utilized dynamic causal modeling (DCM) to assess changes in the endogenous effective connectivity of bidirectional networks in the motor-sensory system and corticolimbic circuit. Results indicate that both LTG and VPA have network-specific effects. When TMS was applied over the motor cortex, both LTG and VPA reduced TMS-specific effective connectivity between primary motor (M1) and pre-motor cortex (PMd), and between M1 and the supplementary area motor (SMA). When TMS was applied over prefrontal cortex, however, LTG alone increased TMS-specific effective connectivity between the left dorsolateral prefrontal cortex (DLPFC) and the anterior cingulate cortex (ACC). In summary, LTG and VPA both inhibited effective connectivity in motor circuits, but LTG alone increased effective connectivity in prefrontal circuits. These results suggest that interleaved TMS/fMRI can assess region- and circuit-specific effects of medications or interventions. Published by Elsevier Ireland Ltd. C1 [Li, Xingbao] Med Univ S Carolina, Brain Stimulat Lab, MUSC IOP, Dept Psychiat, Charleston, SC 29425 USA. [Li, Xingbao; Taylor, Joseph J.; Bohning, Daryl E.; Morgan, Paul; George, Mark S.] Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [Large, Charles H.] GlaxoSmithKline SpA, Med Res Ctr, Verona, Italy. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Li, XB (reprint author), Med Univ S Carolina, Brain Stimulat Lab, MUSC IOP, Dept Psychiat, 502 N,67 President St, Charleston, SC 29425 USA. EM lixi@musc.edu FU GlaxoSmithKline; Center for Advanced Imaging Research; Brain Stimulation Laboratory FX This study was funded primarily by an unrestricted research grant from GlaxoSmithKline to Dr. George, as well as from Center for Advanced Imaging Research and Brain Stimulation Laboratory infrastructure and resources. CHL is a full-time employee of GlaxoSmithKline S.p.A. None of the other authors has equity or financial conflicts. Drs. Li and George had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Presented in abstract form at the annual meeting of American College of Neuropsychopharmacology, Hollywood, FL, Dec 14, 2006 and the annual meeting of the Society of Biological Psychiatry, San Diego, CA, May 21, 2007. NR 50 TC 15 Z9 15 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD NOV 30 PY 2011 VL 194 IS 2 BP 141 EP 148 DI 10.1016/j.pscychresns.2011.04.012 PG 8 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 843QD UT WOS:000296686200005 PM 21924874 ER PT J AU Levine, DA Funkhouser, EM Houston, TK Gerald, JK Johnson-Roe, N Allison, JJ Richman, J Kiefe, CI AF Levine, Deborah A. Funkhouser, Ellen M. Houston, Thomas K. Gerald, Joe K. Johnson-Roe, Nancy Allison, Jeroan J. Richman, Joshua Kiefe, Catarina I. TI Improving Care After Myocardial Infarction Using a 2-Year Internet-Delivered Intervention The Department of Veterans Affairs Myocardial Infarction-Plus Cluster-Randomized Trial SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CORONARY-HEART-DISEASE; CONTINUOUS-QUALITY-IMPROVEMENT; RE-AIM FRAMEWORK; MEDICARE BENEFICIARIES; SECONDARY PREVENTION; MANAGEMENT PROGRAMS; CARDIAC-DISEASE; AMBULATORY-CARE; RISK-FACTORS; MI-PLUS AB Background: Cardiovascular risk reduction in ambulatory patients who survive myocardial infarction (MI) is effective but underused. We sought to evaluate a provider-directed, Internet-delivered intervention to improve cardiovascular management for post-MI outpatients. Methods: The Department of Veterans Affairs (VA) MI-Plus study was a cluster-randomized trial involving 168 community-based primary care clinics and 847 providers in 26 states, the Virgin Islands, and Puerto Rico, from January 1, 2002, through December 31, 2008, with the clinic as the randomization unit. We collected administrative data for 15 847 post-MI patients and medical record data for 10 452 of these. A multicomponent, Internet-delivered intervention included quarterly educational modules, practice guidelines, monthly literature summaries, and automated e-mail reminders delivered to providers for 27 months. Main outcome measures included percentage of patients who achieved each of 7 clinical indicators, a composite score of the 7 clinical indicators, and mean low-density lipoprotein cholesterol and hemoglobin A(1c) levels. Results: Clinics had a median of 3 providers (interquartile range, 2-6), with a median of 50.0% of providers (33.3%-66.7%) participating in the study. Patients in intervention clinics had greater improvements (from 70.0% to 85.5%) in the percentages prescribed beta-blockers than patients in control clinics (71.9% to 84.0%; adjusted improvement gain for intervention vs control, 2.6%; 95% CI, 0.1%-4.1%). We found nonsignificant differences in improvements favoring patients in intervention clinics for 5 of 6 remaining clinical indicators and levels of low-density lipoprotein cholesterol and hemoglobin A(1c). Conclusion: A longitudinal, Internet-delivered intervention improved only 1 of 7 clinical indicators of cardiovascular management in ambulatory post-MI patients. C1 [Levine, Deborah A.] Univ Michigan, Div Gen Med, Dept Med, Ann Arbor, MI 48109 USA. [Levine, Deborah A.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA. [Levine, Deborah A.] Ann Arbor Vet Affairs VA Healthcare Syst, Ann Arbor, MI USA. [Levine, Deborah A.; Funkhouser, Ellen M.] Univ Alabama Birmingham Sch Med, Dept Med, Birmingham, AL USA. [Richman, Joshua] Univ Alabama Birmingham Sch Med, Dept Surg, Birmingham, AL USA. [Johnson-Roe, Nancy; Richman, Joshua] Birmingham VA Med Ctr, VA Res Enhancement Award Program, Birmingham, AL USA. [Houston, Thomas K.; Allison, Jeroan J.; Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Allison, Jeroan J.; Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Transit Risks & Act Coronary Events Ctr Outcomes, Worcester, MA USA. [Houston, Thomas K.] Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Gerald, Joe K.] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Div Publ Hlth Policy & Management, Tucson, AZ USA. RP Levine, DA (reprint author), Univ Michigan, Div Gen Med, Dept Med, 300 N Ingalls St,Room 7C27, Ann Arbor, MI 48109 USA. EM deblevin@umich.edu RI Houston, Thomas/F-2469-2013 OI Allison, Jeroan/0000-0003-4472-2112 FU VA Health Services Research and Development office [IHD-04-387]; National Institutes of Health [R01 HL70786-02] FX This study was supported by grant IHD-04-387 from the VA Health Services Research and Development office and grant R01 HL70786-02 from the National Institutes of Health for a parallel study. NR 51 TC 8 Z9 8 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 28 PY 2011 VL 171 IS 21 BP 1910 EP 1917 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 853JV UT WOS:000297423000006 PM 22123798 ER PT J AU Alia, I de la Cal, MA Esteban, A Abella, A Ferrer, R Molina, FJ Torres, A Gordo, F Elizalde, JJ de Pablo, R Huete, A Anzueto, A AF Alia, Inmaculada de la Cal, Miguel A. Esteban, Andres Abella, Ana Ferrer, Ricard Molina, Francisco J. Torres, Antoni Gordo, Federico Elizalde, Jose J. de Pablo, Raul Huete, Alejandro Anzueto, Antonio TI Efficacy of Corticosteroid Therapy in Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease Receiving Ventilatory Support SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID ACUTE RESPIRATORY-FAILURE; INTENSIVE-CARE-UNIT; COMMUNITY-ACQUIRED PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; INVASIVE MECHANICAL VENTILATION; PLACEBO-CONTROLLED TRIAL; NONINVASIVE VENTILATION; SYSTEMIC GLUCOCORTICOIDS; DISTRESS-SYNDROME; CLINICAL-COURSE AB Background: Randomized trials assessing the effect of systemic corticosteroids on chronic obstructive pulmonary disease (COPD) exacerbations excluded patients who were mechanically ventilated or admitted to the intensive care unit (ICU). Critically ill patients constitute a population of persons who are prone to develop complications that are potentially associated with the use of corticosteroids (eg, infections, hyperglycemia, ICU-acquired paresis) that could prolong the duration of mechanical ventilation and even increase mortality. Methods: A double-blind placebo-controlled trial was conducted to evaluate the efficacy and safety of systemic corticosteroid treatment in patients with an exacerbation of COPD who were receiving ventilatory support (invasive or noninvasive mechanical ventilation). A total of 354 adult patients who were admitted to the ICUs of 8 hospitals in 4 countries from July 2005 through July 2009 were screened, and 83 were randomized to receive intravenous methylprednisolone (0.5 mg/kg every 6 hours for 72 hours, 0.5 mg/kg every 12 hours on days 4 through 6, and 0.5 mg/kg/d on days 7 through 10) or placebo. The main outcome measures were duration of mechanical ventilation, length of ICU stay, and need for intubation in patients treated with noninvasive mechanical ventilation. Results: There were no significant differences between the groups in demographics, severity of illness, reasons for COPD exacerbation, gas exchange variables, and corticosteroid rescue treatment. Corticosteroid treatment was associated with a significant reduction in the median duration of mechanical ventilation (3 days vs 4 days; P=.04), a trend toward a shorter median length of ICU stay (6 days vs 7 days; P=.09), and significant reduction in the rate of NIV failure (0% vs 37%; P=.04). Conclusion: Systemic corticosteroid therapy in patients with COPD exacerbations requiring mechanical ventilation is associated with a significant increase in the success of noninvasive mechanical ventilation and a reduction in the duration of mechanical ventilation C1 [Alia, Inmaculada; de la Cal, Miguel A.; Esteban, Andres; Abella, Ana; Huete, Alejandro] Hosp Univ Getafe, Intens Care Units ICUs, Ctr Invest Biomed Red Enfermedades Resp CIBERes, Getafe, Spain. [Ferrer, Ricard] Consorci Hosp Parc Tauli, CIBERes, Sabadell, Spain. [Torres, Antoni] Hosp Clin Barcelona, CIBERes, Barcelona, Spain. [Molina, Francisco J.] Clin Univ Bolivariana, ICU, Medellin, Colombia. [Gordo, Federico] Hosp Univ Fdn Alcorcon, ICU, Madrid, Spain. [Elizalde, Jose J.] Hosp ABC, ICU, Mexico City, DF, Mexico. [de Pablo, Raul] Hosp Univ Principe Asturias, ICU, Alcala De Henares, Spain. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr, ICU, San Antonio, TX USA. [Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Esteban, A (reprint author), Hosp Getafe, Unidad Cuidados Intens, Carretera Toledo Km 12-5, Getafe 28905, Spain. EM aesteban@ucigetafe.com FU Fondo de Investigacion Sanitaria [PI041233] FX This study was funded in part by grant PI041233 from Fondo de Investigacion Sanitaria. NR 44 TC 30 Z9 30 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 28 PY 2011 VL 171 IS 21 BP 1939 EP 1946 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 853JV UT WOS:000297423000013 PM 22123804 ER PT J AU Tallaj, JA Pamboukian, SV George, JF Brown, RN Pajaro, OE Bourge, RC Cadeiras, M Smallfield, M Kirklin, JK McGiffin, DC AF Tallaj, Jose A. Pamboukian, Salpy V. George, James F. Brown, Robert N. Pajaro, Octavio E. Bourge, Robert C. Cadeiras, Martin Smallfield, Melissa Kirklin, James K. McGiffin, David C. TI Total Lymphoid Irradiation in Heart Transplantation: Long-Term Efficacy and Survival-An 18-Year Experience SO TRANSPLANTATION LA English DT Article DE Total lymphoid irradiation; Outcomes; Heart transplantation ID RISK-FACTORS; LUNG TRANSPLANTATION; CARDIAC TRANSPLANTATION; RECURRENT REJECTION; ALLOGRAFT-REJECTION; HODGKINS-DISEASE; IMMUNOSUPPRESSION; DEATH AB Background. Total lymphoid irradiation (TLI) has been used in transplantation for over 20 years and is currently used in a number of major heart transplant centers as a secondary therapy for recalcitrant recurrent rejection or rejection with hemodynamic compromise. The purpose of this study is to evaluate the long-term risks and efficacy of TLI in the treatment of rejection. Methods. Between 1990 and 1996, 73 adult patients (from 211 adult transplant recipients) received TLI for recurrent rejection (71%), rejection with hemodynamic compromise (25%), and rejection with vasculitis (4%). The treatment consisted of 80 cGy twice per week for 5 weeks. Fifty-five patients received at least 80% of the full dose (>640 cGy). Follow-up ended December 31, 2007, comprising a total 18 year experience. Results. Patients treated with TLI exhibited a short-term decrease in hazard for rejection in the first 12 months posttransplantation (relative risk, 0.36) but exhibited increased cumulative rejection over the long term. There were no differences in the rates of infection, allograft coronary disease, or malignancy, but seven patients developed myelodysplasia or acute myelogenous leukemia, four of those being the rare but uniformly fatal acute megakaryocytic leukemia type 7. Conclusions. Patients treated with TLI seemed to experience a reduction in the early hazard for rejection, but long-term outcomes indicate that such patients continued to accumulate more rejection and rejection-death events, likely because these patients were overall at much higher risk for rejection than the other patient groups. We observed minimal long-term complications, except for the unique occurrence of myelodysplasia and acute megakaryocytic leukemia type 7. C1 [Tallaj, Jose A.; Pamboukian, Salpy V.; Bourge, Robert C.; Cadeiras, Martin; Smallfield, Melissa] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Tallaj, Jose A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. [George, James F.; Brown, Robert N.; Pajaro, Octavio E.; Kirklin, James K.; McGiffin, David C.] Univ Alabama Birmingham, Dept Med, Div Cardiothorac Surg, Birmingham, AL 35294 USA. RP Tallaj, JA (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, THT331,1900 Univ Blvd, Birmingham, AL 35294 USA. EM jtallaj@uab.edu NR 30 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2011 VL 92 IS 10 BP 1159 EP 1164 DI 10.1097/TP.0b013e318231e9d3 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 845BP UT WOS:000296798100021 PM 22015463 ER PT J AU Shen, Q Huang, SL Du, F Duong, TQ AF Shen, Qiang Huang, Shiliang Du, Fang Duong, Timothy Q. TI Probing ischemic tissue fate with BOLD fMRI of brief oxygen challenge SO BRAIN RESEARCH LA English DT Article DE MRI; Perfusion; Diffusion; Oxygen inhalation; Penumbra ID CEREBRAL-BLOOD-FLOW; FUNCTIONAL MRI; QUANTITATIVE PREDICTION; FOCAL ISCHEMIA; PERFUSION; HYPEROXIA; DIFFUSION; PENUMBRA; STROKE; RATS AB It has been recently shown that at-risk tissue exhibits exaggerated T*(2)-weighted MRI signal increases during transient oxygen challenge (OC), suggesting that the tissue is still metabolically active. This study further characterized the effects of transient OC on T*(2)-weighted MRI in permanent focal stroke rats (N=8) using additional quantitative measures. The major findings were: i) the ischemic core cluster showed no significant response, whereas the mismatch cluster showed markedly higher percent changes relative to normal tissue in the acute phase. ii) Many of the mismatch pixels showed exaggerated OC responses which became hyperintense on T(2)-weighted MRI at 24 h. The area with exaggerated OC responses was larger than the mismatch, suggesting that some tissue with reduced diffusion were potentially at risk. iii) Basal T*(2)-weighted intensities on the perfusion-diffusion contourplot were high in normal tissue and low in the core, with a sharp transition in the mismatch. iv) OC-induced changes on the perfusion-diffusion contourplot dropped as perfusion and diffusion values fell below their respective viability thresholds. v) Basal T(1) increased slightly in the ischemic core (P<0.05). OC decreased T(1) in normal (P<0.05) but not in mismatch and core pixels. vi) OC decreased CBF in normal (P<0.05) but not in mismatch and core pixels. T*(2)-weighted MRI of OC has the potential to offer unique clinically relevant data. (C) 2011 Elsevier B.V. All rights reserved. C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol Radiol & Physiol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol Radiol & Physiol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008; Shen, Qiang/B-8784-2008; Huang, Shiliang/F-3143-2010 OI Shen, Qiang/0000-0002-4287-3403; FU NIH [R01-NS45879]; American Heart Association [ELA 0940104 N, SDG 0830293 N]; Clinical and Translational Science Awards [UL1RR025767] FX This work was supported by the NIH (R01-NS45879), the American Heart Association (EIA 0940104 N and SDG 0830293 N) and Clinical and Translational Science Awards (parent grant UL1RR025767). NR 28 TC 17 Z9 18 U1 1 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD NOV 24 PY 2011 VL 1425 BP 132 EP 141 DI 10.1016/j.brainres.2011.09.052 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 862VN UT WOS:000298122300014 PM 22032876 ER PT J AU Bokov, AF Garg, N Ikeno, Y Thakur, S Musi, N DeFronzo, RA Zhang, N Erickson, RC Gelfond, J Hubbard, GB Adamo, ML Richardson, A AF Bokov, Alex F. Garg, Neha Ikeno, Yuji Thakur, Sachin Musi, Nicolas DeFronzo, Ralph A. Zhang, Ning Erickson, Rebecca C. Gelfond, Jon Hubbard, Gene B. Adamo, Martin L. Richardson, Arlan TI Does Reduced IGF-1R Signaling in Igf1r(+/-) Mice Alter Aging? SO PLOS ONE LA English DT Article ID GROWTH-FACTOR-I; LIFE-SPAN EXTENSION; FATAL NEOPLASTIC DISEASES; AMES DWARF MICE; INSULIN-RECEPTOR; CAENORHABDITIS-ELEGANS; CALORIE RESTRICTION; DELAYED OCCURRENCE; LONGEVITY; GENE AB Mutations in insulin/IGF-1 signaling pathway have been shown to lead to increased longevity in various invertebrate models. Therefore, the effect of the haplo-insufficiency of the IGF-1 receptor (Igf1r(+/-)) on longevity/aging was evaluated in C57Bl/6 mice using rigorous criteria where lifespan and end-of-life pathology were measured under optimal husbandry conditions using large sample sizes. Igf1r(+/-) mice exhibited reductions in IGF-1 receptor levels and the activation of Akt by IGF-1, with no compensatory increases in serum IGF-1 or tissue IGF-1 mRNA levels, indicating that the Igf1r(+/-) mice show reduced IGF-1 signaling. Aged male, but not female Igf1r(+/-) mice were glucose intolerant, and both genders developed insulin resistance as they aged. Female, but not male Igf1r(+/-) mice survived longer than wild type mice after lethal paraquat and diquat exposure, and female Igf1r(+/-) mice also exhibited less diquat-induced liver damage. However, no significant difference between the lifespans of the male Igf1r(+/-) and wild type mice was observed; and the mean lifespan of the Igf1r(+/-) females was increased only slightly (less than 5%) compared to wild type mice. A comprehensive pathological analysis showed no significant difference in end-of-life pathological lesions between the Igf1r(+/-) and wild type mice. These data show that the Igf1r(+/-) mouse is not a model of increased longevity and delayed aging as predicted by invertebrate models with mutations in the insulin/IGF-1 signaling pathway. C1 [Bokov, Alex F.; Ikeno, Yuji; Musi, Nicolas; Gelfond, Jon; Hubbard, Gene B.; Adamo, Martin L.; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Bokov, Alex F.; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Garg, Neha; Thakur, Sachin; Adamo, Martin L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Gelfond, Jon] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Ikeno, Yuji; Hubbard, Gene B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Musi, Nicolas; DeFronzo, Ralph A.; Zhang, Ning] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ikeno, Yuji; Musi, Nicolas; Richardson, Arlan] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Erickson, Rebecca C.] Univ Texas Austin, Coll Nat Sci, Austin, TX 78712 USA. RP Bokov, AF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. EM Richardson@uthscsa.edu FU National Institutes of Health (NIH) [AGO-21890]; Beeson Career Development Award [AG-030979, DK-80157, DK-089229, DK-24092 RAD, R01AG026012, AG-19316, AG-13319, AG-23843, AG-26557]; Nathan Shock [1P30-AG-13319]; Department of Veteran's Affairs; University of Texas System FX This work was supported by National Institutes of Health (NIH) (http://grants.nih.gov/grants/oer.htm) AGO-21890 to AFB; AG-030979 (Beeson Career Development Award), DK-80157 and DK-089229 to NM; DK-24092 RAD; R01AG026012 to MLA; AG-19316, AG-13319, AG-23843, and AG-26557 to AR; Nathan Shock: 1P30-AG-13319 to AR; Department of Veteran's Affairs: Research Enhancement Award Program, Merit Grant to AR; and University of Texas System's Graduate Programs Initiative: Translational Science Training (TST) Across Disciplines to NG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 49 Z9 50 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 23 PY 2011 VL 6 IS 11 AR e26891 DI 10.1371/journal.pone.0026891 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 863KL UT WOS:000298162000007 PM 22132081 ER PT J AU Dubin, R Li, YM Ix, JH Shlipak, M Whooley, M Peralta, CA AF Dubin, Ruth Li, Yongmei Ix, Joachim H. Shlipak, Michael Whooley, Mary Peralta, Carmen A. TI Associations of Pentraxin-3 With Cardiovascular Events, Incident Heart Failure and Mortality Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study SO CIRCULATION LA English DT Meeting Abstract DE Biomarkers; Heart failure; Renal function; Epidemiology C1 [Dubin, Ruth; Peralta, Carmen A.] UC San Francisco, San Francisco, CA USA. [Li, Yongmei; Shlipak, Michael; Whooley, Mary] San Francisco VA Med Ctr, San Francisco, CA USA. [Ix, Joachim H.] UC San Diego, La Jolla, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A15991 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738707258 ER PT J AU Dubin, R Schiller, NB Teerlink, JR Alokozai, D Johansen, K AF Dubin, Ruth Schiller, Nelson B. Teerlink, John R. Alokozai, Dean Johansen, Kirsten TI Dialysis-Related Symptoms are Associated with Deterioration of Cardiac Function During Dialysis SO CIRCULATION LA English DT Meeting Abstract DE Kidney; Diastolic function; Ejection fraction C1 [Dubin, Ruth; Schiller, Nelson B.; Johansen, Kirsten] UC San Francisco, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Alokozai, Dean] Cardiocore, Echocardiog, San Francisco, CA USA. RI Teerlink, John/D-2986-2012 NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A11164 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738703153 ER PT J AU Felker, GM Tang, WHW Hernandez, AF Hasselblad, V Armstrong, PW Fonarow, GC Voors, AA Metra, M Butler, J Dickstein, K Troughton, RW Anker, SD Heizer, GM Massie, BM McMurray, JJ Califf, RM Starling, RC O'Connor, CM AF Felker, G. Michael Tang, W. H. Wilson Hernandez, Adrian F. Hasselblad, Vic Armstrong, Paul W. Fonarow, Gregg C. Voors, Adriaan A. Metra, Marco Butler, Javed Dickstein, Kenneth Troughton, Richard W. Anker, Stefan D. Heizer, Gretchen M. Massie, Barry M. McMurray, John J. Califf, Robert M. Starling, Randall C. O'Connor, Christopher M. TI High Sensitivity Troponin I in Acute Decompensated Heart Failure: Insights from the ASCEND-HF Study SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association/Resuscitation Science Symposium CY NOV 12-16, 2011 CL Orlando, FL SP Amer Heart Assoc DE Biomarkers C1 [Felker, G. Michael; Hernandez, Adrian F.; Hasselblad, Vic; Heizer, Gretchen M.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Rsch Inst, Durham, NC USA. [Tang, W. H. Wilson; Starling, Randall C.] Cleveland Clin, Cleveland, OH 44106 USA. [Armstrong, Paul W.] Univ Alberta, Edmonton, AB, Canada. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Metra, Marco] Univ Brescia, Brescia, Italy. [Butler, Javed] Emory Univ, Atlanta, GA 30322 USA. [Dickstein, Kenneth] Univ Bergen, Inst Internal Med, Stavanger Univ Hosp, Bergen, Norway. [Troughton, Richard W.] Univ Otago, Christchurch, New Zealand. [Anker, Stefan D.] Appl Cachexia Rsch, Dept Cardiol, Berlin, Germany. [Massie, Barry M.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [McMurray, John J.] Univ Glasgow, Glasgow, Lanark, Scotland. [Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA. RI Tang, Wai Hong/I-1238-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A13262 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738705098 ER PT J AU Lam, CS Anand, IS Carson, PE Massie, BM Rector, TS Kuskowski, M McKelvie, RS Zile, MR McMurray, JJ Komajda, M Kitzman, DW AF Lam, Carolyn S. Anand, Inder S. Carson, Peter E. Massie, Barry M. Rector, Thomas S. Kuskowski, Michael McKelvie, Robert S. Zile, Michael R. McMurray, John J. Komajda, Michel Kitzman, Dalane W. TI Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients with Heart Failure and Preserved Ejection Fraction: The I-PRESERVE Trial SO CIRCULATION LA English DT Meeting Abstract C1 [Lam, Carolyn S.] Natl Univ Hlth Syst, Natl Univ Heart Ctr Singapore, Singapore, Singapore. [Anand, Inder S.; Rector, Thomas S.; Kuskowski, Michael] Vet Adm Med Ctr, Minneapolis, MN 55417 USA. [Anand, Inder S.] Univ Minnesota, Minneapolis, MN USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Carson, Peter E.] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Massie, Barry M.] Univ Calif San Francisco, Vet Affairs Med Ctr 111C, San Francisco, CA 94143 USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [McKelvie, Robert S.] McMaster Univ, Hamilton, ON, Canada. [Zile, Michael R.] RHJ Dept Vet Affairs Med Ctr, Dept Med, Div Cardiol, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [McMurray, John J.] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Rsch Ctr, Glasgow, Lanark, Scotland. [Komajda, Michel] Univ Paris, Pitie Salpetriere Hosp, Dept Cardiol, F-75252 Paris, France. [Kitzman, Dalane W.] Wake Forest Univ, Dept Internal Med Cardiol & Geriatr, Sch Med, Winston Salem, NC 27109 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A10912 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738703086 ER PT J AU Miller, PS Evangelista, LS Giger, JN Martinez-Maza, O Corvera-Tindel, T Doering, LV AF Miller, Pamela S. Evangelista, Lorraine S. Giger, Joyce Newman Martinez-Maza, Otoniel Corvera-Tindel, Teresita Doering, Lynn V. TI Bypassing Troubles: Relation of Exhaustion, Viral Burden, and Inflammation to Depressive Symptoms After Cardiac Surgery SO CIRCULATION LA English DT Meeting Abstract DE Cardiac surgery; Coronary artery disease; Inflammation C1 [Miller, Pamela S.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Evangelista, Lorraine S.] Univ Calif Irvine, Coll Hlth Sci, Program Nursing Sci, Irvine, CA USA. [Giger, Joyce Newman; Doering, Lynn V.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Corvera-Tindel, Teresita] Vet Affairs Greater Los Angeles Hlth Care Syst, Nursing Rsch Dept, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A14769 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738706205 ER PT J AU Miller, PS Evangelista, LS Giger, JN Corvera-Tindel, T Martinez-Maza, O Dracup, K Doering, LV AF Miller, Pamela S. Evangelista, Lorraine S. Giger, Joyce Newman Corvera-Tindel, Teresita Martinez-Maza, Otoniel Dracup, Kathleen Doering, Lynn V. TI Who is at Risk for Exhaustion Post-Cardiac Surgery SO CIRCULATION LA English DT Meeting Abstract DE Coronary heart disease; Cardiac surgery C1 [Miller, Pamela S.; Dracup, Kathleen] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Evangelista, Lorraine S.] Univ Calif Irvine, Coll Hlth Sci, Program Nursing Sci 2, Irvine, CA USA. [Giger, Joyce Newman; Doering, Lynn V.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Corvera-Tindel, Teresita] Vet Affairs Greater Los Angeles Hlth Care Syst, Nursing Rsch Dept, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A14574 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738706159 ER PT J AU Murray, DR Mummidi, S Valente, AJ Dinarello, CA Delafontaine, P Chandrasekar, B AF Murray, David R. Mummidi, Srinivas Valente, Anthony J. Dinarello, Charles A. Delafontaine, Patrice Chandrasekar, Bysani TI IL-18 Binding Protein (IL-18BP) Inhibits beta-AR Induced Cardiomyocyte Hypertrophy in vitro and Myocardial Hypertrophy in vivo SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophic cardiomyopathy; Heart failure; Inflammation; Signal transduction; Cardioprotection C1 [Murray, David R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Mummidi, Srinivas; Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Dinarello, Charles A.] Univ Colarado, Aurora, CO USA. [Delafontaine, Patrice; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA. RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A8393 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738701090 ER PT J AU Tang, WHW Felker, GM Hernandez, AF Hsu, AP Gottlieb, SS Voors, AA Butler, J Metra, M Anker, SD Troughton, RW McMurray, JJ Armstrong, PW Massie, BM Califf, RM O'Connor, CM Starling, RC AF Tang, W. H. Wilson Felker, G. Michael Hernandez, Adrian F. Hsu, Amy P. Gottlieb, Stephen S. Voors, Adriaan A. Butler, Javed Metra, Marco Anker, Stefan D. Troughton, Richard W. McMurray, John J. Armstrong, Paul W. Massie, Barry M. Califf, Robert M. O'Connor, Christopher M. Starling, Randall C. TI Baseline Cystatin C is Associated with Short-Term Adverse Events in Acute Heart Failure but Does Not Predict Treatment Effects with Nesiritide Therapy SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association/Resuscitation Science Symposium CY NOV 12-16, 2011 CL Orlando, FL SP Amer Heart Assoc DE Renal function C1 [Tang, W. H. Wilson; Hsu, Amy P.; Starling, Randall C.] Cleveland Clin, Cleveland, OH 44106 USA. [Felker, G. Michael; Hernandez, Adrian F.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Rsch Inst, Durham, NC USA. [Gottlieb, Stephen S.] Univ Maryland, Baltimore, MD 21201 USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Butler, Javed] Emory Univ, Atlanta, GA 30322 USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Anker, Stefan D.] Appl Cachexia Rsch, Dept Cardiol, Berlin, Germany. [Troughton, Richard W.] Univ Otago, Christchurch, New Zealand. [McMurray, John J.] Univ Glasgow, Glasgow, Lanark, Scotland. [Armstrong, Paul W.] Univ Alberta, Edmonton, AB, Canada. [Massie, Barry M.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA. RI Tang, Wai Hong/I-1238-2013 NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A13339 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738705119 ER PT J AU Tsai, TT Maddox, TM Nallamothu, BK Stanislawski, MA Adams, JC Box, TL Ho, PM Rao, SV Casserly, IP Rumsfeld, JS Brilakis, ES AF Tsai, Thomas T. Maddox, Thomas M. Nallamothu, Brahmajee K. Stanislawski, Maggie A. Adams, Jill C. Box, Tamara L. Ho, P. Michael Rao, Sunil V. Casserly, Ivan P. Rumsfeld, John S. Brilakis, Emmanouil S. TI Use and Effectiveness of Drug-Eluting versus Bare Metal Stents in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions: Insights from the National VA Clinical Assessment, Reporting and Tracking (CART) Program SO CIRCULATION LA English DT Meeting Abstract DE Percutaneous coronary intervention; Interventional cardiology; Drug eluting stents C1 [Tsai, Thomas T.; Maddox, Thomas M.; Stanislawski, Maggie A.; Adams, Jill C.; Box, Tamara L.; Ho, P. Michael; Casserly, Ivan P.; Rumsfeld, John S.] Denver VAMC, Denver, CO USA. [Nallamothu, Brahmajee K.] Ann Arbor VAMC, Ann Arbor, MI USA. [Rao, Sunil V.] Durham VA Med Cntr, Durham, NC USA. [Brilakis, Emmanouil S.] VA N Texas Hlth Care Syst, Dallas, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A17341 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738708367 ER PT J AU Tsai, TT Maddox, TM Bradley, SM Gylys-Colwell, I McDermott, K Helfrich, CD Fihn, SD Bryson, CL Rumsfeld, JS Ho, PM AF Tsai, Thomas T. Maddox, Thomas M. Bradley, Steven M. Gylys-Colwell, Ina McDermott, Kelly Helfrich, Christian D. Fihn, Stephan D. Bryson, Christopher L. Rumsfeld, John S. Ho, P. Michael TI Long-Term Risk of Bleeding and Impact of Non-Therapeutic INRs in Patients Discharged on Triple Antithrombotic Therapy After Hospitalization For Acute Coronary Syndrome SO CIRCULATION LA English DT Meeting Abstract DE Acute coronary syndromes; Anticoagulants; Antiplatelet drugs C1 [Tsai, Thomas T.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael] Denver VAMC, Denver, CO USA. [Bradley, Steven M.] VA Puget Sound Hlth Care Syst, Internal Med Cardiol, Seattle, WA USA. [Gylys-Colwell, Ina; McDermott, Kelly; Helfrich, Christian D.; Fihn, Stephan D.; Bryson, Christopher L.] VA Puget Sound Hlth Care Syst, Internal Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 SU S MA A14336 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 884WE UT WOS:000299738706085 ER PT J AU McCabe, JM Bhave, PD McGlothlin, D Teerlink, JR AF McCabe, James M. Bhave, Prashant D. McGlothlin, Dana Teerlink, John R. TI Running From Her Past A Case of Rapidly Progressive Dyspnea on Exertion SO CIRCULATION LA English DT Article DE microvascular obstruction; pulmonary hypertension; right ventricular failure; tumor; microangiopathy ID TUMOR THROMBOTIC MICROANGIOPATHY; PULMONARY-HYPERTENSION; DIAGNOSIS; CATHETER C1 [McCabe, James M.; Bhave, Prashant D.; McGlothlin, Dana; Teerlink, John R.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA. RP McCabe, JM (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol, 75 Francis St, Boston, MA 02115 USA. EM mccabe@aya.yale.edu RI Teerlink, John/D-2986-2012 NR 13 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 22 PY 2011 VL 124 IS 21 BP 2355 EP 2361 DI 10.1161/CIRCULATIONAHA.111.045906 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 852BR UT WOS:000297320900020 PM 22105198 ER PT J AU Kuranov, RV Kazmi, S McElroy, AB Kiel, JW Dunn, AK Milner, TE Duong, TQ AF Kuranov, Roman V. Kazmi, Shams McElroy, Austin B. Kiel, Jeffrey W. Dunn, Andrew K. Milner, Thomas E. Duong, Timothy Q. TI In vivo depth-resolved oxygen saturation by dual-wavelength photothermal (DWP) OCT SO OPTICS EXPRESS LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL OXYGENATION; BLOOD-FLOW; TISSUE; RAT; RESOLUTION; TENSION; BRAIN; PHOSPHORESCENCE; ERYTHROCYTES AB Microvasculature hemoglobin oxygen saturation (SaO(2)) is important in the progression of various pathologies. Non-invasive depth-resolved measurement of SaO(2) levels in tissue microvasculature has the potential to provide early biomarkers and a better understanding of the pathophysiological processes allowing improved diagnostics and prediction of disease progression. We report proof-of-concept in vivo depth-resolved measurement of SaO(2) levels in selected 30 mu m diameter arterioles in the murine brain using Dual-Wavelength Photothermal (DWP) Optical Coherence Tomography (OCT) with 800 nm and 770 nm photothermal excitation wavelengths. Depth location of back-reflected light from a target arteriole was confirmed using Doppler and speckle contrast OCT images. SaO(2) measured in a murine arteriole with DWP-OCT is linearly correlated (R-2=0.98) with systemic SaO(2) values recorded by a pulse-oximeter. DWP-OCT are steadily lower (10.1%) than systemic SaO(2) values except during pure oxygen breathing. DWP-OCT is insensitive to OCT intensity variations and is a candidate approach for in vivo depth-resolved quantitative imaging of microvascular SaO(2) levels. (C) 2011 Optical Society of America C1 [Kuranov, Roman V.; Kiel, Jeffrey W.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Kuranov, Roman V.; Kazmi, Shams; McElroy, Austin B.; Dunn, Andrew K.; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Kuranov, RV (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. EM rkuranov@yahoo.com RI Duong, Timothy/B-8525-2008; Dunn, Andrew/I-9527-2014 FU NIH [UL1RR025767, KL2RR025766, R01 EY018855, R01 EY014211]; San Antonio Area Foundation [130977]; Department of Veterans Affairs FX This research was partially supported by NIH KL2 training grants (Parent grants UL1RR025767 and KL2RR025766), San Antonio Area Foundation grant 130977 to RVK, Department of Veterans Affairs (VA MERIT Award) to TQD and NIH (R01 EY018855 and R01 EY014211) to TQD. Authors would like to thank Joe Ho of OptoWaves Inc. (San Jose, CA) for the endowment of 800 nm couplers to combine 770 nm and 800 nm photothermal excitation lights. NR 56 TC 15 Z9 15 U1 0 U2 7 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 1094-4087 J9 OPT EXPRESS JI Opt. Express PD NOV 21 PY 2011 VL 19 IS 24 BP 23831 EP 23844 DI 10.1364/OE.19.023831 PG 14 WC Optics SC Optics GA 865PE UT WOS:000298322000021 PM 22109408 ER PT J AU Thameem, F Puppala, S Arar, NH Blangero, J Duggirala, R Abboud, HE AF Thameem, Farook Puppala, Sobha Arar, Nedal H. Blangero, John Duggirala, Ravindranath Abboud, Hanna E. TI Genetic variants in Transient Receptor Potential cation channel, subfamily M 1 (TRPM1) and their risk of albuminuria-related traits in Mexican Americans SO CLINICA CHIMICA ACTA LA English DT Article DE TRPM1; Type 2 diabetes; Albumin to creatinine ration; Polymorphisms; Association analysis; Mexican Americans ID CORONARY-ARTERY-DISEASE; MEASURED GENOTYPE; CANDIDATE GENES; MELASTATIN; MELANOMA; LINKAGE; SEARCH; CELLS; LOCI AB Background: Evidence for linkage of albuminuria to GABRB3 marker region on chromosome 15q12 was previously reported in Mexican Americans. The objective of this study is to scan a positional candidate gene. Transient Receptor Potential cation channel, subfamily M 1 (TRPM1), for genetic variants that may contribute to the variation in albumin-to-creatinine ratio (ACR). Methods: To identify the sequence variants, the exons and 2 kb putative promoter region of TRPM1 were PCR amplified and sequenced in 32 selected individuals. Identified variants were genotyped in the entire data set (N = 670; 39 large families) by TaqMan assays. Association analyses between the sequence variants and ACR, type 2 diabetes (T2DM) and related phenotypes were carried out using a measured genotype approach as implemented in the program SOLAR. Results: Sequencing analysis identified 18 single nucleotide polymorphisms (SNPs) including 8 SNPs in the coding regions, 7 SNPs in the promoter region and 3 SNPs in introns. Of the 8 SNPs identified in the coding regions, 3 were non synonymous [Met(1)Thr, Ser(32)Asn, Val(1395)Ile] and one SNP caused stop codon (Glu1375/*). Of the SNPs examined, none of them exhibited statistically significant association with ACR after accounting for the effect of age, sex, diabetes, duration of diabetes, systolic blood pressure and anti-hypertensive medications. However, a SNP (rs11070811) located in the putative promoter region showed a modest association with triglycerides levels (P= 0.039). Conclusion: The present investigation found no evidence for an association between sequence variation at the TRPM1 gene and ACR in Mexican Americans, although it appears to have modest influence on T2DM risk factors. (C) 2011 Elsevier B.V. All rights reserved. C1 [Thameem, Farook; Arar, Nedal H.; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Puppala, Sobha; Blangero, John; Duggirala, Ravindranath] Texas Biomed Res Inst, Dept Genet, San Antonio, TX 78227 USA. [Arar, Nedal H.; Abboud, Hanna E.] S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA. RP Thameem, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM thameem@uthscsa.edu FU American Heart Association; Diabetes Action Research and Education Foundation; American Society of Nephrology; Satellite Health Care; George O'Brien Kidney Research Center [P50 DK061597]; VA-Merit Review; National Institute of Diabetes, Digestive and Kidney Diseases [DK42273, DK47482, DK53889]; National Center for Research Resources [UL1 RR025767, KL2 RR025766] FX We thank members of the SAFDGS for their participation and cooperation. This study was supported by the American Heart Association, Diabetes Action Research and Education Foundation, American Society of Nephrology, Satellite Health Care, George O'Brien Kidney Research Center (P50 DK061597), VA-Merit Review, and by grants from the National Institute of Diabetes, Digestive and Kidney Diseases (DK42273, DK47482 and DK53889). This work was also supported by the National Center for Research Resources contracts UL1 RR025767 and KL2 RR025766 for the Institute for Integration of Medicine and Science. We also thank the General Clinical Research Center, and South Texas Healthcare System. NR 33 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD NOV 20 PY 2011 VL 412 IS 23-24 BP 2058 EP 2062 DI 10.1016/j.cca.2011.03.024 PG 5 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 843QC UT WOS:000296686100007 PM 21439949 ER PT J AU Mahon, JL Beam, CA Marcovina, SM Boulware, DC Palmer, JP Winter, WE Skyler, JS Krischer, JP AF Mahon, Jeffrey L. Beam, Craig A. Marcovina, Santica M. Boulware, David C. Palmer, Jerry P. Winter, William E. Skyler, Jay S. Krischer, Jeffrey P. CA Type 1 Diabet TrialNet Study Grp TI Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies SO CLINICA CHIMICA ACTA LA English DT Article DE First-phase insulin release; Insulin radioimmunoassay; Insulin immunoenzymometric assay; Prediction and prevention of type 1 diabetes ID INTRAVENOUS GLUCOSE; INTERVENTION TRIAL; STANDARDIZATION; PROGRESSION; RELATIVES; RISK AB Background: Detection of below-threshold first-phase insulin release or FPIR (1 + 3 minute insulin concentrations during an intravenous glucose tolerance test [IVGTT]) is important in type 1 diabetes prediction and prevention studies including the TrialNet Oral Insulin Prevention Trial. We assessed whether an insulin immunoenzymometric assay (IEMA) could replace the less practical but current standard of a radioimmunoassay (RIA) for FPIR. Methods: One hundred thirty-three islet autoantibody positive relatives of persons with type 1 diabetes underwent 161 IVGTTs. Insulin concentrations were measured by both assays in 1056 paired samples. A rule classifying FPIR (below-threshold, above-threshold, uncertain) by the IEMA was derived and validated against FPIR by the RIA. Results: The insulin IEMA-based rule accurately classified below- and above-threshold FPIRs by the RIA in 110/161(68%) IVGTTs, but was uncertain in 51/161 (32%) tests for which FPIR by RIA is needed. An uncertain FPIR by the IEMA was more likely among below-threshold vs above-threshold FPIRs by the RIA (64%[30/47] vs. 18% [21/114], respectively; p<0.05). Conclusions: An insulin IEMA for FPIR in subjects at risk for type 1 diabetes accurately determined below- and above-threshold FPIRs in 2/3 of tests relative to the current standard of the insulin RIA. but could not reliably classify the remaining FPIRs. TrialNet is limiting the insulin RIA for FPIR to the latter given the practical advantages of the more specific IEMA. (C) 2011 Elsevier B.V. All rights reserved. C1 [Mahon, Jeffrey L.] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada. [Mahon, Jeffrey L.] Univ Western Ontario, Dept Med, London, ON, Canada. [Beam, Craig A.; Boulware, David C.; Krischer, Jeffrey P.] Univ S Florida, Dept Pediat, Pediat Epidemiol Ctr, Tampa, FL 33620 USA. [Marcovina, Santica M.] Univ Washington, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Palmer, Jerry P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Winter, William E.] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA. [Winter, William E.] Univ Florida, Dept Immunol & Lab Med, Gainesville, FL USA. [Skyler, Jay S.] Univ Miami, Div Endocrinol, Miami, FL USA. RP Mahon, JL (reprint author), Robarts Clin Trials, POB 5015,100 Perth Dr, London, ON N6A 5K8, Canada. EM JLMahon@Ihsc.on.ca RI Skyler, Jay/F-4211-2016 FU National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Research Resources; Juvenile Diabetes Research Foundation International; American Diabetes Diabetes Association FX TrialNet is funded by the National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Center for Research Resources; the Juvenile Diabetes Research Foundation International; and the American Diabetes Diabetes Association. NR 16 TC 9 Z9 9 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD NOV 20 PY 2011 VL 412 IS 23-24 BP 2128 EP 2131 DI 10.1016/j.cca.2011.07.019 PG 4 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 843QC UT WOS:000296686100018 PM 21843518 ER PT J AU Liel, MS Klein, R Recht, M Greenberg, DL Taylor, J AF Liel, Meghan S. Klein, Robert Recht, Michael Greenberg, Daniel L. Taylor, Jason TI Reduced Bone Mineral Density in Factor VIII Deficient Mice and the Role of Inflammatory Cytokines SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Klein, Robert] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Dept Endocrinol, Portland, OR 97201 USA. [Recht, Michael; Greenberg, Daniel L.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Taylor, Jason] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 14 EP 14 PG 1 WC Hematology SC Hematology GA 882XL UT WOS:000299597100022 ER PT J AU Lewis, KB Nguyen, PC Schuman, JT Walsh, CE Josephson, NC Howard, TE Matthews, DC Key, NS Pratt, KP AF Lewis, Kenneth B. Phuong-Cac Nguyen Schuman, Jason T. Walsh, Christopher E. Josephson, Neil C. Howard, Tom E. Matthews, Dana C. Key, Nigel S. Pratt, Kathleen P. TI Determination of Anti-Factor VIIII Antibody Titers, Isotypes and Epitopes by SPR Analysis of Human Plasma SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Lewis, Kenneth B.; Phuong-Cac Nguyen; Josephson, Neil C.; Pratt, Kathleen P.] Puget Sound Blood Ctr, Res Inst, Seattle, WA 98104 USA. [Schuman, Jason T.] GE Healthcare, Life Sci, Piscataway, NJ USA. [Walsh, Christopher E.] Mt Sinai Sch Med, New York, NY USA. [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Matthews, Dana C.] Seattle Childrens Hosp, Seattle, WA USA. [Key, Nigel S.] Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 94 EP 95 PG 2 WC Hematology SC Hematology GA 882XL UT WOS:000299597100203 ER PT J AU Lentzsch, S O'Sullivan, A Kennedy, R Abbas, M Gill, N Dai, L Andreas, C Gardner, D Pregja, SL Burt, S Redner, RL Volkin, R Roodman, GD Mapara, MY Viverette, JF Agha, M Waas, JK Shuai, YL Normolle, D Zonder, JA AF Lentzsch, Suzanne O'Sullivan, Amy Kennedy, Ryan Abbas, Mohammad Gill, Navkiranjit Dai, Lijun Andreas, Carrie Gardner, Diane Pregja, Silvana Lalo Burt, Steve Redner, Robert L. Volkin, Robert Roodman, G. David Mapara, Markus Y. Viverette, J. Franklin Agha, Mounzer Waas, John K. Shuai, Yongli Normolle, Daniel Zonder, Jeffrey A. TI Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Lentzsch, Suzanne; O'Sullivan, Amy; Kennedy, Ryan; Abbas, Mohammad; Gill, Navkiranjit; Dai, Lijun; Andreas, Carrie; Gardner, Diane; Redner, Robert L.; Mapara, Markus Y.] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. [Lentzsch, Suzanne; O'Sullivan, Amy; Kennedy, Ryan; Abbas, Mohammad; Gill, Navkiranjit; Dai, Lijun; Andreas, Carrie; Gardner, Diane; Redner, Robert L.; Mapara, Markus Y.] Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA. [Pregja, Silvana Lalo; Burt, Steve; Zonder, Jeffrey A.] Barbara Ann Karmanos Canc Inst, MYELOMA PROGRAM, Detroit, MI USA. [Volkin, Robert; Agha, Mounzer] UPMC Canc Ctr, Pittsburgh, PA USA. [Roodman, G. David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Viverette, J. Franklin; Waas, John K.] UPMC Canc Ctr, Greensburg, PA USA. [Shuai, Yongli; Normolle, Daniel] Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA USA. RI mapara, markus/A-2134-2013 NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 142 EP 142 PG 1 WC Hematology SC Hematology GA 882XL UT WOS:000299597100305 ER PT J AU Mielcarek, M Storer, B Martin, PJ Negrin, RS Forman, SJ Flowers, MED Inamoto, Y Chauncey, T Storb, R Appelbaum, FR Bensinger, WI AF Mielcarek, Marco Storer, Barry Martin, Paul J. Negrin, Robert S. Forman, Stephen J. Flowers, Mary E. D. Inamoto, Yoshihiro Chauncey, Thomas Storb, Rainer Appelbaum, Frederick R. Bensinger, William I. TI Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Mielcarek, Marco; Storer, Barry; Martin, Paul J.; Inamoto, Yoshihiro; Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Negrin, Robert S.] Stanford Univ, Stanford, CA 94305 USA. [Forman, Stephen J.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Hematol & Hematopoiet Cell Transplantat, Dept Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA. [Flowers, Mary E. D.; Storb, Rainer; Bensinger, William I.] Univ Washington, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 149 EP 149 PG 1 WC Hematology SC Hematology GA 882XL UT WOS:000299597100320 ER PT J AU Freytes, CO Vesole, DH Zhong, XB Le-Rademacher, J Dispenzieri, A Lonial, S Milone, G Hari, P AF Freytes, Cesar O. Vesole, David H. Zhong, Xiaobo Le-Rademacher, Jennifer Dispenzieri, Angela Lonial, Sagar Milone, Gustavo Hari, Parameswaran TI Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT) SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Freytes, Cesar O.] S Vet Hlth Care Syst, BMT, San Antonio, TX USA. [Vesole, David H.] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA. [Zhong, Xiaobo] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Le-Rademacher, Jennifer; Hari, Parameswaran] Med Coll Wisconsin CIBMTR, Rochester, MN USA. [Dispenzieri, Angela] Mayo Clin, Rochester, MN USA. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Milone, Gustavo] FUNDALEU, Buenos Aires, DF, Argentina. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 375 EP 375 PG 1 WC Hematology SC Hematology GA 882XL UT WOS:000299597101095 ER PT J AU Pandey, GS Garfield, S Curran, JE Moses, EK Kimchi-Sarfaty, C Yanover, C Howard, TE Sauna, ZE AF Pandey, Gouri Shankar Garfield, Susan Curran, Joanne E. Moses, Eric K. Kimchi-Sarfaty, Chava Yanover, Chen Howard, Tom E. Sauna, Zuben E. TI The Entire Primary Sequence of Factor VIII Is Synthesized As Two Polypeptide Chains in Hemophilia A Patients with the Intron-22-Inversion SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Pandey, Gouri Shankar] US FDA, Lab Hemostasis, DH CBER, Bethesda, MD 20014 USA. [Garfield, Susan] NCI, NIH, Bethesda, MD 20892 USA. [Curran, Joanne E.] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. [Kimchi-Sarfaty, Chava; Sauna, Zuben E.] US FDA, Ctr Biol Evaluat & Res, Div Hematol, Bethesda, MD 20892 USA. [Yanover, Chen] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA. [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 531 EP 532 PG 2 WC Hematology SC Hematology GA 882XL UT WOS:000299597101445 ER PT J AU Dao, KHT Rotelli, MD Petersen, CL Brown, BR Nelson, WD Yates, JE Newell, AH Olson, SB Druker, BJ Bagby, GC AF Dao, Kim-Hien T. Rotelli, Michael D. Petersen, Curtis L. Brown, Brie R. Nelson, Whitney D. Yates, Jane E. Newell, Amy Hanlon Olson, Susan B. Druker, Brian J. Bagby, Grover C., Jr. TI FANCL Ubiquitinates Beta-Catenin and Enhances Its Nuclear Function SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Dao, Kim-Hien T.; Rotelli, Michael D.; Petersen, Curtis L.; Brown, Brie R.; Nelson, Whitney D.] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Knight Canc Inst Hematol Oncol, Portland, OR 97201 USA. [Yates, Jane E.] NW VA Canc Res Ctr, Portland, OR USA. [Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Howard Hughes Med Inst, Portland, OR 97201 USA. [Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 588 EP 589 PG 2 WC Hematology SC Hematology GA 882XL UT WOS:000299597101604 ER PT J AU Newell, LF Othus, M Walter, RB Petergdorf, SH Chauncey, T Anderson, JE Godwin, JE Kopecky, KJ Appelbaum, FR Estey, EH AF Newell, Laura F. Othus, Megan Walter, Roland B. Petergdorf, Stephen H. Chauncey, Thomas Anderson, Jeanne E. Godwin, John E. Kopecky, Kenneth J. Appelbaum, Frederick R. Estey, Elihu H. TI Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Newell, Laura F.; Walter, Roland B.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Petergdorf, Stephen H.; Chauncey, Thomas; Estey, Elihu H.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Anderson, Jeanne E.] Katmai Oncol Grp, Anchorage, AK USA. [Godwin, John E.] So Illinois Univ, Simmons Canc Inst, Div Hematol Oncol, Springfield, IL USA. [Kopecky, Kenneth J.] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, Seattle, WA 98104 USA. RI Walter, Roland/C-1064-2008 OI Walter, Roland/0000-0002-9268-3341 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 628 EP 629 PG 2 WC Hematology SC Hematology GA 882XL UT WOS:000299597102041 ER PT J AU Haile, DJ Utz, K Toro, JJ Frye, BL Neumon, B Shuko, L Freytes, CO AF Haile, David J. Utz, Kenneth Toro, Juan J. Frye, Brenda L. Neumon, Bonita Shuko, Lee Freytes, Cesar O. TI Nicotine Use During Mobilization Is Associated with More Efficient Stem Cell Collection SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Utz, Kenneth] Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, Dept Pharm, San Antonio, TX 78284 USA. [Frye, Brenda L.] Audie Murphy Vet Affairs BMT, San Antonio, TX USA. [Shuko, Lee] S Texas Vet Hlth Care Syst, Res & Dev Serv, San Antonio, TX USA. [Freytes, Cesar O.] Audie L Murphy Mem Vet Adm Med Ctr, Med Serv BMT 111, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 843 EP 843 PG 1 WC Hematology SC Hematology GA 882XL UT WOS:000299597102529 ER PT J AU Thompson, LA Guthrie, KA Budde, LE Till, BG Press, OW Chauncey, T Pagel, JM Petersdorf, SH Bensinger, WI Holmberg, L Shustov, AR Green, DJ Maloney, DG Gopal, AK AF Thompson, Leslie A. Guthrie, Katherine A. Budde, Lihua Elizabeth Till, Brian G. Press, Oliver W. Chauncey, Thomas Pagel, John M. Petersdorf, Stephen H. Bensinger, William I. Holmberg, Leona Shustov, Andrei R. Green, Damian J. Maloney, David G. Gopal, Ajay K. TI The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Thompson, Leslie A.] Seattle Canc Care Alliance, Gen Oncol & Hematol, Seattle, WA USA. [Budde, Lihua Elizabeth] Fed Hutchinson Canc Res Ctr, Seattle, WA USA. [Press, Oliver W.; Pagel, John M.; Bensinger, William I.; Green, Damian J.; Gopal, Ajay K.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Shustov, Andrei R.] Univ Washington, Med Ctr, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 886 EP 887 PG 2 WC Hematology SC Hematology GA 882XL UT WOS:000299597102621 ER PT J AU Cappelli, E Svahn, J Anur, P Corsolini, F Farruggia, P Bagby, GC Dufour, C AF Cappelli, Enrico Svahn, Johanna Anur, Praveen Corsolini, Fabio Farruggia, Piero Bagby, Grover C., Jr. Dufour, Carlo TI Kinase Inhibitors Reduce TNF-Alpha Over-Production in Monocytes From Fanconi Anemia Group A Patients SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Cappelli, Enrico; Svahn, Johanna; Corsolini, Fabio; Dufour, Carlo] Ist Giannina Gaslini, I-16148 Genoa, Italy. [Anur, Praveen] Doernbecher Childrens Hosp, Portland, OR USA. [Anur, Praveen; Bagby, Grover C., Jr.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Farruggia, Piero] G Di Cristina Hosp, Palermo, Italy. [Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA. RI Cappelli, Enrico/K-7954-2016 OI Cappelli, Enrico/0000-0001-5910-9260 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 1036 EP 1036 PG 1 WC Hematology SC Hematology GA 882XL UT WOS:000299597103275 ER PT J AU Kadoch, C Wong, V Chen, LJ Bet-Lachin, A Roy, R Hyun, W Behler, C Lowell, C Rubenstein, JL AF Kadoch, Cicall Wong, Valerie Chen, Lingjing Bet-Lachin, Anna Roy, Ritu Hyun, William Behler, Caroline Lowell, Clifford Rubenstein, James L. TI Dynamic Changes in Macrophage Polarization Correlate with Progression and Response in CNS Lymphoma: Insights Into the Transcriptome of Lymphoma-Associated M2 Macrophages SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Roy, Ritu] UCSF, Ctr Comprehens Canc, San Francisco, CA USA. [Behler, Caroline] San Francisco VA Med Ctr, San Francisco, CA USA. [Lowell, Clifford] Univ CA, San Francisco, CA USA. [Rubenstein, James L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 1390 EP 1390 PG 1 WC Hematology SC Hematology GA 882XL UT WOS:000299597104569 ER PT J AU Gunasekera, D Ettinger, RA Hughes, RJ Epstein, MS Barrett, JC Thompson, AA Withycombe, J Pratt, KP AF Gunasekera, Devi Ettinger, Ruth A. Hughes, Richard J. Epstein, Melinda S. Barrett, John C. Thompson, Alexis A. Withycombe, Janice Pratt, Kathleen P. TI Potential Immunogenicity of Amino Acid Sequences Encoded by Ns-SNPs in Factor VIII SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Gunasekera, Devi; Ettinger, Ruth A.; Pratt, Kathleen P.] Puget Sound Blood Ctr, Res Inst, Seattle, WA 98104 USA. [Hughes, Richard J.; Epstein, Melinda S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Barrett, John C.] Virginia Commonwealth Univ, Cent Virginia Ctr Coagulat Disorders, Richmond, VA USA. [Thompson, Alexis A.] Childrens Mem Hosp, Chicago, IL 60614 USA. [Withycombe, Janice] Palmetto Hlth Childrens Hosp, Columbia, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 1430 EP 1431 PG 2 WC Hematology SC Hematology GA 882XL UT WOS:000299597105059 ER PT J AU D'Souza, S Kurihara, N Shiozawa, Y Joseph, J Taichman, R Galson, D Roodman, D AF D'Souza, Sonia Kurihara, Noriyoshi Shiozawa, Yusuke Joseph, Jeena Taichman, Russell Galson, Deborah Roodman, David TI Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth in the Bone Marrow Microenvironment SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah] Univ Pittsburgh, Bone Biol Ctr, UPMC, Pittsburgh, PA USA. [D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Shiozawa, Yusuke; Joseph, Jeena; Taichman, Russell] Univ Michigan, Ann Arbor, MI 48109 USA. [Roodman, David] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. [Roodman, David] Inst Canc Res, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 1685 EP 1685 PG 1 WC Hematology SC Hematology GA 882XL UT WOS:000299597106112 ER PT J AU Dai, LJ O'Sullivan, A Kennedy, R Abbas, M Shuai, YL Passero, VA Andreas, C Gardner, D Redner, RL Roodman, GD Marks, SM Raptis, A Hou, JZ Petro, D Sun, M Evans, T Pietragallo, LV Waas, JK Viverette, JF Osborn, J Reyes, V Pinkerton, R Crandall, T Fierro, R Volkin, R Normolle, D Mapara, MY Lentzsch, S AF Dai, Lijun O'Sullivan, Amy Kennedy, Ryan Abbas, Mohammad Shuai, Yongli Passero, Vida Almario Andreas, Carrie Gardner, Diane Redner, Robert L. Roodman, G. David Marks, Stanley M. Raptis, Anastasios Hou, Jing-Zhou Petro, Daniel Sun, Min Evans, Terry Pietragallo, Louis V. Waas, John K. Viverette, J. Franklin Osborn, Jennifer Reyes, Vincent Pinkerton, Richard Crandall, Theodore Fierro, Ronald Volkin, Robert Normolle, Daniel Mapara, Markus Y. Lentzsch, Suzanne TI A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results SO BLOOD LA English DT Meeting Abstract CT 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis CY DEC 10-13, 2011 CL San Diego, CA SP Amer Soc Hematol (ASH) C1 [Dai, Lijun; O'Sullivan, Amy; Kennedy, Ryan; Abbas, Mohammad; Passero, Vida Almario; Andreas, Carrie; Gardner, Diane; Redner, Robert L.; Mapara, Markus Y.; Lentzsch, Suzanne] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. [Dai, Lijun; O'Sullivan, Amy; Kennedy, Ryan; Abbas, Mohammad; Passero, Vida Almario; Andreas, Carrie; Gardner, Diane; Redner, Robert L.; Mapara, Markus Y.; Lentzsch, Suzanne] Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA. [Shuai, Yongli; Normolle, Daniel] Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA USA. [Roodman, G. David] VA Pittsburgh Healthcare Syst, Med Hem Onc, Pittsburgh, PA USA. [Marks, Stanley M.; Raptis, Anastasios; Hou, Jing-Zhou; Petro, Daniel; Sun, Min; Pietragallo, Louis V.; Osborn, Jennifer; Reyes, Vincent; Volkin, Robert] UPMC Canc Ctr, Pittsburgh, PA USA. [Evans, Terry; Waas, John K.; Viverette, J. Franklin] UPMC Canc Ctr, Greensburg, PA USA. [Pinkerton, Richard] UPMC Canc Ctr, Indiana, PA USA. [Crandall, Theodore] UPMC Canc Ctr, Wexford, PA USA. [Fierro, Ronald] UPMC Canc Ctr, Clairton, PA USA. RI mapara, markus/A-2134-2013; pinkerton, ross/I-4808-2014 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2011 VL 118 IS 21 BP 1771 EP 1772 PG 2 WC Hematology SC Hematology GA 882XL UT WOS:000299597106309 ER PT J AU Lahar, N Lei, NY Wang, JF Jabaji, Z Tung, SC Joshi, V Lewis, M Stelzner, M Martin, MG Dunn, JCY AF Lahar, Nicholas Lei, Nan Ye Wang, Jiafang Jabaji, Ziyad Tung, Stephaine C. Joshi, Vaidehi Lewis, Michael Stelzner, Matthias Martin, Martin G. Dunn, James C. Y. TI Intestinal Subepithelial Myofibroblasts Support in vitro and in vivo Growth of Human Small Intestinal Epithelium SO PLOS ONE LA English DT Article ID STEM-CELLS; DIFFERENTIATION; RENEWAL; NICHE AB The intestinal crypt-niche interaction is thought to be essential to the function, maintenance, and proliferation of progenitor stem cells found at the bases of intestinal crypts. These stem cells are constantly renewing the intestinal epithelium by sending differentiated cells from the base of the crypts of Lieberkuhn to the villus tips where they slough off into the intestinal lumen. The intestinal niche consists of various cell types, extracellular matrix, and growth factors and surrounds the intestinal progenitor cells. There have recently been advances in the understanding of the interactions that regulate the behavior of the intestinal epithelium and there is great interest in methods for isolating and expanding viable intestinal epithelium. However, there is no method to maintain primary human small intestinal epithelium in culture over a prolonged period of time. Similarly no method has been published that describes isolation and support of human intestinal epithelium in an in vivo model. We describe a technique to isolate and maintain human small intestinal epithelium in vitro from surgical specimens. We also describe a novel method to maintain human intestinal epithelium subcutaneously in a mouse model for a prolonged period of time. Our methods require various growth factors and the intimate interaction between intestinal sub-epithelial myofibroblasts (ISEMFs) and the intestinal epithelial cells to support the epithelial in vitro and in vivo growth. Absence of these myofibroblasts precluded successful maintenance of epithelial cell formation and proliferation beyond just a few days, even in the presence of supportive growth factors. We believe that the methods described here can be used to explore the molecular basis of human intestinal stem cell support, maintenance, and growth. C1 [Lahar, Nicholas; Lei, Nan Ye; Jabaji, Ziyad; Tung, Stephaine C.; Stelzner, Matthias; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Nutr, Dept Surg, Los Angeles, CA 90095 USA. [Lei, Nan Ye; Joshi, Vaidehi; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Bioengn, Div Gastroenterol & Nutr, Los Angeles, CA 90095 USA. [Wang, Jiafang; Tung, Stephaine C.; Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Nutr, Dept Pediat, Los Angeles, CA 90095 USA. [Lewis, Michael] Univ Calif Los Angeles, Dept Pathol, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Lahar, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Nutr, Dept Surg, Los Angeles, CA 90095 USA. EM jdunn@mednet.ucla.edu FU National Institute of Diabetes and Digestive and Kidney Diseases, Intestinal Stem Cell Consortium [DK085535-01, DK085535-02S2]; California Institute for Regenerative Medicine (CIRM) [RT2-01985]; [DK083762]; [DK083319] FX This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases U01 Intestinal Stem Cell Consortium (DK085535-01 and DK085535-02S2), DK083762, DK083319 and the California Institute for Regenerative Medicine (CIRM) (Grant Number RT2-01985). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of CIRM or any other agency of the State of California. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 18 TC 49 Z9 50 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 17 PY 2011 VL 6 IS 11 AR e26898 DI 10.1371/journal.pone.0026898 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 855HZ UT WOS:000297555800010 PM 22125602 ER PT J AU De Franceschi, L Tomelleri, C Matte, A Brunati, AM Bovee-Geurts, PH Bertoldi, M Lasonder, E Tibaldi, E Danek, A Walker, RH Jung, HH Bader, B Siciliano, A Ferru, E Mohandas, N Bosman, GJCGM AF De Franceschi, Lucia Tomelleri, Carlo Matte, Alessandro Brunati, Anna Maria Bovee-Geurts, Petra H. Bertoldi, Mariarita Lasonder, Edwin Tibaldi, Elena Danek, Adrian Walker, Ruth H. Jung, Hans H. Bader, Benedikt Siciliano, Angela Ferru, Emanuela Mohandas, Narla Bosman, Giel J. C. G. M. TI Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity SO BLOOD LA English DT Article ID RED-CELL MEMBRANE; SRC FAMILY KINASES; PHOSPHORYLATION SITES; MULTIPROTEIN COMPLEX; MCLEOD-SYNDROME; NEUROACANTHOCYTOSIS; IDENTIFICATION; PLATELETS; PATHWAYS; VESICLES AB Acanthocytic RBCs are a peculiar diagnostic feature of chorea-acanthocytosis (ChAc), a rare autosomal recessive neurodegenerative disorder. Although recent years have witnessed some progress in the molecular characterization of ChAc, the mechanism(s) responsible for generation of acanthocytes in ChAc is largely unknown. As the membrane protein composition of ChAc RBCs is similar to that of normal RBCs, we evaluated the tyrosine (Tyr)-phosphorylation profile of RBCs using comparative proteomics. Increased Tyr phosphorylation state of several membrane proteins, including band 3, beta-spectrin, and adducin, was noted in ChAc RBCs. In particular, band 3 was highly phosphorylated on the Tyr-904 residue, a functional target of Lyn, but not on Tyr-8, a functional target of Syk. In ChAc RBCs, band 3 Tyr phosphorylation by Lyn was independent of the canonical Syk-mediated pathway. The ChAc-associated alterations in RBC membrane protein organization appear to be the result of increased Tyr phosphorylation leading to altered linkage of band 3 to the junctional complexes involved in anchoring the membrane to the cytoskeleton as supported by coimmunoprecipitation of beta-adducin with band 3 only in ChAc RBC-membrane treated with the Lyn-inhibitor PP2. We propose this altered association between membrane skeleton and membrane proteins as novel mechanism in the generation of acanthocytes in ChAc. (Blood. 2011;118(20):5652-5663) C1 [De Franceschi, Lucia; Tomelleri, Carlo; Matte, Alessandro; Siciliano, Angela; Ferru, Emanuela] Univ Verona, Dept Med, I-37134 Verona, Italy. [Brunati, Anna Maria; Tibaldi, Elena] Univ Padua, Dept Biochem, Padua, Italy. [Bovee-Geurts, Petra H.; Bosman, Giel J. C. G. M.] Radboud Univ Nijmegen, Med Ctr, Dept Biochem, NL-6525 ED Nijmegen, Netherlands. [Lasonder, Edwin] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Ctr Mol & Biomol Informat, NL-6525 ED Nijmegen, Netherlands. [Bertoldi, Mariarita] Univ Verona, Biochem Sect, Dept Life & Reprod Sci, I-37134 Verona, Italy. [Danek, Adrian; Bader, Benedikt] Univ Munich, Dept Neurol, D-8000 Munich, Germany. [Walker, Ruth H.] James J Peters Vet Adm Med Ctr, Dept Neurol, Bronx, NY USA. [Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA. [Jung, Hans H.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland. [Ferru, Emanuela] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy. [Mohandas, Narla] New York Blood Ctr, New York, NY 10021 USA. RP De Franceschi, L (reprint author), Univ Verona, Dept Med, Ple L Scuro 10, I-37134 Verona, Italy. EM lucia.defranceschi@univr.it RI Bosman, G.J.C.G.M./L-4221-2015; Danek, Adrian/G-7339-2011 OI Danek, Adrian/0000-0001-8857-5383 FU Advocacy for Neuroacanthocytosis Patients; Carl H. and Elizabeth S. Pforzheimer III, New York; Ginger and Glenn Irvine, London; Telethon [GPP07007] FX This work was supported by the Advocacy for Neuroacanthocytosis Patients (B. B., P. H. B.-G., E. L., G.J.C. G. M. B., and L. D. F.), Carl H. and Elizabeth S. Pforzheimer III, New York (B. B., P. H. B.-G., E. L., G.J.C. G. M. B., and R. H. W.), Ginger and Glenn Irvine, London (P. B., E. L., and G.J.C. G. M. B.) and Telethon (grant GPP07007, L. D. F.). Preliminary data were generated by Dr Christan Pozzobon. NR 47 TC 24 Z9 24 U1 0 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 17 PY 2011 VL 118 IS 20 BP 5652 EP 5663 DI 10.1182/blood-2011-05-355339 PG 12 WC Hematology SC Hematology GA 851JT UT WOS:000297265400036 PM 21951684 ER PT J AU Del Tredici, K Duda, JE AF Del Tredici, Kelly Duda, John E. TI Peripheral Lewy body pathology in Parkinson's disease and incidental Lewy body disease: Four cases SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article; Proceedings Paper CT 7th International Congress on Mental Dysfunction and other Non-Motor Features in Parkinsons Disease and Related Disorders CY DEC 09-12, 2010 CL Barcelona, SPAIN DE Alpha-synuclein; Auerbach plexus; Autonomic nervous system; Axonal; Brainstem; Celiac ganglion; Cognitive dysfunction; Incidental Lewy body disease; Lewy bodies/Lewy neurites; Non-motor symptoms; Parkinson's disease; Submandibular gland; Superior cervical ganglion; Sympathetic trunk; Synucleinopathy; Thyroid gland ID AUTONOMIC NERVOUS-SYSTEM; HUMAN ALPHA-SYNUCLEIN; NONMOTOR SYMPTOMS; MOVEMENT-DISORDERS; AXONAL-TRANSPORT; BRAIN PATHOLOGY; BODIES; PLEXUSES; GANGLIA; DEGENERATION AB The accumulation of Lewy pathology (LP) within autonomic nervous system tissues has received increased attention recently as a possible induction site for Lewy neurodegeneration and a possible source of biopsy material for biomarkers of early Parkinson's disease (PD). Here, we describe LP accumulation within various tissues involving peripheral autonomic nervous system neurons in three PD cases and one case of incidental Lewy body disease. Findings highlight the value of examining pathology within functional neuroanatomical systems and particularly the importance of Lewy neurites (LNs) in the pathophysiology of PD. Published by Elsevier B.V. C1 [Del Tredici, Kelly] Univ Ulm, Dept Neurol, Clin Res Ctr, D-89081 Ulm, Germany. [Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Duda, John E.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. RP Del Tredici, K (reprint author), Univ Ulm, Dept Neurol, Clin Res Ctr, Helmholtzstr 8-1, D-89081 Ulm, Germany. EM kelly.del-tredici@uni-ulm.de NR 48 TC 10 Z9 10 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD NOV 15 PY 2011 VL 310 IS 1-2 SI SI BP 100 EP 106 DI 10.1016/j.jns.2011.06.003 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 846UA UT WOS:000296927500025 PM 21689832 ER PT J AU Morley, JF Duda, JE AF Morley, James F. Duda, John E. TI Neuropsychological correlates of olfactory dysfunction in Parkinson's disease SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article; Proceedings Paper CT 7th International Congress on Mental Dysfunction and Other Non-Motor Features in Parkinson's Disease and Related Disorders CY DEC 09-12, 2010 CL Barcelona, SPAIN DE Parkinson's disease; Olfaction; Non-motor symptoms; Psychiatric symptoms; Cognitive symptoms ID ODOR IDENTIFICATION; COGNITIVE IMPAIRMENT; BODY PATHOLOGY; DEFICITS; RISK; DISCRIMINATION; SYMPTOMS; SIGN AB Olfactory impairment is a common early non-motor manifestation in Parkinson's disease that has garnered interest as a clinical biomarker for early "pre-motor" diagnosis and prediction of associated clinical phenotypes. Whether olfactory impairment correlates well with motor symptoms is not yet clear, and recent interest has focused on the relationship between hyposmia and other non-motor symptoms. In this paper, we will review emerging evidence for a relationship between hyposmia and neuropsychiatric manifestations, discussing the potential pathophysiology together with challenges and opportunities for future research. Published by Elsevier B.V. C1 [Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. Univ Penn, Dept Neurol, Sch Med, Philadelphia, PA 19104 USA. RP Duda, JE (reprint author), Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM John.Duda@va.gov NR 31 TC 7 Z9 7 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD NOV 15 PY 2011 VL 310 IS 1-2 SI SI BP 228 EP 230 DI 10.1016/j.jns.2011.05.030 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 846UA UT WOS:000296927500050 PM 21658728 ER PT J AU Beyth, RJ Landefeld, CS AF Beyth, Rebecca J. Landefeld, C. Seth TI Learning the Respective Roles of Warfarin and Dabigatran to Prevent Stroke in Patients With Nonvalvular Atrial Fibrillation SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID THERAPY; ANTICOAGULATION C1 [Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94118 USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA 94118 USA. [Beyth, Rebecca J.] Univ Florida, Gainesville, FL 32608 USA. [Beyth, Rebecca J.] N Florida S Georgia Vet Hlth Syst, Gainesville, FL 32608 USA. RP Landefeld, CS (reprint author), Univ Calif San Francisco, Div Geriatr, Suite 380,3333 Calif St, San Francisco, CA 94118 USA. NR 12 TC 2 Z9 2 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 15 PY 2011 VL 155 IS 10 BP 714 EP + DI 10.7326/0003-4819-155-10-201111150-00012 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 849EI UT WOS:000297108000008 PM 22084336 ER PT J AU Furmaga, H Shah, A Frazer, A AF Furmaga, Havan Shah, Aparna Frazer, Alan TI Serotonergic and Noradrenergic Pathways Are Required for the Anxiolytic-like and Antidepressant-like Behavioral Effects of Repeated Vagal Nerve Stimulation in Rats SO BIOLOGICAL PSYCHIATRY LA English DT Article DE 5,7-dihydroxytryptamine; 6-hydroxydopamine; desipramine; forced swim test; novelty suppressed feeding test; sertraline; vagal nerve stimulation ID TREATMENT-RESISTANT DEPRESSION; FORCED SWIMMING TEST; VAGUS NERVE; ANXIETY DISORDERS; ANIMAL-MODEL; NOREPINEPHRINE TRANSPORTERS; ANTIINFLAMMATORY CYTOKINES; MEDULLA-OBLONGATA; INDUCED REMISSION; RAPHE NUCLEUS AB Background: Vagal nerve stimulation (VNS) is used for treatment-refractory depression, but there are few preclinical studies of its effects when administered repeatedly over time using clinically relevant stimulation parameters in nonanesthetized animals. Methods: The novelty-suppressed feeding test (NSFT) and forced swim test (FST) were used to evaluate the anxiolytic- and antidepressant-like potential of VNS in rats, respectively. The behavioral effects of VNS were compared with those of desipramine (DMI; 10 mg/kg/day) and sertraline (7.5 mg/kg/day) administered via osmotic minipump. Such experiments were carried out in intact rats as well as those that had selective destruction of either serotonin or noradrenergic neurons in brain caused by the neurotoxins, 5,7-dihyroxytryptamine (5,7-DHT), or 6-hydroxydopamine (6-OHDA). Results: Repeated administration of VNS, DMI, and sertraline decreased latency to feed in the NSFT. In the FST, repeated VNS, DMI, and sertraline caused decreased immobility; the VNS-induced decrease in immobility resulted from increases in both swimming and climbing behaviors. Effects of VNS and sertraline, but not DMI, in both the NSFT and the FST were abolished in rats treated with 5,7-DHT. Effects of DMI in both behavioral tests, but not those of sertraline, were abolished in 6-OHDA treated rats. VNS effects on immobility and climbing in the FST were not blocked in the 6-OHDA-treated rats. There was no significant difference in locomotor activity caused by any of the treatments or by the lesions. Conclusions: Serotonergic nerves are required for repeated VNS-induced anxiolytic- and antidepressant-like effects. Noradrenergic nerves can also be activated by VNS to cause its anxiolytic-like effect. C1 [Furmaga, Havan; Shah, Aparna; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Frazer, Alan] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Frazer, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM frazer@uthscsa.edu FU National Institute of Mental Health [MH082933]; Cyberonics Inc. FX We acknowledge the technical assistance of Mohona Sadhu and thank Dr. David Morilak for his insightful suggestions throughout the course of the experiment. This work was supported by National Institute of Mental Health Grant No. MH082933 (AF). The electrodes, VNS stimulators, and dummy stimulators were gifts from Cyberonics Inc.; Dr. Furmaga and Ms. Shah report no biomedical financial interests or potential conflicts of interest. Dr. Frazer has served on advisory boards for Lundbeck and for Takeda in the last three years. Previously, Dr. Frazer had received financial compensation as a consultant for Cyberonics Inc. and had also obtained grant support from them for a preclinical study. NR 75 TC 25 Z9 25 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD NOV 15 PY 2011 VL 70 IS 10 BP 937 EP 945 DI 10.1016/j.biopsych.2011.07.020 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 841DX UT WOS:000296493800007 PM 21907323 ER PT J AU Ueno, K Hirata, H Majid, S Tabatabai, ZL Hinoda, Y Dahiya, R AF Ueno, Koji Hirata, Hiroshi Majid, Shahana Tabatabai, Z. Laura Hinoda, Yuji Dahiya, Rajvir TI IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE RCC; IGFBP-4; metastasis; beta-catenin; TOPflash ID FACTOR BINDING-PROTEIN; GROWTH-FACTOR FAMILY; COLORECTAL-CANCER; IMMUNOGLOBULIN SUPERFAMILY; POOR-PROGNOSIS; CLEAR-CELL; TUMOR; IDENTIFICATION; PROGRESSION; TARGET AB The Wnt/beta-catenin signaling pathway is inactivated by Wnt antagonists in most cancers and IGFBP-4 is an antagonist of the Wnt/beta-catenin signaling pathway. However, the function of IGFBP-4 is not currently understood in renal cell carcinoma (RCC). We initially found that the expression of IGFBP-4 was significantly lower in primary RCC and higher in metastatic RCC compared to normal human kidney tissues. To assess the function of IGFBP4, we established IGFBP4 transfectants (primary renal cancer cell line) and performed functional analyses including Tcf reporter assays, cell viability, invasive capability, mortality, and in vivo tumor growth. Interestingly IGFBP-4 transfectants promoted cell growth (in vitro and in vivo), invasion, and motility in primary renal cancer. Tcf transcriptional activity was significantly increased in IGFBP-4 transfectants compared to mock cells and beta-catenin expression was increased. Also the beta-catenin downstream effector, MT1-MMP showed increased expression in IGFBP4 transfectants. Additionally IGFBP4 induced the expression of M-CAM, a marker of tumor progression. In order to assess the role of IGFBP4 in metastatic renal cancer, IGFBP-4 mRNA in a metastatic renal cancer cell lines (ACHN) was knocked-down using a siRNA technique. The cell growth and motility was decreased in si-IGFBP4 transfected ACHN cells compared to cells transfected with control siRNA. Tcf activity in ACHN cells was also decreased with si-IGFBP-4 transfection. This is a first report documenting that IGFBP-4 expression in RCC activates cell growth, metastasis, Wnt/beta-catenin signaling and may be involved in RCC metastasis. C1 [Ueno, Koji; Hirata, Hiroshi; Majid, Shahana; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Ueno, Koji; Hirata, Hiroshi; Majid, Shahana; Tabatabai, Z. Laura; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA. [Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan. RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu FU NIH [R01CA130860, R01CA111470, R01CA138642, T32DK007790]; VA Research Enhancement Award Program (REAP) FX Grant sponsor: NIH; Grant numbers: R01CA130860, R01CA111470, R01CA138642, T32DK007790; Grant sponsor: VA Research Enhancement Award Program (REAP), Merit Review grants NR 32 TC 21 Z9 22 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD NOV 15 PY 2011 VL 129 IS 10 BP 2360 EP 2369 DI 10.1002/ijc.25899 PG 10 WC Oncology SC Oncology GA 824VT UT WOS:000295231000007 PM 21207373 ER PT J AU Landefeld, CS AF Landefeld, C. Seth TI Goals of Care for Hip Fracture Promoting Independence and Reducing Mortality SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID OUTCOMES C1 [Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94118 USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, Geriatr Palliat & Extended Care Serv, San Francisco, CA USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. RP Landefeld, CS (reprint author), Univ Calif San Francisco, Div Geriatr, 3333 Calif St,Ste 380, San Francisco, CA 94118 USA. EM sethl@medicine.ucsf.edu NR 10 TC 2 Z9 2 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 14 PY 2011 VL 171 IS 20 BP 1837 EP 1838 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 848MS UT WOS:000297056300009 PM 22083570 ER PT J AU Jones, CK Engers, DW Thompson, AD Field, JR Blobaum, AL Lindsley, SR Zhou, Y Gogliotti, RD Jadhav, S Zamorano, R Bogenpohl, J Smith, Y Morrison, R Daniels, JS Weaver, CD Conn, PJ Lindsley, CW Niswender, CM Hopkins, CR AF Jones, Carrie K. Engers, Darren W. Thompson, Analisa D. Field, Julie R. Blobaum, Anna L. Lindsley, Stacey R. Zhou, Ya Gogliotti, Rocco D. Jadhav, Satyawan Zamorano, Rocio Bogenpohl, Jim Smith, Yoland Morrison, Ryan Daniels, J. Scott Weaver, C. David Conn, P. Jeffrey Lindsley, Craig W. Niswender, Colleen M. Hopkins, Corey R. TI Discovery, Synthesis, and Structure-Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu(4)) with Oral Efficacy in an Antiparkinsonian Animal Model SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID PARKINSONS-DISEASE; MGLUR4; PHARMACOLOGY; DOPAMINE; LEVODOPA; PAMS AB There is an increasing amount of literature data showing the positive effects on preclinical antiparkinsonian rodent models with selective positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)). However, most of the data generated utilize compounds that have not been optimized for druglike properties, and as a consequence, they exhibit poor pharmacokinetic properties and thus do not cross the blood-brain barrier. Herein, we report on a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides with improved PK properties with excellent potency and selectivity as well as improved brain exposure in rodents. Finally, ML182 was shown to be orally active in the haloperidol induced catalepsy model, a well-established antiparkinsonian model. C1 [Jones, Carrie K.; Engers, Darren W.; Thompson, Analisa D.; Field, Julie R.; Blobaum, Anna L.; Lindsley, Stacey R.; Zhou, Ya; Gogliotti, Rocco D.; Jadhav, Satyawan; Zamorano, Rocio; Morrison, Ryan; Daniels, J. Scott; Weaver, C. David; Conn, P. Jeffrey; Lindsley, Craig W.; Niswender, Colleen M.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. [Jones, Carrie K.; Engers, Darren W.; Thompson, Analisa D.; Blobaum, Anna L.; Lindsley, Stacey R.; Zhou, Ya; Gogliotti, Rocco D.; Jadhav, Satyawan; Zamorano, Rocio; Morrison, Ryan; Daniels, J. Scott; Conn, P. Jeffrey; Lindsley, Craig W.; Niswender, Colleen M.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA. [Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. [Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA. [Weaver, C. David; Conn, P. Jeffrey; Lindsley, Craig W.] Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA. [Engers, Darren W.; Conn, P. Jeffrey; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Specialized Chem Ctr Accelerated Probe, Nashville, TN 37232 USA. [Bogenpohl, Jim; Smith, Yoland] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA. [Bogenpohl, Jim; Smith, Yoland] Emory Univ, Dept Neurol, Atlanta, GA 30329 USA. RP Niswender, CM (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. EM colleen.niswender@vanderbilt.edu; corey.r.hopkins@vanderbilt.edu RI Conn, Peter/D-7848-2012; Zhou, Ya/F-1220-2013 FU National Institute of Mental Health, National Institute of Neurological Disorders and Stroke; Micheal J. Fox Foundation; Vanderbilt Department of Pharmacology; Vanderbilt Institute of Chemical Biology; NIH/MLPCN [5U54MH08465-02] FX The authors warmly acknowledge Emily L. Days, Tasha Nalywajko, Cheryl A. Austin, and Michael Baxter Williams for their critical contributions to the HTS portion of the projects; Matt Mulder, Chris Denicola, Nathan Kett, and Sichen Chang for the purification of compounds utilizing the mass-directed HPLC system; and Katrina Brewer for technical assistance with the PK assays. The dog cassette in vivo experiment was performed at Calvert Labs, and the rhesus in vivo experiment was performed at the Yerkes Primate Center at Emory University, GA. This work was supported by the National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, the Micheal J. Fox Foundation, the Vanderbilt Department of Pharmacology, and the Vanderbilt Institute of Chemical Biology. In addition, the authors thank the NIH/MLPCN (Grant 5U54MH08465-02) for support of this research. Vanderbilt is a member of the MLPCN and houses the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development. NR 27 TC 35 Z9 36 U1 0 U2 6 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD NOV 10 PY 2011 VL 54 IS 21 BP 7639 EP 7647 DI 10.1021/jm200956q PG 9 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 839ZN UT WOS:000296408100018 PM 21966889 ER PT J AU von Korff, M Katon, WJ Lin, EHB Ciechanowski, P Peterson, D Ludman, EJ Young, B Rutter, CM AF von Korff, Michael Katon, Wayne J. Lin, Elizabeth H. B. Ciechanowski, Paul Peterson, Do Ludman, Evette J. Young, Bessie Rutter, Carolyn M. TI Functional outcomes of multi-condition collaborative care and successful ageing: results of randomised trial SO BRITISH MEDICAL JOURNAL LA English DT Article ID QUALITY-OF-LIFE; CORONARY-HEART-DISEASE; MAJOR DEPRESSION; HEALTH-CARE; DISABILITY; MANAGEMENT; THERAPY; ANTIDEPRESSANT; COMPRESSION; VALIDATION AB Objective To evaluate the effectiveness of integrated care for chronic physical diseases and depression in reducing disability and improving quality of life. Design A randomised controlled trial of multi-condition collaborative care for depression and poorly controlled diabetes and/or risk factors for coronary heart disease compared with usual care among middle aged and elderly people Setting Fourteen primary care clinics in Seattle, Washington. Participants Patients with diabetes or coronary heart disease, or both, and blood pressure above 140/90 mm Hg, low density lipoprotein concentration >3.37 mmol/L, or glycated haemoglobin 8.5% or higher, and PHQ-9 depression scores of >= 10. Intervention A 12 month intervention to improve depression, glycaemic control, blood pressure, and lipid control by integrating a "treat to target" programme for diabetes and risk factors for coronary heart disease with collaborative care for depression. The intervention combined self management support, monitoring of disease control, and pharmacotherapy to control depression, hyperglycaemia, hypertension, and hyperlipidaemia. Main outcome measures Social role disability (Sheehan disability scale), global quality of life rating, and World Health Organization disability assessment schedule (WHODAS-2) scales to measure disabilities in activities of daily living (mobility, self care, household maintenance). Results Of 214 patients enrolled (106 intervention and 108 usual care), disability and quality of life measures were obtained for 97 intervention patients at six months (92%) and 92 at 12 months (87%), and for 96 usual care patients at six months (89%) and 92 at 12 months (85%). Improvements from baseline on the Sheehan disability scale (-0.9, 95% confidence interval -1.5 to -0.2; P=0.006) and global quality of life rating (0.7, 0.2 to 1.2; P=0.005) were significantly greater at six and 12 months in patients in the intervention group. There was a trend toward greater improvement in disabilities in activities of daily living (-1.5, -3.3 to 0.4; P=0.10). Conclusions Integrated care that covers chronic physical disease and comorbid depression can reduce social role disability and enhance global quality of life. C1 [von Korff, Michael; Lin, Elizabeth H. B.; Peterson, Do; Ludman, Evette J.; Rutter, Carolyn M.] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Katon, Wayne J.; Ciechanowski, Paul] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA. [Young, Bessie] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Sch Med, Seattle, WA 98195 USA. [Young, Bessie] Univ Washington, Div Nephrol, Sch Med, Dept Med, Seattle, WA 98195 USA. [Rutter, Carolyn M.] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA. RP von Korff, M (reprint author), Grp Hlth Res Inst, 1730 Minor Ave, Seattle, WA 98101 USA. EM vonkorff.m@ghc.org FU Group Health; National Institute of Mental Health Services Division, Bethesda, MD [MH041739, MH069741] FX The TEAMcare study would not have been possible without the support and participation of Group Health patients, primary care physicians, consultants, and leaders. We also acknowledge efforts and expertise by Tara Beatty, Malia Oliver, Sue Ruedebusch, Diana Griffith, and Sandy Randles. We also thank Michelle Wong, R James Dudl, and Kaiser Permanente Care Management Institute for providing the treat to target diabetes guidelines that we adapted. The content is solely the responsibility of the authors and does not necessarily represent the official views of the organisations that employ them.; This study was supported by grants MH041739 and MH069741 from the National Institute of Mental Health Services Division, Bethesda, MD (WJK) and by institutional support from Group Health Cooperative. The sponsors of this research had no influence over the conduct of the study, the analyses of study data, or the content of this paper. NR 41 TC 26 Z9 26 U1 0 U2 13 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD NOV 10 PY 2011 VL 343 AR d6612 DI 10.1136/bmj.d6612 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 848NT UT WOS:000297059000003 PM 22074851 ER PT J AU Wu, YN Johnson, SW AF Wu, Y. -N. Johnson, S. W. TI DOPAMINE OXIDATION FACILITATES ROTENONE-DEPENDENT POTENTIATION OF N-METHYL-D-ASPARTATE CURRENTS IN RAT SUBSTANTIA NIGRA DOPAMINE NEURONS SO NEUROSCIENCE LA English DT Article DE reactive oxygen species; rotenone; N-methyl-D-aspartate; monoamine oxidase; pargyline; reserpine ID PROTEIN-KINASE-C; MITOCHONDRIAL COMPLEX-I; PARKINSONS-DISEASE; NMDA-RECEPTOR; TYROSINE KINASE; DEPRENYL PROTECTS; RAPID DEVELOPMENT; TREATED RATS; PC12 CELLS; TOXICITY AB Rotenone is a mitochondrial poison that causes dopamine cell death and is used as a model of Parkinson's disease in rodents. Recently, we showed that rotenone augments currents evoked by N-methyl-D-aspartate (NMDA) by relieving voltage-dependent Mg(2+) block in rat substantia nigra compacta (SNC) dopamine neurons. Because rotenone is well known to generate reactive oxygen species (ROS), we conducted the present experiments to evaluate the role of ROS in mediating the effect of rotenone on NMDA current augmentation. Using patch pipettes to record whole-cell currents from SNC neurons in slices of rat brain, we found that the ability of rotenone (100 nM) to increase NMDA (3-30 mu M) current was antagonized by the antioxidant agent N-acetylcysteine (1 mM). In contrast, mercaptosuccinate (1 mM), which blocks glutathione peroxidase and raises tissue levels of H(2)O(2), mimicked rotenone by augmenting inward currents evoked by NMDA. Because oxidation of dopamine can also generate ROS, we explored the role of dopamine on this action of rotenone. We prepared dopamine-depleted midbrain slices from rats that had been pretreated with reserpine (5 mg/kg ip) and alpha-methyl-para-tyrosine (AMPT, 250 mg/kg ip). Dopamine depletion blocked the ability of rotenone (100 nM) to increase inward current evoked by NMDA (30 mu M). Rotenone-dependent augmentation of NMDA current was also blocked by the monoamine oxidase inhibitor pargyline (100 mu M) in slices prepared from normal rats. In contrast, the dopamine precursor levodopa potentiated the action of rotenone on NMDA current. These results suggest that ROS and/or dopamine oxidation products mediate the ability of rotenone to potentiate NMDA currents. Because excessive NMDA receptor stimulation can produce excitotoxicity, our results suggest that oxidative metabolism of dopamine might facilitate the neurotoxicity of rotenone. Published by Elsevier Ltd on behalf of IBRO. C1 [Wu, Y. -N.; Johnson, S. W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Johnson, S. W.] Portland VA Med Ctr, Portland, OR 97207 USA. RP Johnson, SW (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. EM johnsost@ohsu.edu FU Veterans Affairs Merit Review [0383]; Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center FX This research was supported by Veterans Affairs Merit Review grant 0383 and by the Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center. NR 53 TC 11 Z9 11 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD NOV 10 PY 2011 VL 195 BP 138 EP 144 DI 10.1016/j.neuroscience.2011.08.041 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 833EF UT WOS:000295863900014 PM 21884756 ER PT J AU Hill-Burns, EM Factor, SA Zabetian, CP Thomson, G Payami, H AF Hill-Burns, Erin M. Factor, Stewart A. Zabetian, Cyrus P. Thomson, Glenys Payami, Haydeh TI Evidence for More than One Parkinson's Disease-Associated Variant within the HLA Region SO PLOS ONE LA English DT Article ID POPULATION; METAANALYSIS; HAPLOTYPES; IMPUTATION; GENETICS; SNCA AB Parkinson's disease (PD) was recently found to be associated with HLA in a genome-wide association study (GWAS). Followup GWAS's replicated the PD-HLA association but their top hits differ. Do the different hits tag the same locus or is there more than one PD-associated variant within HLA? We show that the top GWAS hits are not correlated with each other (0.00 <= r(2)<= 0.15). Using our GWAS (2000 cases, 1986 controls) we conducted step-wise conditional analysis on 107 SNPs with P, 10 23 for PD-association; 103 dropped-out, four remained significant. Each SNP, when conditioned on the other three, yielded P(SNP1) = 5610 24, P(SNP2) = 5610 24, P(SNP3) = 4610 23 and P(SNP4) = 0.025. The four SNPs were not correlated (0.01 <= r(2)<= 0.20). Haplotype analysis (excluding rare SNP2) revealed increasing PD risk with increasing risk alleles from OR = 1.27, P = 5610 23 for one risk allele to OR = 1.65, P = 4610 28 for three. Using additional 843 cases and 856 controls we replicated the independent effects of SNP1 (P(conditioned-on-SNP4) = 0.04) and SNP4 (P(conditioned-on-SNP1) = 0.04); SNP2 and SNP3 could not be replicated. In pooled GWAS and replication, SNP1 had OR(conditioned-on-SNP4) = 1.23, P(conditioned-on-SNP4) = 6610 27; SNP4 had OR(conditioned-on-SNP1) = 1.18, P(conditioned-on-SNP1) = 3610 23; and the haplotype with both risk alleles had OR = 1.48, P = 2x10(-12). Genotypic OR increased with the number of risk alleles an individual possessed up to OR = 1.94, P = 2610 211 for individuals who were homozygous for the risk allele at both SNP1 and SNP4. SNP1 is a variant in HLA-DRA and is associated with HLA-DRA, DRB5 and DQA2 gene expression. SNP4 is correlated (r(2) = 0.95) with variants that are associated with HLA-DQA2 expression, and with the top HLA SNP from the IPDGC GWAS (r(2) = 0.60). Our findings suggest more than one PD-HLA association; either different alleles of the same gene, or separate loci. C1 [Hill-Burns, Erin M.; Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Zabetian, Cyrus P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Thomson, Glenys] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA. RP Hill-Burns, EM (reprint author), New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. EM hpayami@wadsworth.org OI Zabetian, Cyrus/0000-0002-7739-4306 FU National Institute of Neurological Disorders And Stroke (NINDS) [R01 NS36960, R01 NS067469]; Edmond J. Safra Michael J. Fox Foundation Global Genetic Consortium Initiative; Department of Veterans Affairs [I01BX000531]; Close to a Cure Foundation: A Fund for Parkinson's Research of Foundation for the Carolinas; National Institute of Allergy and Infectious Disease [AI40076] FX Study was supported by grants from the National Institute of Neurological Disorders And Stroke (NINDS R01 NS36960 and R01 NS067469 to HP), the Edmond J. Safra Michael J. Fox Foundation Global Genetic Consortium Initiative (HP), the Department of Veterans Affairs ('I01BX000531 to CZ), The Close to a Cure Foundation: A Fund for Parkinson's Research of Foundation for the Carolinas (SF), and the National Institute of Allergy and Infectious Disease (AI40076, GT). Funding support for the replication dataset was provided by the National Institute of Neurological Disorders and Stroke (Foroud/Myers, PI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 20 Z9 20 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 9 PY 2011 VL 6 IS 11 AR e27109 DI 10.1371/journal.pone.0027109 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 852II UT WOS:000297350800027 PM 22096524 ER PT J AU Konno, T Hata, S Hamada, Y Horikoshi-Sakuraba, Y Nakaya, T Saito, Y Yamamoto, T Yamamoto, T Maeda, M Ikeuchi, T Gandy, S Akatsu, H Suzuki, T AF Konno, Tomoko Hata, Saori Hamada, Yukiko Horikoshi-Sakuraba, Yuko Nakaya, Tadashi Saito, Yuhki Yamamoto, Tohru Yamamoto, Takayuki Maeda, Masahiro Ikeuchi, Takeshi Gandy, Sam Akatsu, Hiroyasu Suzuki, Toshiharu CA Japanese Alzheimers Dis TI Coordinated increase of gamma-secretase reaction products in the plasma of some female Japanese sporadic Alzheimer's disease patients: quantitative analysis of p3-Alc alpha with a new ELISA system SO MOLECULAR NEURODEGENERATION LA English DT Article ID TRAUMATIC BRAIN-INJURY; AMYLOID-BETA; APOLIPOPROTEIN-E; ASSOCIATION; ESTROGEN; PEPTIDE; GENE; NEURODEGENERATION; DEGRADATION; METABOLISM AB Background: Aggregatable amyloid beta-peptide (A beta) and non-aggregatable p3-Alc alpha are metabolic products of the gamma-secretase cleavage of amyloid beta-protein precursor (APP) and Alcadein alpha (Alc alpha), respectively. Familial AD (FAD)-linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of gamma-secretase can cause alternative intramembranous processing of APP and Alc alpha, leading to a coordinated generation of variants of both A beta and p3-Alc alpha. Variant Alc alpha peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic Alzheimer's disease (AD). Since, like APP, Alc alpha is largely expressed in brain, one might predict that alternative processing of Alca would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple gamma-secretase substrates might define an endophenotype of p3-Alc alpha, in whom AD is due either to dysfunction of gamma-secretase or to a disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains. Results: We developed a simple procedure for extraction of p3-Alc alpha from plasma and for analyzing this extract in a sensitive, p3-Alc alpha-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alca levels and A beta 40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of these patients, levels of plasma p3-Alc alpha were significantly higher, and were accompanied by parallel changes in A beta 40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not observed in subjects with frontotemporal lobar degeneration (FTLD). Conclusion: Reagents and procedures have been established that enable extraction of p3-Alc alpha from plasma and for quantification of plasma p3-Alc alpha levels by ELISA. Some populations of AD subjects apparently show increased levels of both p3-Alc alpha and A beta 40. Quantification of p3-Alc alpha level may be useful as a readily accessible biomarker for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of gamma-secretase or with a disorder of the clearance of transmembrane domain-derived peptides. C1 [Konno, Tomoko; Hata, Saori; Nakaya, Tadashi; Saito, Yuhki; Yamamoto, Tohru; Suzuki, Toshiharu] Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido 0600812, Japan. [Hamada, Yukiko; Horikoshi-Sakuraba, Yuko; Maeda, Masahiro] Immunobiol Labs Co Ltd IBL, Fujioka 3750005, Japan. [Yamamoto, Takayuki; Akatsu, Hiroyasu] Fukushimura Hosp, Choju Med Inst, Toyohashi, Aichi 4418124, Japan. [Ikeuchi, Takeshi] Niigata Univ, Brain Res Inst, Dept Mol Neurosci, Niigata 9518585, Japan. [Gandy, Sam] Alzheimers Dis Res Ctr, Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] Alzheimers Dis Res Ctr, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Gandy, Sam] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA. RP Suzuki, T (reprint author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido 0600812, Japan. EM tsuzuki@pharm.hokudai.ac.jp RI Hata, Saori /A-3829-2012; Yamamoto, Tohru/A-3801-2012; Suzuki, Toshiharu/B-5342-2013 OI Yamamoto, Tohru/0000-0002-1652-0233; FU Ministry of Education, Culture, Sports, Science and Technology (MEXT); Ministry of Health, Labor and Welfare (MHLW); New Energy and Industrial Technology Development Organization (NEDO) in Japan; NIA Alzheimer's Disease Research Center [P50 05138] FX This work was supported in part by Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), a grant from the Ministry of Health, Labor and Welfare (MHLW), and a grant from the New Energy and Industrial Technology Development Organization (NEDO) in Japan. S.G. was supported by the NIA Alzheimer's Disease Research Center grant P50 05138 to Mary Sano. NR 32 TC 5 Z9 5 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PD NOV 8 PY 2011 VL 6 AR 76 DI 10.1186/1750-1326-6-76 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 864NT UT WOS:000298247600001 PM 22067061 ER PT J AU Singh, T Sharma, SD Katiyar, SK AF Singh, Tripti Sharma, Som D. Katiyar, Santosh K. TI Grape Proanthocyanidins Induce Apoptosis by Loss of Mitochondrial Membrane Potential of Human Non-Small Cell Lung Cancer Cells In Vitro and In Vivo SO PLOS ONE LA English DT Article ID SKH-1 HAIRLESS MICE; DEPENDENT KINASES; ANTICANCER DRUGS; CARCINOMA-CELLS; CYCLE CONTROL; BCL-2 FAMILY; DEATH; INHIBITORS; PROTEIN; GROWTH AB Lung cancer remains the leading cause of cancer-related deaths worldwide, and non-small cell lung cancer (NSCLC) represents approximately 80% of total lung cancer cases. The use of non-toxic dietary phytochemicals can be considered as a chemotherapeutic strategy for the management of the NSCLC. Here, we report that grape seed proanthocyanidins (GSPs) induce apoptosis of NSCLC cells, A549 and H1299, in vitro which is mediated through increased expression of pro-apoptotic protein Bax, decreased expression of anti-apoptotic proteins Bcl2 and Bcl-xl, disruption of mitochondrial membrane potential, and activation of caspases 9, 3 and poly (ADP-ribose) polymerase (PARP). Pre-treatment of A549 and H1299 cells with the caspase-3 inhibitor (z-DEVD-fmk) significantly blocked the GSPs-induced apoptosis of these cells confirmed that GSPs-induced apoptosis is mediated through activation of caspases-3. Treatments of A549 and H1299 cells with GSPs resulted in an increase in G1 arrest. G0/G1 phase of the cell cycle is known to be controlled by cyclin dependent kinases (Cdk), cyclin-dependent kinase inhibitors (Cdki) and cyclins. Our western blot analyses showed that GSPs-induced G1 cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), and a simultaneous decrease in the levels of Cdk2, Cdk4, Cdk6 and cyclins. Further, administration of 50, 100 or 200 mg GSPs/kg body weight of mice by oral gavage (5 d/week) markedly inhibited the growth of s.c. A549 and H1299 lung tumor xenografts in athymic nude mice, which was associated with the induction of apoptotic cell death, increased expression of Bax, reduced expression of anti-apoptotic proteins and activation of caspase-3 in tumor xenograft cells. Based on the data obtained in animal study, human equivalent dose of GSPs was calculated, which seems affordable and attainable. Together, these results suggest that GSPs may represent a potential therapeutic agent for the non-small cell lung cancer. C1 [Singh, Tripti; Sharma, Som D.; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Katiyar, Santosh K.] Univ Alabama, Nutr Obes Res Ctr, Birmingham, AL USA. [Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. RP Singh, T (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award FX This work was supported by funds from the Veterans Administration Merit Review Award (SKK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 34 Z9 37 U1 1 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 8 PY 2011 VL 6 IS 11 AR e27444 DI 10.1371/journal.pone.0027444 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 852HZ UT WOS:000297349700046 PM 22087318 ER PT J AU Azadani, A Chitsaz, S Tseng, E Ge, L AF Azadani, Ali Chitsaz, Sam Tseng, Elaine Ge, Liang TI Finite Element Analysis of Transcatheter Aortic Valve Implantation: Impact of Oversizing on Stent and Leaflet Stresses SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium CY NOV 07-11, 2011 CL San Francisco, CA C1 [Azadani, Ali; Chitsaz, Sam; Tseng, Elaine; Ge, Liang] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Azadani, Ali; Chitsaz, Sam; Tseng, Elaine; Ge, Liang] San Francisco VA Med Ctr, San Francisco, CA USA. RI Chitsaz, Sam/C-4586-2008 NR 0 TC 0 Z9 0 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 8 PY 2011 VL 58 IS 20 SU B BP B198 EP B198 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 846IZ UT WOS:000296891900736 ER PT J AU Chitsaz, S Jaussaud, N Meadows, A Wintermark, M Cambronero, N Azadani, AN Saloner, DA Chuter, TA Ge, L Tseng, EE AF Chitsaz, Sam Jaussaud, Nicolas Meadows, Alison Wintermark, Max Cambronero, Neil Azadani, Ali N. Saloner, David A. Chuter, Timothy A. Ge, Liang Tseng, Elaine E. TI Thoracic Endovascular Aortic Repair for Acute Type A Dissection: A Computational and Anatomic Analysis of Technical Limitations for Available Devices SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium CY NOV 07-11, 2011 CL San Francisco, CA C1 [Chitsaz, Sam; Jaussaud, Nicolas; Wintermark, Max; Cambronero, Neil; Azadani, Ali N.; Chuter, Timothy A.; Ge, Liang; Tseng, Elaine E.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Chitsaz, Sam; Jaussaud, Nicolas; Azadani, Ali N.; Saloner, David A.; Ge, Liang; Tseng, Elaine E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Meadows, Alison; Saloner, David A.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. RI Chitsaz, Sam/C-4586-2008 NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 8 PY 2011 VL 58 IS 20 SU B BP B155 EP B155 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 846IZ UT WOS:000296891900575 ER PT J AU Dattilo, PB Tsai, TT Casserly, IP AF Dattilo, Philip B. Tsai, Thomas T. Casserly, Ivan P. TI Endovascular Therapy of Common Femoral Arterial Disease SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium CY NOV 07-11, 2011 CL San Francisco, CA C1 [Dattilo, Philip B.; Tsai, Thomas T.; Casserly, Ivan P.] Univ Colorado, Sch Med, Aurora, CO USA. [Tsai, Thomas T.; Casserly, Ivan P.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 8 PY 2011 VL 58 IS 20 SU B BP B157 EP B157 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 846IZ UT WOS:000296891900582 ER PT J AU Owens, CD Gasper, WJ Kim, JM Rapp, J Grenon, M Seward, K AF Owens, Christopher D. Gasper, Warren J. Kim, Ji Min Rapp, Joseph Grenon, Marlene Seward, Kirk TI Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy after Femoropopliteal Revascularization: A First in Man Study SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium CY NOV 07-11, 2011 CL San Francisco, CA C1 [Owens, Christopher D.; Gasper, Warren J.; Kim, Ji Min; Rapp, Joseph; Grenon, Marlene] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Owens, Christopher D.; Gasper, Warren J.; Rapp, Joseph; Grenon, Marlene] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Seward, Kirk] Mercator MedSyst Inc, San Leandro, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 8 PY 2011 VL 58 IS 20 SU B BP B155 EP B155 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 846IZ UT WOS:000296891900574 ER PT J AU Rugge, M Fassan, M Pizzi, M Farinati, F Sturniolo, GC Plebani, M Graham, DY AF Rugge, Massimo Fassan, Matteo Pizzi, Marco Farinati, Fabio Sturniolo, Giacomo Carlo Plebani, Mario Graham, David Y. TI Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Gastritis; Staging; Atrophic gastritis; Intestinal metaplasia; Operative link for gastritis assessment; Operative link on intestinal metaplasia assessment ID LYMPH-NODE DISSECTION; ASSISTED DISTAL GASTRECTOMY; OPEN SUBTOTAL GASTRECTOMY; BILLROTH-I GASTRECTOMY; QUALITY-OF-LIFE; CANCER; TRIAL AB AIM: To compare the reliability of gastritis staging systems in ranking gastritis-associated cancer risk in a large series of consecutive patients. METHODS: Gastric mucosal atrophy is the precancerous condition in which intestinal-type gastric cancer (GC) most frequently develops. The operative link for gastritis assessment (OLGA) staging system ranks the GC risk according to both the topography and the severity of gastric atrophy (as assessed histologically on the basis of the Sydney protocol for gastric mucosal biopsy). Both cross-sectional and long-term follow-up trials have consistently associated OLGA stages III-IV with a higher risk of GC. A recently-proposed modification of the OLGA staging system (OLGIM) basically incorporates the OLGA frame, but replaces the atrophy score with an assessment of intestinal metaplasia (IM) alone. A series of 4552 consecutive biopsy sets (2007-2009) was retrieved and reassessed according to both the OLGA and the OLGIM staging systems. A set of at least 5 biopsy samples was available for all the cases considered. RESULTS: In 4460 of 4552 cases (98.0%), both the high-risk stages (III + IV) and the low-risk stages (0 + I + II) were assessed applying the OLGA and OLGIM criteria. Among the 243 OLGA high-risk stages, 14 (5.8%) were down-staged to a low risk using OLGIM. The 67 (1.5%) incidentally-found neoplastic lesions (intraepithelial or invasive) were consistently associated with high-risk stages, as assessed by both OLGA and OLGIM (P < 0.001 for both). Two of 34 intestinal-type GCs coexisting with a high-risk OLGA stage (stage III) were associated with a low-risk OLGIM stage (stage II). CONCLUSION: Gastritis staging systems (both OLGA and OLGIM) convey prognostically important information on the gastritis-associated cancer risk. Because of its clinical impact, the stage of gastritis should be included as a conclusive message in the gastritis histology report. Since it focuses on IM alone, OLGIM staging is less sensitive than OLGA staging in the identification of patients at high risk of gastric cancer. (C) 2011 Baishideng. All rights reserved. C1 [Rugge, Massimo] Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med Diagnost Sci & Special Therapies, Ist Oncol Veneto IOV IRCCS, I-35100 Padua, Italy. [Farinati, Fabio; Sturniolo, Giacomo Carlo] Univ Padua, Dept Gastroenterol & Surg Sci, Gastroenterol Unit, I-35100 Padua, Italy. [Plebani, Mario] Univ Padua, Dept Diagnost Med Sci & Special Therapies, Clin Chem Unit, I-35100 Padua, Italy. [Graham, David Y.] Vet Adm Hosp, Baylor Coll Med, Div Digest Dis, Houston, TX 77030 USA. RP Rugge, M (reprint author), Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med Diagnost Sci & Special Therapies, Ist Oncol Veneto IOV IRCCS, Via Aristide Gabelli 61, I-35100 Padua, Italy. EM massimo.rugge@unipd.it RI Fassan, Matteo/F-5152-2012; Rugge, Massimo/K-7525-2016 OI Fassan, Matteo/0000-0001-6515-5482; FU AIRC from the Veneto Regional Authorities; "Guido Berlucchi" Foundation; "Morgagni" Association for Oncological Research (Padova; PD) FX Supported by An AIRC grant from the Veneto Regional Authorities, 2009; the "Guido Berlucchi" Foundation; and the "Morgagni" Association for Oncological Research (Padova; PD) NR 18 TC 26 Z9 27 U1 0 U2 2 PU BAISHIDENG PUBL GRP CO LTD PI BEIJING PA RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU, BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD NOV 7 PY 2011 VL 17 IS 41 BP 4596 EP 4606 DI 10.3748/wjg.v17.i41.4596 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 861ER UT WOS:000298002500007 PM 22147965 ER PT J AU Sorror, ML Sandmaier, BM Storer, BE Franke, GN Laport, GG Chauncey, TR Agura, E Maziarz, RT Langston, A Hari, P Pulsipher, MA Bethge, W Sahebi, F Bruno, B Maris, MB Yeager, A Petersen, FB Vindelov, L McSweeney, PA Hubel, K Mielcarek, M Georges, GE Niederwieser, D Blume, KG Maloney, DG Storb, R AF Sorror, Mohamed L. Sandmaier, Brenda M. Storer, Barry E. Franke, Georg N. Laport, Ginna G. Chauncey, Thomas R. Agura, Edward Maziarz, Richard T. Langston, Amelia Hari, Parameswaran Pulsipher, Michael A. Bethge, Wolfgang Sahebi, Firoozeh Bruno, Benedetto Maris, Michael B. Yeager, Andrew Petersen, Finn Bo Vindelov, Lars McSweeney, Peter A. Huebel, Kai Mielcarek, Marco Georges, George E. Niederwieser, Dietger Blume, Karl G. Maloney, David G. Storb, Rainer TI Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; MINIMAL RESIDUAL DISEASE; MARROW TRANSPLANTATION; MYELODYSPLASTIC SYNDROMES; COMORBIDITY INDEX; RISK-ASSESSMENT; FLOW-CYTOMETRY; AGE; METHOTREXATE AB Context A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions. Objective To describe outcomes of patients 60 years or older after receiving minimally toxic nonmyeloablative allogeneic HCT. Design, Setting, and Participants From 1998 to 2008, 372 patients aged 60 to 75 years were enrolled in prospective clinical HCT trials at 18 collaborating institutions using conditioning with low-dose total body irradiation alone or combined with fludarabine, 90 mg/m(2), before related (n=184) or unrelated (n=188) donor transplants. Postgrafting immunosuppression included mycophenolate mofetil and a calcineurin inhibitor. Main Outcome Measures Overall and progression-free survival were estimated by Kaplan-Meier method. Cumulative incidence estimates were calculated for acute and chronic graft-vs-host disease, toxicities, achievement of full donor chimerism, complete remission, relapse, and nonrelapse mortality. Hazard ratios (HRs) were estimated from Cox regression models. Results Overall, 5-year cumulative incidences of nonrelapse mortality and relapse were 27% (95% CI, 22%-32%) and 41% (95% CI, 36%-46%), respectively, leading to 5-year overall and progression-free survival of 35% (95% CI, 30%-40%) and 32% (95% CI, 27%-37%), respectively. These outcomes were not statistically significantly different when stratified by age groups. Furthermore, increasing age was not associated with increases in acute or chronic graft-vs-host disease or organ toxicities. In multivariate models, HCT-specific comorbidity index scores of 1 to 2 (HR, 1.58 [95% CI, 1.08-2.31]) and 3 or greater (HR, 1.97 [95% CI, 1.38-2.80]) were associated with worse survival compared with an HCT-specific comorbidity index score of 0 (P=.003 overall). Similarly, standard relapse risk (HR, 1.67 [95% CI, 1.10-2.54]) and high relapse risk (HR, 2.22 [95% CI, 1.43-3.43]) were associated with worse survival compared with low relapse risk (P<.001 overall). Conclusion Among patients aged 60 to 75 years treated with nonmyeloablative allogeneic HCT, 5-year overall and progression-free survivals were 35% and 32%, respectively. JAMA. 2011; 306(17): 1874-1883 C1 [Sorror, Mohamed L.; Sandmaier, Brenda M.; Chauncey, Thomas R.; Mielcarek, Marco; Georges, George E.; Maloney, David G.; Storb, Rainer] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Program, Seattle, WA 98109 USA. [Storer, Barry E.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Clin Stat Program, Seattle, WA 98109 USA. [Sorror, Mohamed L.; Sandmaier, Brenda M.; Chauncey, Thomas R.; Mielcarek, Marco; Georges, George E.; Maloney, David G.; Storb, Rainer] Univ Washington, Sch Med, Dept Med, Div Med Oncol, Seattle, WA 98195 USA. [Storer, Barry E.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Marrow Transplant Unit, Seattle, WA USA. [Franke, Georg N.; Niederwieser, Dietger] Univ Leipzig, Dept Med, Div Hematol Oncol & Hemostaseol, Leipzig, Germany. [Laport, Ginna G.; Blume, Karl G.] Stanford Sch Med, Div Blood & Marrow Transplantat, Dept Med, Stanford, CA USA. [Agura, Edward] Baylor Univ, Hematopoiet Stem Cell Program, Sch Med, Dallas, TX USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Sch Med, Hematopoiet Stem Cell Transplant Program, Portland, OR 97201 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Sch Med, Ctr Hematol Malignancies, Knight Canc Inst, Portland, OR 97201 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Sch Med, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Langston, Amelia] Emory Univ, Sch Med, Div Hematol Oncol, Atlanta, GA USA. [Langston, Amelia] Emory Univ, Bone Marrow & Stem Cell Transplant Ctr, Winship Canc Inst, Atlanta, GA 30322 USA. [Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Sch Med, Milwaukee, WI 53226 USA. [Pulsipher, Michael A.] Univ Utah, Sch Med, Div Hematol Blood & Marrow Transplantat, Salt Lake City, UT USA. [Pulsipher, Michael A.] Primary Childrens Med Ctr, Pediat Blood & Marrow Transplant Program, Huntsman Canc Inst, Salt Lake City, UT 84103 USA. [Bethge, Wolfgang] Univ Tubingen, Sch Med, Tubingen, Germany. [Sahebi, Firoozeh] City Hope Sch Med, Duarte, CA USA. [Bruno, Benedetto] Univ Turin, Sch Med, Turin, Italy. [Maris, Michael B.; McSweeney, Peter A.] Colorado Blood Canc Inst, Denver, CO USA. [Yeager, Andrew] Univ Arizona, Sch Med, Dept Med & Pediat, Tucson, AZ USA. [Petersen, Finn Bo] Intermt Hlth Care, Intermt Blood & Marrow Transplant Acute Leukemia, Salt Lake City, UT USA. [Petersen, Finn Bo] Univ Aarhus, Sch Med, Aarhus, Denmark. [Vindelov, Lars] Rigshosp, Hematopoiet Cell Transplantat Program, Dept Hematol, DK-2100 Copenhagen, Denmark. [McSweeney, Peter A.] Univ Colorado, Sch Med, Boulder, CO 80309 USA. [Huebel, Kai] Univ Cologne, Dept Internal Med, Sch Med, Stem Cell Transplant Program, Cologne, Germany. RP Sorror, ML (reprint author), Fred Hutchinson Canc Res Ctr, Clin Res Div D1 100, 1100 Fairview Ave N, Seattle, WA 98109 USA. EM msorror@fhcrc.org OI Hari, Parameswaran/0000-0002-8800-297X FU Japanese Heath Sciences; Athersys Inc; BMT/CTN; Medac GmbH; Fresenius GmbH; Pfizer; Miltenyi Biotech GmbH; Millennium Pharmaceuticals; Danish Cancer Society; Lundbeck Foundation; Research Council of Rigshospitalet; Region of the Capital of Denmark; National Institutes of Health (NIH) [P01HL036444, P01CA078902, P01CA018029, P30CA015704, R00HL088021]; Leukemia/Lymphoma Society [7008-08] FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Sandmaier reported serving on the board of ArevaMed. Dr Franke reported receiving travel/accommodations/meeting expenses for the European Group of Blood and Marrow Transplantation 2009 meeting. Dr Maziarz reported receiving grants or grants pending (grant money to institution) from Japanese Heath Sciences, Athersys Inc, and BMT/CTN; serving on the speakers bureaus of Millennium Pharmaceuticals Inc and Genzyme Inc; receiving royalties from Springer for publication of a book; and receiving honoraria for lectures (groups change yearly; usually related to community oncology educational efforts). Dr Bethge reported serving as a consultant for Miltenyi Biotech GmbH; receiving grants or grants pending from Medac GmbH, Fresenius GmbH, Pfizer, and Miltenyi Biotech GmbH; receiving payment for lectures from Miltenyi Biotech GmbH; and receiving travel/accommodations/meeting expenses from Medac GmbH. Dr Sahebi reported receiving travel/accommodations/meeting expenses and a research fund from Millennium Pharmaceuticals. Dr Vindelov reported receiving research grants from the Danish Cancer Society, The Lundbeck Foundation, and the Research Council of Rigshospitalet and receiving a travel and research grant from the Region of the Capital of Denmark. No other authors reported disclosures.; Research for this study has been supported by grants from the National Institutes of Health (NIH) (P01HL036444, P01CA078902, P01CA018029, P30CA015704, and R00HL088021) and from the Leukemia/Lymphoma Society (7008-08). NR 38 TC 101 Z9 101 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 2 PY 2011 VL 306 IS 17 BP 1874 EP 1883 DI 10.1001/jama.2011.1558 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 839OD UT WOS:000296376200021 PM 22045765 ER PT J AU Hoang, T Byers, AL Barnes, D Cawthon, PM Yaffe, K AF Hoang, T. Byers, A. L. Barnes, D. Cawthon, P. M. Yaffe, K. TI ALCOHOL CONSUMPTION OVER THE LIFE COURSE AND COGNITIVE OUTCOMES IN OLDER WOMEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hoang, T.; Byers, A. L.; Barnes, D.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Byers, A. L.; Barnes, D.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cawthon, P. M.] Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Neurol, Dept Epidemiol & Biostat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 20 EP 20 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000094 ER PT J AU Spira, AP Covinsky, K Rebok, G Punjabi, N Stone, KL Hillier, TA Ensrud, K Yaffe, K AF Spira, A. P. Covinsky, K. Rebok, G. Punjabi, N. Stone, K. L. Hillier, T. A. Ensrud, K. Yaffe, K. TI OBJECTIVELY MEASURED SLEEP AND FUNCTIONAL DECLINE IN OLDER WOMEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Spira, A. P.; Rebok, G.; Punjabi, N.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Covinsky, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Punjabi, N.] Johns Hopkins Sch Med, Baltimore, MD USA. [Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Hillier, T. A.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. [Ensrud, K.] Minneapolis VAMC, Minneapolis, MN USA. [Ensrud, K.] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 20 EP 20 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000093 ER PT J AU Sanders, J Fitzpatrick, A Boudreau, R Arnold, A Aviv, A Fried, LF Harris, TB Newman, AB AF Sanders, J. Fitzpatrick, A. Boudreau, R. Arnold, A. Aviv, A. Fried, L. F. Harris, T. B. Newman, A. B. TI LEUKOCYTE TELOMERE LENGTH IS ASSOCIATED WITH AGE-RELATED CHRONIC DISEASE BURDEN IN OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Sanders, J.; Boudreau, R.; Newman, A. B.] Univ Pittsburgh, Pittsburgh, PA USA. [Fitzpatrick, A.; Arnold, A.] Univ Washington, Seattle, WA 98195 USA. [Aviv, A.] Univ Med & Dent New Jersey, Newark, NJ 07103 USA. [Fried, L. F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Harris, T. B.] NIA, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 22 EP 23 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000105 ER PT J AU Hilgeman, MM Snow, A Mahaney-Price, AF Kertesz, S Davis, L AF Hilgeman, M. M. Snow, A. Mahaney-Price, A. F. Kertesz, S. Davis, L. TI EXAMINATION OF THE MONTREAL COGNITIVE ASSESSMENT (MOCA): FINDINGS FROM THE ALABAMA VETERANS RURAL HEALTH INITIATIVE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hilgeman, M. M.; Snow, A.; Mahaney-Price, A. F.; Davis, L.] Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA. [Kertesz, S.] Birmingham VA Med Ctr, Birmingham, AL USA. [Kertesz, S.] Univ Alabama Birmingham, Birmingham, AL USA. [Davis, L.] Univ Alabama, Sch Med, Tuscaloosa, AL 35401 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 31 EP 32 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000149 ER PT J AU Bolkan, C Bonner, L Campbell, DG Lanto, A Rubenstein, L Chaney, E AF Bolkan, C. Bonner, L. Campbell, D. G. Lanto, A. Rubenstein, L. Chaney, E. TI THE COMPLEX RELATIONSHIP BETWEEN SOCIAL SUPPORT AND DEPRESSION: THE SIGNIFICANCE OF PATIENT SATISFACTION AND MEDICATION ADHERENCE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bolkan, C.] Washington State Univ, Vancouver, WA USA. [Bonner, L.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Campbell, D. G.] Univ Montana, Missoula, MT 59812 USA. [Lanto, A.; Rubenstein, L.] VA Greater Angeles Healthcare Syst, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Los Angeles, CA USA. [Rubenstein, L.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Rubenstein, L.] RAND Hlth Program, Santa Monica, CA USA. [Chaney, E.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 34 EP 34 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000159 ER PT J AU Kresevic, DM Burant, CJ Denton, JE Ibrahim, S AF Kresevic, D. M. Burant, C. J. Denton, J. E. Ibrahim, S. TI OUTPATIENT ANTICOAGULATION EDUCATION AND OUTCOMES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kresevic, D. M.; Burant, C. J.; Denton, J. E.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Kresevic, D. M.] Univ Hosp, Case Med Ctr, Cleveland, OH USA. [Kresevic, D. M.; Burant, C. J.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA. [Ibrahim, S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 74 EP 74 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000332 ER PT J AU Hughes, J Martin, JL AF Hughes, J. Martin, J. L. TI SLEEP: AN OVERLOOKED COMPONENT OF HEALTH AND QUALITY OF LIFE IN OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hughes, J.; Martin, J. L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 78 EP 78 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000348 ER PT J AU Vitiello, MV Baker, LD Borson, S Friedman, SD Barsness, S Merriam, GR AF Vitiello, M. V. Baker, L. D. Borson, S. Friedman, S. D. Barsness, S. Merriam, G. R. TI TESAMORELIN, A HUMAN GROWTH HORMONE RELEASING HORMONE ANALOGUE, IMPROVES COGNITIVE FUNCTION IN MCI AND HEALTHY AGING: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED TRIAL SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Vitiello, M. V.; Baker, L. D.; Borson, S.; Barsness, S.; Merriam, G. R.] Univ Washington, Seattle, WA 98195 USA. [Friedman, S. D.] Childrens Hosp, Seattle, WA USA. [Merriam, G. R.] VA Puget Sound Hlth Care Syst, Tacoma, WA USA. [Merriam, G. R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 106 EP 106 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000481 ER PT J AU Wittich, AR Williams, BR Woodby, LL Burgio, KL AF Wittich, A. R. Williams, B. R. Woodby, L. L. Burgio, K. L. TI "THE WHOLE POWER OF ATTORNEY": UNDERSTANDING ADVANCE DIRECTIVES AMONG NEXT-OF-KIN IN VA MEDICAL CENTERS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Wittich, A. R.; Williams, B. R.; Woodby, L. L.; Burgio, K. L.] Birmingham VAMC, Birmingham, AL USA. [Williams, B. R.; Woodby, L. L.; Burgio, K. L.] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 136 EP 137 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000623 ER PT J AU Mavandadi, S Mamikonyan, E Duda, JE Weintraub, D AF Mavandadi, S. Mamikonyan, E. Duda, J. E. Weintraub, D. TI INTERPERSONAL FUNCTIONING IN PARKINSON'S DISEASE: A DYADIC ANALYSIS OF VETERANS AND CAREGIVERS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mavandadi, S.; Weintraub, D.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Mavandadi, S.; Mamikonyan, E.; Weintraub, D.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Duda, J. E.; Weintraub, D.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Duda, J. E.] Univ Penn, Dept Neurol, Penn Hosp, Parkinsons Dis & Movement Disorders Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 141 EP 141 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602000643 ER PT J AU Mahaney-Price, AF Hilgeman, MM Kertesz, S Davis, L AF Mahaney-Price, A. F. Hilgeman, M. M. Kertesz, S. Davis, L. TI RURAL ALABAMA VETERAN ADVANCE DIRECTIVE BEHAVIOR AND DESIRE FOR HELP COMPLETING AN ADVANCE DIRECTIVE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mahaney-Price, A. F.; Hilgeman, M. M.; Davis, L.] Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA. [Kertesz, S.] Birmingham VA Med Ctr, Birmingham, AL USA. [Davis, L.] Univ Alabama, Sch Med, Tuscaloosa, AL 35401 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 174 EP 174 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602001103 ER PT J AU Wolden-Hanson, T AF Wolden-Hanson, T. TI HYPOTHALAMIC CONTROL OF THE ANOREXIA OF AGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Wolden-Hanson, T.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Wolden-Hanson, T.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 188 EP 188 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602001162 ER PT J AU Kramer, B Barczi, S Chernoff, R Horvath, KJ Howe, JL Huh, J Tumosa, N Saunders, MJ AF Kramer, B. Barczi, S. Chernoff, R. Horvath, K. J. Howe, J. L. Huh, J. Tumosa, N. Saunders, M. J. TI THE VA GERIATRIC SCHOLARS PROGRAM: ENHANCING SKILLS IN RURAL PRIMARY CARE SETTINGS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kramer, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Horvath, K. J.] Bedford GRECC, Boston, MA USA. [Barczi, S.] Madison GRECC, Madison, WI USA. [Huh, J.] Palo Alto GRECC, Palo Alto, CA USA. [Saunders, M. J.] San Antonio GRECC, San Antonio, TX USA. [Tumosa, N.] St Louis GRECC, St Louis, MO USA. [Chernoff, R.] Birmingham GRECC, Birmingham, AL USA. [Howe, J. L.] Bronx GRECC, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 204 EP 204 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602001244 ER PT J AU Anderson, R AF Anderson, R. TI IMPACT OF CALORIE RESTRICTION (CR) ON CELLULAR ASPECTS OF METABOLIC DECLINE IN AGING RHESUS SKELETAL MUSCLE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Anderson, R.] Univ Wisconsin, Madison, WI USA. [Anderson, R.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 242 EP 242 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602001441 ER PT J AU Garcia, C Espinoza, SE Hazuda, HP AF Garcia, C. Espinoza, S. E. Hazuda, H. P. TI LEVELS OF HEALTH LITERACY AMONG HISPANIC ELDERLY PATIENTS AND THEIR CAREGIVERS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Garcia, C.; Espinoza, S. E.; Hazuda, H. P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Espinoza, S. E.; Hazuda, H. P.] S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 283 EP 283 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602001643 ER PT J AU Pasinetti, GM AF Pasinetti, G. M. TI THE ROLE OF NUTRI-EPIGENETICS AND PERSONALIZED MEDICINE IN DIETARY LIFESTYLE CHOICES IN ALZHEIMER'S DISEASE SO GERONTOLOGIST LA English DT Meeting Abstract C1 Mt Sinai Sch Med, New York, NY USA. James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 296 EP 296 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602001704 ER PT J AU Espinoza, SE Hazuda, HP AF Espinoza, S. E. Hazuda, H. P. TI ETHNIC DIFFERENCE IN PERFORMANCE-BASED MEASURES OF BASIC AND INSTRUMENTAL ACTIVITIES OF DAILY LIVING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Espinoza, S. E.; Hazuda, H. P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Espinoza, S. E.; Hazuda, H. P.] S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 308 EP 309 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602002041 ER PT J AU Jones, LI Kramer, J Chernoff, R Howe, JL Francisco, F AF Jones, L. I. Kramer, J. Chernoff, R. Howe, J. L. Francisco, F. TI CREATING A LEARNING COMMUNITY AND WEBINAR SERIES FOR CLINICIANS WORKING WITH OLDER VETERANS IN RURAL SETTINGS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kramer, J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Howe, J. L.; Francisco, F.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Howe, J. L.; Francisco, F.] James J Peters VAMC, VISN GRECC 3, Bronx, NY USA. [Chernoff, R.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Chernoff, R.] Cent Arkansas Vet Healthcare Syst Little Rock GRE, Little Rock, AR USA. [Jones, L. I.; Kramer, J.] VA Greater Los Angeles Healthcare Syst Greater Lo, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 374 EP 374 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602002363 ER PT J AU Kramer, J Harker, JO Mitchell, M Rubenstein, L AF Kramer, J. Harker, J. O. Mitchell, M. Rubenstein, L. TI INSTEP: MAJOR RESEARCH QUESTIONS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kramer, J.] Univ Calif Los Angeles, David Geffen Sch Med, GRECC, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. [Mitchell, M.] Ctr Study Healthcare Provider Behav, Dept Vet Affairs, Sepulveda, CA USA. [Rubenstein, L.] Univ Oklahoma, Reynolds Dept Geriatr Med, Oklahoma City, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 377 EP 378 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602002379 ER PT J AU Semla, T Damron-Rodriguez, J Berger, S Goodwin, C Beizer, J AF Semla, T. Damron-Rodriguez, J. Berger, S. Goodwin, C. Beizer, J. TI THE RATIONALE AND DEVELOPMENT PROCESS FOR THE PHA MULTIDISCIPLINARY COMPETENCIES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Semla, T.] US Dept Vet Affairs, PBM, Evanston, IL USA. [Semla, T.] Northwestern Univ, Chicago, IL 60611 USA. [Damron-Rodriguez, J.] UCLA Sch Publ Affairs, Los Angeles, CA USA. [Berger, S.] Boston Univ, Coll Hlth & Rehabil Sci, Boston, MA 02215 USA. [Goodwin, C.] Amer Geriatr Soc, New York, NY USA. [Beizer, J.] St Johns Coll Pharmcy, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 377 EP 377 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602002375 ER PT J AU Garrido, MM Penrod, JD AF Garrido, M. M. Penrod, J. D. TI DEPRESSION AND ANXIETY ASSESSMENT AND TREATMENT IN VETERANS RECEIVING PALLIATIVE CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Garrido, M. M.; Penrod, J. D.] James J Peters VA Med Ctr, Bronx, NY USA. [Garrido, M. M.; Penrod, J. D.] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 388 EP 388 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602002436 ER PT J AU Spira, AP Covinsky, K Rebok, G Stone, KL Redline, S Punjabi, N Yaffe, K AF Spira, A. P. Covinsky, K. Rebok, G. Stone, K. L. Redline, S. Punjabi, N. Yaffe, K. TI OBJECTIVELY MEASURED SLEEP FRAGMENTATION AND NURSING HOME PLACEMENT IN OLDER WOMEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Spira, A. P.; Rebok, G.; Punjabi, N.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Covinsky, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Redline, S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Punjabi, N.] Johns Hopkins Sch Med, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 398 EP 398 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602002490 ER PT J AU Cotter, VT Streim, JE O'Donnell, DF Forciea, M Evans, LK AF Cotter, V. T. Streim, J. E. O'Donnell, D. F. Forciea, M. Evans, L. K. TI TRAINING INITIATIVES IN BEHAVIORAL TREATMENT PLANNING IN LONG-TERM CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Cotter, V. T.; Evans, L. K.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Streim, J. E.; Forciea, M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Streim, J. E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [O'Donnell, D. F.] Coatesville VA Med Ctr, Coatesville, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 479 EP 479 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602003163 ER PT J AU Byers, AL Vittinghoff, E Lui, L Covinsky, K Cauley, JA Ensrud, K Hillier, TA Yaffe, K AF Byers, A. L. Vittinghoff, E. Lui, L. Covinsky, K. Cauley, J. A. Ensrud, K. Hillier, T. A. Yaffe, K. TI CHARACTERIZATION OF LONG-TERM DEPRESSIVE TRAJECTORIES AMONG ELDERLY WOMEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Byers, A. L.; Vittinghoff, E.; Covinsky, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Byers, A. L.; Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lui, L.] Calif Pacific Med Ctr Res Inst, San Francisco, CA USA. [Cauley, J. A.] Univ Pittsburgh, Pittsburgh, PA USA. [Ensrud, K.] Univ Minnesota, Minneapolis, MN USA. [Ensrud, K.] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Hillier, T. A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 518 EP 518 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602003331 ER PT J AU Hung, WW Morano, B Boockvar, K AF Hung, W. W. Morano, B. Boockvar, K. TI FEASIBILITY OF INTEGRATING THE USE OF REGIONAL HEALTH INFORMATION ORGANIZATION FOR A VA-BASED CARE TRANSITION INTERVENTION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hung, W. W.; Morano, B.; Boockvar, K.] James J Peters Vet Affairs Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, Bronx, NY USA. [Hung, W. W.; Morano, B.; Boockvar, K.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Hung, W. W.; Morano, B.; Boockvar, K.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 526 EP 526 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602003374 ER PT J AU Vuckovic, NH Edes, T Nichols, LO AF Vuckovic, N. H. Edes, T. Nichols, L. O. TI I COULDN'T MAKE IT WITHOUT THEM: PATIENT AND CAREGIVER PERSPECTIVE OF HOME BASED PRIMARY CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Vuckovic, N. H.] Intel Corp, Hlth Res & Innovat, Beaverton, OR USA. [Edes, T.] US Dept Vet Affairs, Washington, DC USA. [Nichols, L. O.] Vet Affairs Med Ctr, Memphis, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 614 EP 614 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602004207 ER PT J AU Stephens, C Covinsky, K Blegen, MA Lee, S AF Stephens, C. Covinsky, K. Blegen, M. A. Lee, S. TI FALLS ARE A POWERFUL DETERMINANT OF ER USE BY NURSING HOME RESIDENTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Stephens, C.; Covinsky, K.; Blegen, M. A.; Lee, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Stephens, C.; Covinsky, K.; Lee, S.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2011 VL 51 SU 2 BP 627 EP 627 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 936PH UT WOS:000303602004268 ER PT J AU Jue, JJS Metlay, JP AF Jue, J. Jane S. Metlay, Joshua P. TI Web-Based Health Resources at US Colleges: Early Patterns and Missed Opportunities in Preventive Health SO PREVENTING CHRONIC DISEASE LA English DT Article ID STUDENT POPULATION; CONTROLLED-TRIAL; UNITED-STATES; INTERNET USE; INFORMATION; ADOLESCENTS; INTERVENTIONS; TECHNOLOGY; PREVALENCE; BEHAVIOR AB Introduction Web-based health resources on college websites have the potential to reach a substantial number of college students. The objective of this study was to characterize how colleges use their websites to educate about and promote health. Methods This study was a cross-sectional analysis of websites from a nationally representative sample of 426 US colleges. Reviewers abstracted information about Web-based health resources from college websites, namely health information, Web links to outside health resources, and interactive Web-based health programs. Results Nearly 60% of US colleges provided health resources on their websites, 49% provided health information, 48% provided links to outside resources, and 28% provided interactive Web-based health programs. The most common topics of Web-based health resources were mental health and general health. Conclusion We found widespread presence of Web-based health resources available from various delivery modes and covering a range of health topics. Although further research in this new modality is warranted, Web-based health resources hold promise for reaching more US college students. C1 [Jue, J. Jane S.] Philadelphia VA Med Ctr, Dept Vet Affairs, Philadelphia, PA USA. [Jue, J. Jane S.] Univ Penn, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. RP Jue, JJS (reprint author), ECRI Inst, 5200 Butler Pike, Plymouth Meeting, PA 19462 USA. EM janejuemd@gmail.com FU Robert Wood Johnson Foundation at the University of Pennsylvania; Department of Veterans Affairs; University of Pennsylvania [K24-AI073957] FX During the course of this study, Dr Jue was funded by the Robert Wood Johnson Foundation Clinical Scholars Program at the University of Pennsylvania in partnership with the Department of Veterans Affairs. Dr Metlay was funded by a Mid-Career Patient Oriented Investigator Award (K24-AI073957) at the University of Pennsylvania. Neither funding entities had a role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; nor preparation, review, or approval of the manuscript. NR 30 TC 1 Z9 1 U1 2 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD NOV PY 2011 VL 8 IS 6 AR A138 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 896JZ UT WOS:000300563000021 PM 22005631 ER PT J AU Hamburger, M Baraf, HSB Adamson, TC Basile, J Bass, L Cole, B Doghramji, PP Guadagnoli, GA Hamburger, F Harford, R Lieberman, JA Mandel, DR Mandelbrot, DA McClain, BP Mizuno, E Morton, AH Mount, DB Pope, RS Rosenthal, KG Setoodeh, K Skosey, JL Edwards, NL AF Hamburger, Max Baraf, Herbert S. B. Adamson, Thomas C., III Basile, Jan Bass, Lewis Cole, Brent Doghramji, Paul P. Guadagnoli, Germano A. Hamburger, Frances Harford, Regine Lieberman, Joseph A., III Mandel, David R. Mandelbrot, Didier A. McClain, Bonny P. Mizuno, Eric Morton, Allan H. Mount, David B. Pope, Richard S. Rosenthal, Kenneth G. Setoodeh, Katy Skosey, John L. Edwards, N. Lawrence TI 2011 Recommendations for the Diagnosis and Management of Gout and Hyperuricemia SO PHYSICIAN AND SPORTSMEDICINE LA English DT Article DE gout; hyperuricemia; guideline recommendations; rheumatology ID SERUM URIC-ACID; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INDEPENDENT RISK-FACTOR; POPULATION-BASED COHORT; URATE-LOWERING THERAPY; TREATMENT-FAILURE GOUT; CHRONIC-RENAL-FAILURE; METABOLIC SYNDROME; DOUBLE-BLIND; LONG-TERM AB Gout is a major health problem in the United States; it affects 8.3 million people, which is approximately 4% of the adult population. Gout is most often diagnosed and managed in primary care practices; thus, primary care physicians have a significant opportunity to improve patient outcomes. Following publication of the 2006 European League Against Rheumatism (EULAR) gout guidelines, significant new evidence has accumulated, and new treatments for patients with gout have become available. It is the objective of these 2011 recommendations to update the 2006 EULAR guidelines, paying special attention to the needs of primary care physicians. The revised 2011 recommendations are based on the Grading of Recommendations Assessment, Development, and Evaluation approach as an evidence-based strategy for rating quality of evidence and grading the strength of recommendation formulated for use in clinical practice. A total of 26 key recommendations, 10 for diagnosis and 16 for management, of patients with gout were evaluated, resulting in important updates for patient care. The presence of monosodium urate crystals and/or tophus and response to colchicine have the highest clinical diagnostic value. The key aspect of effective management of an acute gout attack is initiation of treatment within hours of symptom onset. Low-dose colchicine is better tolerated and is as effective as a high dose. When urate-lowering therapy (ULT) is indicated, the xanthine oxidase inhibitors allopurinol and febuxostat are the options of choice. Febuxostat can be prescribed at unchanged doses for patients with mild-to-moderate renal or hepatic impairment. The target of ULT should be a serum uric acid level that is 6 mg/dL. For patients with refractory and tophaceous gout, intravenous pegloticase is a new treatment option. This article is a summary of the 2011 clinical guidelines published in Postgraduate Medicine. This article provides a streamlined, accessible overview intended for quick review by primary care physicians, with the full guidelines being a resource for those seeking additional background information and expanded discussion. C1 [Hamburger, Max] Rheumatol Associates Long Isl, Melville, NY 11747 USA. [Hamburger, Max] SUNY Stony Brook, Stony Brook, NY USA. [Hamburger, Max] Amer Soc Clin Rheumatologists, Melville, NY USA. [Baraf, Herbert S. B.] George Washington Univ, Wheaton, IL USA. [Adamson, Thomas C., III] Sharp Rees Stealy Med Grp, Div Rheumatol, San Diego, CA USA. [Basile, Jan] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med, Charleston, SC 29425 USA. [Bass, Lewis] NYCOM, Ridgewood, NY USA. [Bass, Lewis] Touro Coll Osteopath Med TouroCOM, Ridgewood, NY USA. [Doghramji, Paul P.] Ursinus Coll, Collegeville, PA USA. [Guadagnoli, Germano A.] Bridgeport Hosp, Rheumatol Sect, Bridgeport, CT USA. [Hamburger, Frances] Rheumatol Associates Long Isl, Psychol Serv, Dix Hills, NY USA. [Lieberman, Joseph A., III] Jefferson Med Coll, Hockessin, DE USA. [Mandelbrot, Didier A.; Mount, David B.] Harvard Univ, Sch Med, Boston, MA USA. [McClain, Bonny P.] ASSESSmint Analyt & Outcomes, Greensboro, NC USA. [Mizuno, Eric] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Morton, Allan H.] Michigan State Univ, Coll Osteopath Med, E Lansing, MI 48824 USA. [Mount, David B.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Pope, Richard S.] Quinnipiac Univ, Dept PA Studies, Hamden, CT USA. [Skosey, John L.] Univ Chicago, Chicago, IL 60637 USA. [Edwards, N. Lawrence] Univ Florida, Dept Med, Gainesville, FL USA. RP Hamburger, M (reprint author), Rheumatol Associates Long Isl, 1895 Walt Whitman Rd, Melville, NY 11747 USA. EM mcapacious@aol.com FU Regine Harford; MS; MSTPC; URL Pharma; American Society of Clinical Rheumatologists; Mary Shah; MLS; medical library archivist and Caroline Marshall; Danbury Hospital Library; Abbott; Amgen; Bristol-Myers Squibb; Crescendo Bioscience; Genentech; Janssen Biotech; Takeda Pharmaceuticals; North America, Inc; NHLBI (SPRINT); AstraZeneca; Biogen Idec; Celegene; Merck Sharp and Dohme; Novartis; Pfizer; Roche; Stryker; VQ OrthoCare; Nuon Therapeutics FX The authors wish to gratefully acknowledge the invaluable editorial support from Regine Harford, MS, MSTPC, and statistical support from Bonny McClain, MS, DC of ASSESS-mint Analytics. Funding for the preparation of the article was received from URL Pharma, and from the American Society of Clinical Rheumatologists. The authors also wish to acknowledge the invaluable support from Mary Shah, MLS, medical library archivist and Caroline Marshall, MLS, health sciences librarian, both from Danbury Hospital Library.; Max Hamburger, MD is a member of the speakers' bureau for Abbott, Amgen, Bristol-Myers Squibb, Genentech, GSK, HGSI, Novartis, and UCB; is a consultant for Bristol-Myers Squibb, Genentech, and UCB; is in receipt of educational grants in support of CME activities from Abbott, Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Genentech, Janssen Biotech, Takeda Pharmaceuticals, North America, Inc, and URL Pharma. Herbert S. B. Baraf, MD is a member of the speakers' bureau for Savient Pharmaceuticals and Takeda Pharmaceuticals, North America, Inc; is a consultant for Ardea Biosciences and Savient Pharmaceuticals; is an investigator for Ardea Biosciences, Metabolex, Novartis, Regeneron, Savient Pharmaceuticals., and Takeda Pharmaceuticals, North America, Inc; and is a member of the advisory board for Takeda Pharmaceuticals, North America, Inc. Thomas C. Adamson III, MD, FACP, CPE is a member of the speakers' bureau for sanofi-aventis, Takeda Pharmaceuticals, North America, Inc, and Warner Chilcott; and is a consultant for Sanofi-Aventis and Takeda Pharmaceuticals, North America, Inc. Jan Basile, MD is a member of the speakers' bureau for Boehringer Ingelheim, Daiichi-Sankyo, Forest Laboratories, and Takeda Pharmaceuticals, North America, Inc; is a consultant for Daiichi-Sankyo, Eli Lilly/Boehringer Ingelheim, Forest Laboratories, and Takeda Pharmaceuticals, North America, Inc; and has received grant/research support from the NHLBI (SPRINT). Lewis Bass, DO, FACOFP discloses no conflicts of interest. Brent Cole, MD discloses no conflicts of interest. Paul P. Doghramji, MD is a member of the speakers' bureau and advisory board for URL Pharma. Germano A. Guadagnoli, MD is a member of the speakers' bureau for Amgen/Pfizer, Forest Laboratories, and Takeda Pharmaceuticals, North America, Inc. Frances Hamburger, PhD is employed by Miller Professional Group. Regine Harford, MS, MSTPC discloses no conflicts of interest. Joseph A. Lieberman III, MD, MPH is a member of the advisory board for Takeda Pharmaceuticals, North America, Inc and URL Pharma. David R. Mandel, MD is a member of the speakers' bureau for Abbott, Amgen, Auxilium Pharmaceuticals, Forest Laboratories, Forest Pharmaceuticals, GlaxoSmithKline, Lilly, Novartis, Savient Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceuticals, North America, Inc, and UCB; is a member of the advisory board for Amgen, Auxilium Pharmaceuticals, Crescendo Bioscience, Pfizer, and Savient Pharmaceuticals; is a consultant for Amgen, Auxilium Pharmaceuticals; Crescendo Bioscience, Pfizer, Savient Pharmaceuticals, and UCB; and has received research support from Abbott, Amgen, AstraZeneca, Biogen Idec, Celegene, Janssen Biotech, Crescendo Bioscience, Genentech, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Stryker, and VQ OrthoCare. Didier A. Mandelbrot, MD discloses no conflicts of interest. Bonny P. McClain, MS, DC discloses no conflicts of interest. Eric Mizuno, MD is an advisor for Takeda Pharmaceuticals, North America, Inc. Allan H. Morton, DO is a member of the speakers' bureau for Abbott, Amgen, Bristol-Myers Squibb, Genentech, Pfizer, Takeda Pharmaceuticals, North America, Inc, Savient Pharmaceuticals, UCB, URL Pharma, and Warner Chilcott; and is a consultant for Amgen, Bristol-Myers Squibb, Novartis, Pfizer, Savient Pharmaceuticals, UCB, and URL Pharma. David B.; Mount, MD has received grant support from Nuon Therapeutics; is on the medical advisory board and educational planning committees for Savient Pharmaceuticals; and provides internal talks for Takeda Pharmaceuticals, North America, Inc; nd has pending grants with Takeda Pharmaceuticals, North America, Inc and URL Pharma. Richard S. Pope, MPAS, PA-C, DFAAPA is a member of the speakers' bureau for AstraZeneca, Amgen, Takeda Pharmaceuticals, North America, Inc, UCB, and URL Pharma. Kenneth G. Rosenthal, MD, PC discloses no conflicts of interest. Katy Setoodeh, MD, FACR is a member of the speakers' bureau for Amgen and Human Genome Sciences. John L. Skosey, MD, PhD, FACR, FACP is an advisory board participant for Cardinal Health; a director of Theratest Laboratories; and a stockholder in Amgen. N. Lawrence Edwards, MD, FACP, FACR is a consultant for Ardea Biosciences, Savient Pharmaceuticals, Novartis, and Takeda Pharmaceuticals, North America, Inc. NR 137 TC 20 Z9 26 U1 4 U2 20 PU JTE MULTIMEDIA PI BERWYN PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA SN 0091-3847 J9 PHYSICIAN SPORTSMED JI Physician Sportsmed. PD NOV PY 2011 VL 39 IS 4 BP 98 EP 123 DI 10.3810/psm.2011.11.1946 PG 26 WC Primary Health Care; Orthopedics; Sport Sciences SC General & Internal Medicine; Orthopedics; Sport Sciences GA 893VD UT WOS:000300384200016 PM 22293773 ER PT J AU Brooks-Worrell, B Tree, T Mannering, SI Durinovic-Bello, I James, E Gottlieb, P Wong, S Zhou, Z Yang, L Cilio, CM Reichow, J Menart, B Rutter, R Schreiner, R Pham, M de Marquesini, LP Lou, O Scotto, M Mallone, R Schloot, NC AF Brooks-Worrell, B. Tree, T. Mannering, S. I. Durinovic-Bello, I. James, E. Gottlieb, P. Wong, S. Zhou, Z. Yang, L. Cilio, C. M. Reichow, J. Menart, B. Rutter, R. Schreiner, R. Pham, M. de Marquesini, L. Petrich Lou, O. Scotto, M. Mallone, R. Schloot, N. C. CA Immunology Diabet Soc TI Comparison of cryopreservation methods on T-cell responses to islet and control antigens from type 1 diabetic patients and controls SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Article; Proceedings Paper CT 11th International Congress of the Immunology-of-Diabetes-Society (IDS) CY OCT 31-NOV 03, 2010 CL Incheon, SOUTH KOREA SP Immunol Diabet Soc (IDS) DE T cells; proliferation; ELISPOT; tetramer; cryopreservation; CFSE; islet antigens; type 1 diabetes ID BLOOD MONONUCLEAR-CELLS; PROINSULIN; IMMUNOLOGY; PHENOTYPE; PROTEINS; WORKSHOP; SUBSETS; SOCIETY; LYT-2+; L3T4+ AB Background Type 1 diabetes (T1D) is a cell-mediated autoimmune disease characterized by destruction of the pancreatic islet cells. The use of cryopreserved cells is preferable to the use of freshly isolated cells to monitor clinical trials to decrease assay and laboratory variability. Methods The T-Cell Workshop Committee of the Immunology of Diabetes Society compared two widely accepted T-cell freezing protocols (warm and cold) to freshly isolated peripheral blood mononuclear cells from patients with T1D and controls in terms of recovery, viability, cell subset composition, and performance in functional assays currently in use in T1D-related research. Nine laboratories participated in the study with four different functional assays included. Results The cold freezing method yielded higher recovery and viability compared with the warm freezing method. Irrespective of freezing protocol, B cells and CD8+ T cells were enriched, monocyte fraction decreased, and islet antigen-reactive responses were lower in frozen versus fresh cells. However, these results need to take in to account that the overall response to islet autoantigens was low in some assays. Conclusions In the current study, none of the tested T-cell functional assays performed well using frozen samples. More research is required to identify a freezing method and a T-cell functional assay that will produce responses in patients with T1D comparable to responses using fresh peripheral blood mononuclear cells. Copyright (C) 2011 John Wiley & Sons, Ltd. C1 [Brooks-Worrell, B.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Tree, T.] Kings Coll London, Sch Med, London WC2R 2LS, England. [Mannering, S. I.] Univ Melbourne, Dept Med, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia. [Durinovic-Bello, I.; James, E.] Benaroya Res Inst, Seattle, WA USA. [Gottlieb, P.] Univ Colorado, Sch Med, Barbara Davis Ctr Childhood Diabet, Dept Pediat & Med, Denver, CO USA. [Wong, S.] Cardiff Univ, Ctr Endocrine & Diabet Sci, Dept Med, Sch Med, Cardiff, S Glam, Wales. [Zhou, Z.; Yang, L.] Cent S Univ, Sch Med, Changsha, Hunan, Peoples R China. [Cilio, C. M.] Lund Univ, Dept Sci, Cellular Autoimmun Unit, Malmo, Sweden. [Reichow, J.] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Menart, B.; Rutter, R.; Schreiner, R.; Pham, M.; Schloot, N. C.] Univ Dusseldorf, German Diabet Ctr, Inst Clin Diabetol, D-40225 Dusseldorf, Germany. [de Marquesini, L. Petrich] Univ Bristol, Henry Wellcome Lab Integrat Neurosci & Endocrinol, Bristol, Avon, England. [Lou, O.] JDRF Int, JDRF Canadian Clin Trial Network, Toronto, ON, Canada. [Scotto, M.; Mallone, R.] Hop St Vincent de Paul, INSERM, U986, DeAR Lab Avenir, F-75674 Paris, France. [Schloot, N. C.] Univ Dusseldorf, Clin Metab Dis, D-40225 Dusseldorf, Germany. RP Brooks-Worrell, B (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM bbrooks@u.washington.edu RI Mallone, Roberto/H-4430-2013 OI James, Eddie/0000-0002-7217-5729 NR 25 TC 9 Z9 9 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1520-7552 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD NOV PY 2011 VL 27 IS 8 SI SI BP 737 EP 745 DI 10.1002/dmrr.1245 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 889XD UT WOS:000300108000004 PM 22069253 ER PT J AU Finlayson, E Maselli, J Steinman, MA Rothberg, MB Lindenauer, PK Auerbach, AD AF Finlayson, Emily Maselli, Judith Steinman, Michael A. Rothberg, Michael B. Lindenauer, Peter K. Auerbach, Andrew D. TI Inappropriate Medication Use in Older Adults Undergoing Surgery: A National Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE surgery; potentially inappropriate medications (PIMs); older adults ID POTENTIALLY INAPPROPRIATE; ADMINISTRATIVE DATA; SURGICAL-PATIENTS; MEPERIDINE USE; HIP FRACTURE; DELIRIUM; OUTCOMES; INDICATORS; CRITERIA; IMPACT AB OBJECTIVES: To determine the prevalence and factors associated with use of potentially inappropriate medications (PIMs) in older adults undergoing surgery. DESIGN: Retrospective cohort study. SETTING: Three hundred seventy-nine acute care hospitals participating in the nationally representative Perspective database (2006-2008). PARTICIPANTS: Individuals aged 65 and older under going major inpatient gastrointestinal, gynecological, urological, and orthopedic surgery (N=272,351). MEASUREMENTS: Medications were classified as PIMs using previously published criteria defining 33 medications deemed potentially inappropriate in people aged 65 and older. Information about participant and provider characteristics and administration of PIMs was obtained from hospital discharge file data. Logistic regression techniques were used to examine factors associated with use of PIMs in the perioperative period. RESULTS: One-quarter of participants received at least one PIM during their surgical admission. Meperidine was the most frequently prescribed PIM (37,855, 14% of participants). In adjusted analysis, PIM use was less likely as age advanced (adjusted odds ratio (AOR) = 0.98 per year of age, 95% confidence interval (CI) = 0.97-0.98) and in men (AOR = 0.83, 95% CI = 0.81-0.85). PIMs were more likely to be prescribed to participants cared for by orthopedic surgeons than for those cared for by general surgeons (AOR = 1.22, 95% CI = 1.08-1.40). Participants undergoing surgery in the West (AOR = 1.79, 95% CI = 1.02-3.16) and South (AOR = 2.24, 95% CI = 1.38-3.64) were more likely to receive a PIM than those in the Northeast. CONCLUSION: Receipt of PIMs in older adults undergoing surgery is common and varies widely between providers and geographic regions and according to participant characteristics. Interventions aimed at reducing the use of PIMs in the perioperative period should be considered in quality improvement efforts. J Am Geriatr Soc 59:2139-2144, 2011. C1 [Finlayson, Emily] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA. [Finlayson, Emily] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94118 USA. [Maselli, Judith; Auerbach, Andrew D.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94118 USA. [Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94118 USA. [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Rothberg, Michael B.; Lindenauer, Peter K.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA USA. [Rothberg, Michael B.; Lindenauer, Peter K.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. RP Finlayson, E (reprint author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94118 USA. EM emily.finlayson@ucsfmedctr.org FU National Heart, Blood, Lund Institute [K24HL098372]; National Institute on Aging [K08AG028965]; American Federation for Aging Research [K23AG030999] FX Work on this study was funded in part by National Heart, Blood, Lund Institute Award K24HL098372 to Dr. Auerbach. Dr. Finlayson was supported by National Institute on Aging/Paul B. Beeson Clinical Scientist Development Award in Aging K08AG028965. Dr. Steinman was supported by the National Institute on Aging and the American Federation for Aging Research (K23AG030999). NR 23 TC 8 Z9 8 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2011 VL 59 IS 11 BP 2139 EP 2144 DI 10.1111/j.1532-5415.2011.03567.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 853FG UT WOS:000297411000020 PM 21883113 ER PT J AU Wong, CH Landefeld, CS AF Wong, Chek Hooi Landefeld, C. Seth TI Academic Geriatrics in Singapore SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE education; research; geriatrics ID CARE; MEDICINE; POPULATION; EDUCATION AB Singapore is one of the fastest-aging countries in the world. The proportion of adults aged 65 and older is projected to increase from 8.7% to 20% over the next 20 years. The country has developed various strategies to meet the needs of this increase in older adults. There is an acute shortage of geriatricians and a need to train more healthcare workers to care for older adults. Geriatric medicine is a relatively new specialty, and a small number of geriatricians have been tasked with providing an increasing load of clinical service, education, and research. Hence, there is a need to develop a cohesive structure of support for faculty development and retention, advanced specialty trainee recruitment, leadership in medical education, research, and clinical service to care for the rapidly aging population. In addition, geriatric medicine is primarily a hospital-based specialty in Singapore. There is still opportunity to collaborate and improve the academic and practice integration of geriatric medicine into primary care and intermediate and long-term care where it is most needed. J Am Geriatr Soc 59:2145-2150, 2011. C1 [Wong, Chek Hooi] Khoo Teck Puat Hosp, Dept Geriatr Med, Singapore 768828, Singapore. [Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA. RP Wong, CH (reprint author), Khoo Teck Puat Hosp, Dept Geriatr Med, 90 Yishun Cent, Singapore 768828, Singapore. EM chekhooi@yahoo.com FU U.S., Department of State, Bureau of Educational and Cultural Affairs FX Chek Hooi Wong and C. Seth Landefeld both state no financial interest, stock, or derived direct financial benefit. Chek Hooi Wong was funded by a Fulbright Singapore Researcher Program, U.S., Department of State, Bureau of Educational and Cultural Affairs. NR 22 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2011 VL 59 IS 11 BP 2145 EP 2150 DI 10.1111/j.1532-5415.2011.03630.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 853FG UT WOS:000297411000021 PM 22091794 ER PT J AU Beeri, MS Moshier, E Schmeidler, J Godbold, J Uribarri, J Reddy, S Sano, M Grossman, HT Cai, WJ Vlassara, H Silverman, JM AF Beeri, Michal Schnaider Moshier, Erin Schmeidler, James Godbold, James Uribarri, Jaime Reddy, Sarah Sano, Mary Grossman, Hillel T. Cai, Weijing Vlassara, Helen Silverman, Jeremy M. TI Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE Methylglyoxal; Advanced glycation end products; Type 2 diabetes; Cognitive decline; Alzheimer's disease ID ADVANCED GLYCATION ENDPRODUCTS; ALZHEIMERS-DISEASE; CARBONYL SCAVENGERS; CEREBROSPINAL-FLUID; PROTEIN GLYCATION; OXIDATIVE STRESS; OLDEST-OLD; DEMENTIA; AGE; NEUROPATHOLOGY AB Background: Advanced glycations end products increase oxidant stress, inflammation, and neurotoxicity. Serum levels are increased in diabetes and aging. We examined the relationship between serum methylglyoxal derivatives (sMG), and cognitive decline, in 267 non-demented elderly. Methods: Tobit mixed regression models assessed the association of baseline sMG with cognitive decline in the Mini Mental State Exam (MMSE) over time, controlling for sociodemographic factors (age, sex, and years of education), cardiovascular risk factors (diabetes and presence of an ApoE4 allele), and kidney function. sMG was assessed by ELISA. Results: The fully adjusted model showed an annual decline of 0.26 MMSE points per unit increase in baseline sMG (p = 0.03). Significance was unchanged as additional risk factors were added to the model. The interactions of sMG with diabetes, sex, age, kidney function, and ApoE4 genotype were not significant. Conclusions: Higher levels of baseline sMG were associated with a faster rate of cognitive decline, after adjusting for several sociodemographic and clinical characteristics. This relationship did not differ by sex, ApoE4 genotype, or diabetes status suggesting its generality. Since subjects were cognitively normal at the beginning of the study, elevated sMG may be indicative of brain cell injury initiated before clinically evident cognitive compromise. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Beeri, Michal Schnaider; Schmeidler, James; Reddy, Sarah; Sano, Mary; Grossman, Hillel T.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Moshier, Erin; Godbold, James] Mt Sinai Sch Med, Dept Biostat, New York, NY 10029 USA. [Uribarri, Jaime] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Cai, Weijing; Vlassara, Helen] Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA. [Beeri, Michal Schnaider; Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Beeri, MS (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA. EM michal.beeri@mssm.edu FU NIA [K01 AG023515-01, R01 AG034087, P01 AG02219, P50 AG05138, R37AG023188]; Irma T. Hirschl Award; Berkman Trust FX Supported by NIA grants K01 AG023515-01 and R01 AG034087 to Dr. Beeri, Project 4 in P01 AG02219 to Dr. Silverman, P50 AG05138 to Dr. Mary Sano, and R37AG023188 (MERIT) to Dr. Vlassara, as well as by the Irma T. Hirschl Award to Dr. Beeri and the Berkman Trust to Dr. Vahram Haroutunian. NR 39 TC 32 Z9 32 U1 0 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD NOV-DEC PY 2011 VL 132 IS 11-12 BP 583 EP 587 DI 10.1016/j.mad.2011.10.007 PG 5 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 888CG UT WOS:000299980800007 PM 22079406 ER PT J AU Chan, K Lai, MN Groessl, EJ Hanchate, A Hernandez, L Wong, JB Clark, JA Asch, S Gifford, AL Ho, S AF Chan, K. Lai, M. N. Groessl, E. J. Hanchate, A. Hernandez, L. Wong, J. B. Clark, J. A. Asch, S. Gifford, A. L. Ho, S. TI POTENTIAL COSTS ASSOCIATED WITH NEW DIRECT ACTING ANTIVIRAL (DAAS) THERAPY FOR UNTREATED CHRONIC HEPATITIS C GENOTYPE 1 INFECTION IN THE VETERANS HEALTH ADMINISTRATION SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Chan, K.; Hanchate, A.; Hernandez, L.; Clark, J. A.] Boston Univ, Boston, MA 02215 USA. [Lai, M. N.; Ho, S.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Groessl, E. J.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Wong, J. B.] Tufts Univ, Boston, MA 02111 USA. [Asch, S.] VA Greater Los Angeles Healthcare Syst GLA, Los Angeles, CA USA. [Gifford, A. L.] Edith Nourse Rogers Mem Vet Adm Hosp, Bedford, MA 01730 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD NOV PY 2011 VL 14 IS 7 BP A269 EP A270 PG 2 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 876KT UT WOS:000299107100193 ER PT J AU Tanaka, K Babic, I Nathanson, D Akhavan, D Guo, DL Gini, B Dang, J Zhu, SJ Yang, HJ De Jesus, J Amzajerdi, AN Zhang, YN Dibble, CC Dan, HC Rinkenbaugh, A Yong, WH Vinters, HV Gera, JF Cavenee, WK Cloughesy, TF Manning, BD Baldwin, AS Mischel, PS AF Tanaka, Kazuhiro Babic, Ivan Nathanson, David Akhavan, David Guo, Deliang Gini, Beatrice Dang, Julie Zhu, Shaojun Yang, Huijun De Jesus, Jason Amzajerdi, Ali Nael Zhang, Yinan Dibble, Christian C. Dan, Hancai Rinkenbaugh, Amanda Yong, William H. Vinters, Harry V. Gera, Joseph F. Cavenee, Webster K. Cloughesy, Timothy F. Manning, Brendan D. Baldwin, Albert S. Mischel, Paul S. TI Oncogenic EGFR Signaling Activates an mTORC2-NF-kappa B Pathway That Promotes Chemotherapy Resistance SO CANCER DISCOVERY LA English DT Article ID NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; MTOR COMPLEX 2; MAMMALIAN TARGET; MOTIF PHOSPHORYLATION; GLIOBLASTOMA PATIENTS; KINASE INHIBITORS; CANCER-THERAPY; AKT; RICTOR AB Although it is known that mTOR complex 2 (mTORC2) functions upstream of Akt, the role of this protein kinase complex in cancer is not well understood. Through an integrated analysis of cell lines, in vivo models, and clinical samples, we demonstrate that mTORC2 is frequently activated in glioblastoma (GBM), the most common malignant primary brain tumor of adults. We show that the common activating epidermal growth factor receptor (EGFR) mutation (EGFRvIII) stimulates mTORC2 kinase activity, which is partially suppressed by PTEN. mTORC2 signaling promotes GBM growth and survival and activates NF-kappa B. Importantly, this mTORC2-NF-kappa B pathway renders GBM cells and tumors resistant to chemotherapy in a manner independent of Akt. These results highlight the critical role of mTORC2 in the pathogenesis of GBM, including through the activation of NF-kappa B downstream of mutant EGFR, leading to a previously unrecognized function in cancer chemotherapy resistance. These findings suggest that therapeutic strategies targeting mTORC2, alone or in combination with chemotherapy, will be effective in the treatment of cancer. SIGNIFICANCE: This study demonstrates that EGFRvIII-activated mTORC2 signaling promotes GBM proliferation, survival, and chemotherapy resistance through Akt-independent activation of NF-kappa B. These results highlight the role of mTORC2 as an integrator of two canonical signaling networks that are commonly altered in cancer, EGFR/phosphoinositide-3 kinase (PI3K) and NF-kappa B. These results also validate the importance of mTORC2 as a cancer target and provide new insights into its role in mediating chemotherapy resistance, suggesting new treatment strategies. Cancer Discovery; 1(6); 524-38. (C) 2011 AACR. C1 [Mischel, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Ctr Hlth Sci, Los Angeles, CA 90095 USA. [Mischel, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Yong, William H.; Cloughesy, Timothy F.; Mischel, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Henry Singleton Brain Tumor Program, Los Angeles, CA 90095 USA. [Yong, William H.; Cloughesy, Timothy F.; Mischel, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Vinters, Harry V.; Cloughesy, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Gera, Joseph F.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Sepulveda, CA USA. [Guo, Deliang] Ohio State Univ, Sch Med, Dept Radiat Oncol, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA. [Cavenee, Webster K.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA. [Zhang, Yinan; Dibble, Christian C.; Manning, Brendan D.] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA. [Dan, Hancai; Rinkenbaugh, Amanda; Baldwin, Albert S.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. RP Mischel, PS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Ctr Hlth Sci, 10833 Le Conte Ave,Room 13-321, Los Angeles, CA 90095 USA. EM pmischel@mednet.ucla.edu RI Guo, Deliang/I-3735-2014; Zhang, Yinan/N-6432-2014 OI Guo, Deliang/0000-0002-8359-390X; Zhang, Yinan/0000-0002-3471-6598; Nael, Ali/0000-0002-9671-5531 FU NIH [CA119347, NS73831, P01-CA95616, CA122617, CA75080, CA73756]; Accelerate Brain Cancer Cure; STOP Cancer; Fred Miller Family; John W. Carson Foundation; Lya and Harrison Latter endowed Chair; Ziering Family Foundation in memory of Sigi Ziering; Ben and Catherine Ivy Foundation; Art of the Brain Fund; Henry Singleton Brain Cancer Fund; Samuel Waxman Cancer Research Foundation; Uehara Memorial Foundation FX This work was supported by NIH grants CA119347 and NS73831 (P.S. Mischel), Accelerate Brain Cancer Cure (P.S. Mischel), STOP Cancer (P.S. Mischel), The Fred Miller Family (P.S. Mischel), The John W. Carson Foundation (P.S. Mischel), The Lya and Harrison Latter endowed Chair (P.S. Mischel), Ziering Family Foundation in memory of Sigi Ziering (T.F. Cloughesy and P.S. Mischel), The Ben and Catherine Ivy Foundation Fund (W.H. Yong and T.F. Cloughesy), Art of the Brain Fund (W.H. Yong and T.F. Cloughesy), Henry Singleton Brain Cancer Fund (W.H. Yong and T.F. Cloughesy), NIH grant P01-CA95616 (W.K. Cavenee), NIH grant CA122617 (B.D. Manning), NIH grants CA75080 and CA73756 (A.S. Baldwin), Samuel Waxman Cancer Research Foundation (A.S. Baldwin), and Uehara Memorial Foundation (K. Tanaka). NR 54 TC 112 Z9 116 U1 1 U2 11 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 J9 CANCER DISCOV JI Cancer Discov. PD NOV PY 2011 VL 1 IS 6 BP 524 EP 538 DI 10.1158/2159-8290.CD-11-0124 PG 15 WC Oncology SC Oncology GA 880MR UT WOS:000299411700031 PM 22145100 ER PT J AU Kofonow, JM Bhuskute, A Doghramji, L Palmer, JN Cohen, NA Chiu, AG AF Kofonow, Jennifer M. Bhuskute, Aditi Doghramji, Laurel Palmer, James N. Cohen, Noam A. Chiu, Alexander G. TI One-way valve bottle contamination rates in the immediate post-functional endoscopic sinus surgery period SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID RHINOSINUSITIS PATIENTS AB Background: Sinonasal saline irrigation has become an accepted practice in the immediate postoperative management of functional endoscopic sinus surgery (FESS) patients. Recent studies have found that valveless delivery systems of sinonasal irrigation are colonized with bacteria. An alternative delivery system uses a one-way valve to reduce saline backflow and may limit bottle contamination. Our sole objective was to determine whether this system in post-FESS patients eliminates microbial bottle contamination. Methods: Eight patients undergoing FESS were given one-way valve irrigation bottles to use immediately after surgery. Bottles were collected after 1 week of use and another set of bottles after an additional week. Endoscopic-directed cultures of the middle meatus were performed at the time of surgery. Returned used bottles were swabbed for bacteria and the valve system of the bottle was analyzed under scanning electron microscopy (SEM) for the presence of bacteria. Results: All sinus swabs collected at the time of surgery grew bacteria with Staphylococcus sp. present in all samples. After the 1st week of use, 5/8 bottles grew bacterial cultures and showed bacterial presence on the valves by SEM. After the 2nd week, 4/5 bottles had positive culture results and also showed bacterial presence on the valves by SEM. Conclusion: Despite commercial claims that the use of valves and limit of backflow into the bottle will eliminate contamination, our study showed that one-way valve delivery systems become contaminated with bacteria after 1 week of use. We also showed that the bottle valves themselves harbor bacteria after 1 week of use. (Am J Rhinol Allergy 25, 393-396, 2011; doi:10.2500/ajra.2011.25.3664) C1 [Kofonow, Jennifer M.; Doghramji, Laurel; Palmer, James N.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA. [Bhuskute, Aditi; Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM Noam.Cohen@uphs.upenn.edu RI Chiu, Alexander/J-1230-2014 OI Chiu, Alexander/0000-0002-7592-6575; Cohen, Noam/0000-0002-9462-3932 FU NeilMed Pharmaceuticals, Inc. FX J.N. Palmer, N.A. Cohen and A.G. Chiu have in the past received royalties from NeilMed Pharmaceuticals, Inc. The remaining authors have nothing to declare pertaining to this article NR 11 TC 2 Z9 2 U1 0 U2 5 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD NOV-DEC PY 2011 VL 25 IS 6 BP 393 EP 396 DI 10.2500/ajra.2011.25.3664 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA 868RT UT WOS:000298543100019 PM 22185742 ER PT J AU Teitelman, AM Stringer, M Nguyen, GT Hanlon, AL Averbuch, T Stimpfel, AW AF Teitelman, Anne M. Stringer, Marilyn Nguyen, Giang T. Hanlon, Alexandra L. Averbuch, Tali Stimpfel, Amy Witkoski TI Social Cognitive and Clinical Factors Associated with HPV Vaccine Initiation Among Urban, Economically Disadvantaged Women SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING LA English DT Article DE HPV vaccine; theory of planned behavior; sexual health; adolescent; women's health; cervical cancer; prevention ID HUMAN-PAPILLOMAVIRUS VACCINATION; PLANNED BEHAVIOR; REASONED ACTION; UNITED-STATES; CERVICAL-CANCER; ACCEPTABILITY; ACCEPTANCE; INFECTION; DAUGHTERS; KNOWLEDGE AB Objective: To learn more about human papilloma virus (HPV) knowledge and vaccination among teens and young women age 13 to 26 years from an economically disadvantaged, urban community. Our aim was to identify common beliefs about HPV vaccine initiation and describe the relationship between attitudes, norms, perceived control, and intention to receive HPV vaccine, drawing from the theory of planned behavior (TPB). Design: Mixed method, descriptive design. Guided by the TPB, HPV vaccine beliefs were assessed through focus groups. Intention to receive the vaccine, demographic and clinical factors, and theoretical predictor variables (attitudes, norms, and control) were assessed through questionnaires. Setting: After recruitment, focus groups were held at a convenient date and time for our participants in a small university conference room. Participants: Participants were economically disadvantaged young women, age 13 to 26 (N = 34). Methods: Specific behavioral, normative, and control beliefs were elicited in focus groups and analyzed using content analysis. Simple and multivariate general linear modeling with adjustment for prognostic demographic and clinical factors was completed to assess the influence of the theoretical predictor variables on the outcome of HPV vaccine initiation. Results: Influential beliefs toward vaccination were identified. Analysis indicated attitudes, norms, and perceived control toward HPV vaccine initiation were highly significant predictors of intent, as was tobacco use; all p's < .001. Conclusion: Barriers to HPV vaccine initiation were identified, and strong preliminary evidence supports use of the TPB to guide programs to promote urban, economically disadvantaged young women's intent to begin the HPV vaccine. JOGNN, 40, 691-701; 2011. DOI: 10.1111/j.1552-6909.2011.01297.x C1 [Teitelman, Anne M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19194 USA. [Nguyen, Giang T.] Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19194 USA. [Averbuch, Tali] Univ Penn, Sch Nursing, Womens Hlth Nurse Practitioner Program, Philadelphia, PA 19194 USA. [Averbuch, Tali] Univ Penn, Sch Nursing, Nurse Midwifery Program, Philadelphia, PA 19194 USA. RP Teitelman, AM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Fagin Hall 2L,Rm 244,418 Curie Blvd, Philadelphia, PA 19194 USA. EM teitelm@nursing.upenn.edu OI Nguyen, Giang/0000-0003-2031-9943 FU University of Pennsylvania School of Nursing; American Cancer Society [CCCDA-05-161-01] FX Supported by University of Pennsylvania School of Nursing Investing in the Future Grant. Dr. Nguyen was supported by a Cancer Control Career Development Award from the American Cancer Society (CCCDA-05-161-01) and a Pfizer Fellowship in Health Literacy/Clear Health Communication. NR 49 TC 9 Z9 9 U1 2 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0884-2175 J9 JOGNN-J OBST GYN NEO JI JOGNN PD NOV-DEC PY 2011 VL 40 IS 6 BP 691 EP 701 DI 10.1111/j.1552-6909.2011.01297.x PG 11 WC Nursing; Obstetrics & Gynecology SC Nursing; Obstetrics & Gynecology GA 855OY UT WOS:000297575300005 PM 22092373 ER PT J AU Bloch, MJ Basile, JN AF Bloch, Michael J. Basile, Jan N. TI New British Guidelines Mandate Ambulatory Blood Pressure Monitoring to Diagnose Hypertension in All Patients: Not Ready for Prime Time in the United States SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material C1 [Bloch, Michael J.] St Marys Reg Med Ctr, Risk Reduct Ctr, Reno, NV USA. [Basile, Jan N.] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. [Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA. [Basile, Jan N.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Bloch, MJ (reprint author), St Marys Reg Med Ctr, Risk Reduct Ctr, 645 N Arlington St,Suite 460, Reno, NV USA. EM mbloch@aol.com NR 1 TC 12 Z9 12 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD NOV PY 2011 VL 13 IS 11 BP 785 EP 786 DI 10.1111/j.1751-7176.2011.00532.x PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 859DG UT WOS:000297854300001 PM 22051420 ER PT J AU Lynch, CP Strom, JL Egede, LE AF Lynch, Cheryl P. Strom, Joni L. Egede, Leonard E. TI Disparities in diabetes self-management and quality of care in rural versus urban veterans SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Veterans; Diabetes; Quality of care; Self-management; Rural health ID GLYCEMIC CONTROL; HEALTH-CARE; ACCESS; TELEMEDICINE; EDUCATION; POLICY AB Background: There are distinct geographic differences in diabetes-related morbidity and mortality; however, data regarding self-management and clinical outcomes are limited. This study examined diabetes care among veterans residing in rural versus urban areas. Methods: A national data set was analyzed based on 10,570 veterans with type 2 diabetes. Residence was determined according to US census-based metropolitan statistical area. Primary outcomes were self-management behaviors (lifestyle and self-monitoring) and quality of care indicators (provider visits, laboratory monitoring and preventive measures). Multivariate analyses were done using STATA v10 to assess the independent effect of veteran residence on each outcome measure and to account for the complex survey design. Results: Among veterans with diabetes, 21.4% were rural residents. Compared to urban veterans, rural veterans had significantly lower education, less annual income and less received diabetes education (P=.002). The final regression model showed that daily foot self-check was the only self-management behavior significantly higher among rural veterans (odds ratio 1.36, 95% confidence interval 1.10-1.70). Provider-based quality of care was not significantly different between groups. Conclusions: Diabetes self-foot care was significantly better among rural veterans than their urban counterparts, but quality of care was equivalent. This suggests that clinical diabetes care among veterans is uniform; however, greater efforts for patient education and support in diabetes self-management are needed to improve outcomes. Published by Elsevier Inc. C1 [Egede, Leonard E.] Med Univ S Carolina, Charleston VA REAP, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. [Lynch, Cheryl P.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Charleston VA REAP, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK NIH HHS [K24 DK093699] NR 30 TC 7 Z9 7 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD NOV-DEC PY 2011 VL 25 IS 6 BP 387 EP 392 DI 10.1016/j.jdiacomp.2011.08.003 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 865UA UT WOS:000298335200007 PM 21983152 ER PT J AU Murrough, JW Iacoviello, B Neumeister, A Charney, DS Iosifescu, DV AF Murrough, James W. Iacoviello, Brian Neumeister, Alexander Charney, Dennis S. Iosifescu, Dan V. TI Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies SO NEUROBIOLOGY OF LEARNING AND MEMORY LA English DT Review DE Depression; Cognition; Neuropsychology; Emotion regulation; Neuroimaging; Therapeutics; Cognitive dysfunction ID OBSESSIVE-COMPULSIVE DISORDER; WHITE-MATTER HYPERINTENSITIES; POSITRON-EMISSION-TOMOGRAPHY; SUBGENUAL PREFRONTAL CORTEX; UNIPOLAR MAJOR DEPRESSION; HAPPY FACIAL EXPRESSIONS; BRAIN GLUCOSE-METABOLISM; STAR-ASTERISK-D; ANTIDEPRESSANT-TREATMENT; EMOTION REGULATION AB Major depressive disorder (MDD) is a disabling medical condition associated with significant morbidity, mortality and public health costs. However, neurocircuitry abnormalities underlying depression remain incompletely understood and consequently current treatment options are unfortunately limited in efficacy. Recent research has begun to focus specifically on cognitive aspects of depression and potential neurobiological correlates. Two fundamental types of cognitive dysfunction observed in MOD are cognitive biases, which include distorted information processing or attentional allocation toward negative stimuli, and cognitive deficits, which include impairments in attention, short-term memory and executive functioning. In this article, we present a selective review of current research findings in these domains and examine neuroimaging research that is beginning to characterize the neurocircuitry underlying these biases and deficits. We propose that deficient cognitive functioning, attention biases and the sustained negative affect characteristic of MOD can be understood as arising in part from dysfunctional prefrontal-subcortical circuitry and related disturbances in the cognitive control of emotion. Finally, we highlight potential new pharmacological and non-pharmacological therapeutic strategies for MDD based on an evolving mechanistic understanding of the disorder. (C) 2011 Elsevier Inc. All rights reserved. C1 [Murrough, James W.; Iacoviello, Brian; Neumeister, Alexander; Iosifescu, Dan V.] Mt Sinai Sch Med, Dept Psychiat, Mood & Anxiety Disorders Program, New York, NY 10029 USA. [Iacoviello, Brian] James J Peters VA Med Ctr, MIRECC, Bronx, NY USA. [Neumeister, Alexander] VA Connecticut Healthcare Syst, Mol Imaging Program, West Haven, CT USA. [Charney, Dennis S.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Charney, Dennis S.] Mt Sinai Sch Med, Dept Syst Pharmacol & Therapeut, New York, NY 10029 USA. [Charney, Dennis S.] Mt Sinai Sch Med, Off Dean, New York, NY 10029 USA. RP Murrough, JW (reprint author), Mt Sinai Sch Med, Dept Psychiat, Mood & Anxiety Disorders Program, Box 1230, New York, NY 10029 USA. EM james.murrough@mssm.edu RI Murrough, James/J-7129-2013 OI Murrough, James/0000-0001-6286-1242 FU Mount Sinai School of Medicine FX Dr. Charney has been named as an inventor on a use-patent of ketamine for the treatment of depression. If ketamine were shown to be effective in the treatment of depression and received approval from the Food and Drug Administration for this indication, Dr. Chamey and the Mount Sinai School of Medicine could benefit financially. All other authors report no completing interests. NR 175 TC 103 Z9 106 U1 20 U2 68 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1074-7427 J9 NEUROBIOL LEARN MEM JI Neurobiol. Learn. Mem. PD NOV PY 2011 VL 96 IS 4 SI SI BP 553 EP 563 DI 10.1016/j.nlm.2011.06.006 PG 11 WC Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 859UD UT WOS:000297900400006 PM 21704176 ER PT J AU Bowman, CC Johnson, L Cox, M Rick, C Dougherty, M Alt-White, AC Wyte, T Needleman, J Dobalian, A AF Bowman, Candice C. Johnson, Linda Cox, Malcolm Rick, Catherine Dougherty, Mary Alt-White, Anna C. Wyte, Tamar Needleman, Jack Dobalian, Aram TI The Department of Veterans Affairs Nursing Academy (VANA): Forging strategic alliances with schools of nursing to address nursing's workforce needs SO NURSING OUTLOOK LA English DT Article DE Partnerships; Clinical instruction; Veterans Affairs ID INTERORGANIZATIONAL RELATIONSHIPS; EDUCATION AB In 2007, the Department of Veterans Affairs (VA) established the VA Nursing Academy (VANA), a 5-year, $60-million pilot program funding 15 partnerships between schools of nursing and local VA health care facilities nationwide, to expand nursing faculty, enhance clinical faculty development, increase nursing student enrollment, and promote educational innovations. VA is an ideal setting for educating nursing students owing to a well-educated registered nurse staff, an array of traditional and nontraditional settings, a state-of-the-art computerized electronic health record system, and a unique patient population. Challenges related to the complex nature of VANA partnerships, conceptualized as strategic alliances created between disparate subunits, each embedded in a larger organization, require careful governance to ensure smooth implementation. To ensure the program's aims are met, a 6-year national evaluation has been funded to help identify which strategies best achieve VANA's goals. The speed of economic recovery and the resulting changes in the nursing workforce are important determinants of VANA's future. C1 [Bowman, Candice C.; Wyte, Tamar; Dobalian, Aram] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Study Healthcare Provider Behav, Sepulveda, CA 91343 USA. [Johnson, Linda; Cox, Malcolm; Rick, Catherine; Dougherty, Mary; Alt-White, Anna C.] Vet Affairs Nursing Acad, Off Acad Affiliat, Dept Vet Affairs, Washington, DC USA. [Needleman, Jack; Dobalian, Aram] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Bowman, CC (reprint author), VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Study Healthcare Provider Behav, 16111 Plummer St 152, Sepulveda, CA 91343 USA. EM candice.bowman@va.gov RI Needleman, Jack/I-5461-2013 OI Needleman, Jack/0000-0002-2875-0589 FU Department of Veterans Affairs, Veterans Health Administration, Office of Academic Affiliations; Department of Veterans Affairs, Veterans Health Administration, Office of Nursing Service FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Offices of Academic Affiliations and Nursing Service. NR 31 TC 9 Z9 9 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 J9 NURS OUTLOOK JI Nurs. Outlook PD NOV-DEC PY 2011 VL 59 IS 6 BP 299 EP 307 DI 10.1016/j.outlook.2011.04.006 PG 9 WC Nursing SC Nursing GA 854IS UT WOS:000297488800003 PM 21684561 ER PT J AU Tache, Y Stengel, A Vaudry, H AF Tache, Yvette Stengel, Andreas Vaudry, Hubert TI Special Issue: Ghrelin SO PEPTIDES LA English DT Editorial Material ID METABOLISM; PEPTIDES; HORMONE C1 [Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Digest Dis Res Ctr Anim Care, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Stengel, Andreas] Obes Ctr Berlin, Div Psychosomat Med, D-10117 Berlin, Germany. [Vaudry, Hubert] Univ Rouen, Inserm U982, Lab Neuronal & Neuroendocrine Differentiat & Comm, Int Associated Lab Samuel de Champlain,European I, F-76821 Mont St Aignan, France. RP Tache, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Digest Dis Res Ctr Anim Care, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,CURE Bldg 115, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu; hubert.vaudry@univ-rouen.fr NR 12 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD NOV PY 2011 VL 32 IS 11 SI SI BP 2151 EP 2152 DI 10.1016/j.peptides.2011.10.015 PG 2 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 863XO UT WOS:000298201800001 PM 22024141 ER PT J AU Stengel, A Wang, LX Tache, Y AF Stengel, Andreas Wang, Lixin Tache, Yvette TI Stress-related alterations of acyl and desacyl ghrelin circulating levels: Mechanisms and functional implications SO PEPTIDES LA English DT Review DE Abdominal surgery; Food intake; Ghrelin-O-acyltransferase (GOAT); Motility; Somatostatin 2 receptor ID GROWTH-HORMONE SECRETAGOGUE; POSTOPERATIVE GASTRIC ILEUS; GENE-RELATED PEPTIDE; O-ACYLTRANSFERASE GOAT; FASTED PLASMA GHRELIN; ACUTE LUNG INJURY; RAT STOMACH; FOOD-INTAKE; MESSENGER-RNA; RECEPTOR EXPRESSION AB Ghrelin is the only known peripherally produced and centrally acting peptide hormone that stimulates food intake and digestive functions. Ghrelin circulates as acylated and desacylated forms and recently the acylating enzyme, ghrelin-O-acyltransferase (GOAT) and the de-acylating enzyme, thioesterase 1/lysophospholipase 1 have been identified adding new layers of complexity to the regulation of ghrelin. Stress is known to alter gastrointestinal motility and food intake and was recently shown to modify circulating ghrelin and GOAT levels with differential responses related to the type of stressors including a reduction induced by physical stressors (abdominal surgery and immunological/endotoxin injection, exercise) and elevation by metabolic (cold exposure, acute fasting and caloric restriction) and psychological stressors. However, the pathways underlying the alterations of ghrelin under these various stress conditions are still largely to be defined and may relate to stress-associated autonomic changes. There is evidence that alterations of circulating ghrelin may contribute to the neuroendocrine and behavioral responses along with sustaining the energetic requirement needed upon repeated exposure to stressors. A better understanding of these mechanisms will allow targeting components of ghrelin signaling that may improve food intake and gastric motility alterations induced by stress. Published by Elsevier Inc. C1 [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. [Stengel, Andreas; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Stengel, Andreas; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress & Womens Hlth, Div Digest Dis, Los Angeles, CA 90095 USA. [Stengel, Andreas] Univ Med, Charite, Dept Med, Div Psychosomat Med & Psychotherapy, Berlin, Germany. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM andreas.stengel@charite.de; ytache@mednet.ucla.edu FU VA; NIH [DK-33061, DK-57238] FX Y.T. is recipient of VA Research Career Scientist Award and NIH R01grants DK-33061, DK-57238 and VA Merit Award. We thank Ms. Eugenia Hu for careful reading of the manuscript. NR 141 TC 28 Z9 29 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 EI 1873-5169 J9 PEPTIDES JI Peptides PD NOV PY 2011 VL 32 IS 11 SI SI BP 2208 EP 2217 DI 10.1016/j.peptides.2011.07.002 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 863XO UT WOS:000298201800007 PM 21782868 ER PT J AU Vu, JP Wang, HS Germano, PM Pisegna, JR AF Vu, John P. Wang, Hank S. Germano, Patrizia M. Pisegna, Joseph R. TI Ghrelin in neuroendocrine tumors SO PEPTIDES LA English DT Review DE Ghrelin; Metastatic neuroendocrine tumors; Endogenous; Orexigenic; Cancer cachexia ID GROWTH-HORMONE SECRETAGOGUE; DES-ACYL GHRELIN; AGOUTI-RELATED PROTEIN; CARCINOID-TUMORS; MESSENGER-RNA; GASTROINTESTINAL-TRACT; ENDOCRINE TUMORS; CHROMOGRANIN-A; SOMATOSTATIN ANALOGS; HELICOBACTER-PYLORI AB Ghrelin is a 28 amino acid peptide, primarily produced by the oxyntic mucosa X/A like neuroendocrine cells in the stomach. It is also found in the small intestine, hypothalamus, pituitary gland, pancreas, heart, adipose tissue, and immune system. In gastrointestinal neuroendocrine tumors (NETs) ghrelin release has been well documented. Ghrelin is a brain-gut circuit peptide with an important role in the physiological regulation of appetite, response to hunger and starvation, metabolic and endocrine functions as energy expenditure, gastric motility and acid secretion, insulin secretion and glucose homeostasis, as well as in the potential connection to the central nervous system. Recently, there has been a significant interest in the biological effects of ghrelin in NETs. In this article, we present a comprehensive review of ghrelin's expression and a brief summary of ghrelin's physiological role in NETs patients with carcinoids, type A chronic atrophic gastritis (CAG), with or without MEN-1, and with and without liver metastases. We hope, with the research reviewed here, to offer compelling evidence of the potential significance of ghrelin in NETs, as well as to provide a useful guide to the future work in this area. Published by Elsevier Inc. C1 [Vu, John P.; Wang, Hank S.; Germano, Patrizia M.; Pisegna, Joseph R.] Vet Adm GIAHS, Dept Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. [Vu, John P.; Wang, Hank S.; Germano, Patrizia M.; Pisegna, Joseph R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Pisegna, JR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Hepatol, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu NR 73 TC 7 Z9 7 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD NOV PY 2011 VL 32 IS 11 SI SI BP 2340 EP 2347 DI 10.1016/j.peptides.2011.10.006 PG 8 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 863XO UT WOS:000298201800025 PM 22041110 ER PT J AU Maestas, KL Benge, JF Pastorek, NJ LeMaire, A Darrow, R AF Maestas, Kacey Little Benge, Jared F. Pastorek, Nicholas J. LeMaire, Ashley Darrow, Rachel TI Factor Structure of Posttraumatic Stress Disorder Symptoms in OEF/OIF Veterans Presenting to a Polytrauma Clinic SO REHABILITATION PSYCHOLOGY LA English DT Article DE factor analysis; posttraumatic stress; veterans; mild traumatic brain injury ID TRAUMATIC BRAIN-INJURY; CONFIRMATORY FACTOR-ANALYSIS; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MEASUREMENT INVARIANCE; WAR VETERANS; CHRONIC PAIN; CHECKLIST; COMBAT; IRAQ; AFGHANISTAN AB Objective: A significant number of Operation Iraqi Freedom/Operation Enduring Freedom (OEF/OIF) veterans are returning from deployment and presenting to Veterans Health Administration (VHA) polytrauma clinics with elevated rates of posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI). Inherent to the accurate assessment and treatment of this diagnostically complex group of veterans is the assumption that the construct of PTSD is the same in this population as in other trauma groups. To our knowledge, no previous study has examined the structure of PTSD in this relevant and fast-growing population of treatment-seeking OEF/OIF veterans. Evidence suggests that the latent structure of PTSD symptoms is best represented by a four-factor model, rather than the three-factor model found in the current DSM-IV-TR. Thus, we examined the three and four-factor models using the PTSD Check List-Civilian (PCL-C) in a sample of treatment-seeking OEF/OIF veterans seen through a VHA polytrauma clinic. Method: A chart review was conducted for OEF/OIF veterans (N = 361) seen through a VHA outpatient polytrauma clinic from September 2007 through August 2008. Participants completed the PCL-C as part of a comprehensive polytrauma evaluation. Results: Confirmatory factor analyses showed that the DSM-IV-TR three-factor model did not fit the data well. A direct comparison showed that the four-factor model provided a superior fit relative to the three-factor model. Conclusion: Results extend the generalizability of the four-factor model to OEF/OIF veterans presenting to Veterans Health Administration (VHA) polytrauma clinics. C1 [Maestas, Kacey Little] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Maestas, Kacey Little; Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Benge, Jared F.; Pastorek, Nicholas J.] Jack C Montgomery VA Med Ctr, Rehabil Care Line, Muskogee, OK USA. [LeMaire, Ashley] Mem Hosp Gulfport, Dept Neurosci & Rehabil, Gulfport, MS USA. [Darrow, Rachel] Ralph H Johnson VA Med Ctr, Mental Hlth Care Line, Charleston, SC USA. RP Pastorek, NJ (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,RCL 117, Houston, TX 77030 USA. EM nicholas.pastorek@va.gov RI Schueter, nicos/A-3625-2014 NR 51 TC 7 Z9 7 U1 2 U2 6 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD NOV PY 2011 VL 56 IS 4 BP 366 EP 373 DI 10.1037/a0025447 PG 8 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA 862AQ UT WOS:000298062600010 PM 21928917 ER PT J AU Scalapino, KJ Thomas, CR AF Scalapino, Kenneth J. Thomas, Charles R., Jr. TI Preface Paraneoplastic and Cancer Treatment-Related Rheumatic Disorders SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 [Scalapino, Kenneth J.] Portland VA Med Ctr, Rheumatol Sect, Portland, OR 97239 USA. [Thomas, Charles R., Jr.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Radiat Med, Portland, OR 97239 USA. RP Scalapino, KJ (reprint author), Portland VA Med Ctr, Rheumatol Sect, 3710 SW US Verterans Hosp Rd, Portland, OR 97239 USA. EM Kenneth.Scalapino@va.gov; thomasch@ohsu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD NOV PY 2011 VL 37 IS 4 BP IX EP X DI 10.1016/j.rdc.2011.09.005 PG 2 WC Rheumatology SC Rheumatology GA 865KU UT WOS:000298310600001 PM 22075202 ER PT J AU Ashouri, JF Daikh, DI AF Ashouri, Judith F. Daikh, David I. TI Rheumatic Manifestations of Cancer SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Malignancy; Paraneoplastic manifestation; Rheumatic disease; Fasciitis; POEMS; Inflammatory myopathy ID SERONEGATIVE SYMMETRICAL SYNOVITIS; ENDOTHELIAL GROWTH-FACTOR; POPULATION-BASED COHORT; HENOCH-SCHONLEIN PURPURA; GIANT-CELL ARTERITIS; PRIMARY HYPERTROPHIC OSTEOARTHROPATHY; ASPARTATE RECEPTOR ENCEPHALITIS; FASCIITIS-PANNICULITIS SYNDROME; DERMATOMYOSITIS SINE MYOSITIS; PITTING EDEMA SYNDROME AB The wide range of rheumatic and musculoskeletal conditions that can appear in association with cancer emphasizes that rheumatic disease is a major component of the spectrum of paraneoplastic manifestations. Although the pathogenetic mechanisms by which neoplasia causes these manifestations are only partially understood in select cases, many are because of immune-mediated effects stimulated by tumor antigens of endocrine factors produced by tumors. The broad overlap in signs and symptoms of occult malignancy and systemic rheumatic disease emphasizes the importance of considering and investigating the possibility of occult malignancy in the evaluation of patients with these symptoms. C1 [Ashouri, Judith F.; Daikh, David I.] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA 94143 USA. [Ashouri, Judith F.; Daikh, David I.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Daikh, DI (reprint author), Univ Calif San Francisco, Dept Med, Div Rheumatol, 400 Parnassus, San Francisco, CA 94143 USA. EM david.daikh@ucsf.edu NR 156 TC 2 Z9 2 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD NOV PY 2011 VL 37 IS 4 BP 489 EP + DI 10.1016/j.rdc.2011.09.001 PG 18 WC Rheumatology SC Rheumatology GA 865KU UT WOS:000298310600002 PM 22075194 ER PT J AU Lipton, S Schwab, P AF Lipton, Sarah Schwab, Pascale TI Neoplasm Mimics of Rheumatologic Presentations: Sialadenitis, Ocular Masquerade Syndromes, Retroperitoneal Fibrosis, and Regional Pain Syndromes SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Cancer; Sialadenitis; IgG4-related syndrome; Ocular masquerade syndrome; Retroperitoneal fibrosis; Complex regional pain syndrome; Amyloidosis ID REFLEX SYMPATHETIC DYSTROPHY; DIFFUSE INFILTRATING RETINOBLASTOMA; IGG4-RELATED SCLEROSING DISEASE; PRIMARY INTRAOCULAR LYMPHOMA; PRIMARY SYSTEMIC AMYLOIDOSIS; SALIVARY-GLAND TUMORS; SJOGRENS-SYNDROME; CLINICAL-FEATURES; MIKULICZS-DISEASE; LONG-TERM AB This article reviews a group of miscellaneous malignant conditions that may mimic rheumatologic diseases. Primary salivary gland cancer as well as lymphoproliferative conditions such as lymphoma and IgG4 related syndromes should be considered when evaluating a patient with sialadenosis. Primary intraocular lymphoma and melanoma in adults as well as leukemia and retinoblastoma in children may present as idiopathic ocular inflammation and require a high index of suspicion. Retroperitoneal fibrosis may mimic lymphoma or a solid malignancy and poses diagnostic challenges. Regional pain syndromes, such as complex regional pain and carpal tunnel syndromes, may be a manifestation of cancer and amyloidosis respectively. Awareness of these rare mimics may serve in guiding diagnostic investigations. C1 [Lipton, Sarah; Schwab, Pascale] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Arthrit & Rheumat Dis, Portland, OR 97239 USA. RP Schwab, P (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Arthrit & Rheumat Dis, 3181 SW Sam Jackson Pk Rd,OP09, Portland, OR 97239 USA. EM schwabp@ohsu.edu NR 100 TC 2 Z9 2 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X EI 1558-3163 J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD NOV PY 2011 VL 37 IS 4 BP 623 EP + DI 10.1016/j.rdc.2011.09.004 PG 17 WC Rheumatology SC Rheumatology GA 865KU UT WOS:000298310600009 PM 22075201 ER PT J AU Choi, AI Karter, AJ Liu, JY Young, BA Go, AS Schillinger, D AF Choi, Andy I. Karter, Andrew J. Liu, Jennifer Y. Young, Bessie A. Go, Alan S. Schillinger, Dean TI Ethnic Differences in the Development of Albuminuria: The DISTANCE Study SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; POPULATION; ATHEROSCLEROSIS; DISPARITIES; HEALTH; PREVALENCE; MORTALITY AB Objectives: To determine whether ethnic differences in the incidence of albuminuria are present in patients with diabetes, and to identify social, behavioral, and provider factors that explain ethnic differences. Study Design: Survey follow-up design with a race-stratified baseline survey (2005-2006) in diabetic patients from a nonprofit, fully integrated healthcare system in Northern California. We followed the 10,596 respondents (30% whites, 20% blacks, 23% Hispanics, 14% Asians, and 13% Filipinos) without evidence of prevalent albuminuria at baseline. Methods: Incident albuminuria was defined by positive dipstick urinalysis (>= 1) or urine albumin to creatinine level (>= 30 mg/g), and confirmed with repeat testing at least 3 months later. Results: The 27,292 person-years of observation yielded 981 incident albuminuria events. Age-standardized rates of albuminuria (per 1000 person-years) ranged from 13.6 (95% confidence interval [CI] 10.5-17.0) in whites to 27.8 (Cl 18.2-38.3) in blacks. In fully adjusted Cox models, the hazard ratio for blacks (1.22, 95% Cl 1.09-1.38), Asians (1.35, 95% Cl 1.13-1.61), and Filipinos (1.93, 95% Cl 1.61-2.32), but not Hispanics, was significantly greater than it was for whites. In some cases, point estimates changed markedly from the base model when fully adjusted for potential confounders. Moreover, adjustment for an array of potentially mediating factors explained only a small proportion of the observed ethnic disparities. Conclusions: Despite uniform medical care coverage, Filipinos, blacks, and Asians with diabetes developed albuminuria at higher rates than white and Hispanic adults. (Am J Manag Care. 2071;17(11):737-745) C1 [Karter, Andrew J.; Liu, Jennifer Y.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA. [Choi, Andy I.; Schillinger, Dean] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Choi, Andy I.] San Francisco VA Med Ctr, San Francisco, CA USA. [Karter, Andrew J.; Go, Alan S.] Univ Washington, Dept Hlth Serv Res, Seattle, WA 98195 USA. VA Puget Sound Healthcare Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Young, Bessie A.] Univ Washington, Dept Med, Seattle, WA USA. [Schillinger, Dean] Univ Calif San Francisco, San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA USA. RP Karter, AJ (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM andy.j.karter@kp.org FU National Institute of Diabetes, Digestive and Kidney Diseases [R01DK081796, RC1 DK086178, R01 DK080726, R01DK65664]; National Institutes of Health [P60 DK20595] FX This work was supported by the National Institute of Diabetes, Digestive and Kidney Diseases (grants R01DK081796, RC1 DK086178, R01 DK080726, and R01DK65664). The Diabetes Research and Training Center was also supported by the National Institutes of Health (grant P60 DK20595). NR 28 TC 2 Z9 2 U1 0 U2 1 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2011 VL 17 IS 11 BP 737 EP 745 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 854XO UT WOS:000297528300002 PM 22084893 ER PT J AU Kim, H Helmer, DA Zhao, ZL Boockvar, K AF Kim, Hongsoo Helmer, Drew A. Zhao, Zhonglin Boockvar, Kenneth TI Potentially Preventable Hospitalizations Among Older Adults With Diabetes SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID MULTIPLE CHRONIC CONDITIONS; CARE-SENSITIVE CONDITIONS; AVOIDABLE HOSPITALIZATIONS; DISPARITIES; MELLITUS; QUALITY; READMISSIONS; POPULATION; PREVALENCE; INSURANCE AB Objectives: To examine prevalence of and factors associated with different types of potentially preventable hospitalizations (PPHs) among older adults with diabetes. Study Design: Population-based secondary analysis. Methods: We analyzed the California State Inpatient Databases, 2005 to 2006. PPHs for 3 acute and 5 chronic ambulatory care-sensitive conditions relevant for older adults were defined by applying the Prevention Quality Indicator algorithm developed by the Agency for Health Research and Quality. Prevalence and costs of PPHs for acute conditions (acute PPHs) and chronic conditions (chronic PPHs) were examined. Associations of sociodemographic and health-related factors as well as hospitalization history with both types of PPH were estimated. Results: One-fifth of 555,538 hospitalizations of adults 65 years and older with diabetes were PPHs. Of these, 43.7% were acute PPHs and 56.3% were chronic PPHs. The total hospital cost associated with these PPHs was more than $1.1 billion. Having Medi-Cal as the primary payer and hospitalization through the emergency department were positively associated with both types of PPH. Acute PPH rates were lower, but chronic PPH rates were higher, among blacks, patients with multiple chronic conditions, and those with previous admission(s) in the same year. Conclusions: PPHs for common medical conditions are costly and prevalent among older patients with diabetes, suggesting a need for more comprehensive primary care, beyond glycemic control. The groups at risk for acute and chronic PPHs may differ, which suggests that more targeted and tailored approaches are necessary to reduce the rates of each type of PPH. (Am J Manag Care. 2011;17(11):e419-e426) C1 [Kim, Hongsoo] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul 151742, South Korea. [Kim, Hongsoo] Seoul Natl Univ, Inst Hlth & Environm, Seoul 151742, South Korea. [Helmer, Drew A.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Helmer, Drew A.] Baylor Coll Med, Houston, TX 77030 USA. [Zhao, Zhonglin] NYU, Coll Dent, New York, NY USA. [Boockvar, Kenneth] James J Peters VA Med Ctr, Bronx, NY USA. [Boockvar, Kenneth] Mt Sinai Sch Med, New York, NY USA. [Boockvar, Kenneth] Jewish Home Lifecare, New York, NY USA. RP Kim, H (reprint author), Seoul Natl Univ, Grad Sch Publ Hlth, Seoul 151742, South Korea. EM hk65@snu.ac.kr FU Greenwall Foundation FX Dr Boockvar was supported by the Greenwall Foundation. The authors thank the anonymous reviewers for their insightful comments. NR 25 TC 10 Z9 10 U1 0 U2 9 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2011 VL 17 IS 11 BP E419 EP E426 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 854XO UT WOS:000297528300006 PM 22200058 ER PT J AU Carpenter, DJ Fong, R Kraus, JE Davies, JT Moore, C Thase, ME AF Carpenter, David J. Fong, Regan Kraus, John E. Davies, John T. Moore, Christine Thase, Michael E. TI Meta-Analysis of Efficacy and Treatment-Emergent Suicidality in Adults by Psychiatric Indication and Age Subgroup Following Initiation of Paroxetine Therapy: A Complete Set of Randomized Placebo-Controlled Trials SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Review ID SEROTONIN REUPTAKE INHIBITORS; NEW-YORK-CITY; ANTIDEPRESSANT TREATMENT; CLINICAL-TRIALS; MAJOR DEPRESSION; RISK; RATES; ADOLESCENTS; ASSOCIATION; PREVENTION AB Objective: This meta-analysis of placebo-controlled paroxetine trials examines suicidality incidence in adults, focusing on disorder and age as potential risk factors. The findings are put in context with an efficacy meta-analysis of the same trial datasets. Data Sources: GlaxoSmithKline paroxetine clinical trial database(s). Study Selection: All double-blind, randomized, placebo-controlled, parallel-group studies of paroxetine therapy in adults enrolling at least 30 patients total were included in the analysis. The dataset comprised 14,911 patients from 61 trials. Data Extraction: Possible cases of suicidality were identified and blindly categorized by an expert panel, using methodology previously used by the US Food and Drug Administration. Incidences of suicidal behavior (preparatory act, suicide attempt, or completed suicide) and any suicidality (suicidal behavior or ideation) were compared between paroxetine and placebo. Efficacy assessments were based on standard depression rating scales (eg, Hamilton Depression Rating Scale or Montgomery-Asberg Depression Rating Scale) and Clinical Global Impressions Improvement scale (CGI-I) scores. Results: In the primary dataset, ie, all disorders combined, there were no significant differences between paroxetine and placebo for overall suicidality (suicidal behavior or ideation: n/n = 83/8,958 [0.93%] vs n/n = 65/5,953 [1.09%], respectively; OR = 0.9 [95% CI, 0.7-1.3]; P = .649) or for suicidal behavior specifically (n/n = 50/8,958 [0.56%] vs n/n = 40/5,953 [0.67%], respectively; OR = 1.2 [95% CI, 0.8-1.9]; P = .483). However, in patients with major depressive disorder (MDD), a greater incidence of suicidal behavior occurred in paroxetine-treated patients than in placebo-treated patients (n/n = 11/3,455 [0.32%] vs n/n = 1/1,978 [0.05%], respectively; OR = 6.7 [95% CI, 1.1-149.4]; P = .058). Across all indications, a higher incidence of suicidal behavior occurred in paroxetine-treated versus placebo-treated adults aged 18 to 24 years (n/n = 17/776 [2.19%] vs n/n = 5/542 [0.92%], respectively; OR = 2.4 [95% CI, 0.9-7.3]). In older age groups, no increase in suicidality was observed. Efficacy was demonstrated in all disorders evaluated, including MDD. Conclusions: Across all disorders, overall suicidality incidence was similar between paroxetine and placebo. However, a higher frequency of suicidal behavior occurred with paroxetine in MDD, which was largely explained by the higher incidence in young adults. These data support the efficacy of paroxetine therapy; however, they also highlight the need for careful monitoring of suicidality during antidepressant therapy, particularly in younger adults. C1 [Fong, Regan] GlaxoSmithKline Inc, Discovery Med, King Of Prussia, PA 19406 USA. [Kraus, John E.] GlaxoSmithKline Inc, Res Triangle Pk, NC USA. [Davies, John T.] GlaxoSmithKline Inc, Harlow, Essex, England. [Moore, Christine] I3 Res, Cary, NC USA. [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA. RP Fong, R (reprint author), GlaxoSmithKline Inc, Discovery Med, 2301 Renaissance Blvd, King Of Prussia, PA 19406 USA. EM Regan.2.fong@GSK.com FU GlaxoSmithKline; Eli Lilly; National Institute of Mental Health; Sepracor; American Psychiatric Publishing; Guilford Publications; Herald House; W. W. Norton Company FX Drs Carpenter, Fong, and Kraus and Mr Davies are employees of and shareholders in GlaxoSmithKline. Dr Moore is an employee of i3 Research; funding for her contribution to this article was provided by GlaxoSmithKline. Dr Thase has been an advisor or consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, MedAvante, Neuronetics, Novartis, Otsuka, Ortho-McNeil, Pfizer, Schering-Plough, Shire, Supernus, Takeda, and Transcept; has received grant support from Eli Lilly, GlaxoSmithKline, National Institute of Mental Health, and Sepracor; has served on speakers bureaus for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Pfizer; has equity holdings in MedAvante; and has received royalties from American Psychiatric Publishing, Guilford Publications, Herald House, and W. W. Norton & Company. Dr Thase's spouse is an employee of Advogent. NR 75 TC 21 Z9 21 U1 4 U2 10 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD NOV PY 2011 VL 72 IS 11 BP 1503 EP 1514 DI 10.4088/JCP.08m04927blu PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 855ME UT WOS:000297567700009 PM 21367354 ER PT J AU Carpenter, DJ Fong, R Kraus, JE Davies, JT Moore, C Thase, ME AF Carpenter, David J. Fong, Regan Kraus, John E. Davies, John T. Moore, Christine Thase, Michael E. TI Odd Odds Reply SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Letter C1 [Carpenter, David J.; Fong, Regan] GlaxoSmithKline Inc, King Of Prussia, PA USA. [Moore, Christine] I3 Res, Cary, NC USA. [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA. RP Carpenter, DJ (reprint author), GlaxoSmithKline Inc, King Of Prussia, PA USA. EM Regan.2.Fong@gsk.com NR 1 TC 0 Z9 0 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD NOV PY 2011 VL 72 IS 11 BP 1559 EP 1559 DI 10.4088/JCP.11lr07373a PG 1 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 855ME UT WOS:000297567700020 ER PT J AU Odierna, DH Afable-Munsuz, A Ikediobi, O Beattie, M Knight, S Ko, M Wilson, A Ponce, NA AF Odierna, Donna H. Afable-Munsuz, Aimee Ikediobi, Ogechi Beattie, Mary Knight, Sara Ko, Michelle Wilson, Adrienne Ponce, Ninez A. TI Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes? SO PERSONALIZED MEDICINE LA English DT Article DE African-American women; breast cancer mortality; gene-expression profiling; personalized medicine; racial disparities; social determinants of health ID POLYMERASE-CHAIN-REACTION; CORE BIOPSY-TISSUE; SOCIOECONOMIC-STATUS; AFRICAN-AMERICAN; PROGNOSTIC ROLE; UNITED-STATES; ONCOTYPE DX; SURVIVAL; WOMEN; STAGE AB New prognostic tests, such as gene-expression profiling (GEP) of breast tumors, are expected to prolong survival and improve the quality of life for many breast cancer patients. In this article, we argue that GEP has not been adequately validated in minority populations, and that both biological and social factors might affect the broad utility of these tests in diverse populations. We suggest that the widespread use of this technology could potentially lead to suboptimal treatment for black women, resulting in a further increase in black-white patient disparities in treatment response, morbidity and mortality rates. We argue for the need to build a large and diverse evidence base for GEP and other emerging technologies in personalized medicine. C1 [Odierna, Donna H.; Afable-Munsuz, Aimee] SUNY Downstate Sch Publ Hlth, Dept Community Hlth Sci, Brooklyn, NY 11203 USA. [Odierna, Donna H.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco Branch, UC Cochrane Ctr, San Francisco, CA 94118 USA. [Beattie, Mary; Wilson, Adrienne] Univ Calif San Francisco, Div Gen Internal Med, UCSF Canc Risk Program, San Francisco, CA 94143 USA. [Knight, Sara] Univ Calif San Francisco, Hlth Serv Res & Dev Serv, San Francisco Vet Affairs Med Ctr, Dept Psychiat, San Francisco, CA 94143 USA. [Knight, Sara] Univ Calif San Francisco, Hlth Serv Res & Dev Serv, San Francisco Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94143 USA. [Ko, Michelle; Ponce, Ninez A.] UCLA Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA. RP Odierna, DH (reprint author), Univ Calif San Francisco, Dept Clin Pharm, San Francisco Branch, UC Cochrane Ctr, 3333 Calif St,Box 0613, San Francisco, CA 94118 USA. EM Donna.Odierna@ucsf.edu OI Odierna, Donna H/0000-0003-4156-1456; Ponce, Ninez/0000-0001-5151-6718 FU UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), National Cancer Institute (NCI) [P01 CA130818-02A1, P01 CA 130818]; UCSF Clinical and Translational Science Institute, NIH/NCRR UCSF-CTSI [UL-1 RR024131]; Health Services Research and Development, Interdisciplinary Program [IIR 09-135]; UCSF [NCI 2P50 058207]; Avon Foundation; CSF Center for Clinical and Translational Research; Flight Attendant Medical Research Foundation FX The study was supported by the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS P01 CA130818-02A1) National Cancer Institute (NCI) P01 CA 130818 (principal investigator: K Phillips). The study was also supported by the UCSF Clinical and Translational Science Institute, NIH/NCRR UCSF-CTSI Grant Number UL-1 RR024131. Health Services Research and Development, Interdisciplinary Program to Improve Health Care for Veterans with Complex Comorbid Conditions and Health Services Research and Development Investigator Initiated Award (IIR 09-135). Mary Beattie is also funded by the UCSF Breast Specialized Program of Research Excellence (SPORE NCI 2P50 058207) and the Avon Foundation. Adrienne Wilson is funded by the Avon Foundation. Donna H Odierna is funded by the UCSF Center for Clinical and Translational Research and the Flight Attendant Medical Research Foundation. Sara Knight is employed by the Health Services Research and Development Service San Francisco Veterans Affairs Medical Center. This paper is the responsibility of the authors and the perspectives expressed within do not necessarily reflect the views of the Department of Veterans Affairs. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 84 TC 2 Z9 2 U1 0 U2 1 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1741-0541 J9 PERS MED JI Pers. Med. PD NOV PY 2011 VL 8 IS 6 BP 669 EP 679 DI 10.2217/PME.11.67 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 853ZI UT WOS:000297463800016 PM 22190978 ER PT J AU Healy, JM Patel, T Lee, S Sanchez-Reilly, S AF Healy, Jennifer M. Patel, Taral Lee, Shuko Sanchez-Reilly, Sandra TI Do Symptoms Matter When Considering Patients for Phase I Clinical Trials? A Pilot Study of Older Adults With Advanced Cancer SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE phase I; palliative care; symptoms; quality of life; older adults ID COOPERATIVE-ONCOLOGY-GROUP; PROGNOSTIC-FACTORS; BREAST-CANCER; CHEMOTHERAPY; TOXICITY; SURVIVAL; BENEFITS; CRITERIA; AGE AB Older adults (OA) with advanced cancer (AC) undergoing phase 1 clinical trials (PICT) have poor prognosis. There are no studies which describe symptoms experienced by OA. Methods: Retrospective chart review of PICT participants > 60 years. OA were compared by age (> 65 vs 60-65) and by number of symptoms (> 3 vs <= 3). Results: N = 56. Mean age = 67.09; 48.21% female. Median life-expectancy = 5 months (interquartile range = 2-9 months); 80.36% had pain; of those 64% without pain scale. Most did not have interdisciplinary professionals or hospice referrals. Older adults with > 3 symptoms had more admissions (37.5% vs 14.29%; P = .0335), complications (46.43% vs 16.07%; P = .0026), and greater decline in functional status (24 participants > 3 symptoms vs 8; P = .0173). There were no significant differences comparing OA by age. Conclusions: Older adults enrolled in PICT with more symptoms may sacrifice QOL for experimental treatment. C1 [Healy, Jennifer M.; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Care, San Antonio, TX 78229 USA. [Patel, Taral; Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Healy, JM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Care, 7703 Floyd Curl Dr,MC 7875, San Antonio, TX 78229 USA. EM Healyj@uthscsa.edu NR 18 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD NOV PY 2011 VL 28 IS 7 BP 463 EP 466 DI 10.1177/1049909111400723 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 854IA UT WOS:000297487000002 PM 21398266 ER PT J AU Tranah, GJ Blackwell, T Stone, KL Ancoli-Israel, S Paudel, ML Ensrud, KE Cauley, JA Redline, S Hillier, TA Cummings, SR Yaffe, K AF Tranah, Gregory J. Blackwell, Terri Stone, Katie L. Ancoli-Israel, Sonia Paudel, Misti L. Ensrud, Kristine E. Cauley, Jane A. Redline, Susan Hillier, Teresa A. Cummings, Steven R. Yaffe, Kristine CA SOF Res Grp TI Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women SO ANNALS OF NEUROLOGY LA English DT Article ID NURSING-HOME PATIENTS; SLEEP-WAKE PATTERNS; AGE-RELATED-CHANGES; CONSTANT DIM LIGHT; ALZHEIMERS-DISEASE; SUPRACHIASMATIC NUCLEUS; OSTEOPOROTIC FRACTURES; LOCUS-COERULEUS; WRIST ACTIVITY; OREXIN AB Objective: Previous cross-sectional studies have observed alterations in activity rhythms in dementia patients but the direction of causation is unclear. We determined whether circadian activity rhythms measured in community-dwelling older women are prospectively associated with incident dementia or mild cognitive impairment (MCI). C1 [Tranah, Gregory J.] UCSF, San Francisco Coordinating Ctr, Calif Pacific Med Ctr Res Inst, San Francisco, CA 94107 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Paudel, Misti L.; Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA. [Ensrud, Kristine E.] Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Redline, Susan] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res NW Hawaii, Portland, OR USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94107 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94107 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94107 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Tranah, GJ (reprint author), UCSF, San Francisco Coordinating Ctr, Calif Pacific Med Ctr Res Inst, 185 Berry St,Lobby 4,Suite 5700, San Francisco, CA 94107 USA. EM gtranah@sfcc-cpmc.net OI Cauley, Jane A/0000-0003-0752-4408 FU National Institutes of Health [AG05407/NIA, AR35582/NIAMS, AG05394/NIA, AR35583/NIAMS, AG005 407/NIA, AG027576-22/NIA, AG00539422A1, AG08415/NIA, AG030474/NIA, AG027574-22A1/NIA, AG026 720/NIA]; National Institute of Aging [K24 AG031155/NIA]; Novartis Pharmaceuticals; NIA; NIH; Alzheimer Association; DOD; AHAF; California Pacific Medical Center; Roche Molecular Systems; Sepracor and Litbebook, Inc.; NIAMSD FX The Study of Osteoporotic Fractures (SOF) and SOF-WISE is supported by the National Institutes of Health funding (AG05407/NIA/S.R.C., AR35582/NIAMS/J.A.C., AG05394/NIA/K.E.E., AR35583/NIAMS/S.A-I., AG005 407/NIA/S.R.C., AG027576-22/NIA/J.A.C., AG00539422A1/NIA/K.E.E., AG08415/NIA/S.A-I., AG030474/NIA/G.J.T., AG027574-22A1/NIA/J.A.C., and AG026 720/NIA/K.L.S.). Dr Kristine Yaffe is supported in part by the National Institute of Aging grant K24 AG031155/NIA/K.Y. and an Independent Investigator Award from the Alzheimer's Association.; J.A.C. receives research funding and consulting fees from Novartis Pharmaceuticals. K.Y. has received a grant from the NIA; has been a board member at Pfizer, Medivation, NIMH, and Beeson Scientific Advisory; has grants/grants pending from the NIH, Alzheimer Association, DOD, and AHAF; has received travel/accommodations/meeting expenses from the Alzheimer Association, NIH, Beeson, Japan Geriatrics Society, Wake Forest University, and State of California DHS. K.E.E. has received a grant from the NIA; is a federal employee of the Veterans Affairs Medical Center in Minneapolis, MN; and has received research support from California Pacific Medical Center, which receives funding from Roche Molecular Systems. S.R.C., K.L.S., T.B., and G.J.T. are employees of the California Pacific Medical Center and receive research support from Roche Molecular Systems. T.B., J.A.C., G.J.T., and K.L.S. have received a grant from the NIH. S.A.-I. has received a grant from the NIH; has received grants from Sepracor and Litbebook, Inc.; has served as an advisor or consultant to Ferring Pharmaceuticals, Inc., GlaxoSmithKline, Merck, NeuroVigil, Inc., Neurocrine Biosciences, Pfizer, Philips Respironics, sanofi-aventis, Sepracor, Inc., Schering-Plough, and Purdue Pharma LP. T.H. has received grants from the NIH (from the NIAMSD and the NIA). S.R. has been under subcontract from the NIH via California Pacific and is also a recipient of an endowed professorship at Harvard Medical School, donated by Dr. Peter C. Farrell, the CEO of RosMed, Inc. NR 94 TC 100 Z9 101 U1 6 U2 22 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD NOV PY 2011 VL 70 IS 5 BP 722 EP 732 DI 10.1002/ana.22468 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 857TB UT WOS:000297741600009 PM 22162057 ER PT J AU Mintzer, J O'Neill, C AF Mintzer, Jacobo O'Neill, Courtney TI Depression in Alzheimer's disease: consequence or contributing factor? SO EXPERT REVIEW OF NEUROTHERAPEUTICS LA English DT Editorial Material DE Alzheimer's disease; cognitive impairment; dementia; depression ID SERTRALINE; CRITERIA C1 [Mintzer, Jacobo] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [O'Neill, Courtney] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Mintzer, J (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM mintzerj@musc.edu FU NIMH NIH HHS [U01MH066136] NR 10 TC 1 Z9 1 U1 0 U2 2 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7175 EI 1744-8360 J9 EXPERT REV NEUROTHER JI Expert Rev. Neurother. PD NOV PY 2011 VL 11 IS 11 BP 1501 EP 1503 DI 10.1586/ERN.11.145 PG 3 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 856HP UT WOS:000297629900001 PM 22014127 ER PT J AU Gladd, DK Saunders, GH AF Gladd, Dana K. Saunders, Gabrielle H. TI Ambient noise levels in the chemotherapy clinic SO NOISE & HEALTH LA English DT Article DE Chemotherapy; cisplatin; noise disturbance; noise ID OFFICE NOISE; STRESS; OTOTOXICITY; CISPLATIN; EXPOSURE AB Many of the drugs used for chemotherapy treatments are known to be ototoxic, and can result in permanent hearing threshold shifts. The degree of ototoxic damage can be influenced by many factors including dosage, duration of exposure, genetics, and coadministration with other ototoxic agents. Cisplatin is known for its ototoxic effects on hearing thresholds, particularly in the high frequencies. Recent studies have indicated a synergistic relationship between Cisplatin administration and moderate to high noise level exposure starting between 70-85 dB SPL. This study measured the noise levels in the Portland Veterans Affairs Medical Centers outpatient chemotherapy clinic. Average (LAeq) and peak (LCpeak) noise measures were recorded every minute from 7 am until 6 pm on the two busiest clinic days. Patients, visitors, and staff members filled out anonymous surveys regarding their reactions to noise levels. Cumulative noise levels were not at levels known to interact with Cisplatin for a significant period of time. Noise measurement analysis indicated that levels were at or above 70 dB SPL for less than ten minutes during the 11-hour recording window. The patient and visitor surveys indicated that both groups were unbothered by noise in the clinic. However, most staff members were bothered by or concerned about noise levels, and many felt that it caused stress and difficulty communicating on the phone. C1 [Gladd, Dana K.; Saunders, Gabrielle H.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA. RP Gladd, DK (reprint author), 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. EM dana.koltenuk@gmail.com FU NIH [T35 DC008764]; VA RR and D Grant [C4844C] FX Support for this work was provided by NIH Predoctoral Training Grant T35 DC008764 and VA RR and D Grant # C4844C. We thank Patricia Pulliam, A.N.P., and other staff and patients of the Portland VA Medical Center Chemotherapy outpatient clinic for their participation, Roger Ellingson for his assistance with the equipment and Sarah Weidman for her assistance with data collection. NR 19 TC 4 Z9 4 U1 0 U2 2 PU MEDKNOW PUBLICATIONS PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1463-1741 J9 NOISE HEALTH JI Noise Health PD NOV-DEC PY 2011 VL 13 IS 55 BP 444 EP 451 DI 10.4103/1463-1741.90322 PG 8 WC Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health SC Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health GA 855WE UT WOS:000297596000010 PM 22122961 ER PT J AU New, AS AF New, Antonia S. TI Partial Success? SO PERSONALITY AND MENTAL HEALTH LA English DT Editorial Material ID PERSONALITY-DISORDER; DSM-IV C1 [New, Antonia S.] Mt Sinai Sch Med, New York, NY USA. [New, Antonia S.] James J Peters VAMC, Mental Illness Res Educ & Clin Care Ctr, Bronx, NY USA. RP New, AS (reprint author), Mt Sinai Sch Med, New York, NY USA. EM antonia.new@mssm.edu NR 4 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1932-8621 J9 PERSONAL MENT HEALTH JI Personal. Ment. Health PD NOV PY 2011 VL 5 IS 4 SI SI BP 301 EP 303 DI 10.1002/pmh.188 PG 3 WC Psychiatry; Psychology, Social SC Psychiatry; Psychology GA 854OS UT WOS:000297504700010 ER PT J AU Zhang, F Wang, SP Gan, L Vosler, PS Gao, YQ Zigmond, MJ Chen, J AF Zhang, Feng Wang, Suping Gan, Li Vosler, Peter S. Gao, Yanqin Zigmond, Michael J. Chen, Jun TI Protective effects and mechanisms of sirtuins in the nervous system SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE SIRT1; Deacetylation; Cell death; Cerebral ischemia; Neurodegenerative disease; Neuroprotection ID NF-KAPPA-B; GLOBAL CEREBRAL-ISCHEMIA; OXYGEN-GLUCOSE DEPRIVATION; ACTIVATED RECEPTOR-ALPHA; NITRIC-OXIDE SYNTHASE; BASE-EXCISION-REPAIR; FATTY-ACID OXIDATION; SIR2 HISTONE/PROTEIN DEACETYLASES; AMYOTROPHIC-LATERAL-SCLEROSIS; STRESS-RESPONSIVE DEACETYLASE AB Silent information regulator two proteins (sirtuins or SIRTs) are a group of histone deacetylases whose activities are dependent on and regulated by nicotinamide adenine dinucleotide (NAD(+)). They suppress genome-wide transcription, yet upregulate a select set of proteins related to energy metabolism and pro-survival mechanisms, and therefore play a key role in the longevity effects elicited by calorie restriction. Recently, a neuroprotective effect of sirtuins has been reported for both acute and chronic neurological diseases. The focus of this review is to summarize the latest progress regarding the protective effects of sirtuins, with a focus on SIRT1. We first introduce the distribution of sirtuins in the brain and how their expression and activity are regulated. We then highlight their protective effects against common neurological disorders, such as cerebral ischemia, axonal injury, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Finally, we analyze the mechanisms underlying sirtuin-mediated neuroprotection, centering on their non-histone substrates such as DNA repair enzymes, protein kinases, transcription factors, and coactivators. Collectively, the information compiled here will serve as a comprehensive reference for the actions of sirtuins in the nervous system to date, and will hopefully help to design further experimental research and expand sirtuins as therapeutic targets in the future. Published by Elsevier Ltd. C1 [Zhang, Feng; Wang, Suping; Vosler, Peter S.; Gao, Yanqin; Zigmond, Michael J.; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Zhang, Feng; Wang, Suping; Gao, Yanqin; Zigmond, Michael J.; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Zhang, Feng; Wang, Suping; Gao, Yanqin; Zigmond, Michael J.; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Gan, Li] Univ Calif San Francisco, Gladstone Inst Neurol Dis, Dept Neurol, San Francisco, CA 94158 USA. [Zhang, Feng; Wang, Suping; Vosler, Peter S.; Gao, Yanqin; Zigmond, Michael J.; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. EM zhanfx2@upmc.edu; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU Chinese Ministry of Science Technology; National Institutes of Health [NS36736, NS43802, NS45048, NS62157]; American Heart Association [10SDG2560122] FX This work was supported by Special Research Funds from Chinese Ministry of Science & Technology to State Key laboratories (Y. G., M. Z., and J.C.), grants from the National Institutes of Health (NS36736, NS43802, NS45048 and NS62157 to J.C.), and the American Heart Association (10SDG2560122 to F.Z.). We thank Pat Strickler for secretarial support and Carol Culver for editorial assistance. NR 327 TC 69 Z9 74 U1 3 U2 33 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD NOV PY 2011 VL 95 IS 3 BP 373 EP 395 DI 10.1016/j.pneurobio.2011.09.001 PG 23 WC Neurosciences SC Neurosciences & Neurology GA 856CJ UT WOS:000297614000005 PM 21930182 ER PT J AU Schutzer, WE Xue, H Reed, J Oyama, T Beard, DR Anderson, S Mader, SL AF Schutzer, William E. Xue, Hong Reed, John Oyama, Terry Beard, Douglas R. Anderson, Sharon Mader, Scott L. TI Age-related beta-adrenergic receptor-mediated vasorelaxation is changed by altering G protein receptor kinase 2 expression SO VASCULAR PHARMACOLOGY LA English DT Article DE Adenovirus; Adrenergic-beta; Aging; Fischer 344; Vasorelaxation; G protein receptor kinase (GRK) ID VASCULAR SMOOTH-MUSCLE; RAT AORTA; BETA(2)-ADRENERGIC RECEPTOR; BLOOD-PRESSURE; PLASMA-MEMBRANE; GENE-TRANSFER; DESENSITIZATION; MECHANISMS; RELAXATION; PHOSPHORYLATION AB Beta-adrenergic receptor- (beta-AR) mediated vasorelaxation declines with age. This change is likely related to receptor desensitization, rather than down regulation. One kinase responsible for desensitization is G protein receptor kinase 2 (GRK2). We have shown that GRK expression and activity increases with age in Fischer 344 rat aorta. In this study we validated that carotid arteries have similar age-related changes in the beta-AR signaling axis as aorta. This finding allowed use of in vivo infection and delivery of two adenovirus vectors to carotid arteries of 2-month-old (2 M) and 12-month-old (12 M) male Fischer 344 rats. Adeno-GRK2 was used to overexpress GRK2, and adeno-beta-ARK-ct was used to inhibit GRK2 function. Following a five-day infection, vessels were collected and ex vivo tissue bath was used to evaluate vasoreactivity. We used KCl contracted segments, and determined that overexpression of GRK2 significantly impaired isoproterenol (ISO)-mediated vasorelaxation in both age groups. Maximum relaxation (MA)() to ISO in vessels from 2 M decreased from 44% to 21%. MAX to ISO in vessels from 12 M decreased from 12% to 6%. Sensitivity (ED50) in vessels from 2 M and 12 M was also impaired 57%, and 30% respectively. We also determined that expression of adeno-beta-ARK-ct significantly improved ISO-mediated vasorelaxation in both age groups. MAX in vessels from 2 M increased from 44% to 58%. MAX in vessels from 12 M increased from 15% to 69%. ED50 in vessels from 2 M and 12 M was also improved 46%, and 50% respectively. These findings further implicate age-related increases in GRK2 expression as an important regulator of the age-related decline in beta-AR-mediated vasorelaxation. Published by Elsevier Inc. C1 [Schutzer, William E.; Xue, Hong; Reed, John; Oyama, Terry; Beard, Douglas R.; Anderson, Sharon; Mader, Scott L.] Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA. [Schutzer, William E.; Anderson, Sharon; Mader, Scott L.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA. RP Mader, SL (reprint author), Portland VA Med Ctr, Res Serv, RD26,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM scott.mader@va.gov FU Research Service, Department of Veterans Affairs FX This work was supported by the Research Service, Department of Veterans Affairs. We thank Mohammed Gaballa, PhD, Banner Sun Health Research Institute, Sun City, AZ for his guidance with the adenovirus delivery surgical procedures. NR 53 TC 5 Z9 5 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1537-1891 EI 1879-3649 J9 VASC PHARMACOL JI Vasc. Pharmacol. PD NOV-DEC PY 2011 VL 55 IS 5-6 BP 178 EP 188 DI 10.1016/j.vph.2011.09.001 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 858EF UT WOS:000297778000010 PM 21951806 ER PT J AU Weston, A Barton, C Lesselyong, J Yaffe, K AF Weston, Andrea Barton, Cynthia Lesselyong, Julia Yaffe, Kristine TI Functional deficits among patients with mild cognitive impairment SO ALZHEIMERS & DEMENTIA LA English DT Article DE Mild cognitive impairment; Dementia; Functional impairment; Instrumental activities of daily living; Activities of daily living ID DEMENTIA AB Background: Diagnostic criteria for mild cognitive impairment (MCI) include no significant functional decline, but recent studies have suggested that subtle deficits often exist. It is not known whether these differ by MCI type. We investigated the level and type of functional impairment among patients with MCI. Methods: We studied 498 patients, evaluated at the Alzheimer's Disease Research Centers of California between 2006 and 2009, who had multidisciplinary evaluations by experts, including neurologic examination and neuropsychological testing. Patients were diagnosed with MCI and subtype was determined using cognitive domain scores. In a cross-sectional descriptive study, we examined whether functional impairment differed by MCI subtype, using the Blessed Roth Dementia Rating Scale (range: 0-17, higher scores indicating more impairment). Results: Among the participants, the mean age was 75.4 years, 50.7% were women, and 81.7% were white. Patients with amnestic- (n = 392, 78.7%) and nonamnestic-type (n = 106, 21.3%) MCI had similar total Blessed Roth Dementia Rating Scale (1.6 and 1.5, respectively; P = .84) and MiniMental State Examination (26.5 and 26.7, respectively; P = .60) scores. Patients with amnestic MCI were more likely to have difficulty in remembering lists and recalling recent events (P < .05 for both) and less likely to have difficulty in eating and with continence (P = .01 for both), as compared with those with nonamnestic MCI. Conclusions: Despite the MCI diagnostic criteria suggesting no functional impairment, our results indicate that patients with MCI experience mild functional deficits that vary according to the type of MCI. (C) 2011 The Alzheimer's Association. All rights reserved. C1 [Weston, Andrea; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Weston, Andrea; Barton, Cynthia; Lesselyong, Julia; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Barton, Cynthia; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Lesselyong, Julia] No Calif Inst Res & Educ, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Weston, A (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM andrea.weston@ucsf.edu FU National Institute of Aging [K24AG031155]; Mental Illness Research, Educational, and Clinical Cente; Sierra Pacific Veterans Integrated Service Network (VISN) Veteran's Administration FX Dr. Yaffe is supported in part by a Grant from the National Institute of Aging (K24AG031155) and by a Mental Illness Research, Educational, and Clinical Center Grant from the Sierra Pacific Veterans Integrated Service Network (VISN) Veteran's Administration. NR 15 TC 4 Z9 5 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2011 VL 7 IS 6 BP 611 EP 614 DI 10.1016/j.jalz.2010.12.011 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 852WD UT WOS:000297387300008 PM 22055977 ER PT J AU Chou, SW Marousek, G Auerochs, S Stamminger, T Milbradt, J Marschall, M AF Chou, Sunwen Marousek, Gail Auerochs, Sabrina Stamminger, Thomas Milbradt, Jens Marschall, Manfred TI The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants SO ANTIVIRAL RESEARCH LA English DT Article DE Human cytomegalovirus; Antiviral activity of artesunate; Artesunate-related drugs; Therapy-resistant virus mutants; Synergistic effect ID STEM-CELL TRANSPLANTATION; DRUG-RESISTANCE; MARIBAVIR; RECOMBINANT; REPLICATION; INFECTIONS; RECIPIENTS; MUTATIONS; POTENT AB Current therapy options to treat infections with human cytomegalovirus face severe limitations leading to a continued search for novel drug candidates. Here, we describe novel characteristics of the strong antiviral potency of the drug artesunate. In vitro virus replication systems were applied to analyze a number of laboratory and clinically relevant strains of human cytomegalovirus. An inhibitory block at a very early stage of infection was demonstrated. Time-of-addition experiments indicated that the antiviral efficacy could be optimized when artesunate was applied as fractional doses consecutively added post-infection. Artesunate showed a clearly higher anti-cytomegaloviral activity than its parental drug artemisinin (approximately 10-fold) or other artesunate-related compounds. Mean IC(50) values of artesunate for a variety of standard therapy-resistant virus mutants were within a 2-fold range compared to wild-type virus. Furthermore, a synergistic effect was identified when artesunate was combined with the mechanistically distinct antiviral compound maribavir. These findings point to unique antiviral properties of artesunate which may offer an advantage over standard antiviral therapy particularly in cases of drug resistance. (C) 2011 Published by Elsevier B.V. C1 [Auerochs, Sabrina; Stamminger, Thomas; Milbradt, Jens; Marschall, Manfred] Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany. [Chou, Sunwen] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Chou, Sunwen; Marousek, Gail] US Dept Vet Affairs, Med Ctr, Portland, OR USA. RP Marschall, M (reprint author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany. EM manfred.marschall@viro.med.uni-erlangen.de FU Department of Veterans Affairs (USA); Deutsche Forschungsgemeinschaft [MA 1289/7-1, SFB 796 C3/B3]; HHV-6 Foundation (Santa Barbara, CA, USA [M.M. 2009]; Bayerische Forschungsstiftung [4SC-2010] FX We like to thank Herwig Jansen (Dafra Pharma, Turhout, Belgium) and Duong Ngoc Ha (Saokim Pharma, Hanoi, Vietnam) for kindly providing ART, ART-related drugs and product information. We appreciate the cooperations with Thomas Efferth (Inst. Pharmacy and Biochem., Univ. Mainz, Germany) and Dana Wolf (Clin. Virol. Unit, Dept. Clin. Microbiol. Inf. Diseases, Hadassah Univ. Jerusalem, Israel) in the molecular and clinical evaluation of ART, respectively. This work was supported by the Department of Veterans Affairs (USA), Deutsche Forschungsgemeinschaft (Grant MA 1289/7-1 and SFB 796 C3/B3), HHV-6 Foundation (Santa Barbara, CA, USA, Grant M.M. 2009) and Bayerische Forschungsstiftung (Grant 4SC-2010). NR 26 TC 20 Z9 21 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 J9 ANTIVIR RES JI Antiviral Res. PD NOV PY 2011 VL 92 IS 2 BP 364 EP 368 DI 10.1016/j.antiviral.2011.07.018 PG 5 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA 853LG UT WOS:000297427200027 PM 21843554 ER PT J AU Soleimani, M Khazalpour, M Cheng, GM Zhang, ZH Acevedo-Bolton, G Saloner, DA Mishra, R Wallace, AW Guccione, JM Ge, L Ratcliffe, MB AF Soleimani, Mehrdad Khazalpour, Michael Cheng, Guangming Zhang, Zhihong Acevedo-Bolton, Gabriel Saloner, David A. Mishra, Rakesh Wallace, Arthur W. Guccione, Julius M. Ge, Liang Ratcliffe, Mark B. TI Moderate Mitral Regurgitation Accelerates Left Ventricular Remodeling After Posterolateral Myocardial Infarction SO ANNALS OF THORACIC SURGERY LA English DT Article ID MAGNETIC-RESONANCE; 3-DIMENSIONAL ECHOCARDIOGRAPHY; REPAIR; REVASCULARIZATION; QUANTIFICATION; METAANALYSIS; SEVERITY; MYOCYTES; VOLUMES; STRESS AB Background. Chronic ischemic mitral regurgitation (MR) is associated with poor outcome. However, the effect of chronic ischemic MR on left ventricular (LV) remodeling after posterolateral myocardial infarction (MI) remains controversial. We tested the hypothesis that moderate MR accelerates LV remodeling after posterolateral MI. Methods. Posterolateral MI was created in 10 sheep. Cardiac magnetic resonance imaging was performed 2 weeks before and 2, 8, and 16 weeks after MI. Left ventricular and right ventricular volumes were measured, and regurgitant volume was calculated as the difference between LV and right ventricle stroke volumes. Results. Multivariate mixed effects regression showed that LV volumes at end diastole and end systole and LV sphericity were strongly correlated with both regurgitant volume (p < 0.0001, p = 0.0086, and p = 0.0007, respectively) and percent infarct area (p = 0.0156, p = 0.0307, and p < 0.0001, respectively). Conversely, whereas LV hypertrophy (LV wall volume) increased from 2 weeks to 16 weeks after MI, there was no effect of either regurgitant volume or percent infarct. Conclusions. Moderate MR accelerates LV remodeling after posterolateral MI. Further studies are needed to determine whether mitral valve repair is able to slow or reverse MI remodeling after posterolateral MI. (Ann Thorac Surg 2011;92:1614-20) (C) 2011 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Div Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@va.gov FU National Institutes of Health [R01-HL-084431, R01-HL-077921] FX This study was supported by National Institutes of Health grants R01-HL-084431 (Dr Ratcliffe) and R01-HL-077921 (Dr Guccione). NR 33 TC 11 Z9 11 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD NOV PY 2011 VL 92 IS 5 BP 1614 EP 1620 DI 10.1016/j.athoracsur.2011.05.117 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 846TF UT WOS:000296925400020 PM 21945222 ER PT J AU Chang, AY Piette, EW Foering, KP Tenhave, TR Okawa, J Werth, VP AF Chang, Aileen Y. Piette, Evan W. Foering, Kristen P. Tenhave, Thomas R. Okawa, Joyce Werth, Victoria P. TI Response to Antimalarial Agents in Cutaneous Lupus Erythematosus SO ARCHIVES OF DERMATOLOGY LA English DT Article ID SEVERITY INDEX; DISEASE AREA; QUINACRINE; RESISTANT; HYDROXYCHLOROQUINE; CHLOROQUINE; DERMATOLOGY; CLASSIFICATION; ASSOCIATION; THERAPY AB Objective: To demonstrate response to antimalarial agents in patients with cutaneous lupus erythematosus (CLE) using activity scores from the Cutaneous Lupus Erythematosus Disease Area and Severity Index, a validated outcome measure. Design: Prospective, longitudinal cohort study. Setting: University cutaneous autoimmune disease clinic. Participants: A total of 128 patients with CLE who presented from January 2007 to July 2010 and had at least 2 visits with activity scores. Intervention: Administration of antimalarial agents. Main Outcome Measures: Response was defined by a 4-point or 20% decrease in activity score. Response to initiation was determined by the difference between the scores before treatment and at the first visit at least 2 months after treatment. Response to continuation was determined by the difference between the scores at the first visit and the most recent visit while undergoing treatment. Results: Of 11 patients who initiated treatment with hydroxychloroquine, 55% were responders (n = 6), showing a decrease in median (interquartile range [IQR]) activity score from 8.0 (3.5-13.0) to 3.0 (1.8-7.3) (P = .03). Of 15 patients for whom hydroxychloroquine failed, 67% were responders to initiation of hydroxychloroquine-quinacrine therapy (n = 10), showing a decrease in median (IQR) activity score from 6.0 (4.8-8.3) to 3.0 (0.75-5.0) (P = .004). Nine of 21 patients who continued hydroxychloroquine treatment (43%), and 9 of 21 patients who continued hydroxychloroquine-quinacrine (43%) were responders, showing a decrease in median (IQR) activity score from 6.0 (1.5-9.5) to 1.0 (0.0-4.5) (P = .01) and 8.5 (4.25-17.5) to 5.0 (0.5-11.5) (P = .01), respectively. Conclusions: The use of quinacrine with hydroxychloroquine is associated with response in patients for whom hydroxychloroquine monotherapy fails. Further reduction in disease activity can be associated with continuation of treatment with antimalarial agents. C1 [Chang, Aileen Y.; Piette, Evan W.; Foering, Kristen P.; Okawa, Joyce; Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Chang, Aileen Y.; Piette, Evan W.; Foering, Kristen P.; Okawa, Joyce; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Foering, Kristen P.] Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA. [Tenhave, Thomas R.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, 3400 Civ Ctr Blvd,Ste 1-330A, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU National Institutes of Health [NIH K24-AR 18 02207]; Doris Duke Charitable Foundation FX This work was supported by National Institutes of Health grant NIH K24-AR 18 02207 (Dr Werth) and a grant from the Doris Duke Charitable Foundation to the Perelman School of Medicine at the University of Pennsylvania to fund Clinical Research Fellow Ms Chang. NR 30 TC 30 Z9 32 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD NOV PY 2011 VL 147 IS 11 BP 1261 EP 1267 DI 10.1001/archdermatol.2011.191 PG 7 WC Dermatology SC Dermatology GA 850UW UT WOS:000297226000003 PM 21768444 ER PT J AU Wan, J Abuabara, K Kurd, SK Musiek, A Steinemann, JM Vittorio, CC Gelfand, JM AF Wan, Joy Abuabara, Katrina Kurd, Shanu K. Musiek, Amy Steinemann, Jane M. Vittorio, Carmela C. Gelfand, Joel M. TI Reliability and Validity of a Photographic Method for Measuring Facial Hair Density in Men SO ARCHIVES OF DERMATOLOGY LA English DT Letter C1 [Wan, Joy; Abuabara, Katrina; Kurd, Shanu K.; Musiek, Amy; Steinemann, Jane M.; Vittorio, Carmela C.; Gelfand, Joel M.] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Abuabara, Katrina; Kurd, Shanu K.] Univ Penn, Dept Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gelfand, Joel M.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Musiek, Amy] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Gelfand, JM (reprint author), 1471 Penn Tower,1 Convent Ave, Philadelphia, PA 19104 USA. EM Joel.Gelfand@uphs.upenn.edu FU NIAMS NIH HHS [T32-AR07465, T32 AR007465] NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD NOV PY 2011 VL 147 IS 11 BP 1328 EP 1329 PG 2 WC Dermatology SC Dermatology GA 850UW UT WOS:000297226000020 PM 22106126 ER PT J AU Rosenbaum, JT Davey, MP AF Rosenbaum, James T. Davey, Michael P. TI Time for a Gut Check: Evidence for the Hypothesis That HLA-B27 Predisposes to Ankylosing Spondylitis by Altering the Microbiome SO ARTHRITIS AND RHEUMATISM LA English DT Editorial Material ID ACUTE ANTERIOR UVEITIS; HUMAN MONOCYTIC CELLS; IMMUNE-RESPONSE; TRANSGENIC RATS; T-CELLS; DISEASE; KLEBSIELLA; BACTERIA; ARTHRITIS; PEPTIDES C1 [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Davey, Michael P.] Portland VA Med Ctr, Portland, OR USA. RP Rosenbaum, JT (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L467Ad, Portland, OR 97239 USA. EM rosenbaj@ohsu.edu FU NEI NIH HHS [R01 EY019604, R01 EY019604-01, R01-EY-019604] NR 44 TC 25 Z9 27 U1 1 U2 17 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD NOV PY 2011 VL 63 IS 11 BP 3195 EP 3198 DI 10.1002/art.30558 PG 4 WC Rheumatology SC Rheumatology GA 850TC UT WOS:000297221100002 PM 21792826 ER PT J AU Shahouri, SH Michaud, K Mikuls, TR Caplan, L Shaver, TS Anderson, JD Weidensaul, DN Busch, RE Wang, S Wolfe, F AF Shahouri, Shadi H. Michaud, Kaleb Mikuls, Ted R. Caplan, Liron Shaver, Timothy S. Anderson, James D. Weidensaul, David N. Busch, Ruth E. Wang, Shirley Wolfe, Frederick TI Remission of Rheumatoid Arthritis in Clinical Practice Application of the American College of Rheumatology/European League Against Rheumatism 2011 Remission Criteria SO ARTHRITIS AND RHEUMATISM LA English DT Article ID HEALTH-ASSESSMENT QUESTIONNAIRE; MULTILEVEL LOGISTIC-REGRESSION; DISEASE-ACTIVITY SCORE; TRIALS; DEFINITION; AGREEMENT; INDEX; CARE AB Objective. To describe use of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) rheumatoid arthritis (RA) remission criteria in clinical practice. Methods. Remission was examined using data on 1,341 patients with RA (91% men) from the US Department of Veterans Affairs RA (VARA) registry (total of 9,700 visits) and 1,153 patients with RA (25.8% men) in a community rheumatology practice (Arthritis and Rheumatology Clinics of Kansas [ARCK]) (total of 6,362 visits). Cross-sectional and cumulative probabilities were studied, and agreement between the various remission criteria was assessed. Aspects of reliability of the criteria were determined using Boolean-based definitions, as well as the Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) scoring methods proposed by the ACR/EULAR joint committee. Results. When the 3-variable ACR/EULAR definition of remission recommended for use in community practice (swollen and tender joint counts <= 1, and visual analog scale score for patient's global assessment of disease activity <= 1) was applied, cross-sectional remission was 7.5% (95% confidence interval [95% CI] 6.4, 8.7%) for ARCK and 8.9% (95% CI 7.9, 9.9%) for VARA, and cumulative remission (remission at any observation) was 18.0% (for ARCK) and 24.4% (for VARA), over a mean followup of similar to 2.2 years. Addition of the erythrocyte sedimentation rate or C-reactive protein level to the criteria set reduced remission to 5.0-6.2%, and use of the CDAI/SDAI increased the proportions to 6.9-10.1%. Moreover, 1.8-4.6% of the patients met remission criteria at >= 2 visits. Agreement between criteria definitions was good, as assessed by kappa statistics and Jaccard coefficients. Among patients in remission, the probability of a remission lasting 2 years was 6.0-14.1%. Among all patients, the probability of a remission lasting 2 years was <3%. Remission status and examination results for each patient varied substantially among physicians, as determined by multilevel analyses. Conclusion. Cross-sectional remission occurred in 5.0-10.1% of the patients in these cohorts, with cumulative remission being 2-3 times greater; however, long-term remission was rare. Problems with reliability and agreement limit the usefulness of these criteria in the individual patient. However, the criteria can be an effective method for measuring clinical status and treatment effect in groups of patients in the community. C1 [Michaud, Kaleb; Wolfe, Frederick] Natl Data Bank Rheumat Dis, Wichita, KS 67214 USA. [Shahouri, Shadi H.; Shaver, Timothy S.; Anderson, James D.; Weidensaul, David N.; Busch, Ruth E.; Wang, Shirley] Arthrit Clin Kansas, Wichita, KS USA. [Shahouri, Shadi H.; Shaver, Timothy S.; Anderson, James D.; Weidensaul, David N.; Busch, Ruth E.; Wang, Shirley] Rheumatol Clin Kansas, Wichita, KS USA. [Shahouri, Shadi H.; Shaver, Timothy S.; Anderson, James D.; Weidensaul, David N.; Wang, Shirley; Wolfe, Frederick] Univ Kansas, Sch Med, Wichita, KS 67214 USA. [Michaud, Kaleb] Univ Nebraska Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Omaha VA Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska, Omaha, NE 68182 USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Caplan, Liron] Univ Colorado, Denver, CO 80202 USA. [Busch, Ruth E.] Wichita State Univ, Wichita, KS USA. RP Wolfe, F (reprint author), Natl Data Bank Rheumat Dis, 1035 N Emporia,Suite 288, Wichita, KS 67214 USA. EM fwolfe@arthritis-research.org FU VA Health Services Research & Development Service; Arthritis Foundation; NIH [1RC1AR058601-01]; VA Merit grant; VA Career Development Award [CDA 07-221] FX The US VA Rheumatoid Arthritis registry is supported by the VA Health Services Research & Development Service. Dr. Michaud's work was supported in part by an Arthritis Foundation New Investigator Award and a grant from the NIH (American Recovery & Reinvestment Act grant 1RC1AR058601-01). Dr. Mikuls' work was supported by a VA Merit grant. Dr. Caplan's work was supported by a VA Career Development Award (CDA 07-221). NR 29 TC 43 Z9 44 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD NOV PY 2011 VL 63 IS 11 BP 3204 EP 3215 DI 10.1002/art.30524 PG 12 WC Rheumatology SC Rheumatology GA 850TC UT WOS:000297221100004 PM 21739423 ER PT J AU Bartels, CM Everett, C McBride, P Smith, M Kind, AJH Mell, M AF Bartels, Christie M. Everett, Christine McBride, Patrick Smith, Maureen Kind, Amy J. H. Mell, Matthew TI Is the "lipid paradox" in rheumatoid arthritis really a paradox? Comment on the article by Bartels et al Reply SO ARTHRITIS AND RHEUMATISM LA English DT Letter ID MORTALITY C1 [Bartels, Christie M.; Everett, Christine; McBride, Patrick; Smith, Maureen; Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Kind, Amy J. H.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Mell, Matthew] Stanford Univ, Palo Alto, CA 94304 USA. RP Bartels, CM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. NR 6 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD NOV PY 2011 VL 63 IS 11 BP 3645 EP 3646 DI 10.1002/art.30587 PG 2 WC Rheumatology SC Rheumatology GA 850TC UT WOS:000297221100061 ER PT J AU Anderson, JK Zimmerman, L Caplan, L Michaud, K AF Anderson, Jaclyn K. Zimmerman, Lani Caplan, Liron Michaud, Kaleb TI Measures of Rheumatoid Arthritis Disease Activity Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score Without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA) SO ARTHRITIS CARE & RESEARCH LA English DT Article ID HEALTH-ASSESSMENT QUESTIONNAIRE; COLLEGE-OF-RHEUMATOLOGY; VISUAL ANALOG SCALES; RANDOMIZED CONTROLLED-TRIALS; ACUTE-PHASE REACTANTS; FORMAL JOINT COUNTS; CORE SET MEASURES; RESPONSE CRITERIA; FUNCTIONAL-CAPACITY; IMPROVEMENT CRITERIA C1 [Anderson, Jaclyn K.; Zimmerman, Lani; Michaud, Kaleb] Univ Nebraska Med Ctr, Omaha, NE USA. [Anderson, Jaclyn K.] Abbott Labs, Abbott Pk, IL USA. [Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA. [Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. RP Anderson, JK (reprint author), 200 Abbott Pk Rd,Dept R4NE,Bldg AP34-1, Abbott Pk, IL 60064 USA. EM Jaclyn.Anderson@abbott.com OI Anderson, Jaclyn/0000-0002-0893-3900 FU American College of Rheumatology FX Supported in part by the American College of Rheumatology. NR 121 TC 44 Z9 47 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2011 VL 63 SU 11 BP S14 EP S36 DI 10.1002/acr.20621 PG 23 WC Rheumatology SC Rheumatology GA 850SR UT WOS:000297219500003 PM 22588741 ER PT J AU Rider, LG Werth, VP Huber, AM Alexanderson, H Rao, AP Ruperto, N Herbelin, L Barohn, R Isenberg, D Miller, FW AF Rider, Lisa G. Werth, Victoria P. Huber, Adam M. Alexanderson, Helene Rao, Anand Prahalad Ruperto, Nicolino Herbelin, Laura Barohn, Richard Isenberg, David Miller, Frederick W. TI Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) SO ARTHRITIS CARE & RESEARCH LA English DT Article ID IDIOPATHIC INFLAMMATORY MYOPATHIES; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MUSCULAR-DYSTROPHY FSHD; RANDOMIZED PILOT TRIAL; HOME EXERCISE PROGRAM; OF-LIFE; PEDIATRIC RHEUMATOLOGY; NATURAL-HISTORY; PROGNOSTIC-FACTORS; INTERNATIONAL CONSENSUS C1 [Rider, Lisa G.] NIEHS, Environm Autoimmun Grp, Program Clin Res, NIH, Bethesda, MD 20892 USA. [Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA. [Huber, Adam M.] Dalhousie Univ, Halifax, NS, Canada. [Huber, Adam M.] IWK Hlth Ctr, Halifax, NS, Canada. [Alexanderson, Helene] Karolinska Inst, Stockholm, Sweden. [Alexanderson, Helene] Karolinska Univ Hosp, Stockholm, Sweden. [Rao, Anand Prahalad; Ruperto, Nicolino] IRCCS G Gaslini, Paediat Rheumatol Int Trials Org, Genoa, Italy. [Herbelin, Laura; Barohn, Richard] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA. [Isenberg, David] UCL, London, England. RP Rider, LG (reprint author), NIEHS, Environm Autoimmun Grp, Program Clin Res, NIH, CRC 4-2352,MSC 1301,10 Ctr Dr, Bethesda, MD 20892 USA. EM rider1@mail.nih.gov OI Rider, Lisa/0000-0002-6912-2458 FU NIH National Institute of Environmental Health Sciences FX Supported in part by the Intramural Research Program of the NIH National Institute of Environmental Health Sciences. NR 112 TC 51 Z9 54 U1 3 U2 12 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2011 VL 63 SU 11 BP S118 EP S157 DI 10.1002/acr.20532 PG 40 WC Rheumatology SC Rheumatology GA 850SR UT WOS:000297219500011 PM 22588740 ER PT J AU Melloni, C Roe, MT Chen, AY Wang, TY Wiviott, SD Ho, PM Peterson, ED Alexander, KP AF Melloni, Chiara Roe, Matthew T. Chen, Anita Y. Wang, Tracy Y. Wiviott, Stephen D. Ho, P. Michael Peterson, Eric D. Alexander, Karen P. TI Use of Early Clopidogrel by Reperfusion Strategy Among Patients Presenting With ST-Segment Elevation Myocardial Infarction SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE clopidogrel; guideline adherence; fibrinolysis; reperfusion ID PERCUTANEOUS CORONARY INTERVENTION; PLACEBO-CONTROLLED TRIAL; FIBRINOLYTIC THERAPY; ASPIRIN; PRETREATMENT; OUTCOMES; RISK AB Background-The 2007 update of the ACC/AHA guidelines for STEMI patients recommended addition of clopidogrel to aspirin regardless of reperfusion strategy, with a bolus dose in patients <75 years of age. Methods and Results-We evaluated use and dose of early clopidogrel among 52,140 STEMI patients enrolled in 368 hospitals participating in NCDR's ACTION Registry (R)-Get with the Guidelines (GWTG (TM)) from January 2007-September 2009. Patients were stratified by reperfusion strategy: primary percutaneous coronary intervention (PCI, n = 37,108), fibrinolysis (n = 5805), or no-reperfusion (n = 9227), and by age (<75 or >= 75 years). Adjusted odds for in-hospital outcomes are reported by clopidogrel use across reperfusion strategies. Clopidogrel was administered early to 97% of primary PCI, 18% of fibrinolytic, and 6% of non-reperfused patients. Among patients receiving clopidogrel, a loading dose (>= 300 mg) was often used in primary PCI (91%) but less frequently among fibrinolysis-treated (83%) and non-reperfused patients (74%). A positive time trend from Q1 2007-Q3 2009 in overall clopidogrel use was observed only in fibrinolytic patients (15-20%) Use of clopidogrel was associated with a significant increase in major bleeding only among older patients in the no-reperfusion group (21.9% vs. 13.2%; OR 2.19; 95% CI 1.47-3.27). A significantly lower risk of in-hospital death was associated with clopidogrel use across all reperfusion strategies (OR [95% CI], primary PCI: 0.15 [0.13-0.19]; fibrinolysis: 0.26 [0.12-0.57]; no reperfusion: 0.42 [0.27-0.65]). Conclusion-Early clopidogrel use has not yet extended to the routine care of STEMI patients treated with fibrinolysis or those not receiving reperfusion as recommended in the guideline update. (Circ Cardiovasc Qual Outcomes. 2011;4:603-609.) C1 [Melloni, Chiara; Roe, Matthew T.; Chen, Anita Y.; Wang, Tracy Y.; Peterson, Eric D.; Alexander, Karen P.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA. [Melloni, Chiara; Roe, Matthew T.; Chen, Anita Y.; Wang, Tracy Y.; Peterson, Eric D.; Alexander, Karen P.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27705 USA. [Wiviott, Stephen D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ho, P. Michael] Denver VA Med Ctr, Cardiol Sect, Denver, CO USA. Univ Colorado Denver, Denver, CO USA. RP Melloni, C (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA. EM mello004@mc.duke.edu FU Bristol-Myers Squibb (BMS)/Sanofi Pharmaceuticals Partnership; Schering-Plough Corporation; BMS/Sanofi-Aventis; BMS/Sanofi Partnership; Merck/Schering-Plough; AstraZeneca; BMS; Ortho; McNeil; Pfizer; Sanofi-Aventis; Daiichi Sankyo; Eli Lilly; Schering-Plough; VA Research & Development Career Development Award [05-026-2] FX The Bristol-Myers Squibb (BMS)/Sanofi Pharmaceuticals Partnership and Schering-Plough Corporation are founding sponsors of the ACTION Registry-GWTG. Dr Roe receives research grants from BMS/Sanofi-Aventis and Merck/Schering-Plough, is on the speaker's bureau for BMS/Sanofi-Aventis and Merck/Schering-Plough, and consults for Merck/Schering-Plough; Dr Wang receives research grants from BMS/Sanofi Partnership and Merck/Schering-Plough; Dr Wiviott receives honoraria for educational presentations from BMS, Daiichi Sankyo, Eli Lilly, Schering-Plough, Merck, and The Medicine's Company, receives consulting fees from AstraZeneca, BMS, Ortho McNeil, Pfizer, and Sanofi-Aventis, and research grants from Daiichi Sankyo, Eli Lilly, and Schering-Plough; Dr Ho receives research support from a VA Research & Development Career Development Award (05-026-2) and is also a consultant for Wellpoint, Inc; and Dr Peterson receives research grants from BMS. NR 17 TC 2 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2011 VL 4 IS 6 BP 603 EP 609 DI 10.1161/CIRCOUTCOMES.111.961045 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 850BC UT WOS:000297168400006 PM 21988922 ER PT J AU McDonald, WM Durkalski, V Ball, ER Holtzheimer, PE Pavlicova, M Lisanby, SH Avery, D Anderson, BS Nahas, Z Zarkowski, P Sackeim, HA George, MS AF McDonald, William M. Durkalski, Valerie Ball, Edward R., III Holtzheimer, Paul E., III Pavlicova, Martina Lisanby, Sarah H. Avery, David Anderson, Berry S. Nahas, Ziad Zarkowski, Paul Sackeim, Harold A. George, Mark S. TI IMPROVING THE ANTIDEPRESSANT EFFICACY OF TRANSCRANIAL MAGNETIC STIMULATION: MAXIMIZING THE NUMBER OF STIMULATIONS AND TREATMENT LOCATION IN TREATMENT-RESISTANT DEPRESSION SO DEPRESSION AND ANXIETY LA English DT Article DE transcranial magnetic stimulation; rTMS; high frequency rTMS; low frequency rTMS; treatment-resistant depression ID ASTERISK-D REPORT; MAJOR DEPRESSION; CONTROLLED-TRIAL; DISORDER; OUTPATIENTS; THERAPY AB Objective: To assess the efficacy of increasing the number of fast left repetitive transcranial magnetic stimulations (rTMS) (10 Hz @ 120% of motor threshold (MT) over the left dorsolateral prefrontal cortex (DLPFC)) needed to achieve remission in treatment-resistant depression (TRD). And, to determine if patients who do not remit to fast left will remit using slow right rTMS (1 Hz @ 120% MTover the right DLPFC). Method: Patients were part of a multicenter sham-controlled trial investigating the efficacy of fast left rTMS. Patients who failed to meet minimal response criteria in the sham-controlled study could enroll in this open fast left rTMS study for an additional 3-6 weeks. Patients who failed to remit to fast left could switch to slow right rTMS for up to 4 additional weeks. The final outcome measure was remission, defined as a HAM-D score of < 3 or 2 consecutive HAM-D scores less than 10. Results: Forty-three of 141 (30.5%) patients who enrolled in the open phase study eventually met criteria for remission. Patients who remitted during fast left treatment received a mean of 26 active treatments (90,000 pulses). Twenty-six percent of patients who failed fast left remitted during slow right treatment. Conclusion: The total number of rTMS stimulations needed to achieve remission in TRD may be higher than is used in most studies. TRD patients who do not respond to fast left rTMS may remit to slow right rTMS or additional rTMS stimulations. Depression and Anxiety 28: 973-980, 2011. (C) 2011 Wiley Periodicals, Inc. C1 [McDonald, William M.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30329 USA. [Durkalski, Valerie; Ball, Edward R., III] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Pavlicova, Martina] Columbia Univ Coll Phys & Surg, Dept Biostat, New York, NY 10032 USA. [Lisanby, Sarah H.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA. [Avery, David; Zarkowski, Paul] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. [Anderson, Berry S.; Nahas, Ziad; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Sackeim, Harold A.] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. [George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP McDonald, WM (reprint author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, 1841 Clifton Rd NE, Atlanta, GA 30329 USA. EM wmcdona@emory.edu RI Holtzheimer, Paul/B-6212-2015 OI Holtzheimer, Paul/0000-0002-3552-3296 FU National Institute of Mental Health (NIMH) [5R01MH069929, 5R01MH069887, 5R01MH069896, 5R01MH069895, 5R01MH069886]; St. Jude Medical Neuromodulation; AvaCat Consulting; Tetragenex; Neuronetics; Advanced Neuromodulatory Systems; Brainsway; Cyberonics; Takeda; MECTA Corporation; Medtronic; PureTech Ventures; NeoStim and NeoSync; Brainsonix; Cephos FX This study was supported by the National Institute of Mental Health (NIMH) as the Optimization of TMS for the Treatment of Depression Study (OPT-TMS) involving grants 5R01MH069929 (Dr. Avery), 5R01MH069887 (Dr. George), 5R01MH069896 (Dr. George), 5R01MH069895 (Dr. Lisanby), and 5R01MH069886 (Dr. McDonald).; The authors disclose the following financial relationships within the past 3 years: Following a competitive bid and request involving all TMS manufacturers at the time of trial initiation, Neuronetics Inc. was selected and loaned the TMS devices, head holders, and coils for the trial and allowed use of the safety Investigational Device Exemption for their device. Neuronetics did not provide any financial support for the study which was funded by the NIMH. Potential conflicts are reported over the past 3 years. Dr. McDonald is presently an unpaid consultant to NeoStim. Dr. Holtzheimer reports consulting fees from St. Jude Medical Neuromodulation, AvaCat Consulting, and Tetragenex, and is an unpaid consultant to NeoStim. Drs. McDonald and Holtzheimer are faculty at Emory University which holds a patent on TMS technology. Neither received royalties or is involved in the development or promotion of this patent. Dr. Lisanby reports research grants, speaking fees, or advisory board work with Neuronetics, Advanced Neuromodulatory Systems, Brainsway, and Cyberonics. Dr. Lisanby has a patent application with Columbia University on neuromodulation technology for which she receives no royalties or compensation. Dr. Avery has received research support from Neuronetics and Takeda, has been a consultant for Neuronetics and has been on the speaker's bureau for Eli Lilly, Takeda and Forest Pharmaceuticals. Dr. Nahas reports past and current research grants, speaking fees or consulting work with Cyberonics, Neuronetics, MECTA Corporation, and Medtronic. Dr. Nahas has acted as an unpaid consultant for Neuropace. Dr. Sackeim received consultant fees from MECTA Corporation and Cyberonics. Dr. George received consultant fees from PureTech Ventures and reports research grants, speaking fees, or advisory work with Brainsway, Mecta Corporation, Neuronetics, Cephos, NeoStim and NeoSync, Brainsonix, Cyberonics, and Cephos. Dr. George is faculty at MUSC which has two patent applications in Dr. George's name combining MRI and TMS. NR 16 TC 34 Z9 36 U1 0 U2 12 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD NOV PY 2011 VL 28 IS 11 BP 973 EP 980 DI 10.1002/da.20885 PG 8 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 850TH UT WOS:000297221800005 PM 21898711 ER PT J AU Gros, DF Antony, MM McCabe, RE Lydiard, RB AF Gros, Daniel F. Antony, Martin M. McCabe, Randi E. Lydiard, R. Bruce TI A PRELIMINARY INVESTIGATION OF THE EFFECTS OF COGNITIVE BEHAVIORAL THERAPY FOR PANIC DISORDER ON GASTROINTESTINAL DISTRESS IN PATIENTS WITH COMORBID PANIC DISORDER AND IRRITABLE BOWEL SYNDROME SO DEPRESSION AND ANXIETY LA English DT Article DE cognitive behavioral therapy; comorbidity; panic disorder; irritable bowel syndrome ID RANDOMIZED CONTROLLED-TRIAL; ANXIETY STRESS SCALES; DEPRESSION; SYMPTOMS; DYSREGULATION; FIBROMYALGIA; CYTOKINES; AXIS; INFLAMMATION; RELIABILITY AB Background: High comorbidity between panic disorder with/without agoraphobia (PD/A) and irritable bowel syndrome (IBS) has been identified in the literature. These findings have resulted in the recent development of neurobiological models to explain their overlapping symptoms and related origins. This study was a preliminary investigation of the influence of cognitive behavioral therapy (CBT) for PD/A on PD/A patients with and without comorbid IBS. Methods: All patients completed a thorough intake assessment, brief waitlist period, and a 12-week CBT group for PD/A. Results: The results demonstrated significant reductions in the symptoms of anxiety, depression, and overall impairment in both patient groups (ts > 2.3; Ps <.05). In addition, PD/A patients with comorbid IBS also experienced reductions in the disability and distress associated with their gastrointestinal symptoms of IBS (ts > 1.9; Ps <.07). Conclusions: Although additional research still is needed, these preliminary findings suggest that CBT for PD/A can be used to simultaneously treat comorbid symptoms of PD/A and IBS. Implications for the neurobiological models for these comorbid conditions were discussed. Depression and Anxiety 28: 1027-1033, 2011. (C) 2011 Wiley Periodicals, Inc. C1 [Gros, Daniel F.; Lydiard, R. Bruce] Ralph H Johnson VAMC, Mental Hlth Serv, Charleston, SC USA. [Gros, Daniel F.; Lydiard, R. Bruce] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Antony, Martin M.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada. [Antony, Martin M.; McCabe, Randi E.] St Josephs Healthcare, Anxiety Treatment & Res Ctr, Hamilton, ON, Canada. [McCabe, Randi E.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu RI Antony, Martin/K-1991-2012 OI Antony, Martin/0000-0002-3508-377X FU Ralph H. Johnson VAMC FX This material is the result of work supported with resources and the use of facilities at the Ralph H. Johnson VAMC. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 45 TC 2 Z9 2 U1 3 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD NOV PY 2011 VL 28 IS 11 BP 1027 EP 1033 DI 10.1002/da.20863 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 850TH UT WOS:000297221800011 PM 21770001 ER PT J AU Shin, JM Inatomi, N Munson, K Strugatsky, D Tokhtaeva, E Vagin, O Sachs, G AF Shin, Jai Moo Inatomi, Nobuhiro Munson, Keith Strugatsky, David Tokhtaeva, Elmira Vagin, Olga Sachs, George TI Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylm ethanamine Monofumarate (TAK-438) SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; PROTON PUMP INHIBITOR; BINDING-SITES; ESOMEPRAZOLE; H+,K+-ATPASE; ATPASE; LANSOPRAZOLE; SECRETION; MEMBRANES; VESICLES AB Inhibition of the gastric H, K-ATPase by the potassium-competitive acid blocker (P-CAB) 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (TAK-438), is strictly K(+)-competitive with a K(i) of 10 nM at pH 7. In contrast to previous P-CABs, this structure has a point positive charge (pK(a) 9.06) allowing for greater accumulation in parietal cells compared with previous P-CABs [e.g., (8-benzyloxy-2-methyl-imidazo(1,2-a)pyridin-3-yl)acetonitrile (SCH28080), pK(a) 5.6]. The dissociation rate of the compound from the isolated ATPase is slower than other P-CABs, with the t(1/2) being 7.5 h in 20 mM KCl at pH 7. The stoichiometry of binding of TAK-438 to the H,K-ATPase is 2.2 nmol/mg in the presence of Mg-ATP, vanadate, or MgP(i). However, TAK-438 also binds enzyme at 1.3 nmol/mg in the absence of Mg(2+). Modeling of the H, K-ATPase to the homologous Na,K-ATPase predicts a close approach and hydrogen bonding between the positively charged N-methylamino group and the negatively charged Glu795 in the K(+)-binding site in contrast to the planar diffuse positive charge of previous P-CABs. This probably accounts for the slow dissociation and high affinity. The model also predicts hydrogen bonding between the hydroxyl of Tyr799 and the oxygens of the sulfonyl group of TAK-438. A Tyr799Phe mutation resulted in a 3-fold increase of the dissociation rate, showing that this hydrogen bonding also contributes to the slow dissociation rate. Hence, this K(+)-competitive inhibitor of the gastric H,K-ATPase should provide longer-lasting inhibition of gastric acid secretion compared with previous drugs of this class. C1 [Shin, Jai Moo] VA Greater Los Angeles Healthcare Syst, Membrane Biol Lab, Los Angeles, CA 90073 USA. [Shin, Jai Moo; Munson, Keith; Strugatsky, David; Tokhtaeva, Elmira; Vagin, Olga; Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol & Med, Los Angeles, CA 90024 USA. [Inatomi, Nobuhiro] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Osaka, Japan. RP Shin, JM (reprint author), VA Greater Los Angeles Healthcare Syst, Membrane Biol Lab, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. EM jaishin@ucla.edu FU Takeda Pharmaceutical Company Limited; National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [DK053642, DK058333, DK077149]; U.S. VA Merit Grant Award [I01BX001006-01] FX This work was supported by Takeda Pharmaceutical Company Limited; the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grants DK053642, DK058333, DK077149]; and a U.S. VA Merit Grant Award [I01BX001006-01]. NR 30 TC 40 Z9 42 U1 0 U2 10 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD NOV PY 2011 VL 339 IS 2 BP 412 EP 420 DI 10.1124/jpet.111.185314 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 840TS UT WOS:000296464800011 PM 21828261 ER PT J AU Wang, JH Inoue, T Higashiyama, M Guth, PH Engel, E Kaunitz, JD Akiba, Y AF Wang, Joon-Ho Inoue, Takuya Higashiyama, Masaaki Guth, Paul H. Engel, Eli Kaunitz, Jonathan D. Akiba, Yasutada TI Umami Receptor Activation Increases Duodenal Bicarbonate Secretion via Glucagon-Like Peptide-2 Release in Rats SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID VASOACTIVE INTESTINAL POLYPEPTIDE; PIG SMALL-INTESTINE; ENTEROENDOCRINE CELLS; TASTE RECEPTORS; GLP-2 RECEPTOR; GUT; ACID; STIMULATION; MECHANISMS; TRANSPORT AB Luminal nutrient chemosensing during meal ingestion is mediated by intestinal endocrine cells, which regulate secretion and motility via the release of gut hormones. We have reported that luminal coperfusion of L-Glu and IMP, common condiments providing the umami or proteinaceous taste, synergistically increases duodenal bicarbonate secretion (DBS) possibly via taste receptor heterodimers, taste receptor type 1, member 1 (T1R1)/R3. We hypothesized that glucose-dependent insulinotropic peptide (GIP) or glucagon-like peptide (GLP) is released by duodenal perfusion with L-Glu/IMP. We measured DBS with pH and CO(2) electrodes through a perfused rat duodenal loop in vivo. GIP, exendin (Ex)-4 (GLP-1 receptor agonist), or GLP-2 was intravenously infused (0.01-1 nmol/kg/h). L-Glu (10 mM) and IMP (0.1 mM) were luminally perfused with or without bolus intravenous injection (3 or 30 nmol/kg) of the receptor antagonists Pro(3)GIP, Ex-3(9-39), or GLP-2(3-33). GIP or GLP-2 infusion dose-dependently increased DBS, whereas Ex-4 infusion gradually decreased DBS. Luminal perfusion of L-Glu/IMP increased DBS, with no effect of Pro(3)GIP or Ex-3(9-39), whereas GLP-2(3-33) inhibited L-Glu/IMP-induced DBS. Vasoactive intestinal peptide (VIP)(6-28) intravenously or N(G)-nitro-L-arginine methyl ester coperfusion inhibited the effect of L-Glu/IMP. Perfusion of L-Glu/IMP increased portal venous concentrations of GLP-2, followed by a delayed increase of GLP-1, with no effect on GIP release. GLP-1/2 and T1R1/R3 were expressed in duodenal endocrine-like cells. These results suggest that luminal L-Glu/IMP-induced DBS is mediated via GLP-2 release and receptor activation followed by VIP and nitric oxide release. Because GLP-1 is insulinotropic and GLP-2 is intestinotrophic, umami receptor activation may have additional benefits in glucose metabolism and duodenal mucosal protection and regeneration. C1 [Wang, Joon-Ho; Inoue, Takuya; Higashiyama, Masaaki; Kaunitz, Jonathan D.; Akiba, Yasutada] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Engel, Eli] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Kaunitz, Jonathan D.; Akiba, Yasutada] Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Akiba, Y (reprint author), W Los Angeles VA Med Ctr, 11301 Wilshire Blvd,Bldg 114,Suite 217, Los Angeles, CA 90073 USA. EM yakiba@mednet.ucla.edu FU Ajinomoto, Inc. (Tokyo, Japan); Department of Veterans Affairs Merit Review Award; National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK54221, P30-DK0413] FX This work was supported by a research grant from Ajinomoto, Inc. (Tokyo, Japan) (to Y.A.); a Department of Veterans Affairs Merit Review Award (to J.D.K.); the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant R01-DK54221] (to J.D.K.); and the Animal Core of the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant P30-DK0413] (to J. E. Rozengurt). NR 42 TC 38 Z9 39 U1 1 U2 5 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD NOV PY 2011 VL 339 IS 2 BP 464 EP 473 DI 10.1124/jpet.111.184788 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 840TS UT WOS:000296464800016 PM 21846840 ER PT J AU Deyo, RA Smith, DHM Johnson, ES Donovan, M Tillotson, CJ Yang, XH Petrik, AF Dobscha, SK AF Deyo, Richard A. Smith, David H. M. Johnson, Eric S. Donovan, Marilee Tillotson, Carrie J. Yang, Xiuhai Petrik, Amanda F. Dobscha, Steven K. TI Opioids for Back Pain Patients: Primary Care Prescribing Patterns and Use of Services SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Analgesics; Back Pain; Pain Control; Quality of Health Care ID CHRONIC NONCANCER PAIN; UNITED-STATES; MENTAL-HEALTH; TRENDS; PRESCRIPTIONS; ASSOCIATION; INDIVIDUALS; DISORDERS; WORKERS; ABUSE AB Background: Opioid prescribing for noncancer pain has increased dramatically. We examined whether the prevalence of unhealthy lifestyles, psychologic distress, health care utilization, and co-prescribing of sedative-hypnotics increased with increasing duration of prescription opioid use. Methods: We analyzed electronic data for 6 months before and after an index visit for back pain in a managed care plan. Use of opioids was characterized as "none," "acute" (<= 90 days), " episodic," or "long term." Associations with lifestyle factors, psychologic distress, and utilization were adjusted for demographics and comorbidity. Results: There were 26,014 eligible patients. Of these, 61% received a course of opioids, and 19% were long-term users. Psychologic distress, unhealthy lifestyles, and utilization were associated incrementally with duration of opioid prescription, not just with chronic use. Among long-term opioid users, 59% received only short-acting drugs; 39% received both long-and short-acting drugs; and 44% received a sedative-hypnotic. Of those with any opioid use, 36% had an emergency visit. Conclusions: Prescription of opioids was common among patients with back pain. The prevalence of psychologic distress, unhealthy lifestyles, and health care utilization increased incrementally with duration of use. Coprescribing sedative-hypnotics was common. These data may help in predicting long-term opioid use and improving the safety of opioid prescribing. (J Am Board Fam Med 2011;24:717-727.) C1 [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA. [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. [Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. [Deyo, Richard A.; Tillotson, Carrie J.] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR USA. [Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR USA. [Deyo, Richard A.; Smith, David H. M.; Johnson, Eric S.; Donovan, Marilee; Yang, Xiuhai; Petrik, Amanda F.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. [Dobscha, Steven K.] Portland VA Med Ctr, Ctr Study Comorbid Mental & Phys Disorders, Portland, OR USA. RP Deyo, RA (reprint author), Oregon Hlth & Sci Univ, Dept Family Med, Mail Code FM,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM deyor@ohsu.edu FU Oregon Clinical and Translational Research Institute [UL1 RR024140]; National Center for Research Resources, National Institutes of Health; National Institutes of Health Roadmap for Medical Research FX This study was made possible with support from the Oregon Clinical and Translational Research Institute grant no. UL1 RR024140; from the National Center for Research Resources, a component of the National Institutes of Health; and the National Institutes of Health Roadmap for Medical Research. NR 31 TC 48 Z9 49 U1 1 U2 6 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD NOV-DEC PY 2011 VL 24 IS 6 BP 717 EP 727 DI 10.3122/jabfm.2011.06.100232 PG 11 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 849UI UT WOS:000297150400016 PM 22086815 ER PT J AU Nace, DA Perera, S Handler, SM Muder, R Hoffman, EL AF Nace, David A. Perera, Subashan Handler, Steven M. Muder, Robert Hoffman, Erika L. TI Increasing Influenza and Pneumococcal Immunization Rates in a Nursing Home Network SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Nursing homes; immunizations; influenza; health care workers; pneumococcal vaccine ID LONG-TERM-CARE; RANDOMIZED CONTROLLED-TRIAL; QUALITY IMPROVEMENT; UNITED-STATES; VACCINATION RATES; WORKERS; STAFF; HOSPITALIZATIONS; PERFORMANCE; MORTALITY AB Introduction and Rationale: Influenza and pneumonia remain serious health concerns for long-term care (LTC) residents. Vaccination of LTC residents and health care workers are reasonable preventive strategies, although most facilities fall short of Healthy People 2010 goals. Improving immunization rates across multiple LTC facilities remains an elusive challenge. This quality improvement study sought to improve immunization rates across 6 LTC facilities and identify persistent barriers to better performance. Methods: In 2002, 6 facilities associated with the University of Pittsburgh Institute on Aging established a quality improvement network addressing immunization rates. The facilities were provided with a written educational toolkit and shared information through an e-mail distribution list. To help determine optimal program structure in future years, 3 of the facilities participated in a single half-day collaborative training session. Change in immunization rates from baseline to year 2 were compared between those participating in the collaborative training and those not participating. Barriers to improved performance were sought from all groups through focus group analysis. Results: Facilities participating in the single collaborative training program improved immunization rates modestly, whereas facilities not participating in the collaborative training saw decreases in immunization rates. Staff turnover was cited as a significant barrier to improved performance. Discussion: It may be possible to improve immunization rates in LTC facilities, at least modestly, using a collaborative training process. Staff turnover may be an important barrier to improved LTC immunization rates. (J Am Med Dir Assoc 2011; 12: 678-684) C1 [Nace, David A.; Perera, Subashan; Handler, Steven M.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Sch Med, Pittsburgh, PA 15213 USA. [Perera, Subashan] Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [Handler, Steven M.; Muder, Robert; Hoffman, Erika L.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Nace, DA (reprint author), Univ Pittsburgh, Dept Med, Div Geriatr Med, Sch Med, 3471 5th Ave,Suite 500, Pittsburgh, PA 15213 USA. EM naceda@upmc.edu RI Nace, David/D-2638-2014; Perera, Subashan/D-7603-2014 OI Handler, Steven/0000-0002-3940-3224 FU American Medical Directors Association Foundation/Pfizer FX This project was funded by the 2002 American Medical Directors Association Foundation/Pfizer Quality Improvement Awards. NR 41 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD NOV PY 2011 VL 12 IS 9 BP 678 EP 684 DI 10.1016/j.jamda.2010.05.002 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 850ZT UT WOS:000297238800012 PM 21450182 ER PT J AU Short, EB Borckardt, JJ Anderson, BS Frohman, H Beam, W Reeves, ST George, MS AF Short, E. Baron Borckardt, Jeffrey J. Anderson, Berry S. Frohman, Heather Beam, William Reeves, Scott T. George, Mark S. TI Ten sessions of adjunctive left prefrontal rTMS significantly reduces fibromyalgia pain: A randomized, controlled pilot study SO PAIN LA English DT Article DE Depression; Fibromyalgia; Pain; Tender points; Transcranial magnetic stimulation ID TRANSCRANIAL MAGNETIC STIMULATION; MAJOR DEPRESSIVE DISORDER; PLACEBO-CONTROLLED TRIAL; CHRONIC WIDESPREAD PAIN; DOUBLE-BLIND; CLINICAL-TRIAL; MULTICENTER; EFFICACY; CORTEX; MILNACIPRAN AB Transcranial magnetic stimulation (TMS) of the prefrontal cortex can cause changes in acute pain perception. Several weeks of daily left prefrontal TMS has been shown to treat depression. We recruited 20 patients with fibromyalgia, defined by American College of Rheumatology criteria, and randomized them to receive 4000 pulses at 10 Hz TMS (n = 10), or sham TMS (n = 10) treatment for 10 sessions over 2 weeks along with their standard medications, which were fixed and stable for at least 4 weeks before starting sessions. Subjects recorded daily pain, mood, and activity. Blinded raters assessed pain, mood, functional status, and tender points weekly with the Brief Pain Inventory, Hamilton Depression Rating Scale, and Fibromyalgia Impact Questionnaire. No statistically significant differences between groups were observed. Patients who received active TMS had a mean 29% (statistically significant) reduction in pain symptoms in comparison to their baseline pain. Sham TMS participants had a 4% nonsignificant change in daily pain from their baseline pain. At 2 weeks after treatment, there was a significant improvement in depression symptoms in the active group compared to baseline. Pain reduction preceded antidepressant effects. TMS was well tolerated, with few side effects. Further studies that address study limitations are needed to determine whether daily prefrontal TMS may be an effective, durable, and clinically useful treatment for fibromyalgia symptoms. (C) 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 [Short, E. Baron; Borckardt, Jeffrey J.; Frohman, Heather; Beam, William; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Brain Stimulat Lab, Charleston, SC 29425 USA. [Borckardt, Jeffrey J.; Reeves, Scott T.] Med Univ S Carolina, Dept Anesthesia & Perioperat Med, Charleston, SC 29425 USA. [Anderson, Berry S.] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Short, EB (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Brain Stimulat Lab, 67 President St,POB 250861, Charleston, SC 29425 USA. EM shorteb@musc.edu OI Frohman, Heather/0000-0001-5199-7654 FU Office of the Provost and Vice President for Research [P60 AR049459] FX Funding for this pilot project, under Multidisciplinary Clinical Research Center Grant P60 AR049459, was generously provided by the Office of the Provost and Vice President for Research. ClinicalTrials.gov identifier NCT00523302. NR 51 TC 35 Z9 38 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD NOV PY 2011 VL 152 IS 11 BP 2477 EP 2484 DI 10.1016/j.pain.2011.05.033 PG 8 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 842AB UT WOS:000296556200009 PM 21764215 ER PT J AU Liao, YH Tang, JS Deng, QJ Deng, YW Luo, T Wang, XY Chen, HX Liu, TQ Chen, XG Brody, AL Hao, W AF Liao, Yanhui Tang, Jinsong Deng, Qijian Deng, Yongwen Luo, Tao Wang, Xuyi Chen, Hongxian Liu, Tieqiao Chen, Xiaogang Brody, Arthur L. Hao, Wei TI Bilateral Fronto-Parietal Integrity in Young Chronic Cigarette Smokers: A Diffusion Tensor Imaging Study SO PLOS ONE LA English DT Article ID WHITE-MATTER ABNORMALITIES; SPINAL-CORD NEURONS; ANISOTROPIC WATER DIFFUSION; MAGNETIC-RESONANCE; MICROSTRUCTURAL INTEGRITY; HUNTINGTONS-DISEASE; TOBACCO CONTROL; NICOTINE; BRAIN; SMOKING AB Background: Cigarette smoking continues to be the leading cause of preventable morbidity and mortality in China and other countries. Previous studies have demonstrated gray matter loss in chronic smokers. However, only a few studies assessed the changes of white matter integrity in this group. Based on those previous reports of alterations in white matter integrity in smokers, the aim of this study was to examine the alteration of white matter integrity in a large, well-matched sample of chronic smokers and non-smokers. Methodology/Principal Findings: Using in vivo diffusion tensor imaging (DTI) to measure the differences of whole-brain white matter integrity between 44 chronic smoking subjects (mean age, 28.0 +/- 5.6 years) and 44 healthy age- and sex-matched comparison non-smoking volunteers (mean age, 26.3 +/- 5.8 years). DTI was performed on a 3-Tesla Siemens scanner (Allegra; Siemens Medical System). The data revealed that smokers had higher fractional anisotropy (FA) than healthy non-smokers in almost symmetrically bilateral fronto-parietal tracts consisting of a major white matter pathway, the superior longitudinal fasciculus (SLF). Conclusion/Significance: We found the almost symmetrically bilateral fronto-parietal whiter matter changes in a relatively large sample of chronic smokers. These findings support the hypothesis that chronic cigarette smoking involves alterations of bilateral fronto-parietal connectivity. C1 [Liao, Yanhui; Tang, Jinsong; Deng, Qijian; Luo, Tao; Wang, Xuyi; Chen, Hongxian; Liu, Tieqiao; Chen, Xiaogang; Hao, Wei] Cent S Univ, Xiangya Hosp 2, Mental Hlth Inst, Changsha, Hunan, Peoples R China. [Deng, Yongwen] Peoples Hosp Hunan Prov, Dept Neurosurg, Changsha, Hunan, Peoples R China. [Brody, Arthur L.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Brody, Arthur L.] Greater Los Angeles VA Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Brody, Arthur L.] Greater Los Angeles VA Healthcare Syst, Dept Res, Los Angeles, CA USA. RP Liao, YH (reprint author), Cent S Univ, Xiangya Hosp 2, Mental Hlth Inst, Changsha, Hunan, Peoples R China. EM abrody@ucla.edu; weihaochangsha@gmail.com RI Liao, Yanhui/L-1590-2016 OI Liao, Yanhui/0000-0003-4735-3252 FU Central Colleges basic scientific research operating expenses; National Key Technology R&D Program in the 11th Five-Year Plan of China [2011QNZT170, 2007BAI07B01]; Natural Science Foundation of China [81100996, 30971050, 30900486, 81130020]; National Key Basic Research and Development Program(NKBRDP) (973) [2009CB522000]; Hunan Provincial Natural Science Foundation of China [10JJ5038]; Tobacco-Related Disease Research Program [19XT-0135]; National Institute on Drug Abuse [R01 DA20872]; China Scholarship Council; University of Cambridge; Behavioural and Clinical Neuroscience Institute; Veterans Affairs Type I Merit Review Award; Richard Metzner Chair in Clinical Neuropharmacology FX This work was supported by grants from the Central Colleges basic scientific research operating expenses. 2011QNZT170, National Key Technology R&D Program in the 11th Five-Year Plan of China (2007BAI07B01), Natural Science Foundation of China (81100996, 30971050, 30900486, 81130020), National Key Basic Research and Development Program(NKBRDP) (973, 2009CB522000) and from Hunan Provincial Natural Science Foundation of China (10JJ5038). Tobacco-Related Disease Research Program (19XT-0135), the National Institute on Drug Abuse (R01 DA20872), a Veterans Affairs Type I Merit Review Award, and an endowment from the Richard Metzner Chair in Clinical Neuropharmacology. Yanhui Liao is supported by a fellowship from the China Scholarship Council to study at University of Cambridge, Behavioural and Clinical Neuroscience Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 61 TC 20 Z9 21 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 1 PY 2011 VL 6 IS 11 AR e26460 DI 10.1371/journal.pone.0026460 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 849UN UT WOS:000297150900014 PM 22069452 ER PT J AU Kuna, ST AF Kuna, Samuel T. TI Back to the Future or Forward to the Past? SO SLEEP LA English DT Editorial Material ID OBSTRUCTIVE SLEEP-APNEA; NERVE-STIMULATION; HYPOGLOSSAL NERVE; UPPER AIRWAY C1 [Kuna, Samuel T.] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Univ Penn, Philadelphia, PA 19104 USA. RP Kuna, ST (reprint author), Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, 111P,3900 Woodland Av, Philadelphia, PA 19104 USA. EM skuna@mail.med.upenn.edu NR 14 TC 1 Z9 1 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD NOV 1 PY 2011 VL 34 IS 11 BP 1455 EP 1456 DI 10.5665/sleep.1370 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 844DF UT WOS:000296727200003 PM 22043113 ER PT J AU Robinson, TN Wu, DS Stiegmann, GV Moss, M AF Robinson, Thomas N. Wu, Daniel S. Stiegmann, Gregory V. Moss, Marc TI Frailty predicts increased hospital and six-month healthcare cost following colorectal surgery in older adults SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 35th Annual Meeting of the Association of VA Surgeons CY APR 10-12, 2011 CL Irvine, CA SP Assoc VA Surg DE Geriatric; Surgery; Financial; Frailty; Healthcare resources AB BACKGROUND: The purpose of this study was to determine the relationship of frailty and 6-month postoperative costs. METHODS: Subjects aged >= 65 years undergoing elective colorectal operations were enrolled in a prospective observational study. Frailty was assessed by a validated measure of function, cognition, nutrition, comorbidity burden, and geriatric syndromes. Frailty was quantified by summing the number of positive characteristics in each subject. RESULTS: Sixty subjects (mean age, 75 +/- 8 years) were studied. Inpatient mortality was 2% (n = 1). Overall, 40% of subjects (n = 24) were considered nonfrail, 22% (n = 13) were prefrail, and 38% (n = 22) were frail. With advancing frailty, hospital costs increased (P < .001) and costs from discharge to 6-months increased (P < .001). Higher degrees of frailty were related to increased rates of discharge institutionalization (P < .001) and 30-day readmission (P = .044). CONCLUSIONS: A simple, brief preoperative frailty assessment accurately forecasts increased surgical hospital costs and postdischarge to 6-month healthcare costs after colorectal operations in older adults. Published by Elsevier Inc. C1 [Robinson, Thomas N.; Wu, Daniel S.; Stiegmann, Gregory V.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA. [Robinson, Thomas N.; Wu, Daniel S.; Stiegmann, Gregory V.] Univ Colorado Denver, Hlth Sci Ctr, Dept Surg, Aurora, CO USA. [Moss, Marc] Univ Colorado Denver, Hlth Sci Ctr, Dept Med, Aurora, CO USA. RP Robinson, TN (reprint author), Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA. EM thomas.robinson@ucdenver.edu FU NHLBI NIH HHS [K24 HL089223, K24 HL089223-04, K24 HL089223-05, K24-HL-089223]; NIA NIH HHS [K23 AG034632-02, K23 AG034632, K23 AG034632-01A1, K23AG034632] NR 11 TC 73 Z9 74 U1 1 U2 7 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2011 VL 202 IS 5 BP 511 EP 514 DI 10.1016/j.amjsurg.2011.06.017 PG 4 WC Surgery SC Surgery GA 848CJ UT WOS:000297025700005 PM 21890098 ER PT J AU Khot, S Billings, M Owens, D Longstreth, WT AF Khot, Sandeep Billings, Martha Owens, Darrell Longstreth, W. T., Jr. TI Coping With Death and Dying on a Neurology Inpatient Service Death Rounds as an Educational Initiative for Residents SO ARCHIVES OF NEUROLOGY LA English DT Article ID CARE; PATIENT AB Background: Residents in neurology may feel unprepared to care for dying patients. We developed Death Rounds to provide emotional support and end-of-life care teaching for residents caring for dying patients on the inpatient neurology service. Death Rounds are monthly 1-hour clinical case discussions where residents identify issues through shared experiences. Objective: To survey neurology residents' perceptions of Death Rounds with respect to end-of-life care teaching and emotional support. Design, Setting, and Participants: We conducted an electronic survey of all (n = 26) neurology residents and recent residency graduates at the University of Washington 2 years after instituting monthly Death Rounds. Main Outcome Measure: The survey consisted of 10 questions examining residents' perceptions of the extent to which Death Rounds provided emotional support and end-of-life care teaching. We dichotomized responses to statements about Death Rounds as agree or disagree. Results: All 26 residents responded to the survey and attended at least 1 Death Rounds session. More than half of residents attended more than 3 sessions. Residents agreed that Death Rounds helped them cope with dying patients (17 residents [65%]), delivered closure for the team (16 residents [61%]), and provided emotional support, more for the team (18 residents [69%]) than the individual (10 residents [38%]). Most residents felt that Death Rounds provided useful teaching about end-of-life care (18 residents [69%]), and they were satisfied overall with Death Rounds (16 residents [61%]). Conclusions: Death Rounds afford an opportunity for physicians-in-training to process as a group their feelings, intense emotions, and insecurities while learning from the dying process. In our inpatient neurology service, most residents found it a rewarding and valuable experience. C1 [Khot, Sandeep; Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Seattle, WA 98104 USA. [Billings, Martha] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Div Pulm & Crit Care Med, Seattle, WA USA. [Owens, Darrell] Univ Washington, Harborview Med Ctr, Palliat Care Serv, Seattle, WA 98104 USA. RP Khot, S (reprint author), Univ Washington, Dept Neurol, 325 9th Ave,Box 359775, Seattle, WA 98104 USA. EM skhot@uw.edu NR 8 TC 10 Z9 10 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD NOV PY 2011 VL 68 IS 11 BP 1395 EP 1397 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 847ZI UT WOS:000297014900004 PM 22084123 ER PT J AU Wecht, JM Radulovic, M Rosado-Rivera, D Zhang, RL LaFountaine, MF Bauman, WA AF Wecht, Jill M. Radulovic, Miroslav Rosado-Rivera, Dwindally Zhang, Run-Lin LaFountaine, Michael F. Bauman, William A. TI Orthostatic Effects of Midodrine Versus L-NAME on Cerebral Blood Flow and the Renin-Angiotensin-Aldosterone System in Tetraplegia SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Blood pressure; Hypotension; orthostatic; Rehabilitation; Spinal cord injuries ID NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; SIMULATED MICROGRAVITY; TRANSCRANIAL DOPPLER; MYOCARDIAL-INFARCTION; HYPOTENSION; INHIBITION; PRESSURE; RISK; HYDROCHLORIDE AB Objective: To compare responses to head-up tilt (HUT) in individuals with chronic tetraplegia after midodrine hydrochloride (10mg) versus nitro-L-arginine methyl ester (L-NAME, 1mg/kg) administration. Design: Prospective comparative drug trial. Setting: Veterans Affairs medical center. Participants: Participants (N=7) were studied during 3 laboratory visits: no drug, midodrine (administered orally 30min before HUT), and L-NAME (infused over a 60-min period). Interventions: Anti-hypotensive agents, midodrine, and L-NAME. Main Outcome Measures: Mean arterial pressure (MAP), cerebral blood flow (CBF), and markers of the renin-angiotensin-aldosterone system (RAAS, plasma renin and serum aldosterone) were measured in the supine position at baseline (BL) and during a 45 degrees HUT maneuver. Data were compared between BL and the average of 3 assessments collected during HUT. Results: Orthostatic MAP and CBF were increased with the midodrine and L-NAME groups compared with the no drug trial and the relationship between the change in MAP and CBF was significant (r=0.770; P<0.001). Both L-NAME and midodrine appeared to suppress the post-HUT RAAS response compared with no drug. Conclusions: Increasing orthostatic blood pressure with L-NAME or midodrine appears to increase CBF and suppress the RAAS during HUT in persons with tetraplegia, although more data are needed to confirm these preliminary findings. C1 [Wecht, Jill M.; Radulovic, Miroslav; Rosado-Rivera, Dwindally; Zhang, Run-Lin; LaFountaine, Michael F.; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence, Bronx, NY 10468 USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Wecht, Jill M.; Radulovic, Miroslav; LaFountaine, Michael F.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM jm.wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [A6161W, B3203R, B4162C] FX Supported by the Veterans Affairs Rehabilitation Research and Development Service (grant nos. A6161W, B3203R, and B4162C). NR 46 TC 7 Z9 7 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2011 VL 92 IS 11 BP 1789 EP 1795 DI 10.1016/j.apmr.2011.03.022 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 846WT UT WOS:000296934600008 PM 21762873 ER PT J AU Kullgren, JT Werner, RM AF Kullgren, Jeffrey T. Werner, Rachel M. TI Counterpoint: Will Pubic Reporting of Health-care Quality Measures Inform and Educate Patients? No SO CHEST LA English DT Editorial Material ID OF-CARE; CONSUMERS; NETWORK C1 [Kullgren, Jeffrey T.] Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA. [Kullgren, Jeffrey T.; Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kullgren, Jeffrey T.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Kullgren, JT (reprint author), Robert Wood Johnson Fdn Clin Scholars, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kullgren@mail.med.upenn.edu NR 20 TC 4 Z9 4 U1 2 U2 10 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2011 VL 140 IS 5 BP 1117 EP 1120 DI 10.1378/chest.11-2094 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 846UK UT WOS:000296928500006 PM 22045876 ER PT J AU Kullgren, JT Werner, RM AF Kullgren, Jeffrey T. Werner, Rachel M. TI Counterpoint: Will Pubic Reporting of Health-care Quality Measures Inform and Educate Patients? No Reply SO CHEST LA English DT Editorial Material ID HOSPITALS C1 [Kullgren, Jeffrey T.] Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA. [Kullgren, Jeffrey T.; Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kullgren, Jeffrey T.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Kullgren, JT (reprint author), Robert Wood Johnson Fdn Clin Scholars, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kullgren@mail.med.upenn.med NR 7 TC 0 Z9 0 U1 1 U2 2 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2011 VL 140 IS 5 BP 1121 EP 1122 DI 10.1378/chest.11-2095 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 846UK UT WOS:000296928500008 ER PT J AU O'Connor, CM Fiuzat, M Lombardi, C Fujita, K Jia, G Davison, BA Cleland, J Bloomfield, D Dittrich, HC DeLucca, P Givertz, MM Mansoor, G Ponikowski, P Teerlink, JR Voors, AA Massie, BM Cotter, G Metra, M AF O'Connor, Christopher M. Fiuzat, Mona Lombardi, Carlo Fujita, Kenji Jia, Gang Davison, Beth A. Cleland, John Bloomfield, Daniel Dittrich, Howard C. DeLucca, Paul Givertz, Michael M. Mansoor, George Ponikowski, Piotr Teerlink, John R. Voors, Adriaan A. Massie, Barry M. Cotter, Gad Metra, Marco TI Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure Analysis From the PROTECT Pilot Study SO CIRCULATION-HEART FAILURE LA English DT Article DE cardiac troponin; acute heart failure; rolofylline ID IN-HOSPITAL MORTALITY; LONG-TERM PROGNOSIS; CARDIAC TROPONIN; AMBULATORY PATIENTS; ADENOSINE A(1); OPTIMIZE-HF; TASK-FORCE; ASSOCIATION; DYSFUNCTION; GUIDELINES AB Background-Cardiac troponin T (cTnT) elevation is common and is a predictor of outcomes in patients with acute heart failure (AHF). The degree and progression of cTnT release during hospitalization of patients with AHF is unclear. We evaluated the incidence of cTnT release during AHF hospitalization and the relationship of cTnT release with outcomes. Methods and Results-The Placebo-controlled Randomized study of the selective A(1) adenosine receptor antagonist rolofylline for patients hospitalized with acute heart failure and volume Overload to assess Treatment Effect on Congestion and renal funcTion (PROTECT) pilot study was a multicenter, double-blind study of patients with AHF. Measurements of cTnT were collected at randomization and days 2, 3, 4, and 7. Patients were classified on the basis of their serum cTnT levels at baseline: positive (>0.03 ng/mL), detectable (>0.01 ng/mL), and negative (>= 0.01 ng/mL). A detectable cTnT level developed during the study (after baseline) was classified as cTnT conversion: 288 patients were included; 172 (60%) patients had detectable cTnT levels and 97 (34%) had positive values (>0.03 ng/mL) at baseline. Of the 116 patients with negative troponin at baseline, 24 (21%) had elevated cTnT levels by day 7. On multivariable analysis, positive cTnT at baseline was an independent predictor of the composite end point of cardiovascular/renal rehospitalization or death at 60 days (hazard ratio, 1.84; 95% confidence interval, 1.04-3.26; P=0.036). Kaplan-Meier curves showed similar worse outcomes in patients with troponin conversion and positive troponin at baseline. Conclusions-There was a high prevalence of baseline cTnT elevation in this cohort; 21% of those negative at baseline converted to detectable levels by day 7. Positive troponin at baseline, and conversion to positive levels, were associated with worse outcomes at 60 days. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00328692 and NCT00354458. (Circ Heart Fail. 2011;4:724-732.) C1 [O'Connor, Christopher M.; Fiuzat, Mona] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Lombardi, Carlo; Metra, Marco] Univ Brescia, Dept Expt & Appl Med, Brescia, Italy. [Fujita, Kenji; Jia, Gang; Bloomfield, Daniel; Dittrich, Howard C.; DeLucca, Paul; Mansoor, George] Merck Res Labs, Rahway, NJ USA. [Davison, Beth A.; Cotter, Gad] Momentum Res, Durham, NC USA. [Cleland, John] Univ Hull, Kingston Upon Hull HU6 7RX, N Humberside, England. [Givertz, Michael M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. RP O'Connor, CM (reprint author), DUMC Box 3356, Durham, NC 27705 USA. EM oconn002@mc.duke.edu RI Teerlink, John/D-2986-2012; lombardi, carlo /O-2130-2013; Ponikowski, Piotr/O-6454-2015 OI lombardi, carlo /0000-0002-7120-5877; Ponikowski, Piotr/0000-0002-3391-7064; Davison, Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016; Metra, Marco/0000-0001-6691-8568 FU Merck FX Drs O'Connor, Voors, Ponikowski, Dittrich, Metra, Teerlink, Massie, Givertz, Cleland, Weatherley, and Cotter received research funding from Merck. Drs Jia, Fujita, Mansoor, Bloomfield, and DeLucca are employees of Merck. NR 32 TC 40 Z9 41 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD NOV PY 2011 VL 4 IS 6 BP 724 EP 732 DI 10.1161/CIRCHEARTFAILURE.111.961581 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 850AF UT WOS:000297166100012 PM 21900185 ER PT J AU Bhattacharya, A Jernigan, AL Sabia, M Zhang, YQ Li, Y Qi, WB Van Remmen, H AF Bhattacharya, Arunabh Jernigan, Amanda L. Sabia, Marian Zhang, Yiqiang Li, Yan Qi, Wenbo Van Remmen, Holly TI Disruption of the 12/15-Lipoxygenase Gene (Alox15) Protects Against Denervation-Induced Muscle Atrophy SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 18th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine (SFRBM) CY NOV 16-20, 2011 CL Atlanta, GA SP Soc Free Rad Biol & Med (SFRBM) C1 [Bhattacharya, Arunabh; Jernigan, Amanda L.; Sabia, Marian; Zhang, Yiqiang; Li, Yan; Qi, Wenbo; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, San Antonio, TX 78229 USA. [Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2011 VL 51 SU 1 BP S76 EP S76 DI 10.1016/j.freeradbiomed.2011.10.420 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 848FS UT WOS:000297036600186 ER PT J AU Kachadourian, R Day, BJ Pugazhenti, S Franklin, CC Mahaffey, G Gauthier, C Valdameri, G Di Pietro, A Boumendjel, A AF Kachadourian, Remy Day, Brian J. Pugazhenti, Subbiah Franklin, Christopher C. Mahaffey, Gregory Gauthier, Charlotte Valdameri, Glaucio Di Pietro, Attilio Boumendjel, Ahcene TI A New Synthetic Chalcone Derivative is a Potent Inducer of Glutathione Synthesis SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 18th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine (SFRBM) CY NOV 16-20, 2011 CL Atlanta, GA SP Soc Free Rad Biol & Med (SFRBM) C1 [Kachadourian, Remy; Day, Brian J.; Pugazhenti, Subbiah; Franklin, Christopher C.] Univ Colorado Denver, Denver, CO USA. [Pugazhenti, Subbiah; Mahaffey, Gregory] Denver VA Med Ctr, Denver, CO USA. [Gauthier, Charlotte; Valdameri, Glaucio; Di Pietro, Attilio] CNRS, Inst Biol & Chim Prot, Lyon, France. [Boumendjel, Ahcene] Univ Grenoble 1, Grenoble, France. RI Valdameri, Glaucio/G-8354-2017 OI Valdameri, Glaucio/0000-0003-1882-1512 NR 2 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2011 VL 51 SU 1 BP S88 EP S89 DI 10.1016/j.freeradbiomed.2011.10.407 PG 2 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 848FS UT WOS:000297036600221 ER PT J AU Shi, Y Liu, YH Li, Y Hamilton, RT Jernigan, AL Jang, YC Van Remmen, H AF Shi, Yun Liu, Yuhong Li, Yan Hamilton, Ryan T. Jernigan, Amanda L. Jang, Youngmok C. Van Remmen, Holly TI Age-related Changes in Neurotrophic Factors Expression in Skeletal Muscle Undergoing Atrophy SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 18th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine (SFRBM) CY NOV 16-20, 2011 CL Atlanta, GA SP Soc Free Rad Biol & Med (SFRBM) C1 [Shi, Yun; Liu, Yuhong; Li, Yan; Hamilton, Ryan T.; Jernigan, Amanda L.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Jang, Youngmok C.] Harvard Univ, Cambridge, MA 02138 USA. [Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2011 VL 51 SU 1 BP S79 EP S80 DI 10.1016/j.freeradbiomed.2011.10.431 PG 2 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 848FS UT WOS:000297036600197 ER PT J AU Xiang, M Shi, XL Li, YH Xu, J Yin, LH Xiao, GZ Scott, MJ Billiar, TR Wilson, MA Fan, J AF Xiang, Meng Shi, Xiaolian Li, Yuehua Xu, Jia Yin, Lianhua Xiao, Guozhi Scott, Melanie J. Billiar, Timothy R. Wilson, Mark A. Fan, Jie TI Hemorrhagic Shock Activation of NLRP3 Inflammasome in Lung Endothelial Cells SO JOURNAL OF IMMUNOLOGY LA English DT Article ID MOBILITY GROUP BOX-1; INTERLEUKIN-1 RECEPTOR ANTAGONIST; RESPIRATORY-DISTRESS-SYNDROME; NEUTROPHIL NADPH OXIDASE; MULTIPLE ORGAN FAILURE; SEVERE BLUNT TRAUMA; TLR2 UP-REGULATION; NAD(P)H OXIDASE; ISCHEMIA/REPERFUSION INJURY; ALVEOLAR MACROPHAGES AB Hemorrhagic shock (HS) due to major trauma and surgery predisposes the host to the development of systemic inflammatory response syndrome (SIRS), including acute lung injury (ALI), through activating and exaggerating the innate immune response. IL-1 beta is a crucial proinflammatory cytokine that contributes to the development of SIRS and ALI. Lung endothelial cells (EC) are one important source of IL-1 beta, and the production of active IL-1 beta is controlled by the inflammasome. In this study, we addressed the mechanism underlying HS activation of the inflammasome in lung EC. We show that high mobility group box 1 acting through TLR4, and a synergistic collaboration with TLR2 and receptor for advanced glycation end products signaling, mediates HS-induced activation of EC NAD(P) H oxidase. In turn, reactive oxygen species derived from NAD(P) H oxidase promote the association of thioredoxin-interacting protein with the nucleotide-binding oligomerization domain-like receptor protein NLRP3 and subsequently induce inflammasome activation and IL-1 beta secretion from the EC. We also show that neutrophil-derived reactive oxygen species play a role in enhancing EC NAD(P) H oxidase activation and therefore an amplified inflammasome activation in response to HS. The present study explores a novel mechanism underlying HS activation of EC inflammasome and thus presents a potential therapeutic target for SIRS and ALI induced after HS. The Journal of Immunology, 2011, 187: 4809-4817. C1 [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Res & Dev, Pittsburgh, PA 15240 USA. [Xiang, Meng; Shi, Xiaolian; Li, Yuehua; Xu, Jia; Scott, Melanie J.; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Xiang, Meng; Yin, Lianhua] Fudan Univ, Shanghai Med Coll, Dept Physiol & Pathophysiol, Shanghai 200032, Peoples R China. [Shi, Xiaolian] Xi An Jiao Tong Univ, Coll Med, Dept Pharmacol, Xian 710061, Peoples R China. [Xu, Jia] So Med Univ, Dept Pathophysiol, Guangzhou 510515, Guangdong, Peoples R China. [Xiao, Guozhi] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. RP Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Res & Dev, Bldg 1,Room 2W109 151L-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM jif7@pitt.edu FU National Institutes of Health [R01-HL-079669]; National Institutes of Health Center [P50-GM-53789]; Veterans Administration FX This work was supported by National Institutes of Health Grant R01-HL-079669 (to J.F. and M.A.W.), National Institutes of Health Center Grant P50-GM-53789 (to T.R.B. and J.F.), and a Veterans Administration Merit Award (to J.F.). NR 61 TC 53 Z9 60 U1 0 U2 6 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD NOV 1 PY 2011 VL 187 IS 9 BP 4809 EP 4817 DI 10.4049/jimmunol.1102093 PG 9 WC Immunology SC Immunology GA 841ET UT WOS:000296496000046 PM 21940680 ER PT J AU Penrod, JD Luhrs, CA Livote, EE Cortez, TB Kwak, J AF Penrod, Joan D. Luhrs, Carol A. Livote, Elayne E. Cortez, Therese B. Kwak, Jennifer TI Implementation and Evaluation of a Network-Based Pilot Program to Improve Palliative Care in the Intensive Care Unit SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Palliative care; critical care; intensive care unit; ICU; quality improvement AB Background. Intensive care unit (ICU) care could be improved by implementation of time-triggered evidence-based interventions including identification of a patient/family medical decision maker, the patient's advance directive status, and cardiopulmonary resuscitation preferences by Day 1; offer of social work and spiritual support by Day 3; and a family meeting establishing goals of care by Day 5. We implemented a program to improve care for ICU patients in five Department of Veterans Affairs' ICUs. Measures. We measured the percent of ICU patients with lengths of stay of five or more days that received the care processes by the appropriate day. Intervention. Critical care and palliative care providers trained ICU nurse teams to improve care through auditing, performance feedback, improvement tools, education, and monthly team meetings. Outcomes. Pre- and postintervention care were compared. Offering social work and spiritual support, identification of the medical decision maker, and documentation of family meetings significantly improved. Conclusions/Lessons Learned. ICU nurse teams can be engaged to improve care under the aegis of a collaborative quality improvement project. J Pain Symptom Manage 2011;42:668-671. Published by Elsevier Inc. on behalf of U.S. Cancer Pain Relief Committee. C1 [Penrod, Joan D.; Livote, Elayne E.; Kwak, Jennifer] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Luhrs, Carol A.; Cortez, Therese B.] VA New York Harbor Healthcare Syst, Brooklyn, NY USA. RP Penrod, JD (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM joan.penrod@mssm.edu FU Department of Veterans Affairs; Health Services Research; Development Service FX This work was supported in part by the Department of Veterans Affairs, Health Services Research and Development Service. The authors declare no conflicts of interest. NR 5 TC 13 Z9 14 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2011 VL 42 IS 5 BP 668 EP 671 DI 10.1016/j.jpainsymman.2011.06.012 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 847YL UT WOS:000297011800005 PM 22045370 ER PT J AU Villarreal, D Restrepo, MI Healy, J Howard, B Tidwell, J Ross, J Hartronft, S Jawad, M Sanchez-Reilly, S Reed, K Espinoza, SE AF Villarreal, Deborah Restrepo, Marcos I. Healy, Jennifer Howard, Bonita Tidwell, Janet Ross, Jeanette Hartronft, Scotte Jawad, Marriyam Sanchez-Reilly, Sandra Reed, Kristin Espinoza, Sara E. TI A Model for Increasing Palliative Care in the Intensive Care Unit: Enhancing Interprofessional Consultation Rates and Communication SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Palliative care; critical care; end of life; quality improvement; interprofessional ID OUTCOMES; STATES AB Background. Only a minority of patients who die in the medical intensive care unit (MICU) receive palliative care services. At the South Texas Veterans Health Care System Audie L. Murphy Hospital, only 5% of patients who died in the MICU from May to August 2010 received a palliative care consultation. Measures. We measured the percentage of MICU patients for which there was a palliative care consultation during the intervention period. Intervention. Starting October 1, 2010 and ending April 30, 2011, the palliative care and MICU teams participated in daily "pre-rounds'' to identify patients at risk for poor outcomes, who may benefit from a palliative care consultation. Outcomes. Palliative care consultation increased significantly from 5% to 59% for patients who died in the MICU during the intervention period. Additionally, palliative care consultation increased from 5% to 21% for all patients admitted to the MICU during the intervention period. Conclusions/Lessons Learned. Daily pre-rounds between the palliative care and MICU teams increased palliative care services for MICU patients at risk for poor outcomes, who may benefit from a palliative care consultation. J Pain Symptom Manage 2011;42:676-679. Published by Elsevier Inc. on behalf of U.S. Cancer Pain Relief Committee. C1 [Villarreal, Deborah] Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Villarreal, Deborah; Healy, Jennifer; Ross, Jeanette; Jawad, Marriyam; Sanchez-Reilly, Sandra; Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care, San Antonio, TX 78229 USA. [Jawad, Marriyam] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. RP Villarreal, D (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, Div Geriatr Gerontol & Palliat Med, 7400 Merton Minter, San Antonio, TX 78229 USA. EM villarreald4@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 FU U.S. Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Professions FX Dr. Villareal is receiving career development support from the U.S. Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Professions, Geriatric Academic Career Award. NR 9 TC 10 Z9 10 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2011 VL 42 IS 5 BP 676 EP 679 DI 10.1016/j.jpainsymman.2011.07.004 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 847YL UT WOS:000297011800007 PM 22045372 ER PT J AU Vig, EK Sudore, RL Berg, KM Fromme, EK Arnold, RM AF Vig, Elizabeth K. Sudore, Rebecca L. Berg, Karina M. Fromme, Erik K. Arnold, Robert M. TI Responding to Surrogate Requests That Seem Inconsistent With a Patient's Living Will SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Surrogates; decision making; advance directives; substituted judgment ID LIFE DECISION-MAKING; SUSTAINING TREATMENT; PREFERENCES; CHOICES; INTERESTS; JUDGMENTS; STABILITY; DISAGREE; OTHERS; FAMILY AB Clinicians may feel conflicted when a patient's legal decision maker is making decisions that seem inconsistent with a patient's living will. We provide evidence-based information to help clinicians consider whether a surrogate's inconsistent decisions are ethically appropriate. Surrogates are not flawless translators of their loved one's preferences; they are influenced by their own hopes and the current clinical context. Patients may be aware of this, are often concerned about burdening their loved ones, and often grant their surrogates leeway in interpreting their wishes. When appropriate, clinicians should respect surrogates' interpretations of patient values and take steps to decrease surrogate stress during the decision-making process. Finally, if clinicians are cognizant of their own values and preferences, they may recognize how these may affect their responses to certain clinical cases. J Pain Symptom Manage 2011;42:777-782. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Vig, Elizabeth K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Vig, Elizabeth K.] Univ Washington, Seattle, WA 98195 USA. [Sudore, Rebecca L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Berg, Karina M.] Yale Univ, Sch Med, New Haven, CT USA. [Fromme, Erik K.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Arnold, Robert M.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Sect Palliat Care & Med Eth,Ctr Bioeth & Hlth Law, Pittsburgh, PA USA. RP Vig, EK (reprint author), 1660 Columbian Way,S 182 Eth, Seattle, WA 98108 USA. EM vigster@u.washington.edu FU Pfizer Fellowship in Clear Communication FX Dr. Sudore is supported in part by a Pfizer Fellowship in Clear Communication. The other authors have no sponsorship related to this manuscript. The authors have no financial conflicts of interest to disclose. NR 22 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2011 VL 42 IS 5 BP 777 EP 782 DI 10.1016/j.jpainsymman.2011.08.003 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 847YL UT WOS:000297011800017 PM 22045374 ER PT J AU Pierre, JF Heneghan, AF Tsao, FHC Sano, Y Jonker, MA Omata, J Lan, JG Kudsk, KA AF Pierre, Joseph F. Heneghan, Aaron F. Tsao, Francis H. C. Sano, Yoshifumi Jonker, Mark A. Omata, Jiro Lan, Jinggang Kudsk, Kenneth A. TI Route and Type of Nutrition and Surgical Stress Influence Secretory Phospholipase A2 Secretion of the Murine Small Intestine SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article; Proceedings Paper CT Meeting of the American-Society-for-Parenteral-and-Enteral-Nutrition/Clinical Nutrition Week CY FEB 07, 2010 CL Las Vegas, NV SP Amer Soc Parenteral & Enteral Nutr DE secretory phospholipase A2; parenteral nutrition; surgical stress; small intestine; defensins; enteral feeding; innate immunity ID TOTAL PARENTERAL-NUTRITION; BACTERICIDAL PROPERTIES; INFLAMMATORY MEDIATORS; STAPHYLOCOCCUS-AUREUS; ENTERAL NUTRITION; LYMPHOID-TISSUE; CELL-WALL; GROUP-II; A(2); EXPRESSION AB Background: The function of secretory phospholipase A2 (sPLA2) is site dependent. In tissue, sPLA2 regulates eicosanoid production; in circulation, sPLA2 primes neutrophils; and in the intestinal lumen, sPLA2 provides innate bactericidal immunity as a defensin-related protein. Since parenteral nutrition (PN) primes leukocytes while suppressing intraluminal mucosal immunity, the authors hypothesized that (1) PN would diminish luminal sPLA2 activity but increase activity in intestinal tissue and serum and (2) stress would accentuate these changes. Methods: Mice received chow, a complex enteral diet (CED), intragastric PN (IG-PN), or PN in experiment 1 and chow, chow+stress, PN, or PN+stress in experiment 2. Results: In experiment 1, luminal sPLA2 activity was greatest in chow and decreased in CED, IG-PN, and PN, with PN lower than CED and IG-PN. Compared to that after chow, serum sPLA2 activity dropped after CED, IG-PN, and PN. Serum sPLA2 was higher in portal than systemic serum. In experiment 2, PN lowered luminal sPLA2 activity vs chow. Stress lowered luminal sPLA2 activity in chow, without change in PN. Following stress, luminal immunoglobulin A increased in chow but not PN. Serum sPLA2 activity increased in PN. Conclusions: PN attenuates sPLA2 activity in intestinal fluid, consistent with suppressed innate mucosal defense. Stress suppresses luminal fluid sPLA2 activity in chow but not the immunoglobulin A response; PN impairs both. Stress significantly elevates serum sPLA2 in PN-fed mice, consistent with known increased neutrophil priming with PN. PN reduces innate bactericidal immunity of the gut but upregulates serum proinflammatory products poststress. (JPEN J Parenter Enteral Nutr. 2011;35:748-756) C1 [Pierre, Joseph F.; Heneghan, Aaron F.; Sano, Yoshifumi; Jonker, Mark A.; Omata, Jiro; Lan, Jinggang; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Pierre, Joseph F.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA. [Heneghan, Aaron F.; Lan, Jinggang; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Tsao, Francis H. C.] Univ Wisconsin, Dept Med, Div Allergy Pulm & Crit Care Med, Sch Med & Publ Hlth, Madison, WI USA. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@sur-gery.wisc.edu FU NIGMS NIH HHS [R01 GM053439, R01 GM53439] NR 32 TC 13 Z9 13 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD NOV PY 2011 VL 35 IS 6 BP 748 EP 756 DI 10.1177/0148607111414025 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 839UL UT WOS:000296394800011 PM 22042050 ER PT J AU Edwardsen, EA Dichter, ME Walsh, P Cerulli, C AF Edwardsen, Elizabeth A. Dichter, Melissa E. Walsh, Patrick Cerulli, Catherine TI Instructional Curriculum Improves Medical Staff Knowledge and Efficacy for Patients Experiencing Intimate Partner Violence SO MILITARY MEDICINE LA English DT Article ID DOMESTIC VIOLENCE; MENTAL-HEALTH; PRIMARY-CARE; WOMEN; PHYSICIANS; VICTIMS AB Objectives: This study assesses Veterans Affairs mental health providers' understanding of intimate partner violence (IPV) and the perception of patient benefit of routine inquiry and service referral. The impact of an instructional curriculum was also examined following an interactive training. Methods: An evidence-based curriculum was offered to Veterans Affairs mental health providers. The curriculum utilized didactic methods, case scenarios, and resources regarding referrals and statutes regarding crimes related to violence and abuse. The participants completed pre- and post-training surveys to assess their perceptions about IPV and to evaluate the training. Results: Seventy-three individuals completed the training. Fifty-four of the participants were female, and thirty-three were over the age of 45 years. Fifty-one individuals completed both surveys. There were no differences between participants' views of the seriousness of IPV in the community or their practices before or after the training. However, participants scored significantly higher on the knowledge and efficacy measures after the training (p < 0.001). Conclusion: Following an educational intervention, providers demonstrate more knowledge and efficacy regarding routine inquiry and referral for IPV. Barriers to universal implementation still warrant attention. C1 [Edwardsen, Elizabeth A.] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY 14642 USA. [Dichter, Melissa E.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Walsh, Patrick] Univ Rochester, Sch Med & Dent, Ctr Excellence, Dept Psychiat, Rochester, NY 14642 USA. [Cerulli, Catherine] Univ Rochester, Sch Med & Dent, Dept Psychiat, Lab Interpersonal Violence & Victimizat, Rochester, NY 14642 USA. RP Edwardsen, EA (reprint author), Univ Rochester, Sch Med & Dent, Dept Emergency Med, 601 Elmwood Ave, Rochester, NY 14642 USA. FU NIMH [K01MH75965-01]; Center of Excellence for Suicide Prevention, Department of VA FX Funding for this work is provided by NIMH K01MH75965-01 (C. Cerulli). Additional funding is provided by the Center of Excellence for Suicide Prevention, Department of VA. NR 25 TC 3 Z9 4 U1 1 U2 6 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD NOV PY 2011 VL 176 IS 11 BP 1260 EP 1264 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 845NR UT WOS:000296830300009 PM 22165653 ER PT J AU Schinka, JA Casey, RJ Kasprow, W Rosenheck, RA AF Schinka, John A. Casey, Roger J. Kasprow, Wesley Rosenheck, Robert A. TI Requiring Sobriety at Program Entry: Impact on Outcomes in Supported Transitional Housing for Homeless Veterans SO PSYCHIATRIC SERVICES LA English DT Article ID 1ST AB Objective: An important distinction in models of housing for the homeless is whether programs that require abstinence prior to program admission produce better outcomes than unrestricted programs. Data from a large transitional housing program were used to compare client characteristics of and outcomes from programs requiring abstinence at admission and programs not requiring abstinence. Methods: The U.S. Department of Veterans Affairs (VA) Northeast Program Evaluation Center provided records of individuals who were admitted into, and discharged from, the VA Grant and Per Diem program in 2003-2005. Records contained information from intake interviews, program discharge information, and descriptions of provider characteristics. Analyses were based on 3,188 veteran records, 1,250 from programs requiring sobriety at admission and 1,938 from programs without a sobriety requirement. Group differences were examined with t tests and chi square analyses; predictors of program outcome were determined with logistic regression. Results: Individuals using drugs or alcohol at program admission had more problematic histories, as indicated by several general health and mental health variables, and shorter program stays. There were significant differences between groups in the frequency of program completion, recidivism for homelessness, and employment on program discharge, but effect sizes for these analyses were uniformly small and of questionable importance. Regression analyses did not find meaningful support for the importance of sobriety on program entry on any of the outcome measures. Conclusions: The results add evidence to the small body of literature supporting the position that sobriety on program entry is not a critical variable in determining outcomes for individuals in transitional housing programs. (Psychiatric Services 62:1325-1330, 2011) C1 [Schinka, John A.; Casey, Roger J.] Natl Ctr Homelessness Vet, Tampa, FL 33612 USA. [Kasprow, Wesley] US Dept Vet Affairs, NE Program Evaluat Ctr, West Haven, CT USA. [Rosenheck, Robert A.] Yale Univ, Dept Psychiat, West Haven, CT USA. RP Schinka, JA (reprint author), Natl Ctr Homelessness Vet, MHBS 116B,13000 BB Downs Blvd, Tampa, FL 33612 USA. EM jschinka@health.usf.edu RI McCarthy, Jodie/B-5760-2012 FU VA National Center on Homelessness Among Veterans FX This research was supported by the VA National Center on Homelessness Among Veterans. NR 11 TC 5 Z9 5 U1 0 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD NOV PY 2011 VL 62 IS 11 BP 1325 EP 1330 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 843LT UT WOS:000296674000012 PM 22211212 ER PT J AU Kim, HM Pfeiffer, P Ganoczy, D Valenstein, M AF Kim, Hyungjin Myra Pfeiffer, Paul Ganoczy, Dara Valenstein, Marcia TI Intensity of Outpatient Monitoring After Discharge and Psychiatric Rehospitalization of Veterans With Depression SO PSYCHIATRIC SERVICES LA English DT Article ID SUBSTANCE USE DISORDERS; HOSPITALIZATION; PREDICTORS; SUICIDE; RISK; CARE AB Objective: This study assessed whether increased frequency of clinical monitoring during the high-risk period of 12 weeks after discharge from a psychiatric hospitalization reduced subsequent rehospitalization in a national cohort of Veterans Health Administration patients receiving depression treatment between 1999 and 2004. Methods: A case-control design was used. Patients who had at least two inpatient psychiatric hospitalizations were identified (case group, N=17,852) and then individually matched with up to two patients who also had been discharged from psychiatric inpatient settings but were not rehospitalized for the number of days between the case-group patient's discharge and subsequent rehospitalization (N=35,511). Results: Covariate-adjusted relative risk (RR) did not show an association between increased monitoring and subsequent psychiatric hospitalization, but there was a significant negative interaction between monitoring and a comorbid substance use disorder diagnosis (p<.001). Increased monitoring was positively associated with rehospitalization of patients without a substance use disorder, whereas increased monitoring was not associated with increased risk of rehospitalization of those with a comorbid substance use disorder. The RR of rehospitalization associated with a weekly monitoring visit (12 visits per 84 days) versus no monitoring visit was 1.14 for patients without a substance use disorder, whereas the RR was reduced to .94 for patients with a substance use disorder. Conclusions: Increased outpatient monitoring during the high-risk period after discharge appears to have a modest protective effect on rehospitalization among depressed patients with a comorbid substance use disorder. (Psychiatric Services 62:1346-1352, 2011) C1 [Kim, Hyungjin Myra] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA. [Kim, Hyungjin Myra; Pfeiffer, Paul; Ganoczy, Dara; Valenstein, Marcia] US Dept Vet Affairs, Serious Mental Illness Treatment Resource & Evalu, Ann Arbor Ctr Excellence, Ann Arbor, MI USA. [Pfeiffer, Paul; Valenstein, Marcia] Univ Michigan, Dept Psychianj, Ann Arbor, MI 48109 USA. RP Kim, HM (reprint author), Univ Michigan, Ctr Stat Consultat & Res, 3550 Rackham,915 E Washington St, Ann Arbor, MI 48109 USA. EM myrakim@umich.edu FU U.S. Department of Veterans Affairs, Health Services Research and Development Service [IIR 04-211-1, MRP 03-320]; National Institute of Mental Health [R01-MH078698-01] FX The funding sources for this work were grants IIR 04-211-1 and MRP 03-320 from the U.S. Department of Veterans Affairs, Health Services Research and Development Service, and grant R01-MH078698-01 from the National Institute of Mental Health. Resources were also contributed by the Serious Mental Illness Treatment Resource and Evaluation Center, Ann Arbor. NR 19 TC 11 Z9 11 U1 2 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD NOV PY 2011 VL 62 IS 11 BP 1346 EP 1352 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 843LT UT WOS:000296674000015 PM 22211215 ER PT J AU Mendez, MF Ramirez-Bermudez, J AF Mendez, Mario F. Ramirez-Bermudez, Jesus TI Cotard Syndrome in Semantic Dementia SO PSYCHOSOMATICS LA English DT Article ID DELUSIONS; BRAIN C1 [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA. [Ramirez-Bermudez, Jesus] Natl Inst Neurol & Neurosurg Mexico, Dept Neuropsychiat, Mexico City, DF, Mexico. RP Mendez, MF (reprint author), VA Greater Angeles, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU [R01AG034499-03] FX This work was funded and supported by #R01AG034499-03 NR 17 TC 8 Z9 8 U1 1 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD NOV-DEC PY 2011 VL 52 IS 6 BP 571 EP 574 PG 4 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 849PJ UT WOS:000297137300012 PM 22054629 ER PT J AU Horan, WP Kring, AM Gur, RE Reise, SP Blanchard, JJ AF Horan, William P. Kring, Ann M. Gur, Raquel E. Reise, Steven P. Blanchard, Jack J. TI Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS) SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Rating scale; Expression; Experience; Negative symptoms; Clinical trials ID PSYCHIATRIC RATING-SCALE; SCHIZOPHRENIA; DEFICITS AB Progress in the development of new pharmacological and psychosocial treatments for the negative symptoms of schizophrenia is impeded by limitations of available assessment instruments. The multi-site Collaboration to Advance Negative Symptom Assessment in Schizophrenia (CANSAS) was established to develop and validate a new clinical rating scale using a transparent, iterative, and data-driven process. The Clinical Assessment Interview for Negative Symptoms (CAINS) was designed to address limitations of existing measures and assess consensus-based sub-domains, including asociality, avolition, anhedonia, affective blunting, and alogia. The structure and psychometric properties of the CAINS were evaluated in a sample of 281 schizophrenia and schizoaffective outpatients at four sites. Converging structural analyses indicated that the scale was comprised of two moderately correlated factors one reflecting experiential impairments (diminished motivation and enjoyment of social, vocational, and recreational activities) and one reflecting expressive impairments (diminished non-verbal and verbal communication). Item-level analyses revealed generally good distributional properties, inter-rater agreement, discriminating anchor points, and preliminary convergent and discriminant validity. Results indicate that the CAINS is a promising new measure for quantifying negative symptoms in clinical neuroscience and treatment studies, Results guided item modification or deletion, and the reliability and validity of the revised, shorter version of the CAINS is in the final phase of development within the CANSAS project. Published by Elsevier B.V. C1 [Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Kring, Ann M.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Gur, Raquel E.] Univ Penn, Philadelphia, PA 19104 USA. [Blanchard, Jack J.] Univ Maryland, College Pk, MD 20742 USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, 300 UCLA Med Plaza,Suite 2255, Los Angeles, CA 90095 USA. EM horan@ucla.edu FU National Institute of Mental Health [K02-MH079231, R01-MH082839, RO1-MH082890, R01-MH082782, R01-MH82783] FX This work was supported by the National Institute of Mental Health (K02-MH079231 and R01-MH082839 to JJB: RO1-MH082890 to AMK: R01-MH082782 to WPH; and R01-MH82783 to REG). Funding sources had no role in study design or in the collection, analysis and interpretation of data; or in the writing of this report. NR 32 TC 83 Z9 83 U1 4 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2011 VL 132 IS 2-3 BP 140 EP 145 DI 10.1016/j.schres.2011.06.030 PG 6 WC Psychiatry SC Psychiatry GA 848ZB UT WOS:000297092500008 PM 21798716 ER PT J AU Meszaros, ZS Dimmock, JA Ploutz-Snyder, R Chauhan, SVS Abdul-Malak, Y Middleton, FA Batki, SL AF Meszaros, Zsuzsa Szombathyne Dimmock, Jacqueline A. Ploutz-Snyder, Robert Chauhan, Sumerendra Vir Singh Abdul-Malak, Ynesse Middleton, Frank A. Batki, Steven L. TI Accuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorder SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Alcohol; Schizophrenia; Schizoaffective disorder; Medical illness; Self-report ID MENTAL-DISORDERS; UNITED-STATES; COMORBIDITY; CARE; MORBIDITY; MORTALITY; ILLNESS; PEOPLE; HEALTH; SCALE AB Background: Schizophrenia and alcohol dependence (AD) are both major risk factors for a variety of medical problems, yet little is known about the medical status of patients in whom both conditions coexist. Objective: The objectives of this study are to assess accuracy of self-reported medical problems and to compare the accuracy reports in patients with schizophrenia or schizoaffective disorder and co-occurring AD compared to patients with AD only and to controls. Our hypothesis was that medical problems are under-reported in patients with co-occurring disorders, possibly due to the combination of alcohol use and symptoms of schizophrenia. Methods: Self-reported medical diagnoses were recorded and compared to medical records obtained from all area hospitals in 42 patients with schizophrenia and AD, 44 patients with schizoaffective disorder and AD, 41 patients with AD only, and 15 control subjects. Patients underwent medical history, physical examination, and review of medical records. Results: Patients with schizophrenia or schizoaffective disorder and co-occurring AD underreported their medical problems significantly more than patients with AD only and controls. Accuracy of self report was significantly lower in patients with schizophrenia-spectrum disorders plus co-occurring alcohol dependence than in AD alone or in controls. The most commonly underreported diagnoses included coronary artery disease, chronic renal failure, seizure disorder, hyperlipidemia, asthma and hypertension. Discussion: In order to detect potentially unreported medical conditions in patients with co-occurring schizophrenia/schizoaffective disorder and alcohol dependence, the use of targeted screening questionnaires is recommended in addition to physical examination and thorough review of medical records. (C) 2011 Elsevier B.V. All rights reserved. C1 [Meszaros, Zsuzsa Szombathyne; Dimmock, Jacqueline A.; Chauhan, Sumerendra Vir Singh; Abdul-Malak, Ynesse; Batki, Steven L.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Ploutz-Snyder, Robert] NASA, Univ Space Res Assoc, Houston, TX USA. [Middleton, Frank A.] SUNY Upstate Med Univ, Dept Neurosci Physiol, Syracuse, NY 13210 USA. [Batki, Steven L.] UCSF, Dept Psychiat, San Francisco, CA USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Meszaros, ZS (reprint author), SUNY Upstate Med Univ, Dept Psychiat, 750 E Adams St, Syracuse, NY 13210 USA. EM meszaroz@upstate.edu FU NIH-NIAAA [RO1 AA01365501, RO1 AA01615103] FX This research was supported by NIH-NIAAA grant RO1 AA01365501, "Naltrexone Treatment of Alcohol Abuse in Schizophrenia" (PI: Batki) and by NIH-NIAAA grant RO1 AA01615103 "Peripheral Pathophysiogenomic Markers of Ethanol-induced Brain Damage" (PI: Middleton). The NIH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit this paper for publication. NR 32 TC 3 Z9 3 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2011 VL 132 IS 2-3 BP 190 EP 193 DI 10.1016/j.schres.2011.07.033 PG 4 WC Psychiatry SC Psychiatry GA 848ZB UT WOS:000297092500016 PM 21852074 ER PT J AU Paramsothy, P Knopp, RH Kahn, SE Retzlaff, BM Fish, B Ma, LN Ostlund, RE AF Paramsothy, Pathmaja Knopp, Robert H. Kahn, Steven E. Retzlaff, Barbara M. Fish, Brian Ma, Lina Ostlund, Richard E., Jr. TI Plasma sterol evidence for decreased absorption and increased synthesis of cholesterol in insulin resistance and obesity SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; DIETARY-CHOLESTEROL; MASS-SPECTROMETRY; SENSITIVITY; RISK; FAT; QUANTIFICATION; DYSLIPIDEMIA; LIPOPROTEINS AB Background: The rise in LDL with egg feeding in lean insulin-sensitive (LIS) participants is 2- and 3-fold greater than in lean insulin-resistant (LIR) and obese insulin-resistant (OIR) participants, respectively. Objective: We determined whether differences in cholesterol absorption, synthesis, or both could be responsible for these differences by measuring plasma sterols as indexes of cholesterol absorption and endogenous synthesis. Design: Plasma sterols were measured by gas chromatography-mass spectrometry in a random subset of 34 LIS, 37 LIR, and 37 OIR participants defined by the insulin sensitivity index (SI) and by BMI criteria selected from a parent group of 197 participants. Cholestanol and plant sterols provide a measure of cholesterol absorption, and lathosterol provides a measure of cholesterol synthesis. Results: The mean (+/-SD) ratio of plasma total absorption biomarker sterols to cholesterol was 4.48 +/- 1.74 in LIS, 3.25 +/- 1.06 in LIR, and 2.82 +/- 1.08 in OIR participants. After adjustment for age and sex, the relations of the absorption sterol-cholesterol ratios were as follows: LIS. OIR (P < 0.001), LIS. LIR (P < 0.001), and LIR. OIR (P = 0.11). Lathosterol-cholesterol ratios were 0.71 +/- 0.32 in the LIS participants, 0.95 +/- 0.47 in the LIR participants, and 1.29 +/- 0.55 in the OIR participants. After adjustment for age and sex, the relations of lathosterol-cholesterol ratios were as follows: LIS, OIR (P < 0.001), LIS, LIR (P = 0.03), and LIR, OIR (P = 0.002). Total sterol concentrations were positively associated with SI and negatively associated with obesity, whereas lathosterol correlations were the opposite. Conclusions: Cholesterol absorption was highest in the LIS participants, whereas cholesterol synthesis was highest in the LIR and OIR participants. Therapeutic diets for hyperlipidemia should emphasize low-cholesterol diets in LIS persons and weight loss to improve SI and to decrease cholesterol overproduction in LIR and OIR persons. Am J Clin Nutr 2011;94:1182-8. C1 [Paramsothy, Pathmaja] Univ Washington, Div Cardiol, Seattle, WA 98195 USA. [Paramsothy, Pathmaja; Knopp, Robert H.; Retzlaff, Barbara M.; Fish, Brian] Univ Washington, NW Lipid Res Clin, Seattle, WA 98195 USA. [Knopp, Robert H.; Kahn, Steven E.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Ma, Lina; Ostlund, Richard E., Jr.] Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO USA. RP Paramsothy, P (reprint author), 325 9th Ave,PSB 5064,UW Mailstop 359720, Seattle, WA 98104 USA. EM nmbob@uw.edu OI Kahn, Steven/0000-0001-7307-9002 FU Egg Nutrition Center; NIH [1KL2RR025015-01, RO1 50420, DK20579, RR00954]; Clinical Nutrition Research Unit at the University of Washington [DK 35816]; Diabetes and Endocrinology Research Center at the University of Washington [DK 17047]; General Clinical Research Center [RR 00037]; Department of Veterans Affairs FX Supported by a grant in aid from the Egg Nutrition Center (administered through the US Department of Agriculture), NIH 1KL2RR025015-01 (to PP); the Clinical Nutrition Research Unit at the University of Washington (DK 35816), the Diabetes and Endocrinology Research Center at the University of Washington (DK 17047), the General Clinical Research Center (RR 00037), the Department of Veterans Affairs (to SEK), and NIH grants RO1 50420, DK20579 and RR00954 (to REO). NR 38 TC 17 Z9 18 U1 0 U2 4 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD NOV PY 2011 VL 94 IS 5 BP 1182 EP 1188 DI 10.3945/ajcn.110.006668 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 837VV UT WOS:000296236100005 PM 21940599 ER PT J AU Lund, BC Steinman, MA Chrischilles, EA Kaboli, PJ AF Lund, Brian C. Steinman, Michael A. Chrischilles, Elizabeth A. Kaboli, Peter J. TI Beers Criteria as a Proxy for Inappropriate Prescribing of Other Medications Among Older Adults SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE Beers criteria; health care; inappropriate drug use; older adult; quality indicators ID ADVERSE DRUG-REACTIONS; EXPLICIT CRITERIA; QUALITY; EVENTS; OUTPATIENTS; OUTCOMES; PEOPLE AB BACKGROUND: The Beers criteria are a compilation of medications deemed potentially inappropriate for older adults, widely used as a prescribing quality indicator. OBJECTIVE: To determine whether Beers criteria serve as a proxy measure for other forms of inappropriate prescribing, as measured by comprehensive implicit review. METHODS: Data for patients 65 years and older were obtained from the Veterans Affairs Enhanced Pharmacy Outpatient Clinic (EPOC) and the Iowa Medicaid Pharmaceutical Case Management (PCM) studies. Comprehensive measurement of prescribing quality was conducted using expert clinician review of medical records according to the Medication Appropriateness Index (MAI). MAI scores attributable to non-Beers medications were contrasted between patients who did and did not receive a Beers criteria medication. RESULTS: Beers criteria medications accounted for 12.9% (EPOC) and 14.0% (PCM) of total MAI scores. Importantly, non-Beers MAI scores were significantly higher in patients receiving a Beers criteria medication in both studies (EPOC: 15.1 vs 12.4, p = 0.02; PCM: 11.1 vs 8.7, p = 0.04), after adjusting for important confounding factors. CONCLUSIONS: Beers criteria utility extended beyond direct measurement of a limited set of inappropriate prescribing practices by serving as a clinically meaningful proxy for other inappropriate practices. Using prescribing quality indicators to guide interventions should thus identify patients for comprehensive medication review, rather than identifying specific medication targets for discontinuation. Future research should explore both the quality measurement and the intervention targeting applications of the Beers criteria, particularly when integrated with other indicators. C1 [Lund, Brian C.] Vet Affairs Iowa City Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA. [Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Steinman, Michael A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Chrischilles, Elizabeth A.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Kaboli, Peter J.] Univ Iowa, Dept Internal Med, Div Gen Internal Med, Carver Coll Med, Iowa City, IA 52242 USA. RP Lund, BC (reprint author), Vet Affairs Iowa City Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA. EM Brian.Lund@va.gov FU Health Services Research and Development Service, Department of Veterans Affairs [SAF98-152]; Research Career Development award [RCD 01-013-1]; Center for Research in the Implementation of Innovative Strategies in Practice at the Iowa City Veterans Affairs Medical Center [HFP 04-149]; State of Iowa General Assembly; Iowa Pharmacy Foundation, McKesson HBOC; Institute for the Advancement of Community Pharmacy; Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics [5 U18 HS016094]; National Institute on Aging; American Federation for Aging Research [K23-AG030999] FX The Enhanced Pharmacy Outpatient Clinic trial was supported by the Health Services Research and Development Service, Department of Veterans Affairs, through an investigator-initiated research award (SAF98-152); Research Career Development award to Dr. Kaboli (RCD 01-013-1); and the Center for Research in the Implementation of Innovative Strategies in Practice (HFP 04-149) at the Iowa City Veterans Affairs Medical Center. The Iowa Medicaid Pharmaceutical Case Management program evaluation was funded by the State of Iowa General Assembly, the Iowa Pharmacy Foundation, McKesson HBOC, and the Institute for the Advancement of Community Pharmacy. This study was supported in part by an Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics cooperative agreement #5 U18 HS016094. Dr. Steinman was supported by an award from the National Institute on Aging and the American Federation for Aging Research (K23-AG030999). NR 26 TC 19 Z9 23 U1 1 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD NOV PY 2011 VL 45 IS 11 BP 1363 EP 1370 DI 10.1345/aph.1Q361 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 845LK UT WOS:000296824000005 PM 21972251 ER PT J AU Hanratty, R Chonchol, M Havranek, EP Powers, JD Dickinson, LM Ho, PM Magid, DJ Steiner, JF AF Hanratty, Rebecca Chonchol, Michel Havranek, Edward P. Powers, J. David Dickinson, L. Miriam Ho, P. Michael Magid, David J. Steiner, John F. TI Relationship between Blood Pressure and Incident Chronic Kidney Disease in Hypertensive Patients SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID HEMODIALYSIS-PATIENTS; DIABETES-MELLITUS; RENAL-DISEASE; UNITED-STATES; PROGRESSION; POPULATION; PREVALENCE; DECLINE; TRIAL; TIME AB Background and objectives Hypertension is an important cause of chronic kidney disease (CKD). Identifying risk factors for progression to CKD in patients with normal kidney function and hypertension may help target therapies to slow or prevent decline of kidney function. Our objective was to identify risk factors for development of incident CKD and decline in estimated GFR (eGFR) in hypertensive patients. Design, setting, participants, & measurements Cox proportional hazards models were used to assess the relationship between incident CKD (defined as eGFR <60 ml/min per 1.73 m(2)) and potential risk factors for CKD from a registry of hypertensive patients. Results Of 43,305 patients meeting the inclusion criteria, 12.1% (5236 patients) developed incident CKD. Diabetes was the strongest predictor of incident CKD (hazard ratio, 1.96; 95% confidence interval, 1.84 to 2.09) and was associated with the greatest rate of decline in eGFR (-2.2 ml/min per 1.73 m(2) per year). Time-varying systolic BP was associated with incident CKD with risk increasing above 120 mmHg; each 10-mmHg increase in baseline and time-varying systolic BP was associated with a 6% increase in the risk of developing CKD (hazard ratio, 1.06; 95% confidence interval, 1.04 to 1.08 for both). Time-weighted systolic BP was associated with a more rapid decline in eGFR of an additional 0.2 ml/min per 1.73 m(2) per year decline for every 10-mmHg increase in systolic BP. Conclusions We found that time-varying systolic BP was associated with incident CKD, with an increase in risk above a systolic BP of 120 mmHg among individuals with hypertension. Clin J Am Soc Nephrol 6: 2605-2611, 2011. doi: 10.2215/CJN.02240311 C1 [Hanratty, Rebecca] Denver Hlth, Med Ctr, Denver, CO 80204 USA. [Chonchol, Michel] Univ Colorado, Div Renal Dis & Hypertens, Denver, CO 80202 USA. [Powers, J. David; Ho, P. Michael; Magid, David J.; Steiner, John F.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Dickinson, L. Miriam] Univ Colorado, Colorado Hlth Outcomes Program, Denver, CO USA. [Ho, P. Michael] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Hanratty, R (reprint author), Denver Hlth, Med Ctr, 777 Bannock St,MC 3600, Denver, CO 80204 USA. EM Rebecca.hanratty@dhha.org FU National Heart Lung and Blood Institute [U19 HL91179-01]; Veterans Affairs Health Services Research; Development Career Development Award [05-026] FX This study was conducted within the Cardiovascular Research Network, a consortium of research organizations affiliated with the HMO Research Network and sponsored by the National Heart Lung and Blood Institute (U19 HL91179-01). The results presented in this paper have not been published previously in whole or part, except in abstract form at the 43rd Annual American Society of Nephrology Conference.; Dr. Ho is supported by a Veterans Affairs Health Services Research and Development Career Development Award 05-026 and serves as a consultant for Wellpoint, Inc. NR 24 TC 14 Z9 16 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2011 VL 6 IS 11 BP 2605 EP 2611 DI 10.2215/CJN.02240311 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 845KJ UT WOS:000296821300010 PM 21921154 ER PT J AU Lee, CG Boyko, EJ Barrett-Connor, E Miljkovic, I Hoffman, AR Everson-Rose, SA Lewis, CE Cawthon, PM Strotmeyer, ES Orwoll, ES AF Lee, Christine G. Boyko, Edward J. Barrett-Connor, Elizabeth Miljkovic, Iva Hoffman, Andrew R. Everson-Rose, Susan A. Lewis, Cora E. Cawthon, Peggy Mannen Strotmeyer, Elsa S. Orwoll, Eric S. CA Osteoporotic Fractures Men MrOS TI Insulin Sensitizers May Attenuate Lean Mass Loss in Older Men With Diabetes SO DIABETES CARE LA English DT Article ID MUSCLE IN-VIVO; SKELETAL-MUSCLE; OSTEOPOROTIC FRACTURES; 1ST-DEGREE RELATIVES; METFORMIN INCREASES; BODY-COMPOSITION; EXERCISE; PROTEIN; PHOSPHORYLATION; TROGLITAZONE AB OBJECTIVE-To examine longitudinal changes in total and appendicular lean body mass in older men with impaired fasting glucose (IFG) or diabetes and to determine whether these changes differ by diabetes treatment. RESEARCH DESIGN AND METHODS-A total of 3,752 ambulatory men aged 65 years at baseline participated in a multicenter longitudinal cohort study. Baseline glycemic status was categorized as normoglycemia, IFG, undiagnosed/untreated diabetes, or treated diabetes. Insulin sensitizer medication use (metformin and/or thiazolidinediones) was assessed by prescription medication inventory. The change in total lean and appendicular lean mass was derived from dual X-ray absorptiometry scans taken at baseline and 3.5 +/- 0.7 years later. RESULTS-This male cohort included 1,853 individuals with normoglycemia, 1,403 with IFG, 234 with untreated diabetes, 151 with diabetes treated with insulin sensitizers, and 111 with diabetes treated without insulin sensitizers. Men with untreated diabetes, diabetes treated without insulin sensitizers, or IFG had greater percentage loss in total or appendicular lean mass (P <= 0.05 in comparison to normoglycemic men). There remained a significantly greater percentage loss in appendicular lean mass for these groups even after adjustment for medical comorbidities or lifestyle factors. In contrast, the percentage loss in total or appendicular lean mass in men with diabetes treated with insulin sensitizers was significantly less than that in normoglycemic men in minimally and fully adjusted models. CONCLUSIONS-Skeletal muscle loss was accelerated in men with IFG and diabetes, except when the latter was treated with insulin sensitizers. These findings suggest that insulin sensitizers may attenuate muscle loss C1 [Lee, Christine G.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, La Jolla, CA 92093 USA. [Miljkovic, Iva; Strotmeyer, Elsa S.] Univ Pittsburgh, Pittsburgh, PA USA. [Hoffman, Andrew R.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Everson-Rose, Susan A.] Univ Minnesota, Minneapolis, MN USA. [Lewis, Cora E.] Univ Alabama, Birmingham, AL USA. [Cawthon, Peggy Mannen] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. RP Lee, CG (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. EM leechr@ohsu.edu RI Strotmeyer, Elsa/F-3015-2014 OI Orwoll, Eric/0000-0002-8520-7355; Miljkovic, Iva/0000-0002-3155-9777; Strotmeyer, Elsa/0000-0002-4093-6036; Boyko, Edward/0000-0002-3695-192X FU National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA); National Center for Research Resources (NCRR); National Institutes of Health Roadmap for Medical Research [U01-AR45580, U01-AR45614, U01-AR45632, U01-AR45647, U01-AR45654, U01-AR45583, U01-AG18197, U01-AG027810, UL1-RR024140]; Building Interdisciplinary Careers in Women's Health Program [K12-HD043488-09]; American Diabetes Association [1-04-JF-46]; National Institute of Diabetes and Digestive and Kidney Diseases [K01-DK083029] FX The MrOS study was supported by funding from the National Institutes of Health. The following institutes provided support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Center for Research Resources (NCRR), and the National Institutes of Health Roadmap for Medical Research under the following grant numbers: U01-AR45580, U01-AR45614, U01-AR45632, U01-AR45647, U01-AR45654, U01-AR45583, U01-AG18197, U01-AG027810, and UL1-RR024140. C.G.L. received additional support from the Building Interdisciplinary Careers in Women's Health Program (grant number K12-HD043488-09). Additional support was provided by the American Diabetes Association (grant number 1-04-JF-46) to E.S.S. I.M. was supported by the Mentored Research Scientist Development Award from the National Institute of Diabetes and Digestive and Kidney Diseases (K01-DK083029). VA Puget Sound Health Care System provided support for participation of E.J.B. in this research. NR 22 TC 34 Z9 35 U1 1 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD NOV PY 2011 VL 34 IS 11 BP 2381 EP 2386 DI 10.2337/dc11-1032 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 847EQ UT WOS:000296955100010 PM 21926282 ER PT J AU Zorick, T Sugar, CA Hellemann, G Shoptaw, S London, ED AF Zorick, Todd Sugar, Catherine A. Hellemann, Gerhard Shoptaw, Steve London, Edythe D. TI Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Antidepressants; Sertraline; Methamphetamine; Addiction; Craving; Classification and regression trees ID PLACEBO-CONTROLLED TRIAL; DRUG-USERS; DEPRESSION; WITHDRAWAL; SEVERITY; PHARMACOTHERAPY; FLUOXETINE; MANAGEMENT; INVENTORY; OUTCOMES AB Background: Depression is common among individuals with methamphetamine (MA) use disorders. As agents that enhance serotonergic function are frequently used to treat depression, one might predict that they would be useful medications for MA dependence. However, clinical trials of serotonergic agents for MA addiction have been unsuccessful. Objective: To identify factors that distinguish MA-dependent research participants who increased MA self-administration while receiving treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline from other groups of participants. Method: Using a dataset from a 12-week randomized, placebo-controlled trial of sertraline (100 mg daily) for MA addiction, we identified participants who had completed at least 8 weeks of the trial (n = 61 sertraline, n = 68 placebo). We compared the proportions of MA-positive urine tests for weeks 8-12 of the trial for these subjects to their pre-randomization baseline, and identified those subjects who increased MA use during treatment. Using classification trees, we then assessed all data collected during the study to identify factors associated with increasing MA use during treatment with sertraline, compared to placebo. Results: More subjects in the sertraline condition increased MA use during treatment (n = 13) than in the placebo condition (n = 5: p = 0.03). Classification trees identified multiple factors from both pre-treatment and in-treatment data that were associated with increased MA use during treatment. Only elevated in-treatment craving for MA specifically characterized subjects in the sertraline group who increased their MA use. Conclusions: Some MA-abusing individuals treated with SSRIs have sustained craving with an increased propensity to relapse during treatment despite psychosocial treatment interventions. Published by Elsevier Ireland Ltd. C1 [Zorick, Todd] Greater Los Angeles Vet Adm Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. [Zorick, Todd; Sugar, Catherine A.; Hellemann, Gerhard; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA. [Shoptaw, Steve] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90095 USA. [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. RP Zorick, T (reprint author), 11301 Wilshire Blvd,MC 116A, Los Angeles, CA 90073 USA. EM todd.zorick@va.gov FU NIH [R01 DA010923, P50 DA018185, P20 DA022539] FX NIH Grants R01 DA010923 (SS), P50 DA018185 (SS, EDL), P20 DA022539 (EDL), endowments from the Katherine K. and Thomas P. Pike Chair in Addiction Studies (EDL), and the Marjorie M. Greene Trust. NR 34 TC 7 Z9 7 U1 0 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD NOV 1 PY 2011 VL 118 IS 2-3 BP 500 EP 503 DI 10.1016/j.drugalcdep.2011.04.015 PG 4 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 837EL UT WOS:000296173800060 PM 21592681 ER EF